

# PROGRAM

PROGRAM

AMERICAN PSYCHIATRIC ASSOCIATION

## 2002 ANNUAL MEETING



Philadelphia, PA ■ May 18-23, 2002

# 2002 SCIENTIFIC PROGRAM COMMITTEE



**Seated (left to right):** Drs. McDowell, Muskin, Ordorica. **1<sup>st</sup> Row Standing (left to right):** Drs. Judge, Blake, Worley, Pandurangi, LeMelle, Shafii, Anderson, Jayaram, Casey, Dawkins, Foulks. **2<sup>nd</sup> Row Standing (left to right):** Drs. Blinder, Choeng, Taylor, Crone, Baker, Hilty, Kanefield, Groves, Goldfinger, Yeung, MacKenzie, Pandya, Alessi, D'Alli. **Not pictured:** Drs. Kales, Stabinsky

May 18, 2002

Dear Colleagues and Guests:

Welcome to the 155th Annual Meeting of the American Psychiatric Association. The coming week will highlight the best in our profession in the largest psychiatric meeting in the world. Our meeting has become an outstanding international forum to discuss the latest scientific advances and traditional humane values in psychiatry and how we will continue to integrate these bodies of knowledge to provide excellent patient care into the future.

This year's Annual Meeting theme is "The 21<sup>st</sup> Century Psychiatrist." Many sessions throughout the week will highlight an important aspect of the theme. Please make a special effort to attend the Monday afternoon Presidential Symposium, from 2:00 p.m.-5:00 p.m., entitled, "What Will the 21<sup>st</sup> Century Bring to the Training of Psychiatrists?"

I join our colleagues from North America in greeting the thousands of colleagues from other parts of the world who have joined us in Philadelphia. At the Opening Session, from 5:00 p.m.-6:30 p.m., on Sunday, we will officially welcome the leaders from psychiatric societies in the U.S. and around the world. I will present my Presidential Address, and I look forward to seeing you there.

Please also make sure to attend the Convocation on Monday night at 6:00 p.m., where we will honor all those being inducted as fellows and many receiving awards from the APA.

Organizing a meeting like ours represents the best in collaboration between our members and our staff. Special congratulations go to Dr. Philip R. Muskin and the members of the Scientific Program Committee, Marvin Kanefield, D.O., and the members of the Local Arrangements Committee, and to the APA staff who work on the Annual Meeting.

Welcome to Philadelphia 2002.

Sincerely,

Richard K. Harding, M.D.  
President





# American Psychiatric Association

1400 K Street, N.W.  
Washington, D.C. 20005  
Telephone 202.682.6237  
Fax 202.682.6345  
E-mail [apa@psych.org](mailto:apa@psych.org)

May 18, 2002

**155th Annual Meeting**  
**Philadelphia, PA**  
**May 18-23, 2002**

**President**

Richard K. Harding, M.D.

**Scientific Program Committee**

**2001-2002**

Philip R. Muskin, M.D., *Chairperson*

David M. McDowell, M.D.

*Vice-Chairperson*

Patricia I. Orlorica, M.D.

*Vice-Chairperson*

Robert W. Baker, M.D.

David A. Casey, M.D.

Josephine Cheong, M.D.

Catherine C. Crona, M.D.

Karon Dawkins, M.D.

Geetha Jayaram, M.D.

Sheila Judge, M.D.

Helen Kales, M.D.

Stephanie LeMelle, M.D.

Anand Pandya, M.D.

Mohammad Shafiq, M.D.

Harvey Stabinsky, M.D.

David H. Taylor, M.D.

Linda Worley, M.D.

Paul Yeung, M.D.

**Consultants**

Lesley M. Blake, M.D.

Barton J. Blinder, M.D.

Edward Foulks, M.D.

Donald Hilty, M.D.

K. Roy MacKenzie, M.D.

Randall Marshall, M.D.

Ananda Pandurangi, M.D.

Tanya Royster-Anderson, M.D.

**Media Subcommittee**

Richard E. D'Alili, M.D.

*Chairperson*

**Telecommunications**

**Subcommittee**

Norman E. Alessi, M.D.

*Chairperson*

**Committee on Commercial**

**Support**

Stephen M. Goldfinger, M.D.

*Chairperson*

**Annual Meetings Department**

Cathy L. Nash, *Director*

(202) 682-6237

Hope Ball-Mann

*Registrar*

(202) 682-6082

Frank Barry

*Administrator, Commercially-*

*Supported Activities*

(202) 682-6172

Renee Brown

*Administrative Assistant*

(202) 682-6365

Vernetta V. Copeland

*CME Course Coordinator*

(202) 682-6836

Tonya Frazier

*Administrative Assistant*

(202) 682-6849

Kendra W. Grant

*Scientific Program Coordinator*

(202) 682-6191

Sheena L. Majette

*Scientific Program Coordinator*

(202) 682-6170

Celeste M. Mele

*Operations Manager*

(202) 682-6237

Robbie J. Morsette

*Administrative Assistant*

(202) 682-6313

Dear APA Members and Guests:

Welcome to Philadelphia, PA, and the 155th Annual Meeting of the American Psychiatric Association. This historic city, with its vibrancy, cultural diversity, and excitement, provides a perfect setting for the scientific presentations we have planned. As you read through the *Program Book*, you will notice a number of sessions related to the theme "The 21<sup>st</sup> Century Psychiatrist," chosen by our President, Dr. Richard K. Harding. Let me draw your attention to just a few of the many exciting sessions presented this week. On Monday we will present the Presidential Symposium entitled, "What Will the 21<sup>st</sup> Century Bring to the Training of Psychiatrists?" Throughout the week we will feature sessions presented in collaboration with the Substance Abuse and Mental Health Service Administration. David Satcher, M.D., will present the APA's Patient Advocacy Award Lecture on Wednesday, at 9:00 a.m.

The Local Arrangements Committee, under the excellent guidance of its Chairperson, Marvin Kanefield, D.O., has developed a wide array of activities that will help you take advantage of Philadelphia. You will notice that a number of activities are designed especially for families and children.

The Business Meeting will be held on Sunday, from 12:30 p.m. to 1:30 p.m.; all voting members are encouraged to attend. The Opening Session will be held on Sunday, from 5:00 p.m. to 6:30 p.m. Exhibits will be open 11:00 a.m. to 4:30 p.m. on Sunday, 10:00 a.m. to 6:00 p.m. on Monday and Tuesday, and 10:00 a.m. to 3:00 p.m. on Wednesday. Please note that the Convocation will begin at 6:00 p.m., a new time, on Monday, May 20. Rodger McFarlane, recipient of APA's Patient Advocacy Award, will present the William C. Menninger Memorial Lecture during the Convocation.

The Advances in Research session will be held on Monday at 10:30 a.m. This session highlights the latest research findings in psychiatry and summarizes their relevance to clinical practice. This session has become an excellent way to start off the Annual Meeting's research programs, in conjunction with the Young Investigators' Poster and Oral/Slide Sessions also on Monday. You will find an expanded number of small group sessions, including Discussion Groups; Research Consultations with selected experts in the field; and Master Educator Clinical Consultations, a series of clinically-based seminars with outstanding clinician educators, offered to APA members only.

You will note in the *Program Book* that we are continuing with an expanded series of noon Forums. This format allows us to schedule sessions that may not fit in the usual formats or that focus on late-breaking topics of importance to the field. Several forums, as well as numerous other sessions, will focus on aspects of the terrorist attacks, terrorists, and the response efforts to deal with the psychological sequelae of the events.

It is extremely important that you fill out and return the evaluation forms for this meeting. The members of the Scientific Program Committee are interested in your opinion regarding the quality of the content of the Annual Meeting. The information we obtain will be used to plan next year's Annual Meeting.

Once again, welcome to Philadelphia. I look forward to sharing a week of exciting and professionally rewarding activities with you.

Sincerely,

Philip R. Muskin, M.D.  
Chairperson  
Scientific Program Committee



# APA 155th ANNUAL MEETING

Philadelphia, PA ■ May 18-23, 2002

## KEY LOCATIONS - CONVENTION CENTER

<i>American Journal of Psychiatry</i>	APA Resource Center
Annual Meetings Office	Room 304, Level 300
(formerly the Scientific Program Office & Meetings Management)	
APA Communications Center	Room 105 A/B, Street Level
APA Resource Center	Exhibit Halls A-C, Level 200
A/V Preview Room	Room 303 B, Level 300
CME Course Enrollment	Exhibit Halls A-C, Level 200
Computerized Evaluation	APA Resource Center
<i>Daily Bulletin</i>	Room 310, Level 300
Education Office	Room 309, Level 300
Exhibit Office	Level 200
Exhibits/Publishers' Bookfair	Exhibit Halls A-C, Level 200
Information/Locator Center	Street Level
Lost & Found	Room 304, Level 300
Message Center	Bridge, Level 200
On-Site Job Bank and Placement Center	APA Resource Center
<i>Psychiatric Services</i>	APPI Bookstore, Exhibit Halls A-C
Registration	Exhibit Halls A-C, Level 200

## FIRST AID

Located in Room BF2, Exhibit Hall B, Level 200, Convention Center. Hours of operation: Tuesday, May 14, through Thursday, May 23, opens one hour prior to show opening and closes one hour after the last event of the evening. This station will be operated by Registered Nurses. Information on emergency services may be found on page 1 of the *Leisure Time Activities Brochure*.

## COURTESY SHUTTLE BUS SERVICE

Service will begin on Saturday, May 18, at approximately 7:30 a.m., and will operate daily throughout the meeting commensurate with the scientific program schedule, including nighttime activities, and will conclude on Thursday, May 23, at 6:00 p.m. The Convention Center will serve as the "hub" for all shuttle bus routes. A detailed Shuttle Bus Services Schedule will be included in each registration packet and posted in the lobbies of participating hotels. Refer to the city map on page XII for the location of hotels in relation to the Convention Center.

## EXHIBITS

Commercial and educational exhibits are located in Exhibit Halls A-C, Level 200, Convention Center, along with the Publishers' Bookfair and the APA Resource Center. As a convenience to registrants, the APA Resource Center will open on Saturday, May 18, 10:00 a.m.-5:00 p.m., and the Publishers' Bookfair will open on Saturday, May 18, 11:00 a.m.-5:00 p.m. Hours for commercial and educational exhibits: Sunday, May 19, 11:00 a.m.-4:30 p.m.; Monday and Tuesday, May 20-21, 10:00 a.m.-6:00 p.m., and Wednesday, May 22, 10:00 a.m.-3:00 p.m. All exhibits will close on Wednesday, May 22 at 3:00 p.m. Please refer to the *APA Exhibits Guide* for additional information on participating companies. APA periodicals will be located in the APPI Bookstore.

## INFORMATION/LOCATOR CENTER

Located in the Lobby, Street Level, Convention Center and staffed during registration hours. Up-to-date general information about the program, component meetings, the local area, and the locations of various activities and events can be obtained there. Meeting participants also can find out where colleagues who are registered for the meeting are staying.

## MESSAGE CENTER

Located on the Bridge, Level 200, Convention Center and staffed during registration hours. Messages can be left and picked up at the Message Center. Message monitors will be strategically located in the Exhibit Hall and elsewhere at the Convention Center. Registrants whose names appear on these monitors should pick up their messages at the Message Center.

## APA RESOURCE CENTER

Located in Exhibit Halls A-C, Level 200, Convention Center. Hours of operation will be: Saturday, May 18, 10:00 a.m.-5:00 p.m.; Sunday, May 19, 8:00 a.m.-4:30 p.m.; Monday and Tuesday, May 20-21, 10:00 a.m.-6:00 p.m.; and Wednesday, May 22, 10:00 a.m.-3:00 p.m. A few of the many APA activities exhibited include: membership, APA's internet-based programs, continuing medical education, quality improvement, psychiatric services, managed care services, and APA Job Bank.

## APA JOB BANK

Located in the APA Resource Center and open during the Center's hours of operation. The on-line APA Job Bank will power the popular on-site Job Bank providing tools for both employers and candidates at the APA's Annual Meeting. With new features such as résumé posting, enhanced job searching, and response tracking, the Job Bank provides the best opportunity available for career research and on-site interviews. Candidates and employers are encouraged to activate their resume and jobs postings in advance of the meeting for best results. For more information on the Job Bank go to the APA web site, [www.psych.org](http://www.psych.org), and click on the Job Bank icon. You may also contact us by phone (888-884-8242) or e-mail ([employers@healthcareers.com](mailto:employers@healthcareers.com)) prior to the meeting, or stop by the Job Bank booth on-site.

## APA COMMUNICATIONS OFFICE/PRESS OFFICE

Located in Rooms 105 A/B, Street Level, Convention Center. Hours of operation: Saturday, May 18, 12 noon-5:00 p.m.; Sunday-Wednesday, May 19-22, 8:00 a.m.-6:00 p.m.; and Thursday, May 23, 8:00 a.m.-12 noon.

The Press Office is for the use of registered press only. All Annual Meeting sessions are open to the press except CME Courses, the Business Meeting, Clinical and Continuous Clinical Case Conferences, and Master Educator Clinical Consultations.

## DAILY BULLETIN

The *Daily Bulletin* accepts written requests from APA members for publicity of component, committee, and allied group events as space allows. Four issues are published. The issue for Saturday/Sunday is printed in advance. Copy for the Monday, Tuesday, and Wednesday/Thursday issues can be dropped off in Room 310, Level 300, by 12 noon prior to the date of publication.

## CENTER FOR INTERNATIONAL GUESTS Bienvenidos, Willkommen, Bienvenue, Welcome!

Located in the Commonwealth Hall, Second Floor, Loews. Hours of operation: Saturday, May 18, through Wednesday, May 22, 8:00 a.m.-6:00 p.m.; and Thursday, May 23, from 8:00 a.m.-3:00 p.m. All international visitors are invited. These activities are supported by Pfizer Pharmaceuticals Group.



## WOMEN'S RESOURCE CENTER

Located in Room 303A, Level 300, Convention Center. Hours of operation: Sunday, May 19, through Monday, May 20, 7:00 a.m.-5:00 p.m. Meet and network with other women psychiatrists and peruse materials on women's programs offered by APA and other organizations. Special events will include an informal session for women on passing the boards, a meeting of the women's mentoring network, and a networking meeting for District Branch committees on women. The Center is funded by an unrestricted educational grant from Wyeth Pharmaceuticals.

## IMG HOSPITALITY CENTER

Located in Room 303A, Level 300, Convention Center. Hours of operation: Tuesday, May 21, through Wednesday, May 22, 8:00 a.m.-6:00 p.m. Stop by the Center to meet and network with your colleagues. From 12 noon-1:30 p.m. both days, there will be informal sessions on "Acculturation, Language: Problems and Solutions for IMGs and ECFMGs: Friend or Foe?"

## BUSINESS CENTERS

### Convention Center

Location: Between Exhibit Halls B & C

Times of operation: Monday-Sunday, 8:00 a.m.-6:00 p.m.

### Loews

Location: 3<sup>rd</sup> Floor

Times of operation: Monday-Friday, 6:30 a.m.-9:00 p.m.

Saturday-Sunday, 8:00 a.m.-5:00 p.m.

### Marriott - Kinkos

Location: Main Level, Market Street Exit

Times of operation: open 24 hours

## REGISTRATION

### ADMISSION TO ALL SESSIONS BY REGISTRATION BADGE

Located in Exhibit Halls A-C, Level 200, Convention Center. Hours of operation: Saturday, May 18, 10:00 a.m.-5:00 p.m.; Sunday, May 19, 7:30 a.m.-5:00 p.m.; Monday-Tuesday, May 20-21, 7:30 a.m.-6:00 p.m.; Wednesday, May 22, 7:30 a.m.-5:00 p.m.; and Thursday, May 23, 7:30 a.m.-2:00 p.m.

### On-Site Registration Fee Schedule:

#### APA MEMBERS

Full-Time Registration (*North American Members*).....\$235.00

Full-Time Registration (*International Members*).....\$500.00

Members-in-Training (*Member Class MT*).....\$ 70.00

Daily Registration (*North American Members*).....\$120.00

Daily Registration (*International Members*).....\$255.00

Medical Students *no charge*

#### NONMEMBERS

Full-Time Registration .....\$710.00

Nonmember Residents, Students, Advocacy

Group Members or Mental Health Chaplains.....90.00

Daily Registration (*all "Nonmember" categories*).....360.00

Medical Students *no charge*

#### GUEST REGISTRATION

One only per full-time registrant .....95.00

Only one guest is allowed to register with each full-time meeting registrant. *The guest must reside in the same household and be able to receive mail at the same address. APA members cannot register as a "guest"; they must register as an APA member.*

One-Day Exhibit Hall Only Pass (18 and older)..... 10.00

On-site fees can be paid by cash, check, money order, American Express, VISA or MasterCard. Registration fees are waived **only** for *CME Course Faculty, APA Honorary or Distinguished Fellows (does not include APA Life Fellows or Fellows), medical students (with proper identification), District Branch Executive Staff (who are not APA members), active members of the Association of Mental Health Clergy (with proper identification), and nonmember program participants (only for the day(s) they present).*

**NONMEMBER PSYCHIATRIC RESIDENTS AND OTHER FULL-TIME STUDENTS** must present documentation of their qualifications to register in their respective category and qualify for the reduced fee. (Examples include: a valid full-time [12 + hours per semester] student ID; a letter from your instructor or director of training verifying your status as a psychiatric resident; or similar documentation.)

**Note: There are no exemptions or reduced fees available for CME courses.** The registration fee covers admission to all sessions (except courses), shuttle buses, and includes a badge and copy of the *Program Book, APA Exhibits Guide, and New Research Program and Abstracts Books*, and for most categories, a copy of the *Syllabus*.

## NAME BADGES

Badges are required for all sessions including the Opening Session and exhibit area. Only an APA member badge will admit you to the Business Meeting.

**Badge Color Codes:** Blue-Members, Yellow-Nonmembers, Silver-Press, Red-Exhibitors, Green-APA Staff, and Black-Temporary Convention Personnel.

## CME COURSE ENROLLMENT TICKET PURCHASE REQUIRED FOR CME COURSES

Located in Exhibit Halls A-C, Level 200, Convention Center. Hours of operation: Saturday, May 18, 10:00 a.m.-5:00 p.m.; Sunday, May 19, 7:30 a.m.-5:00 p.m.; Monday through Tuesday, May 20-21, 7:30 a.m.-6:00 p.m.; Wednesday, May 22, 7:30 a.m.-5:00 p.m.; and Thursday, May 23, 7:30 a.m.-2:00 p.m. Tickets for CME Courses not sold by April 13 will be on sale to all registrants beginning at 10:00 a.m. on Saturday, May 18. You must show your registration badge before you can enroll in courses.

## APA ART ASSOCIATION

Located in the APA Resource Center and staffed during the Resource Center's hours. The exhibit includes paintings, photography, ceramics, and crafts done by APA members and/or their significant others. Please stop by the exhibit for information on joining the APA Art Association.

## APA AUXILIARY BOOTH

Located on the Bridge, Level 200, Convention Center. Hours of operation: Saturday, May 18, through Wednesday, May 22, 9:00 a.m.-5:00 p.m. Stop by the booth to obtain information on the Auxiliary's program schedule and information on membership.

## APA PERIODICALS

Complimentary copies of the latest issues of *American Journal of Psychiatry, Psychiatric Services, Psychiatric News, Academic Psychiatry, the American Journal of Geriatric Psychiatry, the Journal of Neuropsychiatry, and Psychosomatics* may be obtained at the APA/APPI Periodicals Exhibit in the APA Resource Center. Staff will sell discounted subscriptions to all APA/APPI journals and demonstrate online access for subscribers. They will also show authors and reviewers how to use Manuscript Central, the new Web-based  
(Continued on next page)

manuscript submission and review system. Staff of the *American Journal of Psychiatry* and *Psychiatric Services* will be available to answer authors' questions. Persons who wish to contact editors or reporters of *Psychiatric News* are asked to leave a message on the message board in the Annual Meetings Office, Room 304, Level 300, Convention Center. Written announcements, suggestions for articles, letters to the editor, or other material for the newspaper's consideration may be left with staff at the Periodicals Exhibit.

### AUDIOTAPES

Audiotapes of most sessions are available shortly after each session concludes and may be purchased at the Mobiltape Booth located on the Bridge, Level 200, in the Convention Center.

### CONTINUING MEDICAL EDUCATION

The APA is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The APA designates this educational activity for up to 66 hours in Category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

**Please note:** Most portions of the scientific program, as outlined below, have been approved for CME credit. The scientific sessions of the official Annual Meeting program, with some exceptions, meet the criteria for Category 1 CME credit. Sessions in the following program formats are designated as Category 1: Advances in Psychopharmacology, Advances in Research, Clinical Case and Continuous Clinical Case Conferences, CME Courses, Forums, Industry-Supported Symposia, most Lectures, some Media Sessions, Medical Updates, New Research Oral/Slide Sessions, Research Advances in Medicine, the Presidential Symposium, Review of Psychiatry, Scientific and Clinical Reports, Symposia, Telecommunication sessions, and Workshops. Other program activities may be considered Category 2: Debate, Discussion Groups, Master Educator Clinical Consultations, New Research Poster Sessions, Research Consultations With, Round Table Discussion, and some Media Sessions, and Lectures. Scientific sessions are open to all Annual Meeting registrants, except for the Clinical Case and Continuous Clinical Case Conferences and the Master Educator Clinical Consultations, which are open to APA members only.

**Please note:** APA members are required to maintain their own records of CME hours. Reporting of CME credit is on an honor basis.

To document CME credit earned at the Annual Meeting, participants should record the sessions they attended on the *Certificate of Attendance* log sheet found in the front of the *2002 Annual Meeting CME Syllabus & Proceedings Summary Book*. Credit is earned on an hour-for-hour basis. A parchment *Certificate of Attendance* is also available.

The *Certificate of Attendance* (or copy) may be forwarded to other organizations requiring verification of participation in the APA Annual Meeting.

The APA requires members to participate in a total of 150 hours of CME activities within a three-year reporting period. At least 60 hours must be in Category 1 activities.

CME report forms may be obtained from the Department of CME at the APA. Staff will be available in the APA Resource Center to answer any of your questions about CME.

### ANNUAL MEETING EVALUATION

The Annual Meeting Scientific Program Committee needs your recommendations and evaluations to plan next year's Annual Meeting. A participant evaluation form is enclosed with your registration packet and includes instructions for completing the form. **BEFORE YOU LEAVE THE MEETING, PLEASE COMPLETE YOUR FORM AND DROP IT IN ONE OF THE EVALUATION BOXES LOCATED THROUGHOUT THE MEETING SITES.** You can

receive a parchment *Certificate of Attendance* at the Annual Meeting by returning your completed form (to the Annual Meetings Office, Information/Locator Center, or APA Resource Center, all located in the Convention Center) or by completing the computerized general evaluation in the APA Resource Center.

### SESSION CAPACITY

We expect "sell out" attendance for many of the scientific sessions. So that all in attendance may benefit, we ask your assistance when overcrowding occurs:

- Please find seating as far forward as possible.
- Move to the center of the row and fill all seats so that chairs are available on aisles for additional attendees.
- Store materials under chairs to maximize seating capacity.
- Overcrowding of meeting rooms may subject the session to shutdown by the Fire Marshal; therefore, we urge all attendees to locate seating rather than stand in aisles or against walls.
- If space does not permit you to attend a session, an audiotape of that session may be available. Please check the order form included in your registration packet.

Thank you for your cooperation.

### TAPE RECORDING AND VISUAL REPRODUCTION POLICIES

Audiotape recording is only permitted for personal use and by members of the media. Registrants are welcome to use their own small, portable audiotape recorders to record any session **except the Master Educator Clinical Consultations, Clinical Case Conferences, and the Continuous Clinical Case Conference, or unless prohibited by the presenters.** Larger professional tape recorders, however, are not permitted other than those utilized by members of the media and personnel representing the professional taping firm authorized by APA to audiotape sessions. The badges of personnel representing this firm and members of the media will clearly identify them. **Non-media registrants are not permitted to videotape any session** because the intrusive nature of the recording may disrupt the session. More detailed guidelines for media representatives may be obtained in the Press Office.

### SMOKING POLICY

There will be **NO SMOKING** in scientific sessions or in the exhibit hall. Smoking will only be permitted in **designated areas.**



### CHILD CARE SERVICE

ACCENT in Children's Arrangements, Inc., the official youth program provider for APA, has planned an exciting on-site children's activity program called Camp APA. Camp APA offers both parents and their children a safe, nurturing, and positive experience. ACCENT's professional, specially-trained supervisors are certified in both CPR and pediatric first aid. The ACCENT staff is comprised of teachers, professional childcare providers, and mothers who simply love working with children and have completed ACCENT's specialized training program. Camp APA is headquartered at the Loews Philadelphia Hotel for the exclusive use of APA registrants and their families. Children aged six months to 17 years are welcome and will be provided with developmentally appropriate programs designed specifically for their age group. Activities will take place on site for all children younger than six years old. The older children will enjoy arts and crafts projects, active games, and much more. Field Trips will depart and return to the on-site Camp APA Activity Center each day. ACCENT provides an exceptional caregiver to child ratio: 1:2 for children 6-12 months; 1:3 for children 13-36 months; 1:5 for children 3-12 years; and 1:8 for children 12 years and older. Please complete the Registration Form to participate in this great opportunity. If you have any questions, please e-mail us at [registration@accentoca.com](mailto:registration@accentoca.com).

## GUIDE TO THE PROGRAM BOOK

Below, you will find the table of contents for ease in locating information about this meeting. A topic index is included to assist you with finding sessions of interest. The individual program for each day's sessions is listed by start time with the formats listed alphabetically under those times. **NOTE: To make it easier for you to plan your day, we have prepared a separate "Days-at-a-Glance," which is included in your registration packet.**

If you have any questions about this book or the scientific sessions, please feel free to stop by the Annual Meetings Office in the Convention Center, and we will be glad to help you. Also, all central office APA staff members will be wearing green ribbons on their badges. Please feel free to direct your questions to them.

## FUTURE APA MEETINGS

### APA ANNUAL MEETINGS

2003 May 17-22	San Francisco, CA
2004 May 1-6	New York, NY
2005 May 21-26	Atlanta, GA

### APA CLINICAL MEETINGS

#### THE INSTITUTE ON PSYCHIATRIC SERVICES

2002 October 9-13	Chicago, IL
2003 October 29-Nov. 2	Boston, MA
2004 October 6-10	Atlanta, GA
2005 October 5-9	San Diego, CA

Tentative program schedules and hotel information for the 2002 Institute on Psychiatric Services are available at the Information/Locator Center, located on the Street Level, Convention Center.

## TABLE OF CONTENTS

Floor Plans for Convention Center, Loews, Marriott, and Wyndham .....	VI-XII
City Map.....	XIII
Special Acknowledgments.....	XIV-XV
Format Descriptions.....	XVI-XVII
Disclosure Information.....	XVIII-XXX
Saturday Sessions.....	1-3
Audiotape Sales Information.....	4
Sunday Sessions.....	5-12
Monday Sessions.....	13-36
Tuesday Sessions.....	37-64
Wednesday Sessions.....	65-86
Thursday Sessions.....	87-98
Topic Index.....	99-112
Participant Index.....	113-123
American Psychiatric Publishing Inc. ....	124-125
Call for 2003 Annual Meeting Papers.....	126
Industry-Supported Symposia.....	127-151
2002 Institute on Psychiatric Services.....	152
APA Resource Center.....	Back Cover

Refer to the *APA Exhibits Guide* for information on: Exhibits, Publishers' Bookfair, Hospitality Lounge, and Dining Facilities in the Convention Center.


The information provided and views expressed by presenters on this program are not necessarily those of the American Psychiatric Association, nor does the American Psychiatric Association warrant the accuracy of any information reported.

©American Psychiatric Association.


# Convention Center

One Convention Place, 1101 Arch Street  
215-418-4700

## Street Level



# Convention Center Level 200








# Loews

1200 Market Street  
215-627-1200

## SECOND FLOOR




## SECOND FLOOR MEZZANINE



## THIRD FLOOR




# Loews




Marriott  
1201 Market Street  
215-62572900-1200

# Level 3




# Marriott Level 4



33,000-SQUARE-FOOT FRANKLIN HALL ACCOMMODATES 165-8' x 10' OR 10' x 10' BOOTHS; 9.5' - 14.5' CEILING HEIGHT.


# Level 5



# Wyndham

17<sup>th</sup> & Race Streets


215-448-2000



# Philadelphia City Map

## PHILADELPHIA AREA MAP KEY

- |                                     |                                 |                                      |                                 |
|-------------------------------------|---------------------------------|--------------------------------------|---------------------------------|
| 1. Buttonwood Square Suites         | 9. Four Points Sheraton Airport | 17. Holiday Inn Express Midtown      | 25. Sheraton Rittenhouse Square |
| 2. Clarion Suites Convention Center | 10. Four Seasons                | 18. Holiday Inn-Independence Mall    | 26. Sheraton Society Hill       |
| 3. Comfort Inn Downtown             | 11. Hampton Inn                 | 19. Loews Hotel                      | 27. Sheraton Suites Airport     |
| 4. Courtyard                        | 12. Hampton Inn Airport         | 20. Marriott                         | 28. Westin                      |
| 5. Crowne Plaza                     | 13. Hawthorne Suites            | 21. Park Hyatt Philadelphia          | 29. Windsor Hotel               |
| 6. Doubletree                       | 14. Hilton Garden Inn           | 22. Radisson Plaza Warwick Hotel     | 30. Wyndham Franklin Plaza      |
| 7. Embassy Suites                   | 15. Hilton Philadelphia Airport | 23. Renaissance Philadelphia Airport |                                 |
| 8. Embassy Suites Airport           | 16. Holiday Inn Airport         | 24. Ritz-Carlton                     |                                 |





# SPECIAL ACKNOWLEDGMENTS

The American Psychiatric Association expresses its deep appreciation for the following:

**Abbott Laboratories:** support of the Industry-Supported Symposia, "Diagnosis and Treatment Issues in Child and Adolescent Bipolar Disorders," Sunday, May 19, 8:00 a.m.; "New Developments in the Treatment of Bipolar Disorder," Sunday, May 19, 7:00 p.m.; and support of the Industry-Supported Breakfast Symposia, "The Pathophysiology and Treatment of Impulsivity and Aggression in Psychiatric Disorders," Wednesday, May 22 and Thursday, May 23, 7:00 a.m.

**American Academy of Psychiatry and the Law:** co-support of the Manfred S. Guttmacher Award Lecture, Sunday, May 19, 2:30 p.m.

**American Association of Psychiatric Administrators:** co-support of the Administrative Psychiatry Award Lecture, Thursday, May 23, 9:00 a.m.

**American Psychiatric Foundation:** co-support of the APA Award for Research in Psychiatry; support of the Disaster Psychiatry Fellowship; and support of the APIRE Practice Research Network (PRN).

**Association of Mental Health Clergy:** co-support of the Oskar Pfister Award Lecture, Wednesday, May 22, 9:00 a.m.

**Association of Women Psychiatrists:** support of the joint AWP/APA Women's Career reception and meeting.

**AstraZeneca Pharmaceuticals:** support of the Industry-Supported Symposia, "Customizing Care for Patients with Bipolar Disorder," Sunday, May 19, 1:30 p.m.; "Molecules of the Mind: The Science of Schizophrenia," Sunday, May 19, 7:00 p.m.; "The Burden of Schizophrenia: Why Patients Don't Get Better," Wednesday, May 22, 7:00 p.m.; the Industry-Supported Breakfast Symposia, "Antipsychotic Pharmacotherapy and the Hippocratic Oath: Above All Do No Harm," Monday, May 20 and Tuesday, May 21, 7:00 a.m.; the George Tarjan Award Lecture, Monday, May 20, 9:00 a.m.; the APA/AstraZeneca Fellowship and reception, Tuesday, May 21, 7:00 p.m.; and support of the American Psychiatric Foundation "Conversations" event, Tuesday, May 21, 5:30 p.m.

**Aventis:** support of the Travel Fellowship for Women Resident Leaders in Psychiatry and Leadership Luncheon, Sunday, May 19, 12:00 p.m.

**Bristol-Myers Squibb:** support of the Industry-Supported Symposia, "Advances in the Treatment of Psychosis: Minimizing the Burden of Disease," Sunday, May 19, 8:00 a.m.; "Challenges and Opportunities in the Management of Psychotic Disorders," Sunday, May 19, 1:30 p.m.; the Industry-Supported Breakfast Symposia, "Novel Antipsychotic Drugs: Advances in the Treatment of Psychotic Spectrum Disorders," Monday, May 20 and Tuesday, May 21, 7:00 a.m.; the Solomon Carter Fuller Award Reception; and the shuttle bus system.

**Center for Mental Health Services:** sponsorship of the APA/CMHS Minority Fellowship Program; support of the APIRE Practice Research Network (PRN); support of the special Annual Meeting series "Access to Quality Care: What Really Works?" and training activities of the AIDS Education Project.

**Center for Abuse Prevention:** support of the special Annual Meeting series "Access to Quality Care: What Really Works?"

**Center for Substance Abuse Treatment:** support of the APIRE Practice Research Network (PRN); and support of the special Annual Meeting series "Access to Quality Care: What Really Works?"

**Cephalon Inc.:** support of the Industry-Supported Symposium, "Identification and Management of Daytime Fatigue and Sleepiness in Psychiatry," Wednesday, May 22, 7:00 p.m.

**Cyberonics, Inc.:** support of the Industry-Supported Symposium, "Long-Term Management of Mood Disorders," Sunday, May 19, 1:30 p.m.

**Eisai Inc., Pfizer Inc.:** support of the Industry-Supported Symposia, "Psychiatry Practice Paradigm: The Emerging Role of the Psychiatrist in Treating Alzheimer's Disease," Saturday, May 18, 7:00 p.m.; and "Explorations in Dementia: New and Current Perspectives," Wednesday, May 22, 7:00 p.m.

**Eli Lilly and Company:** support of the Industry-Supported Symposia, "New Approaches for Treating ADHD: The Whole-Life Perspective," Saturday, May 18, 7:00 p.m.; "Treating Psychotic Illness Across the Life Span: Are Drugs Enough?" Sunday, May 19, 8:00 a.m.; "Primary Mood Stabilizers as the Cornerstone of Treatment for Bipolar Disorder," Sunday, May 19, 7:00 p.m.; "Clinical Differences in Serotonin and Norepinephrine Antidepressant Effects," Tuesday, May 21, 7:00 p.m.; support of the Industry-Supported Breakfast Symposia, "One Size Doesn't Fit All: Depression Therapies for the 21st-Century," Monday, May 20 and Tuesday, May 21, 7:00 a.m.; "Therapeutic Challenges, Novel Approaches: Antipsychotics in the Management of Mood and Anxiety Disorders," Wednesday, May 22 and Thursday, May 23, 7:00 a.m.; the APA/Lilly Resident Research Awards; partial support of the *New Research Abstracts* and *New Research Program Books*; and support of the Daniel Freedman Congressional Fellowship.

**Estate of Kun-Po Soo, M.D., Ph.D.:** support of the Kun-Po Soo Award Lecture, Wednesday, May 22, 11:00 a.m.

**Estate of Agnes Purcell McGavin:** support of the Agnes Purcell McGavin Awards in child and adolescent psychiatry.

**Forest Laboratories, Inc.:** support of the Industry-Supported Symposia, "Molecules and Mood Disorders: Drug Discovery and the Treatment of Depression," Saturday, May 18, 7:00 p.m.; "Late-Life Depression: Old Myths and New Data," Sunday, May 19, 8:00 a.m.; and "Noncholinergic Treatments for Alzheimer's Disease: Present Knowledge, Future Hope," Wednesday, May 22, 7:00 p.m.

**GlaxoSmithKline:** support of the Industry-Supported Symposia, "Bipolar Disorder: New Nationwide Data on Misdiagnosis and Community Costs," Saturday, May 18, 7:00 p.m.; "Recent Developments in the Science and Treatment of PTSD," Sunday, May 19, 1:30 p.m.; "Bipolar Depression and Rapid Cycling: Current Management Strategies," Tuesday, May 21, 7:00 p.m.; "The New Neurobiology of Mood and Anxiety Disorders," Tuesday, May 21, 7:00 p.m.; the Industry-Supported Breakfast Symposia, "Clinical Challenges in Depression," Monday, May 20 and Tuesday, May 21, 7:00 a.m.; "Chronic Episodic Disorders: Comorbidity and Comprehensive Integrated Treatment," Wednesday, May 22 and Thursday, May 23, 7:00 a.m.; the APA/GlaxoSmithKline Fellowship Program; the annual contribution to the APA Presidential Fund; the APA/GlaxoSmithKline Young Faculty Award for Research Development in Biological Psychiatry; and the registration portfolios.

**Harding Foundation:** co-support of the Oskar Pfister Award Lecture, Wednesday, May 22, 9:00 a.m.



# SPECIAL ACKNOWLEDGMENTS

**Ittleson Foundation, Inc.:** support of the Blanche F. Ittleson Award for Research in Child Psychiatry.

**Janssen Pharmaceutica and Research Foundation:** support of the Industry-Supported Symposia, "Antipsychotic Therapy and Cardiovascular Disease: The Unfolding Story," Saturday, May 18, 7:00 p.m.; "The Adherence Challenge: Chronic Issues and Emerging Solutions with Antipsychotic Therapy," Sunday, May 19, 1:30 p.m.; "Managing Aggression Across the Life Span: From the Pediatric to the Geriatric Patient," Tuesday, May 21, 7:00 p.m.; the Industry-Supported Breakfast Symposia, "Breaking the Silence of Children's Mental Illness: National Initiatives, Early Detection, and New Pharmacotherapies," Monday, May 20 and Tuesday, May 21, 7:00 a.m.; "New Perspectives on Schizophrenia Spectrum Disorders and Their Treatment," Wednesday, May 22 and Thursday, May 23, 7:00 a.m.; the reception for Kun-Po Soo Award recipients, Wednesday, May 22; and the American Psychiatric Institute for Research and Education/Janssen Research Scholars on Severe Mental Illness Program.

**Johnson & Johnson:** support of the International Leadership Dinner, Wednesday, May 22, 7:00 p.m.

**Lilly Research Laboratories, a division of Eli Lilly & Company:** support of the APA/Lilly Psychiatric Research Fellowship.

**Merck & Co., Inc.:** support of the William C. Menninger Memorial Convocation Lecture, Monday, May 20, 6:00 p.m.; and an unrestricted educational grant in support of various scientific sessions.

**National Institute of Mental Health:** co-support of the APA/NIMH Vestermark Psychiatry Educator Award Lecture, Tuesday, May 21, 11:00 a.m.; American Psychiatric Institute for Research and Education Annual Meeting activities for research trainees; and the Program for Minority Research Training in Psychiatry (PMRTP).

**National Institute on Drug Abuse:** support of the American Psychiatric Institute for Research and Education/Research Training activities and the Drug Abuse Research Scholars in Psychiatry Program (DARSPP).

**Novartis Pharmaceuticals Corporation:** support of the Industry-Supported Symposium, "Behavioral Disturbances in Dementia: Diagnostic and Treatment Guidelines," Tuesday, May 21, 7:00 p.m.

**Organon Inc.:** support of the Industry-Supported Symposia, "Depressive Subtypes: The Multiple Faces of Depression," Sunday, May 19, 8:00 a.m.; and "The Aging Brain and Vulnerability to Depression," Sunday, May 19, 1:30 p.m.

**Ortho-McNeil Pharmaceuticals:** support of the Industry-Supported Symposium, "Advances in the Understanding and Treatment of Binge-Eating Disorder," Wednesday, May 22, 7:00 p.m.

**Professional Risk Management Services, Inc.:** co-support of the Manfred S. Guttmacher Award Lecture, Sunday, May 19, 2:30 p.m.

**Pfizer Inc.:** support of the Industry-Supported Symposia, "Improving Patient Outcomes Across the Spectrum of Bipolar Disorder," Saturday, May 18, 7:00 p.m.; "Treatment of Anxiety Disorders: Where Are We, and Where Are We Going?" Sunday, May 19, 7:00 p.m.; "Raising Expectations in Schizophrenia: Enhancing Long-Term Outcomes," Tuesday, May 21, 7:00 p.m.; the Industry-Supported Breakfast Symposia, "Age, Gender, and Diagnosis: Influences on Drug Response," Wednesday, May 22 and Thursday, May 23, 7:00 a.m.; the Residents' Session, "Meet the Experts: Sunny-Side Up," Monday, May 20, 7:00 a.m.; the "Abstracts-On-Disk" Program; and the APA *Daily Bulletin* newspaper.

**The Pfizer Pharmaceuticals Group:** support of the International Hospitality Suite, a daily visitor center for international delegates.

**The Psychiatrist's Program, The APA-Endorsed Professional Liability Insurance Program:** support of the ECP luncheon, Tuesday, May 21, 12:00 p.m.

**Roche Laboratories, a member of the Roche Group:** support of the Benjamin Rush Award Lecture, Tuesday, May 21, 9:00 a.m.

**Sanofi-Synthelabo, Inc.:** support of the Residents, Medical Student, and Training Directors Luncheon, Tuesday, May 21, 12:00 p.m.

**Sepracor, Inc.:** support of the Industry-Supported Symposium, "Sleep Disorders and Psychiatric Illnesses: Scientific Foundations," Wednesday, May 22, 7:00 p.m.

**Shire US, Inc.:** support of the Industry-Supported Symposium, "Adult ADHD: From Research to Clinical Practice," Wednesday, May 22, 7:00 p.m.

**Solvay Pharmaceuticals, Inc.:** "Treating Fear: Perspectives on the Biology and Therapy of Anxiety Disorders," Tuesday, May 21, 7:00 p.m.; and the beverage service in the exhibit hall.

**Somerset Pharmaceuticals, Inc.:** support of the Industry-Supported Symposium, "Atypical Depression: Overview and New Developments," Sunday, May 19, 7:00 p.m.

**Substance Abuse and Mental Health Services Administration:** support of the special Annual Meeting series "Access to Quality Care: What Really Works?"

**Wyeth Pharmaceuticals:** support of the Industry-Supported Symposia, "Recovery from Depression: New Perspectives to Improve Outcomes," Sunday, May 19, 8:00 a.m.; "Treatment of Mood and Anxiety Disorders in Women: What Is Evidence and What Is Art?" Sunday, May 19, 7:00 p.m.; the Industry-Supported Breakfast Symposia, "Understanding Sleep Medicine: What the Psychiatrist Needs to Know," Monday, May 20 and Tuesday, May 21, 7:00 a.m.; the APA/Wyeth Pharmaceuticals M.D./Ph.D. Psychiatric Research Fellowship; the Women's Resource Center and Display; the IMG Hospitality Suite; the Alexandra Symonds Award Lecture, Tuesday, May 21, 2:00 p.m.; the Jeanne Spurlock, M.D. Congressional Fellowship; and the daily in-house TV program, "APA News Network."

# FORMAT DESCRIPTIONS

---

## ADVANCES IN PSYCHOPHARMACOLOGY

This three-and-one-half hour session will summarize important new clinical and research findings in the field of psychopharmacology, based in part, on material contained in the *American Psychiatric Publishing Textbook of Psychopharmacology, Second Edition*. Authors of selected chapters from the textbook will present material from the chapters. The topics were selected by the editors to represent areas of clinical psychopharmacology of greatest importance to APA members.

## ADVANCES IN RESEARCH

This two-hour session is traditionally chaired by the Chairperson of the Council on Research and co-chaired by the Chairperson of the Scientific Program Committee. After a brief overview of major advances in research in psychiatry and a preview of selected research presentations scheduled at the Annual Meeting, leading clinical researchers present the latest developments in four different, clinically-relevant areas of research.

## CLINICAL CASE CONFERENCES

During these 90-minute sessions, clinical material is presented by videotape or the treating therapist. One or more experts then discuss the case. **THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.**

## CONTINUOUS CLINICAL CASE CONFERENCES

The presenters will review the progress of psychotherapy in two successive three-hour sessions on consecutive days (Monday-Tuesday and Wednesday-Thursday, beginning at 9:00 a.m.). Audience participation will be encouraged throughout. Participants are requested to attend both sessions in their entirety. **THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.**

## COURSES

Courses are designed to emphasize learning experiences that actively involve participants and include the opportunity for informal exchange with the faculty. Offered in four-hour (half-day) and six-hour (full-day) sessions, courses either review basic concepts in a special subject area or present advanced material on a circumscribed topic. Enrollment is limited, and participants must purchase tickets to attend.

## DEBATE

Experts in the field, including psychiatrists and nonpsychiatrists, will debate a controversial topic in psychiatry. The debate format allows for members to hear both pro and con views about important, interesting and timely concerns for our members. Someone who has expertise in the topic area moderates the debate. A portion of the time is allocated for questions from the audience to the presenters with active participation by participants.

## DISCUSSION GROUPS

This 90-minute format allows small groups to meet informally with selected experts in psychiatry to discuss topics chosen by the experts. Some of these are reserved for residents only. These sessions are limited to 25 participants on a first-come, first-served basis.

## FORUMS

These are flexible presentations that afford an opportunity to highlight and select topics that are of timely interest to psychiatrists. Speakers and panel members are chosen for their expertise and leadership in the field.

## LECTURES

Lectures feature a small number of distinguished speakers discussing scientific and cultural topics, many of which will extend our understanding beyond the usual limits of clinical psychiatry. The Scientific Program Committee invites the lecturers.

## MASTER EDUCATOR CLINICAL CONSULTATIONS

These 90-minute, clinically-based seminars are presented by outstanding educators. Formats and subject matter will vary, but all will utilize clinical material offered by participants. These sessions are limited to 25 participants on a first-come, first-served basis. **THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.**

## MEDIA SESSIONS

In these sessions, a videotape of educational value is shown. Videotapes may illustrate innovation in: patient assessment, diagnosis, treatment, and education; practice management, medical records, information systems, and research; professional education; public awareness and education; psychiatric interpretations of meaning in media; assessment of the biopsychosocial effects of media on individuals; social/cultural issues and mental health/illness; and the human spirit as seen in the arts and humanities.

## MEDICAL UPDATES

These 90-minute sessions are designed to provide psychiatrists with the latest clinical developments in other areas of medicine. Topics may range from subspecialty areas of adult or pediatric medicine (infectious disease, cardiology, gastroenterology, etc.) to new techniques or procedures in surgery or radiology. The interface between psychiatry and these areas is not necessarily emphasized. The intent is to give participants an update from a physician in a particular specialty.

## NEW RESEARCH

This format allows for presentation of the very recent findings obtained from ongoing research. The three types of presentations include: Posters, which are visual, self-explanatory presentations; and Young Investigators' Posters, with presentations from young investigators, residents, medical students, and research or clinical fellows; and Young Investigators' Oral/Slide which are fifteen-minute presentations with three minutes for discussion.

## RESEARCH ADVANCES IN MEDICINE

This two-hour format presents an overview of cutting-edge research in various aspects of medicine. In contrast to the Medical Update series, which is more clinically focused, this session will help participants keep pace with the rapidly expanding knowledge base and technology in various branches of medicine. Several speakers, authorities in their fields, will present on their topics.

# FORMAT DESCRIPTIONS

---

## RESEARCH CONSULTATIONS WITH

This 90-minute format provides an opportunity, in a small group setting, for participants to obtain consultations around problems in research from outstanding senior researchers. Participants should come prepared to present a specific problem in research, whether it's one of research design, methodology, subject selection or data analysis, etc., which could be presented briefly to the consultant. These sessions are limited to 25 participants on a first-come, first-served basis.

## REVIEW OF PSYCHIATRY

There will be four, three-and-one-half hour sessions presented, based on the annual American Psychiatric Press Review of Psychiatry Series. Each session includes an abridged presentation by the senior author from each of the chapters in each volume. The topics were selected by the overall editors of the series to represent current areas of new research, new developments in clinical care, and special issues of importance to APA members.

## ROUNDTABLE

This 90-minute format is designed to establish a dialogue between psychiatrists and other citizens about controversial issues of special interest to our profession. The moderator presents a panel of experts with hypothetical scenarios that highlight controversial and problematic situations with which psychiatrists interface.

## SCIENTIFIC AND CLINICAL REPORT SESSIONS

Scientific and Clinical Reports are oral presentations of papers prepared for submission before publication. In this 90-minute format, reports are grouped by topic, with floor discussion from the audience following the presentation of each paper. There is no formal discussant.

## TELECOMMUNICATION SESSIONS

These three-hour sessions are presented in a computer software demonstration format (i.e., on computer and LCD projector provided for projection on a large screen). Topic areas include telepsychiatry, virtual reality, internet, electronic medical records, and information technology.

## SYMPOSIA

Symposia are three-hour sessions consisting of four to six presentations that are thematically linked and focus on a specific topic relevant to clinical psychiatry. They are designed to provide comprehensive treatment of a topic or discussion of the topic from several points of view by the participants and stimulate discussion with the audience. Some symposia are supported by industry and are designated as "Industry-Supported Symposium" in this *Program Book*.

## WORKSHOPS

Workshops are 90-minute sessions, which typically involve brief presentations from individual panel members, followed by the opportunity for lively and informative discussion. This format provides for substantial audience participation and should be highly interactive.

# AMERICAN PSYCHIATRIC ASSOCIATION

## CONTINUING MEDICAL EDUCATION POLICY ON FULL DISCLOSURE

The American Psychiatric Association requires disclosure by presenters at CME activities of any significant financial or other affiliation with commercial goods/organization(s) that may have a direct or indirect interest in the subject matter of the scientific program. A "financial interest" may include, but is not limited to, being a shareholder in the organization; being on retainer with the organization; or having research or honoraria paid by the organization. An "affiliation" may include holding a position on an advisory committee or some other role or benefit to a supporting organization. The existence of such relationships does not necessarily constitute a conflict of interest, but the prospective audience must be informed of the presenter's affiliation with every commercial supporter by an acknowledgement in the printed program and oral or visual disclosure to participants at the session (disclosure by slide or overhead is required if audiovisual equipment is used for the presentation). This policy is intended to openly identify any potential conflict(s) so that members of the audience in an educational activity are able to form their own judgments about the presentation. The APA also requires oral disclosure of discussion of unapproved uses of a commercial product or investigational use of a product not yet approved for this purpose.

The following presenters have indicated a significant financial interest or other affiliation with a commercial supporter of the session and/or with the manufacturer(s) of a commercial product(s) and/or provider of commercial service(s). The presenter's name, the manufacturer's name, and the page number(s) the presenter appears on in this *Program Book* are listed below:

Presenter	Manufacturer(s)	Program Page #
Gene G. Abel, M.D.	Abel Screening, Inc.	67
Lenard A. Adler, M.D.	Eli Lilly and Company; Alza Pharmaceuticals; GlaxoSmithKline	3
Hagop S. Akiskal, M.D.	Janssen Pharmaceutica and Research Foundation; Lilly Research Laboratories, a division of Eli Lilly and Company; Abbott Laboratories	33, 56
George S. Alexopoulos, M.D.	Forest Laboratories, Inc.; National Institute of Mental Health; Lilly Research Laboratories, a division of Eli Lilly and Company; Pfizer Inc.; GlaxoSmithKline; AstraZeneca Pharmaceuticals; Janssen Pharmaceutica and Research Foundation	5, 30
Albert J. Allen, M.D.	Eli Lilly and Company (employer)	3
Anne Alonso, Ph.D.	Eli Lilly and Company	6
Jonathan E. Alpert, M.D.	Abbott Laboratories; Bristol-Myers Squibb; Cyberonics; Eli Lilly and Company; GlaxoSmithKline; Lichtwer Pharma; Novartis Pharmaceuticals Corporation; Organon Inc.; Pfizer Inc.; Pharmacia Corporation; Roche Laboratories, a member of the Roche Group; Sanofi Pharmaceuticals, Inc.; Solvay Pharmaceuticals, Inc.; Synthelabo; Wyeth Pharmaceuticals	61
Jay D. Amsterdam, M.D.	Eli Lilly and Company; Somerset Pharmaceuticals, Inc.; Pfizer Inc.; Organon Inc.; Forest Laboratories, Inc.; Merck & Co., Inc.; Wyeth Pharmaceuticals; GlaxoSmithKline; Biopharm; Organon Inc.	96
Jose C. Appolinario, M.D.	Knoll Pharmaceutical Company	32
Ralph Aquila, M.D.	Eli Lilly and Company	6
Kimberly A. Arlinghaus, M.D.	Pfizer Inc.; Lilly Research Laboratories, a division of Eli Lilly and Company; Forest Laboratories, Inc.; Wyeth Pharmaceuticals; Janssen Pharmaceutica and Research Foundation; Bristol-Myers Squibb; AstraZeneca Pharmaceuticals; Abbott Laboratories; Cephalon, Inc.	5
Jorge L. Armenteros, M.D.	Janssen Pharmaceutica and Research Foundation	63
Peter M. Aupperle, M.D.	Pfizer Inc.; Novartis Pharmaceuticals Corporation; Janssen Pharmaceutica and Research Foundation	7
Robert W. Baker, M.D.	Eli Lilly and Company	24, 75
Benjamin H. K. Balderson, Ph.D.	Group Health Cooperative (employer)	59
Richard Balon, M.D.	Bristol-Myers Squibb; GlaxoSmithKline; Pfizer Inc.; Novartis Pharmaceuticals Corporation; Lilly Research Laboratories, a division of Eli Lilly and Company; Forest Laboratories, Inc.; Parke-Davis, Division of Warner-Lambert Company; Organon Inc.; Solvay Pharmaceuticals, Inc.; Wyeth Pharmaceuticals; Merck & Co., Inc.	97
Paul J. Barreira, M.D.	Eli Lilly and Company	6
Gail M. Barton, M.D.	Wyeth Pharmaceuticals	19
Mark S. Bauer, M.D.	Novartis Pharmaceuticals Corporation; GlaxoSmithKline; Solvay Pharmaceuticals, Inc.	59
Philip M. Becker, M.D.	Cephalon, Inc.	49
Bernard D. Beitman, M.D.	Pfizer Inc.; GlaxoSmithKline	8, 29
Ruth M. Benca, M.D.	Wyeth Pharmaceuticals; Cephalon, Inc.; Sanofi Pharmaceuticals, Inc.; National Institute of Mental Health; Merck & Co., Inc.; Sepracor, Inc.	85
Joseph Biederman, M.D.	Shire U.S., Inc.; Gliatec, Inc.; Cephalon, Inc.; GlaxoSmithKline; Eli Lilly and Company; Alza Pharmaceuticals; Pfizer Inc.; Wyeth Pharmaceuticals	86
Bradley F. Boeve, M.D.	Pfizer Inc.; Eisai Inc.	86
Howard E. Book, M.D.	American Psychiatric Press Inc.	27, 50
Soo Borson, M.D.	Janssen Pharmaceutica and Research Foundation; Pfizer Inc.; Forest Laboratories, Inc.; Wyeth Pharmaceuticals	63

## DISCLOSURE INDEX

Presenter	Manufacturer(s)	Program Page #
Charles L. Bowden, M.D.	Abbott Laboratories; AstraZeneca Pharmaceuticals; Bristol-Myers Squibb; GlaxoSmithKline; Janssen Pharmaceutica and Research Foundation; Lilly Research Laboratories, a division of Eli Lilly and Company; National Institute of Mental Health; Parke-Davis, Division of Warner-Lambert Company; Pfizer Inc.; R.W. Johnson Pharmaceutical Institute; Sanofi Pharmaceuticals, Inc.; Stanley Foundation; UCB Pharma, Inc.	8, 11
Kathleen T. Brady, M.D.	Pfizer Inc.; Abbott Laboratories; Lilly Research Laboratories, a division of Eli Lilly and Company; GlaxoSmithKline; Bristol-Myers Squibb	37, 55, 87
George Brainard, Ph.D.	Bio-Brite, Inc; Philips	8
Olga Brawman-Mintzer, M.D.	AstraZeneca Pharmaceuticals; Eli Lilly and Company; Pfizer Inc.; Janssen Pharmaceutica and Research Foundation	87
Alan F. Breier, M.D.	Eli Lilly and Company	95
William Breitbart, M.D.	Janssen Pharmaceutica and Research Foundation; Johnson and Johnson; Ortho-Biotech; Bristol-Myers Squibb; Eli Lilly and Company	29
Lawrence Brown, M.D.	GlaxoSmithKline; AGVRON	44
Thomas E. Brown, Ph.D.	Alza Pharmaceuticals; American Psychiatric Press Inc.; Cephalon, Inc.; Eli Lilly and Company; GlaxoSmithKline; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Shire U.S., Inc.; The Psychological Corporation; Yale University Press	1, 3, 78
Peter F. Buckley, M.D.	AstraZeneca Pharmaceuticals; Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; Novartis Pharmaceuticals Corporation	86, 96
Kathryn A. Burns, M.D.	Eli Lilly and Company	69
George Bush, M.D.	Pfizer Inc.; Eli Lilly and Company; Shire U.S., Inc.	86
Ira R. Byock, M.D.	Purdue; Pfizer Inc.; Janssen Pharmaceutica and Research Foundation; Knoll	70
Joseph R. Calabrese, M.D.	National Institute of Mental Health; Abbott Laboratories; Ciba Geigy Corporation, Pharmaceutical Division; Merck & Co., Inc.; Forest Laboratories, Inc.; GlaxoSmithKline; Lilly Research Laboratories, a division of Eli Lilly and Company; MacArthur Foundation; National Alliance for Research in Schizophrenia and Affective Disorders; Parke-Davis, Division of Warner-Lambert Company; Robert Wood Johnson Pharmaceutical Research Institute; Sandoz Pharmaceuticals Corporation; Stanley Foundation; TAP Pharmaceuticals; UCB Pharma; Wyeth Pharmaceuticals; AstraZeneca Pharmaceuticals; Elan Pharmaceuticals; Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; Novartis Pharmaceuticals Corporation; Shire U.S., Inc.; Teva Pharmaceuticals	3, 5, 63
Lori Calabrese, M.D.	GlaxoSmithKline; Lilly Research Laboratories, a division of Eli Lilly and Company; Wyeth Pharmaceuticals; Pfizer Inc.; Abbott Laboratories; Bristol-Myers Squibb	37
Joshua W. Calhoun, M.D.	Novartis Pharmaceuticals Corporation; Eli Lilly and Company; Bristol-Myers Squibb; Organon Inc.; GlaxoSmithKline; Janssen Pharmaceutica and Research Foundation; AstraZeneca Pharmaceuticals	80
Linda L. Carpenter, M.D.	Corcept; Pfizer Inc.; Forest Laboratories, Inc.; Merck & Co., Inc.; Cyberonics; Organon Inc.; Abbott Laboratories; Parke-Davis, Division of Warner-Lambert Company; GlaxoSmithKline	6, 11, 52
Diana Carter, M.B.	GlaxoSmithKline	8
William P. Carter, M.D.	Eli Lilly and Company; Wyeth Pharmaceuticals; Ortho-McNeil Pharmaceuticals	86
Daniel E. Casey, M.D.	Abbott Laboratories; AstraZeneca Pharmaceuticals; Lilly Research Laboratories, a division of Eli Lilly and Company; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Janssen Pharmaceutica and Research Foundation	64, 65
David Castle, M.D.	Eli Lilly and Company	55
Patrizia A. Cavazzoni, M.D.	Eli Lilly and Company (employer)	47
Carlyle H. Chan, M.D.	Medscape	38, 52
Kiki D. Chang, M.D.	Abbott Laboratories; Eli Lilly and Company; Solvay Pharmaceuticals, Inc.	5
Kyong-Mi Chang, M.D.	Wyeth Pharmaceuticals; Vivopharma	44
Dennis S. Charney, M.D.	AstraZeneca Pharmaceuticals; Abbott Laboratories; Bristol-Myers Squibb; Cyberonics; Dov Pharmaceuticals; Eli Lilly and Company; Forest Laboratories, Inc.; Infosciber; Janssen Pharmaceutica and Research Foundation; Merck & Co., Inc.; Mindsense; Mitsubishi Chemical; Novartis Pharmaceuticals Corporation; Organon Inc.; Pfizer Inc.; Pharmacia Corporation; R.W. Johnson Pharmaceutical Research Institute; Sepracor, Inc.; Skila; GlaxoSmithKline; Somerset Pharmaceuticals, Inc.; Solvay Pharmaceuticals, Inc.; Velva Pharmaceuticals	34, 97
Joseph A. Cheong, M.D.	Janssen Pharmaceutica and Research Foundation; Pfizer Inc.; Wyeth Pharmaceuticals	25, 51
James C.Y. Chou	Pass the Boards, Inc.	15
Leslie L. Citrome, M.D.	Novartis Pharmaceuticals Corporation; Lilly Research Laboratories, a division of Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; AstraZeneca Pharmaceuticals; Abbott Laboratories; Pfizer Inc.	30
Anita H. Clayton, M.D.	Corcept; Forest Laboratories, Inc.; GlaxoSmithKline; Organon Inc.; Pfizer Inc.; Pharmacia Corporation; Eli Lilly and Company; Bristol-Myers Squibb; Organon, Inc.	65
Judith A. Cohen, M.D.	Pfizer Inc.	71, 94, 95
Lee S. Cohen, M.D.	Forest Laboratories, Inc.; Janssen Pharmaceutica and Research Foundation; Eli Lilly and Company; Organon Inc.; Pfizer Inc.; GlaxoSmithKline; Wyeth Pharmaceuticals; Solvay Pharmaceuticals, Inc.	11, 23, 57

## DISCLOSURE INDEX

Presenter	Manufacturer(s)	Program Page #
Steven A. Cole, M.D.	Eli Lilly and Company; Pfizer Inc.	60
Robert R. Conley, M.D.	AstraZeneca Pharmaceuticals; Janssen Pharmaceutica and Research Foundation; IVAX Pharmaceuticals; Novartis Pharmaceuticals Corporation; Eli Lilly and Company	63, 96
Kathryn M. Connor, M.D.	Pfizer Inc.; Eli Lilly and Company; PureWorld Botanicals; Ancile Pharmaceuticals; GlaxoSmithKline	8
Barbara Cornblatt, Ph.D.	Otsuka Pharmaceuticals; Janssen Pharmaceutica and Research Foundation	65, 87
Paul T. Costa, Jr., Ph.D.	Neo Five-Factor Inventory	82
Andrew J. Cutler, M.D.	Abbott Laboratories; AstraZeneca Pharmaceuticals; Bristol-Myers Squibb; Janssen Pharmaceutica and Research Foundation; Lilly Research Laboratories, a division of Eli Lilly and Company; Pfizer Inc.; Novartis Pharmaceuticals Corporation; Forest Laboratories, Inc.; Shire U.S., Inc.; Otsuka Pharmaceuticals; Sumitomo; Wyeth Pharmaceuticals; GlaxoSmithKline	6
Daniella David, M.D.	Janssen Pharmaceutica and Research Foundation	55
Jonathan R.T. Davidson, M.D.	Pfizer Inc.; American Home Products; GlaxoSmithKline; Proctor and Gamble; Triangle Pharmaceuticals; Solvay Pharmaceuticals, Inc.; Forest Laboratories, Inc.; Eli Lilly and Company; Ancile; Roche Laboratories, a member of the Roche Group; Novartis Pharmaceuticals Corporation; Wyeth Pharmaceuticals; Organon Inc.; PureWorld; Schwabe; MultiHealth Systems, Inc., Guilford Publications; American Psychiatric Association	8, 64
Jonathan S. Davine, M.D.	Solvay Pharmaceuticals, Inc.; GlaxoSmithKline; Pfizer Inc.; Lundbeck; Janssen Pharmaceutica and Research Foundation; AstraZeneca Pharmaceuticals; Eli Lilly and Company; Wyeth Pharmaceuticals	71
Kenneth L. Davis, M.D.	Janssen Pharmaceutica and Research Foundation; Lilly Research Laboratories, a division of Eli Lilly and Company; Abbott Laboratories; Mitsubishi; Scirex	12
Denise De Guzman, M.D.	Pharmacia Corporation	77
Deborah Deas, M.D.	Bristol-Myers Squibb; Pfizer Inc.	58
Pedro L. Delgado, M.D.	National Institute of Mental Health; Bristol-Myers Squibb; Eli Lilly and Company; GlaxoSmithKline; Organon Inc.; Otsuka Pharmaceuticals; Pharmacia Corporation; Solvay Pharmaceuticals, Inc.; Wyeth Pharmaceuticals; Janssen Pharmaceutica and Research Foundation; Boehringer Ingelheim; Forest Laboratories, Inc.; Parke-Davis, Division of Warner-Lambert Company; Pfizer Inc.; Novartis Pharmaceuticals Corporation; AstraZeneca Pharmaceuticals	64
Davangere P. Devanand, M.D.	Pfizer Inc.; Eli Lilly and Company; Wyeth Pharmaceuticals; Pfizer Inc.	30
C. Lindsay DeVane, Pharm.D.	Eli Lilly and Company; Wyeth Pharmaceuticals; AstraZeneca Pharmaceuticals; GlaxoSmithKline; Janssen Pharmaceutica and Research Foundation; Bristol-Myers Squibb; Forest Laboratories, Inc.	2
Mantosh J. Dewan, M.D.	Pfizer Inc.; Lilly Research Laboratories, a division of Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation	38
David F. Dinges, Ph.D.	Cephalon, Inc.	86
Karl Doghramji, M.D.	Sanofi Pharmaceuticals, Inc.; Eli Lilly and Company; Wyeth Pharmaceuticals; Cephalon, Inc.	13, 23, 27, 86
Rachelle S. Doody, M.D.	Eisai Inc.; Pfizer Inc.; Janssen Pharmaceutica and Research Foundation; Merz; Forest Laboratories, Inc.; Fujisawa; Elan Pharmaceuticals	85
P. Murali Doraiswamy, M.D.	Eisai Inc.; Pfizer Inc.; Novartis Pharmaceuticals Corporation; Janssen Pharmaceutica and Research Foundation; GlaxoSmithKline; Elan Pharmaceuticals; Wyeth Pharmaceuticals; Lilly Research Laboratories, a division of Eli Lilly and Company; Merck & Co., Inc.; National Institutes of Health; Forest Laboratories, Inc.; Lundbeck	64
Robert T. Dunn, M.D.	Novartis Pharmaceuticals Corporation	90
David L. Dunner, M.D.	Eli Lilly and Company; Pfizer Inc.; GlaxoSmithKline; Wyeth Pharmaceuticals; Bristol-Myers Squibb; Forest Laboratories, Inc.; Mitsubishi; Cyberonics; Pharmacia Corporation; Organon Inc.	13, 33, 37, 47
Steven A. Epstein, M.D.	Pfizer Inc.; AstraZeneca Pharmaceuticals	49
Milton K. Erman, M.D.	Searle; Pharmacia Corporation; Wyeth Pharmaceuticals; Pfizer Inc.; Takeda Pharmaceuticals; Neurocrine Biosciences; Orphan Medical; Sepracor, Inc.; Resmed Sanofi Pharmaceuticals, Inc.; Cephalon, Inc.; Forest Laboratories, Inc.	13, 37
Javier I. Escobar, M.D.	Pfizer Inc.; Bristol-Myers Squibb; Wyeth Pharmaceuticals; Johnson and Johnson	1
Raymond A. Faber, M.D.	Janssen Pharmaceutica and Research Foundation; Pfizer Inc.	1, 5
Stephen V. Faraone, Ph.D.	Alza Pharmaceuticals; Shire U.S., Inc.; Wyeth Pharmaceuticals; Janssen Pharmaceutica and Research Foundation; Eli Lilly and Company; GlaxoSmithKline; SG Cowan	86
Martin K. Farlow, M.D.	Novartis Pharmaceuticals Corporation	64
Maurizio Fava, M.D.	Eli Lilly and Company; GlaxoSmithKline; Pfizer Inc.; Wyeth Pharmaceuticals; Organon Inc.; Bristol-Myers Squibb; Pharmacia Corporation; Solvay Pharmaceuticals, Inc.; Forest Laboratories, Inc.; Sanofi Pharmaceuticals, Inc.; Janssen Pharmaceutica and Research Foundation; Lundbeck; Knoll Pharmaceuticals; Parke-Davis, Division of Warner-Lambert Company; Somerset Pharmaceuticals, Inc.; Pharmavite; Abbott Laboratories; Roche Laboratories, a member of the Roche Group; Novartis Pharmaceuticals Corporation; Lorex Pharmaceuticals; Lichtwer Pharma	6, 13
Jan A. Fawcett, M.D.	National Institute of Mental Health; Abbott Laboratories; Bristol-Myers Squibb; GlaxoSmithKline; Eli Lilly and Company; Pfizer Inc.; Theodore and Vada Stanley Foundation; Wyeth Pharmaceuticals; Forest Laboratories, Inc.; Merck & Co., Inc.; Parke-Davis, Division of Warner-Lambert Company; Pharmacia Corporation; Solvay Pharmaceuticals, Inc.	29, 96
Joel S. Feiner, M.D.	Eli Lilly and Company; Telecare	32



## DISCLOSURE INDEX

Presenter	Manufacturer(s)	Program Page #
Stephen J. Ferrando, M.D.	Merck & Co., Inc.; Pfizer Inc.	29, 61
Howard Fillit, M.D.	Pfizer Inc.; Novartis Pharmaceuticals Corporation	92
Robert L. Findling, M.D.	Abbott Laboratories; Solvay Pharmaceuticals, Inc.; Janssen Pharmaceutica and Research Foundation; Lilly Research Laboratories, a division of Eli Lilly and Company; AstraZeneca Pharmaceuticals; Bristol-Myers Squibb; Pfizer Inc.; Somerset Pharmaceuticals, Inc.; Shire U.S., Inc.; GlaxoSmithKline; Wyeth Pharmaceuticals; Organon Inc.; Forest Laboratories, Inc.	5, 14, 38
Mara J. Fiorentino, M.D.	Eli Lilly and Company	71
Kathleen M. Fisher, Ph.D.	Pfizer Inc.; Organon Inc.; Novartis Pharmaceuticals Corporation; Lilly Research Laboratories, a division of Eli Lilly and Company; AstraZeneca Pharmaceuticals; Janssen Pharmaceutica and Research Foundation; Wyeth Pharmaceuticals; Manor Health Care; Abbott Laboratories; Bristol-Myers Squibb; Organon Inc.	80
Marc Fishman, M.D.	Potomac Healthcare Foundation; Mortain Manor Treatment Center	84
Lois T. Flaherty, M.D.	Merck & Co., Inc.; Pfizer Inc.	39, 89
Lyle B. Forehand, Jr., M.D.	GlaxoSmithKline	25
Richard J. Frances, M.D.	Abbott Laboratories; Forest Laboratories, Inc.; Schering Plough; Merck & Co., Inc.; Organon Inc.; Pfizer Inc.; Pharmacia Corporation; Suburban Hill Hospital	44
Ellen Frank, Ph.D.	Pfizer Inc.; Forest Laboratories, Inc.; Eli Lilly and Company; National Institute of Mental Health	3, 13, 96
W. Gordon Frankle, M.D.	Janssen Pharmaceutica and Research Foundation; AstraZeneca Pharmaceuticals	8
Jean A. Frazier, M.D.	Eli Lilly and Company	6
Robert Freedman, M.D.	AstraZeneca Pharmaceuticals	12
Matthew J. Friedman, M.D.	Pfizer Inc.; GlaxoSmithKline	71
Mark A. Frye, M.D.	Abbott Laboratories; Eli Lilly and Company; GlaxoSmithKline; Novartis Pharmaceuticals Corporation; Ortho-McNeil Pharmaceuticals; Janssen Pharmaceutica and Research Foundation; Pfizer Inc.; Cephalon, Inc.	2, 3, 5, 34, 63
Glen O. Gabbard, M.D.	Merck & Co., Inc.	33, 56
Joseph Gal, Ph.D.	Forest Laboratories, Inc.	2
David R. Gastfriend, M.D.	Dupont Pharma; Purdue Pharma; Bristol-Myers Squibb; CSAT; State of Oklahoma; Earley Corporation	33
Alan J. Gelenberg, M.D.	Cyberonics; Bristol-Myers Squibb; Pfizer Inc.; Lilly Research Laboratories, a division of Eli Lilly and Company; Wyeth Pharmaceuticals; Hoechst Marion Roussel; Vela Pharmaceuticals; Best Practice; Novartis Pharmaceuticals Corporation; AstraZeneca Pharmaceuticals; GlaxoSmithKline	60, 81
Mark S. George, M.D.	Cyberonics; MagStim; Netonics; Dontec; Medtronic	9, 15, 81
S. Nassir Ghaemi, M.D.	Janssen Pharmaceutica and Research Foundation; AstraZeneca Pharmaceuticals; Novartis Pharmaceuticals Corporation; Abbott Laboratories; GlaxoSmithKline; Forest Laboratories, Inc.; Eli Lilly and Company	33, 62, 65, 88
Leslie H. Gise, M.D.	Merck Medco Managed Care	23, 70
Michael J. Gitlin, M.D.	Wyeth Pharmaceuticals; Lilly Research Laboratories, a division of Eli Lilly and Company; Pfizer Inc.; Forest Laboratories, Inc.; Janssen Pharmaceutica and Research Foundation; GlaxoSmithKline	90
Alexander H. Glassman, M.D.	Pfizer Inc.; GlaxoSmithKline; Lilly Research Laboratories, a division of Eli Lilly and Company; Sanofi Pharmaceuticals, Inc.; Organon Inc.	65, 87
Donald C. Goff, M.D.	Eli Lilly and Company; Pfizer Inc.; Janssen Pharmaceutica and Research Foundation; Cortex Pharmaceuticals; AstraZeneca Pharmaceuticals	3
R. Rao Gogineni, M.D.	Devereux Foundation	31, 84
Joseph F. Goldberg, M.D.	AstraZeneca Pharmaceuticals; Bristol-Myers Squibb; Eli Lilly and Company; Forest Laboratories, Inc.; Abbott Laboratories; GlaxoSmithKline; Janssen Pharmaceutica and Research Foundation; Novartis Pharmaceuticals Corporation; R.W. Johnson; Shire U.S., Inc.; Pharmacia Corporation	11, 33, 62, 63
Stephen M. Goldfinger, M.D.	IVAX Pharmaceuticals; Janssen Pharmaceutica and Research Foundation; Lilly Research Laboratories, a division of Eli Lilly and Company; Pfizer Inc.; Mallinkrodt; AstraZeneca Pharmaceuticals	35, 71, 89
Karl Goodkin, M.D.	Advanced Immunity, Inc.; GlaxoSmithKline; Pharmacia Corporation; Merck & Co., Inc.; Cambridge University Press	29, 61, 89
Marianne Goodman, M.D.	Janssen Pharmaceutica and Research Foundation	84, 87
Paul J. Goodnick, M.D.	Lilly Research Laboratories, a division of Eli Lilly and Company; Pfizer Inc.; AstraZeneca Pharmaceuticals; GlaxoSmithKline	47
Frederick K. Goodwin, M.D.	Abbott Laboratories; GlaxoSmithKline; Solvay Pharmaceuticals, Inc.; Pfizer Inc.; Eli Lilly and Company; Scios Nova Pharmaceuticals; Janssen Pharmaceutica and Research Foundation; AstraZeneca Pharmaceuticals	33, 62, 90
Guy M. Goodwin, M.D.	AstraZeneca Pharmaceuticals	8, 11

## DISCLOSURE INDEX

Presenter	Manufacturer(s)	Program Page #
Jack M. Gorman, M.D.	Eli Lilly and Company; National Institute of Mental Health; NARSAD; Pfizer Inc.; Eli Lilly and Company; Bristol-Myers Squibb; Wyeth Pharmaceuticals; GlaxoSmithKline; AstraZeneca Pharmaceuticals; Janssen Pharmaceutica and Research Foundation; Organon Inc.; Forest Laboratories, Inc.; Lundbeck; Solvay Pharmaceuticals, Inc.; Merck & Co., Inc.; Sanofi Pharmaceuticals, Inc.; UCB Pharma; Purdue; Aventis; Xenova	3, 63
Elizabeth Gould, Ph.D.	GlaxoSmithKline	63
Tana A. Grady-Weliky, M.D.	Pfizer Inc.; Eli Lilly and Company; GlaxoSmithKline	65
Kevin F. Gray, M.D.	Novartis Pharmaceuticals Corporation; Lilly Research Laboratories, a division of Eli Lilly and Company; Pfizer Inc.; Janssen Pharmaceutica and Research Foundation	5
Laurence L. Greenhill, M.D.	Alza Pharmaceuticals; Johnson and Johnson; Celltech; Noven Pharmaceuticals; Novartis Pharmaceuticals Corporation; Shire U.S., Inc.; Somerset Pharmaceuticals, Inc.	83, 98
John H. Greist, M.D.	Abbott Laboratories; GlaxoSmithKline; Janssen Pharmaceutica and Research Foundation; Lilly Research Laboratories, a division of Eli Lilly and Company; Organon Inc.; Pfizer Inc.; Sanofi Pharmaceuticals, Inc.; Solvay Pharmaceuticals, Inc.; Pharmacia Corporation; Wyeth Pharmaceuticals; Bristol-Myers Squibb; Forest Laboratories, Inc.; Hoffman-LaRoche; Novartis Pharmaceuticals Corporation	64
Nichole D. Grier, M.D.	Bristol-Myers Squibb	70
Mark S. Groves, M.D.	GlaxoSmithKline	22
Robert E. Hales, M.D.	Bristol-Myers Squibb; Forest Laboratories, Inc.; GlaxoSmithKline	13, 37
Ellen Haller, M.D.	Pfizer Inc.; Bristol-Myers Squibb	52, 76
Mark B. Hamner, M.D.	AstraZeneca Pharmaceuticals; Lilly Research Laboratories, a division of Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; Bristol-Myers Squibb	55
Roger F. Haskett, M.D.	Eli Lilly and Company; GlaxoSmithKline; Forest Laboratories, Inc.; Pfizer Inc.; Wyeth Pharmaceuticals	23
Keith A. Hawkins, Psy.D.	Eli Lilly and Company	95
Stephen H. Heidel, M.D.	Integrated Insights (employer)	7
Howard A. Heit, M.D.	Purdue Pharma; McNeil Pharmaceutical; Abbott Laboratories	62
David J. Hellerstein, M.D.	Pfizer Inc.; Eli Lilly and Company; GlaxoSmithKline; Bristol-Myers Squibb; Forest Laboratories, Inc.; Dista Products; Wyeth Pharmaceuticals; Merck & Co., Inc.; National Institute of Mental Health; National Institute on Drug Abuse	92
David C. Henderson, M.D.	Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; Pfizer Inc.; AstraZeneca Pharmaceuticals	37, 64
John P. Hendrick, M.D.	AstraZeneca Pharmaceuticals; Forest Laboratories, Inc.; GlaxoSmithKline; Lilly Research Laboratories, a division of Eli Lilly and Company; Pfizer Inc.; Organon Inc.; Wyeth Pharmaceuticals	48
Scott W. Henggeler, Ph.D.	MST Services, Inc.	95
Charles H. Hennekens, M.D.	Pfizer Inc.	64
Paula L. Hensley, M.D.	Janssen Pharmaceutica and Research Foundation; Pfizer Inc.; Eli Lilly and Company; Forest Laboratories, Inc.; Wyeth Pharmaceuticals; Abbott Laboratories; Novartis Pharmaceuticals Corporation; Parke-Davis, Division of Warner-Lambert Company	77
Jerrold W. Hill, Ph.D.	Pfizer Inc.	92
Robert M.A. Hirschfeld, M.D.	Abbott Laboratories; Bristol-Myers Squibb; GlaxoSmithKline; Organon Inc.; Wyeth Pharmaceuticals; Forest Laboratories, Inc.; Eli Lilly and Company; Pfizer Inc.; Pharmacia Corporation; Janssen Pharmaceutica and Research Foundation; Sepracor, Inc.; Novartis Pharmaceuticals Corporation	3, 11
Max Hirshkowitz, Ph.D.	Wyeth Pharmaceuticals; Searle; Lorex Bertek; Pharmacia Corporation; Cephalon, Inc.; Merck & Co., Inc.; Lilly Research Laboratories, a division of Eli Lilly and Company; Sepracor, Inc.; Takeda Pharmaceuticals	78
Eric Hollander, M.D.	Solvay Pharmaceuticals, Inc.; Abbott Laboratories; Wyeth Pharmaceuticals	34, 64, 84, 87
Michael A. Hollifield, M.D.	Eli Lilly and Company	77
Rory P. Houghtalen, M.D.	Wyeth Pharmaceuticals	89
Robert H. Howland, M.D.	Cyberonics, Inc.	52
Rona Hu, M.D.	Janssen Pharmaceutica and Research Foundation; Pfizer Inc.; AstraZeneca Pharmaceuticals; Lilly Research Laboratories, a division of Eli Lilly and Company; Bristol-Myers Squibb	13
James I. Hudson, M.D.	Eli Lilly and Company; Pfizer Inc.; Ortho-McNeil Pharmaceuticals; Elan Pharmaceuticals; Merck & Co., Inc.; Knoll	86
James J. Hudziak, M.D.	Pfizer Inc.; GlaxoSmithKline; Eli Lilly and Company	64
Douglas H. Hughes, M.D.	Janssen Pharmaceutica and Research Foundation	63
Thomas D. Hurwitz, M.D.	Searle; Wyeth Pharmaceuticals	27, 78
Mustafa M. Husain	National Institute of Mental Health; Eli Lilly and Company; Bristol-Myers Squibb; Novartis Pharmaceuticals Corporation; Janssen Pharmaceutica and Research Foundation; GlaxoSmithKline; Pfizer Inc.	52, 64
Michael Y. Hwang, M.D.	Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation	19, 30
Steven E. Hyler, M.D.	Janssen Pharmaceutica and Research Foundation; Eli Lilly and Company	14, 56

## DISCLOSURE INDEX

Presenter	Manufacturer(s)	Program Page #
Naveed Iqbal, M.D.	Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; GlaxoSmithKline; Pfizer Inc.; AstraZeneca Pharmaceuticals; Novartis Pharmaceuticals Corporation; Bristol-Myers Squibb	19
Richard S. Jackson, M.D.	Abbott Laboratories; AstraZeneca Pharmaceuticals; Lilly Research Laboratories, a division of Eli Lilly and Company; Forest Laboratories, Inc.; Pfizer Inc.; Bristol-Myers Squibb; Janssen Pharmaceutica and Research Foundation	7
Richard L. Jaffe, M.D.	Pfizer Inc.	38
Philip G. Janicak, M.D.	Janssen Pharmaceutica and Research Foundation; Bristol-Myers Squibb; Genentech; National Institutes of Health; Pfizer Inc.; Novartis Pharmaceuticals Corporation; GlaxoSmithKline; Sepracor, Inc.; Abbott Laboratories; Lilly Research Laboratories, a division of Eli Lilly and Company	24, 38
Kathleen Jarboe, R.N.	Janssen Pharmaceutica and Research Foundation; Pfizer Inc.; Eli Lilly and Company	9
Robin B. Jarrett, Ph.D.	Cyberonics, Inc.	9
Dilip V. Jeste, M.D.	AstraZeneca Pharmaceuticals; Bristol-Myers Squibb; Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; Pfizer Inc.	37
Michael D. Jibson, M.D.	AstraZeneca Pharmaceuticals; Janssen Pharmaceutica and Research Foundation; Lilly Research Laboratories, a division of Eli Lilly and Company; Pfizer Inc.	85
David C. Jimerson, M.D.	Abbott Laboratories	7
David E. Joranson, M.S.W.	Ortho-McNeil Products; Janssen Pharmaceutica and Research Foundation; Purdue Pharma	62
Ned H. Kalin, M.D.	GlaxoSmithKline; Wyeth Pharmaceuticals; Janssen Pharmaceutica and Research Foundation; Forest Laboratories, Inc.; Neurocrine	11
John M. Kane, M.D.	Pfizer Inc.; Janssen Pharmaceutica and Research Foundation; Novartis Pharmaceuticals Corporation; Abbott Laboratories; Bristol-Myers Squibb; Lundbeck; Lilly Research Laboratories, a division of Eli Lilly and Company; AstraZeneca Pharmaceuticals	9, 13
Shitij Kapur, M.D.	Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; Neuromolecular, Inc.; Pfizer Inc.; Wyeth Pharmaceuticals; AstraZeneca Pharmaceuticals; Bristol-Myers Squibb; GlaxoSmithKline; Solvay Pharmaceuticals, Inc.	82, 96
David J. Katzelnick, M.D.	Abbott Laboratories; AstraZeneca Pharmaceuticals; GlaxoSmithKline; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Solvay Pharmaceuticals, Inc.; MacArthur Foundation; Organon Inc.; Robert Wood Johnson Foundation; Wyeth Pharmaceuticals; Forest Laboratories, Inc.; Lilly Research Laboratories, a division of Eli Lilly and Company; Pharmacia Corporation; Johnson and Johnson; Healthcare Technology Systems, Inc.	60
Paul E. Keck, Jr., M.D.	Abbott Laboratories; AstraZeneca Pharmaceuticals; Bristol-Myers Squibb; GlaxoSmithKline; Lilly Research Laboratories, a division of Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; Pfizer Inc.; Wyeth Pharmaceuticals; Merck & Co., Inc.	11, 81, 93
Samuel J. Keith, M.D.	Janssen Pharmaceutica and Research Foundation; Bristol-Myers Squibb; Pfizer Inc.; Novartis Pharmaceuticals Corporation	9
Martin B. Keller, M.D.	Pfizer Inc.; Bristol-Myers Squibb; Forest Laboratories, Inc.; Wyeth Pharmaceuticals; Merck & Co., Inc.; Janssen Pharmaceutica and Research Foundation; Lilly Research Laboratories, a division of Eli Lilly and Company; Organon Inc.; Pharmacia Corporation; Wyeth Pharmaceuticals; GlaxoSmithKline; AstraZeneca Pharmaceuticals; Mitsubishi Pharmaceuticals; Scirex; Vela Pharmaceuticals; Sepracor, Inc.; Somerset Pharmaceuticals, Inc.; Sanofi Pharmaceuticals, Inc.; Cypress Bioscience	11, 60
Charles H. Kellner, M.D.	Somatics, Inc.	1, 38
Justine M. Kent, M.D.	Solvay Pharmaceuticals, Inc.	63
Ronald C. Kessler, Ph.D.	Pfizer Inc.	10
Terence A. Ketter, M.D.	Abbott Laboratories; Janssen Pharmaceutica and Research Foundation; Eli Lilly and Company; Novartis Pharmaceuticals Corporation; GlaxoSmithKline; Bristol-Myers Squibb; Elan Pharmaceuticals; AstraZeneca Pharmaceuticals; Shire U.S., Inc.; Cephalon, Inc.	5, 63
Paul A. Kettl, M.D.	Pfizer Inc.; Organon Inc.; Novartis Pharmaceuticals Corporation; Lilly Research Laboratories, a division of Eli Lilly and Company; AstraZeneca Pharmaceuticals; Janssen Pharmaceutica and Research Foundation; Wyeth Pharmaceuticals; Manor HealthCare; Abbott Laboratories; Bristol-Myers Squibb	42, 80
Clinton D. Kilts, Ph.D.	Bristol-Myers Squibb; Janssen Pharmaceutica and Research Foundation; Forest Laboratories, Inc.; AstraZeneca Pharmaceuticals; GlaxoSmithKline	63
Steven A. King, M.D.	Wyeth Pharmaceuticals; Janssen Pharmaceutica and Research Foundation; Purdue; Endo	2
Ellen Kingsley, M.A.	Additude Magazine; Alza Pharmaceuticals; Shire U.S., Inc.; Abbott Laboratories; Bristol-Myers Squibb; GlaxoSmithKline; Organon Inc.; Wyeth Pharmaceuticals; Forest Laboratories, Inc.; Eli Lilly and Company; Pharmacia Corporation; Janssen Pharmaceutica and Research Foundation; Novartis Pharmaceuticals Corporation	38
Herbert D. Kleber, M.D.	Schering Plough	34, 43, 66
Mitchel A. Kling, M.D.	Cyberonics, Inc.	52
Harold W. Koenigsberg, M.D.	Janssen Pharmaceutica and Research Foundation	74, 84
Anthony L. Komaroff, M.D.	Cephalon, Inc.	86

## DISCLOSURE INDEX

Presenter	Manufacturer(s)	Program Page #
Lilli Kopala, M.D.	AstraZeneca Pharmaceuticals; Abbott Laboratories; Janssen Pharmaceutica and Research Foundation; Bristol-Myers Squibb; Eli Lilly and Company; Lundbeck; Novartis Pharmaceuticals Corporation; Pfizer Inc.	13
Susan G. Kornstein, M.D.	Pfizer Inc.; Bristol-Myers Squibb; Lilly Research Laboratories, a division of Eli Lilly and Company; GlaxoSmithKline; Forest Laboratories, Inc.; Wyeth Pharmaceuticals; Pharmacia Corporation; Mitsubishi; Biovail; Berlex Laboratories; Novartis Pharmaceuticals Corporation; Merck & Co., Inc. Cyberonics, Inc.	6, 9
Thomas R. Kosten, M.D.	Abbott Laboratories; Schering Pharmaceuticals	66, 95
Robert A. Kowatch, M.D.	Abbott Laboratories; Solvay Pharmaceuticals, Inc.	5
Diana M. Koziupa, M.D.	GlaxoSmithKline; Organon Inc.; Wyeth Pharmaceuticals; Eli Lilly and Company	97
Lois Krahn, M.D.	Wyeth Pharmaceuticals	8, 13, 78
Henry R. Kranzler, M.D.	Best Practice/Drug Abuse Sciences; Contral Pharma	55
Christopher J. Kratochvil, M.D.	Eli Lilly and Company; Alza Pharmaceuticals; Novartis Pharmaceuticals Corporation	3, 83
Ranga K. Krishnan, M.D.	Eisai Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Forest Laboratories, Inc.; Abbott Laboratories; Bristol-Myers Squibb; Dupont Pharma; GlaxoSmithKline; Janssen Pharmaceutica And Research Foundation; Merck & Co., Inc.; Organon Inc.; Pharmacia Corporation; Somerset Pharmaceuticals, Inc.	6, 11
Elisabeth J.S. Kunkel, M.D.	Forest Laboratories, Inc.; Parke-Davis, Division of Warner-Lambert Company; Wyeth Pharmaceuticals; Pfizer Inc.	75
David J. Kupfer, M.D.	Pfizer Inc.; Eli Lilly and Company; Forest Laboratories, Inc.	3, 34, 63
Raymond W. Lam, M.D.	Pfizer Inc.; Eli Lilly and Company; Pharmacia Corporation; Lundbeck; Servier; Litebook; Organon Inc.; Wyeth Pharmaceuticals	2
William B. Lawson, M.D.	AstraZeneca Pharmaceuticals; Janssen Pharmaceutica and Research Foundation; Lilly Research Laboratories, a division of Eli Lilly and Company	17, 58, 70, 94
Arthur L. Lazarus, M.D.	Pfizer Inc.	25, 93
Ellen Leibenluft, M.D.	Pfizer Inc.; Wyeth Pharmaceuticals; Lilly Research Laboratories, a division of Eli Lilly and Company; Abbott Laboratories; Johnson and Johnson	3
Alan I. Levenson, M.D.	Psychiatrists' Purchasing Group, Inc.	18
Frances R. Levin, M.D.	Eli Lilly and Company; GlaxoSmithKline	34, 44, 55
Saul M. Levin, M.D.	SAMHSA/CSAT	90, 93
Jeffrey M. Levine, M.D.	Wyeth Pharmaceuticals; GlaxoSmithKline; Pfizer Inc.	44
David A. Lewis, M.D.	AstraZeneca Pharmaceuticals	12
Jeffrey A. Lieberman, M.D.	Bristol-Myers Squibb; Novartis Pharmaceuticals Corporation; Lilly Research Laboratories, a division of Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; Pfizer Inc.; AstraZeneca Pharmaceuticals; Hoechst Marion Roussel; Pharmacia Corporation	9, 10, 12
Barry D. Liebowitz, Ph.D.	Forest Laboratories, Inc.	85
Walter Ling, M.D.	Roxane Laboratories; Schering Plough	50
Paul S. Links, M.D.	Eli Lilly and Company, Canada, Inc.	81
Sarah H. Lisanby, M.D.	MagStim Company	14
Maria D. Llorente, M.D.	Abbott Laboratories	32
Miklos F. Losonczy, M.D.	Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; AstraZeneca Pharmaceuticals	19
Joe Lovelace, J.D.	Janssen Pharmaceutica and Research Foundation	9
R. Bruce Lydiard, M.D.	Bristol-Myers Squibb; GlaxoSmithKline; Parke-Davis, Division of Warner-Lambert Company; Pfizer Inc.; Eli Lilly and Company; Pharmacia Corporation; Forest Laboratories, Inc.; Roche Laboratories, a member of the Roche Group; AstraZeneca Pharmaceuticals	10, 61, 87
Constanine G. Lyketsos, M.D.	Pfizer Inc.; Janssen Pharmaceutica and Research Foundation; Lilly Research Laboratories, a Division of Eli Lilly and Company; Dupont Pharma; Abbott Laboratories; Eisai Inc.; Bristol-Myers Squibb	7
Gerald A. Maguire, M.D.	Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; Pfizer Inc.	6
Hussein K. Manji, M.D.	Lilly Research Laboratories, a division of Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; Oxford Glycosciences; Chiron; AstraZeneca Pharmaceuticals; Abbott Laboratories; Pharmacia Corporation	12
Lauren B. Marangell, M.D.	National Institutes of Health; Stanley Foundation; Eli Lilly and Company; Martek Biosciences; Cyberonics; Abbott Laboratories; Pfizer Inc.; Parke-Davis, Division of Warner-Lambert Company; Forest Laboratories, Inc.; Bristol-Myers Squibb; GlaxoSmithKline; Janssen Pharmaceutica and Research Foundation; Wyeth Pharmaceuticals; Novartis Pharmaceuticals Corporation	9, 11, 81
John S. March, M.D.	Solvay Pharmaceuticals, Inc.; Pfizer Inc.; GlaxoSmithKline; Wyeth Pharmaceuticals; Shire U.S., Inc.; Lilly Research Laboratories, a division of Eli Lilly and Company; Alza Pharmaceuticals; Somerset Pharmaceuticals, Inc.; Medeva; Celgene; Bristol-Myers Squibb	87
Stephen R. Marder, M.D.	Janssen Pharmaceutica and Research Foundation; Eli Lilly and Company; Pfizer Inc.; AstraZeneca Pharmaceuticals; Bristol-Myers Squibb	9, 38

## DISCLOSURE INDEX

Presenter	Manufacturer(s)	Program Page #
John C. Markowitz, M.D.	National Institute of Mental Health; Pfizer Inc.; Lilly Research Laboratories, a division of Eli Lilly and Company; Bristol-Myers Squibb; Forest Laboratories, Inc.; Organon Inc.; American Psychiatric Press Inc.; Basic Books; Wyeth Pharmaceuticals	6, 48, 66, 96
Robert C. Marks, M.D.	Pfizer Inc.; Janssen Pharmaceutica and Research Foundation	24
Prakash S. Masand, M.D.	AstraZeneca Pharmaceuticals; Janssen Pharmaceutica and Research Foundation; GlaxoSmithKline; Forest Laboratories, Inc.; Wyeth Pharmaceuticals; Health Care Technology; Pfizer Inc.; Abbott Laboratories; Bristol-Myers Squibb; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Searle; Solvay Pharmaceuticals, Inc.	3, 37, 63, 96
Donna Masterman, M.D.	Pfizer Inc.; Eisai Inc.; Novartis Pharmaceuticals Corporation; Janssen Pharmaceutica and Research Foundation; Bayer Corporation, Pharmaceutical Division; Eli Lilly and Company; Fugisawa; Neotherapeutic; Sanofi Pharmaceuticals, Inc.; Pharmacia Corporation	86
Matig R. Mavissakalian, M.D.	Pfizer Inc.; Forest Laboratories, Inc.	22
Una D. McCann, M.D.	Pfizer Inc.; Bristol-Myers Squibb	81
Richard H. McCarthy, M.D.	Lilly Research Laboratories, a division of Eli Lilly and Company; AstraZeneca Pharmaceuticals; Janssen Pharmaceutica and Research Foundation; Novartis Pharmaceuticals Corporation; Parke-Davis, Division of Warner-Lambert Company	71
Christopher J. McDougle, M.D.	Janssen Pharmaceutica and Research Foundation; Pfizer Inc.; Eli Lilly and Company	14
Susan L. McElroy, M.D.	Abbott Laboratories; Eli Lilly and Company; Forest Laboratories, Inc.; Elan Pharmaceuticals; GlaxoSmithKline; Bristol-Myers Squibb; Janssen Pharmaceutica and Research Foundation; Ortho-McNeil Pharmaceuticals	86
Joseph P. McEvoy, M.D.	Bristol-Myers Squibb	9, 10
Patrick D. McGorry, Ph.D.	Janssen Pharmaceutica and Research Foundation; Eli Lilly and Company; Pfizer Inc.; Novartis Pharmaceuticals Corporation; Bristol-Myers Squibb	9
Alan J. Mendelowitz, M.D.	Pfizer Inc.; AstraZeneca Pharmaceuticals; Janssen Pharmaceutica and Research Foundation; Lilly Research Laboratories, a division of Eli Lilly and Company	64, 85
Ricardo P. Mendoza, M.D.	Pfizer Inc.; Forest Laboratories, Inc.; Janssen Pharmaceutica and Research Foundation	70
Matthew A. Menza, M.D.	Cephalon, Inc.	92
David Michelson, M.D.	Eli Lilly and Company (employer)	47
Frederick E. Miller, M.D.	Pfizer Inc.	74
Matthew S. Miller, Ph.D.	Cephalon, Inc. (employer)	49
Jacobo E. Mintzer, M.D.	Abbott Laboratories; Bristol-Myers Squibb; Eli Lilly and Company; Forest Laboratories, Inc.; Janssen Pharmaceutica and Research Foundation; Pfizer Inc.	7, 25, 85
Shaila Misri, M.D.	GlaxoSmithKline; Wyeth Pharmaceuticals	8
James E. Mitchell, M.D.	Lilly Research Laboratories, a division of Eli Lilly and Company; Abbott Laboratories	7, 30
Gary S. Moak, M.D.	Eisai Inc.; Pfizer Inc.; Janssen Pharmaceutica and Research Foundation; Eli Lilly and Company	2
Francisco A. Moreno, M.D.	Solvay Pharmaceuticals, Inc.	18, 64
Philip Morris, Ph.D.	Dupont Pharma	83
Greer M. Murphy, M.D.	Organon Inc.	9
Dominique L. Musselman, M.D.	DANA Foundation; GlaxoSmithKline; National Institutes of Health; Schering Plough; Forest Laboratories, Inc.; Parke-Davis, Division of Warner-Lambert Company; Pfizer Inc.; Wyeth Pharmaceuticals	13
Ziad H. Nahas, M.D.	Cyberonics, Inc.; Neotonus, Inc.	14, 52
Henry A. Nasrallah, M.D.	AstraZeneca Pharmaceuticals; Janssen Pharmaceutica and Research Foundation; Pfizer Inc.; Wyeth Pharmaceuticals; Forest Laboratories, Inc.; National Institutes of Health; Bristol-Myers Squibb	13, 37
Rebecca R. Neal, M.D.	Lilly Research Laboratories, a division of Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation	19
J. Craig Nelson, M.D.	Abbott Laboratories; Bristol-Myers Squibb; Eli Lilly and Company; Forest Laboratories, Inc.; GlaxoSmithKline; Janssen Pharmaceutica and Research Foundation; Organon Inc.; Pfizer Inc.; Pharmacia Corporation; Wyeth Pharmaceuticals	6, 64
Charles B. Nemeroff, M.D.	Abbott Laboratories; AstraZeneca Pharmaceuticals; Bristol-Myers Squibb; Forest Laboratories, Inc.; Janssen Pharmaceutica and Research Foundation; Eli Lilly and Company; Organon Inc.; Pfizer Inc.; Pharmacia Corporation; GlaxoSmithKline; Solvay Pharmaceuticals, Inc.; Wyeth Pharmaceuticals; Acadia Pharmaceuticals; Cypress Biosciences; Otsuka Pharmaceuticals; Merck & Co., Inc.; Neurocrine Biosciences; Sanofi Pharmaceuticals, Inc.; Vela	11, 63
John W. Newcomer, M.D.	Janssen Pharmaceutica and Research Foundation; Eli Lilly and Company; Pfizer Inc.; AstraZeneca Pharmaceuticals	3
Thomas Newton, M.D.	Cypress Bioscience	52
Andrew A. Nierenberg, M.D.	Lilly Research Laboratories, a division of Eli Lilly and Company; Wyeth Pharmaceuticals; GlaxoSmithKline; Janssen Pharmaceutica and Research Foundation; Innapharma; Bristol-Myers Squibb; Cyberonics; Lichtner; Pfizer Inc.; Forest Laboratories, Inc.	2, 6
Carol S. North, M.D.	GlaxoSmithKline; Bristol-Myers Squibb	8, 97
Andrei Novac, M.D.	Pfizer Inc.; GlaxoSmithKline; Forest Laboratories, Inc.	71
H. George Nurnberg, M.D.	Pfizer Inc.; Eli Lilly and Company; GlaxoSmithKline	75
Charles P. O'Brien, M.D.	Dupont Pharma	18, 83, 94

## DISCLOSURE INDEX

Presenter	Manufacturer(s)	Program Page #
Mary B. O'Malley, M.D.	Cephalon, Inc.	49, 86
N. Kalaya Okereke, M.D.	AstraZeneca Pharmaceuticals	47
Lewis A. Opler, M.D.	Multi-Health Systems	5, 19, 25, 30
Michael W. Otto, Ph.D.	Pharmacia Corporation; Janssen Pharmaceutica and Research Foundation; Pfizer Inc.; Ancile Pharma; GlaxoSmithKline; Eli Lilly and Company; Psychological Corporation; Abbott Laboratories	11, 57
Michael J. Owens, Ph.D.	Forest Laboratories, Inc.; GlaxoSmithKline; Abbott Laboratories; Eli Lilly and Company	2, 63, 65
Michelle T. Pato, M.D.	Solvay Pharmaceuticals, Inc.; Lilly Research Laboratories, a division of Eli Lilly and Company; Forest Laboratories, Inc.; Pfizer Inc.	38
Diana O. Perkins, M.D.	Lilly Research Laboratories, a division of Eli Lilly and Company; Pfizer Inc.; AstraZeneca Pharmaceuticals; Janssen Pharmaceutica and Research Foundation; Bristol-Myers Squibb	9, 13, 95
Frederick Petty, M.D.	Janssen Pharmaceutica and Research Foundation; Lilly Research Laboratories, a division of Eli Lilly and Company; Pfizer Inc.	87
Edmond H.T. Pi, M.D.	Eli Lilly and Company	70
Debra A. Pinals, M.D.	Janssen Pharmaceutica and Research Foundation	90
Daniel Pine, M.D.	Solvay Pharmaceuticals, Inc.; Bristol-Myers Squibb; Wyeth Pharmaceuticals	35, 63
Mark H. Pollack, M.D.	Bristol-Myers Squibb; Forest Laboratories, Inc.; Lilly Research Laboratories, a division of Eli Lilly and Company; Parke-Davis, Division of Warner-Lambert Company; Pfizer Inc.; GlaxoSmithKline; Solvay Pharmaceuticals, Inc.; Wyeth Pharmaceuticals	10
Robert M. Post, M.D.	Abbott Laboratories; Bristol-Myers Squibb; GlaxoSmithKline; Janssen Pharmaceutica and Research Foundation; Novartis Pharmaceuticals Corporation; Lilly Research Laboratories, a division of Eli Lilly and Company; Parke-Davis, Division of Warner-Lambert Company; Pfizer Inc.; Pharmacia Corporation; UCB Pharma	62, 63
Marc N. Potenza, M.D.	GlaxoSmithKline; Forest Laboratories, Inc.	83
Steven G. Potkin, M.D.	Novartis Pharmaceuticals Corporation	64
David W. Preven, M.D.	Forest Laboratories, Inc.; Pfizer Inc.	26
Annelle B. Primm, M.D.	Pfizer Inc.	43
Jefferson B. Prince, M.D.	GlaxoSmithKline; Forest Laboratories, Inc.; Lilly Research Laboratories, a division of Eli Lilly and Company; Alza Pharmaceuticals	1, 78
Andres J. Pumariega, M.D.	Center for Mental Health Services	90
Arturo G. Quiason, M.D.	Wyeth Pharmaceuticals; Novartis Pharmaceuticals Corporation; Janssen Pharmaceutica and Research Foundation; Pfizer Inc.	25
Ljiljana Radulovic, M.D.	Abbott Laboratories	92
Paul M. Ramirez, Ph.D.	Multi-Health Systems	5
Mark H. Rapaport, M.D.	Abbott Laboratories; Forest Laboratories, Inc.; GlaxoSmithKline; Pfizer Inc.; Janssen Pharmaceutica and Research Foundation; Lilly Research Laboratories, a division of Eli Lilly and Company; Sanofi Pharmaceuticals, Inc.; Pharmacia Corporation; Robert Wood Johnson; UBC Pharma; Wyeth Pharmaceuticals	33
Natalie L. Rasgon, M.D.	Forest Laboratories, Inc.	2, 34
Scott L. Rauch, M.D.	GlaxoSmithKline; Janssen Pharmaceutica and Research Foundation; Lilly Research Laboratories, a division of Eli Lilly and Company; Pfizer Inc.; Solvay Pharmaceuticals, Inc.	8
William T. Regenold, M.D.	Pfizer Inc.; Lilly Research Laboratories, a division of Eli Lilly and Company; AstraZeneca Pharmaceuticals; Novartis Pharmaceuticals Corporation	43
William E. Reichman, M.D.	Eisai Inc.; Pfizer Inc.; Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; Bristol-Myers Squibb; Organon Inc.; Forest Laboratories, Inc.	2, 7
Roy O. Resnikoff, M.D.	Pfizer Inc.; Bristol-Myers Squibb; Forest Laboratories, Inc.; AstraZeneca Pharmaceuticals; Lilly Research Laboratories, a division of Eli Lilly and Company	66, 93
Kerry J. Ressler, M.D.	Pfizer Inc.; GlaxoSmithKline	63
Charles F. Reynolds III, M.D.	GlaxoSmithKline; Forest Laboratories, Inc.; Organon Inc.	5, 9
Mary Ann Richardson, Ph.D.	Scientific Hospital Supplies, Ltd.	75
Mark A. Riddle, M.D.	Best Practice; Excerpta Medical; Janssen Pharmaceutica and Research Foundation; Bristol-Myers Squibb; Shire U.S., Inc.; Solvay Pharmaceuticals, Inc.; National Institute of Mental Health	98
Gustavo C. Roman, M.D.	Eisai Inc.	86
Steven P. Roose, M.D.	Forest Laboratories, Inc.; GlaxoSmithKline; Wyeth Pharmaceuticals; Bristol-Myers Squibb; Eli Lilly and Company; Organon Inc.; Pharmacia Corporation	5, 9
Mark R. Rosekind, Ph.D.	Wyeth Pharmaceuticals	13
Jerrold F. Rosenbaum, M.D.	Cyberonics; Eli Lilly and Company; Forest Laboratories, Inc.; Lichtwer Pharma; Organon Inc.; Wyeth Pharmaceuticals	2
Thomas Roth, Ph.D.	Wyeth Pharmaceuticals; Sanofi Pharmaceuticals, Inc.; Aventis; Sepracor, Inc.; Neurocrine; Merck & Co., Inc.; Proctor and Gamble; Takeda Pharmaceuticals; Novartis Pharmaceuticals Corporation; Lilly Research Laboratories, a division of Eli Lilly and Company; Bristol-Myers Squibb; Forest Laboratories, Inc.	37, 85
Barbara O. Rothbaum, Ph.D.	Pfizer Inc.; Bristol-Myers Squibb; Wyeth Pharmaceuticals; Virtually Better; Somerset Pharmaceuticals, Inc.	8, 11



**DISCLOSURE INDEX**

<b>Presenter</b>	<b>Manufacturer(s)</b>	<b>Program Page #</b>
A. John Rush, M.D.	Cyberonics; Robert Wood Johnson Foundation; National Institute of Mental Health; Stanley Foundation; Wyeth Pharmaceuticals; Abbott Laboratories; Bristol-Myers Squibb; Eli Lilly and Company; Forest Laboratories, Inc.; GlaxoSmithKline; Janssen Pharmaceutica and Research Foundation; Merck & Co., Inc.; Pfizer Inc.; Pharmacia Corporation	9, 60
Donna H. Ryan, M.D.	Wyeth Pharmaceuticals; Abbott Laboratories; Boots Pharmaceuticals; Roche Laboratories, a member of the Roche Group; Amgen; Bristol-Myers Squibb; Ergo; GlaxoSmithKline; Parke-Davis, Division of Warner-Lambert Company; Warner Lambert; Regeneron Pharmaceuticals; Schering Plough; Proctor and Gamble; TAP Pharmaceuticals; Wyeth Pharmaceuticals	65
J. Michael Ryan, M.D.	Eisai Inc.; Pfizer Inc.; AstraZeneca Pharmaceuticals; Janssen Pharmaceutica and Research Foundation; Novartis Pharmaceuticals Corporation; Eli Lilly and Company; Abbott Laboratories	2, 86
Neal D. Ryan, M.D.	Pfizer Inc.; Abbott Laboratories; Hoffman-LaRoche; AstraZeneca Pharmaceuticals; GlaxoSmithKline; Wyeth Pharmaceuticals	13
Gary S. Sachs, M.D.	Abbott Laboratories; GlaxoSmithKline; Janssen Pharmaceutica and Research Foundation; Eli Lilly and Company; Bristol-Myers Squibb; Novartis Pharmaceuticals Corporation; Elan; Sanofi Pharmaceuticals, Inc.; Scios Nova Pharmaceuticals; Solvay Pharmaceuticals, Inc.; AstraZeneca Pharmaceuticals	8, 11, 92
Harold A. Sackeim, Ph.D.	Pfizer Inc.; Forest Laboratories, Inc.; Cyberonics	5, 9, 81
Mary Sano, Ph.D.	Novartis Pharmaceuticals Corporation; Janssen Pharmaceutica and Research Foundation; Forest Laboratories, Inc.; Merck & Co., Inc.; Fujisawa; Pfizer Inc.	85
Norman Sartorius, M.D.	Bristol-Myers Squibb	6, 60
Seddon R. Savage, M.D.	Muro Asta Medica; Ortho-McNeil Pharmaceuticals; Janssen Pharmaceutica and Research Foundation; Purdue Pharma	62
Franklin R. Schneier, M.D.	Forest Laboratories, Inc.; Solvay Pharmaceuticals, Inc.; Somerset Pharmaceuticals, Inc.; GlaxoSmithKline	61
Nina R. Schooler, Ph.D.	Janssen Pharmaceutica and Research Foundation; Pfizer Inc.; Novartis Pharmaceuticals Corporation	30, 64
S. Charles Schulz, M.D.	Janssen Pharmaceutica and Research Foundation; Lilly Research Laboratories, a division of Eli Lilly and Company; AstraZeneca Pharmaceuticals; Pfizer Inc.	13, 87
Dean Schuyler, M.D.	Wyeth Pharmaceuticals; Pfizer Inc.	27
Marcia Scott, M.D.	Prudential	7
Yvette Sealy, Ph.D.	Bedford Community Health Center	44
Larry J. Seidman, Ph.D.	Forest Laboratories, Inc.; GlaxoSmithKline; Shire U.S., Inc.	86
Stuart N. Seidman, M.D.	Forest Laboratories, Inc.; GlaxoSmithKline	2, 34, 47
Shawn C. Shea, M.D.	GlaxoSmithKline	15
M. Katherine Shear, M.D.	Wyeth Pharmaceuticals	11
David V. Sheehan, M.D.	Abbott Laboratories; Alza Pharmaceuticals; Forest Laboratories, Inc.; GlaxoSmithKline; Layton Bioscience; Lilly Research Laboratories, a division of Eli Lilly and Company; Lundbeck; Organon Inc.; Pharmacia Corporation; Pfizer Inc.; Pierre Fabre; Wyeth Pharmaceuticals; American Medical Association; Anclote Foundation; Bristol-Myers Squibb; Eisai Inc.; International Clinical Research; Janssen Pharmaceutica and Research Foundation; Kali Duphar Laboratories; Mead Johnson Laboratories; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Parke-Davis, Division of Warner-Lambert Company; Quintiles; Sandoz Pharmaceuticals Corporation; Synthelabo; Tampa General Hospital-University Psychiatry Center; TAP Pharmaceuticals; Warner Chilcott Pharmaceutical Company; Worldwide Clinical Trials; AstraZeneca Pharmaceuticals; Boehringer Ingelheim; Boots Pharmaceuticals; Charter Hospitals; Ciba Geigy Corporation, Pharmaceutical Division; Dista Products; Excerpta Medica Asia; Humana; ICI; Marion Merrill Dow; McNeil Pharmaceuticals; Organon Inc.; Novo Nordisk Pharmaceuticals Inc., Rhone-Poulenc Rorer Pharmaceuticals; Roerig; Schering Plough; Corporation; Solvay Pharmaceuticals, Inc.; Layton Bioscience; Medical Outcome Systems	8, 13
Richard C. Shelton, M.D.	Eli Lilly and Company; GlaxoSmithKline; Janssen Pharmaceutica and Research Foundation; Pfizer Inc.; Rhone-Poulenc Rorer Pharmaceuticals; Sanofi Pharmaceuticals, Inc.; Wyeth Pharmaceuticals; AstraZeneca Pharmaceuticals; Abbott Laboratories; Bristol-Myers Squibb; Solvay Pharmaceuticals, Inc.	65, 87, 96
Larry J. Siever, M.D.	Janssen Pharmaceutica and Research Foundation	65, 84, 87
Linmarie Sikich, M.D.	Janssen Pharmaceutica and Research Foundation; Lilly Research Laboratories, a division of Eli Lilly and Company	48
Deborah R. Simkin, M.D.	Pfizer Inc.; Alza Pharmaceuticals; GlaxoSmithKline	83, 84
Gregory E. Simon, M.D.	Group Health Cooperative; Eli Lilly and Company	59
Naomi M. Simon, M.D.	Bristol-Myers Squibb; Forest Laboratories, Inc.; GlaxoSmithKline; Lilly Research Laboratories, a division of Eli Lilly and Company; Pfizer Inc.; Wyeth Pharmaceuticals	10
Samuel G. Siris, M.D.	Pfizer Inc.; Eli Lilly and Company; Merck & Co., Inc.	30
Gary W. Small, M.D.	Pfizer Inc.; Janssen Pharmaceutica and Research Foundation; Abbott Laboratories; Lilly Research Laboratories, a division of Eli Lilly and Company; Novartis Pharmaceuticals Corporation; GlaxoSmithKline; Organon Inc.; Forest Laboratories, Inc.; Eisai Inc.	86

**DISCLOSURE INDEX**

<b>Presenter</b>	<b>Manufacturer(s)</b>	<b>Program Page #</b>
Michael W. Smith, M.D.	Janssen Pharmaceutica and Research Foundation; Lilly Research Laboratories, a division of Eli Lilly and Company; GlaxoSmithKline; AstraZeneca Pharmaceuticals; Kaiser; Bristol-Myers Squibb; Pfizer Inc.; Upsher-Smith; National Institute of Mental Health	5
Thomas J. Spencer, M.D.	Abbott Laboratories; Alza Pharmaceuticals; Boston Life Sciences; Bristol-Myers Squibb; Eisai Inc.; GlaxoSmithKline; Gliatech; Lilly Research Laboratories, a division of Eli Lilly and Company; Medeva; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Shire U.S., Inc.; Solvay Pharmaceuticals, Inc.; Wyeth Pharmaceuticals	3, 86
Stephen M. Stahl, M.D.	Bayer Corporation, Pharmaceutical Division; Boehringer-Ingelheim; Bristol-Myers Squibb; Eli Lilly and Company; Forest Laboratories, Inc.; GlaxoSmithKline; Janssen Pharmaceutica and Research Foundation; Lundbeck; Organon Inc.; Parke-Davis, Division of Warner-Lambert Company; Pfizer Inc.; Pharmacia Corporation; Sanofi Pharmaceuticals, Inc.; Solvay Pharmaceuticals, Inc.; Watson; Wyeth Pharmaceuticals; Yamanouchi; AstraZeneca Pharmaceuticals; Abbott Laboratories; Aventis; Fabre Kramer; Lorex; Lundbeck; Neurocrine; Novartis Pharmaceuticals Corporation; Pierre Fabre; Sanao; Roche; Sumimoto	37, 57
Judy L. Stange, Ph.D.	SAMHSA (employer)	90
Dan J. Stein, M.D.	MRC Unit on Anxiety Disorders (employer)	57
Murray B. Stein, M.D.	Bristol-Myers Squibb; Eli Lilly and Company; Forest Laboratories, Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; GlaxoSmithKline; Solvay Pharmaceuticals, Inc.; Wyeth Pharmaceuticals; Allergan; Alza Pharmaceuticals; Janssen Pharmaceutica and Research Foundation; Hoffman-LaRoche; Pharmacia Corporation	61
Hans Steiner, M.D.	Abbott Laboratories; Pfizer Inc.; Janssen Pharmaceutica and Research Foundation	14, 65
Jonathan W. Stewart, M.D.	Organon Inc.	6
Nada L. Stotland, M.D.	Eli Lilly and Company; Solvay Pharmaceuticals, Inc.; Pfizer Inc.	49
Eric C. Strain, M.D.	Schering-Plough Corp.	55, 66
David L. Sultzzer, M.D.	Pfizer Inc.; Novartis Pharmaceuticals Corporation; Janssen Pharmaceutica and Research Foundation	7
Patricia Suppes, M.D.	Abbott Laboratories; AstraZeneca Pharmaceuticals; Bristol-Myers Squibb; Eli Lilly and Company; GlaxoSmithKline; Janssen Pharmaceutica and Research Foundation; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Pharmaceutical Research Institute	8, 11
Alan C. Swann, M.D.	Abbott Laboratories; GlaxoSmithKline; UCB; Bristol-Myers Squibb; Shire U.S., Inc.; Novartis Pharmaceuticals Corporation; Shire U.S., Inc.; Robert Wood Johnson	65, 87
Holly A. Swartz, M.D.	GlaxoSmithKline; Eli Lilly and Company	3, 37
Carol A. Tamminga, M.D.	AstraZeneca Pharmaceuticals	12
Rajiv Tandon, M.D.	AstraZeneca Pharmaceuticals; Bristol-Myers Squibb; Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; Novartis Pharmaceuticals Corporation; Pfizer Inc.	38, 85, 93
Steven D. Targum, M.D.	AstraZeneca Pharmaceuticals	14
Pierre N. Tariot, M.D.	Abbott Laboratories; AstraZeneca Pharmaceuticals; Bayer Corporation, Pharmaceutical Division; Eisai Inc.; Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; Lundbeck; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Sanofi Pharmaceuticals, Inc. Berlex; Pharmacia Corporation; Schwabe	2, 7, 86
Michael E. Thase, M.D.	Bristol-Myers Squibb; Eli Lilly and Company; Forest Laboratories, Inc.; GlaxoSmithKline; Merck & Co., Inc.; Organon Inc.; Pfizer Inc.; Pharmacia Corporation; Wyeth Pharmaceuticals; Parke-Davis, Division of Warner-Lambert Company; Solvay Pharmaceuticals, Inc.	6, 11, 59, 66
Diane S. Thompson, M.D.	Eli Lilly and Company; GlaxoSmithKline; Organon Inc.; Wyeth Pharmaceuticals; Pfizer Inc.	87
Joyce A. Tinsley, M.D.	Pfizer Inc.	76
Mauricio F. Tohen, M.D.	Eli Lilly and Company (employer)	24, 48
Martin G. Tracy, J.D.	Professional Risk Management Services, Inc.	18, 42, 72
Madhukar H. Trivedi, M.D.	Abbott Laboratories; Akzo; Bayer Corporation, Pharmaceutical Division; Bristol-Myers Squibb; Eli Lilly and Company; Forest Laboratories, Inc.; GlaxoSmithKline; Organon Inc.; Pharmacia Corporation; Solvay Pharmaceuticals, Inc.; Janssen Pharmaceutica and Research Foundation; Johnson and Johnson; National Institute of Mental Health; Mead Johnson; Parke-Davis, Division of Warner-Lambert Company; Pfizer Inc.; Wyeth Pharmaceuticals	9, 60
John W. Tsuang, M.D.	Lilly Research Laboratories, a division of Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation	52
Phebe M. Tucker, M.D.	Eli Lilly and Company; GlaxoSmithKline; Pfizer Inc.; Solvay Pharmaceuticals, Inc.; Ortho-McNeil	8
Atila Turgay, M.D.	Janssen Pharmaceutica and Research Foundation; Purdue Pharmaceuticals; Eli Lilly and Company; Nestle	74, 91
Michael A. Van Ameringen, M.D.	GlaxoSmithKline; Pfizer Inc.; Eli Lilly and Company; Wyeth Pharmaceuticals; AstraZeneca Pharmaceuticals; Janssen Pharmaceutica and Research Foundation; Bristol-Myers Squibb	22
Meera Vaswani, Ph.D.	All India Institute of Medical Sciences (employer)	74
Sanjeev Venkataraman, M.D.	Organon Inc.; Forest Laboratories, Inc.; Janssen Pharmaceutica and Research Foundation	7
Sumer Verma, M.D.	Lilly Research Laboratories, a division of Eli Lilly and Company; Pfizer Inc.; Abbott Laboratories; GlaxoSmithKline; Searle; Janssen Pharmaceutica and Research Foundation; Neotherapeutics	6

## DISCLOSURE INDEX

Presenter	Manufacturer(s)	Program Page #
Garry M. Vickar, M.D.	Eli Lilly and Company; Johnson and Johnson; Merck & Co., Inc.; GlaxoSmithKline; Pfizer Inc.; Elan; Wyeth Pharmaceuticals	33
Bruce S. Victor, M.D.	Eli Lilly and Company; Pfizer Inc.; Wyeth Pharmaceuticals; Bristol-Myers Squibb; Abbott Laboratories	15
Walter V. Vieweg, M.D.	Janssen Pharmaceutica and Research Foundation	3
Adele C. Viguera, M.D.	Wyeth Pharmaceuticals; Eli Lilly and Company	11, 32
Joseph R. Volpicelli, M.D.	Mallinckrodt, Inc.	83
Karen D. Wagner, M.D.	GlaxoSmithKline; Pfizer Inc.; Abbott Laboratories; Lilly Research Laboratories, a division of Eli Lilly and Company; Bristol-Myers Squibb; Organon Inc.; Forest Laboratories, Inc.; Wyeth Pharmaceuticals; Janssen Pharmaceutica and Research Foundation; Celexa; Lamictal	3, 5
B. Timothy Walsh, M.D.	Knoll Pharmaceuticals; Eli Lilly and Company; Ortho-McNeil Pharmaceuticals	59, 86
James K. Walsh, Ph.D.	Pharmacia Corporation; Lorex Pharmaceuticals; Searle; Pfizer Inc.; Abbott Laboratories; Amerian Cyanamid; Hoffman-LaRoche; Merck & Co., Inc.; Bristol-Myers Squibb; Wyeth Pharmaceuticals; Takeda Pharmaceuticals; Ancile Pharmaceuticals; Neurocrine Biosciences; Cephalon, Inc.; Sepracor, Inc.; Whitehall-Robbins; Eli Lilly and Company; Sanofi Pharmaceuticals, Inc.; CoCensys Pharmaceuticals; Proctor and Gamble	85
Khakasa H. Wapenyi, M.D.	AstraZeneca Pharmaceuticals	29, 75
Julia K. Warnock, M.D.	Pfizer Inc.; GlaxoSmithKline; Forest Laboratories, Inc.; Pherin; Solvay Pharmaceuticals, Inc.	65, 87
Deborah Wasilchak	Community Care Behavior Health (employer)	43
Peter J. Weiden, M.D.	AstraZeneca Pharmaceuticals; Bristol-Myers Squibb; Janssen Pharmaceutica and Research Foundation; Lilly Research Laboratories, a division of Eli Lilly and Company; Pfizer Inc.	9, 86, 92
Daniel R. Weinberger, M.D.	Lilly Research Laboratories, a division of Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; Bristol-Myers Squibb	6, 12, 86
Robert M. Weinrieb, M.D.	Dupont Pharma	44
Risa B. Weisberg, Ph.D.	Pfizer Inc.	22
Myrna M. Weissman, Ph.D.	GlaxoSmithKline	3, 97
Elizabeth B. Weller, M.D.	GlaxoSmithKline; Wyeth Pharmaceuticals; Forest Laboratories, Inc.; Organon Inc.; Johnson and Johnson	97
Gary L. Wenk, Ph.D.	Forest Laboratories, Inc.	85
Joyce C. West, Ph.D.	APIRE	60
Mark D. Wiederhold, M.D.	The Virtual Reality Medical Center; VR Health; Interactive Media Institute	98
Timothy E. Wilens, M.D.	Alza Pharmaceuticals; Abbott Laboratories; Meckva; Shire U.S., Inc.; Lilly Research Laboratories, a division of Eli Lilly and Company; GlaxoSmithKline; National Institute of Mental Health; National Institute on Drug Abuse; Novartis Pharmaceuticals Corporation; Janssen Pharmaceutica and Research Foundation; Pfizer Inc.; NICMH	5, 47
Denise E. Wilfley, Ph.D.	Abbott Laboratories; Ortho-McNeil Pharmaceuticals	86
Martin S. Willick, M.D.	Bristol-Myers Squibb	6
John W. Winkelman, M.D.	Eli Lilly and Company; Pfizer Inc.; Cephalon, Inc.; Wyeth Pharmaceuticals; Parke-Davis, Division of Warner-Lambert Company; Searle	10, 27, 86
Donna A. Wirshing, M.D.	Janssen Pharmaceutica and Research Foundation; Lilly Research Laboratories, a division of Eli Lilly and Company; AstraZeneca Pharmaceuticals; Organon Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; PPD Pharmaco	3
Scott W. Woods, M.D.	Eli Lilly and Company	95
Mary R. Worthen	Eli Lilly and Company	11
Janet Wozniak, M.D.	Alza Pharmaceuticals; Pharmacia Corporation; Eli Lilly and Company	3, 38
Jesse H. Wright, M.D.	Mindstreet	18, 26, 30, 66, 78
Kevan R. Wylie, M.D.	Pfizer; Abbott Laboratories; Lilly Research Laboratories, a division of Eli Lilly and Company	49
Joel Yager, M.D.	Eli Lilly and Company	7, 26, 30, 77
Rachel Yehuda, Ph.D.	GlaxoSmithKline; Pfizer Inc.; Janssen Pharmaceutica and Research Foundation; Bristol-Myers Squibb	8, 71
Kimberly A. Yonkers, M.D.	Eli Lilly and Company; GlaxoSmithKline; Berlex; Pfizer Inc.; American Home Products; Wyeth Pharmaceuticals	11, 87
Stuart Yudofsky, M.D.	Bristol-Myers Squibb	13, 37
John M. Zajacka, M.D.	Bristol-Myers Squibb; Eli Lilly and Company; Cephalon, Inc.; Cyberonics; GlaxoSmithKline; Lichtwer Pharma; MIICRO, Inc.; Otsuka Pharmaceuticals; Parke-Davis, Division of Warner- Lambert Company; Pfizer Inc.; Wyeth Pharmaceuticals; Abbott Laboratories; Pharmacia Corporation	37
Douglas M. Ziedonis, M.D.	Janssen Pharmaceutica and Research Foundation; Lilly Research Laboratories, a division of Eli Lilly and Company; GlaxoSmithKline; Novartis Pharmaceuticals Corporation; Pfizer Inc.	33

## DISCLOSURE INDEX

---

*The following presenters on this year's scientific program failed to return the APA disclosure form. The presenter's name and the page number(s) the presenter appears on in this Program Book are listed below:*

Nancy C. Andreasen, M.D.	82	Marvis Frazier	80	Earl C. Lawrence, M.A.	41
William Arroyo, M.D.	89	Amarsingh M. Ghorpade, M.D.	48	Alexandra MacLean, M.D.	59
Gregory L. Barker	41	Jodi Goldstein, J.D.	76	Cesare Maffei, M.D.	31
Guido Belsasso, M.D.	89	Norma Hatot	77	Farris Tuma, Sc.D.	71
Eric G. Bing, M.D.	94	Ruben J. Hernandez-Serrano, M.D.	84	Mike Ward	41
Herve Bokobza, M.D.	59	Michael J. Kittay, M.D.	90	Wendy Williams	80
Gary Cobb	80	Louis J. Kraus, M.D.	89	Lishan Workeneh, M.D.	42

# SATURDAY, MAY 18, 2002

## 15TH ANNUAL MEETING

### 8:00 a.m. Sessions



#### COURSES 1-5

Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.

**COURSE 1** 8:00 a.m.-12 noon  
Room 102 B, Street Level, Convention Center

#### COMPUTER-ASSISTED DIAGNOSTIC INTERVIEW

Co-Directors: Paul R. Miller, M.D., Charles Chiu, M.D.

**COURSE 2** 8:00 a.m.-12 noon  
Room 104 A, Street Level, Convention Center

#### ANTI-PSYCHOTIC-INDUCED MOVEMENT DISORDERS: ASSESSMENT AND TREATMENT

Director: Leonardo Cortese, M.D.  
Faculty: Richard Williams, M.D., Michael Caligiuri, Ph.D.

**COURSE 3** 8:00 a.m.-12 noon  
Room 104 B, Street Level, Convention Center

#### ADD IN CHILDREN AND ADOLESCENTS

Director: Thomas E. Brown, Ph.D.  
Faculty: Jefferson B. Prince, M.D.

**COURSE 4** 8:00 a.m.-12 noon  
Room 109 A, Street Level, Convention Center

#### WRITING ABOUT CLINICAL EXPERIENCES

Director: John S. Strauss, M.D.

**COURSE 5** 8:00 a.m.-12 noon  
Room 203 B, Level 200, Convention Center

#### ECT IN NEUROLOGICAL DISORDERS

Co-Directors: Georgios Petrides, M.D., Charles H. Kellner, M.D.  
Faculty: C. Edward Coffey, M.D., Raymond A. Faber, M.D., Max Fink, M.D., Chitra Malur, M.D.

### 9:00 a.m. Sessions



#### COURSES 6-11

Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.

**COURSE 6** 9:00 a.m.-4:00 p.m.  
Room 102 A, Street Level, Convention Center

#### BASIC CONCEPTS IN ADMINISTRATIVE PSYCHIATRY: THEORY, HUMAN RESOURCES, AND FISCAL MANAGEMENT

Co-Directors: Christopher G. Fichtner, M.D., Thomas A. Simpatico, M.D.  
Faculty: L. Mark Russakoff, M.D., Stuart B. Silver, M.D., S. Atezaz Saeed, M.D., Shivkumar Hatti, M.D.

**COURSE 7** 9:00 a.m.-4:00 p.m.  
Room 106 A, Street Level, Convention Center

#### INTERPERSONAL PSYCHOTHERAPY

Director: Scott P. Stuart, M.D.  
Faculty: Michael Robertson, M.D.

**COURSE 8** 9:00 a.m.-4:00 p.m.  
Room 111 A, Street Level, Convention Center

#### PERSONALITY AND POLITICAL BEHAVIOR

Director: Jerrold M. Post, M.D.

**COURSE 9** 9:00 a.m.-4:00 p.m.  
Room 112 A, Street Level, Convention Center

#### PSYCHIATRY UPDATE FOR THE INTERNATIONAL SPANISH-SPEAKING COLLEAGUE (IN SPANISH)

Director: Gabriel Kaplan, M.D.  
Faculty: Javier I. Escobar, M.D., Jorge R. Petit, M.D., Eduardo Dunayevich, M.D., Rodrigo A. Pizarro, M.D., Dario F. Mirski, M.D., Ana Kaplan, M.D.

## SATURDAY

**COURSE 10** 9:00 a.m.-4:00 p.m.  
Room 112 B, Street Level, Convention Center

### MULTIMODAL TREATMENT OF EATING DISORDERS

Co-Directors: Kathryn J. Zerbe, M.D., Mae S. Sokol, M.D.

**COURSE 11** 9:00 a.m.-4:00 p.m.  
Room 203 A, Level 200, Convention Center

### OUTCOMES: USE OF RATING SCALES

Co-Directors: Luis F. Ramirez, M.D., Martha Sajatovic, M.D.

## 1:00 p.m. Sessions



### COURSES 12-16

Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.

**COURSE 12** 1:00 p.m.-5:00 p.m.  
Room 104 A, Street Level, Convention Center

### EVIDENCE-BASED MANAGEMENT OF SAD: FOCUS ON LIGHT THERAPY

Co-Directors: Raymond W. Lam, M.D., Anthony J. Levitt, M.D.

**COURSE 13** 1:00 p.m.-5:00 p.m.  
Room 104 B, Street Level, Convention Center

### NEUROENDOCRINOLOGY IN MOOD DISORDER: DYSREGULATION AND TREATMENT

Co-Directors: Mark A. Frye, M.D., Natalie L. Rasgon, M.D.  
Faculty: D. Jeffrey Newport, M.D., Stuart N. Seidman, M.D.

### COURSE 14 – WITHDRAWN

**COURSE 15** 1:00 p.m.-5:00 p.m.  
Room 108 B, Street Level, Convention Center

### THE EVALUATION AND MANAGEMENT OF PAIN

Director: Steven A. King, M.D.

**COURSE 16** 1:00 p.m.-5:00 p.m.  
Room 109 A, Street Level, Convention Center

### DREAM TRANSLATION: ONE EMPIRICALLY-BASED APPROACH

Director: Milton Kramer, M.D.

## 7:00 p.m. Sessions

### INDUSTRY-SUPPORTED SYMPOSIA 1-6

#### INDUSTRY-SUPPORTED SYMPOSIUM 1

7:00 p.m.-10:00 p.m.

Millennium Hall, Second Floor, Loews

#### PSYCHIATRY PRACTICE PARADIGM: THE EMERGING ROLE OF THE PSYCHIATRIST IN TREATING ALZHEIMER'S DISEASE

Supported by Eisai Inc., Pfizer Inc.

Chp: Pierre N. Tariot, M.D.

#### A Mild Cognitive Impairment Versus Early Alzheimer's Disease

J. Michael Ryan, M.D.

#### B Mild to Moderate Alzheimer's Disease

Pierre N. Tariot, M.D.

#### C Depression in Alzheimer's Disease

William E. Reichman, M.D.

#### D Dementia with Abnormal Neurological Features

J. Michael Ryan, M.D.

#### E Severe Dementia with Agitation and Nursing Home Issues

William E. Reichman, M.D.

#### F Psychosis in Alzheimer's Disease

William E. Reichman, M.D.

#### G Practice Management

Gary S. Moak, M.D.

#### INDUSTRY-SUPPORTED SYMPOSIUM 2

7:00 p.m.-10:00 p.m.

Regency Ballrooms A-C, Second Floor, Loews

#### MOLECULES AND MOOD DISORDERS: DRUG DISCOVERY AND THE TREATMENT OF DEPRESSION

Supported by Forest Laboratories, Inc.

Chp: Jerrold F. Rosenbaum, M.D.

#### A Antidepressant Drug Discovery: The Ways, Means, and Needs

Michael J. Owens, Ph.D.

#### B The Phenomenon of Single Isomer Drugs

Joseph Gal, Ph.D.

#### C Refining Current Therapies: Clinical Implications to the Treatment of Depression

C. Lindsay DeVane, Pharm.D.

#### D The State-of-the-Art in Treating Depression: 2002

Andrew A. Nierenberg, M.D.

**INDUSTRY-SUPPORTED SYMPOSIUM 3**

7:00 p.m.-10:00 p.m.

Grand Ballroom Salons E/F, Level 5, Marriott

**BIPOLAR DISORDER: NEW NATIONWIDE DATA ON MISDIAGNOSIS AND COMMUNITY COSTS***Supported by GlaxoSmithKline***Chp:** Mark A. Frye, M.D.

- A Prevalence and Burden of Depression in the Community and Primary Care**  
Myrna M. Weissman, Ph.D.
- B The True Prevalence of Bipolar Spectrum Disorder**  
Robert M.A. Hirschfeld, M.D.
- C Human Suffering and Economic Burden in a Large Community Sample**  
Joseph R. Calabrese, M.D.
- D New Developments in the Treatment of Bipolar Depression**  
Mark A. Frye, M.D.
- E The Challenge of Bipolar Disorder in Children and Adolescents**  
Karen D. Wagner, M.D.

**INDUSTRY-SUPPORTED SYMPOSIUM 4**

7:00 p.m.-10:00 p.m.

Grand Ballroom Salons G/H, Level 5, Marriott

**IMPROVING PATIENT OUTCOMES ACROSS THE SPECTRUM OF BIPOLAR DISORDER***Supported by Pfizer Inc.***Chp:** David J. Kupfer, M.D.

- A Managing the Pendulum of Mood in Bipolar Disorder**  
Jack M. Gorman, M.D.
- B Acute Mania: Pharmacologic Treatment Strategies**  
David J. Kupfer, M.D.
- C Phase-Specific Psychotherapy for Bipolar Disorder**  
Holly A. Swartz, M.D.
- D Gender Variation in Bipolar Disorder**  
Ellen Leibenluft, M.D.
- E The Longitudinal Course of Bipolar Disorder Across the Life Cycle**  
Ellen Frank, Ph.D.

**INDUSTRY-SUPPORTED SYMPOSIUM 5**

7:00 p.m.-10:00 p.m.

Wyndham Ballrooms A/B, First Floor, Wyndham

**NEW APPROACHES FOR TREATING ADHD: THE WHOLE-LIFE PERSPECTIVE***Supported by Eli Lilly and Company***Chp:** Christopher J. Kratochvil, M.D.**Co-Chp:** Janet Wozniak, M.D.

- A ADHD: DSM-IV and Beyond**  
Thomas E. Brown, Ph.D.
- B ADHD: Phenotypes and Pathophysiologies**  
Albert J. Allen, M.D., David Michelson, M.D.
- C New ADHD Treatment Options on the Horizon**  
Christopher J. Kratochvil, M.D.
- D From Childhood to Adolescence: Diagnosis and Comorbidity Issues**  
Thomas J. Spencer, M.D.
- E Issues in Diagnosing and Treating the Adult ADHD Patient**  
Lenard A. Adler, M.D.

**Discussant:** Janet Wozniak, M.D.**INDUSTRY-SUPPORTED SYMPOSIUM 6**

7:00 p.m.-10:00 p.m.

Wyndham Ballrooms C/D, First Floor, Wyndham

**ANTIPSYCHOTIC THERAPY AND CARDIOVASCULAR DISEASE: THE UNFOLDING STORY***Supported by Janssen Pharmaceutica***Chp:** Donald C. Goff, M.D.

- A Antipsychotic Therapy in Patients with Comorbidities: Issues and Polypharmacy**  
Donald C. Goff, M.D.
- B Torsade de Pointes, QT, and Antipsychotic Drugs**  
Walter V. Vieweg, M.D.
- C A Focus on Health: Metabolic Consequences of Antipsychotic Therapy**  
Donna A. Wirshing, M.D.
- D Antipsychotics and Diabetes: A Current Perspective on Epidemiology**  
Michael J. Sernyak, M.D.
- E Mechanisms of Antipsychotic-Induced Glucose Dysregulation and Insulin Resistance**  
John W. Newcomer, M.D.



# American Psychiatric Association

**Audiotapes  
Recorded Live!**



***High Quality Continues for  
the 2002 Annual Meeting ...***

Live recordings will be available  
for most of the following:

- Lectures • Advances in Research
- Presidential Symposium • Medical Updates
- Scientific and Clinical Reports • Symposia
- Debate • Research Advances in Medicine

Tapes may be purchased on site at Mobiltape's booth in the Convention Center, Level II Lobby.

**Mobiltape Company, Incorporated**  
24730 Avenue Tibbitts, Suite 170  
Valencia, CA 91355  
Phone: (661) 295-0504 ♦ (800) 369-5718  
Fax: (661) 295-8474  
Webside: [www.mobiltape.com](http://www.mobiltape.com)



# SUNDAY, MAY 19, 2002

## 155TH ANNUAL MEETING

### 8:00 a.m. Sessions



#### COURSES 17-22

Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.

#### COURSE 17 8:00 a.m.-12 noon

Room 107 A, Street Level, Convention Center

#### DSM-IV-TR CULTURAL FORMULATIONS: DIAGNOSIS AND THERAPY

Director: Russell F. Lim, M.D.

Faculty: J. Charles Ndelela, M.D., Candace M. Fleming, Ph.D.,  
Frances G. Lu, M.D., Michael W. Smith, M.D.

#### COURSE 18 8:00 a.m.-12 noon

Room 108 B, Street Level, Convention Center

#### THE PSYCHIATRIST AS EXPERT WITNESS

Director: Phillip J. Resnick, M.D.

#### COURSE 19 8:00 a.m.-12 noon

Room 112 A, Street Level, Convention Center

#### TRAINING IN THE USE OF THE POSITIVE AND NEGATIVE SYNDROME SCALE

Co-Directors: Lewis A. Opler, M.D., Paul M. Ramirez, Ph.D.

#### COURSE 20 8:00 a.m.-12 noon

Room 113 B, Street Level, Convention Center

#### THE EVALUATION AND IDENTIFICATION OF THE MAJOR DEMENTIAS

Director: Raymond A. Faber, M.D.

Faculty: Kevin F. Gray, M.D., Randolph B. Schiffer, M.D.

#### COURSE 21 8:00 a.m.-12 noon

Lecture Hall 114, Street Level, Convention Center

#### ANTICONVULSANTS IN BIPOLAR DISORDER

Co-Directors: Joseph R. Calabrese, M.D., Mark A. Frye, M.D.

Faculty: Terence A. Ketter, M.D.

#### COURSE 22 8:00 a.m.-12 noon

Room 203 B, Level 200, Convention Center

#### APPRECIATING AND ALLEVIATING SPOUSAL CAREGIVER BURDEN IN DEMENTIA

Co-Directors: Sheila M. Loboprabhu, M.D., Kimberly A. Arlinghaus, M.D.

Faculty: Ellen F. Barr, M.S.W., James W. Lomax II, M.D.

### INDUSTRY-SUPPORTED SYMPOSIA 7-12

#### INDUSTRY-SUPPORTED SYMPOSIUM 7

8:00 a.m.-11:00 a.m.

Millennium Hall, Second Floor, Loews

#### DIAGNOSIS AND TREATMENT ISSUES IN CHILD AND ADOLESCENT BIPOLAR DISORDERS

*Supported by Abbott Laboratories*

Chp.: Karen D. Wagner, M.D.

#### A Diagnosis and Course of Bipolar Disorder in Children and Adolescents

Karen D. Wagner, M.D.

#### B Genetic and Environmental Effects of Bipolar Disorder on Families and Offspring

Kiki D. Chang, M.D.

#### C Pharmacologic Treatment of Children and Adolescents with Bipolar Disorders

Robert A. Kowatch, M.D.

#### D Novel and Maintenance Treatment Approaches in Pediatric Bipolarity

Robert L. Findling, M.D.

#### E Diagnostic and Treatment Implications of Psychiatric Comorbidity in Juvenile Bipolar Disorder

Timothy E. Wilens, M.D.

#### INDUSTRY-SUPPORTED SYMPOSIUM 8

8:00 a.m.-11:00 a.m.

Regency Ballrooms A-C, Second Floor, Loews

#### LATE-LIFE DEPRESSION: OLD MYTHS AND NEW DATA

*Supported by Forest Laboratories, Inc.*

Chp.: Steven P. Roose, M.D.

#### A Late-Life Depression: Neuroanatomy and Medical Comorbidity

Anand Kumar, M.D.

#### B Depression: Pseudodementia and Executive Dysfunction

George S. Alexopoulos, M.D.

#### C How Long Should Antidepressant Trials Be in Geriatric Depression?

Harold A. Sackeim, Ph.D., Steven P. Roose, M.D., Tal Burt, M.D.

#### D Treatment of Depression in the Old and the Old-Old

Steven P. Roose, M.D.

#### E Interpersonal Psychotherapy Therapy in Late-Life Depression: Who Benefits?

Charles F. Reynolds III, M.D.

**INDUSTRY-SUPPORTED SYMPOSIUM 9**

8:00 a.m.-11:00 a.m.

Grand Ballroom Salons E/F, Level 5, Marriott

**DEPRESSIVE SUBTYPES: THE MULTIPLE FACES OF DEPRESSION**

*Supported by Organon Inc.*

**Chp.:** Maurizio Fava, M.D.

**A Atypical Depression: An Often Under-Recognized Condition**

Jonathan W. Stewart, M.D.

**B Treatment Challenges in Anxious Depression**

Maurizio Fava, M.D.

**C Melancholic Depression: Are Dual-Action Antidepressants Superior to Selective Agents?**

J. Craig Nelson, M.D.

**D Vascular Depression**

Ranga K. Krishnan, M.D.

**E Practical Approach to Psychotic Depression**

Linda L. Carpenter, M.D.

**INDUSTRY-SUPPORTED SYMPOSIUM 10**

8:00 a.m.-11:00 a.m.

Grand Ballroom Salons G/H, Level 5, Marriott

**RECOVERY FROM DEPRESSION: NEW PERSPECTIVES TO IMPROVE OUTCOMES**

*Supported by Wyeth Pharmaceuticals*

**Chp.:** Michael E. Thase, M.D.

**A Recovery from Depression: Conceptual Underpinnings**

Michael E. Thase, M.D.

**B Augmentation and Combination Strategies for the Newer Antidepressants**

Andrew A. Nierenberg, M.D.

**C Combining Psychotherapy and Medication for Depression**

John C. Markowitz, M.D.

**D Maximizing Efficacy in the Treatment of Chronic Depression**

Susan G. Kornstein, M.D.

**INDUSTRY-SUPPORTED SYMPOSIUM 11**

8:00 a.m.-11:00 a.m.

Wyndham Ballrooms A/B, First Floor, Wyndham

**TREATING PSYCHOTIC ILLNESS ACROSS THE LIFE SPAN: ARE DRUGS ENOUGH?**

*Supported by Eli Lilly and Company*

**Chp.:** Paul J. Barreira, M.D.

**Co-Chp.:** Sumer Verma, M.D.

**A Psychotic Illness in Children**

Jean A. Frazier, M.D.

**B From Getting by to Getting Better**

Gerald A. Maguire, M.D.

**C Raising the Bar of Expectations**

Ralph Aquila, M.D.

**D Madness and the Rest of a Life**

Anne Alonso, Ph.D.

**E Best Practices in Psychosocial Rehabilitation for Psychotic Illnesses**

Paul J. Barreira, M.D.

**F Is the Cheapest Alternative the Most Economical?**

Sumer Verma, M.D.

**INDUSTRY-SUPPORTED SYMPOSIUM 12**

8:00 a.m.-11:00 a.m.

Wyndham Ballrooms C/D, First Floor, Wyndham

**ADVANCES IN THE TREATMENT OF PSYCHOSIS: MINIMIZING THE BURDEN OF DISEASE**

*Supported by Bristol-Myers Squibb Company*

**Chp.:** Daniel R. Weinberger, M.D.

**A The Public Health Impact of Schizophrenia**

Norman Sartorius, M.D.

**B Evolution of Antipsychotic Therapies: Overcoming Treatment Barriers**

Daniel R. Weinberger, M.D.

**C Optimizing Management of Schizophrenia: Bridging the Gap Between Clinical Research and Real World Clinical Practice**

Andrew J. Cutler, M.D.

**D Caring for a Family Member with Schizophrenia: A Personal Account**

Martin S. Willick, M.D.

---

**9:00 a.m. Sessions**

---



**COURSES 23-29**

Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.

**COURSE 23**

9:00 a.m.-4:00 p.m.

Room 102 A, Street Level, Convention Center

**BASIC CONCEPTS IN ADMINISTRATIVE PSYCHIATRY: CARE MANAGEMENT, LAW, AND ETHICS**

Co-Directors: Christopher G. Fichtner, M.D., Wesley Sowers, M.D.  
Faculty: Stephen H. Dinwiddie, M.D., William G. Wood, M.D., Steven Moffic, M.D., John A. Talbott, M.D.

**COURSE 24** 9:00 a.m.-4:00 p.m.  
**Room 102 B, Street Level, Convention Center**

**THE SUBJECTIVE EXPERIENCE: CRUCIAL KEYS TO THERAPY AND TO THE HUMAN MIND**

**Director:** Vincenzo R. Sanguineti, M.D.  
**Faculty:** Donatella Marazziti, M.D.

**COURSE 25** 9:00 a.m.-4:00 p.m.  
**Room 104 A, Street Level, Convention Center**

**THERAPEUTIC INTERVENTIONS IN EATING DISORDERS: BASIC PRINCIPLES**

**Director:** David C. Jimerson, M.D.  
**Faculty:** Michael J. Devlin, M.D., Katherine A. Halmi, M.D., James E. Mitchell, M.D., Joel Yager, M.D.

**COURSE 26** 9:00 a.m.-4:00 p.m.  
**Room 106 A, Street Level, Convention Center**

**MONEY MATTERS: USING THEORY IN CLINICAL PRACTICE**

**Director:** Cecilia M. Mikalac, M.D.

**COURSE 27** 9:00 a.m.-4:00 p.m.  
**Room 108 A, Street Level, Convention Center**

**ALZHEIMER'S DISEASE: ADVANCED APPROACHES TO TREATMENT**

**Director:** William E. Reichman, M.D.  
**Faculty:** Constanine G. Lyketsos, M.D., David L. Sultzer, M.D., Peter M. Aupperle, M.D., Jacobo E. Mintzer, M.D., Pierre N. Tariot, M.D.

**COURSE 28** 9:00 a.m.-4:00 p.m.  
**Room 111 A, Street Level, Convention Center**

**MEDICAL ETHICS 101**

**Director:** Edmund G. Howe, M.D.

**COURSE 29** 9:00 a.m.-4:00 p.m.  
**Room 113 C, Street Level, Convention Center**

**BUILD YOUR OWN RELATIONAL DATABASE ELECTRONIC MEDICAL RECORD**

**Director:** Daniel A. Deutschman, M.D.

**12:30 p.m. Session**

**BUSINESS MEETING**

(Voting Members Only\*)

12:30 p.m.-1:30 p.m.  
 Rooms 201 A-C, Level 200, Convention Center

**CALL TO ORDER**

Richard K. Harding, M.D., *President*

**MEMORIAL TO DECEASED MEMBERS**

**ANNOUNCEMENT OF ELECTION RESULTS**

Catherine S. May, M.D., *Chairperson,*  
*Committee of Tellers*

**REPORTS TO THE MEMBERSHIP**

*Secretary:* Pedro Ruiz, M.D.  
*Treasurer:* Carol A. Bernstein, M.D.  
*Speaker, Assembly:* Nada L. Stotland, M.D.  
*Speaker-Elect, Assembly:* Albert C. Gaw, M.D.  
*Chairperson, By-Laws Committee:*  
 Jo-Ellyn M. Ryall, M.D.  
*Chairperson, Elections Committee:*  
 Yvonne B. Ferguson, M.D.  
*Chairperson, Membership Committee:*  
 Bernard A. Katz, M.D.  
*Medical Director:* Steven M. Mirin, M.D.

**ANNUAL FORUM**

**ADJOURNMENT**

\*Members-in-Training, General Members, Fellows, Life Fellows, and Life Members. Badge or APA membership card necessary for admission. No cameras or tape recorders will be permitted.

**1:00 p.m. Sessions**



**COURSES 30-38**

Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.

**COURSE 30** 1:00 p.m.-5:00 p.m.  
**Room 104 B, Street Level, Convention Center**

**INTRODUCTION TO CORRECTIONAL PSYCHIATRY**

**Co-Directors:** James E. Dillon, M.D., Lee H. Rome, M.D.  
**Faculty:** Richard S. Jackson, M.D., Sanjeev Venkataraman, M.D.

**COURSE 31** 1:00 p.m.-5:00 p.m.  
**Room 107 A, Street Level, Convention Center**

**INTEGRATIVE PSYCHOTHERAPY SUPERVISION: BASIC TOOLS**

**Director:** Paul Rodenhauer, M.D.  
**Faculty:** Ramona Dvorak, M.D., Albert F. Painter, Psy.D., John R. Rudisill, Ph.D.

**COURSE 32** 1:00 p.m.-5:00 p.m.  
**Room 107 B, Street Level, Convention Center**

**CORE COMPETENCIES IN WORKPLACE PSYCHIATRY**  
*APA Committee on Psychiatry in the Workplace, Academy of Organizational and Occupational Psychiatry*

**Director:** Ronald Schouten, M.D.  
**Faculty:** Stephen H. Heidel, M.D., Steven E. Pflanz, M.D., Marcia Scott, M.D.

## SUNDAY

**COURSE 33** 1:00 p.m.-5:00 p.m.  
Room 108 B, Street Level, Convention Center

### PSYCHIATRIC DISORDERS IN PREGNANCY AND POSTPARTUM

**Co-Directors:** Shaila Misri, M.D., Kristin S. Sivertz, M.D.  
**Faculty:** Diana Carter, M.B., Maria R. Corral, M.D., Deirdre M. Ryan, M.B.

**COURSE 34** 1:00 p.m.-5:00 p.m.  
Room 109 A, Street Level, Convention Center

### EVIDENCE-GUIDED DUAL DIAGNOSIS TREATMENT

**Director:** Andrew P. Ho, M.D.  
**Faculty:** Robert Chang, M.D., Davin A. Agustines, M.D., Carol Giannini, M.P.H., James Smith, M.D., David Haponski, M.S.W.

**COURSE 35** 1:00 p.m.-5:00 p.m.  
Room 112 A, Street Level, Convention Center

### IRRESISTIBLE SLEEP: NARCOLEPSY UPDATE

**Director:** Lois Krahn, M.D.  
**Faculty:** Mark R. Hansen, M.D., Steven I. Althuler, M.D., Jarrett W. Richardson, M.D.

**COURSE 36** 1:00 p.m.-5:00 p.m.  
Room 112 B, Street Level, Convention Center

### INTEGRATING PHARMACOTHERAPY AND PSYCHOTHERAPY

**Co-Directors:** Barton J. Blinder, M.D., Bernard D. Beitman, M.D.  
**Faculty:** Mark G. Barad, M.D.

**COURSE 37** 1:00 p.m.-5:00 p.m.  
Room 113 B, Street Level, Convention Center

### PSYCHIATRIC INTERVENTIONS IN DISASTERS: LESSONS FROM EXPERIENCE

**Director:** Carol S. North, M.D.  
**Faculty:** Betty Pfefferbaum, M.D., Phebe M. Tucker, M.D.

**COURSE 38** 1:00 p.m.-5:00 p.m.  
Room 203 B, Level 200, Convention Center

### MELATONIN AND LIGHT TREATMENT OF SAD, SLEEP, AND OTHER BODY CLOCK DISORDERS

**Director:** Alfred J. Lewy, M.D.  
**Faculty:** George Brainard, Ph.D.

## 1:30 p.m. Sessions

### INDUSTRY-SUPPORTED SYMPOSIA 13-18

**INDUSTRY-SUPPORTED SYMPOSIUM 13**  
1:30 p.m.-4:30 p.m.  
Millennium Hall, Second Floor, Loews

**RECENT DEVELOPMENTS IN THE SCIENCE AND TREATMENT OF PTSD**  
*Supported by GlaxoSmithKline*

**Chp.:** Jonathan R.T. Davidson, M.D.  
**Co-Chp.:** Rachel Yehuda, Ph.D.

**A Risk and Resilience Factors in PTSD**  
Rachel Yehuda, Ph.D.

**B What Can Neuroimaging Teach Us About PTSD?**  
Scott L. Rauch, M.D.

**C Medication Strategies in PTSD**  
David V. Sheehan, M.D.

**D Treatment of PTSD with Exposure Therapy**  
Barbara O. Rothbaum, Ph.D.

**E Using Assessment Tools in Clinical Practice: When, Why, and How?**  
Kathryn M. Connor, M.D.

**INDUSTRY-SUPPORTED SYMPOSIUM 14**  
1:30 p.m.-4:30 p.m.  
Regency Ballrooms A-C, Second Floor, Loews

**CUSTOMIZING CARE FOR PATIENTS WITH BIPOLAR DISORDER**  
*Supported by AstraZeneca Pharmaceuticals*

**Chp.:** Gary S. Sachs, M.D.

**A Intervention for Refractory Patients**  
Patricia Suppes, M.D.

**B Significance of Psychosis**  
Charles L. Bowden, M.D.

**C Choosing Initial Mood Stabilizer After Acute Mania**  
Guy M. Goodwin, M.D.

**D Selection of an Acute Treatment Strategy: Sequential Versus Stratified Approach**  
Gary S. Sachs, M.D.

**E Dealing with Common Problems During Ongoing Treatment in Bipolar Disorder**  
W. Gordon Frankle, M.D.

**INDUSTRY-SUPPORTED SYMPOSIUM 15**

1:30 p.m.-4:30 p.m.

Grand Ballroom Salons E/F, Level 5, Marriott

**THE AGING BRAIN AND VULNERABILITY TO DEPRESSION***Supported by Organon Inc***Chp.:** Charles F. Reynolds III, M.D.**A Age, Neurobiology, and Treatment Response**

Madhukar H. Trivedi, M.D.

**B The Impact on Cognition of Pharmacological Treatment for Late-Life Depression**

Ruth O'Hara, Ph.D., Alan F. Schatzberg, M.D., Greer M. Murphy, M.D.

**C Pharmacogenetics in Geriatric Depression**

Greer M. Murphy, M.D.

**D Treatment of the Depressed: Old-Old in Outpatient and Long-Term Care Settings**

Steven P. Roose, M.D.

**INDUSTRY-SUPPORTED SYMPOSIUM 16**

1:30 p.m.-4:30 p.m.

Grand Ballroom Salons G/H, Level 5, Marriott

**LONG-TERM MANAGEMENT OF MOOD DISORDERS***Supported by Cyberonics, Inc***Chp.:** A. John Rush, M.D.**Co-Chp.:** Harold A. Sackeim, Ph.D.**A Does Medication Change the Long-Term Course of Mood Disorders?**

Susan G. Kornstein, M.D.

**B Does Psychotherapy Change the Long-Term Course of Mood Disorders?**

Robin B. Jarrett, Ph.D.

**C Does ECT Alter the Long-Term Course of Mood Disorders?**

Harold A. Sackeim, Ph.D.

**D Vagus Nerve Stimulation for Depression: Methods and Mechanisms**

Mark S. George, M.D.

**E Does Vagus Stimulation Change the Long-Term Course of Mood Disorders?**

Lauren B. Marangell, M.D.

**INDUSTRY-SUPPORTED SYMPOSIUM 17**

1:30 p.m.-4:30 p.m.

Wyndham Ballrooms A/B, First Floor, Wyndham

**THE ADHERENCE CHALLENGE: CHRONIC ISSUES AND EMERGING SOLUTIONS WITH ANTIPSYCHOTIC THERAPY***Supported by Janssen Pharmaceutica***Chp.:** John M. Kane, M.D.**Co-Chp.:** Stephen R. Marder, M.D.**A Approaching the Adherence Challenge**

Stephen R. Marder, M.D., Donna A. Wirshing, M.D., William C. Wirshing, M.D.

**B Pharmacologic Options for Schizophrenia: Implications for Compliance**

John M. Kane, M.D.

**C Research Experience with Long-Acting Atypical Antipsychotic Medication**

Samuel J. Keith, M.D.

**D Views from the Nursing Perspective: Problems and Solutions**

Kathleen Jarboe, R.N.

**Discussant:** Joe Lovelace, J.D.**INDUSTRY-SUPPORTED SYMPOSIUM 18**

1:30 p.m.-4:30 p.m.

Wyndham Ballrooms C/D, First Floor, Wyndham

**CHALLENGES AND OPPORTUNITIES IN THE MANAGEMENT OF PSYCHOTIC DISORDERS***Supported by Bristol-Myers Squibb Company***Chp.:** Diana O. Perkins, M.D.**Co-Chps.:** Jeffrey A. Lieberman, M.D., Joseph P. McEvoy, M.D.**A Intervening Early in the Evolution of Schizophrenia: Need for Novel Approaches During the Prodromal Phase**

Patrick D. McGorry, Ph.D., Lisa Phillips, M.S.C., Alison R. Yung, M.D., Paul Amminger, M.B., John Koutsogiannis, M.D., Jannine Ward, B.A., Phillippe Conus, M.D.

**B New Advances in Schizophrenia Pharmacotherapy: Management of Acute Episodes**

Diana O. Perkins, M.D.

**C Improving Long-Term Outcomes in Patients with Schizophrenia**

Peter J. Weiden, M.D.

*(Continued on next page)*



## SUNDAY

**D The Impact of Safety and Tolerability on Patients' Satisfaction with Therapy**  
Joseph P. McEvoy, M.D.

**E Mechanism of Action as Predictor for Clinical Utility: Lessons from Schizophrenia Research**  
Jeffrey A. Lieberman, M.D.

### 2:30 p.m. Sessions

#### LECTURE 1

2:30 p.m.-4:00 p.m.

Lecture Hall 114, Street Level, Convention Center

**AAPL/APA'S MANFRED S. GUTTMACHER  
AWARD LECTURE**

John Monahan, Ph.D.

**Rethinking Risk Assessment: The MacArthur  
Study of Mental Disorder and Violence**

Chp.: Brian Crowley, M.D.

Co-Chp.: Michael A. Norko, M.D.

Legislatures, courts, and the public have come to expect that mental health professionals can provide accurate assessment of the risk for violence in mentally ill persons. John Monahan, Ph.D., one of the authors of *Rethinking Risk Assessment: The MacArthur Study of Mental Disorder and Violence*, reviews the study's decision-tree approach for identifying patients at risk for violence and discusses the implications of the approach for the everyday clinical practice of risk assessment and risk management. Dr. Monahan, a clinical psychologist, is the Henry L. and Grace Doherty Charitable Foundation Professor of Law at the University of Virginia in Charlottesville, where he is also Professor of Psychology and Legal Medicine. He directed the MacArthur Foundation's Research Network on Mental Health and the Law from 1988 to 1998 and now directs the Foundation's initiative on mandated community treatment. Dr. Monahan formerly received APA's Manfred Guttmacher award for his book *The Clinical Prediction of Violent Behavior* and APA's Isaac Ray Award for his contributions to forensic psychiatry. He has been elected to the Institute of Medicine of the National Academy of Sciences. He received his doctoral degree from Indiana University.

THIS SESSION WILL BE AUDIOTAPED.

### 5:00 p.m. Session

#### OFFICIAL OPENING SESSION

5:00 p.m.-6:30 p.m.

Ballrooms A/B, Ballroom Level, Convention Center

#### CALL TO ORDER

Richard K. Harding, M.D.

President

#### INTRODUCTION OF STAGE GUESTS

#### INTRODUCTION OF CHAIRPERSONS OF THE SCIENTIFIC PROGRAM COMMITTEE AND THE TASK FORCE ON LOCAL ARRANGEMENTS

Philip R. Muskin, M.D.

*Chairperson, Annual Meeting Scientific Program Committee*

Marvin Kanefield, D.O.

*Chairperson, Task Force on Local Arrangements*

#### INTRODUCTION OF VISITING DIGNITARIES

#### PRESIDENTIAL ADDRESS

Richard K. Harding, M.D.

*To be introduced by R. Dale Walker, M.D.*

#### RESPONSE OF THE PRESIDENT-ELECT

Paul S. Appelbaum, M.D.

*To be introduced by Alan A. Stone, M.D.*

#### ADJOURNMENT

### 7:00 p.m. Sessions

#### INDUSTRY-SUPPORTED SYMPOSIA 19-24

#### INDUSTRY-SUPPORTED SYMPOSIUM 19

7:00 p.m.-10:00 p.m.

Millennium Hall, Second Floor, Loews

#### TREATMENT OF ANXIETY DISORDERS: WHERE ARE WE, AND WHERE ARE WE GOING?

*Supported by Pfizer Inc.*

Chp.: R. Bruce Lydiard, M.D.

#### A Comorbidities and Issues to Consider in the Management of Anxiety Disorders

Ronald C. Kessler, Ph.D.

#### B Management of Depression and Demoralization in Anxiety Disorders

Naomi M. Simon, M.D.

#### C Managing the Disordered Sleep Associated with Anxiety and Mood Disorders

John W. Winkelman, M.D.

#### D GAD: Long-Term Treatment to Improve Outcome

Mark H. Pollack, M.D.

#### E Current and Future Treatments for Anxiety: Efficacy and Tolerability

R. Bruce Lydiard, M.D.

**INDUSTRY-SUPPORTED SYMPOSIUM 20**

7:00 p.m.-10:00 p.m.

Regency Ballrooms A-C, Second Floor, Loews

**ATYPICAL DEPRESSION: OVERVIEW AND NEW DEVELOPMENTS***Supported by Somerset Pharmaceuticals, Inc.***Chp.:** Ranga K. Krishnan, M.D.**Co-Chp.:** Charles B. Nemeroff, M.D.**A The Biology of Atypical Depression**

Ranga K. Krishnan, M.D.

**B The Biology of PTSD and Atypical Depression: The Role of Early-Life Trauma**

Linda L. Carpenter, M.D.

**C Diagnostic Issues in Atypical Depression**

Ned H. Kalin, M.D.

**D Psychotherapy in the Treatment of Major Depression**

Barbara O. Rothbaum, Ph.D.

**E New Treatments for Atypical Depression**

Charles B. Nemeroff, M.D.

**Discussant:** Martin B. Keller, M.D.**INDUSTRY-SUPPORTED SYMPOSIUM 21**

7:00 p.m.-10:00 p.m.

Grand Ballroom Salons E/F, Level 5, Marriott

**NEW DEVELOPMENTS IN THE TREATMENT OF BIPOLAR DISORDER***Supported by Abbott Laboratories***Chp.:** Robert M.A. Hirschfeld, M.D.**A Advances in the Treatment of Mania**

Gary S. Sachs, M.D.

**B Update on the Treatment of Bipolar Depression**

Robert M.A. Hirschfeld, M.D.

**C Stabilizing the Course of Refractory Bipolar Illness: Meeting the Challenges of Dysphoric States and Mixed Mania**

Patricia Suppes, M.D.

**D Update on Psychosocial Treatments of Bipolar Disorder**

Michael W. Otto, Ph.D.

**E The Multiple Goals of Maintenance Treatment**

Charles L. Bowden, M.D.

**INDUSTRY-SUPPORTED SYMPOSIUM 22**

7:00 p.m.-10:00 p.m.

Grand Ballroom Salons G/H, Level 5, Marriott

**TREATMENT OF MOOD AND ANXIETY DISORDERS IN WOMEN: WHAT IS EVIDENCE AND WHAT IS ART?***Supported by Wyeth Pharmaceuticals***Chp.:** Kimberly A. Yonkers, M.D.**A Treatment of Mood Disorders in Pregnancy and the Postpartum Period**

Lee S. Cohen, M.D.

**B Course and Treatment of Bipolar Illness During Pregnancy and the Postpartum Period**

Adele C. Viguera, M.D.

**C New Strategies in Managing PMDD**

Kimberly A. Yonkers, M.D.

**D Gender as a Factor**

M. Katherine Shear, M.D.

**INDUSTRY-SUPPORTED SYMPOSIUM 23**

7:00 p.m.-10:00 p.m.

Wyndham Ballrooms A/B, First Floor, Wyndham

**PRIMARY MOOD STABILIZERS AS THE CORNERSTONE OF TREATMENT FOR BIPOLAR DISORDER***Supported by Eli Lilly and Company***Chp.:** Paul E. Keck, Jr., M.D.**A Mania and Mood Stabilization: What's New?**

Lauren B. Marangell, M.D.

**B Practical Approaches to Recognizing and Managing Side Effects**

Paul E. Keck, Jr., M.D.

**C Treating Depression and Suicidality**

Michael E. Thase, M.D.

**D Update on the Treatment of Rapid-Cycling Bipolar Disorder**

Joseph F. Goldberg, M.D.

**E Compliance and Optimizing Function**

Guy M. Goodwin, M.D.

**F The Doctor/Patient Relationship: How to Get Help for the One You Love**

Mary R. Worthen

## SUNDAY

### INDUSTRY-SUPPORTED SYMPOSIUM 24

7:00 p.m.-10:00 p.m.

Wyndham Ballrooms C/D, First Floor, Wyndham

### MOLECULES OF THE MIND: THE SCIENCE OF SCHIZOPHRENIA

*Supported by AstraZeneca Pharmaceuticals*

Chp.: Jeffrey A. Lieberman, M.D.

#### A The Neurobiology of Cognitive Dysfunction in Schizophrenia

David A. Lewis, M.D.

#### B Nicotinic Receptors and the Genetics of Schizophrenia and Bipolar Disorder

Robert Freedman, M.D.

#### C Glutamatergic Transmission in Schizophrenia

Carol A. Tamminga, M.D.

#### D White-Matter Abnormalities in Schizophrenia

Kenneth L. Davis, M.D.

#### E Molecular Biology and Genetics of Cortical Function in Schizophrenia

Daniel R. Weinberger, M.D.

#### F Neuroplasticity and Cellular Resilience in Mood Disorders

Husseini K. Manji, M.D.

## MEDIA SESSIONS 1-2

### MEDIA SESSION 1

7:00 p.m.-10:00 p.m.

Washington Rooms A-C, Third Floor, Loews

### HOLOCAUST MEMORIES

Chp.: Maurice Preter, M.D.

#### 1 Our Children

(68 minutes)

Distributor: Mimi Krant

NCJF-Brandeis University

Lown 102 MS053

Waltham, MA 02454

*Our Children* illustrates the impact of massive psychological trauma on childhood and adult development. In this Yiddish-language feature made in Poland, part docudrama, part melancholic comedy, famous Yiddish comedians Dzigal and Shumacher visit an orphanage near the city of Lodz to perform for an audience of Jewish orphans who survived the Holocaust. Their performance, although well intentioned, stirs up painful memories of recent events, but also offends the children by the sentimentalized and naïve depiction of wartime conditions. Having all lived through the reality of separation and loss, the children take over the stage, outdo the performers, and tell their stories.

Discussants: Maurice Preter, M.D., Yehuda Nir, M.D., Dori Laub, M.D., Harold J. Bursztajn, M.D.

### MEDIA SESSION 2

7:00 p.m.-10:00 p.m.

Congress Rooms A-C, Fourth Floor, Loews

### PSYCHIATRY GOES TO THE MOVIES

Co-Chps.: Steven E. Hyler, M.D., Harvey R. Greenberg, M.D.

#### 2 Memento

(120 minutes)

Distributor: Facets Multimedia

1517 West Fullerton

Chicago, IL 60614

*Memento* is a film about the quest of Leonard Shelby. Although he wears expensive, tailored suits, and drives a late-model Jaguar sedan, he lives in cheap anonymous motels, paying his way with thick wads of cash. Shelby looks like a successful businessman; however, his only work is the pursuit of vengeance. He spends all his time tracking and punishing the man who raped and murdered his wife. The difficulty of locating his wife's killer is compounded by the fact that he suffers from a rare untreatable form of memory loss. Although he can recall details from his life before the "accident," Leonard cannot remember what happened within 15 minutes of the event. The police dismiss his suspicions; therefore, Leonard's complex life has become an all consuming quest for justice.

Discussant: Steven E. Hyler, M.D.



# MONDAY, MAY 20, 2002

## 155TH ANNUAL MEETING

### 7:00 a.m. Sessions

#### PART 1 OF INDUSTRY-SUPPORTED BREAKFAST SYMPOSIA 25-30

##### INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 25, PART 1

7:00 a.m.-8:30 a.m.

Millennium Hall, Second Floor, Loews

##### CLINICAL CHALLENGES IN DEPRESSION

*Supported by GlaxoSmithKline*

Chp.: Prakash S. Masand, M.D.

##### A Special Challenges in Treating Bipolar Depression and Psychotic Depression

David V. Sheehan, M.D.

##### B Growing Up Depressed: The Underserved Child and Adolescent

Neal D. Ryan, M.D.

##### C Cardiovascular Disease and Depression: A Deadly Comorbidity

Dominique L. Musselman, M.D.

##### INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 26, PART 1

7:00 a.m.-8:30 a.m.

Regency Ballrooms A-C, Second Floor, Loews

##### NOVEL ANTIPSYCHOTIC DRUGS: ADVANCES IN THE TREATMENT OF PSYCHOTIC SPECTRUM DISORDERS

*Supported by Bristol-Myers Squibb Company*

Chp.: Robert E. Hales, M.D.

Co-Chp.: Stuart C. Yudofsky, M.D.

##### A Bench to Bedside: Rational Selection of Medications in Treating Schizophrenia

Rona Hu, M.D.

##### B What We Have Learned About the Long-Term Management of Schizophrenia: What Constitutes Treatment Refractoriness?

John M. Kane, M.D.

##### INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 27, PART 1

7:00 a.m.-8:30 a.m.

Grand Ballroom Salons E/F, Level 5, Marriott

##### ANTIPSYCHOTIC PHARMACOTHERAPY AND THE HIPPOCRATIC OATH: ABOVE ALL DO NO HARM

*Supported by AstraZeneca Pharmaceuticals*

Chp.: Henry A. Nasrallah, M.D.

##### A Medical Morbidity and Mortality in Patients with Schizophrenia

S. Charles Schulz, M.D.

##### B Minimizing Acute and Long-Term Movement Disorders with Atypical Antipsychotics

Lilli Kopala, M.D., David Whitehorn, Ph.D., Hazel  
Woodley, R.N., Connie Hault, M.D., Heather Milliken, M.D.,  
S. Devarajan, M.D., Uttam J. Wadhwa, M.D.

##### C Weight Gain and Obesity Secondary to Atypicals: Immediate and Long-Term Health Threats

Diana O. Perkins, M.D.

##### INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 28, PART 1

7:00 a.m.-8:30 a.m.

Grand Ballroom Salons G/H, Level 5, Marriott

##### UNDERSTANDING SLEEP MEDICINE: WHAT THE PSYCHIATRIST NEEDS TO KNOW

*Supported by Wyeth Pharmaceuticals*

Chp.: Milton K. Erman, M.D.

##### A Sleep, Safety, and Public Policy

Mark R. Rosekind, Ph.D.

##### B Sleep Disorders: What the Psychiatrist Needs to Know

Lois Krahn, M.D.

##### C Innovative Strategies in the Management of Insomnia

Karl Doghramji, M.D.

##### INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 29, PART 1

7:00 a.m.-8:30 a.m.

Wyndham Ballrooms A/B, First Floor, Wyndham

##### ONE SIZE DOESN'T FIT ALL: DEPRESSION THERAPIES FOR THE 21ST CENTURY

*Supported by Eli Lilly and Company*

Chp.: David L. Dunner, M.D.

##### A The Physical Manifestations of Depression

John H. Greist, M.D.

##### B Improving Outcomes in the Long-Term Treatment of Depression: Giving Patients a Choice

Maurizio Fava, M.D.

##### C Adapting Psychotherapies to a Patient's Individual Needs

Ellen Frank, Ph.D.

## MONDAY

---

### INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 30, PART 1

7:00 a.m.-8:30 a.m.

Wyndham Ballrooms C/D, First Floor, Wyndham

### BREAKING THE SILENCE OF CHILDREN'S MENTAL ILLNESS: NATIONAL INITIATIVES, EARLY DETECTION, AND NEW PHARMACOTHERAPIES

*Supported by Janssen Pharmaceutica*

Chp.: Robert L. Findling, M.D.

#### A Mental Illness in Children: Diagnosing Outside the Box Hans Steiner, M.D.

#### B Atypical Antipsychotics in Pediatric Psychiatry: Efficacy in Well-Designed Trials

Christopher J. McDougle, M.D.

### RESIDENT'S SESSION

7:00 a.m.-8:30 a.m.

Salon II, First Floor, Courtyard by Marriott

### MEET THE EXPERTS: SUNNY-SIDE UP

Chp.: Richard K. Harding, M.D.

At this breakfast, nationally recognized "experts" will sit at tables with small groups of residents and discuss a variety of career issues and opportunities in psychiatry. Topic areas include addiction/substance abuse, administrative psychiatry, child/adolescent psychiatry, consultation-liaison, cultural competency, emergency/disaster psychiatry, "how to be an expert witness: forensic psychiatry," geriatric psychiatry, leadership development, public/community psychiatry, psychiatry, law and ethics, psychodynamic psychotherapy, research, and women's mental health, among others.

---

## 8:00 a.m. Sessions

---



### COURSES 39-44

Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.

#### COURSE 39

8:00 a.m.-12 noon

Ormandy East, Street Level, DoubleTree

#### INTRODUCTION TO TRANSCRANIAL MAGNETIC STIMULATION

Co-Directors: Ziad H. Nahas, M.D., Leon J. Grunhaus, M.D.

Faculty: Sarah H. Lisanby, M.D., Martin P. Szuba, M.D.

#### COURSE 40

8:00 a.m.-12 noon

Concerto B, Third Floor, DoubleTree

#### PSYCHIATRIC CONSULTATIONS IN MEDICAL SETTINGS: THE BASICS

Director: Richard L. Elliott, M.D.

#### COURSE 41

8:00 a.m.-12 noon

Overture, Third Floor, DoubleTree

#### RISK ASSESSMENT FOR VIOLENCE

Director: Phillip J. Resnick, M.D.

#### COURSE 42

8:00 a.m.-12 noon

Minuet, Fourth Floor, DoubleTree

#### TEACHING PSYCHIATRY? LET HOLLYWOOD HELP!

Director: Steven E. Hyler, M.D.

Faculty: Carol A. Bernstein, M.D., Michael B. First, M.D.

#### COURSE 43

8:00 a.m.-12 noon

Rhapsody, Fourth Floor, DoubleTree

#### FAMILIES AND MEDICAL ILLNESS: AN INTEGRATIVE TREATMENT APPROACH

Director: John S. Rolland, M.D.

#### COURSE 44

8:00 a.m.-12 noon

Sonata 5, Fifth Floor, DoubleTree

#### USING HUMANITIES TO UNDERSTAND MOOD DISORDERS

Director: Emilie S. Passow, Ph.D.

Faculty: Jerome S. Gans, M.D., Steven D. Targum, M.D.

---

## 9:00 a.m. Sessions

---

#### CLINICAL CASE CONFERENCE 1

9:00 a.m.-10:30 a.m.

Room 103 B, Street Level, Convention Center

#### CONTRASTING PSYCHOPATHOLOGY IN ADOLESCENTS AND ADULTS

Moderator: Lynda A. Tenhundfeld, M.D.

**THIS SESSION IS OPEN TO APA MEMBERS ONLY.  
BLUE REGISTRATION BADGE OR APA MEMBER-  
SHIP CARD REQUIRED FOR**

**CONTINUOUS CLINICAL CASE CONFERENCE 1:  
PART 1**

9:00 a.m.-12 noon  
Rooms 106 A/B, Street Level, Convention Center

**LIVES AND TREATMENTS: TWO PATIENTS, TWO  
THERAPISTS**

**Moderator:** James W. Lomax II, M.D.  
**Presenters:** Glen O. Gabbard, M.D., Irma J. Bland, M.D.

**THIS SESSION IS OPEN TO APA MEMBERS ONLY.  
BLUE REGISTRATION BADGE OR APA MEMBER-  
SHIP CARD REQUIRED FOR**



**COURSES 45-50**

Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

**COURSE 45** 9:00 a.m.-4:00 p.m.  
**Ormandy West, Street Level, DoubleTree**

**PASS THE BOARDS! THE PART II ORAL EXAM**

**Director:** James C.Y. Chou, M.D.  
**Faculty:** Gregory C. Bunt, M.D.

**COURSE 46** 9:00 a.m.-4:00 p.m.  
**Orchestra Room, Second Floor, DoubleTree**

**ADVANCED INTERVIEWING TECHNIQUES**

**Director:** Shawn C. Shea, M.D.

**COURSE 47** 9:00 a.m.-4:00 p.m.  
**Aria A, Third Floor, DoubleTree**

**TRAUMATIC BRAIN INJURY: NEUROPSYCHIATRIC  
ASSESSMENT**

**Director:** Robert P. Granacher, M.D.

**COURSE 48** 9:00 a.m.-4:00 p.m.  
**Concerto A, Third Floor, DoubleTree**

**DISORDERS OF THE SELF: DIFFERENTIAL  
DIAGNOSIS AND TREATMENT**

**Director:** James F. Masterson, M.D.

**COURSE 49** 9:00 a.m.-4:00 p.m.  
**Symphony Ballroom, Third Floor, DoubleTree**

**ADVANCES IN NEUROPSYCHIATRY**

**Director:** C. Edward Coffey, M.D.  
**Faculty:** Michael R. Trimble, M.D., Mark S. George, M.D.

**COURSE 50** 9:00 a.m.-4:00 p.m.  
**Sonata 4, Fifth Floor, DoubleTree**

**ISSUES IN TRANSPERSONAL PSYCHIATRY**

**Director:** Bruce W. Scotton, M.D.  
**Faculty:** Allan B. Chinen, M.D., John R. Battista, M.D.,  
William W. Foote, M.D., John F. Hiatt, M.D., Francis G. Lu, M.D.,  
Bruce S. Victor, M.D.

**DISCUSSION GROUPS 1-4**

9:00 a.m.-10:30 a.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

- 1 **Leslie H. Gise, M.D.**, on Save Time, Make Money, Have Fun! Outpatient Group Therapy for the Seriously Mentally Ill Room 410, Level 4, Marriott
- 2 **Lenore C. Terr, M.D.**, on What Makes People Change? Room 413, Level 4, Marriott
- 3 **Kelly L. Cozza, M.D.**, and **Scott C. Armstrong, M.D.**, on Quickie Guide to the Cytochrome P450 System (*Meet the Authors*) Room 501, Level 5, Marriott
- 4 **Nehama Dresner, M.D.**, on Postpartum Depression: Prevention and Intervention Room 502, Level 5, Marriott

**LECTURES 2-3**

**LECTURE 2**

9:00 a.m.-10:30 a.m.  
Rooms 108 A/B, Street Level, Convention Center

**John M. Oldham, M.D.**

**Personality Disorders: New Findings and  
Current Controversies**

Chp.: John G. Gunderson, M.D.  
Co-Chp.: Andrew E. Skodol II, M.D.

Patterns of adaptive and maladaptive behavior have been described for centuries, and broad personality types have been identified, yet whether maladaptive behavior fits within familiar medical models of pathology remains controversial. John M. Oldham, M.D., draws on recent neurobiological research and clinical, longitudinal studies of *DSM-IV* personality disorders to examine current debate about the relationship between personality and personality disorder. Dr. Oldham is Director of the New York State Psychiatric Institute

(Continued on next page)



and Chief Medical Officer of the New York State Office of Mental Health. He is also the Elizabeth K. Dollard Professor of Clinical Psychiatry, Medicine, and Law and Acting Chairman of the Department of Psychiatry at Columbia University College of Physicians and Surgeons. In addition, he is a Training and Supervising Psychoanalyst at Columbia University Center for Psychoanalytic Training and Research and maintains a private practice of adult and forensic psychiatry. An APA Fellow, Dr. Oldham chaired the APA work group that developed the *Practice Guideline for the Treatment of Borderline Personality Disorder* and currently chairs the APA Committee on Quality Indicators. Dr. Oldham graduated from Baylor College of Medicine in Houston and received his psychiatric training at New York State Psychiatric Institute and his psychoanalytic training at Columbia University.

Distinguished Psychiatrist Lecture Series  
THIS SESSION WILL BE AUDIOTAPED.

LECTURE 3

9:00 a.m.-10:30 a.m.

Rooms 109 A/B, Street Level, Convention Center

APA'S GEORGE TARJAN AWARD LECTURE

Pedro Ruiz, M.D.

Accessing Care: A Challenge to the Poor  
and Disadvantaged

Chp.: Gopalakrishna D. Upadhyia, M.D.

Co-Chp.: Godehard Oepen, M.D.

Despite overall improvement in the socioeconomic conditions of the United States during the last decade, major gaps remain in the health and mental health delivery system. Pedro Ruiz, M.D., discusses the disproportionate representation of the poor and disadvantaged among Americans who lack health insurance and suggests ways of improving access to health and mental health care for this group. Dr. Ruiz is Professor and Vice-Chair for Clinical Affairs and Medical Director of the Mental Sciences Institute at the University of Texas Health Science Center in Houston. Dr. Ruiz has held senior leadership positions in several professional organizations, including the APA, where he currently serves as Secretary as well as Chairperson of the Ethics Appeal Board, Vice-Chairperson of the Council on Addiction Psychiatry, and a member of the Commission on Global Psychiatry. He has received the Simon Bolivar Award, the Administrative Psychiatry Award, and a Special Presidential Commendation from APA, and the Exemplary Psychiatrist Award from the National Alliance for the Mentally Ill. The author of more than 350 publications, he is the co-editor of *Substance Abuse: A Comprehensive Textbook*. Born in Cuba, Dr. Ruiz graduated from the University of Paris, France, and trained in psychiatry at the University of Miami Medical School.

THIS SESSION WILL BE AUDIOTAPED.

MASTER EDUCATOR CLINICAL  
CONSULTATIONS 1-2

9:00 a.m.-10:30 a.m.

These sessions are limited to 25 participants on a first-come, first-served

- 1 **Elissa P. Benedek, M.D.**, on Child Forensic Psychiatry  
Contemporary Issues  
Room 111 A, Street Level, Convention Center
- 2 **Francine Cournos, M.D.**, on the Aftermath of Childhood  
Parental Loss  
Room 301, Level 3, Marriott

THESE SESSIONS ARE OPEN TO APA MEMBERS  
ONLY. BLUE REGISTRATION BADGE OR APA  
MEMBERSHIP CARD REQUIRED FOR

MEDIA SESSIONS 3-4

MEDIA SESSION 3

9:00 a.m.-10:30 a.m.

Washington Rooms A-C, Third Floor, Loews

AMERICAN FRENZY

Chp.: Jonathan M. Metz, M.D.

- 3 **Time Frenzy**  
(58 minutes)

**Distributor:** University of California Extension  
Center for Media and Independent Learning  
2000 Center Street, 4th Floor  
Berkeley, CA 94704

*Time Frenzy*, produced by Bob Gliner, a multi-award-winning documentarian and Professor of Sociology at San Jose State University, is a thought-provoking documentary that explores the psychological, sociological, philosophical, and cultural ramifications of our increasingly fast-paced lives. *Time Frenzy* examines this new "24-7" reality, compares the American "work and consume" lifestyle with that of other countries, and probes the impact of technology on personal relationships, education, health, and the environment.

MEDIA SESSION 4

9:00 a.m.-10:30 a.m.

Congress Rooms A-C, Fourth Floor, Loews

PUPPETRY OF PERSONALITY

Chp.: Ian E. Alger, M.D.

Co-Chp.: Ferruccio A. DiCori, M.D.

- 4 **The Puppets of Di Cori: New Psychodrama Approach**  
(70 minutes)

**Distributor:** Ian E. Alger, M.D.  
500 East 77th Street, #132  
New York, NY 10162

Ferruccio A. di Cori, M.D., is an innovator of many therapeutic techniques that combine the arts and various theoretical approaches to handling problems in relationships throughout the life cycle. In this demonstration, two adolescent students from the "therapeutic theater course," which Dr. di Cori gives to an audience of over 100 students at the University of Rome, volunteer to participate. They are invited to throw to the floor two loosely articulated, amorphous rag doll figures that land in unanticipated positions vis-à-vis each other on the floor. He then directs the students in pairs and small groups in an imaginative discourse as they project themselves into the lives of the rag doll figures on the floor. This involvement leads to an emerging recognition by them of their personalities, ambitions, and conflicts.

### NEW RESEARCH YOUNG INVESTIGATORS' POSTER SESSION 1

9:00 a.m.-10:30 a.m.

Exhibit Hall D, Street Level, Convention Center

For further information on New Research Sessions, please refer to the *New Research Program and Abstracts Book* included in your registration packet.

### ROUNDTABLE DISCUSSION

9:00 a.m.-10:30 a.m.

Rooms 107 A/B, Street Level, Convention Center

### GOVERNMENT RESPONSE TO TERRORISM

**Moderator:** Randall D. Marshall, M.D.

**Participants:** John J. Worthington III, M.D., Mary Jane England, M.D., Sharon E. Carpinello, Ph.D., Regina Dolan-Sewell, Ph.D., Chip J. Felton, M.S.W., Peter S. Jensen, M.D., Matthew J. Friedman, M.D., Robert S. Pynoos, M.D., Jane D. Plapinger, M.P.H., Arieh Y. Shalev, M.D.

### SYMPOSIUM 1

9:00 a.m.-12 noon

Room 113 B, Street Level, Convention Center

### EVIDENCE-BASED PSYCHODYNAMIC THERAPY PART I: STUDYING CLINICAL WORK

*American Academy of Psychoanalysis and American Psychoanalytic Association*

**Chp.:** Sheila Hafter-Gray, M.D.

**Co-Chp.:** Ann-Louise S. Silver, M.D.

### A The Analytic Process Scales II: Intervention Quality and Patient Productivity

Sherwood Waldron, Jr., M.D.

### B The Analytic Process Scales

Anna M. Burton, M.D.

### C An Outcome Study for Psychodynamic Psychotherapy of Panic Disorder

Barbara L. Milrod, M.D., Fredric N. Busch, M.D.

THIS SESSION WILL BE AUDIOTAPED.

## WORKSHOPS

### COMPONENTS 1-11

**COMPONENT WORKSHOP 1** 9:00 a.m.-10:30 a.m.

Rooms 102 A/B, Street Level, Convention Center

### HOW TO CONVINCE CORPORATE CEOS THAT MENTAL HEALTH IS A GOOD INVESTMENT

*APA Committee on APA/Business Relationships*

**Co-Chps.:** Norman A. Clemens, M.D., Lloyd I. Sederer, M.D.

**Participants:** Leonard T. Sperry, M.D., Paul W. Heck

**COMPONENT WORKSHOP 2** 9:00 a.m.-10:30 a.m.

Room 103 A, Street Level, Convention Center

### JUSTICE AND HEALTH EQUITY IN GLOBAL PSYCHIATRY

*APA Commission on Global Psychiatry*

**Chp.:** Arthur M. Kleinman, M.D.

**Participants:** Benedetto Saraceno, M.D., Ahmed M.F. Okasha, M.D., Carl C. Bell, M.D., Vikram Patel, Ph.D.

**COMPONENT WORKSHOP 3** 9:00 a.m.-10:30 a.m.

Room 104 A, Street Level, Convention Center

### THE AMERICAN PSYCHIATRIC ASSOCIATION AND ITS ALLIANCE GO TO AMERICA'S SCHOOLS

*APA Alliance*

**Chp.:** Alicia A. Munoz, B.S.C.

**Participants:** Carol Skiljan, Jorge A. Zapatel, M.D.

**COMPONENT WORKSHOP 4** 9:00 a.m.-10:30 a.m.

Room 104 B, Street Level, Convention Center

### WHEN YOUR PHYSICIAN PATIENT IS FROM AN ETHNIC MINORITY: A CROSS-CULTURAL APPROACH TO TREATMENT

*APA Committee on Physician Health, Illness, and Impairment*

**Co-Chps.:** Carmen T. Webb, M.D., Patti Tighe, M.D.

**Participants:** William B. Lawson, M.D., Raymond M. Reyes, M.D., Hagit Bat-Avi, M.D., Jimmie C. Holland, M.D.

**MONDAY**

**COMPONENT WORKSHOP 5** 9:00 a.m.-10:30 a.m.  
**Room 111 B, Street Level, Convention Center**

**THE PSYCHIATRIST AND MIGRATION IN THE 21ST CENTURY**  
*APA Rhode Island Psychiatric Society*

**Co-Chps.:** Shahbaz A. Khan, M.D., Thomas O. Osinowo, M.D.  
**Participants:** Alison M. Heru, M.D., Kazi M. Salahuddin, M.D., Madelyn H. Hicks, M.D., Deji Ayonrinde, M.D.

**COMPONENT WORKSHOP 6** 9:00 a.m.-10:30 a.m.  
**Rooms 112 A/B, Street Level, Convention Center**

**RISK MANAGEMENT ISSUES IN PSYCHIATRIC PRACTICE**  
*APA Psychiatrists' Purchasing Group, Inc.*

**Chp.:** Alan I. Levenson, M.D.  
**Participants:** Ellen R. Fischbein, M.D., Martin G. Tracy, J.D., Jacqueline M. Melonas, J.D.

**COMPONENT WORKSHOP 7** 9:00 a.m.-10:30 a.m.  
**Rooms 302/303, Level 3, Marriott**

**THE PHILADELPHIA STORY: A VA UNIVERSITY OF ADDICTION RESEARCH COLLABORATION**  
*APA Consortium on Organized Service Systems*

**Chp.:** Laurent S. Lehmann, M.D.  
**Participants:** George E. Woody, M.D., Charles P. O'Brien, M.D., Laura F. McNicholas, M.D., A. Thomas McLellan, Ph.D.

**COMPONENT WORKSHOP 8** 9:00 a.m.-10:30 a.m.  
**Room 307, Level 3, Marriott**

**SUBSTANCE ABUSE IN SPECIAL POPULATIONS**  
*APA Council on Addiction Psychiatry*

**Chp.:** Ramon Solhkhah, M.D.  
**Participants:** Richard T. Suchinsky, M.D., Seeth Vivek, M.D.

**COMPONENT WORKSHOP 9** 9:00 a.m.-10:30 a.m.  
**Independence Ballrooms II/III, Level 3, Marriott**

**AGING AND MOURNING IN THE GAY AND LESBIAN COMMUNITY**  
*APA New York County District Branch's Committee on Gay and Lesbian Issues*

**Co-Chps.:** Benjamin H. McCommon, Jr., M.D., Jordan F. Karp, M.D.  
**Participants:** Alan Schwartz, M.D., Duane D. Shubert, M.D., Jennifer I. Downey, M.D.

**COMPONENT WORKSHOP 10** 9:00 a.m.-10:30 a.m.  
**Rooms 401-403, Level 4, Marriott**

**PSYCHIATRY IN THE NEUROSCIENCE CURRICULUM: PROMISE AND PERIL**  
*APA Committee on Medical Student Education*

**Chp.:** Carl B. Greiner, M.D.  
**Participants:** Jonathan Polan, M.D., Linda F. Pessar, M.D., Surender P. Punia, M.D., Michael J. Vergare, M.D.

**COMPONENT WORKSHOP 11** 9:00 a.m.-10:30 a.m.  
**Rooms 407-409, Level 4, Marriott**

**THE ROLE OF THE GERIATRIC PSYCHIATRIST IN PALLIATIVE CARE**  
*APA Committee on Access and Effectiveness of Psychiatric Services for the Elderly*

**Chp.:** Judith H. W. Crossett, M.D.  
**Participants:** Julian Offsay, M.D., Colleen J. Northcott, M.D., Jaime M. Benitez, M.D.

**ISSUES 1-18**

**ISSUE WORKSHOP 1** 9:00 a.m.-10:30 a.m.  
**Room 113 A, Street Level, Convention Center**

**HOW TO GET THE MOST OUT OF SUPERVISION: WHAT RESIDENTS NEED TO KNOW**

**Chp.:** Sarah M. Whitman, M.D.

**ISSUE WORKSHOP 2** 9:00 a.m.-10:30 a.m.  
**Room 113 C, Street Level, Convention Center**

**NURSING HOME PSYCHIATRY: PROBLEMS AND SOLUTIONS**

**Chp.:** Marc I. Rothman, M.D.  
**Participants:** Istvan J.E. Boksay, M.D., David L. Snyder, M.D., Nancy O'Dowd

**ISSUE WORKSHOP 3** 9:00 a.m.-10:30 a.m.  
**Room 202 A, Level 200, Convention Center**

**COGNITIVE-BEHAVIORAL THERAPY TRAINING FOR RESIDENTS: HOW TO TEACH, MEASURE, AND ATTAIN RESIDENT**

**Chp.:** Donna M. Sudak, M.D.  
**Participants:** Judith S. Beck, Ph.D., Jesse H. Wright, M.D., Hinda F. Dubin, M.D.

**ISSUE WORKSHOP 4** 9:00 a.m.-10:30 a.m.  
**Room 202 B, Level 200, Convention Center**

**SUPERVISION 101: SEX, LIES, AND VIDEOTAPE?**

**Chp.:** Chelsea L. Chesen, M.D.  
**Participants:** Francisco A. Moreno, M.D., Gayle Masterson, M.D., John C. Racy, M.D.



**ISSUE WORKSHOP 5** 9:00 a.m.-10:30 a.m.  
Room 203 A, Level 200, Convention Center

**CHILDREN OF PSYCHIATRISTS: 21ST-CENTURY INSIGHTS**

**Co-Chps.:** Leah J. Dickstein, M.D., Michelle B. Riba, M.D.  
**Participants:** Gail M. Barton, M.D., Zachary Myers, Elizabeth Bakalar

**ISSUE WORKSHOP 6** 9:00 a.m.-10:30 a.m.  
Room 203 B, Level 200, Convention Center

**THE POLICING OF PHYSICIAN-PATIENT BOUNDARIES: SOME INTERNATIONAL PERSPECTIVES**

**Chp.:** Gail E. Robinson, M.D.  
**Participants:** Werner Tschan, M.D., Carolyn Quadrio, M.D., Linda M. Jorgenson, J.D.

**ISSUE WORKSHOP 7** 9:00 a.m.-10:30 a.m.  
Room 204 A, Level 200, Convention Center

**PERSONALITY DISORDERS IN THE MENTAL RETARDATION AND DEVELOPMENT DISORDERS POPULATION**

**Co-Chps.:** Harvey Stabinsky, M.D., Susan Stabinsky, M.D.  
**Participant:** Michael M. Scimeca, M.D.

**ISSUE WORKSHOP 8** 9:00 a.m.-10:30 a.m.  
Rooms 304-306, Level 3, Marriott

**THE IMPACT ON CLINICIANS OF SUICIDE**

**Co-Chps.:** Eric M. Plakun, M.D., Jane G. Tillman, Ph.D.  
**Participants:** Edward R. Shapiro, M.D., Edward K. Rynearson, M.D.

**ISSUE WORKSHOP 9** 9:00 a.m.-10:30 a.m.  
Liberty Ballroom B, Level 3, Marriott

**CAREER DEVELOPMENT FOR INTERNATIONAL MEDICAL GRADUATES**

**Chp.:** Renato D. Alarcon, M.D.  
**Participants:** Nyapati R. Rao, M.D., Norma C. Panahon, M.D., Gabrielle F. Beaubrun, M.D.

**ISSUE WORKSHOP 10** 9:00 a.m.-10:30 a.m.  
Rooms 411/412, Level 4, Marriott

**EVALUATION OF TELEPSYCHIATRY SERVICES IN AN INTEGRATED HOSPITAL SYSTEM IN THE VETERANS ADMINISTRATION AND DEPARTMENT OF DEFENSE**

**Co-Chps.:** Paul E. Ruskin, M.D., Stephen J. Cozza, M.D.  
**Participants:** Brian J. Grady, M.D., Stephen I. Deutsch, M.D., James J. Nocks, M.D.

**ISSUE WORKSHOP 11** 9:00 a.m.-10:30 a.m.  
Rooms 414/415, Level 4, Marriott

**ACCESS TO PSYCHOTHERAPY TRAINING IN RESIDENCY: A CURRENT PERSPECTIVE**

**Chp.:** Robert W. Guynn, M.D.  
**Participants:** Sandra Sexson, M.D., Anu A. Matorin, M.D., Vinay Kapoor, M.D.

**ISSUE WORKSHOP 12** 9:00 a.m.-10:30 a.m.  
Grand Ballroom Salon A, Level 5, Marriott

**USE OF THE PERSONAL DIGITAL ASSISTANT IN PSYCHIATRY**

*Psychiatric Society of Informatics*

**Chp.:** John Luo, M.D.  
**Participants:** Daniel A. Deutschman, M.D., Sol Herman, M.D.

**ISSUE WORKSHOP 13** 9:00 a.m.-10:30 a.m.  
Grand Ballroom Salon B, Level 5, Marriott

**SCHIZOPHRENIA WITH COMORBID CONDITIONS: CLINICAL AND RESEARCH ISSUES**

**Co-Chps.:** Michael Y. Hwang, M.D., Miklos F. Losonczy, M.D.  
**Participants:** Lewis A. Opler, M.D., Naveed Iqbal, M.D.

**ISSUE WORKSHOP 14** 9:00 a.m.-10:30 a.m.  
Grand Ballroom Salon C, Level 5, Marriott

**PSYCHOTHERAPY TRAINING FOR THE 21ST-CENTURY PSYCHIATRIST**

**Co-Chps.:** Diane M. Roston, M.D., Rebecca R. Neal, M.D.

**ISSUE WORKSHOP 15** 9:00 a.m.-10:30 a.m.  
Grand Ballroom Salon D, Level 5, Marriott

**TRAINING A CULTURALLY COMPETENT PSYCHIATRIC WORKFORCE**

**Co-Chps.:** Janet E. Osterman, M.D., Albert C. Gaw, M.D.  
**Participant:** Joop De Jong, M.D.

**ISSUE WORKSHOP 16** 9:00 a.m.-10:30 a.m.  
Grand Ballroom Salon I, Level 5, Marriott

**TRANSGENDER CARE: NEW PERSPECTIVES**

**Chp.:** Dan H. Karasic, M.D.  
**Participants:** Daniel Garza, M.D., Vernon A. Rosario, M.D., Melanie E. Spritz, D.O.

## MONDAY

**ISSUE WORKSHOP 17** 9:00 a.m.-10:30 a.m.  
Grand Ballroom Salon J, Level 5, Marriott

### HOW TO EFFECTIVELY INTEGRATE MENTAL HEALTH SERVICES IN GENERAL CARE SYSTEMS

**Chp.:** Ann Marie T. Sullivan, M.D.

**Participants:** Neal L. Cohen, M.D., Martin H. Maurer, M.D., Juan E. Mezzich, M.D., Amy S. Hoffman, M.D., Richard A. Young, M.D.

**ISSUE WORKSHOP 18** 9:00 a.m.-10:30 a.m.  
Grand Ballroom Salon K, Level 5, Marriott

### BREAKING THE CYCLE OF MATERNAL ADDICTION: AN INTEGRATED TREATMENT PROGRAM MAKING A DIFFERENCE

**Chp.:** Cynthia C. Crone, A.P.N.

**Participants:** Linda L.M. Worley, M.D., Leanne Whiteside-Mansell, Ed.D., Veronica L. Williams, M.D.

---

## 10:30 a.m. Session

---

### ADVANCES IN RESEARCH

10:30 a.m.-12:30 p.m.

Rooms 201 A-C, Level 200, Convention Center

### UNDERSTANDING THE BRAIN AND BODY IN THE TREATMENT OF DEPRESSION AND SCHIZOPHRENIA

*APA Scientific Program Committee and APA Council on Research*

**Chp.:** Herbert Pardes, M.D.

**Co-Chp.:** Philip R. Muskin, M.D.

**Participants:** Robert Carney, M.D., on **Depression and Coronary Heart Disease: Epidemiology, Treatment, and Mechanisms**

Alexander H. Glassman, M.D., on **Depression, Coronary Artery Disease and Mortality**

Carol A. Tamminga, M.D., on **Schizophrenia: What Can Functional Brain Imaging Tell?**

Herbert Y. Meltzer, M.D., on **Advances in Psychopharmacologic Treatment of Schizophrenia and Related Psychosis**

**THIS SESSION WILL BE AUDIOTAPED.**

---

## 11:00 a.m. Sessions

---

### DISCUSSION GROUPS 5-8

11:00 a.m.-12:30 p.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

**5** Glen O. Gabbard, M.D., on **Psychodynamic Psychiatry in Clinical Practice: Third Edition** (*Meet the Authors*)  
Room 308, Level 3, Marriott

**6** William Breitbart, M.D., on **Psychiatry and Palliative Medicine**  
Room 410, Level 4, Marriott

**7** Charles E. Schwartz, M.D., on **Working with HIV-Positive Patients and Their Physicians**  
Room 413, Level 4, Marriott

**8** Brian A. Fallon, M.D., on **Recognizing and Treating Neuropsychiatric Lyme Disease**  
Room 501, Level 5, Marriott

## LECTURES 4-5

### LECTURE 4

11:00 a.m.-12:30 p.m.

Rooms 108 A/B, Street Level, Convention Center

Gerald D. Fischbach, M.D.

### Neuroscience in the New Millennium

**Chp.:** Stuart C. Yudofsky, M.D.

**Co-Chp.:** Mark G. Barad, M.D.

Advances at all levels of neuroscience continue to revolutionize the theory and practice of psychiatry. Gerald D. Fischbach, M.D., describes research strategies leading to more accurate functional and molecular characterizations of psychiatric disorders and discusses new therapeutic approaches that can emerge with refinements in diagnosis. Dr. Fischbach is Vice President for Health and Biomedical Sciences, Dean of the Faculties of Health Sciences, and Dean of the Faculty of Medicine at the College of Physicians and Surgeons of Columbia University in New York City. He served as Director of the National Institute of Neurological Disorders and Stroke within the National Institutes of Health from 1998 to 2001. Throughout his career, Dr. Fischbach has studied the formation and maintenance of synapses. He pioneered the use of cultural neurons and muscle cells to characterize the biochemical, cellular, and electrophysiological mechanisms underlying the neuromuscular junction. His current research focuses on trophic factors that influence synaptic efficacy and nerve cell survival. A Past President of the Society of Neuroscience, Dr. Fischbach is a member of the National Academy of Sciences, the American Academy of Arts and Sciences, and the Institute of Medicine. He received his medical degree from Cornell University Medical School.

Frontiers of Science Lecture Series

**THIS SESSION WILL BE AUDIOTAPED.**

## LECTURE 5

11:00 a.m.-12:30 p.m.  
Rooms 109 A/B, Street Level, Convention Center

Mary Jeanne Kreek, M.D.

Opioids and Single-Nucleotide Polymorphisms:  
Implications for Heroin and Cocaine Addictions

Chp.: Richard N. Rosenthal, M.D.

Co-Chp.: Joyce A. Tinsley, M.D.

Mary Jeanne Kreek, M.D., examines the contributions of the endogenous opioid system to the "rewarding" effects of drugs of abuse and to drug-induced changes in the brain and discusses gene polymorphisms of the endogenous opioid system that may play a role in addictions. Dr. Kreek is Professor and Head of the Laboratory of the Biology of Addictive Disease at Rockefeller University and Senior Physician at Rockefeller University Hospital in New York. In the 1960s, she was part of the Rockefeller Institute team that conducted the initial studies on methadone in the management of heroin addiction. More recently her research has focused on the molecular and neurobiological basis of addictive diseases and on human molecular genetics in the development of addictions. A Fellow of the American College of Neuropsychopharmacology and the New York Academy of Sciences, Dr. Kreek has received the R. Brinkley Smithers Distinguished Scientist Award from the American Society on Addiction Medicine and the Nathan B. Eddy Memorial Award for Lifetime Excellence in Drug Abuse Research from the College on Problems of Drug Dependence. Dr. Kreek received her medical degree from Columbia University College of Physicians and Surgeons and her postgraduate training in internal medicine, gastroenterology, and neuroendocrinology at Cornell University-New York Hospital Medical Center. Frontiers of Science Lecture Series  
THIS SESSION WILL BE AUDIOTAPED.

### MASTER EDUCATOR CLINICAL CONSULTATIONS 3-4

11:00 a.m.-12:30 p.m.

These sessions are limited to 25 participants on a first-come, first-served

- 3 **Allan Tasman, M.D.**, on the Doctor-Patient Relationship in Pharmacotherapy  
Room 111 A, Street Level, Convention Center
- 4 **Salman Akhtar, M.D.**, on Psychotherapy with Immigrant Patients  
Room 301, Level 3, Marriott

THIS SESSION IS OPEN TO APA MEMBERS ONLY.  
BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR

### MEDIA SESSIONS 5-6

#### MEDIA SESSION 5

11:00 a.m.-2:00 p.m.

Washington Rooms A-C, Third Floor, Loews

#### CULTURAL COLLISIONS

Chp.: Jacquelyn B. Chang, M.D.

#### 5 **Carved from the Heart: A Portrait of Grief, Healing, and Community** (30 minutes)

**Distributor:** New Day Films  
22-D Hollywood Avenue  
Ho Ho Kus, NJ 07423

Grieving father, Stan Marsden, loses his son to a cocaine overdose. A Tsimshian wood carver, Marsden decides to create a totem pole and invites the town of Craig, Alaska, to help. The project grows and brings people of diverse ages and backgrounds together. It acknowledges common problems of drug abuse and violence and promotes healing within the community. *Carved from the Heart* acknowledges the intergenerational grief that grows out of rapid changes in lifestyles and interruptions to the passage of tradition and knowledge within Alaska Native and American Indian communities.

**Discussant:** Yadollah M. Jabbarpour, M.D.

#### 6 **Homeland** (57 minutes)

**Distributor:** University of California Extension  
**For V6** Center for Media and Independent Learning  
**& V7** 2000 Center Street, 4th Floor  
Berkeley, CA 94704

Set against the stunning backdrop of the Northern Plains, *Homeland* is a rich and engaging documentary that weaves together the stories of four Lakota Indian families on the Pine Ridge Indian Reservation in South Dakota. Shot over several years, the film provides an inspiring and intimate portrait of contemporary Native American life, as well as a unique and compelling depiction of the strength and vitality of Native culture as it unfolds to the viewer over the course of the years. Ultimately, the film balances the many troubles that beset the reservation system with the resilience and fortitude of Lakota culture and spirituality. In doing so, it challenges viewers to recognize and appreciate the power of family, the immense spirit of the natural world, and the healing potential of humor and faith.

#### 7 **Between Worlds** (57 minutes)

*Between Worlds* explores over a period of six years the lives of several Vietnamese Amerasians and their families who left Vietnam in 1992. Each of the families was sent to a refugee camp in the Philippines for six months of cultural orientation, before resettling in the U.S. The film details their experiences in camp and follows their lives for five years as they struggle to learn English, find jobs, and pursue their education.

MONDAY

**MEDIA SESSION 6** 11:00 a.m.-12:30 p.m.

Congress Rooms A-C, Fourth Floor, Loews

**IMAGES IN BLACK AND WHITE**

Chp.: Elyse D. Dubo, M.D.

8 **M & M Smith: For Prosperity's Sake**  
(57 minutes)

Distributor: New Day Films  
22-D Hollywood Avenue  
Ho Ho Kus, NJ 07423

*M & M Smith: For Posterity's Sake* eloquently explores the lives and work of Morgan and Marvin Smith, twin brothers and prolific African-American artists. The Smiths moved from Kentucky to New York in 1933 to pursue careers unavailable to them in the segregated South. In 1937, they opened a studio next to Harlem's Apollo Theatre and began 50 year-long careers as artists and still and motion film photographers. The Smiths and their cameras covered events in Harlem such as political rallies, street corner orators, the training ground of Joe Louis, and the exciting nightclub scene. They documented the celebrated and common citizens of their community and opened doors for models and actresses as they sought careers in the white dominated media. The film features Marvin and Morgan Smith, performer Eartha Kitt, and photo historian Deborah Willis.

**MEDICAL UPDATE 1**

11:00 a.m.-12:30 p.m.

Room 103 A, Street Level, Convention Center

**MIGRAINE: DIAGNOSIS, TREATMENT, AND COMORBIDITY**

Chp.: N. Kalaya Okereke, M.D.

Presenter: Stephen C. Silberstein, M.D.

THIS SESSION WILL BE AUDIOTAPED.

**SCIENTIFIC AND CLINICAL REPORT SESSIONS 1-12**

**SCIENTIFIC AND CLINICAL REPORT SESSION 1**

11:00 a.m.-12:30 p.m.

Room 103 C, Street Level, Convention Center

**ANXIETY DISORDERS**

Chp.: Michael J. Vergare, M.D.

Co-Chp.: David H. Taylor, M.D.

11:00 a.m.

2 **Switching from Imipramine to Sertraline in Panic Disorder with Agoraphobia**  
Matig R. Mavissakalian, M.D.

11:30 a.m.

3 **Atypical Depression in Primary Anxiety Disorders**  
Michael A. Van Ameringen, M.D., Catherine L. Mancini, M.D.,  
Jonathan Oakman, Ph.D., Mira Campbell, B.A., Chris Watson

12 noon

4 **Risk Factors for PTSD in North Korean Defectors**  
Wootae Jeon, M.D., Sung-Kil Min, M.D.

THIS SESSION WILL BE AUDIOTAPED.

**SCIENTIFIC AND CLINICAL REPORT SESSION 2**

11:00 a.m.-12:30 p.m.

Room 111 B, Street Level, Convention Center

**EATING DISORDERS**

Chp.: Helen C. Kales, M.D.

Co-Chp.: Houshang G. Hamadani, M.D.

11:00 a.m.

5 **Perfectionism, Training, and Eating Behaviors in Runners**

Jason M. Andrus, M.D., Deborah Goebert, Ph.D., Alayne Yates, M.D.

11:30 a.m.

6 **Self-Reported Hunger and Parasympathetic Tone**  
Alayne Yates, M.D., George P. Danko, Ph.D., John H. Draeger, M.D.

12 noon

7 **Topiramate Treatment of Bulimia Nervosa**

Scott P. Hoopes, M.D., Frederick W. Reimherr, M.D.,  
Marc Kamin, M.D., Debra Karvois, M.S., Norman E.  
Rosenthal, M.D., Rezaul Karim, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

**SCIENTIFIC AND CLINICAL REPORT SESSION 3**

11:00 a.m.-12:30 p.m.

Room 202 A, Level 200, Convention Center

**CONSULTATION-LIAISON PSYCHIATRY**

Chp.: Catherine A. Crone, M.D.

Co-Chp.: Mark S. Groves, M.D.

11:00 a.m.

8 **Mixed Anxiety Depressive Disorder in a Sample of Primary Care Patients**

Risa B. Weisberg, Ph.D., Larry Culpepper, M.D., Martin B. Keller, M.D.

11:30 a.m.

9 **Psychopathological Aspects in 86 Chronic Fatigue Syndrome Patients**

Massimo di Giannantonio, M.D., Anatolia Salone, M.D.,  
Delia Racciatti, M.D., Daniela Mezzano, M.D., Eligio Pizzigallo, M.D., Maria F. Ferro



12 noon  
**10 Low Expression of Negative Affect and Denial Predict Breast Cancer Recurrence**  
 Karen L. Weihs, M.D., Timothy Enright, Ph.D.  
**THIS SESSION WILL BE AUDIOTAPED.**

**SCIENTIFIC AND CLINICAL REPORT SESSION 4**  
 11:00 a.m.-12:30 p.m.  
 Room 202 B, Level 200, Convention Center

**ISSUES IN CROSS-CULTURAL PSYCHIATRY**

**Chp.:** Giovanni Caracci, M.D.  
**Co-Chp.:** Dinu P. Gangure, M.D.

11:00 a.m.  
**11 Is the Wechsler Intelligence Scale for Children, Third Edition (WISC-III UK) Applicable to Ghana?**  
 Ama K. Edwin, M.B.

11:30 a.m.  
**12 Dissociation, Childhood Trauma, and Ataque De Nervios**  
 Roberto Lewis-Fernandez, M.D., Pedro J. Garrido, Ph.D., Amaro Lakia, Ph.D., Maricarmen Bennasar, Psy.D., Guoguang Ma, M.S., Elsie Parrilla, L.C.S.W., Eva Petkova, Ph.D.

12 noon  
**13 Trauma, Creative Cognition, and Success Among Tribal South-African Students**  
 Albert Rothenberg, M.D.  
**THIS SESSION WILL BE AUDIOTAPED.**

**SCIENTIFIC AND CLINICAL REPORT SESSION 5**  
 11:00 a.m.-12:30 p.m.  
 Room 203 A, Level 200, Convention Center

**ISSUES IN MID LIFE AND BEYOND**

**Chp.:** Lesley M. Blake, M.D.  
**Co-Chp.:** Dylan P. Wint, M.D.

11:00 a.m.  
**14 Long-Term Effects of Depression on Symptoms and Function in Mid-Life Women**  
 Joyce T. Bromberger, Ph.D., Charlotte Brown, Ph.D., Adriana Cordal, M.D., Howard M. Kravitz, D.O., Karen Matthews, Ph.D.

11:30 a.m.  
**15 Socioeconomic Status and Depression Among Older Adults**  
 John Cairney, M.A., Terrance J. Wade, Ph.D.

12 noon  
**16 Psychotherapy with the Elderly**  
 Daniel A. Plotkin, M.D.  
**THIS SESSION WILL BE AUDIOTAPED.**

**SCIENTIFIC AND CLINICAL REPORT SESSION 6**  
 11:00 a.m.-12:30 p.m.  
 Room 204 A, Level 200, Convention Center

**PSYCHOPHARMACOLOGY OF MOOD DISORDERS**

**Chp.:** Leslie H. Gise, M.D.  
**Co-Chp.:** Roger F. Haskett, M.D.

11:00 a.m.  
**17 Fluoxetine-Induced Weight Change in Depressive Subtypes**  
 Christina M. Dording, M.D., Robert L. Gresham, B.A., Heidi D. Montoya, B.A., John J. Worthington III, M.D., Jonathan E. Alpert, M.D., Andrew A. Nierenberg, M.D., Maurizio Fava, M.D.

11:30 a.m.  
**18 Adjunct Modafinil for Fatigue and Wakefulness in MDD**  
 Karl Doghramji, M.D., Matthew A. Menza, M.D., Murray H. Rosenthal, D.O., Ronald R. Fieve, M.D.

12 noon  
**19 Short-Term Use of Estradiol as an Antidepressant Strategy in Perimenopausal and Postmenopausal Women**  
 Lee S. Cohen, M.D., Claudio N. Soares, M.D., Jennifer Poitras, B.A., Jan L. Shifren, M.D., Allison B. Alexander, M.D.  
**THIS SESSION WILL BE AUDIOTAPED.**

**SCIENTIFIC AND CLINICAL REPORT SESSION 7**  
 11:00 a.m.-12:30 p.m.  
 Room 204 B, Level 200, Convention Center

**MANAGEMENT OF BIPOLAR DISORDER**

**Chp.:** Ellen H. Sholevar, M.D.  
**Co-Chp.:** Martins A. Adoeye, M.D.

11:00 a.m.  
**20 A Comparison of the Prevalence and Correlates of Anger Attacks in Bipolar Disorder**  
 Roy H. Perlis, M.D., Jordan W. Smoller, M.D., Stephanie Racette, B.A., Pamela A. Roffi, B.S., Grace E. F. Rubenstein, B.A., Gary S. Sachs, M.D., Maurizio Fava, M.D.

11:30 a.m.  
**21 Topiramate Treatment of Rapid-Cycling Mood Disorder**  
 Mohammad Z. Hussain, M.D., Zabaïda A. Chaudhry, M.D., Seema Hussain, M.D.

12 noon  
**22 Cognitive and Psychosocial Deficits in Bipolar Disorder and Schizophrenia**  
 Joseph Ventura, Ph.D., Lori L. Altshuler, M.D., Wilfred G. Van Gorp, Ph.D., David Theberge, Ph.D., Jim Mintz, Ph.D.  
**THIS SESSION WILL BE AUDIOTAPED.**

**MONDAY**

**SCIENTIFIC AND CLINICAL REPORT SESSION 8**

11:00 a.m.-12:30 p.m.

Independence Ballroom I, Level 3, Marriott

**SUICIDE**

Chp.: Maria A. Oquendo, M.D.

Co-Chp.: Robert C. Marks, M.D.

11:00 a.m.

**23 Suicides in Youths Involved with Juvenile Justice and Child Welfare Services**

Johanne Renaud, M.D., Francois Chagnon, Ph.D., Lambert Farand, M.D.

11:30 a.m.

**24 Predictors of Suicide Attempts in a Personality Disorder Sample**

Shirley Yen, Ph.D., M. Tracie Shea, Ph.D., Carlos M. Grilo, Ph.D., Charles A. Sanislow, Ph.D., Mary C. Zanarini, Ed.D., Robert L. Stout, Ph.D., John G. Gunderson, M.D.

12 noon

**25 Hostility and Impulsivity Among Suicidal Bipolar Patients**

Benjamin H. Michaelis, M.A., Glen P. Davis, B.A., Joseph F. Goldberg, M.D.

**THIS SESSION WILL BE AUDIOTAPED.**

**SCIENTIFIC AND CLINICAL REPORT SESSION 9**

11:00 a.m.-12:30 p.m.

Independence Ballrooms II/III, Level 3, Marriott

**BPD**

Chp.: Vivian B. Pender, M.D.

Co-Chp.: Jennifer K. Coffman, M.D.

11:00 a.m.

**26 BPD, Medical Illness, Lifestyle Choices, and Health Care Utilization**

Frances R. Frankenburg, M.D., Mary C. Zanarini, Ed.D., John Hennen, Ph.D., Kenneth R. Silk, M.D.

11:30 a.m.

**27 Impulsivity, Gender, and 5HT in BPD**

Paul H. Soloff, M.D., Thomas M. Kelly, Ph.D., Stephen J. Strutmeyer, M.P.H., Kevin M. Malone, M.D., J. John Mann, M.D.

12 noon

**28 Diagnostic Efficiency of BPD and Antisocial Personality Disorder (APD) Criteria in Monolingual Hispanic Men**

Daniel F. Becker, M.D., Carlos M. Grilo, Ph.D., Luis M. Anez, Psy.D., Thomas H. McGlashan, M.D.

**THIS SESSION WILL BE AUDIOTAPED.**

**SCIENTIFIC AND CLINICAL REPORT SESSION 10**

11:00 a.m.-12:30 p.m.

Rooms 407-409, Level 4, Marriott

**TOPICS IN SCHIZOPHRENIA**

Chp.: Lawrence A. Real, M.D.

Co-Chp.: Brian Martis, M.D.

11:00 a.m.

**29 The Relationship Between Negative and Positive Symptoms: A 15-Year Follow-Up**

Martin Harrow, Ph.D., Ellen S. Herbener, Ph.D., Thomas H. Jobe, M.D., Joseph F. Goldberg, M.D., Eileen M. Martin, Ph.D.

11:30 a.m.

**30 Neurological Soft Signs and Psychopathology in Schizophrenia**

Giuseppe Bersani, Simona Gherardelli, M.D., Paolo Pancheri

12 noon

**31 Heterogeneity in Schizophrenia: Cognitive Deficits and Brain Abnormalities**

Bruce E. Wexler, M.D., Patricia S. Goldman-Rakic, Ph.D., Robert K. Fulbright, M.D., John C. Gore, Ph.D., Bradley S. Peterson, M.D.

**THIS SESSION WILL BE AUDIOTAPED.**

**SCIENTIFIC AND CLINICAL REPORT SESSION 11**

11:00 a.m.-12:30 p.m.

Grand Ballroom Salon B, Level 5, Marriott

**OLANZAPINE: BIPOLAR DISORDERS AND AGITATION**

Chp.: Philip G. Janicak, M.D.

Co-Chp.: Paul P. Yeung, M.D.

11:00 a.m.

**32 Effectiveness of Rapid Initial Dose Escalation of Oral Olanzapine for Acute Agitation**

Robert W. Baker, M.D., Bruce J. Kinon, M.D., Hong Liu, Ph.D., Angela Richey, B.S., Angela L. Hill, Pharm.D., Richard F. Bergstrom, Ph.D., Leslie M. Schuh, Ph.D.

11:30 a.m.

**33 Olanzapine Combined with Lithium or Valproate for Relapse Prevention of Bipolar Disorder: An 18-Month Study**

Mauricio F. Tohen, M.D., K.N. Roy Chengappa, M.D., Patricia Suppes, M.D., Robert W. Baker, M.D., Richard C. Risser, M.S.C., Angela R. Evans, Ph.D., Joseph R. Calabrese, M.D.

12 noon

**34 Olanzapine Versus Divalproex Sodium for Mania: A 47-Week Study**

Robert W. Baker, M.D., Mauricio F. Tohen, M.D., Lori L. Altshuler, M.D., Carlos M. Zarate, Jr., M.D., Patricia Suppes, M.D., Terence A. Ketter, M.D., Richard C. Risser, M.S.C.

**THIS SESSION WILL BE AUDIOTAPED.**



SCIENTIFIC AND CLINICAL REPORT SESSION 12

11:00 a.m.-12:30 p.m.

Grand Ballroom Salon C, Level 5, Marriott

HEALTH SERVICES RESEARCH

Chp.: Arthur L. Lazarus, M.D.

Co-Chp.: Alisa B. Busch, M.D.

11:00 a.m.

35 Consensus Development on Core Quality Measures for Mental Health Care

Richard C. Hermann, M.D., Scott E. Provost, M.S.W., Jeffrey Chan, B.S., Greta Lagodmos, B.A., Michael Shwartz, Ph.D., R. Heather Palmer, M.D.

11:40 a.m.

36 Improving the Competency of Clinicians Treating People with Mental Illness

Alexander S. Young, M.D., Sandra L. Forquer, Ph.D., Matthew J. Chinman, Ph.D., Melissa Rowe, Ph.D., Anita Miller, Ph.D., Edward Knight, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

WORKSHOPS

COMPONENTS 12-18

COMPONENT WORKSHOP 12 11:00 a.m.-12:30 p.m.

Rooms 102 A/B, Street Level, Convention Center

NAVIGATING GERIATRIC PSYCHIATRY RESEARCH: ISSUES FOR THE BEGINNING RESEARCHER

APA Committee on Ethnic Minority Elderly and APA Council on Aging

Chp.: Josepha A. Cheong, M.D.

Participants: Arturo G. Quiason, M.D., Warachal E. Faison, M.D., Michael J. Pratts, M.D., Jacobo E. Mintzer, M.D.

COMPONENT WORKSHOP 13 11:00 a.m.-12:30 p.m.

Room 103 B, Street Level, Convention Center

EXPERTS OR PAWNS? PSYCHIATRIC CONSULTATION FOR GOVERNMENT AGENCIES

APA Committee on Misuse and Abuse of Psychiatry and Psychiatrists

Chp.: Robert P. Cabaj, M.D.

Participants: Jerry M. Wiener, M.D., Jose E. de La Gandara, M.D., Abraham L. Halpern, M.D., Juan E. Mezzich, M.D.

COMPONENT WORKSHOP 14 11:00 a.m.-12:30 p.m.

Room 104 A, Street Level, Convention Center

LEGAL AND PSYCHIATRIC CONTROVERSIES IN INTERFERON TREATMENT OF HEPATITIS-C

APA New York County District Branch's AIDS Committee

Co-Chps.: Kristina L. Jones, M.D., Scott Burriss, J.D.

Participants: Silvia Hafliger, M.D., John A.R. Grimaldi, Jr., M.D.

COMPONENT WORKSHOP 15 11:00 a.m.-12:30 p.m.

Room 104 B, Street Level, Convention Center

THE GOOD-ENOUGH MENTOR: PERSPECTIVES ON MENTORING IN PSYCHIATRIC TRAINING

APA/GlaxoWellcome Fellows

Chp.: Paul E. Holtzheimer III, M.D.

Participants: Laurel L. Williams, D.O., Seema Malhotra, M.D., Lyle B. Forehand, Jr., M.D., John B. Levine, M.D.

COMPONENT WORKSHOP 16 11:00 a.m.-12:30 p.m.

Rooms 112 A/B, Street Level, Convention Center

TALKING ON YOUR FEET: SURVIVAL TIPS AND TECHNIQUES FOR MEDIA INTERVIEWS

APA Joint Commission on Public Affairs

Co-Chps.: Michael Blumenfield, M.D., Sandra C. Walker, M.D.

Participants: William E. Callahan, Jr., M.D., James M. Maier, M.D., John B. Blamphin

COMPONENT WORKSHOP 17 11:00 a.m.-12:30 p.m.

Room 203 B, Level 200, Convention Center

PSYCHIATRY WITHOUT BORDERS: BREAKING THE BARRIERS

APA Committee on International Medical Graduates

Co-Chps.: Gopalakrishna K. Upadhya, M.D., Godehard Oepen, M.D.

Participants: Bruce Singh, M.D., Deborah Spitz, M.D.

COMPONENT WORKSHOP 18 11:00 a.m.-12:30 p.m.

Rooms 401-403, Level 4, Marriott

PSYCHIATRIC CASUALTIES IN THE MENTAL HEALTH OF HISPANIC IMMIGRANTS

APA Committee of Hispanic Psychiatrists

Co-Chps.: Ana E. Campo, M.D., Eugenio M. Rothe, M.D.

Participant: Rodrigo A. Munoz, M.D.

ISSUES 19-28

ISSUE WORKSHOP 19 11:00 a.m.-12:30 p.m.

Rooms 302/303, Level 3, Marriott

TREATING PSYCHOSIS ACROSS DIAGNOSIS

Chp.: Lewis A. Opler, M.D.

Participants: Ian E. Alger, M.D., Clarice J. Kestenbaum, M.D., Eric R. Marcus, M.D.

MONDAY

**ISSUE WORKSHOP 20** 11:00 a.m.-12:30 p.m.  
Room 307, Level 3, Marriott

**CHALLENGES OF THE CHIEF RESIDENT IN PSYCHIATRY**

**Chp.:** Sadiq H. Al-Samarrai, M.D.  
**Participant:** Thomas S. Newmark, M.D.

**ISSUE WORKSHOP 21** 11:00 a.m.-12:30 p.m.  
Rooms 309-310, Level 3, Marriott

**NONSEXUAL BOUNDARY VIOLATIONS: SPECIAL PROBLEMS IN SMALL COMMUNITIES**

**Chp.:** Malkah T. Notman, M.D.  
**Participants:** Elissa P. Benedek, M.D., Linda M. Jorgenson, J.D., Carl P. Malmquist, M.D., Carol C. Nadelson, M.D.

**ISSUE WORKSHOP 22** 11:00 a.m.-12:30 p.m.  
Liberty Ballroom C, Level 3, Marriott

**COGNITIVE THERAPY FOR PERSONALITY DISORDERS**

**Chp.:** Judith S. Beck, Ph.D.

**ISSUE WORKSHOP 23** 11:00 a.m.-12:30 p.m.  
Rooms 411/412, Level 4, Marriott

**ASSESSING PSYCHOTHERAPY COMPETENCIES OF RESIDENTS**

**Chp.:** Joel Yager, M.D.  
**Participants:** David A. Goldberg, M.D., Lisa A. Mellman, M.D., Jerald Kay, M.D., Jesse H. Wright, M.D.

**ISSUE WORKSHOP 24** 11:00 a.m.-12:30 p.m.  
Rooms 414/415, Level 4, Marriott

**PROFESSIONALISM IN THE TEACHER/LEARNER RELATIONSHIP**

**Chp.:** Alison M. Heru, M.D.  
**Participants:** Marilyn Price, M.D., Patricia R. Recupero, M.D.

**ISSUE WORKSHOP 25** 11:00 a.m.-12:30 p.m.  
Grand Ballroom Salon D, Level 5, Marriott

**PSYCHOTHERAPY TERMINATION: A CHALLENGE IN PSYCHIATRIC RESIDENCY TRAINING**

**Chp.:** Anu A. Matorin, M.D.  
**Participants:** Pedro Ruiz, M.D., Vinay Kapoor, M.D., David W. Preven, M.D., Madhuri V. Kamble, M.D.

**ISSUE WORKSHOP 26** 11:00 a.m.-12:30 p.m.  
Grand Ballroom Salon I, Level 5, Marriott

**CONFIDENTIALITY ISSUES AND LEGAL ESSENTIALS IN SEXUAL HARASSMENT CASES**

**Co-Chps.:** Rita R. Newman, M.D., Annette J. Hollander, M.D.  
**Participants:** Diane K. Shrier, M.D., Margaret F. Jensvold, M.D., David W. Garland, Esq., Francine Weiss, Esq.

**ISSUE WORKSHOP 27** 11:00 a.m.-12:30 p.m.  
Grand Ballroom Salon J, Level 5, Marriott

**PSEUDODEMENTIA IN THE 21ST CENTURY**

**Chp.:** Maurice Preter, M.D.  
**Participants:** Randolph B. Schiffer, M.D., Robin C. Hilsabeck, Ph.D.

**ISSUE WORKSHOP 28** 11:00 a.m.-12:30 p.m.  
Grand Ballroom Salon K, Level 5, Marriott

**WHAT WORKS IN SUBSTANCE ABUSE TREATMENT?**

*Substance Abuse and Mental Health Services Administration*

**Chp.:** A. Thomas McLellan, Ph.D.  
**Participants:** D. Dwayne Simpson, Ph.D., Joseph C. J. Finney, M.D., Shelly F. Greenfield, M.D.

---

**12 noon Sessions**

---

**FORUMS 1-4**

**FORUM 1** 12 noon-1:30 p.m.  
Rooms 107 A/B, Street Level, Convention Center

**NEW YORK ACADEMIC CENTERS' RESPONSE TO THE WORLD TRADE CENTER ATTACK**

**Chp.:** Randall D. Marshall, M.D.  
**Participants:** Rachel Yehuda, M.D., Marylene Cloitre, Ph.D., Spencer Eth, M.D., Harold S. Koplewicz, M.D.

**FORUM 2** 12 noon-1:30 p.m.  
Room 113 A, Street Level, Convention Center

**LEADERSHIP CHALLENGES IN MENTAL HEALTH AND SUBSTANCE ABUSE: A MEETING OF THE MINDS**

*Substance Abuse and Mental Health Services Administration*

**Chp.:** Charles Curie

**FORUM 3** 12 noon-1:30 p.m.  
Room 113 C, Street Level, Convention Center

**EVIL**

**Chp.:** Samuel C. Klagsbrun, M.D.  
**Participants:** Professor Robert Pollack, Carl Goldberg, Ph.D.

**FORUM 4** 12 noon-1:30 p.m.  
 Liberty Ballroom A, Level 3, Marriott

**MUSIC AND MOOD DISORDERS: TCHAIKOVSKY**

**Chp.:** Richard Kogan, M.D.

**12:30 p.m. Session**

**MEDIA SESSION 7**

12:30 p.m.-2:00 p.m.  
 Congress Rooms A-C, Fourth Floor, Loews

**WHEN NOT TO KEEP A SECRET**

*APA Alliance*

**Chp.:** Alicia A. Munoz, B.S.C.

**9 In the Mix**  
 (30 minutes)

**Distributor:** Sue Castle  
 Castle Entertainment  
 114 East 32nd Street, #903  
 New York, NY 10016

*In the Mix* is a weekly, half-hour PBS television series produced for, with, and by teens. From alcohol to activism, school violence to careers, fashion to finding money for college, music to relationships, the series tackles the topics teen care about in probing, thought-provoking investigative reports, and provides information teens need to make positive life choices and to be savvy consumers. In this segment, teens find a way to share their concerns about violence and mental illness affecting their peers and community.

**Discussant:** Alicia A. Munoz, B.S.C.

**1:00 p.m. Sessions**



**COURSES 51-56**

Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.

**COURSE 51** 1:00 p.m.-5:00 p.m.  
 Ormandy East, Street Level, DoubleTree

**OVERVIEW AND UPDATE OF SLEEP DISORDERS MEDICINE**

**Director:** Karl Doghramji, M.D.  
**Faculty:** John W. Winkelman, M.D., Thomas D. Hurwitz, M.D.

**COURSE 52** 1:00 p.m.-5:00 p.m.  
 Concerto B, Third Floor, DoubleTree

**TREATING MEDICAL STUDENTS AND PHYSICIANS**

**Co-Directors:** Michael F. Myers, M.D., Leah J. Dickstein, M.D.

**COURSE 53** 1:00 p.m.-5:00 p.m.  
 Overture, Third Floor, DoubleTree

**COGNITIVE THERAPY: THE BASICS**

**Director:** Dean Schuyler, M.D.

**COURSE 54** 1:00 p.m.-5:00 p.m.  
 Minuet, Fourth Floor, DoubleTree

**ENHANCING THE DOCTOR-PATIENT RELATIONSHIP**

**Director:** Geoffrey M. Margo, M.D.  
**Faculty:** Katherine L. Margo, M.D., Laurel C. Milberg, Ph.D., C. Paul Scott, M.D.

**COURSE 55** 1:00 p.m.-5:00 p.m.  
 Rhapsody, Fourth Floor, DoubleTree

**ENGAGING RESISTANT AND HOSTILE PATIENTS INTO PARTICIPATORY TREATMENT**

**Director:** David Mee-Lee, M.D.

**COURSE 56** 1:00 p.m.-5:00 p.m.  
 Sonata 5, Fifth Floor, DoubleTree

**BRIEF PSYCHODYNAMIC PSYCHOTHERAPY: THE CORE CONFLICTUAL RELATIONSHIP THEME METHOD**

**Director:** Howard E. Book, M.D.

**NEW RESEARCH YOUNG INVESTIGATORS' ORAL/SLIDE SESSIONS 2-4**

1:00 p.m.-2:30 p.m.

- 2 SCHIZOPHRENIA  
 Room 202 A, Level 200, Convention Center
- 3 SUBSTANCE ABUSE AND MOOD DISORDERS  
 Room 202 B, Level 200, Convention Center
- 4 ANXIETY DISORDERS AND ETHICS  
 Room 203 A, Level 200, Convention Center

For further information on New Research Sessions, please refer to the *New Research Program and Abstracts Book* included in your registration packet.

**2:00 p.m. Sessions**

**ADVANCES IN PSYCHOPHARMACOLOGY**

2:00 p.m.-5:30 p.m.

Rooms 201 A-C, Level 200, Convention Center

**AN UPDATE ON THE ESSENTIALS OF CLINICAL PSYCHOPHARMACOLOGY**

Chp.: Alan F. Schatzberg, M.D.

Co-Chp.: Charles B. Nemeroff

**1 New Antidepressants in Development: Corticotrophin Releasing Hormone and Neurokinin Antagonists**

Ranga K. Krishnan, M.D.

**2 Nonbenzodiazepine Anxiolytics**

Philip T. Ninan

**3 Atypical Antipsychotics**

Michael J. Owens, M.D.

**4 Anticonvulsants as Mood Stabilizers**

Susan L. McElroy, M.D.

**5 Treatment of the Pregnant or Postpartum Woman**

Zachary N. Stowe, M.D.

**LECTURE 6**

2:00 p.m.-3:30 p.m.

Rooms 109 A/B, Street Level, Convention Center

Richard Mayeux, M.D.

**Alzheimer's Disease: The Challenges of Big Risks and Small Gains**

Chp.:

Co-Chp.: Gregory H. Pelton, M.D.

Important clues to the etiology of Alzheimer's disease have come from genetic and epidemiological investigations of patients and their families. Richard Mayeux, M.D., discusses the complex pathogenesis of Alzheimer's disease and the various therapeutic targets that have been identified over the last decade. Dr. Mayeux is the Gertrude H. Sergievsky Professor of Neurology, Psychiatry, and Epidemiology at Columbia University College of Physicians and Surgeons in New York City. He is currently Director of the Gertrude H. Sergievsky Center for the epidemiological investigation of neurological diseases and the Co-Director of the Taub Institute for Research on Alzheimer's Disease and the Aging Brain at Columbia University Health Sciences Center. Dr. Mayeux is the author of more than 250 publications dealing with various aspects of Alzheimer's disease and other degenerative diseases of

the aging brain. He has received the Leadership and Excellence in Alzheimer's Disease Award from the National Institute on Aging and has been honored for his work by the Alzheimer's Association. Dr. Mayeux received his medical degree from the University of Oklahoma and completed residencies in internal medicine at Boston City Hospital and in neurology at Columbia Presbyterian Medical Center in New York.

Frontiers of Science Lecture Series

THIS SESSION WILL BE AUDIOTAPED.

**MEDIA SESSIONS 8-9**

**MEDIA SESSION 8**

2:00 p.m.-5:00 p.m.

Washington Rooms A-C, Third Floor, Loews

**TRANSGENDER TRIALS**

Chp.: Dan H. Karasic, M.D.

**10 Southern Comfort**

(90 minutes)

Distributor: Kate Davis

412 West End Avenue, #3E

New York, NY 10024

*Southern Comfort* is the story of the last year of life for Robert Eades, a female-to-male transsexual in rural Georgia, and his found family of transgendered people. Mr. Eades is a pipe-smoking, self-proclaimed hillbilly, comfortable in his country environment. But the intolerant world in which he lives is evident in his difficulty obtaining medical care when he develops ovarian cancer. The film is able to demonstrate many truths about the lives of transgendered people in general, and is named after a highlight for Eades and his friends, an annual convention for transgendered people in Atlanta.

Discussant: Dan H. Karasic, M.D.

**11 Just Call Me Kade**

(26 minutes)

Distributor: Frameline Distribution

346 Ninth Street

San Francisco, CA 94103-3809

Kade Farlow Collins is a 16-year old female-to-male transgendered person residing in Tucson, Arizona. Kade's parents maintain a supportive and nurturing relationship to help their teenage child face many challenges. As Kade's body began to transform during puberty, he became nearly suicidal. Realizing that the issue was more complex than Kade being a tomboy or lesbian, the family searched for information. Through a local support group and the internet, Kade's mother found books and other resources pertaining to transgenderism. The family agreed to have their lives documented in order to bring awareness to the subject.

**MEDIA SESSION 9** 2:00 p.m.-5:00 p.m.  
 Congress Rooms A-C, Fourth Floor, Loews

**MOB MENTALITY: THE ANALYSIS OF TONY SOPRANO**

**Chp.:** Harvey R. Greenberg, M.D.

12 Sopranos  
 (90 minutes)

**Distributor:** Home Box Office  
 Home Box Office Store  
 www.store.hbo.com

HBO series, *The Sopranos* is a complex drama built around a mobster, Tony Soprano, who struggles with two families; his wife and kids, and his gun-toting gang. The first season was built around what Tony learns when, whipsawed between those two worlds, he finds himself plunged into depression and seeks psychotherapy. With analysis built into the very spine of the show's elaborate episodic structure, creator/writer David Chase, produces an unpredictable series of parallel plots that twist from tragedy, to farce, to social realism.

**PRESIDENTIAL SYMPOSIUM**

2:00 p.m.-5:00 p.m.  
 Room 103 B, Street Level, Convention Center

**WHAT WILL THE 21ST CENTURY BRING TO THE TRAINING OF PSYCHIATRISTS?**

**Chp.:** Lisa A. Mellman, M.D.  
**Co-Chp.:** Ronald O. Rieder, M.D.  
**Presenters:** Richard K. Harding, M.D., Carol A. Bernstein, M.D., David Leach, M.D., Charles F. Reynolds III, M.D., Juan E. Mezzich, M.D.

**Discussant:** Sheldon I. Miller, M.D.  
**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIA 2-26**

**SYMPOSIUM 2** 2:00 p.m.-5:00 p.m.  
 Rooms 102 A/B, Street Level, Convention Center

**ADVANCES IN THE DIAGNOSIS AND TREATMENT OF DELIRIUM**

**Chp.:** John W. Barnhill, M.D.  
**Co-Chp.:** Khakasa H. Wapenyi, M.D.

- A The Experience of Delirium in Cancer Patients**  
 William Breitbart, M.D.
- B The Clinical Diagnosis of Delirium**  
 John W. Barnhill, M.D.

**C Clinical Utility and Cost-Benefit Profile of Diagnostic Testing in Delirium**  
 Christopher I. Kauffman, M.D.

**D The Use of Atypical Antipsychotics in the Treatment of Delirium**  
 Stephen J. Ferrando, M.D.

**E An Open Trial of Olanzapine in the Treatment of Delirium**  
 William Breitbart, M.D.

**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 3** 2:00 p.m.-5:00 p.m.  
 Room 103 A, Street Level, Convention Center

**PLAGUES, PRIONS, AND PARANOIA: THE NEUROPSYCHIATRY OF INFECTIOUS DISEASE**

**Chp.:** Stanley N. Caroff, M.D.  
**Co-Chp.:** E. Cabrina Campbell, M.D.

**A Psychiatric and Cognitive Features of Lyme Disease**  
 Felice A. Tager, Ph.D., Brian A. Fallon, M.D.

**B Regional Specificity and the Neuropathophysiology of HIV-1 in Brain**  
 Karl Goodkin, M.D., Frances L. Wilkie, Ph.D., Diana Lee, Psy.D., Robert Lecusay, Teri T. Baldewicz, Ph.D., Deshratn Asthana, Ph.D., Paul Shapshak, Ph.D.

**C The Neuropsychiatry of the Transmissible Spongiform Encephalopathies**  
 David N. Irani, M.D.

**D Psychiatric Manifestations of Acute Viral Encephalitis**  
 Stanley N. Caroff, M.D., Stephan C. Mann, M.D., Michael F. Gliatto, M.D., Kenneth A. Sullivan, Ph.D., E. Cabrina Campbell, M.D.

**E Neurosyphilis: A History and Clinical Review**  
 Michael F. Gliatto, M.D., Stanley N. Caroff, M.D.

**Discussant:** Jan A. Fawcett, M.D.  
**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 4** 2:00 p.m.-5:00 p.m.  
 Room 103 C, Street Level, Convention Center

**FEAR AND LOATHING IN THE MEDICATION CLINIC**

*APA Commission on Psychotherapy by Psychiatrists*

**Chp.:** Bernard D. Beitman, M.D.

**A To Monitor or to Relate?**  
 Jerald Kay, M.D.

*(Continued on next page)*

**MONDAY**

---

**B Split-Treatment Angst**  
Michelle B. Riba, M.D.

**C The Divided Hour: Psychotherapy in the Medication Check and Other Brief Sessions**  
Jesse H. Wright, M.D.

Discussant: Rachel Z. Ritvo, M.D.  
**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 5** 2:00 p.m.-5:00 p.m.  
Rooms 106 A/B, Street Level, Convention Center

**HEALTH INSURANCE PORTABILITY AND ACCOUNTABILITY ACT: CLINICAL APPLICATIONS AND IMPLICATIONS**

Chp.: Norman E. Alessi, M.D.

**A Basic Health Insurance Portability and Accountability Act Overviews**  
Norman E. Alessi, M.D.

**B Confidentiality and Security Concerns Under Health Insurance Portability and Accountability Act**  
Charles J. Rainey, M.D.

**C Data Protection in Practice: The Impact of the Data Protection Act and Other Legislation in the United Kingdom**  
Brian Lunn, M.D.

**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 6** 2:00 p.m.-5:00 p.m.  
Rooms 107 A/B, Street Level, Convention Center

**EATING DISORDERS 2002: BIOLOGICAL, CLINICAL, AND SOCIAL PERSPECTIVES**

Chp.: Joel Yager, M.D.  
Co-Chp.: David B. Herzog, M.D.

**A Trait-Related 5HT 1A Disturbances in Anorexia Nervosa: Relationship to Susceptibility**  
Walter H. Kaye, M.D., Guido Frank, M.D., Carolyn C. Meltzer, M.D., Julie Price, Ph.D.

**B Who's Dying from an Eating Disorder?**  
David B. Herzog, M.D., Pamela K. Keel, Ph.D., David J. Dorer, Ph.D., Debra Franko, Ph.D., Kamryn T. Eddy, B.A., Valerie E. Charat, B.A., Dana Charatan, B.A.

**C The Role of the Dentist in the Care of Eating-Disorder Patients**  
James E. Mitchell, M.D., James Roerig, Pharm.D., Ross D. Crosby, Ph.D., Stephen A. Wonderlich, Ph.D., Melissa Burgard, B.S.

**D Primary Prevention of Eating Disorders: A Tale of Two Countries**  
Katherine A. Halmi, M.D., Claire V. Wiseman, Ph.D., Suzanne R. Sunday, Ph.D., Francesca Bortolotti, M.D.

**E E-Technologies and Eating Disorders: Problems and Prospects**  
Joel Yager, M.D.  
**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 7** 2:00 p.m.-5:00 p.m.  
Room 111 B, Street Level, Convention Center

**MANAGEMENT OF SCHIZOPHRENIA WITH COMORBID DISORDERS**

Chp.: Michael Y. Hwang, M.D.  
Co-Chp.: Leslie L. Citrome, M.D.

**A Management of Schizophrenia with Depression**  
Samuel G. Siris, M.D.

**B Management of Schizophrenia with Comorbid Anxiety Disorders**  
Michael Y. Hwang, M.D.

**C Clinical Management of Persistent Aggressive Behavior in Schizophrenia**  
Leslie L. Citrome, M.D., Jan Volavka, M.D.

**D Long-Term Outcome and Comorbid Conditions: Why Do We Know so Little?**  
Nina R. Schooler, Ph.D.

Discussants: Lewis A. Opler, M.D., Ming T. Tsuang, M.D.  
**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 8** 2:00 p.m.-5:00 p.m.  
Rooms 112 A/B, Street Level, Convention Center

**DEPRESSIVE SPECTRUM DISORDER IN LATE LIFE: IMPLICATIONS FOR CLINICAL CARE**

Chp.: Helen Lavretsky, M.D.

**A Nonmajor Clinically Significant Depression: The Existing Evidence of a Continuum**  
Anand Kumar, M.D.

**B Clinical Features of a Depressive Continuum**  
George S. Alexopoulos, M.D.

**C Dysthymic Disorder in the Elderly**  
Davangere P. Devanand, M.D.

**D Depression and Symptomatic Anxiety**  
Alastair J. Flint, M.B.  
**THIS SESSION WILL BE AUDIOTAPED.**



**SYMPOSIUM 9** 2:00 p.m.-5:00 p.m.

Room 113 A, Street Level, Convention Center

**INTERACTION OF STRESS AND PERSONALITY***Association for Research in Personality Disorders***Chp.:** James H. Reich, M.D.**A Stress and Personality: Biological Implications**

Kenneth R. Silk, M.D.

**B Clinical Characteristics of Stress-Induced Personality Disorders**

James H. Reich, M.D.

**C Relationship Between Adjustment, Anxiety, and Depressive Disorders**

Peter Tyrer, M.D.

**D Job Stress Among Young Physicians: Working Conditions or Personality, A Prospective Study**

Per Vaglum, M.D., Reidar Tyssen, M.D., Nina Gronvold, M.D., Oivind Ekeberg, M.D.

**E Schema-Focused Cognitive Therapy and Stress-Exacerbated Personality Disorders**

David P. Bernstein, Ph.D.

**Discussant:** Cesare Maffei, M.D.**THIS SESSION WILL BE AUDIOTAPED.****SYMPOSIUM 10** 2:00 p.m.-5:00 p.m.

Room 113 B, Street Level, Convention Center

**EVIDENCE-BASED PSYCHODYNAMIC THERAPY PART II: WHAT DO THE DATA SHOW?***American Academy of Psychoanalysis and American Psychoanalytic Association***Chp.:** Sheila Hafter-Gray, M.D.**Co-Chp.:** Ann-Louise S. Silver, M.D.**A The Benefits of Individual Psychotherapy for Schizophrenia Patients: A Meta-Analytic Review**

William H. Gottdiener, Ph.D., Nick Haslam

**B Controlled Trials of Psychoanalytic Therapies for Young People**

Peter Fonagy, Ph.D., Geoffrey Baruch, M.D., Anthony Bateman, M.D.

**C The Limited Effectiveness of Short-Term Therapy for Anorexia Nervosa**

Athur L. Robin, Ph.D., Patricia Siegel, Ph.D.

**D Randomized Clinical Trial of a Psychoanalytic Treatment of BPD**

Anthony Bateman, M.D.

**THIS SESSION WILL BE AUDIOTAPED.****SYMPOSIUM 11** 2:00 p.m.-5:00 p.m.

Room 113 C, Street Level, Convention Center

**SOCIAL PSYCHIATRIC ASPECTS OF VIOLENCE AND TRAUMA***American Association for Social Psychiatry***Chp.:** Pedro Ruiz, M.D.**Co-Chp.:** Lawrence Hartmann, M.D.**A Trauma and Violence: A U.S. Perspective**

Carl C. Bell, M.D.

**B Social Aspect of Trauma**

S. Arshad Husain, M.D.

**C Nostalgia as a Defense Against Fully Experiencing the Trauma of Immigration**

Salman Akhtar, M.D.

**D Consequences of Psychosocial Interventions: The Potential to Harm and Help**

Daniel L. Creson, M.D., Pedro Ruiz, M.D., Patricia Blakeney, Ph.D.

**E PTSD and Cultural Competency**

Edward F. Foulks, M.D.

**Discussants:** Steven S. Sharfstein, M.D., R. Rao Gogineni, M.D.**THIS SESSION WILL BE AUDIOTAPED.****SYMPOSIUM 12** 2:00 p.m.-5:00 p.m.

Room 203 B, Level 200, Convention Center

**SADISTIC PERSONALITY DISORDER: ITS WIDE RANGE AND IMPORTANCE AS A DIAGNOSIS****Chp.:** Michael H. Stone, M.D.**A Sadism and Forensic Psychiatry**

Michael M. Welner, M.D.

**B Sadistic Personality Disorder: The Need to Reinstate in Future Editions of DSM**

Michael H. Stone, M.D.

**C Sadistic Behaviors and Victim Response**

Ann Burgess, D.N.

**D The Empirical Relationship Between Psychopathy and Sadism**

J. Reid Meloy, Ph.D.

**THIS SESSION WILL BE AUDIOTAPED.****SYMPOSIUM 13** 2:00 p.m.-5:00 p.m.

Rooms 302/303, Level 3, Marriott

**FROM RESEARCH TO PRACTICE: PRIMARY CARE RESEARCH IN SUBSTANCE ABUSE AND MENTAL HEALTH SERVICES FOR ELDERLY***Substance Abuse and Mental Health Services Administration**(Continued on next page)*

MONDAY

Chp.: Sue E. Levkoff, Sc.D.  
Co-Chp.: Maria D. Llorente, M.D.

- A **Integration of Mental Health and Substance Abuse Services in Primary Care for the Elderly**  
John S. McIntyre, M.D.
- B **Consumers' and Researchers' Perspective on Improving Elderly Asian-Americans' and Hispanic-Americans' Participation in Mental Health and Substance Abuse Research**  
Hongtu Chen, Ph.D., Guiseppe Costantino, Ph.D., Sue E. Levkoff, Sc.D., Herman Sanchez, A.B.
- C **Consumers and Researchers: New Partnership Challenges and Opportunities**  
Cynthia Zubritsky, Ph.D., Rosa Wims, Trudy Persky, M.S.W., William Faust, Paul Wohlford, Ph.D.
- D **Identification and Treatment of Alcohol Problems in Primary Care**  
David W. Oslin, M.D., Frederic C. Blow, Ph.D.
- E **Health Policy Implications of (PRISMe) and the Promise of Research on Mental Health and Substance Abuse Treatment of Older Persons in Primary Care**  
Stephen J. Bartels, M.D., Betsy McDonel-Herr, Ph.D.

Discussants: Michael English, Ph.D., Junius J. Gonzales, M.D.  
THIS SESSION WILL BE AUDIOTAPED.

**SYMPOSIUM 14** 2:00 p.m.-5:00 p.m.  
Rooms 304-306, Level 3, Marriott

**EXTINCTION VERSUS ADAPTATION: THE FUTURE OF STATE HOSPITAL PSYCHIATRY**  
*APA Caucus of State Hospital Psychiatrists and American Association of Psychiatric Administrators*

Chp.: Yadollah M. Jabbarpour, M.D.  
Co-Chp.: Beatrice M. Kovaszny, M.D.

- A **Building, Unbuilding, and Rebuilding America's State Hospitals**  
Jeffrey L. Geller, M.D.
- B **The Future of State Hospital Psychiatry Part II: Surviving Political Changes**  
Thomas W. Hester, M.D.
- C **Recruitment and Retention**  
Joel S. Feiner, M.D.
- D **Medical Leadership in State Hospital Systems**  
Christopher G. Fichtner, M.D., Daniel J. Luchins, M.D., Thomas A. Simpatico, M.D., Louis J. Mini, M.D.  
THIS SESSION WILL BE AUDIOTAPED.

**SYMPOSIUM 15** 2:00 p.m.-5:00 p.m.  
Independence Ballroom I, Level 3, Marriott

**THE SOCIAL BRAIN AND PSYCHOTHERAPY**  
*World Psychiatric Association*

Chp.: Russell J. Gardner, Jr., M.D.  
Co-Chp.: John O. Beahrs, M.D.

- A **Clinical Sociophysiology**  
Russell J. Gardner, Jr., M.D.
  - B **Sociodynamics in Psychotherapy**  
John O. Beahrs, M.D.
  - C **The Social Brain as Site of Truth and Deception**  
Godehard Oepen, M.D.
  - D **Biology of Family Psychotherapy**  
Douglas A. Kramer, M.D.
  - E **A Skeptic's View of Bridging Efforts**  
Alan A. Stone, M.D.
- THIS SESSION WILL BE AUDIOTAPED.

**SYMPOSIUM 16** 2:00 p.m.-5:00 p.m.  
Independence Ballrooms II/III, Level 3, Marriott

**SPECIAL TOPICS IN WOMEN'S MENTAL HEALTH**

Chp.: Claudio N. Soares, M.D.  
Co-Chp.: Adele C. Viguera, M.D.

- A **Mood Disturbance and Pregnancy: Pros and Cons of Pharmacological Treatment**  
Adele C. Viguera, M.D., Claudio N. Soares, M.D., Lee S. Cohen, M.D.
- B **Psychiatric Characteristics of Binge Eating Disorder in Obese Women**  
Jose C. Appolinario, M.D.
- C **Gender and Addiction: What Is New?**  
Monica L. Zilberman, Ph.D., Hermano Tavares, Ph.D., Nady El-Guebaly, M.D.
- D **Impact of Estrogen and Other Sexual Hormones on Mood Disturbances**  
Claudio N. Soares, M.D., Jennifer Poitras, B.A., Jennifer Prouty, R.N.C., Lee S. Cohen, M.D.
- E **Estrogens and Alzheimer's Disease in Elderly Women**  
Monica Z. Scalco, M.D., Robert Van Reekum, M.D.  
THIS SESSION WILL BE AUDIOTAPED.

**SYMPOSIUM 17** 2:00 p.m.-5:00 p.m.  
Rooms 401-403, Level 4, Marriott

**PRACTICING PSYCHIATRY IN 2002**

Chp.: Rodrigo A. Munoz, M.D.  
Co-Chp.: Harold I. Eist, M.D.

- A The Minnesota Physician-Patient Alliance**  
Lee H. Beecher, M.D.
- B Solo Practice Psychiatry in the Community**  
Thomas W. Dodson, M.D.
- C Brain and Mind in Clinical Practice**  
Ronald D. Abramson, M.D.
- D Psychiatry in the 21st Century**  
Garry M. Vickar, M.D.
- E Practicing Public Psychiatry in the 21st Century**  
Roger Peele, M.D.
- F General Hospital Psychiatry for the Future**  
John C. Urbaitis, M.D.
- G Practicing Psychiatry Today with Enjoyment and Integrity Despite Managed Care**  
Brian Crowley, M.D.

Discussants: Edward Gordon, M.D., Janis G. Chester, M.D.  
THIS SESSION WILL BE AUDIOTAPED.

**SYMPOSIUM 18** 2:00 p.m.-5:00 p.m.  
Rooms 407-409, Level 4, Marriott

**LOVE FROM PATHOLOGY TO NORMALITY**

- Chp.:** Yves Thoret, M.D.  
**Co-Chp.:** John A. Talbott, M.D.
- A Change of Heart Between Attachment Network and Romantic Love in Arranged Marriages**  
Danielle Groleau, Ph.D.
- B Clinical Considerations About Pedophilia: Love, Sex, and Transgressions**  
Roland M. Coutanceau, M.D., Arnaud Martorell, M.D., Anne Andronikof, Ph.D.
- C The Love Life of Melancholics**  
Peter D. Kramer, M.D.
- D Skin Deep: Transsexuality, Gender Identity, and the Psychopathology of Love**  
Nancy M. Blake, Ph.D.
- E Love as a Mirror of Human Distress: A Transcultural Perspective**  
Richard Rechtman, M.D., James K. Boehnlein, M.D.

Discussant: Glen O. Gabbard, M.D.  
THIS SESSION WILL BE AUDIOTAPED.

**SYMPOSIUM 19** 2:00 p.m.-5:00 p.m.  
Rooms 411/412, Level 4, Marriott

**ADOLESCENCE: THE TUMULTUOUS YEARS**

**Chp.:** Mark H. Rapaport, M.D.

- A Meeting the Needs of Students Exposed to Violence Through School-Based Programs**  
Bradley D. Stein, M.D., Sheryl H. Kataoka, M.D., Lisa Jaycox, Ph.D., Marleen Wong, M.S.W., Arlene Fink, Ph.D.
- B Adolescent Alcohol and Drug Abuse: Challenges and Transitions**  
Sandra A. Brown, Ph.D.
- C Treatment Implications of Teen-Onset Mania**  
Gabrielle Carlson, M.D.
- D Diagnosis and Treatment of Dysthymia and Double Depression**  
David L. Dunner, M.D.

Discussant: Mark H. Rapaport, M.D.  
THIS SESSION WILL BE AUDIOTAPED.

**SYMPOSIUM 20** 2:00 p.m.-5:00 p.m.  
Rooms 414/415, Level 4, Marriott

**IS THERE A BIPOLAR SPECTRUM?**

- Chp.:** S. Nassir Ghaemi, M.D.  
**Co-Chp.:** Frederick K. Goodwin, M.D.
- A The Validity of the Bipolar Spectrum**  
Hagop S. Akiskal, M.D.
- B Predictors of Unipolar to Bipolar Conversion in Affective Disorders**  
Joseph F. Goldberg, M.D.
- C The Bipolar Spectrum: The Clinician's View**  
Jacob J. Katzow, M.D.
- D Criticism of the Bipolar Spectrum as a Concept**  
S. Nassir Ghaemi, M.D.

THIS SESSION WILL BE AUDIOTAPED.

**SYMPOSIUM 21** 2:00 p.m.-5:00 p.m.  
Grand Ballroom Salon A, Level 5, Marriott

**UPDATE ON TREATMENT OF STIMULANT ABUSE**

- Chp.:** David A. Gorelick, M.D.
- A Recovery-Oriented Psychosocial Treatments**  
Douglas M. Ziedonis, M.D., Jonathan Krejci, Ph.D., Marc Steinberg, M.A., Jill Williams, M.D., Sylvia Atdjian, Jeffrey A. Berman, M.D.
- B Therapy and Placement Approaches for Cocaine-Abuse Treatment**  
David R. Gastfriend, M.D., Estee Sharon, Psy.D., Sandrine Pirard, M.D.

*(Continued on next page)*

**MONDAY**

---

**C Pharmacological Treatment of Stimulant Abuse**

David A. Gorelick, M.D.

**D Psychiatric Comorbidity in Stimulant Abusers**

Richard N. Rosenthal, M.D.

**E Methamphetamine Abuse: 2002 Update**

Steven L. Batki, M.D.

**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 22**

**2:00 p.m.-5:00 p.m.**

**Grand Ballroom Salon B, Level 5, Marriott**

**NEW FRONTIERS IN THE  
NEUROENDOCRINOLOGY OF AFFECTIVE  
DISORDERS**

**Chp.:** Natalie L. Rasgon, M.D.

**Co-Chp.:** Mark A. Frye, M.D.

**A Assessing Vulnerability to Depression: Role of HPA  
Axis Dysfunction**

D. Jeffrey Newport, M.D.

**B Gender Differences in Thyroid Indices in Depression**

Mark A. Frye, M.D., George Klee, M.D., Natasha S.  
Sane, M.D., Teresa Huggins, Ph.D., Lori L. Altshuler, M.D.,  
Michael J. Gitlin, M.D., Robert M. Post, M.D.

**C Testosterone and Depression in Men: A Clinical Review**

Stuart N. Seidman, M.D., Steven P. Roose, M.D.

**D Estrogen Use, Mood, and Cerebral Metabolism in  
Menopausal Women**

Natalie L. Rasgon, M.D., Gary W. Small, M.D., Prahba  
Siddarth, Karen Miller, Linda M. Ercoli, Susan Y.  
Bookheimer, Micheal E. Phelps, M.D.

**Discussants:** Stuart N. Seidman, M.D., D. Jeffrey Newport, M.D.

**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 23**

**2:00 p.m.-5:00 p.m.**

**Grand Ballroom Salon C, Level 5, Marriott**

**ADDICTIONS: CUTTING EDGE TREATMENTS FOR  
GAMBLING AND SUBSTANCE ABUSE**

**Chp.:** Herbert D. Kleber, M.D.

**Co-Chp.:** David M. McDowell, M.D.

**A Treatment of Cocaine Dependence**

Adam M. Bisaga, M.D.

**B Treatment of Heroin Dependence**

Herbert D. Kleber, M.D.

**C Marijuana and Club Drugs: Cutting-Edge  
Developments, New and Potential Treatments**

David M. McDowell, M.D.

**D Cutting-Edge Treatment of Gambling Addiction**

Eric Hollander, M.D., Stefano Pallanti, M.D., Erica Sood, B.A.,  
Nicolo Baldini-Rossi, M.D., Sallie J. Hadley, M.D.

**E Treatment of Comorbid Conditions**

Frances R. Levin, M.D.

**Discussant:** Edward V. Nunes, M.D.

**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 24**

**2:00 p.m.-5:00 p.m.**

**Grand Ballroom Salon D, Level 5, Marriott**

**PSYCHOTHERAPY RESEARCH: CHALLENGES FOR  
THE 21ST CENTURY**

**Chp.:** John C. Perry, M.D.

**A Patient Response to the Brief Psychodynamic  
Investigation**

Jean-Nicolas Despland, M.D., Yves De Roten

**B Matching Patients to Therapy: A Review of Empirical  
Studies of Psychotherapy**

Per A. Hoglend, M.D.

**C Moving Cognitive Therapy from the Research Clinic to  
General Psychiatric Practice**

Robert J. DeRubeis, Ph.D.

**D Are Recovery and Healthy Functioning Achievable  
Treatment Goals for Axis II Disorders?**

John C. Perry, M.D.

**E Long-Term Psychotherapy: Current Status and Future  
Directions**

Paul Crits-Christoph, Ph.D.

**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 25**

**2:00 p.m.-5:00 p.m.**

**Grand Ballroom Salon I, Level 5, Marriott**

**A RESEARCH AGENDA FOR DSM-V**

**Chp.:** David J. Kupfer, M.D.

**Co-Chp.:** Darrel A. Regier, M.D.

**A Nomenclature Recommendations**

Bruce J. Rounsaville, M.D., Renato D. Alarcon, M.D.,  
Gavin Andrews, M.D., James S. Jackson, Ph.D., Robert E.  
Kendell, M.D., Kenneth S. Kendler, M.D., Laurence J.  
Kirmayer, M.D.

**B Neuroscience Recommendations**

Dennis S. Charney, M.D., David Barlow, Ph.D., Kelly N.  
Botteron, M.D., Jonathan D. Cohen, M.D., Raquel E.  
Gur, M.D., Keh-Ming Lin, M.D., Eric J. Nestler, M.D.

**C Developmental Recommendations**

Daniel Pine, M.D., Margarita Alegria, Ph.D., Edwin H. Cook, Jr., M.D., E. Jane Costello, Ph.D., Ronald E. Dahl, M.D., Mina K. Dulcan, M.D., Doreen S. Koretz, Ph.D.

**D Disability and Impairment Recommendations**

Anthony F. Lehman, M.D., George S. Alexopoulos, M.D., Howard H. Goldman, M.D., Dilip V. Jeste, M.D., Dan Offord, M.D., T. Bedirhan Ustun, M.D.

**E Cross-Cultural Recommendations**

Renato D. Alarcon, M.D., Margarita Alegria, Ph.D., Carl C. Bell, M.D., James S. Jackson, Ph.D., Laurence J. Kirmayer, M.D., Keh-Ming Lin, M.D., T. Bedirhan Ustun, M.D.

**F Gaps in the Current System: Recommendations**

Michael B. First, M.D., Carl C. Bell, M.D., John H. Krystal, M.D., David Reiss, M.D., M. Tracie Shea, Ph.D., Thomas A. Widiger, Ph.D., Katherine L. Wisner, M.D.

**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 26**

**2:00 p.m.-5:00 p.m.**

**Grand Ballroom Salon J, Level 5, Marriott**

**ACADEMIC AND COMMUNITY MENTAL HEALTH:  
CAN THIS MARRIAGE BE SAVED?**

*American Association of Community Psychiatrists*

**Chp.:** Peter L. Forster, M.D.

**Co-Chp.:** Stephen M. Goldfinger, M.D.

**A Public Academic Liaison: Can This Marriage Be Saved?**

Anita Everett, M.D.

**B How Do You Keep Them Down on the Farm? Training, Recruitment, and Retention**

Barbara M. Rohland, M.D.

**C UC Davis and Sacramento County: A Shotgun Wedding Turned Shared Vision for Public Mental Health**

Thomas J. Sullivan, M.S.W., Jonathan Neufeld, Ph.D.

**THIS SESSION WILL BE AUDIOTAPED.**

**3:00 p.m. Session**

**NEW RESEARCH YOUNG INVESTIGATORS' POSTER SESSION 5**

**3:00 p.m.-5:00 p.m.**

**Exhibit Hall D, Street Level, Convention Center**

For further information on New Research Sessions, please refer to the *New Research Program and Abstracts Book* included in your registration packet.

**6:00 p.m. Session**

**CONVOCATION OF FELLOWS**

6:00 p.m.

Ballrooms A/B, Ballroom Level, Convention Center

All Fellows, members, and registered guests are invited.

**Presiding:** Richard K. Harding, M.D., *President*

**Grand Marshals:** Richard G. Lonsdorf, M.D., Helen S. Wagenheim, M.D.

**Marshals:** Roger F. Haskett, M.D., Barbara A. Schindler, M.D.

**INTRODUCTION OF LIFE FELLOWS**

Paul S. Appelbaum, M.D., *President-Elect*

**INDUCTION OF FELLOWS**

Paul S. Appelbaum, M.D.

**INTRODUCTION OF FIFTY-YEAR LIFE FELLOWS, LIFE MEMBERS, AND INTERNATIONAL FELLOWS**

Richard K. Harding, M.D.

**PRESENTATION OF SPECIAL PRESIDENTIAL COMMENDATIONS**

Richard K. Harding, M.D.

**PRESENTATION OF DISTINGUISHED SERVICE AWARDS**

Richard K. Harding, M.D.

**INTRODUCTION OF THE MEMBERSHIP COMMITTEE CHAIRPERSON AND AWARD BOARD CHAIRPERSONS**

Richard K. Harding, M.D.

**PRESENTATION OF AWARDS**

Richard K. Harding, M.D.

APA Award for Research in Psychiatry

APA/Lilly Resident Research Awards

Francis J. Braceland Award for Public Service

Human Rights Award

Blanche F. Ittleson Award for Research in Child Psychiatry

Kempf Fund Awards for Research Development in Psychobiological Psychiatry

Agnes Purcell McGavin Awards

*(Continued on next page)*



Robert T. Morse Writers Awards  
Isaac Ray Award  
Jack Weinberg Memorial Award for  
Geriatric Psychiatry

**WILLIAM C. MENNINGER MEMORIAL  
CONVOCATION LECTURE**  
Rodger McFarlane

**LECTURE 7**

6:00 p.m.-7:30 p.m.  
Ballrooms A/B, Ballroom Level  
Convention Center

**WILLIAM C. MENNINGER  
MEMORIAL LECTURE  
AND  
APA'S PATIENT ADVOCACY  
AWARD WINNER**

Rodger McFarlane

**Psychiatry and the Medical Consumer Movement**

Rodger McFarlane is one of America's most respected medical consumer activists. He is author of the bestseller, "The Complete Bedside Companion: No-Nonsense Advice on Caring for the Seriously Ill" (Simon & Schuster). He is a former director of clinical outcomes research for the American Association of Health Plans, and a former senior executive at Empire Blue Cross Blue Shield, charged with consumer medical-decision support. In 1982, Mr. McFarlane started America's first AIDS hotline on his personal answering service. He served as Executive Director of the first and largest AIDS service group, the Gay Men's Health Crisis, Inc. He is President-Emeritus of Bailey House, the nation's largest supportive housing program for terminally ill, dual-diagnosis patients. He is a founder and former executive director of Broadway Cares, and one of the instigators of the red ribbon AIDS awareness campaign on all the awards show telecasts. He has helped raise over \$200 million for AIDS groups worldwide. During the 1980's, Mr. McFarlane was a senior consultant to the Commissioner of Mental Health of NYC, in charge of developing HIV screening, referral, and treatment capabilities in every hospital and psychiatric facility in all five boroughs. Mr. McFarlane is also a Tony-winning producer, an elite competitive athlete in several disciplines, and veteran of seven over-ice treks to the North Pole (including three solo). He represented the U.S. in the 1998 Eco-Challenge ("the world's toughest race"), and will again represent the U.S. there this fall. He is an honorably discharged and highly decorated former U.S. Navy "nuke," having run the nuclear engineering plant on the attack submarine that set the still-standing under-ice navigation record. In this year's

William C. Menninger Memorial Convocation Lecture, Mr. McFarlane will address the effect of consumer empowerment on psychiatric practice, as well as the impact of information available on the Internet, in broadcast, and in print advertising. He will delineate the new power of consumers in influencing directly FDA approval of new drugs, Congressional appropriations for research at NIH (and NIMH), their influence with America's largest employers, and the handful of giant companies that compete to underwrite employee health. Mr. McFarlane will outline how new legislation could benefit both mental health practitioners, as well as the consumer/patient. He will discuss the creation of specific alliances between medical professional associations and organized consumer advocacy in order to pursue mutual goals in the new century.  
**THIS SESSION WILL BE AUDIOTAPED.**



# TUESDAY, MAY 21, 2002

## 155TH ANNUAL MEETING

### 7:00 a.m. Sessions

#### PART 2 OF INDUSTRY-SUPPORTED BREAKFAST SYMPOSIA 25-30

##### INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 25, PART 2

7:00 a.m.-8:30 a.m.

Millennium Hall, Second Floor, Loews

##### CLINICAL CHALLENGES IN DEPRESSION

*Supported by GlaxoSmithKline*

**Chp.:** Prakash S. Masand, M.D.

##### **A Can Long-Term Outcome Be Improved in Depression?**

**The Role of Side Effects and Compliance**

Prakash S. Masand, M.D.

##### **B Helping Patients with Sexual Dysfunction During Antidepressant Treatment**

Lori Calabrese, M.D.

##### INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 26, PART 2

7:00 a.m.-8:30 a.m.

Regency Ballrooms A-C, Second Floor, Loews

##### NOVEL ANTIPSYCHOTIC DRUGS: ADVANCES IN THE TREATMENT OF PSYCHOTIC SPECTRUM DISORDERS

*Supported by Bristol-Myers Squibb Company*

**Chp.:** Robert E. Hales, M.D.

**Co-Chp.:** Stuart C. Yudofsky, M.D.

##### **A The Role of Antipsychotics in Acute Mania**

John M. Zajecka, M.D.

##### **B Clinical Challenges in Managing Psychosis in the Elderly**

Dilip V. Jeste, M.D., Christian Dolder, Pharm.D., Hoang A. Nguyen, M.D., Laura B. Dunn, M.D., Jorge F. Porrás, M.D., Enid Rockwell, M.D.

##### INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 27, PART 2

7:00 a.m.-8:30 a.m.

Grand Ballroom Salons E/F, Level 5, Marriott

##### ANTIPSYCHOTIC PHARMACOTHERAPY AND THE HIPPOCRATIC OATH: ABOVE ALL DO NO HARM

*Supported by AstraZeneca Pharmaceuticals*

**Chp.:** Henry A. Nasrallah, M.D.

##### **A Avoiding Neuroendocrine Disruptions with Atypical Antipsychotic Agents**

David C. Henderson, M.D.

##### **B Emerging Bioethical Issues in Antipsychotic Pharmacotherapy: Do Unto Others**

Henry A. Nasrallah, M.D.

##### INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 28, PART 2

7:00 a.m.-8:30 a.m.

Grand Ballroom Salons G/H, Level 5, Marriott

##### UNDERSTANDING SLEEP MEDICINE: WHAT THE PSYCHIATRIST NEEDS TO KNOW

*Supported by Wyeth Pharmaceuticals*

**Chp.:** Milton K. Erman, M.D.

##### **A Morbidity of Insomnia**

Thomas Roth, Ph.D.

##### **B Mechanism of Action of Hypnotics**

Stephen Stahl, M.D.

##### INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 29, PART 2

7:00 a.m.-8:30 a.m.

Wyndham Ballrooms A/B, First Floor, Wyndham

##### ONE SIZE DOESN'T FIT ALL: DEPRESSION THERAPIES FOR THE 21ST CENTURY

*Supported by Eli Lilly and Company*

**Chp.:** David L. Dunner, M.D.

##### **A Lost in Depression: The Treatment-Resistant Patient**

Holly A. Swartz, M.D.

##### **B Depression and Substance Use**

Kathleen T. Brady, M.D.

##### **C Putting the Pieces Together: Treatments for the Present and Future**

David L. Dunner, M.D.

##### INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 30, PART 2

7:00 a.m.-8:30 a.m.

Wyndham Ballrooms C/D, First Floor, Wyndham

##### BREAKING THE SILENCE OF CHILDREN'S MENTAL ILLNESS: NATIONAL INITIATIVES, EARLY DETECTION, AND NEW PHARMACO- THERAPIES

*Supported by Janssen Pharmaceutica*

(Continued on next page)

## TUESDAY

---

**Chp.:** Robert L. Findling, M.D.

**A Evolving Treatments for Psychiatric Disorders in Young Patients with Evidence from Bipolar and Other Conditions**  
Janet Wozniak, M.D., Joseph Biederman, M.D., Jennifer Richards, B.A.

**B Antipsychotic Pharmacotherapy in Children and Adolescents: What Is the Evidence for Long-Term Safety?**  
Robert L. Findling, M.D.

**C A Parent's Perspective on Interventions for Children's Mental Health**  
Ellen Kingsley, M.A.

---

### 8:00 a.m. Sessions

---



#### COURSES 57-64

Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.

---

**COURSE 57** 8:00 a.m.-12 noon  
Ormandy East, Street Level, DoubleTree

#### DRUG TREATMENT OF SCHIZOPHRENIA

**Director:** Philip G. Janicak, M.D.  
**Faculty:** Stephen R. Marder, M.D., Rajiv Tandon, M.D., Rajiv P. Sharma, M.D.

---

**COURSE 58** 8:00 a.m.-12 noon  
Ormandy West, Street Level, DoubleTree

#### THE DETECTION OF MALINGERED MENTAL ILLNESS

**Director:** Phillip J. Resnick, M.D.

---

**COURSE 59** 8:00 a.m.-12 noon  
Aria A, Third Floor, DoubleTree

#### SEXUAL DISORDERS: DIAGNOSIS AND TREATMENT

**Director:** Waguih W. Ishak, M.D.  
**Faculty:** Marina Bussel, M.D., Steve A. Eklund, M.D., Romana Markvitsa, M.D., Anatoly Postolov, M.D.

---

**COURSE 60** 8:00 a.m.-12 noon  
Overture, Third Floor, DoubleTree

#### ECT PRACTICE UPDATE

**Director:** Charles H. Kellner, M.D.  
**Faculty:** Richard L. Jaffe, M.D., W. Vaughn McCall, M.D., Richard D. Weiner, M.D.

---

**COURSE 61** 8:00 a.m.-12 noon  
Maestro, Fourth Floor, DoubleTree

#### HOW TO USE YOUR PALM PERSONAL DIGITAL ASSISTANT IN PSYCHIATRIC PRACTICE

**Director:** John Luo, M.D.  
**Faculty:** Carlyle H. Chan, M.D., Charles J. Rainey, M.D., Richard A. Montgomery, M.D.

---

**COURSE 62** 8:00 a.m.-12 noon  
Minuet, Fourth Floor, DoubleTree

#### HOW TO SET UP AND RUN A JUVENILE JUSTICE CLINIC

**Director:** Gabriel Kaplan, M.D.  
**Faculty:** Honorable Lee Forrester, Michael Swerdlow, Ph.D., Denise M. Williams-Johnson, Ph.D., Dorothy Adam

---

**COURSE 63** 8:00 a.m.-12 noon  
Rhapsody, Fourth Floor, DoubleTree

#### DOING RESEARCH ON A SHOESTRING BUDGET

**Director:** Mantosh J. Dewan, M.D.  
**Faculty:** Michelle T. Pato, M.D., Edward K. Silberman, M.D.

---

**COURSE 64** 8:00 a.m.-12 noon  
Sonata 5, Fifth Floor, DoubleTree

#### PARTIAL HOSPITALIZATION FOR PATIENTS WITH BPD

**Director:** Lawrence L. Kennedy, M.D.

---

### 9:00 a.m. Sessions

---

**CLINICAL CASE CONFERENCE 2**  
9:00 a.m.-10:30 a.m.  
Room 103 B, Street Level, Convention Center

#### DEPRESSION IN THE MEDICAL SETTING REVISITED: THE PROBLEM OF THE DEPRESSIVE SPECTRUM DISORDERS

**Moderator:** Robert J. Boland, M.D.  
**Presenter:** Colin J. Harrington, M.D.

**THIS SESSION IS OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.**

**CONTINUOUS CLINICAL CASE CONFERENCE 1:  
PART 2**

9:00 a.m.-12 noon

Rooms 106 A/B, Street Level, Convention Center

**LIVES AND TREATMENTS: TWO PATIENTS, TWO  
THERAPISTS****Moderator:** James W. Lomax II, M.D.**Presenters:** Glen O. Gabbard, M.D., Irma J. Bland, M.D.**THIS SESSION IS OPEN TO APA MEMBERS ONLY.  
BLUE REGISTRATION BADGE OR APA MEMBER-  
SHIP CARD REQUIRED FOR ADMITTANCE.****COURSES 65-69**Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.**COURSE 65** 9:00 a.m.-4:00 p.m.

Orchestra Room, Second Floor, DoubleTree

**DAVANLOO'S INTENSIVE SHORT-TERM DYNAMIC  
PSYCHOTHERAPY IN CLINICAL PRACTICE****Director:** James Q. Schubmehl, M.D.**Faculty:** Alan R. Beeber, M.D., Tewfik Said, M.D.**COURSE 66** 9:00 a.m.-4:00 p.m.

Concerto B, Third Floor, DoubleTree

**INTRODUCTION TO COGNITIVE-BEHAVIORAL  
THERAPY****Co-Directors:** Robert M. Goisman, M.D., Philip G. Levendusky, Ph.D.**COURSE 67** 9:00 a.m.-4:00 p.m.

Symphony Ballroom, Third Floor, DoubleTree

**MED-PSYCH DRUG-DRUG INTERACTIONS: AN  
UPDATE****Co-Directors:** Scott C. Armstrong, M.D., Kelly L. Cozza, M.D.**Faculty:** Jessica R. Oesterheld, M.D., David Benedek, M.D.**COURSE 68** 9:00 a.m.-4:00 p.m.

Sonata 3, Fifth Floor, DoubleTree

**BEING AN EFFECTIVE SCHOOL CONSULTANT****Director:** Lois T. Flaherty, M.D.**Faculty:** Trina B. Allen, M.D., Richard L. Gross, M.D.,  
Eugenio M. Rothe, M.D.**COURSE 69** 9:00 a.m.-4:00 p.m.

Sonata 4, Fifth Floor, DoubleTree

**TRANSPERSONAL PSYCHIATRY: CLINICAL  
APPLICATIONS****Co-Directors:** John F. Hiatt, M.D., William W. Foote, M.D.**DEBATE**

9:00 a.m.-10:30 a.m.

Rooms 107 A/B, Street Level, Convention Center

**RESOLVED: POLITICAL CORRECTNESS HAS NO  
PLACE IN MEDICINE?****Moderator:** Patricia I. Ordonica, M.D.**Affirmative:** Sally L. Satel, M.D.**Negative:** Paul S. Appelbaum, M.D.**THIS SESSION WILL BE AUDIOTAPED.****DISCUSSION GROUPS 9-13**

9:00 a.m.-10:30 a.m.

**These sessions are limited to 25 participants on a first-  
come, first-served basis.**

- 9 **Carol A. Bernstein, M.D.**, on Surviving Residency: Perspectives from the Training Office  
Room 308, Level 3, Marriott
- 10 **Silvia Hafliger, M.D.**, on Living Organ Donation: Psychiatric Aspects and Ethical Dilemmas for Donor and Recipient  
Room 410, Level 4, Marriott
- 11 **Paula T. Trzepacz, M.D.**, on Delirium: Phenomenology, Neuropathogenesis, and Treatment Interrelationships  
Room 413, Level 4, Marriott
- 12 **Stuart C. Yudofsky, M.D.**, on Neuropsychiatry and the Future of Psychiatry (*Meet the Authors*)  
Room 501, Level 5, Marriott
- 13 **Robert I. Simon, M.D. and Daniel W. Shuman**, on Retrospective Assessment of Mental States in Litigation: Predicting the Past (*Meet the Authors*)  
Room 502, Level 5, Marriott

LECTURES 8-10

LECTURE 8

9:00 a.m.-10:30 a.m.

Rooms 108 A/B, Street Level, Convention Center

Mary Jane Massie, M.D.

You Are Twenty-Four and You Have What?

Chp.: Donna E. Stewart, M.D.

Co-Chp.: Diana Chapa, M.D.

Researchers have described the psychological concerns of women with breast cancer, but little attention has been given to young women with this disease and the special problems they face in education, work and career, body image, relationships, sexuality, child-bearing, and childrearing. Mary Jane Massie, M.D., discusses the risk factors for and treatment of breast cancer in young women and the issues that arise in the psychiatric treatment of young women with this disease. Dr. Massie is Director of the Barbara White Fishman Center for Psychological Counseling at Memorial Sloan-Kettering Cancer Center in New York and Professor of Clinical Psychiatry at Weill Medical College of Cornell University in New York. Her current research focuses on community outreach to improve opportunities for breast cancer education and screening of minority women. A Fellow of the APA, Dr. Massie has chaired the APA Committee on Consultation/Liaison Psychiatry and Primary Care Education and the Elections Committee. She is currently President-Elect of the Academy of Psychosomatic Medicine. Dr. Massie received her medical degree from the State University of New York at Buffalo School of Medicine and completed her residency in psychiatry at Montefiore Hospital/Albert Einstein College of Medicine in the Bronx and a fellowship in psychiatric oncology at Memorial Sloan-Kettering Cancer Center.  
Distinguished Psychiatrist Lecture Series

LECTURE 9

9:00 a.m.-10:30 a.m.

Rooms 109 A/B, Street Level, Convention Center

APA'S BENJAMIN RUSH AWARD LECTURE

James P. Comer, M.D.

Problems Facing Inner-City School Educators and the Role of Psychiatry in Addressing Them

Chp.: Richard J. Thurrell, M.D.

Co-Chp.: Jack C. Westman, M.D.

Academic and personal development can be significantly improved for students from marginal and

difficult environments through the application of child development and mental health principles in schools. James P. Comer, M.D., founder of the School Development Program, which has been disseminated to more than 700 schools across the country, discusses the program's approach for mobilizing school staff and parents to support students' learning and overall development. Dr. Comer is the Maurice Falk Professor of Child Psychiatry at Yale Child Study Center and Associate Dean of Yale University School of Medicine in New Haven, Connecticut. His research interests in schools as a preventive psychiatry focus, race relations, and child rearing are reflected in his books *School Power*, *Beyond Black and White*, and *Raising Black Children* and in numerous other publications in psychiatry and education. A Fellow of the American Academy of Arts and Sciences, Dr. Comer has received APA's Special Presidential Commendation and the Presidential Citation of the American Educational Research Association. Dr. Comer graduated from Howard University School of Medicine in Washington, D.C., completed a master's degree in public health at the University of Michigan, and received his training in psychiatry at Yale University School of Medicine, Yale Child Study Center, and Hillcrest Children's Center in Washington, D.C.

THIS SESSION WILL BE AUDIOTAPED.

LECTURE 10 - CANCELLED

MASTER EDUCATOR CLINICAL CONSULTATIONS 5-6

9:00 a.m.-10:30 a.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

5 Kenneth Z. Altshuler, M.D., on the Psychotherapies: Do Similarities Outweigh Differences?

Room 111 A, Street Level, Convention Center

6 Lisa A. Mellman, M.D., on Brief Dynamic Therapy: For the Patient or for Managed Care?

Room 301, Level 3, Marriott

THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

MEDIA SESSIONS 10-11

MEDIA SESSION 10

9:00 a.m.-10:30 a.m.

Washington Rooms A-C, Third Floor, Loews

PLANETARY PRESSURES

Chp.: Elyse D. Dubo, M.D.



**13 Six Billion and Beyond**  
(56 minutes)

**Distributor:** University of California Extension  
For V13, Center for Media and Independent Learning  
V14 & V15 2000 Center Street, 4th Floor  
Berkeley, CA 94704

Half of the world's six billion people are under the age of 25. The decisions they make about how many children to have and when to have them will be critical in shaping life on earth in the next 50 years. This thought-provoking documentary is perhaps the most comprehensive introduction available on video to the interconnected issues of population growth, economic development, equal rights and opportunities for women, and environmental protection around the world.

**MEDIA SESSION 11** 9:00 a.m.-10:30 a.m.  
Congress Rooms A-C, Fourth Floor, Loews

**UP CLOSE AND PERSONAL**

**Chp.:** Ian E. Alger, M.D.

**14 Slippery Blisses**  
(42 minutes)

Kissing is one of our most complex and delicate forms of communication. It brings our senses of touch, smell, and taste together with a variety of powerful emotions and behavioral messages. *Slippery Blisses* interweaves the commentary of ordinary people who recall their best and worst kisses with a quirky cast of behavioral experts who discuss the "science" of kissing and raise numerous discussion-inducing questions. The film depicts a visit to Paris, the world's most romantic city, and along the way explores the turbulent history of kissing in the movies, interviews a sex therapist, and features a socialite hairdresser who shows how cheek-kissing bonds high-society together. *Slippery Blisses* ultimately demonstrates that, as with all human behavior and communication, there is nothing simple about a simple kiss.

**15 Personal Space: Exploring Human Proxemics**  
(28 minutes)

Space is a silent language, and we all speak it, whether consciously or not. *Personal Space: Exploring Human Proxemics* is a fascinating and frequently funny video that portrays the effects of space on everyday human behavior in an engaging and dramatic manner. Topics covered in the video include: 1) individual reactions to invasions of personal space; 2) the powerful effect of cultural differences and strong habitual patterns in how individuals use space; 3) family spatial arrangements; 4) how spatial factors affect our perceptions of relationships; and 5) hierarchical space in organizations. The video blends student testimony and often amusing field experiments to illuminate the use of space, territory, and touching in virtually every facet of life.

**RESEARCH ADVANCES IN MEDICINE**  
9:00 a.m.-11:00 a.m.  
Room 111 B, Street Level, Convention Center

**LONG-TERM MECHANICAL CIRCULATORY SUPPORT**

**Chp.:** Peter A. Shapiro, M.D.  
**Co-Chp.:** James L. Levenson, M.D.

**Participant:** Eric Rose, M.D.

**Frontiers of Science Lecture**  
**THIS SESSION WILL BE AUDIOTAPED.**

**REVIEW OF PSYCHIATRY: SECTION 1**  
9:00 a.m.-12:30 p.m.  
Rooms 201 A-C, Level 200, Convention Center

**EMERGENCY PSYCHIATRY**

**Chp.:** Michael H. Allen, M.D.

- 1 **The Structure and Function of Psychiatric Emergency Services**  
Richard E. Breslow, M.D.
- 2 **Medical, Psychiatric, and Cognitive Assessment in Psychiatric Emergencies**  
Glenn W. Currier, M.D.
- 3 **Assessment and Treatment of the Suicidal Patient**  
Peter L. Forster, M.D.
- 4 **Emergency Treatment of Agitation and Aggression**  
Jean-Pierre Lindenmayer, M.D.
- 5 **Psychosocial Interventions in the Psychiatric Emergency Service: A Skills Approach**  
Ronald C. Rosenberg, M.D.

**TELECOMMUNICATIONS SESSION 1**  
9:00 a.m.-12 noon  
Room 204 C, Level 200, Convention Center

**APPLICATIONS OF ADVANCED INFORMATION TECHNOLOGIES**

**Chp.:** Norman E. Alessi, M.D.

- 9:15 a.m.
- 1 **The Use of Digital Streaming Video for Distance Education in Telepsychiatry**  
Gregory L. Barker
- 10:00 a.m.
- 2 **DAVID: Depression Animation Video Image Database**  
Earl C. Lawrence, M.A., Mike Ward
- 11:00 a.m.
- 3 **Open Infrastructure for Outcomes: From Plug and Play Web Forms to Evidence-Guided Treatment**  
Andrew P. Ho, M.D.

**TUESDAY**

---

**WORKSHOPS**

**COMPONENTS 19-22**

**COMPONENT WORKSHOP 19** 9:00 a.m.-10:30 a.m.  
Room 103 C, Street Level, Convention Center

**HEALTH CARE LEGISLATION: THE ROLE FOR  
THE 21ST-CENTURY BLACK PSYCHIATRIST**  
*APA Committee of Black Psychiatrists*

**Co-Chps.:** Michelle O. Clark, M.D., Lishan Workeneh, M.D.  
**Participants:** Bethany J. Tucker, M.D., Honorable Louis Stokes

**COMPONENT WORKSHOP 20** 9:00 a.m.-10:30 a.m.  
Liberty Ballroom C, Level 3, Marriott

**HOW TO LAUNCH A SUCCESSFUL PRIVATE  
PRACTICE: PART I**  
*APA Committee of Early Career Psychiatrists*

**Co-Chps.:** William E. Callahan, Jr., M.D., Keith W. Young, M.D.  
**Participants:** Jacqueline M. Melonas, J.D., Martin G. Tracy, J.D.

**COMPONENT WORKSHOP 21** 9:00 a.m.-10:30 a.m.  
Rooms 407-409, Level 4, Marriott

**MEDICAL STUDENT EDUCATION IN ADDICTION:  
COMPETENCIES AND RESOURCES**  
*APA Committee on Training and Education in Addiction Psychiatry and  
American Academy of Addiction Psychiatry*

**Co-Chps.:** Jonathan I. Ritvo, M.D., Richard S. Schottenfeld, M.D.  
**Participants:** William M. Greenberg, M.D., Timothy W. Fong, M.D.,  
Christopher J. Welsh, M.D., Marjorie E. Waldbaum, M.D.

**COMPONENT WORKSHOP 22** 9:00 a.m.-10:30 a.m.  
Rooms 411/412, Level 4, Marriott

**DISCUSSION: SURGEON GENERAL'S REPORT ON  
AMERICAN INDIANS AND ALASKA NATIVES**  
*APA Committee of American Indian, Alaska Native, and Native  
Hawaiian Psychiatrists*

**Co-Chps.:** Frank W. Brown, M.D., Yvonne L. De Cory-  
Woronoff, M.D.  
**Participants:** Mary H. Roessel, M.D., Richard L. Livingston, M.D.,  
R. Dale Walker, M.D.

**ISSUES 29-57**

**ISSUE WORKSHOP 29** 9:00 a.m.-10:30 a.m.  
Rooms 102 A/B, Street Level, Convention Center

**WORKING WITH PARENTS DURING THEIR BABY'S  
FIRST YEAR OF LIFE**

**Chp.:** James M. Murphy, M.D.

**ISSUE WORKSHOP 30** 9:00 a.m.-10:30 a.m.  
Room 103 A, Street Level, Convention Center

**THE NEUROBIOLOGY OF LEARNING:  
IMPLICATIONS FOR TEACHING**

**Chp.:** Janet E. Osterman, M.D.

**ISSUE WORKSHOP 31** 9:00 a.m.-10:30 a.m.  
Room 104 A, Street Level, Convention Center

**EXPLORING THE MEDIA'S ROLE IN IMITATION  
VIOLENCE**

**Chp.:** Paul A. Kettl, M.D.  
**Participant:** Kathleen Jamison, Ph.D.

**ISSUE WORKSHOP 32** 9:00 a.m.-10:30 a.m.  
Room 104 B, Street Level, Convention Center

**WE CAN IMPROVE CARE FOR THOSE WITH  
MENTAL HEALTH AND SUBSTANCE ABUSE  
DISORDERS**

**Chp.:** Katherine E. Watkins, M.D.  
**Participants:** John Sheeche, M.S.W., Dina Daleo, Ph.D.

**ISSUE WORKSHOP 33** 9:00 a.m.-10:30 a.m.  
Rooms 112 A/B, Street Level, Convention Center

**COUPLES TREATMENT BY PARALLEL  
COORDINATED INDIVIDUAL PSYCHOTHERAPY**

**Chp.:** Michael C. Hughes, M.D.  
**Participant:** Eva C. Ritvo, M.D.

**ISSUE WORKSHOP 34** 9:00 a.m.-10:30 a.m.  
Room 113 A, Street Level, Convention Center

**MOTION PICTURES: THE THERAPEUTIC  
MODALITY OF THE 21ST CENTURY**

**Chp.:** M. Fuat Ulus, M.D.  
**Participants:** Conni Sharp, Ed.D., Eda Ulus, B.S.

**ISSUE WORKSHOP 35** 9:00 a.m.-10:30 a.m.  
Room 113 B, Street Level, Convention Center

**INNOVATIVE STRATEGIES IN THIRD-YEAR  
MEDICAL STUDENT PSYCHIATRIC EDUCATION**

**Chp.:** Molly J. Hall, M.D.  
**Participants:** Timothy J. Lacy, M.D., Brenda J. Roman, M.D.,  
Donald A. West, M.D., Stephen B. Shanfield, M.D.



**ISSUE WORKSHOP 36** 9:00 a.m.-10:30 a.m.  
Room 113 C, Street Level, Convention Center

**NATIONAL COMMISSION ON MARIJUANA AND  
DRUG ABUSE REPORT: 30 YEARS LATER**

**Chp.:** J. Thomas Ungerleider, M.D.  
**Participant:** Michael R. Sonnenreich, J.D.

**ISSUE WORKSHOP 37** 9:00 a.m.-10:30 a.m.  
Room 202 A, Level 200, Convention Center

**BRIDGING THE GAP: DEPRESSION, CHRONIC  
MEDICAL DISEASE, CULTURE, AND ETHNICITY**

**Chp.:** Annelie B. Primm, M.D.  
**Participants:** William T. Regenold, M.D., Evelyn L. Lewis, M.D.

**ISSUE WORKSHOP 38** 9:00 a.m.-10:30 a.m.  
Room 202 B, Level 200, Convention Center

**OLFACTORY DYSFUNCTION IN PSYCHIATRY AND  
NEUROLOGY**

**Co-Chps.:** Teodor T. Postolache, M.D., Richard L. Doty, Ph.D.  
**Participants:** Paul J. Moberg, Ph.D., Marilyn Jones-Gotman, Ph.D.

**ISSUE WORKSHOP 39** 9:00 a.m.-10:30 a.m.  
Room 203 A, Level 200, Convention Center

**NEUROBEHAVIORAL SEQUELAE OF TRAUMA TO  
THE FRONTAL LOBES**

**Chp.:** Marilyn F. Kraus, M.D.  
**Participants:** Harvey Levin, Ph.D., Thomas Gualtieri, M.D.

**ISSUE WORKSHOP 40** 9:00 a.m.-10:30 a.m.  
Room 203 B, Level 200, Convention Center

**CULTURAL COMPETENCE IN PSYCHIATRIC  
RESIDENCY TRAINING PROGRAMS**

*Substance Abuse and Mental Health Services Administration*

**Chp.:** Francis G. Lu, M.D.  
**Participants:** Renato D. Alarcon, M.D., Pedro Ruiz, M.D.,  
James W. Thompson, M.D.

**ISSUE WORKSHOP 41** 9:00 a.m.-10:30 a.m.  
Room 204 A, Level 200, Convention Center

**A LEGAL PRIMER FOR PSYCHIATRISTS INVOLVED  
IN ISSUES OF SEXUAL ORIENTATION**

**Co-Chps.:** John E. Fryer, M.D., Mark-Allen Taylor, J.D.  
**Participants:** Nancy J. Knauer, J.D., David L. Scasta, M.D.

**ISSUE WORKSHOP 42** 9:00 a.m.-10:30 a.m.  
Room 204 B, Level 200, Convention Center

**TEN YEARS OF TEACHING ABOUT BOUNDARIES:  
WHAT HAVE WE LEARNED?**

**Chp.:** Gregg E. Gorton, M.D.  
**Participants:** Steven E. Samuel, Ph.D., Gail Zivin, Ph.D.

**ISSUE WORKSHOP 43** 9:00 a.m.-10:30 a.m.  
Rooms 302/303, Level 3, Marriott

**EVIDENCE-BASED TREATMENT FOR MARIJUANA  
DEPENDENCE**

*Substance Abuse and Mental Health Services Administration*

**Chp.:** Karen Steinberg, Ph.D.  
**Participants:** Roger A. Roffman, D.S.W., Ronald Kadden, Ph.D.,  
Jerome H. Jaffe, M.D.

**ISSUE WORKSHOP 44** 9:00 a.m.-10:30 a.m.  
Rooms 304-306, Level 3, Marriott

**ENHANCING AND FUNDING MENTAL HEALTH  
SERVICES: NEW FREEDOM INITIATIVE**

*Substance Abuse and Mental Health Services Administration*

**Co-Chps.:** Mary Jane England, M.D., Eileen Elias, M.Ed.  
**Participants:** Shelley E. Bishop, Vincent J. Hughes, Eileen C.  
Wolkstein, Ph.D., Marilyn L. Eckley, M.P.A.

**ISSUE WORKSHOP 45** 9:00 a.m.-10:30 a.m.  
Room 307, Level 3, Marriott

**BUPRENORPHINE: A NEW OFFICE-BASED  
TREATMENT FOR OPIOID DEPENDENCE**

*Substance Abuse and Mental Health Services Administration*

**Co-Chps.:** Herbert D. Kleber, M.D., H. Westley Clark, M.D.

**ISSUE WORKSHOP 46** 9:00 a.m.-10:30 a.m.  
Independence Ballroom I, Level 3, Marriott

**IMPROVING THE QUALITY OF SERVICE IN A  
MEDICAID HMO**

**Chp.:** James M. Schuster, M.D.  
**Participants:** Deborah Wasilchak, Frank Ghinassi, Kelly  
Kelleher, M.D.

**ISSUE WORKSHOP 47** 9:00 a.m.-10:30 a.m.  
Independence Ballrooms II/III, Level 3, Marriott

**IMPLEMENTATIONS OF DBT IN CORRECTIONAL  
ENVIRONMENTS**

**Chp.:** Robert L. Trestman, M.D.  
**Participants:** Daniel Bannish, Psy.D., M. Paul Chaplin, Ph.D.

## TUESDAY

**ISSUE WORKSHOP 48** 9:00 a.m.-10:30 a.m.  
**Rooms 401-403, Level 4, Marriott**

### HEPATITIS-C IN ADDICTION PSYCHIATRY

**Chp.:** Vasant P. Dhopes, M.D.  
**Participants:** Kyong-Mi Chang, M.D., Robert M. Weinrieb, M.D.

**ISSUE WORKSHOP 49** 9:00 a.m.-10:30 a.m.  
**Rooms 414/415, Level 4, Marriott**

### GROUP PSYCHOTHERAPY FOR SUBSTANCE ABUSERS

**Co-Chps.:** David W. Brook, M.D., Henry I. Spitz, M.D.

**ISSUE WORKSHOP 50** 9:00 a.m.-10:30 a.m.  
**Grand Ballroom Salon A, Level 5, Marriott**

### WORLD FEDERATION OF PSYCHIATRIC TRAINEES: SATISFACTION AND INTERNATIONAL EXCHANGE IN PSYCHIATRIC

**Co-Chps.:** Victor J.A. Buwalda, M.D., Michelle B. Riba, M.D.

**ISSUE WORKSHOP 51** 9:00 a.m.-10:30 a.m.  
**Grand Ballroom Salon B, Level 5, Marriott**

### SPIRITUAL DIMENSION AND RELIGIOUS ISSUES IN AN URBAN CMHC CLINICAL PRACTICE

*Haitian-American Psychiatric Association*

**Chp.:** Jean B. Tropnas, M.D.  
**Participants:** Ophie Franklin, Yvette Sealy, Ph.D., Meeta Gandhi, M.S.W., Donna M. Serrant, M.S.W.

**ISSUE WORKSHOP 52** 9:00 a.m.-10:30 a.m.  
**Grand Ballroom Salon C, Level 5, Marriott**

### ETHICS OF PHARMACEUTICAL INVOLVEMENT IN PSYCHIATRIC EDUCATION

**Chp.:** Nalini V. Juthani, M.D.  
**Participants:** Jeffrey M. Levine, M.D., Uday K. Mukherjee, M.D., Huma K. Khan, M.D., Mikhail Y. Ziskin, M.D.

**ISSUE WORKSHOP 53** 9:00 a.m.-10:30 a.m.  
**Grand Ballroom Salon D, Level 5, Marriott**

### THE PORTRAYAL OF PSYCHIATRY IN RECENT AMERICAN FILMS

**Chp.:** Steven E. Pflanz, M.D.

**ISSUE WORKSHOP 54** 9:00 a.m.-10:30 a.m.  
**Grand Ballroom Salon I, Level 5, Marriott**

### HIV, AIDS, HEPATITIS-C, MENTAL ILLNESS, AND SUBSTANCE ABUSE: CONVERGING ILLNESS

*Substance Abuse and Mental Health Services Administration*

**Chp.:** Marshall Forstein, M.D.  
**Participants:** Marvin S. Swartz, M.D., Lawrence Brown, M.D., Jennifer F. Havens, M.D.

**ISSUE WORKSHOP 55** 9:00 a.m.-10:30 a.m.  
**Grand Ballroom Salon J, Level 5, Marriott**

### ADDICTION TREATMENT 2002: NEW DIRECTIONS

**Chp.:** Richard J. Frances, M.D.  
**Participants:** Sheila B. Blume, M.D., Sheldon I. Miller, M.D., Marc Galanter, M.D., Robert B. Millman, M.D., Lionel P. Solursh, M.D., Frances R. Levin, M.D.

**ISSUE WORKSHOP 56** 9:00 a.m.-10:30 a.m.  
**Grand Ballroom Salon K, Level 5, Marriott**

### TARASOFF REVISITED: CHANGING TRENDS IN DUTY TO WARN THIRD PARTIES

**Chp.:** Chowallur D. Chacko, M.D.  
**Participants:** Robert L. Sadoff, M.D., Liz M. Chacko

**ISSUE WORKSHOP 57** 9:00 a.m.-10:30 a.m.  
**Grand Ballroom Salon L, Level 5, Marriott**

### IMPLEMENTING AN EFFECTIVE TRUANCY-REDUCTION PROGRAM

**Chp.:** Stephen M. Soltys, M.D.  
**Participants:** Mary Jo Davoren, M.Ed., David Mahrer, Ph.D., Kenneth M. Rogers, M.D.

---

## 11:00 a.m. Sessions

---

### DISCUSSION GROUPS 14-18

11:00 a.m.-12:30 p.m.

**These sessions are limited to 25 participants on a first-come, first-served basis.**

- 14 **Rachel Yehuda, Ph.D.**, on Treatment of Trauma Survivors: Theory Versus Practice (*Meet the Authors*)  
**Room 308, Level 3, Marriott**
- 15 **Frances R. Levin, M.D.**, on Treating Substance Abusers with Comorbid Psychiatric Disorders: Potential Pitfalls  
**Room 410, Level 4, Marriott**
- 16 **Thomas N. Wise, M.D.**, on Depression in the Medically Ill  
**Room 413, Level 4, Marriott**
- 17 **Elisabeth J.S. Kunkel, M.D.**, on Managing Depression and Anxiety in Patients with Cancer and Other Medical Illnesses  
**Room 501, Level 5, Marriott**
- 18 **Karen K. Milner, M.D.**, on Integrating Physical-Mental Health Care: The WCHO Experience  
**Room 502, Level 5, Marriott**

## LECTURES 11-12

## LECTURE 11

11:00 a.m.-12:30 p.m.

Rooms 108 A/B, Street Level, Convention Center

APA/NIMH VESTERMARK PSYCHIATRY  
EDUCATOR AWARD LECTURE

Marc Galanter, M.D.

## Healing Through Social and Spiritual Affiliation

Chp.: Richard Balon, M.D.

Co-Chp.: Patricia I. Ordorica, M.D.

Although largely overlooked by conventional biomedical practice, social and spiritual affiliation can be valuable in promoting recovery from psychiatric disorders, particularly substance abuse. Marc Galanter, M.D., draws on research on addicted patients' experience in Alcoholics Anonymous to illustrate the potent impact of a spiritual message imparted in a cohesive social group. He also discusses the model of ideologically grounded affiliation as it relates to behavioral changes observed in cultic, terrorist, and mental health support groups. Dr. Galanter is Professor of Psychiatry and Director of the Division of Alcoholism and Drug Abuse at New York University School of Medicine. A Fellow of the APA, Dr. Galanter is Past President of the American Academy of Addiction Psychiatry and the American Society of Addiction Medicine and the Editor-in-Chief of *Substance Abuse*. He received the McGovern Award from the Association for Medical Education and Research in Substance Abuse, and his clinical program received the APA Gold Achievement Award for innovative care. His research is presented in more than 250 publications, including two books, *Cults: Faith, Healing, and Coercion* and *Network Therapy for Alcohol and Drug Abuse*. Dr. Galanter received his medical and psychiatric training at Albert Einstein College of Medicine in the Bronx.

THIS SESSION WILL BE AUDIOTAPED.

## LECTURE 12

11:00 a.m.-12:30 p.m.

Rooms 109 A/B, Street Level, Convention Center

Ira R. Byock, M.D.

Dying Well: Beyond Symptoms and Suffering,  
Human Development at the End-of-Life

Chp.: Mary E. Foti, M.D.

Co-Chp.: Maurice D. Steinberg, M.D.

Narratives of people confronting life's end provide empiric evidence of the range of human experience that

can occur during the time of life termed "dying." Although suffering is common among dying patients, the ability to make meaning, review one's life, complete relationships, express love, and explore spiritual realms all may continue to exist. Ira R. Byock, M.D., describes a developmental conceptual framework for understanding the nature of suffering and opportunity at the end of life and discusses ways in which psychiatric specialists can alleviate suffering and preserve the opportunity for people to grow, individually and together, through the very end of life. Dr. Byock is Director of Palliative Care Service in Missoula, Montana, and Research Professor in the Department of Philosophy at the University of Montana, where he is also a faculty member in the Practical Ethics Center. His numerous publications on end-of-life care include the book *Dying Well: The Prospect for Growth at the End of Life*. He has received the National Hospice Organization's Person of the Year award and the National Coalition of Cancer Survivorship's Natalie Davis Spingarn Writers Award. Dr. Byock graduated from the University of Colorado School of Medicine and completed his residency in family practice at Valley Medical Center in Fresno, California.

Frontiers of Science Lecture Series

THIS SESSION WILL BE AUDIOTAPED.

MASTER EDUCATOR CLINICAL  
CONSULTATIONS 7-8

11:00 a.m.-12:30 p.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

7 **Jerald Kay, M.D.**, on Integrating Psychotherapy and Pharmacotherapy  
Room 111 A, Street Level, Convention Center

8 **Lawrence Hartmann, M.D.**, on Child and Adolescent Clinical Work: Integrating Bio-, Psycho-, and Social  
Room 301, Level 3, Marriott

THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

## MEDIA SESSIONS 12-13

MEDIA SESSION 12

11:00 a.m.-1:00 p.m.

Washington Rooms A-C, Third Floor, Loews

## AFTER APARTHEID

Chp.: J. Charles Ndlela, M.D.

(Continued next page)

**16 Long Night's Journey into Day**  
(94 minutes)

**Distributor:** California Newsreel  
149 9th Street, Suite 420  
San Francisco, CA 94103

This film captures some of the pain with an outpouring of emotions during the hearing before the Truth and Reconciliation Commission, which was a process chosen by South Africa to facilitate healing from Apartheid trauma. Nobel Prize Laureate Archbishop Desmond Tutu states, "This is an impressive, heart-rending film and deserves wide circulation." The directors have attempted to explore the workings of the "restorative justice" in a dramatic presentation accompanied by rich, emotionally arousing South African music.

**Discussant:** J. Charles Ndlela, M.D.

**MEDIA SESSION 13** 11:00 a.m.-12:30 p.m.  
**Congress Rooms A-C, Fourth Floor, Loews**

**VICTIMS AT AN EARLY AGE**

**Chp.:** Edward K. Rynearson, M.D.

**17 Making Visible the Hidden: Serving Child Victims in the Healthcare Community**  
(15 minutes)

**Distributor:** Deborah Spungen, M.S.S.  
AVP  
633 West Rittenhouse Street, #C-14  
Philadelphia, PA 19144

Healthcare providers are often the first to respond to child victims of violence, but their focus on treating the physical wounds sometimes causes them to overlook children's emotional and mental (the hidden) needs. Without timely and appropriate intervention, the effects of trauma can last a lifetime. *Making Visible the Hidden: Serving Child Victims in the Healthcare Community* highlights three programs in which professionals in medical settings are incorporating victim-oriented practices into the service they provide. The stories of child victims vividly illustrate the importance of early intervention.

**Discussant:** Deborah Spungen, M.S.S.

**18 Take This Heart**  
(58 minutes)

**Distributor:** University of California Extension  
Center for Media and Independent Learning  
2000 Center Street, 4th Floor  
Berkeley, CA 94704

For the nearly one million American children who are compelled to live in foster care, daily life is a forbidding venture. Cast adrift at an early age, dispossessed of everyone they have known or loved, they are left to grow up in a world

that has proven deeply unreliable, with strangers who may or may not offer comfort and protection. *Take This Heart* is the story of three boys who struggle to make sense of their harsh fates, each in his own way. Their stories reveal the remarkable resiliency and the tough-minded will with which they go on with their lives, not utterly consoled, but not broken. The film explores the experiences of a few children in one foster home in Seattle, and in so doing gives voice to an invisible population of children otherwise consigned to silence at the margins of society.

**MEDICAL UPDATE 2**

11:00 a.m.-12:30 p.m.  
**Room 103 A, Street Level, Convention Center**

**CARDIAC EFFECTS OF OPIOID ADDICTION PHARMACOTHERAPY**

*Substance Abuse and Mental Health Services Administration*

**Chp.:** Richard S. Schottenfeld, M.D.

**Presenters:** Elinore F. McCance-Katz, M.D., Robert Maslansky, M.D.

**THIS SESSION WILL BE AUDIOTAPED.**

**RESEARCH CONSULTATION WITH**

11:00 a.m.-12:30 p.m.

**This session is limited to 25 participants on a first-come, first-served basis.**

- 1 **Steven P. Roose, M.D., on Depressed Patients with Heart Disease and Late-Life Depression**  
**Anthony Room, Third Floor, Loews**

**SCIENTIFIC AND CLINICAL REPORT SESSIONS 13-24**

**SCIENTIFIC AND CLINICAL REPORT SESSION 13**

11:00 a.m.-12:30 p.m.  
**Room 103 C, Street Level, Convention Center**

**GENDER ISSUES**

**Chp.:** Antonia L. Baum, M.D.  
**Co-Chp.:** Melva I. Green, M.D.

11:00 a.m.

**37 Meat Consumption and Risk of Depression: A Prospective, Population-Based Study**

Antti Tanskanen, M.D., Heimo Viinamaki, M.D., Kaisa Haatainen, M.H.S.C., Kristiina Nyyssonen, Ph.D., Tiina H. Rissanen, R.N., Sari Voutilainen, Ph.D., Jukka T. Salonen, M.D.

11:30 a.m.

**38 A Multinational Study of the Emergence of Gender Differences in Depression**

Terrance J. Wade, Ph.D., John Cairney, M.A., David J. Pevalin, M.A.

12 noon

**39 Efficacy and Safety of Sildenafil Citrate in Men with Depression and Erectile Dysfunction: Six-Month, Open-Label Treatment**

Stuart N. Seidman, M.D., Steven P. Roose, M.D., Vera J. Stecher, Ph.D., Matthew A. Menza, M.D., Raymond C. Rosen, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

**SCIENTIFIC AND CLINICAL REPORT SESSION 14**

11:00 a.m.-12:30 p.m.

Room 113 B, Street Level, Convention Center

**BIPOLAR TREATMENT ISSUES**

Chp.: David L. Dunner, M.D.

Co-Chp.: N. Kalaya Okereke, M.D.

11:00 a.m.

**40 End-Stage Chronic Renal Failure from Prolonged Lithium Therapy**

Gregory Braden, M.D., David L. Honeyman, M.D., Anthony Poindexter, M.D., Jane Garb, M.S., Michael Germain, M.D., Lewis M. Cohen, M.D.

11:30 a.m.

**41 Topiramate in the Treatment of Refractory Bipolar Depression**

Mohammad Z. Hussain, M.D., Zabaida A. Chaudhry, M.D., Seema Hussain, M.D.

12 noon

**42 Prescribing Practices in Bipolar Disorder**

Bonnie L. Szarek, R.N., John W. Goethe, M.D., Uzma S. Faheem, M.D.

THIS SESSION WILL BE AUDIOTAPED.

**SCIENTIFIC AND CLINICAL REPORT SESSION 15**

11:00 a.m.-12:30 p.m.

Room 113 C, Street Level, Convention Center

**DRUG THERAPY OF ADHD**

Chp.: Paul P. Yeung, M.D.

Co-Chp.: Albert Y. Ma, M.D.

11:00 a.m.

**43 Once-Daily Administration of Atomoxetine: A New Treatment for ADHD**

David Michelson, M.D.

11:30 a.m.

**44 ADHD Treatment with a Once-Daily Formulation of Methylphenidate Hydrochloride: A Two-Year Study**

Timothy E. Wilens, M.D., William E. Pelham, Jr., Ph.D., Mark Stein, Ph.D., C. Keith Conners, Ph.D., Howard Abikoff, Ph.D.

12 noon

**45 Long-Term Safety and Efficacy of Adderall Extended Release in Children with ADHD**

Mark C. Chandler, M.D., Frank A. Lopez, M.D., Joseph Biederman, M.D.

**SCIENTIFIC AND CLINICAL REPORT SESSION 16**

11:00 a.m.-12:30 p.m.

Room 204 A, Level 200, Convention Center

**CULTURAL ISSUES IN VIOLENCE**

Chp.: Jose M. Canive, M.D.

Co-Chp.: Martin A. Adeoye, M.D.

11:00 a.m.

**46 Partner Violence and Risk of Major Depression in Chinese-American Women**

Madelyn H. Hicks, M.D.

11:30 a.m.

**47 Violence in Colombia: Mental Health Impact in Children**

Ruby C. Castilla-Puentes, M.D., Ivan S. Gomez, M.D., Sandra-Rocio Castilla Puentes, M.D., Wilma-Ines Castilla Puentes, M.D., Miguel Habeych, M.D., Linda McWilliams, M.P.H., Boris Birmaher, M.D.

12 noon

**48 Epidemiology, Trauma, and Transcultural Psychiatry**

Joop De Jong, M.D., Ivan Kompore, Ph.D., Mark Van

Ommeren, Daya Somasundaram, M.D.

THIS SESSION WILL BE AUDIOTAPED.

**SCIENTIFIC AND CLINICAL REPORT SESSION 17**

11:00 a.m.-12:30 p.m.

Room 204 B, Level 200, Convention Center

**BIPOLAR DISORDER**

Chp.: Paul J. Goodnick, M.D.

Co-Chp.: Daniel Tsao, M.D.

11:00 a.m.

**49 Increased Rates of Antipsychotic-Induced EPS in Mood Disorders: Myth or Reality?**

Patrizia A. Cavazzoni, M.D., Paul H. Berg, M.S., Robert W. Baker, M.D., Angela R. Evans, Ph.D., Mauricio F. Tohen, M.D.

*(Continued next page)*



11:30 a.m.

**50 Cyclothymia in Atypical Depression: The Borderline-Bipolar II Connection**

Giulio Perugi, M.D., Christina Toni, M.D., Chiara Traverso, M.D., Giuseppe Ruffolo, M.D., Hagop S. Akiskal, M.D.

12 noon

**51 Substance Use and Perceived Symptom Improvement in Bipolar Disorder**

Roger D. Weiss, M.D., Monika Kolodziej, Ph.D., Margaret L. Griffin, Ph.D., Lisa M. Najavits, Ph.D., Lara M. Jacobson, B.A., Shelly F. Greenfield, M.D.

THIS SESSION WILL BE AUDIOTAPED.

**SCIENTIFIC AND CLINICAL REPORT SESSION 18**

11:00 a.m.-12:30 p.m.

Independence Ballrooms II/III, Level 3, Marriott

**PREDICTORS OF OUTCOME**

Chp.: Linmarie Sikich, M.D.

Co-Chp.: Michael A. Scharf, M.D.

11:00 a.m.

**52 Outcome of Early-Phase Psychosis Concurrent with Substance Use**

Carol L.M. Caton, Ph.D., Deborah S. Hasin, Ph.D., Michael B. First, M.D., Ellen M. Stevenson, M.D., Robert E. Drake, M.D., Francine Cournos, M.D., Patrick Shrout, Ph.D.

11:30 a.m.

**53 Predictors of Syndromal and Functional Recovery in Patients with First-Episode Mania**

Mauricio F. Tohen, M.D., John Hennen, Ph.D., Carlos M. Zarate, Jr., M.D., Stephan M. Strakowski, M.D., Ross J. Baldessarini, M.D.

12 noon

**54 High Birth Weight as a Predictor of Schizophrenia: A 31-Year Follow-Up**

Kristiina Moilanen, M.D., Jari Jokelainen, M.S.C., Anna-Liisa Hartikainen, Ph.D., Marjo-Riitta Jarvelin, Ph.D., Peter B. Jones, Ph.D., Matti K. Isohanni, M.D.

THIS SESSION WILL BE AUDIOTAPED.

**SCIENTIFIC AND CLINICAL REPORT SESSION 19**

11:00 a.m.-12:30 p.m.

Rooms 407-409, Level 4, Marriott

**BEHAVIOR AND COGNITIVE THERAPY**

Chp.: John C. Markowitz, M.D.

Co-Chp.: Anton C. Trinidad, M.D.

11:00 a.m.

**55 Does Cognitive-Behavioral Group Treatment Improve Personality Measures in Panic Disorder Patients?**

Frederico Cavaglia, M.S.C., Cristina Pablo, M.D., Ana Matos-Pires, M.S.C., Nuno Goncalves, M.D.

11:30 a.m.

**56 Visually Enhanced Psychosexual Therapy**

Frank G. Sommers, M.D.

12 noon

**57 Dichotomous Thinking and Thought Suppression in Managing Anger**

David M. Magder, M.D.

THIS SESSION WILL BE AUDIOTAPED.

**SCIENTIFIC AND CLINICAL REPORT SESSION 20**

11:00 a.m.-12:30 p.m.

Grand Ballroom Salon B, Level 5, Marriott

**ETHICAL AND EXPLANATORY MODELS IN PSYCHIATRY**

Chp.: Alan M. Gruenberg, M.D.

Co-Chp.: David M. McDowell, M.D.

11:00 a.m.

**58 Principles of Clinical Explanation in 21st-Century Psychiatry**

David H. Brendel, M.D.

11:30 a.m.

**59 Experience of Research Participation by Patients with Severe Mental Illness**

Russell S. Omens, Psy.D., Cherise Rosen, M.A., Sheila Donovan, Ph.D., Martin Harrow, Ph.D., Philip G. Janicak, M.D.

12 noon

**60 Attitudes of Physicians Towards Gifts from the Pharmaceutical Industry: A Pilot Study**

Amarsingh M. Ghorpade, M.D., Saurabh Kaushik, M.D., Parinda Parikh, M.D., Vasundhara Kalasapudi, M.D., Sheldon S. Berman, M.D.

THIS SESSION WILL BE AUDIOTAPED.

**SCIENTIFIC AND CLINICAL REPORT SESSION 21**

11:00 a.m.-12:30 p.m.

Grand Ballroom Salon C, Level 5, Marriott

**RELIGION, SPIRITUALITY, AND PSYCHIATRY**

Chp.: David A. Casey, M.D.

Co-Chp.: John P. Hendrick, M.D.

11:00 a.m.

**61 Effects of Falun Gong Practice on Physical and Mental Health**

Jing-Duan Yang, M.D., Ashwin A. Patkar, M.D., Li-Shan Huang, Ph.D., Daniel A. Monti, M.D., Sue Jiang, M.S., Cuirong Ren, Ph.D.

11:40 a.m.

**62 Moral Conflict as a Component of Anxiety and Worry**

Jerome L. Kroll, M.D., Kathleen S. Carey, M.S., Paul Erickson, M.D., Elizabeth Egan, Ph.D., Myles Johnson, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

**SCIENTIFIC AND CLINICAL REPORT SESSION 22**

11:00 a.m.-12:30 p.m.

Grand Ballroom Salon J, Level 5, Marriott

**USES OF MODAFINIL****Chp.:** Maria T. Caserta, M.D.**Co-Chp.:** Kevan R. Wylie, M.D.

11:00 a.m.

**63 Effect of Modafinil on Mood and Quality of Life in Patients with Narcolepsy**

Philip M. Becker, M.D., Jonathan Schwartz, M.D., Neil Feldman, M.D., Rod J. Hughes, Ph.D.

11:30 a.m.

**64 Long-Term Safety and Efficacy of Modafinil for Daytime Sleepiness**

Mary B. O'Malley, M.D.

12 noon

**65 Modafinil Enhances Motivation in the Absence of Overt Sleepiness**

Matthew S. Miller, Ph.D., Elaine Fiocchi, B.S., Dorothy G. Flood, Ph.D., Amy DiCamillo, M.S.

**THIS SESSION WILL BE AUDIOTAPED.****SCIENTIFIC AND CLINICAL REPORT SESSION 23**

11:00 a.m.-12:30 p.m.

Grand Ballroom Salon K, Level 5, Marriott

**CROSS-CULTURAL PSYCHIATRY: ASIAN ISSUES****Chp.:** Maria R. Yee, M.D.**Co-Chp.:** Victor Hong

11:00 a.m.

**66 Integrating Psychiatry and Primary Care Improves Treatment Acceptability Among Asian Americans**

Albert Yeung, M.D., Grace E. F. Rubenstein, B.A., Henry Chung, M.D., Pamela A. Roffi, B.S., Andrew A. Nierenberg, M.D., Maurizio Fava, M.D., David Mischoulon, M.D.

11:30 a.m.

**67 Anger Discomfort in Japanese, Chinese, and Caucasian Females**

Alayne Yates, M.D., Jeanne Edman, Ph.D., Mata Aruguette, Ph.D.

12 noon

**68 Anatomy of Jeong**

Christopher K. Chung, M.D., Samson J. Cho, M.D.

**THIS SESSION WILL BE AUDIOTAPED.****SCIENTIFIC AND CLINICAL REPORT SESSION 24**

11:00 a.m.-12:30 p.m.

Grand Ballroom Salon L, Level 5, Marriott

**EPIDEMIOLOGY****Chp.:** Steven A. Epstein, M.D.**Co-Chp.:** Henry W.J. Weisman, M.D.

11:00 a.m.

**69 The Burden of Hepatitis-C Among Mentally Ill Persons in Long-Term Care**

Elsie J. Freeman, M.D., Kenneth S. Duckworth, M.D.

11:30 a.m.

**70 Double Jeopardy: Mental Illness, Medical Conditions, and Early Death**

Elsie J. Freeman, M.D., Kenneth S. Duckworth, M.D., Robert Goldstein, Ph.D., MaryLou Sudders

12 noon

**71 Prevalence and Symptom Patterns of Depression Among College Students**

Shamsah B. Sonawalla, M.D., Nicole B. Neault, B.A., Christina M. Dording, M.D., Megan E. Hughes, B.A., Albert Yeung, M.D., Timothy J. Petersen, Ph.D., Maurizio Fava, M.D.

**THIS SESSION WILL BE AUDIOTAPED.****WORKSHOPS****COMPONENTS 23-31****COMPONENT WORKSHOP 23** 11:00 a.m.-12:30 p.m.

Rooms 102 A/B, Street Level, Convention Center

**MENTAL HEALTH CARE FOR ASIAN AMERICANS AND PACIFIC ISLANDERS***APA Committee of Asian-American Psychiatrists***Co-Chps.:** Nang Du, M.D., Surinder S. Nand, M.D.**Participants:** Francis G. Lu, M.D., Keh-Ming Lin, M.D., Kana Enomoto, M.A.**COMPONENT WORKSHOP 24** 11:00 a.m.-12:30 p.m.

Room 104 A, Street Level, Convention Center

**SURVIVOR MUR: WHO GETS VOTED IN?***APA Assembly Committee of Representatives of Minority/Underrepresented Groups***Co-Chps.:** Jeffrey Akaka, M.D., Ana E. Campo, M.D.**Participants:** Donna M. Norris, M.D., Rodrigo A. Munoz, M.D., Pedro Ruiz, M.D., Nada L. Stotland, M.D., R. Dale Walker, M.D.**COMPONENT WORKSHOP 25** 11:00 a.m.-12:30 p.m.

Room 104 B, Street Level, Convention Center

**AMBULATORY DETOXIFICATION FROM ALCOHOL: HOW TO DO IT WELL AND GET PAID TOO***APA Committee on Treatment Services for Addicted Patients***Co-Chps.:** George F. Kolodner, M.D., Samuel M. Silverman, M.D.**Participants:** Brealyn M. Sellers, M.D., Victor Sierra, M.D.

TUESDAY

**COMPONENT WORKSHOP 26** 11:00 a.m.-12:30 p.m.  
Rooms 112 A/B, Street Level, Convention Center

**THE TERRORIST CRISIS OF 2001: USE AND IMPACT OF ELECTRONIC COMMUNICATION**

*APA Committee on Information Technology, APA New York County District Branch, and the Psychiatric Society for Informatics*

Co-Chps.: Ronnie S. Stangler, M.D., Julie K. Schulman, M.D.

**COMPONENT WORKSHOP 27** 11:00 a.m.-12:30 p.m.  
Room 202 A, Level 200, Convention Center

**KIDS, SCHOOLS, AND PARENTS: FROM THE 20TH CENTURY INTO THE 21ST CENTURY**

*APA Committee on History and Library*

Chp.: Richard J. Thurrell, M.D.

Participants: David F. Musto, M.D., James P. Comer, M.D., Elissa P. Benedek, M.D., Jack C. Westman, M.D.

**COMPONENT WORKSHOP 28** 11:00 a.m.-12:30 p.m.  
Rooms 302/303, Level 3, Marriott

**THE MENTAL HEALTH CARVEOUT: STRATEGIES TO ERASE THE STIGMA**

*APA Work Group on Carveouts*

Co-Chps.: Lawrence B. Lurie, M.D., Jonathan E. Gudeman, M.D.

Participants: Janis G. Chester, M.D., Norman A. Clemens, M.D., Jerome H. Rogoff, M.D., Kenneth R. Silk, M.D.

**COMPONENT WORKSHOP 29** 11:00 a.m.-12:30 p.m.  
Room 307, Level 3, Marriott

**MISSION IMPOSSIBLE II: WHEN THE DISORDERED CHILD BECOMES AN ADULT**

*APA Committee on Children with Mental or Developmental Disorders*

Chp.: Roxanne C. Dryden-Edwards, M.D.

Participants: Paula J. Lockhart, M.D., Donald J. Mordecai, M.D., Lisa J. Nelson, M.D., Lee M. Price, L.S.W.

**COMPONENT WORKSHOP 30** 11:00 a.m.-12:30 p.m.  
Liberty Ballroom A, Level 3, Marriott

**CLINICIAN SAFETY**

*APA Task Force on Psychiatric Aspects of Violence*

Chp.: Arthur Z. Berg, M.D.

Participants: Carl C. Bell, M.D., Bradley R. Johnson, M.D.

**COMPONENT WORKSHOP 31** 11:00 a.m.-12:30 p.m.  
Liberty Ballroom C, Level 3, Marriott

**HOW TO LAUNCH A SUCCESSFUL PRIVATE PRACTICE: PART II**

*APA Committee of Early Career Psychiatrists*

Co-Chps.: William E. Callahan, Jr., M.D., Keith W. Young, M.D.

Participants: Tracy R. Gordy, M.D., Chester W. Schmidt, Jr., M.D.

**ISSUES 58-68**

**ISSUE WORKSHOP 58** 11:00 a.m.-12:30 p.m.  
Room 202 B, Level 200, Convention Center

**PSYCHODYNAMICS IN TREATMENT-REFRACTORY DEPRESSION**

Co-Chps.: Eric M. Plakun, M.D., Edward R. Shapiro, M.D.

Participant: David L. Mintz, M.D.

**ISSUE WORKSHOP 59** 11:00 a.m.-12:30 p.m.  
Room 203 A, Level 200, Convention Center

**THE ART OF THE UNCONSCIOUS: SHAKESPEARE, POETRY, FILM, AND PSYCHIATRY**

Co-Chps.: Steven E. Pflanz, M.D., Charles R. Joy, M.D.

**ISSUE WORKSHOP 60** 11:00 a.m.-12:30 p.m.  
Room 203 B, Level 200, Convention Center

**USE OF RESTRAINTS IN PSYCHIATRIC PRACTICE: PROS, CONS, AND ALTERNATIVES**

Chp.: Ann Marie T. Sullivan, M.D.

Participants: William Fisher, M.D., Charles T. Barron, M.D., Janet Bezmen, R.N., John O'Brien, M.D., Yuange Hu, M.D.

**ISSUE WORKSHOP 61** 11:00 a.m.-12:30 p.m.  
Rooms 309-310, Level 3, Marriott

**METHAMPHETAMINE TREATMENT: WHAT PSYCHIATRISTS NEED TO KNOW**

*Substance Abuse and Mental Health Services Administration*

Chp.: Richard A. Rawson, M.D.

Participants: William F. Haning III, M.D., Walter Ling, M.D.

**ISSUE WORKSHOP 62** 11:00 a.m.-12:30 p.m.  
Liberty Ballroom B, Level 3, Marriott

**FROM PSYCHOANALYTIC PSYCHOTHERAPIST TO PSYCHOANALYTIC ORGANIZATIONAL CORPORATE CONSULTANT: AN INTRODUCTORY WORKSHOP**

Chp.: Howard E. Book, M.D.

Participant: Jeffrey P. Kahn, M.D.

**ISSUE WORKSHOP 63** 11:00 a.m.-12:30 p.m.  
Independence Ballroom I, Level 3, Marriott

**ROLE OF AMYTAL IN CONVERSION DISORDER**

Chp.: Sadiq H. Al-Samarrai, M.D.

Participant: Thomas S. Newmark, M.D.

**ISSUE WORKSHOP 64** 11:00 a.m.-12:30 p.m.  
Rooms 401-403, Level 4, Marriott

**MINORITY PSYCHIATRISTS WHO HAVE SUFFERED MENTAL ILLNESS: OVERCOMING STIGMA**  
*National Alliance for the Mentally Ill*

**Co-Chps.:** Michael F. Myers, M.D., Leah J. Dickstein, M.D.  
**Participants:** Michelle O. Clark, M.D., Raymond M. Reyes, M.D., Suzanne E. Vogel-Scibilia, M.D.

**ISSUE WORKSHOP 65** 11:00 a.m.-12:30 p.m.  
Rooms 411/412, Level 4, Marriott

**THE CHALLENGE OF PARENTAL MENTAL ILLNESS**  
*Substance Abuse and Mental Health Services Administration*

**Chp.:** Judith Katz-Leavy, M.Ed.  
**Participants:** Beth Hinden, Ph.D., Lucinda Mallen, William R. Beardslee, M.D., Joanne Nicholson, Ph.D.

**ISSUE WORKSHOP 66** 11:00 a.m.-12:30 p.m.  
Rooms 414/415, Level 4, Marriott

**AFTERMATH OF PROFESSIONAL BOUNDARIES VIOLATIONS: TREATMENT OF VICTIMS**

**Chp.:** Gail E. Robinson, M.D.  
**Participants:** P. Susan Penfold, M.D., Werner Tschan, M.D., Gary R. Schoener, Psy.D.

**ISSUE WORKSHOP 67** 11:00 a.m.-12:30 p.m.  
Grand Ballroom Salon D, Level 5, Marriott

**A RECIPE FOR ACADEMIC/PERSONAL SUCCESS: SOME KEY INGREDIENTS**  
*Association for Academic Psychiatry*

**Chp.:** Linda L.M. Worley, M.D.  
**Participants:** Josepha A. Cheong, M.D., Robert J. Boland, M.D., Donald M. Hilty, M.D., Michelle B. Riba, M.D.

**ISSUE WORKSHOP 68** 11:00 a.m.-12:30 p.m.  
Grand Ballroom Salon I, Level 5, Marriott

**THE BODY IN 21ST-CENTURY PSYCHIATRY: DIAGNOSTIC DIMENSIONS AND THERAPEUTIC CHALLENGES**

**Co-Chps.:** Elena B. Bezzubova, M.D., Barton J. Blinder, M.D.  
**Participants:** Jon E. Grant, M.D., Donca Vianu, M.D.

## 12 noon Sessions

### FORUMS 5-8

**FORUM 5** 12 noon-1:30 p.m.  
Room 103 B, Street Level, Convention Center

**HOMOSEXUALITY AND RELIGION: HEALING THE WOUND**  
*Association of Gay and Lesbian Psychiatrists and APA Committee on Gay, Lesbian, and Bisexual Issues*

**Chp.:** Daniel W. Hicks, M.D.  
**Participants:** David L. Scasta, M.D., Stuart M. Sotsky, M.D., Thomas P. Welch, M.D.

**FORUM 6** 12 noon-1:30 p.m.  
Rooms 107 A/B, Street Level, Convention Center

**THE DEATH PENALTY AND THE ROAD TO EXECUTION: PSYCHOLOGICAL ISSUES FOR CORRECTIONAL OFFICERS; APPROPRIATE AND INAPPROPRIATE ROLES FOR PSYCHIATRISTS**

**Chp.:** Robert Michels, M.D.  
**Co-Chp.:** Philip G. Zimbardo, Ph.D.  
**Participants:** Michael J. Osofsky, Howard J. Osofsky, M.D., Warden B. Cain

**FORUM 7 - CANCELLED**

**FORUM 8** 12 noon-1:30 p.m.  
Room 113 A, Street Level, Convention Center

**THE CHALLENGES OF IDENTIFYING AND INTERVIEWING POTENTIAL SUBSTANCE ABUSERS**  
*Substance Abuse and Mental Health Services Administration*

**Chp.:** Joseph H. Autry III, M.D.  
**Co-Chp.:** H. Westley Clark, M.D.

**NEW RESEARCH POSTER SESSION 6**  
12 noon-2:00 p.m.  
Exhibit Hall D, Street Level, Convention Center

**BRAIN IMAGING; GENETICS; RESEARCH ISSUES; COMBINED PHARMACOTHERAPY AND PSYCHOTHERAPY; BEHAVIOR AND COGNITIVE THERAPIES; NEUROPSYCHIATRY; BIOLOGICAL, CONSULTATION-LIAISON, AND GERIATRIC PSYCHIATRY; OCD; AND COGNITIVE, SOMATOFORM, AND ANXIETY DISORDERS**

For further information on New Research Sessions, please refer to the *New Research Program and Abstracts Book* included in your registration packet.

**1:00 p.m. Sessions**



**COURSES 70-78**

Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.

**COURSE 70** 1:00 p.m.-5:00 p.m.  
Ormandy East, Street Level, DoubleTree

**VAGAL NERVE STIMULATION**

**Co-Directors:** Ziad H. Nahas, M.D., Mustafa M. Husain, M.D.  
**Faculty:** Linda L. Carpenter, M.D., Robert H. Howland, M.D., Mitchel A. Kling, M.D.

**COURSE 71** 1:00 p.m.-5:00 p.m.  
Ormandy West, Street Level, DoubleTree

**I FOUND IT AT THE MOVIES: USING FILM CLIPS TO UNDERSTAND AND TEACH PSYCHIATRY**

**Director:** Frederick W. Engstrom, M.D.

**COURSE 72** 1:00 p.m.-5:00 p.m.  
Aria A, Third Floor, DoubleTree

**THE ADVANCED PRACTICE OF PSYCHOTHERAPY**

**Director:** T. Byram Karasu, M.D.

**COURSE 73** 1:00 p.m.-5:00 p.m.  
Concerto A, Third Floor, DoubleTree

**ACHIEVING EFFECTIVE DUAL DIAGNOSIS TREATMENT**

**Director:** John W. Tsuang, M.D.  
**Faculty:** Andrew P. Ho, M.D., Thomas Newton, M.D.

**COURSE 74** 1:00 p.m.-5:00 p.m.  
Overture, Third Floor, DoubleTree

**INTEGRATED MODEL FOR TREATMENT OF CO-OCCURRING PSYCHIATRIC AND SUBSTANCE DISORDERS**

**Director:** Kenneth Minkoff, M.D.

**COURSE 75** 1:00 p.m.-5:00 p.m.  
Maestro, Fourth Floor, DoubleTree

**COMPUTERS IN PSYCHIATRY: A PRIMER**

**Director:** Robert S. Kennedy, M.A.  
**Faculty:** Carlyle H. Chan, M.D., John Luo, M.D.

**COURSE 76** 1:00 p.m.-5:00 p.m.  
Minuet, Fourth Floor, DoubleTree

**MULTICULTURAL APPROACH TO THE TREATMENT OF WOMEN**

**Director:** Susan R. Downs, M.D.  
**Faculty:** Ellen Haller, M.D., Sylvia W. Olarte, M.D., Gloria Pitts, D.O., Alice C. Tso, M.D.

**COURSE 77** 1:00 p.m.-5:00 p.m.  
Rhapsody, Fourth Floor, DoubleTree

**ARTS AND HUMANITIES FOR SELF-RENEWAL**

**Director:** Paul R. Miller, M.D.  
**Faculty:** Margaret Nazarey, M.S.N.

**COURSE 78** 1:00 p.m.-5:00 p.m.  
Sonata 5, Fifth Floor, DoubleTree

**SEXUAL HARASSMENT: PSYCHOLOGICAL AND LEGAL ASPECTS**

**Director:** Gail E. Robinson, M.D.  
**Faculty:** Renee L. Binder, M.D., Sharyn A. Lenhart, M.D., Michael F. Myers, M.D.

**MEDIA SESSIONS 14-15**

**MEDIA SESSION 14** 1:00 p.m.-2:00 p.m.  
Washington Rooms A-C, Third Floor, Loews

**WE ARE WHAT WE EAT**

**Chp.:** Sandra C. Walker, M.D.

**19 A World of Food: Tastes and Taboos in Different Cultures**  
(34 minutes)

**Distributor:** University of California Extension  
Center for Media and  
Independent Learning  
2000 Center Street, 4th Floor  
Berkeley, CA 94704

From vegans to cannibals, human beings consume an infinite variety of foods. They also form fiercely emotional views about people who follow food practices unlike their own. Many Americans, for example, are horrified by the consumption of dog meat in certain Asian countries. But staples of the American diet may be equally horrifying to others. *A World of Food* is the perfect antidote to ethnocentrism, the all too common assumption that one's own culture is superior to others. This video will teach the critical lesson that all cultures consume foods that people in other cultures see as highly debatable, inherently disgusting, or simply too bizarre to eat at all. It will help develop an enhanced understanding of food practices in other cultures



and a deeper awareness of the need for cross-cultural understanding in an increasingly interconnected world.

**MEDIA SESSION 15** 1:00 p.m.-2:00 p.m.  
Congress Rooms A-C, Fourth Floor, Loews

**ATTACK ON AMERICA: LOOKING BACK, LOOKING INWARD AND VIRTUAL REALITY ENHANCED EXPOSURE THERAPY FOR PTSD AFTER SEPTEMBER 11**

**Co-Chps.:** Richard E. D'Alli, M.D., Ian E. Alger, M.D., Edward K. Rynearson, M.D., JoAnn Difede, Ph.D.

**20 World Trade Center and Pentagon Disasters**  
(30 minutes)

**Distributor:** Richard E. D'Alli, M.D.  
Department of Psychiatry  
Johns Hopkins Medical Institute  
600 N. Wolfe Street, CMSC 387  
Baltimore, MD 21287

LECTURE 14

From the first horrifying images of lower Manhattan and the Pentagon on September 11, 2001, through the war that followed, the media refocused America, if not much of the world, on a common enemy. How did the media's choice of imagery affect the meaning of the course of events since that dark day? Dr. Difede will give a presentation, which will enable the audience to view the "virtual world" of the World Trade Center attack.

**2:00 p.m. Sessions**

**LECTURES 13-14**

**LECTURE 13**

2:00 p.m.-3:30 p.m.  
Rooms 108 A/B, Street Level, Convention Center

George S. Alexopoulos, M.D.

**What Can Late Life Teach Us About Depression?**

**Chp.:** Gary J. Kennedy, M.D.  
**Co-Chp.:** Josepha A. Cheong, M.D.

Late-life depression occurs in the context of ill health and disability. George S. Alexopoulos, M.D., discusses recent research on the pathophysiology of late-life depression and its potential impact on the development of pharmacological and nonpharmacological interventions. Dr. Alexopoulos is Professor of Psychiatry at Weill Medical College of Cornell University and Professor at the Graduate School of Medical Sciences at Cornell University. He is Director of the NIMH-funded Clinical Research Center for Geriatric Mood Disorders at the Cornell Institute of Geriatric

Psychiatry, of which he is the founding Director. Dr. Alexopoulos has conducted studies on clinical, neuropsychological, electrophysiological, neurochemical, imaging, and treatment aspects of geriatric mood disorders. His research has focused on course and long-term outcomes as means of addressing the heterogeneity of geriatric mood disorders. Dr. Alexopoulos has received the Senior Investigator's Award from the American Association of Geriatric Psychiatry. He is the Editor for North America of the *International Journal of Geriatric Psychiatry*. He received his medical degree from the National University of Athens (Greece) and completed his residency in psychiatry at New Jersey Medical School, New Jersey College of Medicine and Dentistry.

**Distinguished Psychiatrist Lecture Series**  
**THIS SESSION WILL BE AUDIOTAPED.**

**LECTURE 14**

2:00 p.m.-3:30 p.m.  
Rooms 109 A/B, Street Level, Convention Center

**APA'S ALEXANDRA SYMONDS  
AWARD LECTURE**

Carol C. Nadelson, M.D.

**Women's Leadership in Medicine and Psychiatry**

**Chp.:** Donna E. Stewart, M.D.  
**Co-Chp.:** Cheryl F. McCartney, M.D.

Throughout history women have been caretakers and healers and, more rarely, leaders and policy makers in health and mental health. Carol C. Nadelson, M.D., reviews the history of women's health care roles and proposes strategies to advance women's leadership in contemporary medicine and psychiatry. Dr. Nadelson is Clinical Professor of Psychiatry at Harvard Medical School. She was the first woman to serve as APA President, in 1984-1986. A former President and Chief Executive Officer of the American Psychiatric Press, Inc., she has served on the Editorial Boards of many journals, including *Hospital and Community Psychiatry*, *Journal of Marital and Family Therapy*, and *Journal of Psychosomatic Obstetrics and Gynecology*. She is the author of more than 200 papers and book chapters and is the co-editor of 20 books. Dr. Nadelson has received the Elizabeth Blackwell Award from the American Medical Women's Association, the Distinguished Service Award from the American College of Psychiatrists, and the Seymour Vestermark Award from APA. She graduated from the University of Rochester Medical School, was a resident in psychiatry at Massachusetts Mental Health Center and Beth Israel Hospital in Boston, and received her psychoanalytic training at the Boston Psychoanalytic Institute.

**THIS SESSION WILL BE AUDIOTAPED.**



## MEDIA SESSIONS 16-17

**MEDIA SESSION 16** 2:00 p.m.-5:00 p.m.  
 Washington Rooms A-C, Third Floor, Loews

## WOMANHOOD... SISTERHOOD

Chp.: Robert L. Sadoff, M.D.

**21 Standing on My Sisters' Shoulders**  
 (60 minutes)

**Distributor:** Laura J. Lipson  
 ABC  
 802 Sierra Drive  
 Beverly Hills, CA 90210

*Standing on My Sister's Shoulders* is a documentary that dramatically portrays the involvement of both black and white women working together during the Civil Rights period. Their efforts helped to change the rules of race relations in the South forever. Issues relating to voter registration; desegregation of schools; and individual, family, and community involvement will be experienced through the words and feelings of women who were there and who participated in the historical events. The film is certain to touch the lives of those who view it.

**Discussants:** Robert L. Sadoff, M.D., Joan Sadoff, M.S.W.

**22 Women of the Wall**  
 (31 minutes)

**Distributor:** New Day Films  
 22-D Hollywood Avenue  
 Ho Ho Kus, NJ 07423

In 1989, a group of Jewish women marched toward the Western Wall in Jerusalem carrying a Torah scroll, determined to pray openly as women without male leadership or approval. Violently attacked by right-wing opposition, the *Women of the Wall* filed a petition with the Supreme Court asserting their right to pray openly. This documentary is an insightful exploration of the women's struggle for free spiritual expression in a climate of increasing governmental control over religious practice.

**23 Loyalties**  
 (58 minutes)

**Distributor:** Filmmakers Library  
 Attn: Linda Gottesman  
 124 East 40th Street  
 New York, NY 10016

*Loyalties* is the poignant story of two women who discover they share two halves of a common past in the painful lineage of slave and slave holder. Carmelita Robertson, a black graduate student who worked at a museum of national history and her co-worker, Dr. Ruth Holmes Whitehead, a white ethnologist, met for a professional lunch. They soon discover that they have a strange common thread. Almost certainly, one of Ruth's

ancestors owned one of Carmelita's as a slave. As a result, the pair decide to travel to South Carolina to unravel their linked heritage. This video shows their journey through pain, resentment, embarrassment, and ultimately acceptance, as each woman, in her own way, comes to terms with their shared history.

**MEDIA SESSION 17** 2:00 p.m.-5:00 p.m.  
 Congress Rooms A-C, Fourth Floor, Loews

## PSYCHIATRY GOES TO THE MOVIES

Chp.: Ronald L. Kamm, M.D.

**24 Remember the Titans**  
 (114 minutes)

**Distributor:** Buena Vista Home Entertainment  
 Department CS  
 Burbank, CA 91521

Next to a family, a team is one of the most influential groups to which an individual ever belongs. *Remember the Titans* tells the true story of the 1971 integration of a previously all-white Alexandria, Virginia, high school and its football team. Not only are black students bussed to the school over the objection of the white community, but also a black coach, played by Denzel Washington, is brought in to replace a beloved, white coach. Washington's character, Herman Boone, is faced with the daunting task of creating a cohesive, winning team when half his squad is racially at war with the other. The coach's strengths are his unwavering commitment to win, his caring relationship with players of both races, and the evolving willingness of his white counterpart, Bill Yoast, to take a subordinate role for the sake of the team. This is a class study of how to form a cohesive group to all those trying to bridge the racial divide that still exists.

**Discussants:** Ian R. Tofler, M.D., Herman Boone, Coach Bill Yoast, Terry "Rev." Harris (the Titans Quarterback)

**REVIEW OF PSYCHIATRY: SECTION 2**  
 2:00 p.m.-5:30 p.m.  
 Rooms 201 A-C, Level 200, Convention Center

## THE MANY FACES OF DEPRESSION IN CHILDHOOD AND ADOLESCENCE

Co-Chps.: David Shaffer, M.D., Bruce D. Waslick, M.D.

**6 Depression in Children and Adolescents: An Overview**  
 Bruce D. Waslick, M.D., Rachel Kandel, Aphrodite Kakourou

**7 Psychotherapy for Depression and Suicidal Behavior in Children and Adolescents**  
 Laura Mufson, Ph.D., Drew M. Velting, Ph.D.

**8 Pharmacological Treatment of Children and Adolescents with MDD**  
 Boris Birmaher, M.D., David A. Brent, M.D.

9 **Bipolar Disorder in Youth: A Critical Review**  
Gabrielle Carlson, M.D.

10 **Child and Adolescent Suicide and Suicidal Behavior**  
David Shaffer, M.D., Ted Greenberg, M.P.H.

**SYMPOSIA 27-56**

**SYMPOSIUM 27** 2:00 p.m.-5:00 p.m.

Rooms 102 A/B, Street Level, Convention Center

**NEW TREATMENT TARGET IN SCHIZOPHRENIA:  
UPDATE ON SOCIAL ANXIETY**

Chp.: Stefano Pallanti, M.D.  
Co-Chp.: Robert G. Stern, M.D.

**A Shyness, Sociability, and Social Dysfunction in  
Schizophrenia**  
Joel Goldberg, Ph.D., La Schmidt, M.D., M.K. Jetha

**B Comparison and Assessment Procedures of Primary  
Versus Comorbid Social Anxiety**  
Stefano Pallanti, M.D., Leonardo Quercioli, M.D., Adolfo  
Pazzagli, Ph.D.

**C Determining and Treating Social Anxiety in Psychosis**  
David Castle, M.D.

**D The Relationship of Social Anxiety to Level of Function  
Over Time in Patients with Schizophrenia**  
Robert G. Stern, M.D., Denise Frank, B.A., Suhaila Farook, M.D.,  
Michelle Beyer, B.A.

**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 28** 2:00 p.m.-5:00 p.m.

Room 103 A, Street Level, Convention Center

**PSYCHOTIC SYMPTOMS IN CHRONIC PTSD:  
PREVALENCE, COMORBIDITY, AND TREATMENT**

Chp.: Daniella David, M.D.

**A Psychotic Features, Illness Severity, and Atypical  
Antipsychotics in PTSD**  
Mark B. Hamner, M.D., Christopher B. Frueh, Ph.D.,  
Helen G. Ulmer, M.S.W., George W. Arana, M.D.

**B Adjunctive Risperidone Treatment in Combat Veterans  
with Chronic PTSD**  
Daniella David, M.D., Ludmila Defaria, M.D., Olga M.  
Lapeyra, M.D., Thomas A. Mellman, M.D.

**C Racial Differences in Psychotic Symptoms Among  
Combat Veterans with PTSD**  
Christopher B. Frueh, Ph.D., Mark B. Hamner, M.D.,  
Jason B. Belant, Ph.D., George W. Arana, M.D.,  
Samuel M. Turner, Ph.D., Terence M. Keane, Ph.D.

**D Familial and Biological Characteristics of Psychotic  
PTSD**

Fredric J. Sautter, Ph.D., Janet J. Johnson, M.D., Arth  
Issette, Ph.D., Justin Wiley, Ph.D., John Cornwell, Ph.D.,  
Madeline Uddo, Ph.D., Gina Mire, Ph.D.

**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 29** 2:00 p.m.-5:00 p.m.

Room 103 B, Street Level, Convention Center

**NEW DEVELOPMENT IN MEDICATIONS FOR THE  
TREATMENT OF SUBSTANCE ABUSE**

*American Academy of Addiction Psychiatry*

Chp.: Marc Galanter, M.D.

**A Overview of Medications Development for Alcohol and  
Drug Dependence**  
Henry R. Kranzler, M.D.

**B Buprenorphine for Opioid Dependence**  
Eric C. Strain, M.D.

**C Stimulant Treatment of Cocaine Dependence**  
Frances R. Levin, M.D.

**D Ondansetron Is Effective in Treating Biological  
Alcoholism**  
Bankole A. Johnson, M.D., Nassima Ait-Daoud, M.D.

**E Anticonvulsants in Substance-Use Disorders**  
Kathleen T. Brady, M.D., Hugh Myrick, M.D., Robert J.  
Malcolm, Jr., M.D.

Discussants: Richard N. Rosenthal, M.D., Jonathan I. Ritvo, M.D.  
**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 30** 2:00 p.m.-5:00 p.m.

Room 103 C, Street Level, Convention Center

**HYPERAROUSAL AND BPD: NEW STUDIES ON  
ORIGINS, IMAGING, TAXONOMY, AND  
TREATMENT**

Chp.: Thomas H. McGlashan, M.D.

**A Construct Validity of BPD**  
Carlos M. Grilo, Ph.D., Charles A. Sanislow, Ph.D.,  
Thomas H. McGlashan, M.D.

**B Borderline Symptoms in Maltreated Children**  
Joan Kaufman, Ph.D., Deborah S. Lipschitz, M.D., Seth R.  
Axelrod, Ph.D., Steven M. Southwick, M.D.

**C Exploring the Phenomenological Interface of BPD and  
PTSD**  
Seth R. Axelrod, Ph.D., Carlos M. Grilo, Ph.D., Charles A.  
Sanislow, Ph.D., Deborah S. Lipschitz, M.D., Thomas H.  
McGlashan, M.D., Steven M. Southwick, M.D.

*(Continued next page)*

**TUESDAY**

---

- D Neural Substrates of Affective Dysregulation in BPD**  
Nelson H. Donegan, Ph.D., Charles A. Sanislow, Ph.D.,  
Robert K. Fulbright, M.D., John C. Gore, Ph.D., Pawel  
Skudlarski, Ph.D., Thomas H. McGlashan, M.D., Bruce E.  
Wexler, M.D.
- E Repetitive Transcranial Magnetic Stimulation for BPD**  
Adrian Preda, M.D., Ralph E. Hoffman, M.D., Thomas H.  
McGlashan, M.D.
- F The BPD Status Change Scale: An Interview to Assess  
Change and Functioning**  
Charles A. Sanislow, Ph.D., Carlos M. Grilo, Ph.D.,  
Thomas H. McGlashan, M.D.

**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 31** 2:00 p.m.-5:00 p.m.  
Rooms 106 A/B, Street Level, Convention Center

**FALSE MEMORY SYNDROME: RECOVERY AND  
FAMILY RECONCILIATION**

Chp.: Paul R. McHugh, M.D.  
Co-Chp.: Harold I. Lief, M.D.

- A The False Memory Foundation and Its Survey of Family  
Reconciliations**  
Pamela Freyd
- B Recovered Memory Accusers of Incest: Interactions  
with Their Families**  
Harold I. Lief, M.D., Janet M. Fetkewicz, B.A.
- C Memory and Hypnosis: Facts and Fictions**  
Herbert Spiegel, M.D.
- D Recovered Memory in the Courts**  
Alan A. Stone, M.D.

- E The Recovered Memory Craze Onset and Offset from  
1990-1998**  
Paul R. McHugh, M.D.

**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 32** 2:00 p.m.-5:00 p.m.  
Rooms 107 A/B, Street Level, Convention Center

**COURSE AND TREATMENT OF BPD**

Chp.: John M. Oldham, M.D.  
Co-Chp.: Andrew E. Skodol II, M.D.

- A Course of Diagnoses and Impairment in Patients with  
BPD**  
Andrew E. Skodol II, M.D., Thomas H. McGlashan, M.D.,  
M. Tracie Shea, Ph.D., John G. Gunderson, M.D., Leslie C.  
Morey, Ph.D., Robert L. Stout, Ph.D., Ingrid R.  
Dyck, M.P.H.

- B BPD and MDD: Their Co-Occurrence and Implications  
for Treatment**  
John G. Gunderson, M.D.

- C Principles of Psychotherapy for BPD**  
Glen O. Gabbard, M.D.

- D A Comparison of Cognitive-Behavioral and  
Psychodynamic Therapy for BPD**  
John F. Clarkin, Ph.D., Ken Levy, Ph.D.

- E Do Patients with BPD Receive Appropriate Medications**  
John M. Oldham, M.D., Andrew E. Skodol II, M.D.,  
Donna S. Bender, Ph.D., Ingrid R. Dyck, M.P.H.

Discussant: Mary C. Zanarini, Ed.D.  
**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 33** 2:00 p.m.-5:00 p.m.  
Room 111 B, Street Level, Convention Center

**DARWINIAN EVOLUTION: AFFECTIVE  
TEMPERAMENT AND CLINICAL  
CONSIDERATIONS**

Chp.: Daniel R. Wilson, M.D.  
Co-Chp.: Hagop S. Akiskal, M.D.

- A Affective Temperaments: Evolutionary Significance**  
Hagop S. Akiskal, M.D.
- B Evolutionary Epidemiology and the Neuropsychiatry of  
Manic Depression**  
Daniel R. Wilson, M.D.
- C Affective Disorders as Communicational State: Brain  
Research Implications**  
Russell J. Gardner, Jr., M.D.
- D Evolutionary Trait Variation: Implications for Clinical  
Care and Research**  
Michael McGuire, M.D.

Discussant: Russell J. Gardner, Jr., M.D.  
**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 34** 2:00 p.m.-5:00 p.m.  
Rooms 112 A/B, Street Level, Convention Center

**SUCCESSFUL CLINICAL APPLICATIONS OF  
TELEPSYCHIATRY**

Chp.: Steven E. Hyler, M.D.

- A The Invisible Interface of Telepsychiatry: Is It Really?**  
Norman E. Alessi, M.D.
- B Sustaining an Extensive Prison Telepsychiatry Network**  
William M. Tucker, M.D., Gerald Segal, M.S., Steven E.  
Hyler, M.D.

**C Telepsychiatry: A Canadian Perspective on Program Design and Implementation**  
Harry Karlinsky, M.D., James Coyle, M.A., Julian Somers, Ph.D., Elliot M. Goldner, M.D., Susan Quinn, R.N.

**D Success of Telepsychiatry with Geriatric Patients**  
Beverly N. Jones, M.D.

**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 35** 2:00 p.m.-5:00 p.m.  
Room 113 A, Street Level, Convention Center

**DEPRESSION AND THE TRANSITION TO PERIMENOPAUSE: THE HARVARD STUDY OF MOODS AND CYCLES**

**Chp.:** Lee S. Cohen, M.D.

**Co-Chp.:** Bernard L. Harlow, Ph.D.

**A The Methods and Characteristics of Women Participants in the Harvard Study of Moods and Cycles**  
Bernard L. Harlow, Ph.D., Lee S. Cohen, M.D., Michael W. Otto, Ph.D., D. Speigelman, Daniel W. Cramer, M.D.

**B The Impact of a Mood Disorder on Reproductive Function During the Menopausal Transition**  
Lee S. Cohen, M.D., Michael W. Otto, Ph.D., Claudio N. Soares, M.D., Bernard L. Harlow, Ph.D.

**C Depression and Its Influence on Menopausal Transitions: Clinical and Public Health Implications**  
Claudio N. Soares, M.D., Lee S. Cohen, M.D., Michael W. Otto, Ph.D., Bernard L. Harlow, Ph.D.

**D Psychosocial Predictors of Depression in the Harvard Study of Moods and Cycles**  
Michael W. Otto, Ph.D., Lee S. Cohen, M.D., Bernard L. Harlow, Ph.D.

**Discussant:** Stephen M. Stahl, M.D.

**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 36** 2:00 p.m.-5:00 p.m.  
Room 113 B, Street Level, Convention Center

**THE PSYCHOLOGICAL WOUNDS OF NATIONAL TRAUMA: CAUSES, CONSEQUENCES, AND TREATMENTS**

**Chp.:** Jerrold M. Post, M.D.

**A Hate-Mongering Leaders and Vulnerable Followers: The Psychopolitics of Hatred**  
Jerrold M. Post, M.D.

**B Processing Collective Trauma: The Israeli Society and the Mental Health Community**  
Arie Nadler, Ph.D.

**C The Enemy's Daughter: Psychological Effects of Stalinism on Female Children of Political Prisoners**  
Jana H. Svehlova, Ph.D.

**D Telling Histories: Survivors' Testimonies of Political Violence**  
Stevan M. Weine, M.D.

**E Countering Sequelae of Culturecide in Kosovo**  
James L. Griffith, M.D., Ferid Agani, M.D., Stevan M. Weine, M.D., Afrim Blita, M.D., John S. Rolland, M.D., Shqipe Ukshini, Ph.D., Melita Kallaba, M.D.

**F Recovery from the Cambodian Holocaust: The Role of Political, Religious, and Medical Leaders**  
David S. Liebling, M.D.

**Discussant:** David A. Rothstein, M.D.

**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 37** 2:00 p.m.-5:00 p.m.  
Room 113 C, Street Level, Convention Center

**UNDERSTANDING PSYCHOLOGICAL TRAUMA: MULTIDISCIPLINARY PERSPECTIVE**

**Chp.:** Randall D. Marshall, M.D.

**A The Cognitive-Affective Science of Trauma and Development**  
Dan J. Stein, M.D.

**B Variable for Aging Demand Rearing in Primates: Relevance to Trauma**  
Jeremy D. Coplan, M.D., Eric L. Smith, Ph.D., Bruce A. Scharf, Shirm Baptiste, Altamash I. Qureshi, M.D., Jack M. Gorman, M.D., Leonard A. Rosenblum, Ph.D.

**C Ethnocultural Factors in PTSD**  
Roberto Lewis-Fernandez, M.D., J. Blake Turner, Ph.D., Randall D. Marshall, M.D., Bruce Dohrenwend, Ph.D.

**D Contemporary Psychodynamic Perspective on Trauma**  
Arieh Y. Shalev, M.D.

**E Integrating Therapeutic Models for Psychological Trauma**  
Randall D. Marshall, M.D.

**Discussant:** Charles R. Marmar, M.D.

**THIS SESSION WILL BE AUDIOTAPED.**

TUESDAY

**SYMPOSIUM 38** 2:00 p.m.-5:00 p.m.  
Room 202 A, Level 200, Convention Center

**BEYOND THE SURGEON GENERAL'S REPORT:  
PSYCHIATRY FOR A DIVERSE POPULATION**  
*Substance Abuse and Mental Health Services Administration*

Chp.: William B. Lawson, M.D.

**A Policy Implications of the Surgeon General's Report for  
a Diverse Population**  
Kana Enomoto, M.A.

**B Mental Health: Culture, Race, and Ethnicity**  
Jeanne Miranda, Ph.D.

**C Interface Between Biology, Pharmacology, and Culture**  
William B. Lawson, M.D.

**D Alcohol and Drug Use in College Samples: Racial  
Differences**  
Deborah Deas, M.D.

**E Influence of Culture on Child Development and Early  
Psychopathology in the 21st Century**  
Harry H. Wright, M.D.

THIS SESSION WILL BE AUDIOTAPED.

**SYMPOSIUM 39** 2:00 p.m.-5:00 p.m.  
Room 202 B, Level 200, Convention Center

**DEFINING EVIL: CLINICAL AND FORENSIC  
IMPLICATIONS**

Chp.: Michael M. Welner, M.D.

**A Dilemmas in Defining Depravity at the Criminal Law  
and Psychiatry Interface**  
Michael M. Welner, M.D.

**B Sadistic Mothers and Fathers: Parents at the Edge of  
Evil**  
Michael H. Stone, M.D.

**C Theology Challenges to Defining Depravity: Can  
Accountability Meet Therapy and Redemption?**  
Lawrence Gesy, M.D.

**D Depravity at the Workplace: Clinical and Forensic  
Implications**  
Joseph P. Merlino, M.D.

**E The Depravity Scale: Validating a Psychiatric and  
Forensic Measure of Evil Actions**  
Michael M. Welner, M.D.

THIS SESSION WILL BE AUDIOTAPED.

**SYMPOSIUM 40** 2:00 p.m.-5:00 p.m.  
Room 203 A, Level 200, Convention Center

**THE THERAPEUTIC MISCONCEPTION IN  
RESEARCH: BARRIER OR NECESSITY?**

Chp.: Philip J. Candilis, M.D.

**A An Empirical Study of Therapeutic Misconception**  
Charles Lidz, Ph.D., Paul S. Appelbaum, M.D., Thomas  
Grisso, M.D.

**B Decisional Capacity and Therapeutic Misconception in  
Alzheimer's Disease**  
Scott Y. Kim, M.D.

**C Historical Perspectives on the Therapeutic  
Misconception**  
Gary S. Belkin, M.D.

**D Therapeutic Misconception and Therapeutic Intent:  
Where Do the Problems Lie?**  
Donna T. Chen, M.D.

THIS SESSION WILL BE AUDIOTAPED.

**SYMPOSIUM 41** 2:00 p.m.-5:00 p.m.  
Room 203 B, Level 200, Convention Center

**COMBINED TREATMENT: DYNAMIC  
PSYCHOTHERAPY AND MEDICATION**  
*American College of Psychoanalysts and APA Illinois Psychiatric Society*

Chp.: Jerome A. Winer, M.D.

**A Dilemmas for Psychiatrists Doing Split Psychotherapy  
and Pharmacotherapy**  
Malkah T. Notman, M.D.

**B The Ethics of the Pharmaceutical Dynamic Complex**  
Brenda C. Solomon, M.D.

**C The Teaching and Learning of Conjoint Psychotherapy  
and Pharmacotherapy**  
Sidney H. Weissman, M.D.

**D When the Well-Meaning Psychiatrist Becomes the  
Patient's Negative Other**  
Jerome A. Winer, M.D.

THIS SESSION WILL BE AUDIOTAPED.

**SYMPOSIUM 42** 2:00 p.m.-5:00 p.m.  
Room 204 A, Level 200, Convention Center

**AMERICA ATTACKED: THE AMERICAN  
PSYCHIATRIC ASSOCIATION AND ITS MEMBERS  
RESPOND**

*APA Committee on Psychiatric Dimensions of Disasters*

Chp.: Ann E. Norwood, M.D.  
Co-Chp.: Michael Blumenfeld, M.D.



**A The American Psychiatric Association Leadership Responds to the Terrorism: Lessons Learned**  
Richard K. Harding, M.D.

**B The Saint Vincent's Psychiatric Response to the September 11th Terrorist Attack**  
Spencer Eth, M.D.

**C New York City Responds to the Attack on the World Trade Center**  
Neal L. Cohen, M.D.

**D Psychiatry at Ground Zero**  
Vivian B. Pender, M.D.

**E Psychiatric Intervention at the Pentagon Following the September 11th Terrorist Attack**  
Stephen J. Cozza, M.D.

**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 43** 2:00 p.m.-5:00 p.m.  
Room 204 B, Level 200, Convention Center

**WHAT'S NEW IN EATING DISORDERS: A CLINICAL RESEARCH TREATMENT UPDATE**

**Chp.:** Evelyn Attia, M.D.

**A Treatment of Bulimia in a Primary Care Setting**  
B. Timothy Walsh, M.D., Christopher Fairburn, M.D., Diane Mickley, M.D., Robyn Sysko, B.A.

**B Optimizing Treatment for Binge-Eating Disorders**  
Michael J. Devlin, M.D., Juli A. Goldfein, Ph.D., Pamela S. Raizman, Ph.D., B. Timothy Walsh, M.D.

**C Partial Hospitalization for Anorexia Nervosa: Who Gains, How and at What Cost?**  
Angela S. Guarda, M.D., Leslie J. Heinberg, Ph.D.

**D Family-Based Treatment for Adolescents with Anorexia Nervosa**  
Katherine L. Loeb, Ph.D., Ilene M. Reeman, M.D., B. Timothy Walsh, M.D., James D. Lock, M.D.

**E Bulimia Nervosa in Adolescents: Do Adult Treatments Translate to Teens?**  
Lisa A. Kotler, M.D., Michael J. Devlin, M.D., B. Timothy Walsh, M.D.

**Discussant:** G. Terrence Wilson, Ph.D.

**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 44** 2:00 p.m.-5:00 p.m.  
Rooms 302/303, Level 3, Marriott

**EVIDENCE-BASED PSYCHIATRY: PRINCIPLES, EXAMPLES, AND CRITIQUES IN THE U.S. AND FRANCE**

*French Federation of Psychiatry*

**Chp.:** John A. Talbott, M.D.  
**Co-Chp.:** Herve Bokobza, M.D.

**A Principles of Evidence-Based Practice: U.S. Style**  
Robert A. Rosenheck, M.D.

**B Effective Implementation of Guidelines: An Example of Suicide Prevention in France**  
Jacques Glikman, M.D., Boland Bouet, M.D., Catherine Mayault, M.D., Jean-Louis Terra, M.D.

**C Assertive Community Treatment as Evidence-Based Practice**  
Robert E. Drake, M.D., Kim T. Mueser, Ph.D., Gary R. Bond, Ph.D.

**D The French Sectorization System: What Evidence?**  
Francois C. Petitjean, M.D., Valerie Siari, M.D., Jean-Claude Demant, M.D., Denis Leguay, M.D.

**E The Efficacy-Effectiveness Gap Limits Confidence in Evidence-Based Practices**  
Lisa B. Dixon, M.D.

**F Evidence-Based Medicine in the Treatment of Patients with Schizophrenia: A Critical Point of View**  
J. M. Vanelle, J. C. Loirat

**Discussant:** Alexandra MacLean, M.D.

**SYMPOSIUM 45** 2:00 p.m.-5:00 p.m.  
Rooms 304-306, Level 3, Marriott

**COLLABORATIVE PRACTICE IN PSYCHIATRY: DATA AND PRINCIPLES FOR PRACTICE**

**Chp.:** Mark S. Bauer, M.D.  
**Co-Chp.:** Gregory E. Simon, M.D.

**A Collaborative Practice for Bipolar Disorder: A Multisite Controlled Trial**  
Mark S. Bauer, M.D.

**B Using Collaborative Care Models to Improve the Treatment of Schizophrenia**  
Alexander S. Young, M.D., Donna L. Bean, M.B.A., Stephen R. Marder, M.D.

**C Collaborative Management of Depression**  
Gregory E. Simon, M.D.

**D Improving Depression Care for Older Adults**  
Jurgen Unutzer, M.D.

**E Collaborative Management of Chronic Lower Back Pain**  
Benjamin H. K. Balderson, Ph.D.

**Discussants:** Lydia J. Lewis, B.A., Michael E. Thase, M.D.  
**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 46** 2:00 p.m.-5:00 p.m.  
**Liberty Ballroom C, Level 3, Marriott**

**HOW TO LAUNCH A SUCCESSFUL PRIVATE PRACTICE: PART III**

*APA Committee of Early Career Psychiatrists*

Chp.: William E. Callahan, Jr., M.D.

Co-Chp.: Keith W. Young, M.D.

**A Personal Factors Leading to a Successful Private Practice**

Ann S. Maloney, M.D.

**B Office Location and Design for Efficiency and Success**

Barry W. Wall, M.D.

**C Streamlining Overhead and Managing Your Business in Private Practice**

Keith W. Young, M.D.

**D Marketing Your Unique Private Practice**

William E. Callahan, Jr., M.D.

Discussants: Ann S. Maloney, M.D., Barry W. Wall, M.D.

**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 47** 2:00 p.m.-5:00 p.m.  
**Independence Ballroom I, Level 3, Marriott**

**MAJOR DEPRESSION: CURRENT GUIDELINES, PRACTICES, AND EFFECTIVENESS RESEARCH**

Chp.: Darrel A. Regier, M.D.

Co-Chp.: John S. McIntyre, M.D.

**A Evidence-Based Treatment Guidelines for MDD**

Alan J. Gelenberg, M.D.

**B Sequenced Treatment Alternatives to Relieve Depression (STAR\*D)**

A. John Rush, M.D.

**C Results from the Texas Medication Algorithm Project MDD Treatment Module**

Madhukar H. Trivedi, M.D.

**D The Treatment of MDD in Routine Practice**

Joyce C. West, Ph.D., Farifteh F. Duffy, Ph.D., Steve Marcus, William E. Narrow, M.D., Victoria E. Cosgrove, B.A., Darrel A. Regier, M.D.

Discussant: Martin B. Keller, M.D.

**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 48** 2:00 p.m.-5:00 p.m.  
**Independence Ballrooms II/III, Level 3, Marriott**

**DEPRESSION CARE IN MEDICAL SETTINGS: APPROACHES FOR THE FUTURE**

Chp.: Steven A. Cole, M.D.

**A Interrelationships of Mental Health and Primary Care**

Harold A. Pincus, M.D., Constance M. Pechura, Ph.D., Lynn I. Elinson, Ph.D., Amy R. Pettit, B.A.

**B Improving Outcomes of Depression with Stepped-Care Principles**

Wayne J. Katon, M.D., Michael Von Korff, Sc.D.

**C Depression Breakthrough Series: Quality Improvement in Primary Care Dissemination Project**

David J. Katzelnick, M.D.

**D The MacArthur Initiative on Depression in Primary Care**

Thomas E. Oxman, M.D., Allen Dietrich, M.D., Kurt Kroenke, M.D., James E. Barrett, M.D., Paul Nutting, M.D., John Williams, M.D., Kathryn M. Rost, Ph.D.

**E Depression in Patients with Congestive Heart Failure**

Steven A. Cole, M.D., Nancy Farber, R.N., Joseph S. Weiner, M.D., Michelle Sulfaro, R.N., Alan Silver, M.D., David J. Katzelnick, M.D.

**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 49** 2:00 p.m.-5:00 p.m.  
**Rooms 401-403, Level 4, Marriott**

**GLOBAL PSYCHIATRY AND PATIENTS' RIGHTS: INFORMED CONSENT**

Chp.: Rodrigo A. Munoz, M.D.

Co-Chp.: Harold I. Eist, M.D.

**A Overview of Informed Consent: A Public Perspective**

Debra Lappin, J.D.

**B Constrained Consent: The Law and Research in Special Populations**

Rosemary Quigley, J.D.

**C National and International Application of Standard Federal Regulations for Conduct of Research**

Harold I. Eist, M.D., Norman Sartorius, M.D.

**D World Psychiatric Association Committee to Review the Abuse of Psychiatry**

Marianne C. Kastrup, M.D.

**E Cultural Factors and Informed Consent**

Norman Sartorius, M.D.

Discussant: Paul S. Appelbaum, M.D.

**SYMPOSIUM 50** 2:00 p.m.-5:00 p.m.  
 Rooms 407-409, Level 4, Marriott

**THE PSYCHIATRIC TREATMENT OF HIV DISEASE  
 IN THE THIRD DECADE OF AIDS**  
*APA Commission on AIDS*

Chp.: Marshall Forstein, M.D.

**A HIV Treatment Update**  
 Marshall Forstein, M.D.

**B CNS Manifestations**  
 Karl Goodkin, M.D.

**C Mood and Anxiety Disorders**  
 Stephen J. Ferrando, M.D.

**D The Multiply Diagnosed HIV Patient and Drug-Drug  
 Interactions**  
 Francine Cournos, M.D.

THIS SESSION WILL BE AUDIOTAPED.

**SYMPOSIUM 51** 2:00 p.m.-5:00 p.m.  
 Rooms 411/412, Level 4, Marriott

**AMERICAN PSYCHIATRIC ASSOCIATION'S  
 RESPONSES TO THE SURGEON GENERAL'S  
 REPORTS ON MENTAL HEALTH**

Chp.: Altha J. Stewart, M.D.

**A Mental Health: A Report of the Surgeon General**  
 Zebulon C. Taintor, M.D.

**B Suicide: An American Psychiatric Association Plan of  
 Action**  
 Selby C. Jacobs, M.D.

**C Child and Adolescent Disorders: Treatment and  
 Prevention**  
 G. Pirooz Sholevar, M.D.

**D Youth Violence: A Report of the Surgeon General**  
 Carl C. Bell, M.D.

**E Mental Health: Cultural Issues**  
 Altha J. Stewart, M.D.

THIS SESSION WILL BE AUDIOTAPED.

**SYMPOSIUM 52** 2:00 p.m.-5:00 p.m.  
 Rooms 414/415, Level 4, Marriott

**SOCIAL ANXIETY DISORDER AND COMORBID  
 MAJOR DEPRESSION**

Chp.: Franklin R. Schneier, M.D.

**A Perspectives on Social Phobia and Depressive  
 Comorbidity**  
 Murray B. Stein, M.D.

**B Implications of Comorbid Social Phobia for Major  
 Depressive Subtypes and Course**

Jonathan E. Alpert, M.D., Megan E. Hughes, B.A., Joel A.  
 Pava, Ph.D., Nicole B. Neault, B.A., Timothy J. Petersen, Ph.D.,  
 Andrew A. Nierenberg, M.D., Maurizio Fava, M.D.

**C Interpersonal Sensitivity in SAD**

Gerlinde C. Harb, M.S., Richard G. Heimberg, Ph.D., Vito  
 Agosti, M.S.W., Franklin R. Schneier, M.D., Michael R.  
 Liebowitz, M.D.

**D Social Phobia and Comorbidity with Depression: A  
 Dichotic Listening Study**

Gerard E. Bruder, Ph.D., Franklin R. Schneier, M.D.,  
 Jonathan W. Stewart, M.D., Patrick J. McGrath, M.D., Paul  
 Leite, M.A., Frederick M. Quitkin, M.D.

**E Citalopram Treatment of Comorbid Social Anxiety  
 Disorder and Major Depression**

Franklin R. Schneier, M.D., Michael R. Liebowitz, M.D.,  
 Raphael Campeas, M.D., Carlos Bianco, M.D., Roberto  
 Lewis-Fernandez, M.D., Randall D. Marshall, M.D., J. Arturo  
 Sanchez-Lacay, M.D.

Discussant: R. Bruce Lydiard, M.D.

THIS SESSION WILL BE AUDIOTAPED.

**SYMPOSIUM 53** 2:00 p.m.-5:00 p.m.  
 Grand Ballroom Salon A, Level 5, Marriott

**ADAPTATIONS TO SEVERE STRESS: NORMAL  
 RESPONSES AND THERAPEUTIC STRATEGIES**

Chp.: Lenore C. Terr, M.D.

**A Preschool Witnesses of Domestic Violence: Pathways to  
 Recovery**

Alicia F. Lieberman, Ph.D., Patricia Van Horn, Ph.D.,  
 Chandra Ghosh-Ippen, Ph.D.

**B The Effect of Trauma on the Grieving Process in  
 Children When One Parent Kills the Other**

Guinevere Tufnell, M.R.C., Dora Black, Tony Kaplan, M.R.C.,  
 Jean Harris-Hendriks

**C Gender Similarities and Differences in the Stress  
 Reaction of Kurdish and Swedish Boys and Girls**

Viveka Sundelin-Wahlsten, Ph.D., Abdulbaghi Ahmad, M.D.

**D Coping with the Diagnosis and Progression of Cancer**

David Spiegel, M.D., Lisa Butler, Ph.D., Cheryl Koopman, Ph.D.,  
 Matthew Cordova, Ph.D.

**E Natural Healing Processes in the Essays of 111  
 Columbine Students at 2-3 Weeks**

Lenore C. Terr, M.D., Daniel Bloch, Ph.D.

Discussant: Robert Michels, M.D.

THIS SESSION WILL BE AUDIOTAPED.

**SYMPOSIUM 54** 2:00 p.m.-5:00 p.m.  
Grand Ballroom Salon B, Level 5, Marriott

**FAMILY TREATMENT OUTCOMES OF ADOLESCENTS WITH SUBSTANCE USE DISORDERS: CULTURAL ISSUES**

Chp.: Jose M. Canive, M.D.  
Co-Chp.: Joan D. Koss-Chioino, Ph.D.

- A Engagement and Retention in Family Therapy for Mexican-American Adolescents**  
Luis Vargas, Ph.D., Joan D. Koss-Chioino, Ph.D., Jose M. Canive, M.D.
- B Outcomes of Treating Southwestern Latino Youth: Salient Questions**  
Joan D. Koss-Chioino, Ph.D., Luis Vargas, Ph.D., Jose M. Canive, M.D.
- C Involving Parents and Adolescents in Adolescent Drug-Abuse Treatment**  
Michael S. Robbins, Ph.D., James F. Alexander, Ph.D., Charles W. Turner, Ph.D.
- D Clinical Trial Outcomes for Treatment of Adolescent Alcohol and Drug Abuse**  
Holly B. Waldron, Ph.D., Charles W. Turner, Ph.D., Janet Brody, Ph.D., Thomas R. Peterson, M.S., Sheryl Kern-Jones, Ph.D.
- E Trauma Exposure and Consequences: The Case of Latino Adolescents**  
Jose M. Canive, M.D., Joan D. Koss-Chioino, Ph.D., Luis Vargas, Ph.D.

Discussant: Pedro Ruiz, M.D.

**SYMPOSIUM 55** 2:00 p.m.-5:00 p.m.  
Grand Ballroom Salon C, Level 5, Marriott

**COMBINATION THERAPY FOR BIPOLAR DISORDER: RATIONALES AND CONTROVERSIES**

Chp.: Joseph F. Goldberg, M.D.

- A The Rationale for Combining Medications in the Management of Bipolar Disorder**  
Frederick K. Goodwin, M.D.
- B Complex Combination Therapy in Refractory Bipolar Illness**  
Robert M. Post, M.D.
- C The Use of Atypical Antipsychotics Plus Standard Mood Stabilizers in Bipolar Disorder**  
Joseph F. Goldberg, M.D.

**D Bipolar Depression: Mood Stabilizers Alone, or Antidepressant Augmentation?**  
S. Nassir Ghaemi, M.D.

**E Augmenting Treatment of Bipolar Disorder with Psychotherapy**  
David J. Miklowitz, Ph.D.  
**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 56** 2:00 p.m.-5:00 p.m.  
Grand Ballroom Salon D, Level 5, Marriott

**PAIN IN THE ADDICTED PATIENT: BASIC SCIENCE, THE LAW, AND TREATMENT**  
*Substance Abuse and Mental Health Services Administration*

Chp.: Howard A. Heit, M.D.

- A Neurobiology of Pain**  
David Borsook, M.D.
- B Addiction Mechanisms: Receptors, Neurotransmitters, and Pathways**  
Eliot L. Gardner, Ph.D.
- C Relieving Pain While Preventing Diversion**  
David E. Joranson, M.S.W.
- D Addiction, Physical Dependence, and Tolerance with Opioid Pain Management**  
Howard A. Heit, M.D.
- E Approach to the Pain Patient with the Disease of Addiction**  
Seddon R. Savage, M.D.  
**THIS SESSION WILL BE AUDIOTAPED.**

**TELECOMMUNICATIONS SESSION 2**  
2:00 p.m.-5:00 p.m.  
Room 204 C, Level 200, Convention Center

**EVIDENCE-BASED MEDICINE AND TELEPSYCHIATRY**

Chp.: Gregory E. Gray, M.D.

- 2:15 p.m.
  - 1 Introduction to Evidence-Based Mental Health**  
Gregory E. Gray, M.D.
- 3:30 p.m.
  - 2 Individual and Group Psychotherapy Via Telepsychiatry**  
Brian J. Grady, M.D.

---

### 3:00 p.m. Session

---

#### NEW RESEARCH POSTER SESSION 7

3:00 p.m.-5:00 p.m.

Exhibit Hall D, Street Level, Convention Center

MOOD DISORDERS; SEXUAL AND GENDER DISORDERS; WOMEN'S HEALTH; PMDD; GENDER ISSUES; AND PSYCHOIMMUNOLOGY

For further information on New Research Sessions, please refer to the *New Research Program and Abstracts Book* included in your registration packet.

---

### 7:00 p.m. Sessions

---

#### INDUSTRY-SUPPORTED SYMPOSIA 31-37

##### INDUSTRY-SUPPORTED SYMPOSIUM 31

7:00 p.m.-10:00 p.m.

Ballrooms A/B, Ballroom Level, Convention Center

##### BIPOLAR DEPRESSION AND RAPID CYCLING: CURRENT MANAGEMENT STRATEGIES

*Supported by GlaxoSmithKline*

Chp.: Joseph R. Calabrese, M.D.

##### A The Underestimated Need and Treatment Challenges of Bipolar Depression

Mark A. Frye, M.D.

##### B Stabilizing Mood in Bipolar Disorder from Below Baseline Over Long Periods

Joseph F. Goldberg, M.D.

##### C Rapid Cycling: Clinical Presentation and Treatment Approaches

Robert M. Post, M.D.

##### D Managing Common Benign and Uncommon Serious Adverse Effects

Terence A. Ketter, M.D.

#### INDUSTRY-SUPPORTED SYMPOSIUM 32

7:00 p.m.-10:00 p.m.

Millennium Hall, Second Floor, Loews

##### THE NEW NEUROBIOLOGY OF MOOD AND ANXIETY DISORDERS

*Supported by GlaxoSmithKline*

Chp.: Charles B. Nemeroff, M.D.

##### A Clinical Relevance of Norepinephrine in Mood Disorders

Kerry J. Ressler, M.D.

##### B Childhood Trauma and the Neurobiology of Mood Disorders

Charles B. Nemeroff, M.D.

##### C Advances in Functional Brain Imaging in Depression and Anxiety

Clinton D. Kilts, M.D.

##### D Neurobiology, Sleep, and Mood Disorders: A New Look

David J. Kupfer, M.D.

##### E Stress, Neurogenesis, and the Adult Brain

Elizabeth Gould, Ph.D.

Discussant: Michael J. Owens, Ph.D.

#### INDUSTRY-SUPPORTED SYMPOSIUM 33

7:00 p.m.-10:00 p.m.

Regency Ballrooms A-C, Second Floor, Loews

##### MANAGING AGGRESSION ACROSS THE LIFE SPAN: FROM THE PEDIATRIC TO THE GERIATRIC PATIENT

*Supported by Janssen Pharmaceutica*

Chp.: Douglas H. Hughes, M.D.

##### A Managing the Aggressive Patient

Douglas H. Hughes, M.D.

##### B Evidence-Based Approach to Pharmacotherapy of the Aggressive Child

Jorge L. Armenteros, M.D.

##### C Aggression and Psychiatric Disorders: Confronting the War Within

Robert R. Conley, M.D.

##### D Strategies and Interventions for Late-Life Aggression

Soo Borson, M.D.

##### E Long-Term Adverse Effects of Antipsychotic Therapy

Prakash S. Masand, M.D.

#### INDUSTRY-SUPPORTED SYMPOSIUM 34

7:00 p.m.-10:00 p.m.

Grand Ballroom Salons E/F, Level 5, Marriott

##### TREATING FEAR: PERSPECTIVES ON THE BIOLOGY AND THERAPY OF ANXIETY DISORDERS

*Supported by Solvay Pharmaceuticals, Inc.*

Chp.: Jack M. Gorman, M.D.

##### A Neurobiology of Fear and Social Anxiety

Justine M. Kent, M.D.

##### B Developmental Antecedents of Anxiety Disorders

Daniel Pine, M.D.

*(Continued next page)*



**C New Developments in Pharmacotherapy of Anxiety Disorders**

Jonathan R.T. Davidson, M.D.

**D Accelerating Response and Treating Comorbidity in Anxiety**

Eric Hollander, M.D., Sallie J. Hadley, M.D., Stefano Pallanti, M.D., Sherie L. Novotny, M.D., Erica Sood, B.A., Nicolo Baldini-Rossi, M.D., Jennifer Friedberg, B.S.

**E Minimizing Side Effects and Enhancing Compliance of Antianxiety Treatments**

Francisco A. Moreno, M.D.

**INDUSTRY-SUPPORTED SYMPOSIUM 35**

7:00 p.m.-10:00 p.m.

Grand Ballroom Salons G/H, Level 5, Marriott

**RAISING EXPECTATIONS IN SCHIZOPHRENIA: ENHANCING LONG-TERM OUTCOMES**

*Supported by Pfizer Inc.*

Chp.: Daniel E. Casey, M.D.

Co-Chp.: Nina R. Schooler, Ph.D.

**A Acute Psychotic Agitation: Challenges and Treatment**

Alan J. Mendelowitz, M.D.

**B Long-Term Treatment Goals**

Nina R. Schooler, Ph.D.

**C Adverse Effects Profile of New Antipsychotic Agents**

Daniel E. Casey, M.D.

**D Mechanisms of Medication-Associated Glucose Metabolism Impairment**

David C. Henderson, M.D.

**E Schizophrenia and the Risk of Cardiovascular Disease**

Charles H. Hennekens, M.D.

**INDUSTRY-SUPPORTED SYMPOSIUM 36**

7:00 p.m.-10:00 p.m.

Wyndham Ballrooms A/B, First Floor, Wyndham

**CLINICAL DIFFERENCES IN SEROTONIN AND NOREPINEPHRINE ANTIDEPRESSANT EFFECTS**

*Supported by Eli Lilly and Company*

Chp.: J. Craig Nelson, M.D.

**A Serotonin and Norepinephrine Mechanisms of Action**

Gerard Sanacora, M.D.

**B Clinical Outcome of Serotonin and Norepinephrine Agents in Depression**

Pedro L. Delgado, M.D.

**C The Spectrum of Serotonin-Responsive Disorders**

John H. Greist, M.D.

**D The Spectrum of Norepinephrine-Responsive Disorders**

James J. Hudziak, M.D.

**E Combining Serotonin and Norepinephrine Mechanisms in Depression**

J. Craig Nelson, M.D.

**INDUSTRY-SUPPORTED SYMPOSIUM 37**

7:00 p.m.-10:00 p.m.

Wyndham Ballrooms C/D, First Floor, Wyndham

**BEHAVIORAL DISTURBANCES IN DEMENTIA: DIAGNOSTIC AND TREATMENT GUIDELINES**

*Supported by Novartis Pharmaceuticals Corporation*

Chp.: Steven G. Potkin, M.D.

Co-Chp.: Mustafa M. Husain, M.D.

**A The Pathophysiology of Abnormal Behavior and Mood in Dementia**

Mustafa M. Husain, M.D.

**B Impact of Cholinesterase Inhibitors on Sleep Disturbance in Alzheimer's Disease**

P. Murali Doraiswamy, M.D.

**C Dementia with Lewy Bodies: The Frontiers of Effective Treatment and Diagnosis**

Martin K. Farlow, M.D.

**D Treating Behavioral Disturbances Observed in Alzheimer's Disease: Pharmacological and Nonpharmacologic Interventions**

Steven G. Potkin, M.D.

# WEDNESDAY, MAY 22, 2002

## 155TH ANNUAL MEETING

### 7:00 a.m. Sessions

#### PART 1 OF INDUSTRY-SUPPORTED BREAKFAST SYMPOSIA 38-42

##### INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 38, PART 1

7:00 a.m.-8:30 a.m.

Ballrooms A/B, Ballroom Level, Convention Center

##### CHRONIC EPISODIC DISORDERS: COMORBIDITY AND COMPREHENSIVE INTEGRATED TREATMENT

*Supported by GlaxoSmithKline*

Chp.: Julia K. Warnock, M.D.

##### A Unraveling the Complexity: Comorbidity, Mechanistic Link, and Pharmacologic Response

Anita H. Clayton, M.D.

##### B New Development in Obesity

Donna H. Ryan, M.D.

##### C Comorbid Physical Symptoms Associated with Female- Specific Mood Disorders

Julia K. Warnock, M.D.

##### INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 39, PART 1

7:00 a.m.-8:30 a.m.

Millennium Hall, Second Floor, Loews

##### AGE, GENDER, AND DIAGNOSIS: INFLUENCES ON DRUG RESPONSE

*Supported by Pfizer Inc.*

Chp.: Alexander H. Glassman, M.D.

##### A Can Treating Depression Alter Cardiovascular Disease?

Alexander H. Glassman, M.D.

##### B Comorbidity and Its Implications on Treatment: Change Over the Life Span

Tana A. Grady-Weliky, M.D.

##### INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 40, PART 1

7:00 a.m.-8:30 a.m.

Regency Ballrooms A-C, Second Floor, Loews

##### THERAPEUTIC CHALLENGES, NOVEL APPROACHES: ANTIPSYCHOTICS IN THE MANAGEMENT OF MOOD AND ANXIETY DISORDERS

*Supported by Eli Lilly and Company*

Chp.: Richard C. Shelton, M.D.

##### A Pharmacological Properties of Antipsychotics: Teasing Out Potential Mechanisms of Action

Michael J. Owens, Ph.D.

##### B Restoring the Balance in Manic or Depressive Bipolar Patients Through Thoughtful Pharmacotherapy

S. Nassir Ghaemi, M.D.

##### C Augmentation Strategies to Expand Pharmacotherapeutic Potential in Treatment-Refractory Major Depression

Richard C. Shelton, M.D.

##### INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 41, PART 1

7:00 a.m.-8:30 a.m.

Grand Ballroom Salons E/F, Level 5, Marriott

##### THE PATHOPHYSIOLOGY AND TREATMENT OF IMPULSIVITY AND AGGRESSION IN PSYCHIATRIC DISORDERS

*Supported by Abbott Laboratories*

Chp.: Alan C. Swann, M.D.

##### A Mechanisms of Impulsivity

Alan C. Swann, M.D.

##### B Mood Stabilizers as Adjunctive Treatment in Schizophrenia

Daniel E. Casey, M.D.

##### C Aggression, Violence, and Psychopathology: A Developmental Approach

Hans Steiner, M.D.

##### INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 42, PART 1

7:00 a.m.-8:30 a.m.

Grand Ballroom Salons G/H, Level 5, Marriott

##### NEW PERSPECTIVES ON SCHIZOPHRENIA SPECTRUM DISORDERS AND THEIR TREATMENT

*Supported by Janssen Pharmaceutica*

Chp.: Larry J. Siever, M.D.

Co-Chp.: Barbara Cornblatt, Ph.D.

##### A Validating Schizotaxia Criteria for Future Prevention of Schizophrenia

Ming T. Tsuang, M.D.

##### B The Schizophrenia Prodrome: Early Treatment Findings

Barbara Cornblatt, M.D., Todd Lencz, Ph.D., Michael  
Obuchowski, Christopher Smith, M.S., Manoj R. Shah, M.D.

**8:00 a.m. Sessions**



**COURSES 79-84**

Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.

**COURSE 79** 8:00 a.m.-12 noon

Ormandy East, Street Level, DoubleTree

**COGNITIVE THERAPY FOR SEVERE MENTAL DISORDERS**

Director: Jesse H. Wright, M.D.

Faculty: Monica A. Basco, Ph.D., Michael E. Thase, M.D.

**COURSE 80** 8:00 a.m.-12 noon

Aria A, Third Floor, DoubleTree

**INSANITY DEFENSE EVALUATIONS**

Director: Phillip J. Resnick, M.D.

**COURSE 81** 8:00 a.m.-12 noon

Maestro, Fourth Floor, DoubleTree

**INTERPERSONAL PSYCHOTHERAPY**

Director: John C. Markowitz, M.D.

**COURSE 82** 8:00 a.m.-12 noon

Rhapsody, Fourth Floor, DoubleTree

**EVIDENCE-BASED MEDICINE: AN INTRODUCTION FOR PSYCHIATRISTS**

Director: Gregory E. Gray, M.D.

Faculty: Gabrielle F. Beaubrun, M.D., Letitia A. Pinson, M.D.

**COURSE 83** 8:00 a.m.-12 noon

Sonata 5, Fifth Floor, DoubleTree

**PERSONALITY DISORDERS: COMBINED INTERPERSONAL AND PHARMACOTHERAPY**

Director: Roy O. Resnikoff, M.D.

**COURSE 84** 8:00 a.m.-5:00 p.m.

Ormandy West, Street Level, DoubleTree

**OFFICE-BASED TREATMENT OF OPIATE DEPENDENT PATIENTS**

*American Academy of Addiction Psychiatry, APA Council on Addiction Psychiatry, and Substance Abuse and Mental Health Services Administration*

Co-Directors: Eric C. Strain, M.D., Thomas R. Kosten, M.D.

Faculty: H. Westley Clark, M.D., David Fiellin, M.D.,

Herbert D. Kleber, M.D., Laura F. McNicholas, M.D.

**9:00 a.m. Sessions**

**CLINICAL CASE CONFERENCE 3**

9:00 a.m.-10:30 a.m.

Room 103 B, Street Level, Convention Center

**MOTIVATIONAL ENHANCEMENT THERAPY FOR THE MEDICALLY ILL, SUBSTANCE ABUSE PATIENT WITH DEPRESSION**

Moderator: Robert M. Weinrieb, M.D.

Presenter: Deborah H.A. Van Dorn, Ph.D.

**THIS SESSION IS OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.**

**CONTINUOUS CLINICAL CASE CONFERENCE 2: PART 1**

9:00 a.m.-12 noon

Rooms 106 A/B, Street Level, Convention Center

**MANAGING NEGATIVE OUTCOMES IN GENERAL PSYCHIATRY**

Moderator: Richard G. Hersh, M.D.

Presenter: Mary S. Scitutto, M.D.

**THIS SESSION IS OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.**



**COURSES 85-90**

Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.

**COURSE 85** 9:00 a.m.-4:00 p.m.

Orchestra Room, Second Floor, DoubleTree

**PSYCHOTHERAPY OF BORDERLINE PERSONALITY**

Co-Directors: Otto F. Kernberg, M.D., Frank E. Yeomans, M.D.

Faculty: John F. Clarkin, Ph.D., Eve Caligor, M.D.

**COURSE 86** 9:00 a.m.-4:00 p.m.

Concerto A, Third Floor, DoubleTree

**HOW TO PRACTICE EVIDENCE-BASED PSYCHIATRY**

Director: David R.S. Haslam, M.D.

Faculty: John Geddes, M.R.C., Elliot M. Goldner, M.D.,

David M. Gardner, Pharm.D.

**COURSE 87** 9:00 a.m.-4:00 p.m.  
**Concerto B, Third Floor, DoubleTree**

**CARING FOR REFUGEES AND SURVIVORS OF TORTURE**

**Director:** Linda Piwowarczyk, M.D.  
**Faculty:** Michael A. Grodin, M.D., Ricardo Restrepo, M.D., Terence M. Keane, Ph.D.

**COURSE 88** 9:00 a.m.-4:00 p.m.  
**Symphony Ballroom, Third Floor, DoubleTree**

**A PRACTICAL APPROACH TO HERBS AND NUTRIENTS IN PSYCHIATRY**

**Co-Directors:** Richard P. Brown, M.D., Patricia L. Gerbarg, M.D.

**COURSE 89** 9:00 a.m.-4:00 p.m.  
**Minuet, Fourth Floor, DoubleTree**

**THE ASSESSMENT AND TREATMENT OF CHILD MOLESTERS**

**Director:** John M. Bradford, M.B.  
**Faculty:** Gene G. Abel, M.D., Graham G. Glancey, M.B., J. Paul Fedoroff, M.D.

**COURSE 90** 9:00 a.m.-4:00 p.m.  
**Sonata 3, Fifth Floor, DoubleTree**

**THE BIOPSYCHOSOCIAL FORMULATION: AN APPROACH TO ORAL BOARD PRESENTATIONS**

**Co-Directors:** Robert M. Rohrbaugh, M.D., William H. Campbell, M.D.  
**Faculty:** Catherine Chiles, M.D., Paul D. Kirwin, M.D., Richard Belitsky, M.D.

**DISCUSSION GROUPS 19-22**

9:00 a.m.-10:30 a.m.

**These sessions are limited to 25 participants on a first-come, first-served basis.**

- 19 **Alan F. Schatzberg, M.D.**, on Essentials of Clinical Psychopharmacology (*Meet the Authors*)  
**Room 308, Level 3, Marriott**
- 20 **Jesse S. Rosenthal, M.D.**, on Psychopharmacologic Treatment of Comorbid Attention Disorders in Adults  
**Room 410, Level 4, Marriott**
- 21 **Peter A. Shapiro, M.D.**, on Psychiatric Aspects of Cardiovascular Disease  
**Room 413, Level 4, Marriott**
- 22 **Norman A. Clemens, M.D.**, on the APA Business Initiative and the Future of Psychiatric Practice  
**Room 502, Level 5, Marriott**

**LECTURES 15-18**

**LECTURE 15**

9:00 a.m.-10:30 a.m.  
**Rooms 108 A/B, Street Level, Convention Center**

**Philip G. Zimbardo, Ph.D.**

**Evil in the World and Terror in Our Nation:  
 Transferring Vulnerabilities into Resilience**

**Chp.:** Howard J. Osofsky, M.D.  
**Co-Chp.:** Seeth Vivek, M.D.

On September 11, the well-coordinated terrorist attacks on the World Trade Center and the Pentagon plunged the United States into grief and terror. Americans found it almost inconceivable that an organized group would be willing to kill thousands of innocent individuals and methodically plan their own suicides by piloting hijacked planes to destruction. Philip G. Zimbardo, Ph.D., examines how situational forces contribute to evil behaviors and how propaganda is utilized to shape the beliefs of a culture. He also discusses mental health professionals' contributions to increasing the resilience of citizens faced with an uncertain terrorist threat. Dr. Zimbardo, the current President of the American Psychological Association, is Professor of Psychology at Stanford University and Director of the Stanford University Social Psychology Graduate Research Training Program. He is the author of more than 250 professional articles and book chapters and several books, including the introductory psychology text *Psychology and Life* and the trade books *Shyness* and *The Shy Child*. Dr. Zimbardo has won numerous awards for his distinguished teaching at Stanford and from other institutions and has also received awards for his research in social psychology and hypnosis. He received his doctoral degree from Yale University.

**THIS SESSION WILL BE AUDIOTAPED.**

**LECTURE 16**

9:00 a.m.-10:30 a.m.  
**Rooms 109 A/B, Street Level, Convention Center**

**APA'S OSKAR PFISTER AWARD LECTURE**

**TBA**

**The Nearly Forgotten Factor in Psychiatry: What a Difference a Decade Makes**

**Chp.:** Irving S. Wiesner, M.D.  
**Co-Chp.:** Reverend Clark S. Aist, Ph.D.

Spiritual and religious factors that might either help patients cope or add to patients' conflicts have historically drawn scant attention in psychiatry. During

(Continued on next page)



the past decade, however, a quiet but constructive transformation has increased the recognition and clinical understanding of spiritual and religious issues in patients' lives. David B. Larson, M.D., highlights the changes in psychiatric research, education, and care that have characterized this transformation. Dr. Larson is the President of the International Center for the Integration of Health and Spirituality in Rockville, Maryland. He also serves as Adjunct Professor at Duke University Medical Center in Durham, North Carolina, Northwestern University Medical School in Chicago, and the Uniformed Services University of the Health Sciences in Bethesda, Maryland. Formerly a Senior Researcher in the Office of the Director at the National Institutes of Health, Dr. Larson is the author of more than 250 scientific papers and book chapters examining the impact of spirituality on a variety of physical and mental health outcomes. A Fellow of the APA, he received his medical degree from Temple University Medical School in Philadelphia, completed his residency in psychiatry and a geriatric fellowship at Duke University Medical Center, and received his master's degree in public health at the University of North Carolina in Chapel Hill.

THIS SESSION WILL BE AUDIOTAPED.

LECTURE 17

9:00 a.m.-10:30 a.m.

Room 113 B, Street Level, Convention Center

APA'S MARMOR AWARD LECTURE

Lenore C. Terr, M.D.

Terror, Horror, and Fright: Past and Current Perspectives

Chp.: John F. Greden, M.D.  
Co-Chp.: Marcia K. Goin, M.D.

To understand the psychological challenges to our nation from war waged by terrorists, psychiatrists may need to become increasingly knowledgeable about the effects of trauma-related conditions. Lenore Terr, M.D., discusses the psychological effects of traumatizing events and the possibilities for healing, drawing on her research on children's reactions to the 1976 Chowchilla, California, school bus kidnapping, the 1986 Challenger space shuttle disaster, the 1999 Columbine High School shootings, and the terrorist attacks of September 11, 2001. Dr. Terr is Clinical Professor of Psychiatry at the University of California, San Francisco, and Attending Physician at the Langley Porter Neuropsychiatric Institute, and is in the private practice of adult and child psychiatry. Her books include *Too Scared to Cry: Psychic Trauma in Childhood* and *Beyond Love and Work: Why Adults Need to Play*. A Fellow of the APA and the American Academy of Child and Adolescent Psychiatry, she has received APA's Blanche F. Ittleson Award

and Samuel G. Hibbs Award. Dr. Terr graduated from the University of Michigan Medical School in Ann Arbor and completed a residency in psychiatry at the University of Michigan Neuropsychiatric Institute and a fellowship in child psychiatry at the University of Michigan Children's Psychiatric Hospital.

THIS SESSION WILL BE AUDIOTAPED.

LECTURE 18

9:00 a.m.-10:30 a.m.

Lecture Hall 114, Street Level, Convention Center

APA'S PATIENT ADVOCACY AWARD LECTURE

David Satcher, M.D.

Mental Health: A Perspective from the Surgeon General Who Listens

Chp.: Carl C. Bell, M.D.  
Co-Chp.: Neal L. Cohen, M.D.

David Satcher, M.D., was the 16th Surgeon General of the United States, serving a four-year term that ended in February 2002. Currently a Fellow at the Henry J. Kaiser Family Foundation, Dr. Satcher will assume the post of Director of the National Center for Primary Care at Morehouse School of Medicine in Atlanta in the fall of 2002. Dr. Satcher was Director of the Centers for Disease Control and Prevention and Administrator of the Agency for Toxic Substances and Disease Registry from 1993 to 1998 and President of Meharry Medical College in Nashville from 1982 to 1993. A former Robert Wood Johnson Clinical Scholar, Dr. Satcher has received numerous honors, including top awards from the American Medical Association, the American College of Physicians, the American Academy of Family Physicians, and *Ebony* magazine. He is a Fellow of the American Academy of Family Physicians, the American College of Preventive Medicine, and the American College of Physicians. Dr. Satcher received his medical and doctorate degrees from Case Western Reserve University in Cleveland and received residency and fellowship training at Strong Memorial Hospital in Rochester, New York, the University of Rochester, UCLA, and King-Drew Medical Center in Los Angeles.

THIS SESSION WILL BE AUDIOTAPED.

MASTER EDUCATOR CLINICAL CONSULTATIONS 9-11

9:00 a.m.-10:30 a.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

- 9 Carol C. Nadelson, M.D., on Changing and Evoking Roles for the Clinicians  
Room 111 A, Street Level, Convention Center

10 **Barbara A. Schindler, M.D.**, on the Addicted Woman:  
Diagnostic and Treatment Challenges  
Room 301, Level 3, Marriott

11 **Eric R. Marcus, M.D.**, on Adults with Learning Disabilities  
and Mood Disorders  
Room 501, Level 5, Marriott

**THESE SESSIONS ARE OPEN TO APA MEMBERS  
ONLY. BLUE REGISTRATION BADGE OR APA  
MEMBERSHIP CARD REQUIRED FOR  
ADMITTANCE.**

## MEDIA SESSIONS 18-19

**MEDIA SESSION 18** 9:00 a.m.-10:30 a.m.  
Washington Rooms A-C, Third Floor, Loews

### SOUL OF A SISTER

**Chp.:** Lesly T. Mega, M.D.

25 **Leona's Sister Gerri**  
(57 minutes)

**Distributor:** New Day Films  
22-D Hollywood Avenue  
Ho Ho Kus, NJ 07423

*Leona's Sister Gerri* is the story of Gerri Santoro, the real person in the police photograph of an anonymous woman collapsed on a motel room floor, dead from an illegal abortion. Reprinted thousands of times in newspapers, magazines, and books, this image has become a symbol for reproductive freedom. Addressing issues of reproductive rights and domestic violence, this video is the dramatic and engrossing story of a woman's life and society's response to her death.

**MEDIA SESSION 19** 9:00 a.m.-10:30 a.m.  
Congress Rooms A-C, Fourth Floor, Loews

### DENYING THE DEMON

**Chp.:** Richard E. D'Alli, M.D.

26 **Blink**  
(57 minutes)

**Distributor:** University of Calif. Extension  
Center for Media and Independent Learning  
2000 Center Street, 4th Floor  
Berkeley, CA 94704

This powerful and thought-provoking documentary examines the dramatic story of one-time white supremacist leader Gregory Withrow, and in so doing, explores the underlying strains of violence and domination in American life and culture. Withrow's flight from the militant white Aryan resistance captured the attention of the national media when Withrow was found beaten and his hands nailed to a board. Now, more than a decade later, Withrow is married to a Mexican-American woman and lives a low-key, semi-isolated rural existence. *Blink* explores the complex middle ground where Withrow still battles his demons and questions the possibility of fundamental personal change.

**REVIEW OF PSYCHIATRY: SECTION 3**  
9:00 a.m.-12:30 p.m.  
Rooms 201 A-C, Level 200, Convention Center

## PSYCHIATRY IN MEDICINE

**Chp.:** Nada L. Stotland, M.D.

11 **Psychiatric Disorders and the Menstrual Cycle**  
Laura J. Miller, M.D.

12 **Psychiatric Factors in Solid Organ Transplantation**  
Catherine A. Crone, M.D.

13 **Gastroenterology**  
Thomas N. Wise, M.D.

14 **Mind and Heart: The Interplay Between Psychiatric and  
Cardiac Illness**  
Theodore A. Stern, M.D.

## WORKSHOPS

### COMPONENTS 32-41

**COMPONENT WORKSHOP 32** 9:00 a.m.-10:30 a.m.  
Room 104 A, Street Level, Convention Center

**COMPETENCE REQUIREMENTS IN RESIDENT  
EDUCATION: PROGRESS AND PROBLEMS**  
*APA Task Force on Competency and Graduate Education*

**Chp.:** Sherwyn M. Woods, M.D.

**Participants:** Lisa A. Mellman, M.D., Eugene V. Beresin, M.D.,  
Stephen C. Scheiber, M.D., Francis G. Lu, M.D.

**COMPONENT WORKSHOP 33** 9:00 a.m.-10:30 a.m.  
Room 104 B, Street Level, Convention Center

**QUALITY INDICATORS FOR CHILDREN AND  
ADOLESCENTS: WHO CARES?**  
*APA Council on Quality Improvement*

**Chp.:** James C. MacIntyre II, M.D.

**Participants:** John M. Oldham, M.D., Rhonda Joyce R. Beale, M.D.,  
Richard C. Hermann, M.D.

**COMPONENT WORKSHOP 34** 9:00 a.m.-10:30 a.m.  
Room 111 B, Street Level, Convention Center

**PRACTICING REWARDING PSYCHIATRY IN JAILS  
AND PRISONS: A PRACTICUM**  
*APA Council on Psychiatric Services*

**Chp.:** Henry C. Weinstein, M.D.

**Participants:** Kathryn A. Burns, M.D., Kenneth G. Gilbert, M.D.,  
Cassandra F. Newkirk, M.D., Annette L. Hanson, M.D., John S.  
Zil, M.D.



WEDNESDAY

**COMPONENT WORKSHOP 35** 9:00 a.m.-10:30 a.m.  
Rooms 112 A/B, Street Level, Convention Center

**WHOSE CHILDREN? PSYCHIATRY IN THE CULTURAL MOSAIC OF AMERICA'S SCHOOLS**  
*APA Committee on Psychiatry and Mental Health in the Schools*

**Chp.:** Mary E. Schwab-Stone, M.D.  
**Participants:** Trina B. Allen, M.D., Eugenio M. Rothe, M.D., Hong Shen, M.D., Nichole D. Grier, M.D.

**COMPONENT WORKSHOP 36** 9:00 a.m.-10:30 a.m.  
Room 202 A, Level 200, Convention Center

**IT'S NOT GAY ENOUGH: INTERPRETING ANTIGAY BIAS IN THE 21ST CENTURY**  
*APA Committee on Gay, Lesbian, and Bisexual Issues*

**Chp.:** Jack Drescher, M.D.  
**Participants:** Kenneth B. Ashley, M.D., Daniel W. Hicks, M.D., Howard C. Rubin, M.D., Julie K. Schulman, M.D., Susan A. Turner, M.D., Serena Yuan Volpp, M.D.

**COMPONENT WORKSHOP 37** 9:00 a.m.-10:30 a.m.  
Rooms 304-306, Level 3, Marriott

**DYNAMIC DUEL: DILEMMAS OF SPLIT TREATMENT**  
*APA Consortium on Treatment Issues*

**Co-Chps.:** Sally L. Godard, M.D., Richard J. Kessler, D.O.

**COMPONENT WORKSHOP 38** 9:00 a.m.-10:30 a.m.  
Room 307, Level 3, Marriott

**TALKING WITH THE TERMINALLY ILL ABOUT DEATH AND DYING**  
*APA Committee on End-of-Life Issues*

**Co-Chps.:** Maurice D. Steinberg, M.D., Edwin H. Cassem, M.D.  
**Participants:** Ira R. Byock, M.D., Samuel C. Klagsbrun, M.D.

**COMPONENT WORKSHOP 39** 9:00 a.m.-10:30 a.m.  
Rooms 309-310, Level 3, Marriott

**PSYCHOLOGIST PRESCRIPTION PRIVILEGES: IS IT COMING? SHOULD IT?**  
*APA Commission on Public Policy, Litigation, and Advocacy*

**Co-Chps.:** Amin N. Azzam, Raymond J. Kotwicki, M.D.  
**Participant:** Frederick Y. Huang, M.D.

**COMPONENT WORKSHOP 40** 9:00 a.m.-10:30 a.m.  
Liberty Ballroom A, Level 3, Marriott

**COMBINED RESIDENCY TRAINING: YOU WANT TO DO WHAT?**  
*APA Committee on Consultation-Liaison Psychiatry and Primary Care Education*

**Co-Chps.:** Shannon T. Suo-Chan, M.D., Susan L. Padrino, M.D.  
**Participants:** Quinton E. Moss, Jodi E. Star, Dylan P. Wint, M.D.

**COMPONENT WORKSHOP 41** 9:00 a.m.-10:30 a.m.  
Grand Ballroom Salon J, Level 5, Marriott

**THE RULES OF THE CLUB: CAREER ADVANCEMENT FOR WOMEN**  
*APA Committee on Women*

**Co-Chps.:** Donna E. Stewart, M.D., Anu A. Matorin, M.D.  
**Participants:** Deborah Spitz, M.D., Leslie H. Gise, M.D.

**ISSUES 69-88**

**ISSUE WORKSHOP 69** 9:00 a.m.-10:30 a.m.  
Rooms 102 A/B, Street Level, Convention Center

**TREATING GAY AND LESBIAN YOUTH AT RISK**

**Co-Chps.:** William Resnick, M.D., Steven Sokoll, M.D.

**ISSUE WORKSHOP 70** 9:00 a.m.-10:30 a.m.  
Room 103 A, Street Level, Convention Center

**GRIEVOUS BODILY HARM AND CLUB DRUGS: TREATMENT AND OTHER CONSIDERATIONS**

**Chp.:** Jeffrey N. Wilkins, M.D.  
**Participants:** Waguih W. Ishak, M.D., Romana Markvitsa, M.D., Katherine Mellott, M.D., Lewis Nelson, M.D.

**ISSUE WORKSHOP 71** 9:00 a.m.-10:30 a.m.  
Room 103 C, Street Level, Convention Center

**RECENT STUDIES ON PARITY AND EMPLOYER-SPONSORED INSURANCE**  
*Substance Abuse and Mental Health Services Administration*

**Chp.:** Darrel A. Regier, M.D.  
**Participants:** Jeffrey Buck, Ph.D., Mady Chalk, Ph.D.

**ISSUE WORKSHOP 72** 9:00 a.m.-10:30 a.m.  
Room 113 A, Street Level, Convention Center

**PSYCHOPHARMACOGENETICS AND ETHNICITY: CURRENT PERSPECTIVES**

**Co-Chps.:** Pedro Ruiz, M.D., Keh-Ming Lin, M.D.  
**Participants:** William B. Lawson, M.D., Edmond H.T. Pi, M.D., Ricardo P. Mendoza, M.D., Tarek A. Okasha, M.D.

**ISSUE WORKSHOP 73** 9:00 a.m.-10:30 a.m.  
Room 202 B, Level 200, Convention Center

**PRACTICAL PHARMACOTHERAPY OF MOOD DISORDERS**

**Co-Chps.:** Gary E. Miller, M.D., Richard L. Noel, M.D.

**ISSUE WORKSHOP 74** 9:00 a.m.-10:30 a.m.  
Room 203 A, Level 200, Convention Center

**MINDFULNESS AND AWARENESS PRACTICE IN THE MEDICINE BUDDHA TRADITION OF TIBET**

**Chp.:** James T. Sacamano, M.D.

**ISSUE WORKSHOP 75** 9:00 a.m.-10:30 a.m.  
Room 203 B, Level 200, Convention Center

**DRUG THERAPY FOR FUNCTIONAL SOMATIC SYNDROMES**

**Chp.:** Peter Manu, M.D.

**ISSUE WORKSHOP 76** 9:00 a.m.-10:30 a.m.  
Room 204 A, Level 200, Convention Center

**IN SEARCH OF THE EMPATHIC HEALER**

**Chp.:** Michael J. Bennett, M.D.

**ISSUE WORKSHOP 77** 9:00 a.m.-10:30 a.m.  
Room 204 B, Level 200, Convention Center

**DISABILITY MYTHS: UNDERSTANDING THE SOCIAL SECURITY ADMINISTRATION DISABILITY PROGRAM**

**Chp.:** Bernard J. Arseneau, D.O.  
**Participants:** Cathy Lively, Ph.D., Henry G. Conroe, M.D.

**ISSUE WORKSHOP 78** 9:00 a.m.-10:30 a.m.  
Liberty Ballroom B, Level 3, Marriott

**NEW DIRECTIONS IN MENTAL HEALTH RESPONSE TO DISASTERS AND LARGE-SCALE CRISES**

*Substance Abuse and Mental Health Services Administration*

**Chp.:** Mary E. Nelson, M.S.W.  
**Participants:** Matthew J. Friedman, M.D., Sharon E. Carpinello, Ph.D., Farris Tuma, Sc.D., Chip J. Felton, M.S.W., Elissa P. Benedek, M.D.

**ISSUE WORKSHOP 79** 9:00 a.m.-10:30 a.m.  
Independence Ballrooms II/III, Level 3, Marriott

**CHILDHOOD TRAUMA INTERVENTION AND AFTERMATH: ACCESS TO QUALITY CARE**

*Substance Abuse and Mental Health Services Administration*

**Chp.:** Malcolm A. Gordon, Ph.D.  
**Participants:** Judith A. Cohen, M.D., Mary Beth Williams, Ph.D., Chris M. Kirchner, M.S.W.

**ISSUE WORKSHOP 80** 9:00 a.m.-10:30 a.m.  
Room 406, Level 4, Marriott

**TEACHING BEHAVIORAL SCIENCES TO FAMILY DOCTORS**

**Chp.:** Jonathan S. Davine, M.D.

**ISSUE WORKSHOP 81** 9:00 a.m.-10:30 a.m.  
Rooms 407-409, Level 4, Marriott

**MUSIC AS MIRROR: REFLECTIONS OF THE PSYCHE IN WORKS BY THE GREAT COMPOSERS**

**Chp.:** Chelsea L. Chesen, M.D.  
**Participant:** Eli S. Chesen, M.D.

**ISSUE WORKSHOP 82** 9:00 a.m.-10:30 a.m.  
Rooms 411/412, Level 4, Marriott

**ASSISTING PHYSICIANS AND OTHER PROFESSIONALS WHO VIOLATE BOUNDARIES**

**Chp.:** Werner Tschan, M.D.  
**Participants:** Michael F. Myers, M.D., Carolyn Quadrio, M.D., Gary R. Schoener, Psy.D.

**ISSUE WORKSHOP 83** 9:00 a.m.-10:30 a.m.  
Rooms 414/415, Level 4, Marriott

**WOMEN AND SMOKING**

**Co-Chps.:** Sarah M. Whitman, M.D., David Rubenstein, Psy.D.

**ISSUE WORKSHOP 84** 9:00 a.m.-10:30 a.m.  
Grand Ballroom Salon A, Level 5, Marriott

**CLOZAPINE USE IN HIV**

**Chp.:** Richard H. McCarthy, M.D.  
**Participant:** Mara J. Fiorentino, M.D.

**ISSUE WORKSHOP 85** 9:00 a.m.-10:30 a.m.  
Grand Ballroom Salon B, Level 5, Marriott

**INTERGENERATIONAL ASPECT OF TRAUMA AND TRAUMA-RELATED BEHAVIORAL PATTERNS**

**Chp.:** Andrei Novac, M.D.  
**Participants:** Rita R. Newman, M.D., Rachel Yehuda, Ph.D.

**ISSUE WORKSHOP 86** 9:00 a.m.-10:30 a.m.  
Grand Ballroom Salon C, Level 5, Marriott

**DO RESTRICTED FORMULARIES SERVE AS BARRIERS TO CARE?**

**Co-Chps.:** Mitchel J. Stein, M.D., Joseph R. Mawhinney, M.D.  
**Participants:** Stephen M. Goldfinger, M.D., Kenneth S. Duckworth, M.D., Peter L. Forster, M.D.

**ISSUE WORKSHOP 87** 9:00 a.m.-10:30 a.m.  
**Grand Ballroom Salon D, Level 5, Marriott**

**ADVOCACY 101: INFLUENCING MENTAL HEALTH POLICY**

**Chp.:** Jay B. Cutler, J.D.  
**Participants:** Heather Whyte, Helen M. Foster, M.D., John E. Kraus, Jr., M.D., Jason Pray

**ISSUE WORKSHOP 88** 9:00 a.m.-10:30 a.m.  
**Grand Ballroom Salon I, Level 5, Marriott**

**CAREER DEVELOPMENT AND RISK MANAGEMENT**

**Chp.:** Barry W. Wall, M.D.  
**Participants:** Martin G. Tracy, J.D., Jacqueline M. Melonas, J.D., Joseph M. Schwartz, M.D.

---

**11:00 a.m. Sessions**

---

**LECTURES 19-21**

**LECTURE 19**

11:00 a.m.-12:30 p.m.  
Rooms 108 A/B, Street Level, Convention Center

Edwin H. Cassem, M.D.

**Can the Third Millennium Psychiatrist Help Persons at the End-of-Life?**

**Chp.:** Jonathan F. Borus, M.D.  
**Co-Chp.:** Theodore A. Stern, M.D.

Data from the Netherlands suggest that terminally ill patients who request euthanasia frequently do so for reasons involving psychiatric, psychosocial, cultural, existential, and spiritual factors. Edwin H. Cassem, M.D., discusses the effects of terminal illness on patients' sense of dignity and meaning and describes ways psychiatrists can help terminally ill persons and their family members to find new goals, enhance self-respect, and improve quality of life in the dying person's remaining time. An ordained priest in the Jesuit Order, Dr. Cassem is Professor of Psychiatry at Harvard Medical School and a psychiatrist at Massachusetts General Hospital in Boston. He is a member of the Editorial Board of several journals, including *Journal of Geriatric Psychiatry and Neurology*, *Psychosomatics*, and *Harvard Review of Psychiatry*. Dr. Cassem is a Fellow of APA, the American College of Physicians, and the Academy of Psychosomatic Medicine. He formerly was President of the American Psychosomatic Society and the Academy of Psychosomatic Medicine. A graduate of Harvard Medical School, Dr. Cassem

completed residencies in psychiatry at Massachusetts Mental Health Center and Massachusetts General Hospital, where he also completed a clinical and research fellowship in psychiatry.  
**Distinguished Psychiatrist Lecture Series**  
**THIS SESSION WILL BE AUDIOTAPED.**

**LECTURE 20**

11:00 a.m.-12:30 p.m.  
Rooms 109 A/B, Street Level, Convention Center

**APA'S KUN-PO SOO AWARD LECTURE**

Keh-Ming Lin, M.D.

**Journey to the West: Reflections on Culture and Psychiatry Entering the New Century**

**Chp.:** Nang Du, M.D.  
**Co-Chp.:** John Luo, M.D.

Rooted in Western traditions, psychiatry has transcended sociocultural divides to find its niche nearly everywhere in the world. At the same time, cross-cultural experiences have challenged the universality of prevailing psychiatric concepts and practices. Keh-Ming Lin, M.D., examines the influence of culture on vulnerability and resilience to psychiatric illness and response to interventions and discusses the importance of integrating cultural and biomedical perspectives in psychiatric assessment and care. Dr. Lin is Professor of Psychiatry at the University of California, Los Angeles, and Director of the National Institute of Mental Health/Harbor-UCLA Research Center on the Psychobiology of Ethnicity. The founder of two mental health centers serving Asian Americans in California, he has made major contributions in cross-ethnic psychopharmacology and psychiatric nosology, epidemiology, medical anthropology, and refugee mental health. Dr. Lin is a Fellow of the APA, the American Association for Social Psychiatry, and the Pacific Rim College of Psychiatrists and currently serves on APA's Council on Research. A member of the Editorial Board of American Psychiatric Press, Inc., he is the author of more than 150 articles and book chapters and the author, editor, or translator of eight books. Dr. Lin received his medical training at National Taiwan University and postgraduate training at the University of Washington in Seattle.  
**THIS SESSION WILL BE AUDIOTAPED.**

**LECTURE 21**

11:00 a.m.-12:30 p.m.  
Lecture Hall 114, Street Level, Convention Center

Elio J. Frattaroli, M.D.



Healing the Soul in the Age of the Brain:  
Reflections on the Meaning of Psychiatry After  
September 11

Chp.: David M. McDowell, M.D.  
Co-Chp.: Patricia I. Ordorica, M.D.

The root meaning of the word "psychiatry" is "healing the soul," but psychiatry has increasingly become focused on the physical and the external (brain and behavior) and given less attention to the emotional and the spiritual. Elio J. Frattaroli, M.D., discusses the disparity between biological and psychotherapeutic approaches in psychiatry in terms of a larger cultural conflict between opposing philosophies of life and the nature of illness and health. Dr. Frattaroli is a psychiatrist and psychoanalyst in private practice in Bala Cynwyd, Pennsylvania. He is also Assistant Clinical Professor of Psychiatry at the University of Pennsylvania, a member of the faculty of the Psychoanalytic Center of Philadelphia, and Associate Director of the center's Psychodynamic Psychotherapy Training Program. Dr. Frattaroli studied Shakespeare at Harvard University and trained with Bruno Bettelheim at the University of Chicago before turning to medicine. He has written and lectured on Shakespeare as well as on psychiatry and psychoanalysis. Dr. Frattaroli received his medical degree at the University of Chicago, completed his residency in psychiatry at the Institute of Pennsylvania Hospital, and received his psychoanalytic training at the Institute of the Philadelphia Association for Psychoanalysis.

THIS SESSION WILL BE AUDIOTAPED.

MASTER EDUCATOR CLINICAL  
CONSULTATION

11:00 a.m.-12:30 p.m.

This session is limited to 25 participants on a first-come, first-served

12 Michelle T. Pato, M.D., on Obsessive Compulsive and  
Related Disorders  
Room 111 A, Street Level, Convention Center

THIS SESSION IS OPEN TO APA MEMBERS ONLY.  
BLUE REGISTRATION BADGE OR APA  
MEMBERSHIP CARD REQUIRED FOR  
ADMITTANCE.

MEDIA SESSIONS 20-21

MEDIA SESSION 20 11:00 a.m.-12:30 p.m.  
Washington Rooms A-C, Third Floor, Loews

GROWING UP GAY

Chp.: Steven Sokoll, M.D.

27 "In the Life" Television News Magazine  
(57 minutes)

Distributor: David P. Martin  
In the Life Media, Inc.  
30 West 26th Street, 7th Floor  
New York, NY 10010

*In the Life* is a national television series in a newsmagazine format that reports on gay and lesbian issues and culture. Episode 701, "Back to School," addresses multiple issues relevant to the education and mental health of gay and lesbian youth and to the families of gay and lesbian youth. The first segment focuses on adolescent suicide, followed by segments on the process involved in establishing a Gay Student's Rights Bill and gay-straight alliances. Final segments report on model gay and lesbian support centers.

Discussant: Steven Sokoll, M.D.

MEDIA SESSION 21 11:00 a.m.-2:00 p.m.  
Congress Rooms A-C, Fourth Floor, Loews

TEMPERING TROUBLED MINDS

Chp.: Bill Lichtenstein

28 West 47th Street  
(108 minutes)

Distributor: Bill Lichtenstein  
Lichtenstein Creative Media  
25 West 36th Street  
New York, NY 10018

*West 47<sup>th</sup> Street* offers an unprecedented window in the lives of people who are often feared, ignored, and seldom understood. This warm and intimate film follows five people with mental illness, off the streets and out of homeless shelters, in and out of the hospital, and at home and at work, over a three year period. The film presents a story about people who approach tremendous obstacles with humor, optimism, and grace.

Discussants: Bill Lichtenstein, June Peoples, Michael M. Faenza, M.S.S.W., Wayne S. Fenton, M.D., John A. Talbott, M.D.

MEDICAL UPDATE 3

11:00 a.m.-12:30 p.m.  
Room 103 A, Street Level, Convention Center

STRATEGIC UPDATE OF ALZHEIMER'S DISEASE:  
LINKING DISEASE WITH THERAPEUTICS

Chp.: Marion Z. Goldstein, M.D.  
Presenter: Carol Lippa, M.D.  
THIS SESSION WILL BE AUDIOTAPED.

RESEARCH CONSULTATION WITH

11:00 a.m.-12:30 p.m.

This session is limited to 25 participants on a first-come, first-served basis.

- 2 Raquel E. Gur, M.D., on Brain Behavior Studies in Schizophrenia  
Anthony Room, Third Floor, Loews

SCIENTIFIC AND CLINICAL REPORT SESSIONS 25-33

SCIENTIFIC AND CLINICAL REPORT SESSION 25

11:00 a.m.-12:30 p.m.

Room 111 B, Street Level, Convention Center

TREATMENT OF PERSONALITY DISORDERS

Chp.: Andrew J. Kolodny, M.D.  
Co-Chp.: David A. Rothstein, M.D.

11:00 a.m.

72 Risperidone Treatment of Schizotypal Personality Disorder

Harold W. Koenigsberg, M.D., Marianne Goodman, M.D.,  
Antonia S. New, M.D., Vivian Mitropoulou, M.A., Robert L.  
Trestman, M.D., Jeremy Silverman, Ph.D., Larry J. Siever, M.D.

11:30 a.m.

73 A Preliminary Trial of Omega-3 Fatty Acids in Women with BPD

Mary C. Zanarini, Ed.D., Frances R. Frankenburg, M.D.,  
Anna Vujanovic, A.B., Elizabeth A. Parachini, B.A.

12 noon

74 Is Chemical Imbalance a Useful Concept in Treating Personality Disorders?

Kenneth R. Silk, M.D., Joann Heap, M.S.W.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 26

11:00 a.m.-12:30 p.m.

Room 113 B, Street Level, Convention Center

ISSUES IN CHILD PSYCHIATRY

Chp.: Tanya R. Anderson, M.D.  
Co-Chp.: Duru Sakhrani M.D.

11:00 a.m.

75 ADHD Comorbidity: Age and Gender Differences

Atila Turgay, M.D., Levent Tonga, M.D., Rubaba Ansari, M.A.,  
Hashem Khosroshahi, M.D., David Ng, M.D.

11:30 a.m.

76 Psychiatric Diagnosis for Children Under Age Five Referred to a Public Mental Health System

Harry H. Wright, M.D., Michael L. Cuccaro, Ph.D.,  
Rosetta H. Penny, M.S.W., Tami V. Leonhardt, Ph.D.,  
Kristin M. Wieduwilt, Ruth K. Abramson, Ph.D.

12 noon

77 Modafinil in Children with ADHD: A Double-Blind, Placebo-Controlled Study

Thomas A. Rugino, M.D., Teresa C. Samscock, M.S., Laura Adkins, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 27

11:00 a.m.-12:30 p.m.

Room 113 C, Street Level, Convention Center

PSYCHOTHERAPIES

Chp.: Jerald Kay, M.D.  
Co-Chp.: Frederick E. Miller, M.D.

11:00 a.m.

78 Music Therapy and Medication Compliance in Psychotic Patients

Ruby C. Castilla-Puentes, M.D., Nora Danies, M.D., Janeth Valero, M.S.C., Janeth Vargas, R.N., Orlando Gongora, M.S.C.,  
Carmenleonora Pava, M.S.C., James Perel, Ph.D.

11:30 a.m.

79 Controlled Study of NAMI Family-to-Family Education Program

Lisa B. Dixon, M.D., Joyce Burland, Ph.D., Alicia Lucksted, Ph.D.,  
Bette Stewart, B.S., Leticia T. Postrado, Ph.D., Colleen McGuire, M.A., Marcia Hoffman, M.A.

12 noon

80 An Additional Guideline for Choosing Appropriate Supportive Psychotherapy Techniques

Frederick S. Mendelsohn, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 28

11:00 a.m.-12:30 p.m.

Room 202 A, Level 200, Convention Center

ADDICTION PSYCHIATRY

Chp.: David W. Brook, M.D.  
Co-Chp.: Meera Vaswani, Ph.D.

11:00 a.m.

81 Ecstasy: Complications and Neurotoxicity

Tina M. Vreys, M.D.



11:30 a.m.

**82 Predicting Treatment Outcome of Cocaine-Dependent Patients**

Ashwin A. Patkar, M.D., Raman N. Gopalakrishnan, M.D., Charles C. Thornton, Ph.D., Stephen P. Weinstein, Ph.D., Edward Gottheil, M.D., Wade H. Berrettini, M.D., Kevin P. Hill, B.A.

12 noon

**83 5HT Uptake, Impulsivity, Aggression, and Craving Among Cocaine Abusers**

Ashwin A. Patkar, M.D., Raman N. Gopalakrishnan, M.D., Edward Gottheil, M.D., Wade H. Berrettini, M.D., Sean Parnell, Kevin P. Hill, B.A., Stephen P. Weinstein, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

**SCIENTIFIC AND CLINICAL REPORT SESSION 29**

11:00 a.m.-12:30 p.m.

Room 202 B, Level 200, Convention Center

**ISSUES IN PSYCHIATRIC TREATMENT**

Chp.: Dinu P. Gangure, M.D.

Co-Chp.: Daniel P. Chapman, Ph.D.

11:00 a.m.

**84 Civil Commitment in Turkey: Reflections on a Bill Drafted by Psychiatrists**

Rasim Arıkan, M.D., Paul S. Appelbaum, M.D., Mustafa Sercan, M.D., Solmaz Turkan, M.D., Nevzat Satmis, M.D., Aslihan Polat, M.D.

11:30 a.m.

**85 Malpractice Liability in Shared Treatment**

Eugene L. Lowenkopf, M.D., Abe M. Rychik, J.D.

12 noon

**86 Assertive Community Treatment Team Patient Employment Outcomes**

Jessica Hebrank, B.A., Carolyn M. Young, M.D., Catherine Laughlan, Richard Leong, C.S.W., Brian F. Meade, Sandy Pastor, M.S., Ranganathan Ram, M.D.

THIS SESSION WILL BE AUDIOTAPED.

**SCIENTIFIC AND CLINICAL REPORT SESSION 30**

11:00 a.m.-12:30 p.m.

Room 203 A, Level 200, Convention Center

**SOCIAL AND COMMUNITY PSYCHIATRY**

Chp.: Susan Stabinsky, M.D.

Co-Chp.: Nelda F. Scott, M.D.

11:00 a.m.

**87 Defining Disability Down**

Howard W. Telson, M.D.

11:30 a.m.

**88 Marital Disruption and Mental Health: A Nine Wave Panel Study**

Terrance J. Wade, Ph.D., David J. Pevalin, M.A.

12 noon

**89 Divorce and Marital Instability in Different Subtypes of Major Affective Disorders**

Zoltan Rihmer, M.D., Erika Szadoczky, M.D., Sandor Rozsa, Kitty Kiss, Janos Furedi, M.D.

THIS SESSION WILL BE AUDIOTAPED.

**SCIENTIFIC AND CLINICAL REPORT SESSION 31**

11:00 a.m.-12:30 p.m.

Room 204 A, Level 200, Convention Center

**ISSUES IN MEDICATION MANAGEMENT**

Chp.: Lon R. Hays, M.D.

Co-Chp.: Elisabeth J.S. Kunkel, M.D.

11:00 a.m.

**90 Compliance and Treatment Discontinuation in Panic-Disorder Patients**

Giulio Perugi, M.D., Christina Toni, M.D., Franco Frare, M.D., Carlo Torti, M.D.

11:30 a.m.

**91 Meta-Analysis of Antidepressant Levels in Lactating Mothers' Breastmilk and Nursing Infants**

Alicia M. Weissman, M.D., Arthur J. Hartz, Ph.D., Suzanne Bentler, M.S., Micca Donohue, Vicki L. Ellingrodringold, Ph.D., Katherine L. Wisner, M.D.

12 noon

**92 Clinical Problems in the Treatment of Adults with Comorbid ADD**

Marc D. Schwartz, M.D.

THIS SESSION WILL BE AUDIOTAPED.

**SCIENTIFIC AND CLINICAL REPORT SESSION 32**

11:00 a.m.-12:30 p.m.

Room 204 B, Level 200, Convention Center

**MANAGING SIDE EFFECTS AND DEFICITS**

Chp.: Robert W. Baker, M.D.

Co-Chp.: Khakasa H. Wapenyi, M.D.

11:00 a.m.

**93 Branched-Chain Amino Acid Treatment of Tardive Dyskinesia**

Mary Ann Richardson, Ph.D., Margaret L. Bevans, R.N., Helen M. Chao, Ph.D., Laura L. Read, Ph.D., Leslie L. Citrome, M.D., James D. Clelland

11:30 a.m.

**94 Nonadrenergic Noncholinergic Sildenafil Treatment of SRI-Associated Sexual Dysfunction**

H. George Nurnberg, M.D., Paula L. Hensley, M.D., Alan J. Gelenberg, M.D., Maurizio Fava, M.D., John Lauriello, M.D., Susan Paine, M.D.

(Continued next page)

## WEDNESDAY

12 noon

- 95 **Rivastigmine Tartrate in Neurocognitive Deficits in Schizophrenia Patients Treated with Clozapine**  
Mohammad Z. Hussain, M.D., Zabaida A. Chaudhry, M.D.,  
Seema Hussain, M.D.

### SCIENTIFIC AND CLINICAL REPORT SESSION 33

11:00 a.m.-12:30 p.m.

Liberty Ballroom A, Level 3, Marriott

### MANAGEMENT OF DEPRESSION

Chp.: Megan T. Marumoto, M.D.  
Co-Chp.: Abel A. Gonzalez, M.D.

11:00 a.m.

- 96 **Psychosocial Functioning as a Predictor of Response to Nortriptyline in Treatment-Resistant Depression**  
Timothy J. Petersen, Ph.D., Heidi D. Montoya, B.A.,  
Robert L. Gresham, B.A., George Papakostas, M.D., Andrew A.  
Nierenberg, M.D., Jonathan E. Alpert, M.D., Maurizio  
Fava, M.D.

11:30 a.m.

- 97 **Efficacy of Citalopram as an Augmenting Strategy for Menopausal Women with Estrogen-Resistant Depression**  
Claudio N. Soares, M.D., Jennifer Poitras, B.A., Jan L.  
Shifren, M.D., Allison B. Alexander, M.D., Lee S. Cohen, M.D.

12 noon

- 98 **Polypharmacy with Antidepressants**  
John W. Goethe, M.D., Bonnie L. Szarek, R.N.  
THIS SESSION WILL BE AUDIOTAPED.

### WORKSHOPS

#### COMPONENTS 42-49

**COMPONENT WORKSHOP 42** 11:00 a.m.-12:30 p.m.  
Rooms 102 A/B, Street Level, Convention Center

**EDUCATING THE COURTS: RECENT APA AMICUS CURIAE BRIEFS**  
*APA Commission on Judicial Action*

Chp.: Renee L. Binder, M.D.  
Participants: Howard V. Zonana, M.D., Richard G. Taranto, J.D.

**COMPONENT WORKSHOP 43** 11:00 a.m.-12:30 p.m.  
Room 104 A, Street Level, Convention Center

**MEDICARE UPDATE 2002**  
*APA Medicare Advisory Committee*

Chp.: Edward Gordon, M.D.  
Participants: Irvin L. Muszynski, J.D., Ellen Jaffe, Seth P. Stein, J.D.,  
Gerald Rogan, M.D., Lloyd I. Sederer, M.D.

**COMPONENT WORKSHOP 44** 11:00 a.m.-12:30 p.m.  
Room 104 B, Street Level, Convention Center

**CRITICAL ISSUES FOR TREATING DOMESTIC VIOLENCE SURVIVORS AND THEIR CHILDREN**  
*APA Committee on Family Violence and Sexual Abuse*

Co-Chps.: Carole L. Warshaw, M.D., Graeme Hanson, M.D.  
Participants: Susan M. Ditter, M.D., Sandra L. Bloom, M.D.

**COMPONENT WORKSHOP 45** 11:00 a.m.-12:30 p.m.  
Rooms 112 A/B, Street Level, Convention Center

**PSYCHIATRY'S RESPONSE TO THE DATA: SPIRITUALITY AS A RELEVANT CLINICAL FACTOR**  
*APA Committee on Religion, Spirituality, and Psychiatry*

Chp.: Irving S. Wiesner, M.D.  
Participants: Harold G. Koenig, M.D., Francis G. Lu, M.D.,  
S. Atezzaz Saeed, M.D.

**COMPONENT WORKSHOP 46** 11:00 a.m.-12:30 p.m.  
Room 203 B, Level 200, Convention Center

**LESBIAN, GAY, BISEXUAL, AND TRANSGENDERED RESIDENTS: CHALLENGES IN TRAINING**  
*APA Northern California Psychiatric Society's Committee on Lesbian, Gay, Bisexual, and Transgender Issues*

Chp.: Dan H. Karasic, M.D.  
Participants: Ellen Haller, M.D., Rodney J. Erwin, M.D.,  
Kristin P. Riley-Lazo

**COMPONENT WORKSHOP 47** 11:00 a.m.-12:30 p.m.  
Liberty Ballroom B, Level 3, Marriott

**NEW TRENDS AND CHALLENGES IN RESIDENCY EDUCATION**  
*APA Committee on Graduate Education*

Co-Chps.: Joyce A. Tinsley, M.D., Paul E. Holtzheimer III, M.D.  
Participants: Leighton Y. Huey, M.D., Laura B. Dunn, M.D.

**COMPONENT WORKSHOP 48** 11:00 a.m.-12:30 p.m.  
Grand Ballroom Salon D, Level 5, Marriott

**HIPAA PRIVACY RULE: WHAT EVERY PSYCHIATRIST NEEDS TO KNOW**  
*APA Council on Psychiatry and Law and APA Committee on Confidentiality*

Chp.: Jeffrey L. Metzner, M.D.  
Participants: Margo P. Goldman, M.D., William M. Reinhart, M.D.

**COMPONENT WORKSHOP 49** 11:00 a.m.-12:30 p.m.  
Grand Ballroom Salon K, Level 5, Marriott

**MEETING THE MENTAL HEALTH NEEDS OF  
MINORITIES IN THE 21ST CENTURY**

*APA/Center for Mental Health Services Minority Fellows and  
APA/AstraZeneca Minority Fellows*

**Chp.:** Michael J. Pratts, M.D.  
**Participants:** Alvaro Camacho, M.D., Cherry Chevy, M.D.,  
Denise De Guzman, M.D., Nancy Sheng-Shih Wu, M.D.,  
Bethany J. Tucker, M.D.

**ISSUES 89-95**

**ISSUE WORKSHOP 89** 11:00 a.m.-12:30 p.m.  
Liberty Ballroom C, Level 3, Marriott

**ASSESSING EDUCATIONAL EXPERIENCES IN  
PSYCHIATRY**

**Chp.:** Joel Yager, M.D.  
**Participants:** Paula L. Hensley, M.D., Deepa N. Nadiga,  
Michael A. Hollifield, M.D.

**ISSUE WORKSHOP 90** 11:00 a.m.-12:30 p.m.  
Independence Ballrooms II/III, Level 3, Marriott

**THE PSYCHIATRIC FITNESS-FOR-DUTY EXAM**

**Chp.:** Robert C. Larsen, M.D.

**ISSUE WORKSHOP 91** 11:00 a.m.-12:30 p.m.  
Rooms 401-403, Level 4, Marriott

**YOUTH VIOLENCE: A REPORT OF THE SURGEON  
GENERAL**

*Substance Abuse and Mental Health Services Administration*

**Co-Chps.:** Marilyn B. Benoit, M.D., Norma Hatot  
**Participants:** Delbert Elliott, Ph.D., Carl C. Bell, M.D.

**ISSUE WORKSHOP 92** 11:00 a.m.-12:30 p.m.  
Grand Ballroom Salon B, Level 5, Marriott

**SELF-MUTILATION IN PRISON**

**Co-Chps.:** Lee H. Rome, M.D., James E. Dillon, M.D.

**ISSUE WORKSHOP 93** 11:00 a.m.-12:30 p.m.  
Grand Ballroom Salon C, Level 5, Marriott

**PSYCHIATRIC ILLNESS AND THE WORKPLACE**

**Chp.:** Steven E. Pflanz, M.D.

**ISSUE WORKSHOP 94** 11:00 a.m.-12:30 p.m.  
Grand Ballroom Salon I, Level 5, Marriott

**ELECTRONIC MEDICAL RECORDS ENHANCE  
QUALITY AND PRODUCTIVITY: THE TIME HAS  
COME**

**Chp.:** Daniel A. Deutschman, M.D.  
**Participant:** Joshua E. Freedman, M.D.

**ISSUE WORKSHOP 95** 11:00 a.m.-12:30 p.m.  
Grand Ballroom Salon J, Level 5, Marriott

**DILEMMAS OF MELANCHOLIA: LET PHILOSOPHY  
HELP**

*Association for the Advancement of Philosophy and Psychiatry*

**Chp.:** Michael F. Myers, M.D.  
**Participants:** Jennifer Radden, Ph.D., Deborah Spitz, M.D.,  
Leah J. Dickstein, M.D., Zachary Myers

**12 noon Sessions**

**FORUMS 9-11**

**FORUM 9** 12 noon-1:30 p.m.  
Room 103 B, Street Level, Convention Center

**KILLING IN THE NAME OF GOD: OSAMA BIN  
LADEN AND RADICAL ISLAM**

**Chp.:** Jerrold M. Post, M.D.  
**Participants:** Ambassador Nathaniel Howell, Ph.D., Jessica  
Stern, Ph.D., Vamik D. Volkan, M.D.

**FORUM 10** 12 noon-1:30 p.m.  
Room 103 C, Street Level, Convention Center

**ABPN UPDATE: REQUIREMENTS FOR ABPN  
EXAMINATION**

**Chp.:** Stephen C. Scheiber, M.D.  
**Participants:** Glenn C. Davis, M.D., Michael H. Ebert, M.D.,  
Larry R. Faulkner, M.D., Burton V. Reifler, M.D., Pedro Ruiz, M.D.,  
James H. Scully, Jr., M.D., Elizabeth B. Weller, M.D., Daniel K.  
Winstead, M.D.

**FORUM 11** 12 noon-1:30 p.m.  
Room 113 A, Street Level, Convention Center

**LATIN AMERICA**

**Chp.:** Rodrigo A. Munoz, M.D.  
**Participants:** Harold I. Eist, M.D., Gerardo Heinze, M.D.,  
Juan E. Mezzich, M.D., Miguel R. Jorge, M.D., Gonzalo F.  
Viale, M.D., Rodrigo J. Munoz T, M.D.

**NEW RESEARCH POSTER SESSION 8**

12 noon-2:00 p.m.

Exhibit Hall D, Street Level, Convention Center

**SCHIZOPHRENIA; CHILD AND ADOLESCENT PSYCHIATRY; TREATMENT TECHNIQUES AND OUTCOME STUDIES; SOCIAL AND COMMUNITY PSYCHIATRY; CROSS-CULTURAL AND MINORITY ISSUES; HEALTH SERVICES RESEARCH; AND PSYCHIATRIC REHABILITATION**

For further information on New Research Sessions, please refer to the *New Research Program and Abstracts Book* included in your registration packet.

---

**12:30 p.m. Session**

---

**MEDIA SESSION 22**

12:30 p.m.-2:00 p.m.

Washington Rooms A-C, Third Floor, Loews

**ACROSS THE GENERATIONS**

Chp.: David C. Martinez, M.F.A.

**29 *Bubbeh Lee and Me***

(35 minutes)

**Distributor:** New Day Films  
22-D Hollywood Avenue  
Ho Ho Kus, NJ 07423

What can a grandchild discover through a grandparent? When the filmmaker of *Bubbeh Lee and Me* arrives in Florida to visit his feisty, 87-year old Jewish grandmother and speaks with her heart-to-heart about love, death, and sexuality, their two worlds collide and the strength of their bond emerges. A spirited reflection on aging, identity, diversity, and acceptance, this classic film examines the legacies passed through families and generations, and shows that the journey of self-discovery can begin at any age.

**30 *The Frog in the Well: The Life and Work of Hoh-Kun Yuen***

Yuen

(28 minutes)

**Distributor:** The Freedom Archives  
522 Valencia  
San Francisco, CA 94110

This video chronicles the life and work of Hoh-Kun Yuen, physicist, father, ice skater, and radical documentarian. Yuen, a Chinese-American immigrant, recorded decades of social movements in and around Berkeley and the Bay Area beginning in 1963 with the Free Speech movement, including the Black Panther movement, the Women's Movement, the anti-Vietnam War Movement, and the Anti-Apartheid struggles of the 80's. His work, inspired by a radical view of science and history, is described using photos, tape recordings, newsprint,

and film from Yuen's archives which he named *The Frog in the Well* after a Chinese fable. The relationship of personal development and creativity; the immigrant experience in America; the boundary between productivity and obsessional dysfunction are issues raised by this video.

**Discussant:** David C. Martinez, M.F.A.

---

**1:00 p.m. Sessions**

---



**COURSES 91-96**

Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.

---

**COURSE 91** 1:00 p.m.-5:00 p.m.

Ormandy East, Street Level, DoubleTree

**SLEEP MEDICINE UPDATE: ADVANCED TOPICS**

**Director:** Thomas D. Hurwitz, M.D.

**Faculty:** Max Hirshkowitz, Ph.D., Lois Krahn, M.D.

---

**COURSE 92** 1:00 p.m.-5:00 p.m.

Aria A, Third Floor, DoubleTree

**COGNITIVE THERAPY FOR SCHIZOPHRENIA**

**Co-Directors:** Jesse H. Wright, M.D., Aaron T. Beck, M.D.

**Faculty:** Jan L. Scott, M.D.

---

**COURSE 93** 1:00 p.m.-5:00 p.m.

Overture, Third Floor, DoubleTree

**ADVANCED ASSESSMENT AND TREATMENT OF ADD**

**Director:** Thomas E. Brown, Ph.D.

**Faculty:** Jefferson B. Prince, M.D.

---

**COURSE 94** 1:00 p.m.-5:00 p.m.

Maestro, Fourth Floor, DoubleTree

**CPT CODING AND DOCUMENTATION 2002**

**Director:** Chester W. Schmidt, Jr., M.D.

---

**COURSE 95** 1:00 p.m.-5:00 p.m.

Rhapsody, Fourth Floor, DoubleTree

**IMPROVING MEDIA COVERAGE OF SUICIDE: THE ROLE OF THE PSYCHIATRIST**

*American Foundation for Suicide Prevention*

**Co-Directors:** Herbert Hendin, M.D., Kathleen Jamison, Ph.D.

**Faculty:** John T. Maltzberger, M.D., Madelyn Gould, Ph.D., Patrick Jamieson

**COURSE 96** **1:00 p.m.-5:00 p.m.**  
**Sonata 5, Fifth Floor, DoubleTree**

**TREATMENT OF CREATIVE PATIENTS**

**Director:** Albert Rothenberg, M.D.

**2:00 p.m. Sessions**

**LECTURES 22-23**

**LECTURE 22**

2:00 p.m.-3:30 p.m.  
 Rooms 108 A/B, Street Level, Convention Center

**Benedetto Saraceno, M.D.**

**Global Implications on the World Health  
 Organization's World Health Report 2001 on  
 Mental Health**

**Chp.:** Darrel A. Regier, M.D.  
**Co-Chp.:** Regina C. Casper, M.D.

The World Health Organization World Health Report for 2001, *Mental Health: New Understanding, New Hope*, analyzes the costs of mental disorders in human, social, and economic terms and describes core actions needed to improve mental health in a manner compatible with the realities of development in individual countries. Benedetto Saraceno, M.D., Director of the WHO Department of Mental Health and Substance Dependence in Geneva, highlights the key findings and recommendations discussed in the report. Dr. Saraceno previously served as Head of the Laboratory of Epidemiology and Social Psychiatry and Director of the WHO Collaborating Center for Research in Mental Health at Mario Negri Institute in Milan and as advisor to the Pan American Health Organization, where he assisted policy makers in mental health services reform in several South and Central American countries. He was President of the World Association for Psychosocial Rehabilitation and a Founding Member and Vice-President of the Società Italiana di Epidemiologia Psichiatrica. The author of more than 100 scientific articles and the co-author or editor of several books, Dr. Saraceno received his medical degree from the University of Milan, his postdoctoral degree in psychiatry from the University of Parma, and his training in public health and epidemiology at Mario Negri Institute.

**International Psychiatrist Lecture Series  
 THIS SESSION WILL BE AUDIOTAPED.**

**LECTURE 23**

2:00 p.m.-3:30 p.m.  
 Rooms 109 A/B, Street Level, Convention Center

**Elizabeth B. Weller, M.D.**

**Mania in Youth: A Transition from Ignorance to  
 Enlightenment to Confusion**

**Chp.:** Jerry M. Wiener, M.D.  
**Co-Chp.:** Sandra Y. Lotan, M.D.

Bipolar disorder has not been well studied in children and adolescents. Historically it was assumed that children and adolescents had immature ego development and thus could not suffer from mood disorders. Elizabeth B. Weller, M.D., reviews the development of support for the diagnosis of bipolar disorder in children and adolescents and discusses advances in diagnostic tools and progress in genetic studies that promise to clarify the nature of this disorder in this age group. Dr. Weller is Professor of Psychiatry and Pediatrics and Vice Chair of the Department of Psychiatry at the University of Pennsylvania School of Medicine in Philadelphia. A Fellow of APA and the American Academy of Child and Adolescent Psychiatry, she has received several clinical research awards from the American Academy of Clinical Psychiatry. She is the author of numerous professional articles and book chapters on the diagnosis and treatment of mood disorders in children and adolescents. Dr. Weller received her medical degree from the American University of Beirut in Lebanon and completed residencies in general and child and adolescent psychiatry at Washington University School of Medicine in St. Louis and University of Kansas Medical Center in Kansas City.

**Distinguished Psychiatrist Lecture Series**

**MEDIA SESSIONS 23-24**

**MEDIA SESSION 23** **2:00 p.m.-5:00 p.m.**  
**Washington Rooms A-C, Third Floor, Loews**

**PSYCHIATRY GOES TO THE MOVIES**

**Chp.:** Max Fink, M.D.

**31 A Beautiful Mind**  
 (122 minutes)

**Distributor:** Facets Multimedia  
 1517 West Fullerton  
 Chicago, IL 60614

*A Beautiful Mind* is the true story of John Forbes Nash, Jr., a man whose formulas established the mathematical principles

*(Continued next page)*



of the "Game Theory" of economics. The theory eventually won Mr. Nash the Nobel Prize. By the age of 30, John Nash, Jr., was diagnosed with paranoid schizophrenia. He had a varied sexual life, which included an arrest for indecent exposure in a men's restroom, and fathering a child out of wedlock. The film focuses on his relationship with his wife and the path his life took from success to mental illness to recovery.

**MEDIA SESSION 24** 2:00 p.m.-5:00 p.m.  
Congress Rooms A-C, Fourth Floor, Loews

**PSYCHIATRY GOES TO THE MOVIES**

Chp.: Alan A. Stone, M.D.

**32 King of Masks: Gender and Tradition in China**  
(101 minutes)

Distributor: Sameul Goldwyn Studio  
1133 Broadway  
New York, NY 10010

*The King of Masks* is the story of a proud artist in a Sichuan Province. The province has been shaken by war and ravaged by floods. Starving parents are selling their sons and will give their daughters to anyone who promises the child a home. The artist, called *The King of Masks*, takes advantage of the opportunity to buy a child. He does not want the daughters who are thrust at him by their mothers, but he wants a son. He is just about to give up when a child's voice cries out "Yeh Yeh," (grandfather in Chinese). *The King of Masks* turns back to behold who he thought was the son he always wanted, but is really a girl, and agrees upon a price. The film shows how this indignant little girl conquers that age-old tradition to the benefit of everyone.

Discussants: Alan A. Stone, M.D., Francis G. Lu, M.D.,  
Nada L. Stotland, M.D.

**REVIEW OF PSYCHIATRY: SECTION 4**  
2:00 p.m.-5:30 p.m.  
Rooms 201 A-C, Level 200, Convention Center

**MENTAL HEALTH ISSUES IN THE LESBIAN/GAY/  
BISEXUAL/TRANSGENDER COMMUNITY**

Co-Chps.: Billy E. Jones, M.D., Marjorie Hill, Ph.D.

**15 Gay, Lesbian, Bisexual, and Transgender Youth**  
Jeffrey S. Akman, M.D., Garry Fisher, M.D.

**16 Taboo Topics in Psychiatry: Aging and Sexual  
Orientation**  
Douglas C. Kimmel, Ph.D.

**17 Psychiatric Evaluation of Gay or Lesbian Identified  
Persons for Legal Processing**  
Richard G. Dudley, Jr., M.D.

**18 History and Update on Sexual Conversion (Reparative)  
Therapies**  
Jack Drescher, M.D.

**19 The Intersection of Transgender Mental Health with  
Homosexuality and Race**  
Donald E. Tarver II, M.D.

**SYMPOSIA 57-75**

**SYMPOSIUM 57** 2:00 p.m.-5:00 p.m.  
Room 103 A, Street Level, Convention Center

**SPORTS THROUGH THE LIFE CYCLE**  
*International Society for Sport Psychiatry*

Chp.: Ronald L. Kamm, M.D.

**A The Pros and Cons of Coaching One's Own Child**  
Ronald L. Kamm, M.D.

**B The Mid-Career Athlete: Coping with Psychiatric Illness**  
Antonia L. Baum, M.D.

**C When the Cheering Stops: Career Termination Issues in  
Athletes**  
Joshua W. Calhoun, M.D.

Discussants: Marvis Frazier, Wendy Wilson, Gary Cobb  
**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 58** 2:00 p.m.-5:00 p.m.  
Rooms 106 A/B, Street Level, Convention Center

**COMMUNITY CARE IN GERIATRIC PSYCHIATRY IN  
THE 21ST CENTURY**

Chp.: Paul A. Kettl, M.D.

**A Mental Health Disorders Among Rural Elders**  
Kathleen M. Fisher, Ph.D.

**B Primary Care Management of Late-Life Depression**  
Ira R. Katz, M.D.

**C Managing the Behavioral Complications of Dementia**  
Robert P. Roca, M.D.

**D Caring for Elder Depression in the 21st Century**  
Paul A. Kettl, M.D.

**E Depression in Patients with Recent-Onset-Bilateral-  
Age-Related Macular Degeneration**  
Barry W. Rovner, M.D., Robin Casten, Ph.D.  
**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 59** 2:00 p.m.-5:00 p.m.  
 Room 111 B, Street Level, Convention Center

**BRAIN STIMULATION IN NEUROPSYCHIATRIC ILLNESS**

**Chp.:** Mark S. George, M.D.  
**Co-Chp.:** Michael R. Trimble, M.D.

**A Brain Stimulation from Above and Below: Theoretical Issues**

Mark S. George, M.D., Ziad H. Nahas, M.D., Andrew F. Kozel, M.D., Xingpao Li, M.D., Jeong-Ho Chae, M.D.

**B Seizures, ECT, and Transcranial Magnetic Stimulation: Therapeutic Options and New Directions**

Harold A. Sackeim, Ph.D., Sarah H. Lisanby, M.D.

**C Brain Stimulation, Mood, and Epilepsy**

Michael R. Trimble, M.D.

**D Vagus Nerve Stimulation in Affective Disorders: New Findings**

Lauren B. Marangell, M.D.

THIS SESSION WILL BE AUDIOTAPED.

**SYMPOSIUM 60** 2:00 p.m.-5:00 p.m.  
 Rooms 112 A/B, Street Level, Convention Center

**LIFE-THREATENING HYPERTHERMIC SYNDROMES IN PSYCHIATRY**

**Chp.:** Stanley N. Caroff, M.D.  
**Co-Chp.:** Stephan C. Mann, M.D.

**A 5HT Syndrome**

Paul E. Keck, Jr., M.D., Lesley M. Arnold, M.D.

**B Stimulant-Induced Hyperthermia**

Una D. McCann, M.D.

**C NMS: Still a Syndrome After All These Years?**

Ronald J. Gurrera, M.D.

**D The Malignant Catatonia Syndrome**

Stephan C. Mann, M.D., Stanley N. Caroff, M.D., E. Cabrina Campbell, M.D., Henry R. Bleier, M.D., Robert A. Greenstein, M.D.

**E Heatstroke, Heatwaves, and Psychiatric Illness**

Nigel M. Bark, M.D.

**Discussant:** Alan J. Gelenberg, M.D.

THIS SESSION WILL BE AUDIOTAPED.

**SYMPOSIUM 61** 2:00 p.m.-5:00 p.m.  
 Room 113 B, Street Level, Convention Center

**COURSE OF PSYCHOPATHOLOGY AND FUNCTIONING IN PERSONALITY DISORDERS**

**Chp.:** Andrew E. Skodol II, M.D.  
**Co-Chp.:** Mary C. Zanarini, Ed.D.

**A Six-Year Symptomatic and Functional Course of BPD**  
 Mary C. Zanarini, Ed.D., Frances R. Frankenburg, M.D., John Hennen, Ph.D., Kenneth R. Silk, M.D.

**B Two-Year Diagnostic Stability of Four DSM-IV Personality Disorders: Schizotypal Personality Disorder, BPD, Avoidant Personality Disorder, and OCD**

Thomas H. McGlashan, M.D., John G. Gunderson, M.D., Andrew E. Skodol II, M.D., M. Tracie Shea, Ph.D., Robert L. Stout, Ph.D., Charles A. Sanislow, Ph.D., Carlos M. Grilo, Ph.D.

**C Using Factor Analysis to Test Dimensional Stability of Personality Disorder Constructs**

Charles A. Sanislow, Ph.D., Carlos M. Grilo, Ph.D., Leslie C. Morey, Ph.D., M. Tracie Shea, Ph.D., Andrew E. Skodol II, M.D., Robert L. Stout, Ph.D., Thomas H. McGlashan, M.D.

**D Course of Functional Impairment in Personality Disorders Over Two Years**

Andrew E. Skodol II, M.D., John G. Gunderson, M.D., Thomas H. McGlashan, M.D., Leslie C. Morey, Ph.D., M. Tracie Shea, Ph.D., Robert L. Stout, Ph.D., Donna S. Bender, Ph.D.

**E Personality Disorders and Axis I Disorders: Longitudinal Associations of Course**

M. Tracie Shea, Ph.D., Robert L. Stout, Ph.D., Thomas H. McGlashan, M.D., John G. Gunderson, M.D., Andrew E. Skodol II, M.D., Shirley Yen, Ph.D., Leslie C. Morey, Ph.D.

**Discussant:** Paul S. Links, M.D.

THIS SESSION WILL BE AUDIOTAPED.

**SYMPOSIUM 62** 2:00 p.m.-5:00 p.m.  
 Room 113 C, Street Level, Convention Center

**CIRCUITRY OF FAILED COGNITIVE STRATEGIES IN ADDICTION**

**Chp.:** Edythe London, Ph.D.  
**Co-Chp.:** Igor I. Galynker, M.D.

**A Brain Metabolism During Early Abstinence from Methamphetamine Abuse**

Edythe London, Ph.D., Yun Dong, M.D., Sara Simon, Ph.D., Steven Berman, M.P.H., Ann Shinn, Ph.D., Mark Mandelkern, Ph.D., John A. Matochik, Ph.D.

**B Impaired Decision Making and Impulse Control Associated with Drug Misuse and Personality Disorders**  
 Robert D. Rogers, M.D.

**C Nicotine and Cerebral Blood Flow During a Working Memory Task**

Monique Ernst, M.D., John A. Matochik, Ph.D., Stephen J. Heishman, Ph.D., John D. Van Horn, Ph.D., Jack E. Henningfield, Ph.D.

*(Continued next page)*

**D Differences in Cerebral Glucose Metabolism in Patients On and Off Opiate Replacement Therapy**  
Igor I. Galynker, M.D., John A. Matochik, Ph.D., Carlo Contaregg, M.D., Alane S. Kimes, Ph.D., Monique Ernst, M.D., Richard N. Rosenthal, M.D., Edythe London, Ph.D., Carrie Weaver, M.A., Enid C. Gertmenian-King, B.A., Varughese Kurian, M.P.H., Donald C. Des Jarlais, Ph.D., Christian R. Miner, Ph.D.

**E Prefrontal Lobe Functioning in Cocaine Users**  
Karen I. Bolla, M.D., Monique Ernst, M.D., Maria Mouratidis, M.A., John A. Matochik, Ph.D., Dana Eldreth, B.A., Kent Kiehl, Varughese Kurian, M.P.H.

THIS SESSION WILL BE AUDIOTAPED.

**SYMPOSIUM 63** 2:00 p.m.-5:00 p.m.  

---

Room 202 A, Level 200, Convention Center

**PERSONALITY AND PERSONALITY DISORDERS IN THE COMMUNITY**

**Chp.:** Gerald Nestadt, M.D.

**A Prevalence and Correlates of Personality Disorders in a Community Sample**  
Jack F. Samuels, Ph.D., William W. Eaton, Ph.D., Oscar J. Bienvenu III, M.D., Clayton Brown, Ph.D., Paul T. Costa, Jr., Ph.D., Gerald Nestadt, M.D.

**B The Five Factor Model of Personality and Personality Disorders in a Community Study**  
Paul T. Costa, Jr., Ph.D., Jeffrey H. Herbst, Ph.D., Jack F. Samuels, Ph.D., Gerald Nestadt, M.D., Oscar J. Bienvenu III, M.D., Irving M. Reti, M.D., William W. Eaton, Ph.D.

**C Dimensions of DSM-IV Personality Disorders and Their Relationship to the NEO-PI-R**  
Gerald Nestadt, M.D., Fang-Chi Hsu, Ph.D., Jack F. Samuels, Ph.D., Oscar J. Bienvenu III, M.D., Paul T. Costa, Jr., Ph.D., Irving M. Reti, M.D., William W. Eaton, Ph.D.

**D Comorbidity of Anxiety and Depressive Disorders and Normal Personality Traits**  
Oscar J. Bienvenu III, M.D., Jack F. Samuels, Ph.D., Kung-Ye Liang, Ph.D., Paul T. Costa, Jr., Ph.D., William W. Eaton, Ph.D., Gerald Nestadt, M.D.

**E The Role of Parenting in the Development of Personality**  
Irving M. Reti, M.D., William W. Eaton, Ph.D., Jack F. Samuels, Ph.D., Gerald Nestadt, M.D., Paul T. Costa, Jr., Ph.D., Oscar J. Bienvenu III, M.D.

**Discussant:** Thomas A. Widiger, Ph.D.  
THIS SESSION WILL BE AUDIOTAPED.

**SYMPOSIUM 64** 2:00 p.m.-5:00 p.m.  

---

Room 202 B, Level 200, Convention Center

**LESSONS LEARNED: LOOKING BACK TO MOVE FORWARD**

*Association of Women Psychiatrists*

**Chp.:** Leah J. Dickstein, M.D.  
**Co-Chp.:** Marion Z. Goldstein, M.D.

**A Retrospective Career and Family Transitions for a Clearer Vision into the 21st Century**  
Marion Z. Goldstein, M.D.

**B Looking Back to Move Forward: The African-American Experience**  
Altha J. Stewart, M.D.

**C Women and National Leadership Roles: Getting There, Functioning Effectively**  
Carol C. Nadelson, M.D.

**D Academic Leadership Opportunities, Gender, Assumptions, and Outcomes**  
Leah J. Dickstein, M.D.

**E The Hand That Rocks the Cradle Rocks the Boat: The Empowerment of Women**  
Ann R. Turkel, M.D.

**Discussants:** Nancy C. Andreasen, M.D., Marian I. Butterfield, M.D.  
THIS SESSION WILL BE AUDIOTAPED.

**SYMPOSIUM 65** 2:00 p.m.-5:00 p.m.  

---

Room 203 A, Level 200, Convention Center

**TAKING CONTROL OF THE FUTURE: ACADEMIC PSYCHIATRY AND 21ST-CENTURY PRACTICE**

**Chp.:** Lee McCabe, Ph.D.

**A Psychiatry of the 21st Century: The Role of Academic Health Systems**  
Leighton Y. Huey, M.D.

**B Shaping the Future Through Education**  
Michael A. Hoge, Ph.D.

**C Successful Models of Depression Disease Management**  
David J. Katzelnick, M.D.

**D The Use of Performance Indicators in Quality Improvement and Financial Reimbursement**  
Allen S. Daniels, Ed.D.

**E Academic Psychiatry Managing Managed Care**  
Joseph M. Schwartz, M.D., Peter J. Fagan, Ph.D., Chester W. Schmidt, Jr., M.D.

**Discussant:** Steven S. Sharfstein, M.D.  
THIS SESSION WILL BE AUDIOTAPED.

**SYMPOSIUM 66** 2:00 p.m.-5:00 p.m.  
 Room 203 B, Level 200, Convention Center

**RECENT PERSPECTIVES ON BEHAVIORAL ADDICTIONS**

**Chp.:** David A. Gorelick, M.D.  
**Co-Chp.:** Michel Lejoyeux, M.D.

**A Application of Dependence Criteria to Uncontrolled Behaviors**  
 Jean Ades, M.D.

**B Pathological Gambling: Relationship to Substance Abuse**  
 David A. Gorelick, M.D.

**C Neurobiology of Pathological Gambling**  
 Marc N. Potenza, M.D.

**D Compulsive Buying: Clinical Aspects and Comorbidity**  
 Michel Lejoyeux, M.D.

**E Are Deviant Sexual Behaviors a Form of Addiction?**  
 Florence Thibaut, M.D.  
**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 67** 2:00 p.m.-5:00 p.m.  
 Room 204 A, Level 200, Convention Center

**DIAGNOSIS AND TREATMENT OF ADHD IN YOUNG CHILDREN**

**Chp.:** Christopher J. Kratochvil, M.D.

**A A Population Perspective on Psychopharmacologic Treatment of ADHD in Youths: Review and Update**  
 Julio M. Zito, Ph.D.

**B Diagnostic Challenges in Preschool Children**  
 Helen L. Egger, M.D.

**C Development and Initiation of the Preschool ADHD Treatment Study (PATS)**  
 Laurence L. Greenhill, M.D.

**D Pharmacotherapies in Young Children with ADHD**  
 Christopher J. Kratochvil, M.D.  
**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 68** 2:00 p.m.-5:00 p.m.  
 Room 204 B, Level 200, Convention Center

**CLUB DRUGS: TRENDS, TOXICITIES, AND TREATMENTS**  
*Substance Abuse and Mental Health Services Administration*

**Chp.:** David M. McDowell, M.D.  
**Co-Chp.:** Jane C. Maxwell, Ph.D.

**A Trends and Patterns in Club-Drug Use**  
 Jane C. Maxwell, Ph.D.

**B Neurotoxic Effects of 4-Methylenedioxymethamphetamine (Ecstasy)**  
 George A. Ricaurte, M.D.

**C Club Drugs: Emergency Management Issues**  
 Brett A. Roth, M.D.

**D A Review of Psychiatric Symptoms and Treatment for Club-Drug Use**  
 Karen A. Miotto, M.D.

**E Club Drugs: Current and Potential Treatments**  
 David M. McDowell, M.D.  
**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 69** 2:00 p.m.-5:00 p.m.  
 Rooms 401-403, Level 4, Marriott

**NALTREXONE TREATMENT OF ALCOHOLISM: A DECADE OF CLINICAL PROGRESS**

**Chp.:** Joseph R. Volpicelli, M.D.  
**Co-Chp.:** Charles P. O'Brien, M.D.

**A Efficacy of Naltrexone in the Treatment of Alcoholism**  
 Charles P. O'Brien, M.D., Helen Pettinati, Ph.D., David W. Oslin, M.D.

**B Optimizing Naltrexone Treatment of Alcohol Dependence**  
 Joseph R. Volpicelli, M.D., Ronald R. Ulm, Ph.D.

**C Naltrexone: Alcoholism in Patients with Comorbid Mental Illness**  
 Stephanie S. O'Malley, Ph.D., Rajita Sinha, Ph.D., Ismene L. Petrakis, M.D., John H. Krystal, M.D., Bruce Rousaville, M.D.

**D International Studies with Naltrexone**  
 Philip Morris, Ph.D.

**Discussant:** Raye Z. Litten, Ph.D.  
**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 70** 2:00 p.m.-5:00 p.m.  
 Grand Ballroom Salon B, Level 5, Marriott

**STATE-OF-THE-ART ADOLESCENT SUBSTANCE ABUSE PREVENTION AND TREATMENT**  
*Substance Abuse and Mental Health Services Administration*

**Chp.:** Deborah R. Simkin, M.D.  
**Co-Chp.:** Michael L. Dennis, Ph.D.

**A Effective Prevention: Center for Substance Abuse Prevention's National Study of High-Risk Youth Programs**  
 J. Fred Springer, Ph.D., Soledad Sambrano, Ph.D.

*(Continued next page)*

**B Psychiatric Comorbidity and Pharmacology Among Adolescents Presenting to Treatment**  
Deborah R. Simkin, M.D.

**C Main Findings of the Cannabis Youth Treatment Randomized Experiment**  
Michael L. Dennis, Ph.D.

**D Outcomes from the Adolescent Treatment Model Programs**  
Marc Fishman, M.D.

**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 71** 2:00 p.m.-5:00 p.m.

**Grand Ballroom Salon C, Level 5, Marriott**

**TREATMENT OF VIOLENCE AND CONDUCT DISORDERS IN CHILDREN AND ADOLESCENTS**

**Chp.:** R. Rao Gogineni, M.D.

**A Functional Family Therapy in the Treatment of Youth with Conduct Disorder**  
Ellen H. Sholevar, M.D.

**B Community-Based Treatment of Conduct Disorder**  
G. Pirooz Sholevar, M.D.

**C Medication Usage in Conduct Disorders**  
Jacquelyn M. Zavodnick, M.D.

**Discussant:** David A. Baron, D.O.

**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 72** 2:00 p.m.-5:00 p.m.

**Grand Ballroom Salon D, Level 5, Marriott**

**AFFECTIVE INSTABILITY IN BPD**

**Chp.:** Harold W. Koenigsberg, M.D.

**A Affective Instability and Borderline Symptoms and Defenses**  
Harold W. Koenigsberg, M.D., Philip D. Harvey, Ph.D., Marianne Goodman, M.D., Antonia S. New, M.D., Vivian Mitropoulou, M.A., Larry J. Siever, M.D.

**B The Relationship Between Childhood Trauma and Affective Instability in BPD**  
Marianne Goodman, M.D., Harold W. Koenigsberg, M.D., Antonia S. New, M.D., Vivian Mitropoulou, M.A., Tenko Raykov, Ph.D., Larry J. Siever, M.D.

**C Treating the Affective Instability Domain in BPD**  
Eric Hollander, M.D., Daphne Simeon, M.D., Andrea Allen, Ph.D., Jennifer Greenberg, B.A.

**D Early Maltreatment and the Neurobiology of Affective Instability**  
Martin H. Teicher, M.D., Susan Andersen, Ph.D., Ann M. Polcari, R.N., Carl M. Anderson, Ph.D., Caryl P. Navalta, Ph.D.

**Discussant:** Larry J. Siever, M.D.

**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 73** 2:00 p.m.-5:00 p.m.

**Grand Ballroom Salon I, Level 5, Marriott**

**CLINICAL AND TREATMENT CHALLENGES WITH HISPANIC PATIENTS**

*Inter-American Council of Psychiatric Organizations*

**Chp.:** Roberto E. Chaskel, M.D.

**Co-Chp.:** Ruben J. Hernandez-Serrano, M.D.

**A The Hispanic Patient and the DSM-IV**  
Carlos Berganza, M.D., Miguel R. Jorge, M.D.

**B Perception of Illness in the Hispanic Patient**  
Carlos Leon-Andrade, M.D., Nestor F. Marchant, M.D.

**C Personality and Hispanic Patients**  
Andres Heerlein, M.D., Roberto E. Chaskel, M.D.

**D Psychotherapeutic Intervention with the Hispanic Patient**  
Amelia Mvsacchio, M.D., Rodolfo D. Fahrner, M.D.

**E Psychopharmacological Issues with Hispanic Patients**  
Antonio Pacheco, M.D., Ruben J. Hernandez-Serrano, M.D.

**Discussant:** Renato D. Alarcon, M.D.

**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 74** 2:00 p.m.-5:00 p.m.

**Grand Ballroom Salon J, Level 5, Marriott**

**PATIENTS WITH CHRONIC PAIN: MULTIDISCIPLINARY TREATMENT APPROACHES**

**Chp.:** Allen Lebovits, Ph.D.

**Co-Chp.:** Matthew B. Smith, M.D.

**A Pain and Psychiatry: A General Overview**  
Matthew B. Smith, M.D.

**B An Integrative Model of the Psychobiology of Pain**  
Jeffrey D. Rome, M.D.

**C The Use of Analgesics in Chronic Pain**  
Michel Dubois, M.D.

**D Chronic Pain: Nonanalgesic and Adjuvant Pharmacological Options**  
Michael R. Clark, M.D.

**E Cognitive-Behavioral Approaches to Chronic Pain**  
Allen Lebovits, Ph.D.

**Discussant:** Paul Gusmorino, M.D.

**THIS SESSION WILL BE AUDIOTAPED.**



**SYMPOSIUM 75** 2:00 p.m.-5:00 p.m.  
Grand Ballroom Salon K, Level 5, Marriott

**PHYSICIAN DISABILITY: TREATMENT, INDEPENDENT EVALUATION, INSURANCE, AND CONFLICTS**

Chp.: Michael H. Gendel, M.D.  
Co-Chp.: Richard F. Limoges, M.D.

**A Area of Conflict Between Disabled Physician Patients and Disability Insurers**  
Richard F. Limoges, M.D.

**B Disability Insurance: Technical and Legal Aspects**  
Mark F. Seltzer, Esq.

**C Treating the Disabled Physician**  
Michael F. Myers, M.D.

**D Performing an Independent Psychiatric Disability Evaluation as a Physician**  
Michael H. Gendel, M.D.

Discussant: Linda Logsdon, M.D.  
**THIS SESSION WILL BE AUDIOTAPED**

---

**3:00 p.m. Session**

---

**NEW RESEARCH POSTER SESSION 9**  
3:00 p.m.-5:00 p.m.  
Exhibit Hall D, Street Level, Convention Center

**PSYCHOPHARMACOLOGY; ADDICTION PSYCHIATRY; ALCOHOL AND DRUG RELATED DISORDERS; EATING, PERSONALITY, AND DISSOCIATIVE DISORDERS; STRESS, VIOLENCE, TRAUMA, AND VICTIMIZATION; SUICIDE; AND DIAGNOSTIC ISSUES**

For further information on New Research Sessions, please refer to the *New Research Program and Abstracts Book* included in your registration packet.

---

**7:00 p.m. Sessions**

---

**INDUSTRY-SUPPORTED SYMPOSIA 43-49**

**INDUSTRY-SUPPORTED SYMPOSIUM 43**  
7:00 p.m.-10:00 p.m.  
Ballrooms A/B, Ballroom Level, Convention Center

**NONCHOLINERGIC TREATMENTS FOR ALZHEIMER'S DISEASE: PRESENT KNOWLEDGE, FUTURE HOPE**  
*Supported by Forest Laboratories, Inc.*

Chp.: Jacobo E. Mintzer, M.D.

**A The Diagnosis and Treatment of Alzheimer's Disease: An Overview**  
Barry D. Liebowitz, Ph.D.

**B Current Treatments for Alzheimer's Disease: Cholinesterase Inhibitors**  
Rachelle S. Doody, M.D.

**C The Neuroanatomy of Alzheimer's Disease**  
Gary L. Wenk, Ph.D.

**D Beyond Acetylcholine: The Search for Better Treatment Options (Part 1)**  
Jacobo E. Mintzer, M.D.

**E Beyond Acetylcholine: The Search for Better Treatment Options (Part 2)**  
Mary Sano, Ph.D.

**INDUSTRY-SUPPORTED SYMPOSIUM 44**  
7:00 p.m.-10:00 p.m.  
Millennium Hall, Second Floor, Loews

**SLEEP DISORDERS AND PSYCHIATRIC ILLNESSES: SCIENTIFIC FOUNDATIONS**  
*Supported by Sepracor, Inc.*

Chp.: Ruth M. Benca, M.D.

**A Epidemiology and Economic Burden of Insomnia**  
James K. Walsh, Ph.D.

**B Sleep and Psychiatric Illnesses**  
Thomas Roth, Ph.D.

**C Current and Next Generation Therapeutic Approaches to Sleep**  
Ruth M. Benca, M.D.

**INDUSTRY-SUPPORTED SYMPOSIUM 45**  
7:00 p.m.-10:00 p.m.  
Regency Ballrooms A-C, Second Floor, Loews

**THE BURDEN OF SCHIZOPHRENIA: WHY PATIENTS DON'T GET BETTER**  
*Supported by AstraZeneca Pharmaceuticals*

Chp.: Rajiv Tandon, M.D.

**A Defining Nonresponse in Schizophrenia: Why Patients Don't Do Well**  
Rajiv Tandon, M.D.

**B When Psychosis Doesn't Improve**  
Alan J. Mendelowitz, M.D.

**C Negative and Cognitive Function**  
Michael D. Jibson, M.D.

*(Continued next page)*

**D Comorbidities in Schizophrenia: Depression and Substance Abuse**  
Peter F. Buckley, M.D.

**E Why Patients Stop Their Antipsychotics and What to Do About It**  
Peter J. Weiden, M.D.

**INDUSTRY-SUPPORTED SYMPOSIUM 46**  
7:00 p.m.-10:00 p.m.  
Grand Ballroom Salons E/F, Level 5, Marriott

**IDENTIFICATION AND MANAGEMENT OF DAYTIME FATIGUE AND SLEEPINESS IN PSYCHIATRY**  
*Supported by Cephalon Inc.*

**Chp.:** John W. Winkelman, M.D.

**A Sleepiness and Fatigue: Neurobehavioral and Physiological Features**  
David F. Dinges, Ph.D.

**B Primary Sleep Disorders Associated with Excessive Daytime Sleepiness**  
Mary B. O'Malley, M.D.

**C Fatigue and Excessive Daytime Sleepiness in Psychiatric Disorders**  
Karl Doghramji, M.D.

**D Clinical Manifestations of Fatigue in Chronic Fatigue Syndrome**  
Anthony L. Komaroff, M.D.

**E Novel Molecular Targets in Deficit Syndromes**  
Daniel R. Weinberger, M.D.

**INDUSTRY-SUPPORTED SYMPOSIUM 47**  
7:00 p.m.-10:00 p.m.  
Grand Ballroom Salons G/H, Level 5, Marriott

**ADULT ADHD: FROM RESEARCH TO CLINICAL PRACTICE**  
*Supported by Shire US, Inc.*

**Chp.:** Joseph Biederman, M.D.  
**Co-Chp.:** Thomas J. Spencer, M.D.

**A Overview and Patterns of Comorbidity in Adults with ADHD**  
Joseph Biederman, M.D.

**B The Neuropsychology of Adult ADHD**  
Larry J. Seidman, Ph.D., Joseph Biederman, M.D., E. Valera, Ph.D., Allysa Doyle, Ph.D., Michael Monoteaux, B.A., Stephen V. Faraone, Ph.D.

**C A Genetic Perspective of the Validity of Adult ADHD**  
Stephen V. Faraone, Ph.D.

**D Functional and Structural Neuroimaging in ADHD**  
George Bush, M.D.

**E Pharmacotherapy of Adults with ADHD**  
Thomas J. Spencer, M.D.

**INDUSTRY-SUPPORTED SYMPOSIUM 48**  
7:00 p.m.-10:00 p.m.  
Wyndham Ballrooms A/B, First Floor, Wyndham

**ADVANCES IN THE UNDERSTANDING AND TREATMENT OF BINGE-EATING DISORDER**  
*Supported by Ortho-McNeil Pharmaceutical*

**Chp.:** James I. Hudson, M.D.

**A Binge-Eating Disorder: Diagnosis and Behavior**  
B. Timothy Walsh, M.D.

**B Epidemiology and Risk Factors**  
William P. Carter, M.D.

**C Treatment with Antidepressants**  
James I. Hudson, M.D.

**D Treatment with Appetite Suppressants and Antiepileptics**  
Susan L. McElroy, M.D.

**E Psychological Treatment**  
Denise E. Wilfley, Ph.D.

**INDUSTRY-SUPPORTED SYMPOSIUM 49**  
7:00 p.m.-10:00 p.m.  
Wyndham Ballrooms C/D, First Floor, Wyndham

**EXPLORATIONS IN DEMENTIA: NEW AND CURRENT PERSPECTIVES**  
*Supported by Eisai Inc., Pfizer Inc.*

**Chp.:** Gary W. Small, M.D.  
**Co-Chp.:** Donna Masterman, M.D.

**A Early Detection and Genetic Risk Assessment in Alzheimer's Disease**  
Gary W. Small, M.D.

**B Differential Diagnosis of Dementia Syndromes: A Psychiatric Perspective**  
J. Michael Ryan, M.D.

**C Contemporary Issues in Mild Cognitive Impairment: Fact or Fiction?**  
Bradley F. Boeve, M.D.

**D Charting the Course in Cerebrovascular Dementia**  
Gustavo C. Roman, M.D.

**E Alzheimer's Disease Therapy in the 21st Century: Examining the Evidence**  
Pierre N. Tariot, M.D.

**F Managing Behavioral Disturbances in Dementia: Practical Approaches to Treatment**  
Donna Masterman, M.D.

# THURSDAY, MAY 23, 2002

## 155TH ANNUAL MEETING

### 7:00 a.m. Sessions

#### PART 2 OF INDUSTRY-SUPPORTED BREAKFAST SYMPOSIA 38-42

##### INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 38, PART 2

7:00 a.m.-8:30 a.m.

Ballrooms A/B, Ballroom Level, Convention Center

##### CHRONIC EPISODIC DISORDERS: COMORBIDITY AND COMPREHENSIVE INTEGRATED TREATMENT

*Supported by GlaxoSmithKline*

Chp.: Julia K. Warnock, M.D.

##### A The Relationship Between Psychiatric Illness and Irritable Bowel Syndrome

R. Bruce Lydiard, M.D.

##### B Management of Pain Syndromes: Fibromyalgia, Migraines, and Chronic Pain

Diane S. Thompson, M.D.

##### INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 39, PART 2

7:00 a.m.-8:30 a.m.

Millennium Hall, Second Floor, Loews

##### AGE, GENDER, AND DIAGNOSIS: INFLUENCES ON DRUG RESPONSE

*Supported by Pfizer Inc.*

Chp.: Alexander H. Glassman, M.D.

##### A Epidemiology, Course, and Drug Response: How Are Mood and Anxiety Disorders Different in Children?

John S. March, M.D.

##### B Treatment of Mood Disorders in Women

Kimberly A. Yonkers, M.D.

##### INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 40, PART 2

7:00 a.m.-8:30 a.m.

Regency Ballrooms A-C, Second Floor, Loews

##### THERAPEUTIC CHALLENGES, NOVEL APPROACHES: ANTIPSYCHOTICS IN THE MANAGEMENT OF MOOD AND ANXIETY DISORDERS

*Supported by Eli Lilly and Company*

Chp.: Richard C. Shelton, M.D.

##### A Prognosis and Pharmacological Management of Men and Women with PTSD

Frederick Petty, M.D.

##### B Interplay Between Disease and Treatment Regimen: Special Safety Considerations

Olga Brawman-Mintzer, M.D.

##### INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 41, PART 2

7:00 a.m.-8:30 a.m.

Grand Ballroom Salons E/F, Level 5, Marriott

##### THE PATHOPHYSIOLOGY AND TREATMENT OF IMPULSIVITY AND AGGRESSION IN PSYCHIATRIC DISORDERS

*Supported by Abbott Laboratories*

Chp.: Alan C. Swann, M.D.

##### A Violence, Substance Use Disorders, and PTSD

Kathleen T. Brady, M.D.

##### B The Impulsive-Aggression Symptom Domain in Personality Disorders

Eric Hollander, M.D.

##### INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 42, PART 2

7:00 a.m.-8:30 a.m.

Grand Ballroom Salons G/H, Level 5, Marriott

##### NEW PERSPECTIVES ON SCHIZOPHRENIA SPECTRUM DISORDERS AND THEIR TREATMENT

*Supported by Janssen Pharmaceutica*

Chp.: Larry J. Siever, M.D.

Co-Chp.: Barbara Cornblatt, Ph.D.

##### A Neurobiology and Pharmacologic Treatment of Schizotypal Personality: Implications for Pharmacology

Larry J. Siever, M.D., Harold W. Koenigsber, M.D., Vivian Mitropoulou, M.A., Marianne Goodman, M.D., Monte S. Buchsbaum, M.D.

##### B Cognitive Enhancers in the Schizophrenia Spectrum

Marianne Goodman, M.D., Vivian Mitropoulou, M.A., Harold W. Koenigsber, M.D., Antonia S. New, M.D., Liza Maldari, M.A., Larry J. Siever, M.D.

##### C The Promise of Atypical Antipsychotics for Borderline Disorders

S. Charles Schulz, M.D., Kelly L. Camlin, M.S.W., Sally A. Berry, M.D., Yanjee Adit, M.D., Lee Friedman, Ph.D.

### 8:00 a.m. Sessions



#### COURSES 97-99

Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.

#### COURSE 97

8:00 a.m.-12 noon

Ormandy East, Street Level, DoubleTree

#### ETHICAL DECISION-MAKING IN CLINICAL PRACTICE

Director: Stephen A. Green, M.D.

Faculty: Sydney Bloch, M.D.

## THURSDAY

**COURSE 98** 8:00 a.m.-12 noon  
Aria A, Third Floor, DoubleTree

### THE MISSING PIECE OF THE PUZZLE: TIC DISORDERS IN ADULTS WITH OCD OR ADD

**Director:** Maria A. Pugliese, M.D.  
**Faculty:** J. Paul Hieble, Ph.D., Michael N. Rubenstein, M.D., Orrin Palmer, M.D., Sue Levi-Pearl, Mary Lou Reaver, R.N.

**COURSE 99** 8:00 a.m.-12 noon  
Concerto A, Third Floor, DoubleTree

### ASSESSING THE RISK FOR VIOLENCE

**Director:** Bradley R. Johnson, M.D.  
**Faculty:** Judith Becker, Ph.D.

## 9:00 a.m. Sessions

### CONTINUOUS CLINICAL CASE CONFERENCE 2: PART 2

9:00 a.m.-12 noon  
Rooms 106 A/B, Street Level, Convention Center

### MANAGING NEGATIVE OUTCOMES IN GENERAL PSYCHIATRY

**Moderator:** Richard G. Hersh, M.D.  
**Presenter:** Mary S. Sciutto, M.D.

**THIS SESSION IS OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR**



**COURSES 100-102**  
Course descriptions are available in the *CME Course Brochure* included in your registration packet. Admission by ticket only.

**COURSE 100** 9:00 a.m.-4:00 p.m.  
Maestro, Fourth Floor, DoubleTree

**Director:** John R. Ewaldson, M.D.  
**Faculty:** Mark Erickson, M.D., Annette J. Hollander, M.D., David Mullen, M.D., Daniel R. Wilson, M.D.

**COURSE 101** 9:00 a.m.-4:00 p.m.  
Sonata 3, Fifth Floor, DoubleTree

### PTSD: AN HISPANIC UPDATE OF A UNIVERSAL PROBLEM (IN SPANISH)

**Director:** Luis F. Ramirez, M.D.  
**Faculty:** Jose M. Canive, M.D., Dora Cardona, M.D., Roxana Galeno, M.D., Daniel Toledo, M.D., Renato D. Alarcon, M.D.

**COURSE 102** 9:00 a.m.-4:00 p.m.  
Sonata 5, Fifth Floor, DoubleTree

### THE CONCEPTUAL BASIS OF PSYCHIATRY

**Co-Directors:** S. Nassir Ghaemi, M.D., David H. Brendel, M.D.

#### LECTURE 24

9:00 a.m.-10:30 a.m.  
Rooms 109 A/B, Street Level, Convention Center

#### APA'S ADMINISTRATIVE PSYCHIATRY AWARD LECTURE

Steven S. Sharfstein, M.D.

*Does the Psychiatric Hospital Have a Future?*

**Chp.:** William H. Reid, M.D.  
**Co-Chp.:** S. Atezaz Saeed, M.D.

Ten years ago, in response to managed care's challenge to psychiatric hospital treatment and lengths of stay, Sheppard and Enoch Pratt Hospital, a not-for-profit, freestanding psychiatric hospital in Baltimore, began reorganization to become a continuum of care, the Sheppard Pratt Health System. Steven S. Sharfstein, M.D., President and Chief Executive Officer, describes the hospital's reinvention, considers the forms that psychiatric hospitals are likely to take in the future, and discusses his personal experiences as a psychiatrist/administrator facing intensive change. Dr. Sharfstein is also Clinical Professor and Vice Chairman of the Department of Psychiatry at the University of Maryland. A Fellow of the APA, Dr. Sharfstein formerly served as APA Secretary and Chairperson of the Ethics Appeals Board. He currently is Vice Chairperson of the APA Joint Commission on Government Relations and the Committee on Reimbursement for Psychiatric Care. He is the author of 150 professional articles and book chapters and the author or editor of ten books. Dr. Sharfstein graduated from Albert Einstein College of Medicine in New York, completed his residency in psychiatry at the Massachusetts Mental Health Center in Boston, and holds a master's degree in public administration from the John F. Kennedy School of Government at Harvard University.

**THIS SESSION WILL BE AUDIOTAPED.**

## WORKSHOPS

### COMPONENTS 50-55

**COMPONENT WORKSHOP 50** 9:00 a.m.-10:30 a.m.  
Room 104 A, Street Level, Convention Center

#### CAREER CHOICES IN PSYCHIATRY

*APA Assembly Committee of Area Member-in-Training Representatives*

**Co-Chps.:** Shauna P. Reinblatt, M.D., Pamela J. Petersen-Craig, M.D.  
**Participants:** Blaine S. Greenwald, M.D., Keith W. Young, M.D., Scott Masters, M.D.

**COMPONENT WORKSHOP 51** 9:00 a.m.-10:30 a.m.  
Room 104 B, Street Level, Convention Center

**CODING AND DOCUMENTATION UPDATE**  
*APA Committee on RBR VS, Codes, and Reimbursements*

**Co-Chps.:** Chester W. Schmidt, Jr., M.D., Tracy R. Gordy, M.D.  
**Participants:** Ronald A. Shellow, M.D., Gerald Rogan, M.D.,  
Joseph M. Schwartz, M.D., Edward Gordon, M.D.

**COMPONENT WORKSHOP 52** 9:00 a.m.-10:30 a.m.  
Rooms 107 A/B, Street Level, Convention Center

**PSYCHOLOGICAL ISSUES OF PEOPLE LIVING  
LONGER WITH HIV**  
*APA Commission on AIDS*

**Chp.:** Warren M. Liang, M.D.  
**Participants:** Karl Goodkin, M.D., Ellen M. Tedaldi, M.D.,  
Robert S. Stasko, M.D.

**COMPONENT WORKSHOP 53** 9:00 a.m.-10:30 a.m.  
Room 111 B, Street Level, Convention Center

**INFORMATION TECHNOLOGY: CORE  
COMPETENCIES FOR PSYCHIATRISTS**  
*APA Committee on Information Technology*

**Chp.:** Ronnie S. Stangler, M.D.  
**Participants:** Thomas A.M. Kramer, M.D., Zebulon C.  
Taintor, M.D., David F. McMahon, M.D.

**COMPONENT WORKSHOP 54** 9:00 a.m.-10:30 a.m.  
Washington C, Third Floor, Loews

**SURGEON GENERAL'S REPORT ON CULTURE,  
RACE, AND ETHNICITY: CLINICAL IMPLICATIONS**  
*APA Council on National Affairs*

**Co-Chps.:** Sylvia W. Olarte, M.D., Theresa M. Miskimen, M.D.  
**Participants:** Robert P. Cabaj, M.D., Nang Du, M.D., R. Dale  
Walker, M.D.

**COMPONENT WORKSHOP 55** 9:00 a.m.-10:30 a.m.  
Rooms 401-403, Level 4, Marriott

**BAD BOYS, BAD GIRLS: THE DEMONIZATION OF  
ADOLESCENCE**  
*APA Committee on Juvenile Justice Issues*

**Chp.:** Louis J. Kraus, M.D.  
**Participants:** Michael G. Kalogerakis, M.D., Daphne  
Dorce, M.D., Lois T. Flaherty, M.D., William Arroyo, M.D.

**ISSUES 96-112**

**ISSUE WORKSHOP 96** 9:00 a.m.-10:30 a.m.  
Rooms 102 A/B, Street Level, Convention Center

**STIGMA STAYED: THE COST OF PREJUDICE IN  
HIGH PLACES**

**Chp.:** Karl S. Burgoyne, M.D.  
**Participants:** Milton H. Miller, M.D., Marvin Southard, D.S.W.,  
James Allen, M.B.A.

**ISSUE WORKSHOP 97** 9:00 a.m.-10:30 a.m.  
Room 103 A, Street Level, Convention Center

**THE OTHER SIDE OF THE MOUNTAIN: FROM  
RESIDENCY TO REALITY**

**Chp.:** Stephen M. Goldfinger, M.D.  
**Participants:** Deborah J. Hales, M.D., Mary Kay Smith, M.D.,  
Ronald C. Albucher, M.D.

**ISSUE WORKSHOP 98** 9:00 a.m.-10:30 a.m.  
Room 103 C, Street Level, Convention Center

**TOWARDS GLOBAL DECRIMINALIZATION OF  
DRUG ADDICTION**

**Co-Chps.:** Rodrigo A. Munoz, M.D., Guido Belsasso, M.D.  
**Participants:** Gretchen Bergman, Pedro Ruiz, M.D., Jorge A.  
Zapatel, M.D., Harold I. Eist, M.D., Maria C. Bayon, M.D.

**ISSUE WORKSHOP 99** 9:00 a.m.-10:30 a.m.  
Rooms 112 A/B, Street Level, Convention Center

**POEMS ON PSYCHIATRY**

**Chp.:** Charles R. Joy, M.D.

**ISSUE WORKSHOP 100** 9:00 a.m.-10:30 a.m.  
Room 113 A, Street Level, Convention Center

**HOW TO GIVE A MORE EFFECTIVE LECTURE:  
PUNCH, PASSION, AND POLISH**

**Chp.:** Phillip J. Resnick, M.D.

**ISSUE WORKSHOP 101** 9:00 a.m.-10:30 a.m.  
Room 113 B, Street Level, Convention Center

**TEACHING PRIMARY CARE RESIDENTS ABOUT  
DEPRESSION AND SUICIDE: CAN TECHNOLOGY  
ALTER OUTCOMES?**

**Chp.:** Donna M. Sudak, M.D.  
**Participant:** Rory P. Houghtalen, M.D.



## THURSDAY

---

**ISSUE WORKSHOP 102** 9:00 a.m.-10:30 a.m.  
Room 113 C, Street Level, Convention Center

### RELIGIOUS AND SPIRITUAL ASSESSMENT IN CLINICAL PRACTICE

**Chp.:** Francis G. Lu, M.D.  
**Participant:** Christina M. Puchalski, M.D.

**ISSUE WORKSHOP 103** 9:00 a.m.-10:30 a.m.  
Room 201 A, Level 200, Convention Center

### LITHIUM REVISITED: INTEGRATING RECENT FINDINGS INTO CLINICAL PRACTICE

**Co-Chps.:** Robert T. Dunn, M.D., Eric G. Smith, M.D.  
**Participants:** Frederick K. Goodwin, M.D., Michael J. Gitlin, M.D.

**ISSUE WORKSHOP 104** 9:00 a.m.-10:30 a.m.  
Room 201 B, Level 200, Convention Center

### THE DISRUPTIVE PHYSICIANS AND HOSPITAL CULTURE

**Co-Chps.:** Glenn N. Siegel, M.D., Mary Pittman, M.S.

**ISSUE WORKSHOP 105** 9:00 a.m.-10:30 a.m.  
Room 201 C, Level 200, Convention Center

### EVIDENCE-BASED TABLES OF SIDE EFFECTS OF PSYCHOTROPIC MEDICATIONS: USEFUL?

**Co-Chps.:** David N. Osser, M.D., Andrew A. Sassani, M.D.  
**Participants:** Alfredo Martija, M.D., Alexandrina Darabus, M.D., Michael J. Kittay, M.D.

**ISSUE WORKSHOP 106** 9:00 a.m.-10:30 a.m.  
Room 203 B, Level 200, Convention Center

### USING YOUR PSYCHIATRIC SKILLS TO BUILD A PRODUCTIVE TEAM AT WORK

**Chp.:** Saul M. Levin, M.D.  
**Participant:** Judy L. Stange, Ph.D.

**ISSUE WORKSHOP 107** 9:00 a.m.-10:30 a.m.  
Room 204 A, Level 200, Convention Center

### THE FRONTIER OF PUBLIC HEALTH PSYCHIATRY: PREVENTING SUICIDE

*Substance Abuse and Mental Health Services Administration*

**Chp.:** Eric D. Caine, M.D.  
**Participants:** David A. Litts, O.D., Madelyn Gould, Ph.D., Yeates Conwell, M.D.

**ISSUE WORKSHOP 108** 9:00 a.m.-10:30 a.m.  
Room 204 B, Level 200, Convention Center

### MEDICATION USE FOR CHILDREN IN SYSTEMS OF CARE

*Substance Abuse and Mental Health Services Administration*

**Co-Chps.:** Rolando Santiago, Ph.D., David Fassler, M.D.  
**Participants:** Wayne Holden, Ph.D., Andres J. Pumariega, M.D., Peter S. Jensen, M.D., Gayle Porter, Psy.D.

**ISSUE WORKSHOP 109** 9:00 a.m.-10:30 a.m.  
Room 204 C, Level 200, Convention Center

### WORKING THROUGH IN PSYCHOTHERAPY

**Chp.:** Steven H. Lipsius, M.D.

**ISSUE WORKSHOP 110** 9:00 a.m.-10:30 a.m.  
Washington A, Third Floor, Loews

### ALPHA-DOWN EEG BIOFEEDBACK: A NOVEL TREATMENT FOR ANXIETY

**Chp.:** Thomas M. Brod, M.D.  
**Participants:** William M.W. Scott, M.D., Meredith L. Sagan, M.D.

**ISSUE WORKSHOP 111** 9:00 a.m.-10:30 a.m.  
Washington B, Third Floor, Loews

### JOINING FORCES: WORKING WITH LAW ENFORCEMENT TO SERVE THE MENTALLY ILL

**Chp.:** Debra A. Pinals, M.D.  
**Participants:** Heidi S. Vermette, M.D., Richard M. Stanley, Kamlyn R. Haynes, M.D.

**ISSUE WORKSHOP 112** 9:00 a.m.-10:30 a.m.  
Congress Rooms A-C, Fourth Floor, Loews

### ERIK ERIKSON EPIGENESIS AS DEPICTED IN ANDREW LLOYD WEBBER'S MUSICALS

**Co-Chps.:** Hani Raoul Khouzam, M.D., Robert W. Hierholzer, M.D.

---

## 11:00 a.m. Sessions

---

**MEDICAL UPDATE 4**  
11:00 a.m.-12:30 p.m.  
Room 103 A, Street Level, Convention Center

### COMPREHENSIVE HIV CARE: TREATMENT AND SERVICE UPDATE

**Chp.:** Velda Y. Rexach, M.D.  
**Presenter:** Marla J. Gold, M.D.  
**THIS SESSION WILL BE AUDIOTAPED.**

## RESEARCH CONSULTATION WITH

11:00 a.m.-12:30 p.m.

This session is limited to 25 participants on a first-come, first-served basis.

- 3 Elizabeth B. Weller, M.D., on Bipolar Disorders in Children and Adolescents  
Adams Room, Third Floor, Loews

## SCIENTIFIC AND CLINICAL REPORT SESSIONS 34-42

## SCIENTIFIC AND CLINICAL REPORT SESSION 34

11:00 a.m.-12:30 p.m.

Room 103 B, Street Level, Convention Center

## FORENSIC PSYCHIATRY

Chp.: Rahn K. Bailey, M.D.  
Co-Chp.: Thomas G. Cobb, M.D.

11:00 a.m.

- 99 Medications, Strange Intoxications, and Violent Crime  
Michael M. Welner, M.D.

11:30 a.m.

- 100 Treating Mentally Ill Offenders in a Residential Treatment Unit  
Cristinel M. Coconcea, M.D., Nicoleta Coconcea, M.D.

12 noon

- 101 Presidential Assassination Syndrome Revisited: New Understanding  
David A. Rothstein, M.D.

THIS SESSION WILL BE AUDIOTAPED.

## SCIENTIFIC AND CLINICAL REPORT SESSION 35

11:00 a.m.-12:30 p.m.

Room 103 C, Street Level, Convention Center

## ISSUES IN TRAUMA AND VIOLENCE

Chp.: Sandra L. Bloom, M.D.  
Co-Chp.: Richard P. Kluff, M.D.

11:00 a.m.

- 102 Predicting Chronicity in Vietnam Veterans with PTSD: New Findings from the National Vietnam Veterans Readjustment Study  
Randall D. Marshall, M.D., J. Blake Turner, Ph.D., Roberto Lewis-Fernandez, M.D., Karestan Koenan, Ph.D., Yuval Yuria, M.D., Bruce Dohrenwend, Ph.D.

11:30 a.m.

- 103 Community and Inpatient Violence in Major Psychiatric Disorders  
Menahem I. Krakowski, M.D.

12 noon

## 104 Parental Separation at Birth and Criminality in Adulthood

Pirjo H. Maki, M.D., Helina Hakko, Ph.D., Matti Joukamaa, Ph.D., Matti K. Isohanni, M.D., Juha M. Veijola, M.D.

THIS SESSION WILL BE AUDIOTAPED.

## SCIENTIFIC AND CLINICAL REPORT SESSION 36

11:00 a.m.-12:30 p.m.

Room 113 B, Street Level, Convention Center

## USES OF ANTIPSYCHOTICS

Chp.: Harvey Stabinsky, M.D.  
Co-Chp.: Paul E. Holtzheimer III, M.D.

11:00 a.m.

- 105 Polypharmacy in Patients with Schizophrenia  
Robert E. McCue, M.D., Rubina Waheed, M.D., Leonel Urcuyo, M.D.

11:45 a.m.

- 106 The Use of Atypical Antipsychotics in Adults with Developmental Disability  
Karen J. Shedlack, M.D., Christine Magee, M.S., Robert Sisson, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

## SCIENTIFIC AND CLINICAL REPORT SESSION 37

11:00 a.m.-12:30 p.m.

Room 113 C, Street Level, Convention Center

## MOOD DISORDERS IN CHILDREN

Chp.: Jodi E. Star  
Co-Chp.: Daniel A. Nelson, M.D.

11:00 a.m.

- 107 Anxiety Disorders in Children and Adolescents with Bipolar Disorder  
Giulio Perugi, M.D., Gabriele Masi, M.D., Christina Toni, M.D., Maria Mucci, M.D., Stefania Millepiedi, M.D., Hagop S. Akiskal, M.D.

11:30 a.m.

- 108 Comorbidity in Child and Adolescent Major Depression  
Atilla Turgay, M.D., David Ng, M.D., Lillian Mok, M.D., Joanna Blanchard, M.A.

12 noon

- 109 Evaluation and Intervention of Prodromal Symptoms of Bipolar I Disorder  
Mohammad Z. Hussain, M.D., Zabaida A. Chaudhry, M.D., Seema Hussain, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 38

11:00 a.m.-12:30 p.m.

Room 204 A, Level 200, Convention Center

ISSUES IN DEPRESSION

Chp.: Teodor T. Postolache, M.D.

Co-Chp.: Mercedes M. Rodriguez, M.D.

11:00 a.m.

- 110 **Dysthymic Disorder: Integrating Research Findings into Clinical Treatment**

David J. Hellerstein, M.D.

11:30 a.m.

- 111 **Effect of Adjunct Modafinil on Energy and Concentration in Depressed Patients**

Matthew A. Menza, M.D., Karl Doghramji, M.D.,  
xRonald R. Fieve, M.D., Murray H. Rosenthal, D.O.

12 noon

- 112 **Parental Separation at Birth and Depression in Adulthood**

Juha M. Veijola, M.D., Pirjo H. Maki, M.D., Matti Joutamaa, Ph.D., Helina Hakko, Ph.D., Matti K. Isohanni, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 39

11:00 a.m.-12:30 p.m.

Room 204 B, Level 200, Convention Center

CLINICAL APPROACHES IN SCHIZOPHRENIA

Chp.: Abel A. Gonzalez, M.D.

Co-Chp.: Donald M. Hilty, M.D.

11:00 a.m.

- 113 **Low-Frequency Transcranial Magnetic Stimulation Curtails Medication-Resistant Auditory Hallucinations**

Ralph E. Hoffman, M.D., Keith A. Hawkins, Psy.D.,  
Faddie H. Rachid, M.D., Ralitza Gueorguieva, Ph.D.,  
Kathleen M. Carroll, Ph.D., Nashaat N. Boutros, M.D.,  
John H. Krystal, M.D.

11:30 a.m.

- 114 **Sibutramine Treatment of Obesity in Schizophrenia**

Ljiljana Radulovic, M.D., Peter J. Weiden, M.D., David B. Allison, Ph.D., Catherine Camille, M.A.

12 noon

- 115 **The Stabilization Phase of Schizophrenia: A Review of the Literature**

Peter J. Weiden, M.D., Judy Greene, B.A., Nina R. Schooler, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 40

11:00 a.m.-12:30 p.m.

Room 204 C, Level 200, Convention Center

MANAGED CARE AND HEALTH CARE FINDINGS

Chp.: David A. Casey, M.D.

Co-Chp.: Daniel P. Chapman, M.D.

11:00 a.m.

- 116 **Alzheimer's Disease Increases Costs of Comorbidities in Medicare-Managed Care**

Howard Fillit, M.D., Jerrold W. Hill, Ph.D., Robert Futterman, Ph.D., John R. Lloyd, B.S., Vera Mastey, M.S.

11:30 a.m.

- 117 **Donepezil Is Associated with Lower Health Care Costs in Medicare-Managed Care**

Jerrold W. Hill, Ph.D., Howard Fillit, M.D., Robert Futterman, Ph.D., Vera Mastey, M.S.

12 noon

- 118 **Managed Care and Malpractice Liability: Update 2002**

Eugene L. Lowenkopf, M.D., Abe M. Rychik, J.D.

SCIENTIFIC AND CLINICAL REPORT SESSION 41

11:00 a.m.-12:30 p.m.

Congress Rooms A-C, Fourth Floor, Loews

TREATMENT TECHNIQUES

Chp.: Gary S. Sachs, M.D.

Co-Chp.: David M. McDowell, M.D.

11:00 a.m.

- 119 **Matching Treatment to Type of Poor-Prognostic, Substance-Dependent Patients**

Edward Gottheil, M.D., Charles C. Thornton, Ph.D.,  
Stephen P. Weinstein, Ph.D.

11:30 a.m.

- 120 **Tiagabine, a Selective GABA Reuptake Inhibitor for the Treatment of Anxiety**

Daniel L. Crane, M.D.

12 noon

- 121 **Adjunctive Use of Tiagabine with Antidepressants in PTSD**

Michael E. Lara, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 42

11:00 a.m.-12:30 p.m.

Rooms 401-403, Level 4, Marriott

TRENDS IN SUICIDE RATES

Chp.: David I. Greenspan, M.D.

Co-Chp.: Hagit Bat-Avi, M.D.

(Continued on next page)

11:00 a.m.  
**122 Female Suicides in Texas Cities: 1994-1998**  
 Veena R. Doddakashi, M.D., Richard Wilcox, Ph.D.,  
 Lawrence A. Hauser, M.D.

11:30 a.m.  
**123 Trends in Suicide Rates in New York City:  
 Implications for a Prevention Initiative**  
 Neal L. Cohen, M.D., Susan Wilt, Ph.D.

12 noon  
**124 Changing Suicide Rates in Europe: Possible Causes**  
 Zoltan Rihmer, M.D., Annamaria Rihmer  
**THIS SESSION WILL BE AUDIOTAPED.**

**WORKSHOPS**

**COMPONENTS 56-57**

**COMPONENT WORKSHOP 56** 11:00 a.m.-12:30 p.m.  
 Room 104 A, Street Level, Convention Center

**GUIDELINES FOR THE TREATMENT OF SUICIDAL  
 BEHAVIORS**  
*APA Steering Committee on Practice Guidelines*

**Chp.:** John S. McIntyre, M.D.  
**Participants:** Douglas G. Jacobs, M.D., Yeates Conwell, M.D.

**COMPONENT WORKSHOP 57** 11:00 a.m.-12:30 p.m.  
 Room 104 B, Street Level, Convention Center

**ASIAN AMERICANS IN INTERMARRIAGES:  
 PSYCHOSOCIAL ADJUSTMENT AND IDENTITY**  
*APA Caucus of Asian-American Psychiatrists*

**Chp.:** Jagannathan Srinivasaraghavan, M.D.  
**Participants:** Prakash N. Desai, M.D., Kathleen M. Kim, M.D.,  
 Francis G. Lu, M.D., Cynthia M. Nguyen, M.D.

**ISSUES 113-119**

**ISSUE WORKSHOP 113** 11:00 a.m.-12:30 p.m.  
 Rooms 112 A/B, Street Level, Convention Center

**BRIDGES FOR HEALING: INTEGRATING FAMILY  
 THERAPY AND PSYCHOPHARMACOLOGY**

**Chp.:** Roy O. Resnikoff, M.D.

**ISSUE WORKSHOP 114** 11:00 a.m.-12:30 p.m.  
 Room 201 B, Level 200, Convention Center

**VIDEO CASE STUDIES OF COUPLES IN  
 TREATMENT**

**Chp.:** Ian E. Alger, M.D.

**ISSUE WORKSHOP 115** 11:00 a.m.-12:30 p.m.  
 Room 201 C, Level 200, Convention Center

**OUTPATIENT COMMITMENT: KENDRA'S LAW  
 AND THE NEW YORK CITY EXPERIENCE**

**Co-Chps.:** David A. Trachtenberg, M.D., Michael S. Lesser, M.D.  
**Participants:** Scott D. Rogge, M.D., Daniel Garza, M.D.,  
 Robert H. Berger, M.D.

**ISSUE WORKSHOP 116** 11:00 a.m.-12:30 p.m.  
 Room 202 B, Level 200, Convention Center

**CREATING EFFECTIVE ALLIANCES WITH  
 PHARMACEUTICAL INDUSTRY PHYSICIANS**

**Chp.:** Arthur L. Lazarus, M.D.  
**Participants:** Paul E. Keck, Jr., M.D., David L. Garver, M.D.,  
 Rajiv Tandon, M.D.

**ISSUE WORKSHOP 117** 11:00 a.m.-12:30 p.m.  
 Room 203 A, Level 200, Convention Center

**SUBSTANCE ABUSE PREVENTION AND  
 TREATMENT: A PSYCHIATRIC PERSPECTIVE**  
*Substance Abuse and Mental Health Services Administration*

**Chp.:** Sheila Harmison, D.S.W.  
**Participants:** Ruth Sanchez-Way, Ph.D., H. Westley Clark, M.D.

**ISSUE WORKSHOP 118** 11:00 a.m.-12:30 p.m.  
 Room 203 B, Level 200, Convention Center

**HOW TO DEVELOP A LECTURE**

**Co-Chps.:** Marianne T. Guschwan, M.D., Susan Tapert, Ph.D.  
**Participants:** Christopher J. Welsh, M.D., Donna L. Londino, M.D.

**ISSUE WORKSHOP 119** 11:00 a.m.-12:30 p.m.  
 Washington A, Third Floor, Loews

**A CLINICIAN'S GUIDE TO SUBSTANCE ABUSE  
 TREATMENT FOR GAY, LESBIAN, BISEXUAL, AND  
 TRANSGENDER PERSONS**  
*Substance Abuse and Mental Health Services Administration*

**Chp.:** Saul M. Levin, M.D.  
**Participants:** Frank Y. Wong, Ph.D., Michele J. Eliason, Ph.D.

**12 noon Sessions**

**FORUMS 12-13**

**FORUM 12** 12 noon-1:30 p.m.  
 Rooms 102 A/B, Street Level, Convention Center

**PSYOP: PSYCHOLOGICAL OPERATIONS IN THE  
 WAR AGAINST TERRORISM**

**Chp.:** Ronnie S. Stangler, M.D.

**FORUM 13** 12 noon-1:30 p.m.  
Rooms 107 A/B, Street Level, Convention Center

**THE PHARMACEUTICAL INDUSTRY AND THE APA:  
CONTROVERSIES AND APPROACHES**  
*APA Committee on Commercial Support*

**Chp.:** Stephen M. Goldfinger, M.D.  
**Participants:** Nyapati R. Rao, M.D., Troy L. Thompson II, M.D.,  
William B. Lawson, M.D., Anand Pandya, M.D., Philip R.  
Muskin, M.D., Paula G. Panzer, M.D., David S. Wahl, M.D.,  
Charles R. Goldman, M.D., James W. Thompson, M.D.

---

**2:00 p.m. Sessions**

---

**SYMPOSIA 76-93**

**SYMPOSIUM 76** 2:00 p.m.-5:00 p.m.  
Rooms 102 A/B, Street Level, Convention Center

**CULTURALLY COMPETENT MENTAL HEALTH  
CARE: IDENTIFYING AND REDUCING  
DISPARITIES**

**Chp.:** Carl C. Bell, M.D.  
**Co-Chp.:** Renato D. Alarcon, M.D.

- A Bipolar Disorder in African Americans**  
William B. Lawson, M.D.
- B Mental Health Care in Hispanic Populations: Clinical and  
Therapeutic Issues**  
Renato D. Alarcon, M.D.
- C Cultural Competence Standards for Mental Health Services**  
Francis G. Lu, M.D.
- D Race, Ethnicity, and Variations in Psychiatric Diagnosis  
and Treatment**  
Diane M. Herbeck, M.A., Carl C. Bell, M.D., Diana J. Fitek, B.A.,  
Joyce C. West, Ph.D.  
**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 77** 2:00 p.m.-5:00 p.m.  
Room 103 A, Street Level, Convention Center

**HIV TREATMENT DIMENSIONS AMONG DIVERSE  
ETHNIC AND CULTURAL POPULATIONS**  
*APA Commission on AIDS*

**Chp.:** Altha J. Stewart, M.D.

- A HIV-Positive Patient Panel**  
Altha J. Stewart, M.D.
- B Cultural Considerations for Treating HIV-Infected  
African-American Patients**  
Eric G. Bing, M.D.

**C Cultural Considerations for Treating HIV-Infected  
Latino Patients**  
Milton L. Wainberg, M.D.

**SYMPOSIUM 78** 2:00 p.m.-5:00 p.m.  
Room 103 B, Street Level, Convention Center

**BRAIN SUBSTRATES OF ADDICTION:  
NEUROIMAGING AS A TOOL OF CHOICE IN THE  
21ST CENTURY**

**Chp.:** Anna R. Childress, Ph.D.  
**Co-Chp.:** Charles P. O'Brien, M.D.

- A Using PET to Image the Neuroanatomical and  
Neurochemical Substrates of Cocaine Craving**  
Anna R. Childress, Ph.D., Paul Acton, Ph.D., Kyle M.  
Kampman, M.D., Teresa R. Franklin, Ph.D., Anna Fornash,  
Charles P. O'Brien, M.D.
- B Bold fMRI Versus Spin-Tagging in Cue-Induced  
Cocaine Craving (4T)**  
John M. Listerud, M.D., Jionjiong Wang, Ph.D., J. Detre, M.D.,  
Jason Gray, B.A., Charles P. O'Brien, M.D., Anna R. Childress, Ph.D.
- C Functional MRI During Heroin Craving in Methadone-  
Maintained Subjects**  
Daniel D. Langleben, M.D., Jionjiong Wang, Ph.D., Jason  
Gray, B.A., John M. Listerud, M.D., Charles P. O'Brien, M.D.,  
Anna R. Childress, Ph.D.
- D fMRI of Cue-Induced Nicotine Craving**  
Teresa R. Franklin, Ph.D., Jason Gray, B.A., Charles P.  
O'Brien, M.D., Anna R. Childress, Ph.D.
- E Brain Substrates for Self-Control May Be Defective in  
Addiction**  
John R. Monterosso, Ph.D., Ronald Ehram, Ph.D., Kimberly  
Napier, B.A., Anna R. Childress, Ph.D., Charles P. O'Brien, M.D.  
**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 79** 2:00 p.m.-5:00 p.m.  
Room 103 C, Street Level, Convention Center

**OPTIMAL STRATEGIES FOR IDENTIFYING AND  
TREATING TRAUMATIZED CHILDREN**

**Chp.:** Judith A. Cohen, M.D.

- A Screening for Traumatic Exposure and PTSD  
Symptoms in Pediatric Settings**  
Anthony P. Mannarino, Ph.D., Judith A. Cohen, M.D.,  
Daphne Ruben, L.C.S.W.
- B Cognitive-Behavioral Therapy for Traumatized Children  
and Their Parents**  
Esther Deblinger, Ph.D.
- C Developmental Traumatology: Neurobiological  
Development in Childhood PTSD**  
Michael D. DeBellis, M.D., Matcheri S. Keshavan, M.D.,  
Sue R. Beers, Ph.D., Neal D. Ryan, M.D.



**D Pharmacological Treatments for Traumatized Children**  
Judith A. Cohen, M.D.

**E Treating Child and Adolescent Victims of Crime: The New California Guidelines**  
Graeme Hanson, M.D.

THIS SESSION WILL BE AUDIOTAPED.

**SYMPOSIUM 80** 2:00 p.m.-5:00 p.m.  
Room 104 A, Street Level, Convention Center

**OPIATE-SUBSTITUTION TREATMENT:  
INTERNATIONAL TRENDS AND PERSPECTIVES**

**Chp.:** Richard N. Rosenthal, M.D.

**Co-Chp.:** Michael Krausz, Ph.D.

**A Buprenorphine: Experiences with Office-Based Substitution Treatment in Europe**  
Marc Auriacombe, M.D., Pascale Franques, M.D., Jean-Pierre Daulouede, M.D., Jean L. Tignol, M.D.

**B Morphine Maintenance in the Treatment of Heroin Addiction**  
Gabriele Fischer, M.D., Romana Ortner, M.D., Shiro Schindler, M.D., Harald Eder, M.D.

**C Is There a Gold Standard Medication in Opiate-Substitution Treatment?**  
Robert G. Newman, M.D.

**D Heroin-Assisted Treatment Approaches in Europe**  
Wim Van Den Brink, M.D., Vincent Hendriks, Ph.D., Peter Blaken, M.A., Jan Van Ree

**E Outcome Criteria and Guidelines from an International Point of View**  
Richard N. Rosenthal, M.D.

**Discussant:** Thomas R. Kosten, M.D.

THIS SESSION WILL BE AUDIOTAPED.

**SYMPOSIUM 81** 2:00 p.m.-5:00 p.m.  
Room 104 B, Street Level, Convention Center

**ALCOHOL INTERVENTIONS ACROSS THE SPECTRUM FOR COMMUNITY PRACTITIONERS**  
*Substance Abuse and Mental Health Services Administration*

**Chp.:** Sheila B. Blume, M.D.

**A Underage Drinking: Changing Community Norms**  
Robert Voas, Ph.D.

**B Identification of Fetal Alcohol Syndrome: Differentiating Developmental Disorders from Fetal Alcohol Syndrome**  
Larry J. Burd, Ph.D., Jacob Kerbeshian, M.D.

**C Implementing Naltrexone in Alcohol Treatment in Community Settings**  
Sherrie Gillette, M.A.

**D Multisystemic Treatment of Alcohol-Abusing Adolescents: Outcomes**  
Scott W. Henggeler, Ph.D., Colleen A. Halliday-Boykins, Ph.D., Philippe B. Cunningham, Ph.D., Jeff Randall, Ph.D.

**E Implementing Motivational Enhancement Therapy**  
Allen Zweben, D.S.W.

THIS SESSION WILL BE AUDIOTAPED.

**SYMPOSIUM 82** 2:00 p.m.-5:00 p.m.  
Rooms 106 A/B, Street Level, Convention Center

**THE SCHIZOPHRENIA PRODROME: UPDATE OF RESEARCH 2002**

**Chp.:** Scott W. Woods, M.D.

**A Intervention in the Schizophrenic Prodrome: Rationale, Studies, and Ethics**  
Thomas H. McGlashan, M.D., Robert B. Zipursky, M.D., Diana O. Perkins, M.D., Jean M. Addington, Ph.D., Mauricio F. Tohen, M.D., Alan Ereier, M.D., Scott W. Woods, M.D.

**B Diagnosis and Symptom Assessment in the Schizophrenia Prodrome**  
Tandy J. Miller, Ph.D., Thomas H. McGlashan, M.D., Joanna L. Rosen, Ph.D., Jaak Rakkfeldt, M.D., Shelly Nyman-Rose, M.S.W., Phillip Markovich, B.A., Scott W. Woods, M.D.

**C A Trial of Olanzapine Versus PBO in the Prodrome: Protocol and Baseline Sample**  
Alan F. Breier, M.D., Robert B. Zipursky, M.D., Diana O. Perkins, M.D., Jean M. Addington, Ph.D., Mauricio F. Tohen, M.D., Stacy R. David, Ph.D., Thomas H. McGlashan, M.D.

**D Neuropsychological Status of the First-Episode Prodrome**  
Keith A. Hawkins, Psy.D., Diana O. Perkins, M.D., Jean M. Addington, Ph.D., Robert B. Zipursky, M.D., Kimberly B. Edwards, Ph.D., Stacy R. David, Ph.D., Thomas H. McGlashan, M.D.

**E MRI and MRS Findings in Subjects with Prodromal Symptoms**  
Diana O. Perkins, M.D., Robert B. Zipursky, M.D., Guido Geric, Ph.D., Cecil Charles, Ph.D., Hongbin Gu, Ph.D., Jeffrey A. Lieberman, M.D.

**F Olanzapine Versus Placebo for Prodromal Symptoms**  
Scott W. Woods, M.D., Robert B. Zipursky, M.D., Diana O. Perkins, M.D., Jean M. Addington, Ph.D., Tandy J. Miller, Ph.D., Alan F. Breier, M.D., Thomas H. McGlashan, M.D.

THIS SESSION WILL BE AUDIOTAPED.

**SYMPOSIUM 83** 2:00 p.m.-5:00 p.m.  
Rooms 107 A/B, Street Level, Convention Center

**THE DUTY TO WARN AND PROTECT FOR THE 21ST-CENTURY PSYCHIATRIST**

**Chp.:** Alan R. Felthous, M.D.

**Co-Chp.:** Claudia A. Kachigian, M.D.

**A The Fin de Millenaire: Duty to Warn or Protect?**  
Alan R. Felthous, M.D., Claudia A. Kachigian, M.D.

**B Judicial Responses to Tarasoff Statutes**  
Claudia A. Kachigian, M.D., Alan R. Felthous, M.D.

**C Novel Approaches to Tarasoff**  
Ralph Slovenko, L.L.B.

**D Encroachments on Psychotherapist-Patient Privilege**  
Robert Weinstock, M.D.

**E Risk Assessment in Tarasoff Situations**  
Randy Borum, Psy.D.

Discussant: Paul S. Appelbaum, M.D.  
**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 84** 2:00 p.m.-5:00 p.m.  
Room 111 B, Street Level, Convention Center

**CLINICAL CHALLENGES IN TREATING SCHIZOPHRENIA**

Chp.: Prakash S. Masand, M.D.

**A From First Psychotic Episode to Long-Term Outcome in Schizophrenia**  
John L. Waddington, D.Sc., Paul J. Scully, M.D., David J. Meagher, M.D., John F. Quinn, M.D., Patizia A. Baldwin, M.D., Maria G. Morgan, M.D., Anthony Kinsella, M.S.C.

**B PET Imaging Studies of Atypical Antipsychotics: Implications of Dosing and Mechanism of Action**  
Shitij Kapur, M.D.

**C Managing Violent Behavior in Patients with Schizophrenia: Emerging Standards of Care**  
Peter F. Buckley, M.D.

**D Augmentation Strategies in Treatment-Refractory Schizophrenia**  
Robert R. Conley, M.D., Deanna L. Kelly, Pharm.D.

**E Management of Long-Term Side Effects of Novel Antipsychotics**  
Prakash S. Masand, M.D.  
**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 85** 2:00 p.m.-5:00 p.m.  
Rooms 112 A/B, Street Level, Convention Center

**COGNITIVE THERAPY VERSUS MEDICATIONS FOR SEVERE DEPRESSION**

Chp.: Jan A. Fawcett, M.D.

**A Background and Design of a Placebo-Controlled Comparison**  
Robert J. DeRubeis, Ph.D., Jay D. Amsterdam, M.D., John P. O'Reardon, M.D., Paula R. Young, Ph.D.

**B Response to Acute Treatment**  
Jay D. Amsterdam, M.D., Robert J. DeRubeis, Ph.D., John P. O'Reardon, M.D., Paula R. Young, Ph.D.

**C Prevention of Relapse**  
Steven D. Hollon, Ph.D., Richard C. Shelton, M.D., Richard Salomon, M.D., Margaret Lovett, M.Ed.

**D Who Responds and Who Relapses**  
Richard C. Shelton, M.D., Steven D. Hollon, Ph.D., Richard Salomon, M.D., Margaret Lovett, M.Ed.  
**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 86** 2:00 p.m.-5:00 p.m.  
Room 113 A, Street Level, Convention Center

**REDUCING AGGRESSIVE BEHAVIOR: CHANGING THE TRAJECTORY FOR DRUG USE**  
*Substance Abuse and Mental Health Services Administration*

Chp.: Ralph E. Tarter, Ph.D.  
Co-Chp.: Oscar G. Bukstein, M.D.

**A Intimate Partner Violence Among Whites, Blacks, and Hispanics**  
Raul Caetano, M.D., Craig Field, Ph.D., Scott Nelson, B.A., Susie Miller, Ph.D., John Schafer, Ph.D.

**B Modifying Aggressive Behavior via Strategic Peer Involvement**  
Gerald August, Ph.D., George M. Realmuto, M.D., Joel Hektner

**C Cognitive-Behavioral Intervention for Aggressive Preadolescent Children (Ages 9-11)**  
John E. Lochman, Ph.D., Karen C. Wells, Ph.D.

**D Diagnostic-Specific Treatments for Adolescents with Substance-Use Disorders and Comorbidity**  
Oscar G. Bukstein, M.D.

**E Family, Psychiatric, Drug Use, and Social Predictors of Violence Between Adolescence and Adulthood**  
Ralph E. Tarter, Ph.D.  
**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 87** 2:00 p.m.-5:00 p.m.  
Room 113 B, Street Level, Convention Center

**NEW DEVELOPMENTS IN INTERPERSONAL PSYCHOTHERAPY RESEARCH**

Chp.: John C. Markowitz, M.D.

**A Maintenance Interpersonal Psychotherapy in Recurrent Depression: Appropriate for Which Patients?**  
Ellen Frank, Ph.D., David J. Kupfer, M.D., Holly A. Swartz, M.D., Kate Harkness, Ph.D., Patricia Houck

**B Treatment Strategies for Dysthmic Disorders**  
John C. Markowitz, M.D., Kathryn L. Bleiberg, Ph.D., James H. Kocsis, M.D.

**C Interpersonal Psychotherapy Groups for Low-Income Women with PTSD**  
Janice L. Krupnick, Ph.D., Bonnie L. Green, Ph.D., Jeanne Miranda, Ph.D.

**D Individual Interpersonal Psychotherapy for PTSD**  
Kathryn L. Bleiberg, Ph.D., John C. Markowitz, M.D.

**E Interpersonal Therapy Versus Supportive Therapy for Social Phobia**  
Joshua D. Lipsitz, Ph.D.

Discussant: Myrna M. Weissman, Ph.D.  
THIS SESSION WILL BE AUDIOTAPED.

**SYMPOSIUM 88** 2:00 p.m.-5:00 p.m.  
Room 113 C, Street Level, Convention Center

**TREATING MENTAL ILLNESS AND SUBSTANCE ABUSE IN THE CRIMINAL JUSTICE SYSTEM**  
*Substance Abuse and Mental Health Services Administration*

Chp.: Jeffrey L. Metzner, M.D.  
Co-Chp.: Michael English, Ph.D.

**A Family Drug Courts: Early Evaluation Findings**  
Nancy Young

**B Pelican Bay Super Max: Treatment in Correctional Settings**  
Shama Chaiken, Ph.D.

**C Jail Diversion: Mechanisms and Services**  
Henry Steadman

**D Successful Community Reintegration of Offenders with Mental Illness**  
Fred C. Osher, M.D.  
THIS SESSION WILL BE AUDIOTAPED.

**SYMPOSIUM 89** 2:00 p.m.-5:00 p.m.  
Room 201 B, Level 200, Convention Center

**TRAUMATIC RESPONSE TO DISASTER: NEUROBIOLOGY AND TREATMENT**

Chp.: Carol S. North, M.D.  
Co-Chp.: Elissa P. Benedek, M.D.

**A Neurobiological Mechanisms of PTSD**  
Dennis S. Charney, M.D.

**B The Range of Human Response to Catastrophic Trauma**  
Carol S. North, M.D.

**C Disaster Overview: Clinical Presentation National and International Perspectives**  
David Benedek, M.D.

**D Psychopharmacotherapy of PTSD in Children and Adolescents**  
Elizabeth B. Weller, M.D., Arman K. Danielyan, M.D., Ronald A. Weller, M.D.

**E Psychopharmacology of Traumatic Response in Adults**  
Richard Balon, M.D.

Discussant: Elissa P. Benedek, M.D.  
THIS SESSION WILL BE AUDIOTAPED.

**SYMPOSIUM 90** 2:00 p.m.-5:00 p.m.  
Room 201 C, Level 200, Convention Center

**PSYCHIATRY AND THE PHARMACEUTICAL INDUSTRY: WHERE IS THE BOUNDARY?**

Chp.: Amy C. Brodkey, M.D.

**A Pharmaceutical Promotion: There Is no Free Lunch**  
Amy C. Brodkey, M.D.

**B Academia, Medical Education, and the Pharmaceutical Industry**  
Frederick S. Sierles, M.D.

**C The Pharmaceutical Industry and Public Psychiatry**  
Robert M. Factor, M.D.

**D Industry-Supported Medical Education: When Educators Serve Two Masters**  
Diana M. Koziupa, M.D.  
THIS SESSION WILL BE AUDIOTAPED.

**SYMPOSIUM 91** 2:00 p.m.-5:00 p.m.  
Room 203 B, Level 200, Convention Center

**THE EMPLOYMENT INTERVENTION DEMONSTRATION PROJECT: OUTCOME OF BEST PRACTICE**

Chp.: William R. McFarlane, M.D.

**A Best Practice in Employment Research: Views from the Employment Intervention Demonstration Program Coordinating Center**  
Judith A. Cook, Ph.D.

**B The Hartford Study of Supported Employment for Severe Mental Illness: Employment and Nonvocational Outcomes**  
Kim T. Mueser, Ph.D., Robin E. Clark, Ph.D., Michael Haines, M.A., Robert E. Drake, M.D., Gary R. Bond, Ph.D., Deborah R. Becker, M.Ed., Gregory McHugo, Ph.D., Susan M. Essock, Ph.D., Rosemarie Wolfe, M.A., Anjana Sengupta, Ph.D.

**C Effects of Fact and an Employers Consortium on Employment in Severe Mental Illness**  
William R. McFarlane, M.D., William Cook, Ph.D., Richard Balsler, Cindy Boyak, M.D., Renee Leavitt, O.T.

**D Improving Employment Outcomes for Persons with Severe Mental Illness**  
Anthony F. Lehman, M.D.

**E Effectiveness of Long-Term Employment Support for Individuals with Severe Mental Illness**  
Laura E. Bianhertz, Ph.D.

(Continued next page)

## THURSDAY

---

**F Rural-Based Supported Employment Approaches: Results from the South Carolina Site of the Employment Intervention Demonstration Project**  
Neil Meisler, M.S.W.

**G The Texas EARNs Supported Employment Demonstration Project**  
Marcia Toprac, Ph.D., Sue K. Hoppe, Ph.D., Pamela Daggett, M.A., Kate Wambach, Ph.D., Steven Onken, Ph.D., Susan Burek, Shelley Blozis, Ph.D.

Discussant: Crystal Byler, Ph.D.

**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 92** 2:00 p.m.-5:00 p.m.

Room 204 A, Level 200, Convention Center

### TREATMENT OF ADHD: FROM CLINICAL TRIALS TO ROUTINE CLINICAL PRACTICE

Chp.: Benedetto Vitiello, M.D.

Co-Chp.: Farifteh F. Duffy, Ph.D.

**A The AACAP Stimulant Medication Practice Parameter for Treatment of ADHD**  
Laurence L. Greenhill, M.D.

**B Treatment of ADHD: From Multimodal Treatment ADHD Trials to Routine Psychiatric Practice**  
Peter S. Jensen, M.D.

**C Stimulant and Psychosocial Treatment of ADHD in Latino Children**  
Gloria Canino, Ph.D., Jose J. Bauermeister, Ph.D., Maritza Rubio-Stipec, Sc.D.

**D The Role of Comorbidity in the Treatment of ADHD in Routine Psychiatric Practice**  
Farifteh F. Duffy, Ph.D., William E. Narrow, M.D., Donald Rae, M.A.

**E Insurance Factors and ADHD Treatment in Psychiatric Practice**  
William E. Narrow, M.D., Donald Rae, M.A., Farifteh F. Duffy, Ph.D.

Discussant: Mark A. Riddle, M.D.

**THIS SESSION WILL BE AUDIOTAPED.**

**SYMPOSIUM 93** 2:00 p.m.-5:00 p.m.

Room 204 B, Level 200, Convention Center

### VIRTUAL REALITY AND MENTAL HEALTH: STATE OF THE ART AND FUTURE DIRECTIONS

Chp.: Henry J. Moller, M.D.

Co-Chp.: Albert A. Rizzo, Ph.D.

**A Virtual Environments: Using a Driving Simulator to Understand Consciousness**  
Henry J. Moller, M.D.

**B Embracing the Real World: Virtually fMRI and Virtual Reality**  
Konstantine K. Zakzanis, Ph.D.

**C Virtual Reality Neuropsychological Assessment and Rehabilitation: Present and Future**  
Albert A. Rizzo, Ph.D.

**D Application of Advanced Information Technologies in the Creation of Virtual Humans**  
Norman E. Alessi, M.D.

**E Virtual Reality Therapy: A Cost-Benefit Analysis**  
Mark D. Wiederhold, M.D.

**THIS SESSION WILL BE AUDIOTAPED.**

# 2002 ANNUAL MEETING

## TOPIC AREAS FOR THE SCIENTIFIC PROGRAM

### DISORDERS

1. AIDS and HIV-Related Disorders
2. Alcohol and Drug-Related Disorders
3. Anxiety Disorders
4. Attention Spectrum Disorders
5. Cognitive Disorders (Delirium, Dementia, Amnesic, etc.)
6. Eating Disorders
7. Mental Retardation (Child/Adolescent/Adult)
8. Mood Disorders
9. Personality Disorders
10. Schizophrenia and Other Psychotic Disorders
11. Sexual and Gender Identity Disorders
12. Sleep Disorders
13. Somatoform Disorders

### PRACTICE AREAS/SETTINGS

14. Psychiatric Administration and Services: Public, Private, and University
15. Other

### SUBSPECIALTY AREAS OR SPECIAL INTERESTS

16. Addiction Psychiatry
17. Biological Psychiatry and Neuroscience
18. Brain Imaging
19. Child and Adolescent Psychiatry and Disorders
20. Consultation-Liaison and Emergency Psychiatry
21. Cross-Cultural and Minority Issues
22. Diagnostic Issues
23. Epidemiology
24. Ethics and Human Rights
25. Forensic Psychiatry
26. Geriatric Psychiatry
27. Neuropsychiatry
28. Psychiatric Education
29. Psychiatric Rehabilitation

30. Psychoanalysis
31. Research Issues
32. Social and Community Psychiatry
33. Stress
34. Suicide
35. Violence, Trauma, and Victimization

### TREATMENTS

36. Behavior and Cognitive Therapies
37. Combined Pharmacotherapy and Psychotherapy
38. Couple and Family Therapies
39. Group Therapy
40. Individual Psychotherapies
41. Psychopharmacology
42. Other Somatic Therapies
43. Treatment Techniques and Outcome Studies

### OTHER ISSUES

44. Computers
45. Creativity and the Arts
46. Electronic Medical Records
47. Gender Issues
48. Health Services Research
49. Historical Questions
50. Information Technology
51. Lesbian/Gay/Bisexual/Transgender Issues
52. Managed Care and Health Care Funding
53. Men's Health Issues
54. Political Questions
55. Professional and Personal Issues
56. Religion, Spirituality, and Psychiatry
57. Resident and Medical Student Concerns
58. Presidential Theme: The 21<sup>st</sup> Century Psychiatrist
59. Stigma/Advocacy
60. Telepsychiatry
61. Virtual Reality
62. Women's Health Issues

---

---

### GUIDE TO USING THE TOPIC INDEX

Use this index to find sessions of interest to you. There are five overall topics: Disorders, Practice Areas/Settings, Subspecialty Areas or Special Interests, Treatments, and Other Issues. Under each overall topic, you will find subtopics listed in alphabetical order with the formats (type of session) listed alphabetically underneath. Within each format you will find the title of the individual session listed by number. The listing will also show the page number the session appears on. You should refer to the page number in this *Program Book* to obtain further details about the session.

## TOPIC INDEX

<b>DISORDERS</b>	<b>Page #</b>	<b>DISCUSSION GROUP</b>	<b>Page #</b>
<b>TOPIC 1: AIDS AND HIV-RELATED DISORDERS</b>		17 Managing Depression and Anxiety in Patients with Cancer and Other Medical Illnesses	44
<b>DISCUSSION GROUP</b>		<b>INDUSTRY-SUPPORTED SYMPOSIA</b>	
7 Working with HIV-Positive Patients and Their Physicians	20	2 Switching from Imipramine to Sertraline in Panic Disorder with Agoraphobia	22
<b>MEDICAL UPDATE</b>		3 Atypical Depression in Primary Anxiety Disorders	22
4 Comprehensive HIV Care: Treatment and Service Update	90	4 Risk Factors for PTSD in North Korean Defectors	22
<b>SYMPOSIA</b>		8 Mixed Anxiety Depressive Disorder in a Sample of Primary Care Patients	22
50 The Psychiatric Treatment of HIV Disease in the Third Decade of AIDS	61	<b>MASTER EDUCATOR CLINICAL CONSULTATION</b>	
77 HIV Treatment Dimensions Among Diverse Ethnic and Cultural Populations	94	12 Obsessive Compulsive and Related Disorders	73
<b>WORKSHOP - COMPONENT</b>		<b>SCIENTIFIC AND CLINICAL REPORTS</b>	
52 Psychological Issues of People Living Longer with HIV	89	17 PTSD Versus Panic Disorder: Differences in HPA Axis/ Noradrenergic Functioning	23
<b>WORKSHOP - ISSUE</b>		18 Beyond One-Year Imipramine Maintenance in Panic Disorder with Agoraphobia	23
54 HIV, AIDS, Hepatitis-C, Mental Illness, and Substance Abuse: Converging Illness	44	19 Social Phobia Treatment Survey	23
<b>TOPIC 2: ALCOHOL AND DRUG-RELATED DISORDERS</b>		25 Cigarette Smoking and Risk for Anxiety Disorders	23
<b>COURSE</b>		121 Adjunctive Use of Tiagabine with Antidepressants in PTSD	92
74 Integrated Model for Treatment of Co-Occurring Psychiatric and Substance Disorders	52	<b>SYMPOSIA</b>	
<b>FORUM</b>		28 Psychotic Symptoms in Chronic PTSD: Prevalence, Comorbidity, and Treatment	55
2 Leadership Challenges in Mental Health and Substance Abuse: A Meeting of the Minds	26	52 Social Anxiety Disorder and Comorbid Major Depression	61
<b>SCIENTIFIC AND CLINICAL REPORT</b>		<b>TOPIC 4: ATTENTION SPECTRUM DISORDERS</b>	
81 Ecstasy: Complications and Neurotoxicity	74	<b>COURSE</b>	
<b>SYMPOSIA</b>		93 Advanced Assessment and Treatment of ADD	78
21 Update on Treatment of Stimulant Abuse	33	<b>DISCUSSION GROUP</b>	
81 Alcohol Interventions Across the Spectrum for Community Practitioners	95	20 Psychopharmacologic Treatment of Comorbid Attention Disorders in Adults	67
<b>WORKSHOP - COMPONENT</b>		<b>INDUSTRY-SUPPORTED SYMPOSIA</b>	
25 Ambulatory Detoxification from Alcohol: How to Do It Well and Get Paid Too	49	5 New Approaches for Treating ADHD: The Whole-Life Perspective	3
<b>WORKSHOPS - ISSUES</b>		47 Adult ADHD: From Research to Clinical Practice	86
18 Breaking the Cycle of Maternal Addiction: An Integrated Treatment Program Making a Difference	20	<b>MASTER EDUCATOR CLINICAL CONSULTATION</b>	
28 What Works in Substance Abuse Treatment?	26	11 Adults with Learning Disabilities and Mood Disorders	69
36 National Commission on Marijuana and Drug Abuse Report: 30 Years Later	43	<b>TOPIC 5: COGNITIVE DISORDERS (DELIRIUM, DEMENTIA, AMNESTIC, ETC.)</b>	
43 Evidence-Based Treatment for Marijuana Dependence	43	<b>COURSE</b>	
49 Group Psychotherapy for Substance Abusers	44	27 Alzheimer's Disease: Advanced Approaches to Treatment	7
61 Methamphetamine Treatment: What Psychiatrists Need to Know	50	<b>DISCUSSION GROUP</b>	
70 Grievous Bodily Harm and Club Drugs: Treatment and Other Considerations	70	11 Delirium: Phenomenology, Neuropathogenesis, and Treatment Interrelationships	39
98 Towards Global Decriminalization of Drug Addiction	89	<b>INDUSTRY-SUPPORTED SYMPOSIA</b>	
117 Substance Abuse Prevention and Treatment: A Psychiatric Perspective	93	1 Psychiatry Practice Paradigm: The Emerging Role of the Psychiatrist in Treating Alzheimer's Disease	2
<b>TOPIC 3: ANXIETY DISORDERS</b>		43 Noncholinergic Treatments for Alzheimer's Disease: Present Knowledge, Future Hope	85
<b>COURSES</b>		<b>MEDIA PROGRAM</b>	
98 The Missing Piece of the Puzzle: TIC Disorders in Adults with OCD or ADD	88	2 Memento	12
101 PTSD: An Hispanic Update of a Universal Problem (In Spanish)	88		



<b>TOPIC 6: EATING DISORDERS</b>	<b>Page #</b>			<b>Page #</b>
<b>COURSES</b>				
10 Multimodal Treatment of Eating Disorders	2		25 Clinical Challenges in Depression, Part 1	13
25 Therapeutic Interventions in Eating Disorders: Basic Principles	7		25 Clinical Challenges in Depression, Part 2	37
<b>INDUSTRY-SUPPORTED SYMPOSIUM</b>			31 Bipolar Depression and Rapid Cycling: Current Management Strategies	63
48 Advances in the Understanding and Treatment of Binge-Eating Disorder	86		39 Age, Gender, and Diagnosis: Influences on Drug Response, Part 1	65
			39 Age, Gender, and Diagnosis: Influences on Drug Response, Part 2	87
<b>SCIENTIFIC AND CLINICAL REPORTS</b>			40 Therapeutic Challenges, Novel Approaches: Antipsychotics in the Management of Mood and Anxiety Disorders, Part 1	65
5 Perfectionism, Training, and Eating Behaviors in Runners	22		40 Therapeutic Challenges, Novel Approaches: Antipsychotics in the Management of Mood and Anxiety Disorders, Part 2	87
6 Self-Reported Hunger and Parasympathetic Tone	22			
7 Topiramate Treatment of Bulimia Nervosa	22		<b>LECTURE</b>	
114 Sibutramine Treatment of Obesity in Schizophrenia	92		13 What Can Late Life Teach Us About Depression?	53
<b>SYMPOSIA</b>			<b>RESEARCH CONSULTATION</b>	
6 Eating Disorders 2002: Biological, Clinical, and Social Perspectives	30		1 Depressed Patients with Heart Disease and Late-Life Depression	46
43 What's New in Eating Disorders: A Clinical Research Treatment Update	59		<b>REVIEW OF PSYCHIATRY: SECTION 1</b>	
			Treatment of Recurrent Depression: A Call to Arms	29
<b>TOPIC 7: MENTAL RETARDATION (CHILD/ADOLESCENT/ADULT)</b>			<b>SCIENTIFIC AND CLINICAL REPORTS</b>	
<b>SCIENTIFIC AND CLINICAL REPORT</b>			17 Fluoxetine-Induced Weight Change in Depressive Subtypes	23
106 The Use of Atypical Antipsychotics in Adults with Developmental Disability	91		18 Adjunct Modafinil for Fatigue and Wakefulness in MDD	23
			19 Short-Term Use of Estradiol as an Antidepressant Strategy in Perimenopausal and Postmenopausal Women	23
<b>TOPIC 8: MOOD DISORDERS</b>			20 A Comparison of the Prevalence and Correlates of Anger Attacks in Bipolar Disorder	23
<b>ADVANCES IN PSYCHOPHARMACOLOGY</b>			21 Topiramate Treatment of Rapid-Cycling Mood Disorder	23
Anticonvulsants as Mood Stabilizers	28		22 Cognitive and Psychosocial Deficits in Bipolar Disorder and Schizophrenia	23
<b>ADVANCES IN RESEARCH</b>			49 Increased Rates of Antipsychotic-Induced EPS in Mood Disorders: Myth or Reality?	47
Depression and Coronary Heart Disease: Epidemiology, Treatment, And Mechanisms	20		50 Cyclothymia in Atypical Depression: The Borderline-Bipolar II Connection	48
Depression, Coronary Artery Disease, and Mortality	20		51 Substance Use and Perceived Symptom Improvement in Bipolar Disorder	48
<b>CLINICAL CASE CONFERENCE</b>			96 Psychosocial Functioning as a Predictor of Response to Nortriptyline in Treatment-Resistant Depression	76
2 Depression in the Medical Setting Revisited: The Problem of the Depressive Spectrum Disorders	38		97 Efficacy of Citalopram as an Augmenting Strategy for Menopausal Women with Estrogen-Resistant Depression	76
			98 Polypharmacy with Antidepressants	76
<b>COURSES</b>			109 Evaluation and Intervention of Prodromal Symptoms of Bipolar I Disorder	91
12 Evidence-Based Management of SAD: Focus on Light Therapy	2		110 Dysthymic Disorder: Integrating Research Findings into Clinical Treatment	92
13 Neuroendocrinology in Mood Disorder: Dysregulation and Treatment	2		111 Effect of Adjunct Modafinil on Energy and Concentration in Depressed Patients	92
21 Anticonvulsants in Bipolar Disorder	5		112 Parental Separation at Birth and Depression in Adulthood	92
38 Melatonin and Light Treatment of SAD, Sleep, and Other Body Clock Disorders	8		<b>SYMPOSIA</b>	
44 Using Humanities to Understand Mood Disorders	14		20 Is There a Bipolar Spectrum?	33
102 The Conceptual Basis of Psychiatry	88		22 New Frontiers in the Neuroendocrinology of Affective Disorders	34
<b>DISCUSSION GROUP</b>			35 Depression and the Transition to Perimenopause: The Harvard Study of Moods and Cycles	57
16 Depression in the Medically Ill	44		47 Major Depression: Current Guidelines, Practices, and Effectiveness Research	60
			48 Depression Care in Medical Settings: Approaches for the Future	60
<b>INDUSTRY-SUPPORTED SYMPOSIA</b>			55 Combination Therapy for Bipolar Disorder: Rationales and Controversies	62
3 Bipolar Disorder: New Nationwide Data on Misdiagnosis and Community Costs	3		<b>WORKSHOP - ISSUE</b>	
4 Improving Patient Outcomes Across the Spectrum of Bipolar Disorder	3		37 Bridging the Gap: Depression, Chronic Medical Disease, Culture, and Ethnicity	43
9 Depressive Subtypes: The Multiple Faces of Depression	6		<b>TOPIC 9: PERSONALITY DISORDERS</b>	
10 Recovery from Depression: New Perspectives to Improve Outcomes	6		<b>COURSES</b>	
14 Customizing Care for Patients with Bipolar Disorder	8		48 Disorders of the Self: Differential Diagnosis and Treatment	15
15 The Aging Brain and Vulnerability to Depression	9		64 Partial Hospitalization for Patients with BPD	38
16 Long-Term Management of Mood Disorders	9		83 Personality Disorders: Combined Interpersonal and Pharmacotherapy	66
20 Atypical Depression: Overview and New Developments	11		85 Psychotherapy of Borderline Personality	66
21 New Developments in the Treatment of Bipolar Disorder	11			

(Continued on next page)

## TOPIC INDEX

<b>LECTURE</b>	<b>Page #</b>	<b>MEDIA PROGRAM</b>	<b>Page #</b>
2 Personality Disorders: New Findings and Current Controversies	15	31 A Beautiful Mind	79
<b>SCIENTIFIC AND CLINICAL REPORTS</b>		<b>RESEARCH CONSULTATION</b>	
26 BPD, Medical Illness, Lifestyle Choices, and Health Care Utilization	24	2 Brain Behavior Studies in Schizophrenia	74
27 Impulsivity, Gender, and 5HT in BPD	24		
28 Diagnostic Efficiency of BPD and Antisocial Personality Disorder (APD) Criteria in Monolingual Hispanic Men	24	<b>SCIENTIFIC AND CLINICAL REPORTS</b>	
72 Risperidone Treatment of Schizotypal Personality Disorder	74	29 The Relationship Between Negative and Positive Symptoms: A 15-Year Follow-Up	24
73 A Preliminary Trial of Omega-3 Fatty Acids in Women with BPD	74	30 Neurological Soft Signs and Psychopathology in Schizophrenia	24
74 Is Chemical Imbalance a Useful Concept in Treating Personality Disorders?	74	31 Heterogeneity in Schizophrenia: Cognitive Deficits and Brain Abnormalities	24
<b>SYMPOSIA</b>		52 Outcome of Early-Phase Psychosis Concurrent with Substance Use	48
9 Interaction of Stress and Personality	31	53 Predictors of Syndromal and Functional Recovery in Patients with First-Episode Mania	48
12 Sadistic Personality Disorder: Its Wide Range and Importance as a Diagnosis	31	54 High Birth Weight as a Predictor of Schizophrenia: A 31-Year Follow-Up	48
30 Hyperarousal and BPD: New Studies on Origins, Imaging, Taxonomy, and Treatment	55	113 Low-Frequency Transcranial Magnetic Stimulation Curtails Medication-Resistant Auditory Hallucinations	92
32 Course and Treatment of BPD	56	115 The Stabilization Phase of Schizophrenia: A Review of the Literature	92
61 Course of Psychopathology and Functioning in Personality Disorders	81		
63 Personality and Personality Disorders in the Community	82	<b>SYMPOSIA</b>	
72 Affective Instability in BPD	84	7 Management of Schizophrenia with Comorbid Disorders	30
82 The Schizophrenia Prodrome: Update of Research 2002	95	27 New Treatment Target in Schizophrenia: Update on Social Anxiety	55
		84 Clinical Challenges in Treating Schizophrenia	96
<b>WORKSHOPS - ISSUES</b>		<b>WORKSHOPS - ISSUES</b>	
3 Cognitive-Behavioral Therapy Training for Residents: How to Teach, Measure, and Attain Resident Competency	18	13 Schizophrenia with Comorbid Conditions: Clinical and Research Issues	19
7 Personality Disorders in the Mental Retardation and Development Disorders Population	19	84 Clozapine Use in HIV	71
22 Cognitive Therapy for Personality Disorders	26		
101 Teaching Primary Care Residents About Depression and Suicide: Can Technology Alter Outcomes?	89	<b>TOPIC 11: SEXUAL AND GENDER IDENTITY DISORDERS</b>	
<b>TOPIC 10: SCHIZOPHRENIA AND OTHER PSYCHOTIC DISORDERS</b>			
<b>ADVANCES IN RESEARCH</b>		<b>COURSES</b>	
Schizophrenia: What Can Functional Brain Imaging Tell?	20	59 Sexual Disorders: Diagnosis and Treatment	38
Advances in Psychopharmacologic Treatment of Schizophrenia and Related Psychoses	20	89 The Assessment and Treatment of Child Molesters	67
<b>COURSE</b>		<b>MEDIA PROGRAM</b>	
19 Training in the Use of the Positive and Negative Syndrome Scale	5	11 Just Call Me Kade	28
<b>INDUSTRY-SUPPORTED SYMPOSIA</b>		<b>SYMPOSIUM</b>	
6 Antipsychotic Therapy and Cardiovascular Disease: The Unfolding Story	3	18 Love from Pathology to Normality	33
12 Advances in the Treatment of Psychosis: Minimizing the Burden of Disease	6	<b>TOPIC 12: SLEEP DISORDERS</b>	
17 The Adherence Challenge: Chronic Issues and Emerging Solutions with Antipsychotic Therapy	9	<b>COURSES</b>	
18 Challenges and Opportunities in the Management of Psychotic Disorders	9	35 Irresistible Sleep: Narcolepsy Update	8
26 Novel Antipsychotic Drugs: Advances in the Treatment of Psychotic Spectrum Disorders, Part 1	13	51 Overview and Update of Sleep Disorders Medicine	27
26 Novel Antipsychotic Drugs: Advances in the Treatment of Psychotic Spectrum Disorders, Part 2	13	91 Sleep Medicine Update: Advanced Topics	78
33 Managing Aggression Across the Life Span: From the Pediatric to the Geriatric Patient	63	<b>INDUSTRY-SUPPORTED SYMPOSIA</b>	
35 Raising Expectations in Schizophrenia: Enhancing Long-Term Outcomes	64	28 Understanding Sleep Medicine: What the Psychiatrist Needs to Know, Part 1	13
42 New Perspectives on Schizophrenia Spectrum Disorders and Their Treatment, Part 1	65	28 Understanding Sleep Medicine: What the Psychiatrist Needs to Know, Part 2	13
42 New Perspectives on Schizophrenia Spectrum Disorders and Their Treatment, Part 2	87	44 Sleep Disorders and Psychiatric Illnesses: Scientific Foundations	85
		46 Identification and Management of Daytime Fatigue and Sleepiness in Psychiatry	86
		<b>SCIENTIFIC AND CLINICAL REPORTS</b>	
		63 Effect of Modafinil on Mood and Quality of Life in Patients with Narcolepsy	49
		64 Long-Term Safety and Efficacy of Modafinil for Daytime Sleepiness	49

**TOPIC 13: SOMATOFORM DISORDERS** **Page #**

**COURSE**

15 The Evaluation and Management of Pain 2

**SYMPOSIUM**

74 Patients with Chronic Pain: Multidisciplinary Treatment Approaches 84

**PRACTICE AREAS/SETTINGS**

**TOPIC 14: PSYCHIATRIC ADMINISTRATION AND SERVICES: PUBLIC, PRIVATE, AND UNIVERSITY**

**COURSES**

6 Basic Concepts in Administrative Psychiatry: Theory, Human Resources, and Fiscal Management 1

23 Basic Concepts in Administrative Psychiatry: Care Management, Law, and Ethics 6

94 CPT Coding and Documentation 2002 78

**DISCUSSION GROUP**

18 Integrating Physical-Mental Health Care: The WCHO Experience 44

**LECTURES**

14 Women's Leadership in Medicine and Psychiatry 53

24 Does the Psychiatric Hospital Have a Future? 88

**SYMPOSIA**

14 Extinction Versus Adaptation: The Future of State Hospital Psychiatry 32

65 Taking Control of the Future: Academic Psychiatry and 21st-Century Practice 82

**WORKSHOP - COMPONENT**

51 Coding and Documentation Update 89

**WORKSHOP - ISSUE**

62 From Psychoanalytic Psychotherapist to Psychoanalytic Organizational Corporate Consultant: An Introductory Workshop 50

**TOPIC 15 OTHER**

**CLINICAL CASE CONFERENCE**

1 Contrasting Psychopathology in Adolescents and Adults 14

**DEBATE**

Resolved: Political Correctness Has No Place in Medicine? 39

**DISCUSSION GROUP**

13 Retrospective Assessment of Mental States in Litigation: Predicting the Past (*Meet the Authors*) 39

**FORUM**

10 ABPN Update: Requirements for ABPN Examination 77

**ROUND TABLE DISCUSSION**

Government Response to Terrorism 17

**SUBSPECIALTY AREAS OR SPECIAL INTERESTS**

**TOPIC 16: ADDICTION PSYCHIATRY**

**COURSES**

34 Evidence-Guided Dual Diagnosis Treatment 8

73 Achieving Effective Dual Diagnosis Treatment 52

84 Office-Based Treatment of Opiate Dependent Patients 66

**DISCUSSION GROUP** **Page #**

15 Treating Substance Abusers with Comorbid Psychiatric Disorders: Potential Pitfalls 44

**FORUM**

8 The Challenges of Identifying and Interviewing Potential Substance Abusers 51

**LECTURE**

5 Opioids and Single-Nucleotide Polymorphisms: Implications for Heroin and Cocaine Addictions 21

**MEDICAL UPDATE**

2 Cardiac Effects of Opioid Addiction Pharmacotherapy 46

**SCIENTIFIC AND CLINICAL REPORTS**

82 Predicting Treatment Outcome of Cocaine-Dependent Patients 75

83 5HT Uptake, Impulsivity, Aggression, and Craving Among Cocaine Abusers 75

**SYMPOSIA**

23 Addictions: Cutting Edge Treatments for Gambling and Substance Abuse 34

56 Pain in the Addicted Patient: Basic Science, the Law, and Treatment 62

66 Recent Perspectives on Behavioral Addictions 83

68 Club Drugs: Trends, Toxicities, and Treatments 83

69 Naltrexone Treatment of Alcoholism: A Decade of Clinical Progress 83

80 Opiate-Substitution Treatment: International Trends and Perspectives 95

**WORKSHOPS - COMPONENTS**

7 The Philadelphia Story: A VA University of Addiction Research Collaboration 18

8 Substance Abuse in Special Populations 18

21 Medical Student Education in Addiction: Competencies and Resources 42

**WORKSHOPS - ISSUES**

45 Buprenorphine: A New Office-Based Treatment for Opioid Dependence 43

48 Hepatitis-C in Addiction Psychiatry 44

55 Addiction Treatment 2002: New Directions 44

83 Women and Smoking 71

**TOPIC 17: BIOLOGICAL PSYCHIATRY AND NEUROSCIENCE**

**COURSES**

24 The Subjective Experience: Crucial Keys to Therapy and to the Human Mind 7

39 Introduction to Transcranial Magnetic Stimulation 14

**INDUSTRY-SUPPORTED SYMPOSIA**

2 Molecules and Mood Disorders: Drug Discovery and the Treatment of Depression 2

32 The New Neurobiology of Mood and Anxiety Disorders 63

**SYMPOSIA**

33 Darwinian Evolution: Affective Temperament and Clinical Considerations 56

59 Brain Stimulation in Neuropsychiatric Illness 81

**WORKSHOP - ISSUE**

38 Olfactory Dysfunction in Psychiatry and Neurology 43

**TOPIC 18: BRAIN IMAGING**

**SYMPOSIUM**

62 Circuitry of Failed Cognitive Strategies in Addiction 81

## TOPIC INDEX

<b>TOPIC 19: CHILD AND ADOLESCENT PSYCHIATRY AND DISORDERS</b>	<b>Page #</b>	<b>WORKSHOPS - COMPONENTS</b>	<b>Page #</b>
<b>COURSES</b>		3 The American Psychiatric Association and Its Alliance Go to America's Schools	17
3 ADD in Children and Adolescents	1	29 Mission Impossible II: When the Disordered Child Becomes an Adult	50
68 Being an Effective School Consultant	39	<b>WORKSHOP - ISSUE</b>	
<b>INDUSTRY-SUPPORTED SYMPOSIA</b>		57 Implementing an Effective Truancy-Reduction Program	44
7 Diagnosis and Treatment Issues in Child and Adolescent Bipolar Disorders	5	<b>TOPIC 20: CONSULTATION-LIAISON AND EMERGENCY PSYCHIATRY</b>	
30 Breaking the Silence of Children's Mental Illness: National Initiatives, Early Detection, and New Pharmacotherapies, Part 1	14	<b>COURSE</b>	
30 Breaking the Silence of Children's Mental Illness: National Initiatives, Early Detection, and New Pharmacotherapies, Part 2	14	40 Psychiatric Consultations in Medical Settings: The Basics	14
<b>LECTURE</b>		<b>MEDICAL UPDATE</b>	
23 Mania in Youth: A Transition from Ignorance to Enlightenment to Confusion	79	1 Migraine: Diagnosis, Treatment, and Comorbidity	22
<b>MASTER EDUCATOR CLINICAL CONSULTATIONS</b>		<b>RESEARCH ADVANCES IN MEDICINE</b>	
1 Child Forensic Psychiatry Contemporary Issues	16	Long-Term Mechanical Circulatory Support	41
2 the Aftermath of Childhood Parental Loss	16	<b>REVIEW OF PSYCHIATRY SECTIONS</b>	
8 Child and Adolescent Clinical Work: Integrating Bio-, Psycho-, and Social	45	1 Emergency Psychiatry	41
<b>MEDIA PROGRAMS</b>		3 Psychiatry in Medicine	69
9 In the Mix	27	<b>SCIENTIFIC AND CLINICAL REPORTS</b>	
17 Making Visible the Hidden: Serving Child Victims in the Healthcare Community	46	9 Psychopathological Aspects in 86 Chronic Fatigue Syndrome Patients	22
18 Take This Heart	46	10 Low Expression of Negative Affect and Denial Predict Breast Cancer Recurrence	23
<b>RESEARCH CONSULTATION</b>		<b>SYMPOSIUM</b>	
3 Bipolar Disorders in Children and Adolescents	91	2 Advances in the Diagnosis and Treatment of Delirium	29
<b>REVIEW OF PSYCHIATRY: SECTION 2</b>		<b>WORKSHOP - COMPONENT</b>	
The Many Faces of Depression in Childhood and Adolescence	54	14 Legal and Psychiatric Controversies in Interferon Treatment of Hepatitis-C	25
<b>SCIENTIFIC AND CLINICAL REPORTS</b>		<b>WORKSHOP - ISSUE</b>	
38 A Multinational Study of the Emergence of Gender Differences in Depression	47	17 How to Effectively Integrate Mental Health Services in General Care Systems	20
43 Once-Daily Administration of Atomoxetine: A New Treatment for ADHD	47	<b>TOPIC 21: CROSS-CULTURAL AND MINORITY PSYCHIATRY</b>	
44 ADHD Treatment with a Once-Daily Formulation of Methylphenidate Hydrochloride: A Two-Year Study	47	<b>COURSES</b>	
45 Long-Term Safety and Efficacy of Adderall Extended Release in Children with ADHD	47	17 DSM-IV-TR Cultural Formulations: Diagnosis and Therapy	5
75 ADHD Comorbidity: Age and Gender Differences	74	76 Multicultural Approach to the Treatment of Women	52
77 Modafinil in Children with ADHD: A Double-Blind, Placebo-Controlled Study	74	<b>DISCUSSION GROUP</b>	
107 Anxiety Disorders in Children and Adolescents with Bipolar Disorder	91	6 Psychiatry and Palliative Medicine	20
108 Comorbidity in Child and Adolescent Major Depression	91	<b>FORUM</b>	
<b>SYMPOSIA</b>		11 Latin America	77
19 Adolescence: The Tumultuous Years	33	<b>LECTURES</b>	
54 Family Treatment Outcomes of Adolescents with Substance Use Disorders: Cultural Issues	62	9 Problems Facing Inner-City School Educators and the Role of Psychiatry in Addressing Them	40
57 Sports Through the Life Cycle	80	20 Journey to the West: Reflections on Culture and Psychiatry Entering the New Century	72
67 Diagnosis and Treatment of ADHD in Young Children	83	<b>MEDIA PROGRAMS</b>	
70 State-of-the-Art Adolescent Substance Abuse Prevention and Treatment	83	5 Carved from the Heart: A Portrait of Grief, Healing, and Community	21
71 Treatment of Violence and Conduct Disorders in Children and Adolescents	84	6 Homeland	21
86 Reducing Aggressive Behavior: Changing the Trajectory for Drug Use	96	7 Between Worlds	21
92 Treatment of ADHD: From Clinical Trials to Routine Clinical Practice	98	19 A World of Food: Tastes and Taboos in Different Cultures	52
		21 Standing on My Sisters' Shoulders	54

**SCIENTIFIC AND CLINICAL REPORTS**

**Page #**

11	Is the Wechsler Intelligence Scale for Children, Third Edition (WISC-III UK) Applicable to Ghana?	23
12	Dissociation, Childhood Trauma, and Ataque De Nervios	23
13	Trauma, Creative Cognition, and Success Among Tribal South-African Students	23
66	Integrating Psychiatry and Primary Care Improves Treatment Acceptability Among Asian Americans	49
67	Anger Discomfort in Japanese, Chinese, and Caucasian Females	49
68	Anatomy of Jeong	49
71	Prevalence and Symptom Patterns of Depression Among College Students	49

**SYMPOSIA**

38	Beyond the Surgeon General's Report: Psychiatry for a Diverse Population	58
51	American Psychiatric Association's Responses to the Surgeon General's Reports on Mental Health	61
73	Clinical and Treatment Challenges with Hispanic Patients	84
76	Culturally Competent Mental Health Care: Identifying and Reducing Disparities	94

**WORKSHOPS - COMPONENTS**

4	When Your Physician Patient Is from an Ethnic Minority: A Cross-Cultural Approach to Treatment	17
17	Psychiatry Without Borders: Breaking the Barriers	25
18	Psychiatric Casualties in the Mental Health of Hispanic Immigrants	25
19	Health Care Legislation: The Role for the 21st-Century Black Psychiatrist	42
22	Discussion: Surgeon General's Report on American Indians and Alaska Natives	42
23	Mental Health Care for Asian Americans and Pacific Islanders	49
35	Whose Children? Psychiatry in the Cultural Mosaic of America's Schools	70
49	Meeting the Mental Health Needs of Minorities in the 21st Century	77
54	Surgeon General's Report on Culture, Race, and Ethnicity: Clinical Implications	89
57	Asian Americans in Inter marriages: Psychosocial Adjustment and Identity	93

**WORKSHOPS - ISSUES**

9	Career Development for International Medical Graduates	19
15	Training a Culturally Competent Psychiatric Workforce	19
72	Psychopharmacogenetics and Ethnicity: Current Perspectives	70

**TOPIC 22: DIAGNOSTIC ISSUES**

**COURSE**

46	Advanced Interviewing Techniques	15
----	----------------------------------	----

**TOPIC 23: EPIDEMIOLOGY**

**SCIENTIFIC AND CLINICAL REPORTS**

69	The Burden of Hepatitis-C Among Mentally Ill Persons in Long-Term Care	49
70	Double Jeopardy: Mental Illness, Medical Conditions, and Early Death	49

**TOPIC 24: ETHICS AND HUMAN RIGHTS**

**COURSES**

28	Medical Ethics 101	7
97	Ethical Decision-Making in Clinical Practice	87

**DISCUSSION GROUP**

10	Living Organ Donation: Psychiatric Aspects and Ethical Dilemmas for Donor and Recipient	39
----	---	----

**LECTURES**

**Page #**

12	Dying Well: Beyond Symptoms and Suffering, Human Development at the End-of-Life	45
19	Can the Third Millennium Psychiatrist Help Persons at the End-of-Life?	72

**SCIENTIFIC AND CLINICAL REPORTS**

59	Experience of Research Participation by Patients with Severe Mental Illness	48
60	Attitudes of Physicians Towards Gifts from the Pharmaceutical Industry: A Pilot Study	48

**WORKSHOPS - COMPONENTS**

2	Justice and Health Equity in Global Psychiatry	17
13	Experts or Pawns? Psychiatric Consultation for Government Agencies	25

**WORKSHOPS - ISSUES**

6	The Policing of Physician-Patient Boundaries: Some International Perspectives	19
21	Nonsexual Boundary Violations: Special Problems in Small Communities	26
26	Confidentiality Issues and Legal Essentials in Sexual Harassment Cases	26

**TOPIC 25: FORENSIC PSYCHIATRY**

**COURSES**

18	The Psychiatrist as Expert Witness	5
30	Introduction to Correctional Psychiatry	7
58	The Detection of Malingered Mental Illness	38
62	How to Set Up and Run a Juvenile Justice Clinic	38
80	Insanity Defense Evaluations	66

**SCIENTIFIC AND CLINICAL REPORTS**

84	Civil Commitment in Turkey: Reflections on a Bill Drafted by Psychiatrists	75
85	Malpractice Liability in Shared Treatment	75
99	Medications, Strange Intoxications, and Violent Crime	91
100	Treating Mentally Ill Offenders in a Residential Treatment Unit	91
101	Presidential Assassination Syndrome Revisited: New Understanding	91

**SYMPOSIA**

39	Defining Evil: Clinical and Forensic Implications	58
83	The Duty to Warn and Protect for the 21st-Century Psychiatrist	95

**WORKSHOPS - COMPONENTS**

34	Practicing Rewarding Psychiatry in Jails and Prisons: A Practicum	69
42	Educating the Courts: Recent APA Amicus Curiae Briefs	76

**WORKSHOPS - ISSUES**

56	Tarasoff Revisited: Changing Trends in Duty to Warn Third Parties	44
90	The Psychiatric Fitness-for-Duty Exam	77
92	Self-Mutilation in Prison	77

**TOPIC 26: GERIATRIC PSYCHIATRY**

**COURSE**

22	Appreciating and Alleviating Spousal Caregiver Burden in Dementia	5
----	---	---

**INDUSTRY-SUPPORTED SYMPOSIA**

8	Late-Life Depression: Old Myths and New Data	5
37	Behavioral Disturbances in Dementia: Diagnostic and Treatment Guidelines	64
49	Explorations in Dementia: New and Current Perspectives	86

**LECTURE**

6	Alzheimer's Disease: The Challenges of Big Risks and Small Gains	28
---	--	----

*(Continued on next page)*

## TOPIC INDEX

<b>MEDIA PROGRAM</b>			<b>WORKSHOPS - ISSUES</b>	
29 Bubbeh Lee and Me		78	23 Assessing Psychotherapy Competencies of Residents	26
<b>MEDICAL UPDATE</b>			25 Psychotherapy Termination: A Challenge in Psychiatric Residency Training	26
3 Strategic Update of Alzheimer's Disease: Linking Disease with Therapeutics		73	30 The Neurobiology of Learning: Implications for Teaching	42
<b>SCIENTIFIC AND CLINICAL REPORTS</b>			40 Cultural Competence in Psychiatric Residency Training Programs	43
15 Socioeconomic Status and Depression Among Older Adults		23	42 Ten Years of Teaching About Boundaries: What Have We Learned?	43
16 Psychotherapy with the Elderly		23	80 Teaching Behavioral Sciences to Family Doctors	71
<b>SYMPOSIA</b>			100 How to Give a More Effective Lecture: Punch, Passion, and Polish	89
8 Depressive Spectrum Disorder in Late Life: Implications for Clinical Care		30	118 How to Develop a Lecture	93
58 Community Care in Geriatric Psychiatry in the 21st Century		80		
<b>WORKSHOPS - COMPONENTS</b>			<b>TOPIC 29: PSYCHIATRIC REHABILITATION</b>	
11 The Role of the Geriatric Psychiatrist in Palliative Care		18	<b>MEDIA PROGRAM</b>	
12 Navigating Geriatric Psychiatry Research: Issues for the Beginning Researcher		25	28 West 47th Street	73
<b>WORKSHOP - ISSUE</b>			<b>SCIENTIFIC AND CLINICAL REPORT</b>	
2 Nursing Home Psychiatry: Problems and Solutions		18	86 Assertive Community Treatment Team Patient Employment Outcomes	75
<b>TOPIC 27: NEUROPSYCHIATRY</b>			<b>SYMPOSIUM</b>	
<b>COURSES</b>			75 Physician Disability: Treatment, Independent Evaluation, Insurance, and Conflicts	85
5 ECT in Neurological Disorders		1	<b>TOPIC 30: PSYCHOANALYSIS</b>	
20 The Evaluation and Identification of the Major Dementias		5	<b>SYMPOSIA</b>	
47 Traumatic Brain Injury: Neuropsychiatric Assessment		15	1 Evidence-Based Psychodynamic Therapy Part I: Studying Clinical Work	17
49 Advances in Neuropsychiatry		15	10 Evidence-Based Psychodynamic Therapy Part II: What Do the Data Show?	31
<b>DISCUSSION GROUPS</b>			<b>TOPIC 31: RESEARCH ISSUES</b>	
8 Recognizing and Treating Neuropsychiatric Lyme Disease		20	<b>COURSE</b>	
12 Neuropsychiatry and the Future of Psychiatry ( <i>Meet the Authors</i> )		39	63 Doing Research on a Shoestring Budget	38
<b>INDUSTRY-SUPPORTED SYMPOSIUM</b>			<b>NEW RESEARCH SESSIONS</b>	
24 Molecules of the Mind: The Science of Schizophrenia		12	1 Young Investigators' Poster Session	17
<b>LECTURE</b>			2 Young Investigators' Oral/Slide Session	27
4 Neuroscience in the New Millennium		20	3 Young Investigators' Oral/Slide Session	27
<b>SYMPOSIUM</b>			4 Young Investigators' Oral/Slide Session	27
3 Plagues, Prions, and Paranoia: The Neuropsychiatry of Infectious Disease		29	5 Poster Session	35
<b>WORKSHOP - ISSUE</b>			6 Poster Session	51
27 Pseudodementia in the 21st Century		26	7 Poster Session	63
<b>TOPIC 28: PSYCHIATRIC EDUCATION</b>			8 Poster Session	78
<b>COURSES</b>			9 Poster Session	85
31 Integrative Psychotherapy Supervision: Basic Tools		7	<b>SYMPOSIA</b>	
42 Teaching Psychiatry? Let Hollywood Help!		14	25 A Research Agenda for DSM-V	34
45 Pass the Boards! The Part II Oral Exam		15	40 The Therapeutic Misconception in Research: Barrier or Necessity?	58
54 Enhancing the Doctor-Patient Relationship		27	<b>WORKSHOPS - ISSUES</b>	
71 I Found It at the Movies: Using Film Clips to Understand and Teach Psychiatry		52	39 Neurobehavioral Sequelae of Trauma to the Frontal Lobes	43
86 How to Practice Evidence-Based Psychiatry		66	116 Creating Effective Alliances with Pharmaceutical Industry Physicians	93
90 The Biopsychosocial Formulation: An Approach to Oral Board Presentations		67	<b>TOPIC 32: SOCIAL AND COMMUNITY PSYCHIATRY</b>	
<b>WORKSHOPS - COMPONENTS</b>			<b>COURSE</b>	
15 The Good-Enough Mentor: Perspectives on Mentoring in Psychiatric Training		25	37 Psychiatric Interventions in Disasters: Lessons from Experience	8
32 Competence Requirements in Resident Education: Progress and Problems		69	<b>LECTURE</b>	
47 New Trends and Challenges in Residency Education		76	3 Accessing Care: A Challenge to the Poor and Disadvantaged	16
			<b>MEDIA PROGRAMS</b>	
			13 Six Billion and Beyond	41
			14 Slippery Blisses	41
			15 Personal Space: Exploring Human Proxemics	41
			24 Remember the Titans	54



<b>SCIENTIFIC AND CLINICAL REPORTS</b>	<b>Page #</b>
87 Defining Disability Down	75
88 Marital Disruption and Mental Health: A Nine Wave Panel Study	75
89 Divorce and Marital Instability in Different Subtypes of Major Affective Disorders	75

<b>SYMPOSIA</b>	
26 Academic and Community Mental Health: Can This Marriage Be Saved?	35
42 America Attacked: The American Psychiatric Association and Its Members Respond	58

<b>WORKSHOPS - ISSUES</b>	
32 We Can Improve Care for Those with Mental Health and Substance Abuse Disorders	42
65 The Challenge of Parental Mental Illness	51
77 Disability Myths: Understanding the Social Security Administration Disability Program	71
111 Joining Forces: Working with Law Enforcement to Serve the Mentally Ill	90
115 Outpatient Commitment: Kendra's Law and the New York City Experience	93

**TOPIC 33: STRESS**

<b>MEDIA PROGRAM</b>	
3 Time Frenzy	16

<b>SYMPOSIUM</b>	
53 Adaptations to Severe Stress: Normal Responses and Therapeutic Strategies	61

<b>WORKSHOP - ISSUE</b>	
93 Psychiatric Illness and the Workplace	77

**TOPIC 34: SUICIDE**

<b>COURSE</b>	
95 Improving Media Coverage of Suicide: The Role of the Psychiatrist	78

<b>SCIENTIFIC AND CLINICAL REPORTS</b>	
23 Suicides in Youths Involved with Juvenile Justice and Child Welfare Services	24
24 Predictors of Suicide Attempts in a Personality Disorder Sample	24
25 Hostility and Impulsivity Among Suicidal Bipolar Patients	24
122 Female Suicides in Texas Cities: 1994-1998	93
123 Trends in Suicide Rates in New York City: Implications for a Prevention Initiative	93
124 Changing Suicide Rates in Europe: Possible Causes	93

<b>WORKSHOP - COMPONENT</b>	
56 Guidelines for the Treatment of Suicidal Behaviors	93

<b>WORKSHOPS - ISSUES</b>	
8 The Impact on Clinicians of Suicide	19
107 The Frontier of Public Health Psychiatry: Preventing Suicide	90

**TOPIC 35: VIOLENCE, TRAUMA, AND VICTIMIZATION**

<b>COURSES</b>	
41 Risk Assessment for Violence	14
43 Families and Medical Illness: An Integrative Treatment Approach	14
78 Sexual Harassment: Psychological and Legal Aspects	52
87 Caring for Refugees and Survivors of Torture	67
99 Assessing the Risk for Violence	88

<b>DISCUSSION GROUP</b>	<b>Page #</b>
14 Treatment of Trauma Survivors: Theory Versus Practice ( <i>Meet the Authors</i> )	44

<b>FORUMS</b>	
1 New York Academic Centers' Response to the World Trade Center Attack	26
3 Evil	26
9 Killing in the Name of God: Osama bin Laden and Radical Islam	77
12 PSYOP: Psychological Operations in the War Against Terrorism	93

<b>LECTURES</b>	
1 Rethinking Risk Assessment: The MacArthur Study of Mental Disorder and Violence	10
17 Terror, Horror, and Fright: Past and Current Perspectives	68
21 Healing the Soul in the Age of the Brain: Reflections on the Meaning of Psychiatry After September 11	73

<b>MEDIA PROGRAMS</b>	
1 Our Children	12
20 World Trade Center and Pentagon Disasters	53
26 Blink	69

<b>SCIENTIFIC AND CLINICAL REPORTS</b>	
46 Partner Violence and Risk of Major Depression in Chinese-American Women	47
47 Violence in Colombia: Mental Health Impact in Children	47
48 Epidemiology, Trauma, and Transcultural Psychiatry	47
102 Predicting Chronicity in Vietnam Veterans with PTSD: New Findings from the National Vietnam Veterans Readjustment Study	91
103 Community and Inpatient Violence in Major Psychiatric Disorders	91
104 Parental Separation at Birth and Criminality in Adulthood	91

<b>SYMPOSIA</b>	
11 Social Psychiatric Aspects of Violence and Trauma	31
36 The Psychological Wounds of National Trauma: Causes, Consequences, and Treatments	57
37 Understanding Psychological Trauma: Multidisciplinary Perspective	57
79 Optimal Strategies for Identifying and Treating Traumatized Children	94
89 Traumatic Response to Disaster: Neurobiology and Treatment	97

<b>WORKSHOPS - COMPONENTS</b>	
30 Clinician Safety	50
44 Critical Issues for Treating Domestic Violence Survivors and Their Children	76
55 Bad Boys, Bad Girls: The Demonization of Adolescence	89

<b>WORKSHOPS - ISSUES</b>	
31 Exploring the Media's Role in Imitation Violence	42
78 New Directions in Mental Health Response to Disasters and Large-Scale Crises	71
79 Childhood Trauma Intervention and Aftermath: Access to Quality Care	71
85 Intergenerational Aspect of Trauma and Trauma-Related Behavioral Patterns	71
91 Youth Violence: A Report of the Surgeon General	77

**TREATMENTS**

**TOPIC 36: BEHAVIOR AND COGNITIVE THERAPIES**

<b>COURSES</b>	
53 Cognitive Therapy: The Basics	27
55 Engaging Resistant and Hostile Patients into Participatory Treatment	27
66 Introduction to Cognitive-Behavioral Therapy	39
79 Cognitive Therapy for Severe Mental Disorders	66
92 Cognitive Therapy for Schizophrenia	78

(Continued on next page)

## TOPIC INDEX

### SCIENTIFIC AND CLINICAL REPORTS

Page #

- 55 Does Cognitive-Behavioral Group Treatment Improve Personality Measures in Panic Disorder Patients? 48  
56 Visually Enhanced Psychosexual Therapy 48  
57 Dichotomous Thinking and Thought Suppression in Managing Anger 48

### WORKSHOP - ISSUE

- 47 Implementations of DBT in Correctional Environments 43

### TOPIC 37: COMBINED PHARMACOTHERAPY AND PSYCHOTHERAPY

#### COURSES

- 26 Money Matters: Using Theory in Clinical Practice 7  
36 Integrating Pharmacotherapy and Psychotherapy 8

#### INDUSTRY-SUPPORTED SYMPOSIA

- 11 Treating Psychotic Illness Across the Life Span: Are Drugs Enough? 6  
29 One Size Doesn't Fit All: Depression Therapies for the 21st Century, Part 1 13  
29 One Size Doesn't Fit All: Depression Therapies for the 21st Century, Part 2 37

#### MASTER EDUCATOR CLINICAL CONSULTATIONS

- 3 The Doctor-Patient Relationship in Pharmacotherapy 21  
7 Integrating Psychotherapy and Pharmacotherapy 45

#### SCIENTIFIC AND CLINICAL REPORT

- 78 Music Therapy and Medication Compliance in Psychotic Patients 74

#### SYMPOSIA

- 4 Fear and Loathing in the Medication Clinic 29  
45 Collaborative Practice in Psychiatry: Data and Principles for Practice 59

#### WORKSHOPS - ISSUES

- 19 Treating Psychosis Across Diagnosis 25  
58 Psychodynamics in Treatment-Refractory Depression 50  
113 Bridges for Healing: Integrating Family Therapy and Psychopharmacology 93

### TOPIC 38: COUPLE AND FAMILY THERAPIES

#### SCIENTIFIC AND CLINICAL REPORT

- 79 Controlled Study of NAMI Family-to-Family Education Program 74

#### WORKSHOPS - ISSUES

- 5 Children of Psychiatrists: 21st-Century Insights 19  
29 Working with Parents During Their Baby's First Year of Life 42  
33 Couples Treatment by Parallel Coordinated Individual Psychotherapy 42  
114 Video Case Studies of Couples in Treatment 93

### TOPIC 39: GROUP THERAPY

#### DISCUSSION GROUP

- 1 Save Time, Make Money, Have Fun! Outpatient Group Therapy for the Seriously Mentally Ill 15

#### MEDIA PROGRAM

- 4 The Puppets of Di Cori: New Psychodrama Approach 17

### TOPIC 40: INDIVIDUAL PSYCHOTHERAPIES

#### COURSES

- 7 Interpersonal Psychotherapy 1  
16 Dream Translation: One Empirically-Based Approach 2

Page #

- 56 Brief Psychodynamic Psychotherapy: The Core Conflictual Relationship Theme Method 27  
65 Davanloo's Intensive Short-Term Dynamic Psychotherapy in Clinical Practice 39  
72 The Advanced Practice of Psychotherapy 52  
81 Interpersonal Psychotherapy 66

#### DISCUSSION GROUP

- 5 Psychodynamic Psychiatry in Clinical Practice: Third Edition (*Meet the Authors*) 20

#### MASTER EDUCATOR CLINICAL CONSULTATIONS

- 4 Psychotherapy with Immigrant Patients 21  
5 The Psychotherapies: Do Similarities Outweigh Differences? 40

#### MEDIA PROGRAM

- 12 Sopranos 29

#### SCIENTIFIC AND CLINICAL REPORTS

- 80 An Additional Guideline for Choosing Appropriate Supportive Psychotherapy Techniques 74  
92 Clinical Problems in the Treatment of Adults with Comorbid ADD 75

#### SYMPOSIA

- 15 The Social Brain and Psychotherapy 32  
41 Combined Treatment: Dynamic Psychotherapy and Medication 58  
87 New Developments in Interpersonal Psychotherapy Research 96

#### WORKSHOPS - ISSUES

- 95 Dilemmas of Melancholia: Let Philosophy Help 77  
109 Working Through in Psychotherapy 90

### TOPIC 41: PSYCHOPHARMACOLOGY

#### ADVANCES IN RESEARCH

- An Update on the Essentials of Clinical Psychopharmacology 28  
Atypical Antipsychotics 28  
Nonbenzodiazepine Anxiolytics 28

#### COURSES

- 2 Antipsychotic-Induced Movement Disorders: Assessment and Treatment 1  
9 Psychiatry Update for the International Spanish-Speaking Colleague (In Spanish) 1  
57 Drug Treatment of Schizophrenia 38  
67 Med-Psych Drug-Drug Interactions: An Update 39

#### DISCUSSION GROUPS

- 3 Quickie Guide to the Cytochrome P450 System (*Meet the Authors*) 15  
19 Essentials of Clinical Psychopharmacology (*Meet the Authors*) 67

#### INDUSTRY-SUPPORTED SYMPOSIA

- 23 Primary Mood Stabilizers as the Cornerstone of Treatment for Bipolar Disorder 11  
27 Antipsychotic Pharmacotherapy and the Hippocratic Oath: Above All Do No Harm, Part 1 13  
27 Antipsychotic Pharmacotherapy and the Hippocratic Oath: Above All Do No Harm, Part 2 37  
36 Clinical Differences in Serotonin and Norepinephrine Anti-depressant Effects 64  
41 The Pathophysiology and Treatment of Impulsivity and Aggression in Psychiatric Disorders, Part 1 65  
41 The Pathophysiology and Treatment of Impulsivity and Aggression in Psychiatric Disorders, Part 2 87  
45 The Burden of Schizophrenia: Why Patients Don't Get Better 85

<b>SCIENTIFIC AND CLINICAL REPORTS</b>		<b>Page #</b>
32	Effectiveness of Rapid Initial Dose Escalation of Oral Olanzapine for Acute Agitation	24
33	Olanzapine Combined with Lithium or Valproate for Relapse Prevention of Bipolar Disorder: An 18-Month Study	24
34	Olanzapine Versus Divalproex Sodium for Mania: A 47-Week Study	24
40	End-Stage Chronic Renal Failure from Prolonged Lithium Therapy	47
41	Topiramate in the Treatment of Refractory Bipolar Depression	47
42	Prescribing Practices in Bipolar Disorder	47
65	Modafinil Enhances Motivation in the Absence of Overt Sleepiness	49
90	Compliance and Treatment Discontinuation in Panic-Disorder Patients	75
91	Meta-Analysis of Antidepressant Levels in Lactating Mothers' Breastmilk and Nursing Infants	75
93	Branched-Chain Amino Acid Treatment of Tardive Dyskinesia	75
94	Nonadrenergic Noncholinergic Sildenafil Treatment of SRI-Associated Sexual Dysfunction	75
95	Rivastigmine Tartrate in Neurocognitive Deficits in Schizophrenia Patients Treated with Clozapine	76
105	Polypharmacy in Patients with Schizophrenia	91
<b>SYMPOSIUM</b>		
60	Life-Threatening Hyperthermic Syndromes in Psychiatry	81
<b>WORKSHOPS – ISSUES</b>		
73	Practical Pharmacotherapy of Mood Disorders	70
103	Lithium Revisited: Integrating Recent Findings into Clinical Practice	90
105	Evidence-Based Tables of Side Effects of Psychotropic Medications: Useful?	90
108	Medication Use for Children in Systems of Care	90
<b>TOPIC 42: OTHER SOMATIC THERAPIES</b>		
<b>COURSES</b>		
60	ECT Practice Update	38
70	Vagal Nerve Stimulation	52
88	A Practical Approach to Herbs and Nutrients in Psychiatry	67
<b>WORKSHOPS - ISSUES</b>		
63	Role of Amytal in Conversion Disorder	50
75	Drug Therapy for Functional Somatic Syndromes	71
110	Alpha-Down EEG Biofeedback: A Novel Treatment for Anxiety	90
<b>TOPIC 43: TREATMENT TECHNIQUES AND OUTCOME STUDIES</b>		
<b>ADVANCES IN PSYCHOPHARMACOLOGY</b>		
	New Antidepressants in Development: Corticotrophin Releasing Hormone and Neurokinin Antagonists	28
<b>CLINICAL CASE CONFERENCE</b>		
3	Motivational Enhancement Therapy for the Medically Ill, Substance Abuse Patient with Depression	66
<b>CONTINUOUS CLINICAL CASE CONFERENCES</b>		
1	Lives and Treatments: Two Patients, Two Therapists: Part 1	15
2	Lives and Treatments: Two Patients, Two Therapists: Part 2	39
1	Managing Negative Outcomes in General Psychiatry: Part 1	66
2	Managing Negative Outcomes in General Psychiatry: Part 2	88
<b>COURSE</b>		
32	Core Competencies in Workplace Psychiatry	7
<b>DISCUSSION GROUPS</b>		
2	What Makes People Change?	15
22	The APA Business Initiative and the Future of Psychiatric Practice	67

<b>SCIENTIFIC AND CLINICAL REPORTS</b>		<b>Page #</b>
119	Matching Treatment to Type of Poor-Prognostic, Substance-Dependent Patients	92
120	Tiagabine, a Selective GABA Reuptake Inhibitor for the Treatment of Anxiety	92
<b>SYMPOSIA</b>		
29	New Development in Medications for the Treatment of Substance Abuse	55
85	Cognitive Therapy Versus Medications for Severe Depression	96
88	Treating Mental Illness and Substance Abuse in the Criminal Justice System	97
91	The Employment Intervention Demonstration Project: Outcome of Best Practice	97
<b>WORKSHOPS - ISSUES</b>		
34	Motion Pictures: The Therapeutic Modality of the 21st Century	42
60	Use of Restraints in Psychiatric Practice: Pros, Cons, and Alternatives	50
66	Aftermath of Professional Boundaries Violations: Treatment of Victims	51

**OTHER ISSUES**

**TOPIC 44: COMPUTERS**

**COURSE**

75	Computers in Psychiatry: A Primer	52
----	-----------------------------------	----

**WORKSHOP - ISSUE**

12	Use of the Personal Digital Assistant in Psychiatry	19
----	---	----

**TOPIC 45: CREATIVITY AND THE ARTS**

**COURSES**

4	Writing About Clinical Experiences	1
96	Treatment of Creative Patients	79

**FORUM**

4	Music and Mood Disorders: Tchaikovsky	27
---	---------------------------------------	----

**MEDIA PROGRAM**

8	M & M Smith: For Prosperity's Sake	22
---	------------------------------------	----

**WORKSHOPS - ISSUES**

53	The Portrayal of Psychiatry in Recent American Films	44
59	The Art of the Unconscious: Shakespeare, Poetry, Film, and Psychiatry	50
81	Music as Mirror: Reflections of the Psyche in Works by the Great Composers	71
99	Poems on Psychiatry	89
112	Erik Erikson Epigenesis as Depicted in Andrew Lloyd Webber's Musicals	90

**TOPIC 46: ELECTRONIC MEDICAL RECORDS**

**COURSES**

1	Computer-Assisted Diagnostic Interview	1
29	Build Your Own Relational Database Electronic Medical Record	7

**TELECOMMUNICATIONS PRESENTATION**

3	Open Infrastructure for Outcomes: From Plug and Play Web Forms to Evidence-Guided Treatment	41
---	---	----

**WORKSHOP - ISSUE**

94	Electronic Medical Records Enhance Quality and Productivity: The Time Has Come	77
----	--	----

## TOPIC INDEX

<b>TOPIC 47: GENDER ISSUES</b>	<b>Page #</b>	<b>REVIEW OF PSYCHIATRY: SECTION 4</b>	<b>Page #</b>
<b>MEDIA PROGRAM</b>		Mental Health Issues in the Lesbian/Gay/Bisexual/Transgender Community	80
32 King of Masks: Gender and Tradition in China	80	<b>WORKSHOPS - COMPONENTS</b>	
<b>SYMPOSIUM</b>		9 Aging and Mourning in the Gay and Lesbian Community	18
44 Evidence-Based Psychiatry: Principles, Examples, and Critiques in the U.S. and France	59	36 It's Not Gay Enough: Interpreting Antigay Bias in the 21st Century	70
<b>WORKSHOP - COMPONENT</b>		46 Lesbian, Gay, Bisexual, and Transgendered Residents: Challenges in Training	76
41 The Rules of the Club: Career Advancement for Women	70	<b>WORKSHOPS - ISSUES</b>	
<b>TOPIC 48: HEALTH SERVICES RESEARCH</b>		16 Transgender Care: New Perspectives	19
<b>COURSE</b>		41 A Legal Primer for Psychiatrists Involved in Issues of Sexual Orientation	43
11 Outcomes: Use of Rating Scales	2	69 Treating Gay and Lesbian Youth at Risk	70
<b>DISCUSSION GROUP</b>		119 A Clinician's Guide to Substance Abuse Treatment for Gay, Lesbian, Bisexual, and Transgender Persons	93
21 Psychiatric Aspects of Cardiovascular Disease	67	<b>TOPIC 52: MANAGED CARE AND HEALTH CARE FUNDING</b>	
<b>SCIENTIFIC AND CLINICAL REPORTS</b>		<b>MASTER EDUCATOR CLINICAL CONSULTATION</b>	
35 Consensus Development on Core Quality Measures for Mental Health Care	25	6 Brief Dynamic Therapy: For the Patient or for Managed Care?	40
36 Improving the Competency of Clinicians Treating People with Mental Illness	25	<b>SCIENTIFIC AND CLINICAL REPORTS</b>	
76 Psychiatric Diagnosis for Children Under Age Five Referred to a Public Mental Health System	74	116 Alzheimer's Disease Increases Costs of Comorbidities in Medicare-Managed Care	92
<b>SYMPOSIA</b>		117 Donepezil Is Associated with Lower Health Care Costs in Medicare-Managed Care	92
13 From Research to Practice: Primary Care Research in Substance Abuse and Mental Health Services for Elderly (PRISMe)	32	118 Managed Care and Malpractice Liability: Update 2002	92
49 Global Psychiatry and Patients' Rights: Informed Consent	60	<b>WORKSHOPS - COMPONENTS</b>	
<b>TOPIC 49: HISTORICAL QUESTIONS</b>		1 How to Convince Corporate CEOs that Mental Health Is a Good Investment	17
<b>MEDIA PROGRAM</b>		28 The Mental Health Carveout: Strategies to Erase the Stigma	50
30 The Frog in the Well: The Life and Work of Hoh-Kun Yuen	78	43 Medicare Update 2002	76
<b>WORKSHOP - COMPONENT</b>		<b>WORKSHOPS - ISSUES</b>	
27 Kids, Schools, and Parents: From the 20th Century into the 21st Century	50	44 Enhancing and Funding Mental Health Services: New Freedom Initiative	43
<b>TOPIC 50: INFORMATION TECHNOLOGY</b>		46 Improving the Quality of Service in a Medicaid HMO	43
<b>COURSES</b>		71 Recent Studies on Parity and Employer-Sponsored Insurance	70
61 How to Use Your Palm Personal Digital Assistant in Psychiatric Practice	38	86 Do Restricted Formularies Serve as Barriers to Care?	71
82 Evidence-Based Medicine: An Introduction for Psychiatrists	66	<b>TOPIC 53: MEN'S HEALTH ISSUES</b>	
<b>TELECOMMUNICATIONS PRESENTATIONS</b>		<b>SCIENTIFIC AND CLINICAL REPORTS</b>	
1 The Use of Digital Streaming Video for Distance Education in Telepsychiatry	41	37 Meat Consumption and Risk of Depression: A Prospective, Population-Based Study	46
4 Introduction to Evidence-Based Mental Health	62	39 Efficacy and Safety of Sildenafil Citrate in Men with Depression and Erectile Dysfunction: Six-Month, Open-Label Treatment	47
<b>WORKSHOP - COMPONENT</b>		<b>TOPIC 54: POLITICAL QUESTIONS</b>	
53 Information Technology: Core Competencies for Psychiatrists	89	<b>COURSE</b>	
<b>TOPIC 51: LESBIAN/GAY/BISEXUAL/TRANSGENDER ISSUES</b>		8 Personality and Political Behavior	1
<b>FORUM</b>		<b>FORUMS</b>	
5 Homosexuality and Religion: Healing the Wound	51	6 The Death Penalty and the Road to Execution: Psychological Issues for Correctional Officers; Appropriate and Inappropriate Roles for Psychiatrists	51
<b>MEDIA PROGRAMS</b>		13 The Pharmaceutical Industry and the APA: Controversies and Approaches	94
10 Southern Comfort	28	<b>WORKSHOP - COMPONENT</b>	
27 "In the Life" Television News Magazine	73	39 Psychologist Prescription Privileges: Is It Coming? Should It?	70

<b>TOPIC 55: PROFESSIONAL AND PERSONAL ISSUES</b>	<b>Page #</b>	<b>RESIDENTS' SESSION</b>	<b>Page #</b>
		Meet the Experts Sunny-Side Up	14
<b>COURSES</b>		<b>SYMPOSIUM</b>	
52 Treating Medical Students and Physicians	27	46 How to Launch a Successful Private Practice: Part III	60
77 Arts and Humanities for Self-Renewal	52		
<b>LECTURES</b>		<b>WORKSHOPS - COMPONENTS</b>	
8 You Are Twenty-Four and You Have What?	40	10 Psychiatry in the Neuroscience Curriculum: Promise and Peril	18
22 Global Implications on the World Health Organization's World Health Report 2001 on Mental Health	79	20 How to Launch a Successful Private Practice: Part I	42
		31 How to Launch a Successful Private Practice: Part II	50
		40 Combined Residency Training: You Want to Do What?	70
		50 Career Choices in Psychiatry	88
<b>SYMPOSIA</b>		<b>WORKSHOPS - ISSUES</b>	
17 Practicing Psychiatry in 2002	32	1 How to Get the Most Out of Supervision: What Residents Need to Know	18
64 Lessons Learned: Looking Back to Move Forward	82	4 Supervision 101: Sex, Lies, and Videotape?	18
90 Psychiatry and the Pharmaceutical Industry: Where Is the Boundary?	97	11 Access to Psychotherapy Training in Residency: A Current Perspective	19
		20 Challenges of the Chief Resident in Psychiatry	26
<b>WORKSHOPS - COMPONENTS</b>		35 Innovative Strategies in Third-Year Medical Student Psychiatric Education	42
6 Risk Management Issues in Psychiatric Practice	18	50 World Federation of Psychiatric Trainees: Satisfaction and International Exchange in Psychiatric Education	44
24 Survivor MUR: Who Gets Voted In?	49	89 Assessing Educational Experiences in Psychiatry	77
38 Talking with the Terminally Ill About Death and Dying	70	97 The Other Side of the Mountain: From Residency to Reality	89
48 HIPAA Privacy Rule: What Every Psychiatrist Needs to Know	76		
<b>WORKSHOPS - ISSUES</b>		<b>TOPIC 58: PRESIDENTIAL THEME: "THE 21<sup>ST</sup> CENTURY PSYCHIATRIST"</b>	
24 Professionalism in the Teacher/Learner Relationship	26		
52 Ethics of Pharmaceutical Involvement in Psychiatric Education	44	<b>COURSE</b>	
64 Minority Psychiatrists Who Have Suffered Mental Illness: Overcoming Stigma	51	100 Back to the Future: The Evolutionary Framework for Psychiatry	88
67 A Recipe for Academic/Personal Success: Some Key Ingredients	51	<b>MASTER EDUCATOR CLINICAL CONSULTATION</b>	
82 Assisting Physicians and Other Professionals Who Violate Boundaries	71	9 Changing and Evoking Roles for the Clinicians	68
88 Career Development and Risk Management	72	<b>PRESIDENTIAL SYMPOSIUM</b>	
104 The Disruptive Physicians and Hospital Culture	90	What Will the 21st Century Bring to the Training of Psychiatrists?	29
106 Using Your Psychiatric Skills to Build a Productive Team at Work	90	<b>SCIENTIFIC AND CLINICAL REPORT</b>	
		58 Principles of Clinical Explanation in 21st-Century Psychiatry	48
<b>TOPIC 56: RELIGION, SPIRITUALITY, AND PSYCHIATRY</b>		<b>SYMPOSIA</b>	
		5 Health Insurance Portability and Accountability Act: Clinical Applications and Implications	30
<b>COURSES</b>		24 Psychotherapy Research: Challenges for the 21st Century	34
50 Issues in Transpersonal Psychiatry	15	78 Brain Substrates of Addiction: Neuroimaging as a Tool of Choice in the 21st Century	94
69 Transpersonal Psychiatry: Clinical Applications	39	<b>WORKSHOPS - COMPONENTS</b>	
<b>LECTURES</b>		5 The Psychiatrist and Migration in the 21st Century	18
11 Healing Through Social and Spiritual Affiliation	45	26 The Terrorist Crisis of 2001: Use and Impact of Electronic Communication	50
16 The Nearly Forgotten Factor in Psychiatry: What a Difference a Decade Makes	67	33 Quality Indicators for Children and Adolescents: Who Cares?	69
<b>MEDIA PROGRAM</b>		<b>WORKSHOPS - ISSUES</b>	
16 Long Night's Journey into Day	46	14 Psychotherapy Training for the 21st-Century Psychiatrist	19
<b>SCIENTIFIC AND CLINICAL REPORTS</b>		68 The Body in 21st-Century Psychiatry: Diagnostic Dimensions and Therapeutic Challenges	51
61 Effects of Falun Gong Practice on Physical and Mental Health	48	76 In Search of the Empathic Healer	71
62 Moral Conflict as a Component of Anxiety and Worry	48	<b>TOPIC 59: STIGMA/ADVOCACY</b>	
<b>WORKSHOP - COMPONENT</b>			
45 Psychiatry's Response to the Data: Spirituality as a Relevant Clinical Factor	76	<b>LECTURES</b>	
<b>WORKSHOPS - ISSUES</b>		7 Psychiatry and the Medical Consumer Movement	36
51 Spiritual Dimension and Religious Issues in an Urban CMHC Clinical Practice	44	18 Mental Health: A Perspective from the Surgeon General Who Listens	68
74 Mindfulness and Awareness Practice in the Medicine Buddha Tradition of Tibet	71		
102 Religious and Spiritual Assessment in Clinical Practice	90		
<b>TOPIC 57: RESIDENT AND MEDICAL STUDENT CONCERNS</b>			
<b>DISCUSSION GROUP</b>			
9 Surviving Residency: Perspectives from the Training Office	39		

(Continued on next page)

## TOPIC INDEX

---

<b>SYMPOSIUM</b>	<b>Page #</b>	<b>TOPIC 62: WOMEN'S HEALTH ISSUES</b>	<b>Page #</b>
31 False Memory Syndrome: Recovery and Family Reconciliation	56		
<b>WORKSHOP - COMPONENT</b>		<b>ADVANCES IN RESEARCH</b>	
16 Talking on Your Feet: Survival Tips and Techniques for Media Interviews	25	Treatment of the Pregnant or Postpartum Woman	28
<b>WORKSHOPS - ISSUES</b>		<b>COURSE</b>	
87 Advocacy 101: Influencing Mental Health Policy	72	33 Psychiatric Disorders in Pregnancy and Postpartum	8
96 Stigma Stayed: The Cost of Prejudice in High Places	89	<b>DISCUSSION GROUP</b>	
<b>TOPIC 60: TELEPSYCHIATRY</b>		4 Postpartum Depression: Prevention and Intervention	15
<b>SYMPOSIUM</b>		<b>INDUSTRY-SUPPORTED SYMPOSIA</b>	
34 Successful Clinical Applications of Telepsychiatry	56	22 Treatment of Mood and Anxiety Disorders in Women: What Is Evidence and What Is Art?	11
<b>TELECOMMUNICATIONS PRESENTATION</b>		38 Chronic Episodic Disorders: Comorbidity and Comprehensive Integrated Treatment, Part 1	65
5 Individual and Group Psychotherapy Via Telepsychiatry	62	38 Chronic Episodic Disorders: Comorbidity and Comprehensive Integrated Treatment, Part 2	87
<b>WORKSHOP - ISSUE</b>		<b>MASTER EDUCATOR CLINICAL CONSULTATION</b>	
10 Evaluation of Telepsychiatry Services in an Integrated Hospital System in the Veterans Administration and Department of Defense	19	10 The Addicted Woman: Diagnostic and Treatment Challenges	69
<b>TOPIC 61: VIRTUAL REALITY</b>		<b>MEDIA PROGRAMS</b>	
<b>SYMPOSIUM</b>		22 Women of the Wall	54
93 Virtual Reality and Mental Health: State of the Art and Future Directions	98	23 Loyalties	54
<b>TELECOMMUNICATIONS PRESENTATION</b>		25 Leona's Sister Gerri	69
2 DAVID: Depression Animation Video Image Database	41	<b>SCIENTIFIC AND CLINICAL REPORT</b>	
		14 Long-Term Effects of Depression on Symptoms and Function in Mid-Life Women	23
		<b>SYMPOSIUM</b>	
		16 Special Topics in Women's Mental Health	32



# PARTICIPANT INDEX

## APA 155<sup>TH</sup> ANNUAL MEETING

### A

Abel, Gene G.....	67
Abikoff, Howard.....	47
Abramson, Ronald D.....	33
Abramson, Ruth K.....	74
Acton, Paul.....	94
Adam, Dorothy.....	38
Addington, Jean M.....	95
Adeoye, Martins A.....	23, 47
Ades, Jean.....	83
Adit, Yanjee.....	87
Adkins, Laura.....	74
Adler, Lenard A.....	3
Agani, Ferid.....	57
Agosti, Vito.....	61
Agustines, Davin A.....	8
Ahmad, Abdulbaghi.....	61
Aist, Reverend Clark S.....	67
Ait-Daoud, Nassima.....	55
Akaka, Jeffrey.....	49
Akhtar, Salman.....	21, 31
Akiskal, Hagop S.....	33, 48, 56, 91
Akman, Jeffrey S.....	80
Al-Samarrai, Sadiq H.....	26, 50
Alarcon, Renato D.....	19, 34, 35, 43, 84, 88, 94
Albucher, Ronald C.....	89
Alegria, Margarita.....	35
Alessi, Norman E.....	30, 41, 56, 98
Alexander, Allison B.....	23, 76
Alexander, James F.....	62
Alexopoulos, George S.....	5, 30, 35, 53
Alger, Ian E.....	16, 25, 41, 53, 93
Allen, Albert J.....	3
Allen, Andrea.....	84
Allen, James.....	89
Allen, Michael H.....	41
Allen, Trina B.....	39, 70
Allison, David B.....	92
Alonso, Anne.....	6
Alpert, Jonathan E.....	23, 61, 76
Altchuler, Steven I.....	8
Altshuler, Kenneth Z.....	40
Altshuler, Lori L.....	23, 24, 34
Amminger, Paul.....	9
Amsterdam, Jay D.....	96
Andersen, Susan.....	84
Anderson, Carl M.....	84
Anderson, Tanya R.....	74
Andreasen, Nancy C.....	82
Andrews, Gavin.....	34
Andronikof, Anne.....	33
Andrus, Jason M.....	22
Anez, Luis M.....	24
Ansari, Rubaba.....	74
Appelbaum, Paul S.....	10, 35, 39, 58, 60, 75, 96
Appolinario, Jose C.....	32
Aquila, Ralph.....	6
Arana, George W.....	55
Arikan, Rasim.....	75
Arlinghaus, Kimberly A.....	5
Armenteros, Jorge L.....	63
Armstrong, Scott C.....	15, 39
Arnold, Lesley M.....	81
Arroyo, William.....	89
Arseneau, Bernard J.....	71
Aruguette, Mata.....	49
Ashley, Kenneth B.....	70

Asthana, Deshratn.....	29
Atdjian, Sylvia.....	33
Attia, Evelyn.....	59
August, Gerald.....	96
Aupperle, Peter M.....	7
Auriacombe, Marc.....	95
Autry III, Joseph H.....	51
Axelrod, Seth R.....	55
Ayonrinde, Deji.....	18
Azzam, Amin N.....	70

### B

Bailey, Rahn K.....	91
Bakalar, Elizabeth.....	19
Baker, Robert W.....	24, 47, 75
Balderson, Benjamin H. K.....	59
Baldessarini, Ross J.....	48
Baldewicz, Teri T.....	29
Baldini-Rossi, Nicolo.....	34, 64
Baldwin, Patizia A.....	96
Balon, Richard.....	45, 97
Balsler, Richard.....	97
Bannish, Daniel.....	43
Baptiste, Shim.....	57
Barad, Mark G.....	8, 20
Bark, Nigel M.....	81
Barker, Gregory L.....	41
Barlow, David.....	34
Barnhill, John W.....	29
Baron, David A.....	84
Barr, Ellen F.....	5
Barreira, Paul J.....	6
Barrett, James E.....	60
Barron, Charles T.....	50
Bartels, Stephen J.....	32
Barton, Gail M.....	19
Baruch, Geoffrey.....	31
Basco, Monica A.....	66
Bat-Avi, Hagit.....	17, 92
Bateman, Anthony.....	31
Batki, Steven L.....	34
Battista, John R.....	15
Bauer, Mark S.....	59
Bauermeister, Jose J.....	98
Baum, Antonia L.....	46, 80
Bayon, Maria C.....	89
Beahrs, John O.....	32
Beale, Rhonda Joyce R.....	69
Bean, Donna L.....	59
Beardslee, William R.....	51
Beaubrun, Gabrielle F.....	19, 66
Beck, Aaron T.....	78
Beck, Judith S.....	18, 26
Becker, Daniel F.....	24
Becker, Deborah R.....	97
Becker, Judith.....	88
Becker, Philip M.....	49
Beeber, Alan R.....	39
Beecher, Lee H.....	33
Beers, Sue R.....	94
Beitman, Bernard D.....	8, 29
Belant, Jason B.....	55
Belitsky, Richard.....	67
Belkin, Gary S.....	58
Bell, Carl C.....	17, 31, 35, 50, 61, 68, 77, 94
Belsasso, Guido.....	89
Benca, Ruth M.....	85

Bender, Donna S.....	56, 81
Benedek, David.....	39, 97
Benedek, Elissa P.....	16, 26, 50, 71, 97
Benitez, Jaime M.....	18
Bennasar, Maricarmen.....	23
Bennett, Michael J.....	71
Benoit, Marilyn B.....	77
Bentler, Suzanne.....	75
Beresin, Eugene V.....	69
Berg, Arthur Z.....	50
Berg, Paul H.....	47
Berganza, Carlos.....	84
Berger, Robert H.....	93
Bergman, Gretchen.....	89
Bergstrom, Richard F.....	24
Berman, Jeffrey A.....	33
Berman, Sheldon S.....	48
Berman, Steven.....	81
Bernstein, Carol A.....	7, 14, 29, 39
Bernstein, David P.....	31
Berrettini, Wade H.....	75
Berry, Sally A.....	87
Bersani, Giuseppe.....	24
Bevans, Margaret L.....	75
Beyer, Michelle.....	55
Bezmen, Janet.....	50
Bezzubova, Elena B.....	51
Bianco, Carlos.....	61
Bianhertz, Laura E.....	97
Biederman, Joseph.....	38, 47, 86
Bienvenu III, Oscar J.....	82
Binder, Renee L.....	52, 76
Bing, Eric G.....	94
Birmaher, Boris.....	47, 54
Bisaga, Adam M.....	34
Bishop, Shelley E.....	43
Black, Dora.....	61
Blake, Lesley M.....	23
Blake, Nancy M.....	33
Blaken, Peter.....	95
Blakeney, Patricia.....	31
Blamphin, John B.....	25
Blanchard, Joanna.....	91
Bland, Irma J.....	15, 39
Bleiberg, Kathryn L.....	96, 97
Bleier, Henry R.....	81
Blinder, Barton J.....	8, 51
Blita, Afrim.....	57
Bloch, Daniel.....	61
Bloch, Sydney.....	87
Bloom, Sandra L.....	76, 91
Blow, Frederic C.....	32
Blozis, Shelley.....	98
Blume, Sheila B.....	44, 95
Blumenfeld, Michael.....	25, 58
Boehnlein, James K.....	33
Boeve, Bradley F.....	86
Bokobza, Herve.....	59
Boksay, Istvan J.E.....	18
Boland, Robert J.....	38, 51
Bolla, Karen I.....	82
Bond, Gary R.....	59, 97
Book, Howard E.....	27, 50
Bookheimer, Susan Y.....	34
Boone, Herman.....	54
Borson, Soo.....	63
Borsook, David.....	62
Bortolotti, Francesca.....	30
Borum, Randy.....	96

PARTICIPANT INDEX

Borus, Jonathan F. ....72  
 Botteron, Kelly N. ....34  
 Bouet, Boland .....59  
 Boutros, Nashaat N. ....92  
 Bowden, Charles L. ....8, 11  
 Boyak, Cindy .....97  
 Braden, Gregory .....47  
 Bradford, John M. ....67  
 Brady, Kathleen T. ....37, 55, 87  
 Brainard, George .....8  
 Brawman-Mintzer, Olga .....87  
 Breier, Alan F. ....95  
 Breitbart, William .....20, 29  
 Brendel, David H. ....48, 88  
 Brent, David A. ....54  
 Breslow, Richard E. ....41  
 Brod, Thomas M. ....90  
 Brodkey, Amy C. ....97  
 Brody, Janet .....62  
 Bromberger, Joyce T. ....23  
 Brook, David W. ....44, 74  
 Brown, Charlotte .....23  
 Brown, Clayton .....82  
 Brown, Frank W. ....42  
 Brown, Lawrence .....44  
 Brown, Richard P. ....67  
 Brown, Sandra A. ....33  
 Brown, Thomas E. ....1, 3, 78  
 Bruder, Gerard E. ....61  
 Buchsbaum, Monte S. ....87  
 Buck, Jeffrey .....70  
 Buckley, Peter F. ....86, 96  
 Bukstein, Oscar G. ....96  
 Bunt, Gregory C. ....15  
 Burd, Larry J. ....95  
 Burek, Susan .....98  
 Burgard, Melissa .....30  
 Burgess, Ann .....31  
 Burgoyne, Karl S. ....89  
 Burland, Joyce .....74  
 Burns, Kathryn A. ....69  
 Burris, Scott .....25  
 Bursztajn, Harold J. ....12  
 Burt, Tal .....5  
 Burton, Anna M. ....17  
 Busch, Alisa B. ....25  
 Busch, Fredric N. ....17  
 Bush, George .....86  
 Bussel, Marina .....38  
 Butler, Lisa .....61  
 Butterfield, Marian I. ....82  
 Buwalda, Victor J.A. ....44  
 Byler, Crystal .....98  
 Byock, Ira R. ....45, 70

C

Cabaj, Robert P. ....25, 89  
 Caetano, Raul .....96  
 Cain, Warden B. ....51  
 Caine, Eric D. ....90  
 Cairney, John .....23, 47  
 Calabrese, Joseph R. ....3, 5, 24, 63  
 Calabrese, Lori .....37  
 Calhoun, Joshua W. ....80  
 Caligiuri, Michael .....1  
 Caligor, Eve .....66  
 Callahan, Jr., William E. ....25, 42, 50, 60  
 Camacho, Alvaro .....77  
 Camille, Catherine .....92  
 Camlin, Kelly L. ....87  
 Campbell, E. Cabrina .....29, 81  
 Campbell, Mira .....22  
 Campbell, William H. ....67

Campeas, Raphael .....61  
 Campo, Ana E. ....25, 49  
 Candilis, Philip J. ....58  
 Canino, Glorisa .....98  
 Canive, Jose M. ....47, 62, 88  
 Caracci, Giovanni .....23  
 Cardona, Dora .....88  
 Carey, Kathleen S. ....48  
 Carlson, Gabrielle .....33, 55  
 Carney, Robert .....20  
 Caroff, Stanley N. ....29, 81  
 Carpenter, Linda L. ....6, 11, 52  
 Carpinello, Sharon E. ....17, 71  
 Carroll, Kathleen M. ....92  
 Carter, Diana .....8  
 Carter, William P. ....86  
 Caserta, Maria T. ....49  
 Casey, Daniel E. ....64, 65  
 Casey, David A. ....48, 92  
 Casper, Regina C. ....79  
 Cassem, Edwin H. ....70, 72  
 Casten, Robin .....80  
 Castilla-Puentes, Ruby C. ....47, 74  
 Castilla Puentes, Sandra-Rocio .....47  
 Castilla Puentes, Wilma-Ines .....47  
 Castle, David .....55  
 Caton, Carol L.M. ....48  
 Cavaglia, Frederico .....48  
 Cavazzoni, Patrizia A. ....47  
 Chacko, Chowallur D. ....44  
 Chacko, Liz M. ....44  
 Chae, Jeong-Ho .....81  
 Chagnon, Francois .....24  
 Chaiken, Shama .....97  
 Chalk, Mady .....70  
 Chan, Carlyle H. ....38, 52  
 Chan, Jeffrey .....25  
 Chandler, Mark C. ....47  
 Chang, Jacquelyn B. ....21  
 Chang, Kiki D. ....5  
 Chang, Kyong-Mi .....44  
 Chang, Robert .....8  
 Chao, Helen M. ....75  
 Chapa, Diana .....40  
 Chaplin, M. Paul .....43  
 Chapman, Daniel P. ....75, 92  
 Charat, Valerie E. ....30  
 Charatan, Dana .....30  
 Charles, Cecil .....95  
 Charney, Dennis S. ....34, 97  
 Chaskel, Roberto E. ....84  
 Chaudhry, Zabaida A. ....23, 47, 76, 91  
 Chen, Donna T. ....58  
 Chen, Hongtu .....32  
 Chengappa, K.N. Roy .....24  
 Cheong, Josepha A. ....25, 51, 53  
 Chesen, Chelsea L. ....18, 71  
 Chesen, Eli S. ....71  
 Chester, Janis G. ....33, 50  
 Chevy, Cherry .....77  
 Childress, Anna R. ....94  
 Chiles, Catherine .....67  
 Chinen, Allan B. ....15  
 Chinman, Matthew J. ....25  
 Chin, Charles .....1  
 Cho, Samson J. ....49  
 Chou, James C. ....15  
 Chung, Christopher K. ....49  
 Chung, Henry .....49  
 Citrome, Leslie L. ....30, 75  
 Clark, H. Westley .....43, 51, 66, 93  
 Clark, Michael R. ....84  
 Clark, Michelle O. ....42, 51  
 Clark, Robin E. ....97  
 Clarkin, John F. ....56, 66

Clayton, Anita H. ....65  
 Clelland, James D. ....75  
 Clemens, Norman A. ....17, 50, 67  
 Cloitre, Marylene .....26  
 Cobb, Gary .....80  
 Cobb, Thomas G. ....91  
 Coconcea, Cristinel M. ....91  
 Coconcea, Nicoleta .....91  
 Coffey, C. Edward .....1, 15  
 Coffman, Jennifer K. ....24  
 Cohen, Jonathan D. ....34  
 Cohen, Judith A. ....71, 94, 95  
 Cohen, Lee S. ....11, 23, 32, 57, 76  
 Cohen, Lewis M. ....47  
 Cohen, Neal L. ....20, 59, 68, 93  
 Cole, Steven A. ....60  
 Comer, James P. ....40, 50  
 Conley, Robert R. ....63, 96  
 Connors, C. Keith .....47  
 Connor, Kathryn M. ....8  
 Conroe, Henry G. ....71  
 Conteregg, Carlo .....82  
 Conus, Phillippe .....9  
 Conwell, Yeates .....90, 93  
 Cook, Judith A. ....97  
 Cook, William .....97  
 Cook, Jr., Edwin H. ....35  
 Coplan, Jeremy D. ....57  
 Cordal, Adriana .....23  
 Cordova, Matthew .....61  
 Cornblatt, Barbara .....65, 87  
 Cornwell, John .....55  
 Corral, Maria R. ....8  
 Cortese, Leonardo .....1  
 Cosgrove, Victoria E. ....60  
 Costa, Jr., Paul T. ....82  
 Costantino, Guiseppe .....32  
 Costello, E. Jane .....35  
 Cournos, Francine .....16, 48, 61  
 Coutanceau, Roland M. ....33  
 Coyle, James .....57  
 Cozza, Kelly L. ....15, 39  
 Cozza, Stephen J. ....19, 59  
 Cramer, Daniel W. ....57  
 Crane, Daniel L. ....92  
 Creson, Daniel L. ....31  
 Crits-Christoph, Paul .....34  
 Crone, Catherine A. ....22, 69  
 Crone, Cynthia C. ....20  
 Crosby, Ross D. ....30  
 Crossett, Judith H. W. ....18  
 Crowley, Brian .....10, 33  
 Cuccaro, Michael L. ....74  
 Culpepper, Larry .....22  
 Cunningham, Philippe B. ....95  
 Curie, Charles .....26  
 Currier, Glenn W. ....41  
 Cutler, Andrew J. ....6  
 Cutler, Jay B. ....72

D

Daggett, Pamela .....98  
 Dahl, Ronald E. ....35  
 Daleo, Dina .....42  
 D'Alli, Richard E. ....53, 69  
 Daniels, Allen S. ....82  
 Danielyan, Arman K. ....97  
 Danies, Nora .....74  
 Danko, George P. ....22  
 Darabus, Alexandrina .....90  
 Daulouede, Jean-Pierre .....95  
 David, Daniella .....55  
 David, Stacy R. ....95  
 Davidson, Jonathan R.T. ....8, 64

- Davine, Jonathan S. ....71  
 Davis, Glen P. ....24  
 Davis, Glenn C. ....77  
 Davis, Kenneth L. ....12  
 Davoren, Mary Jo .....44  
 Deas, Deborah .....58  
 DeBellis, Michael D. ....94  
 Deblinger, Esther .....94  
 De Cory-Woronoff, Yvonne L. ....42  
 Defaria, Ludmila .....55  
 De Guzman, Denise .....77  
 De Jong, Joop .....19, 47  
 de La Gandara, Jose E. ....25  
 Delgado, Pedro L. ....64  
 Demant, Jean-Claude .....59  
 Dennis, Michael L. ....83, 84  
 De Roten, Yves .....34  
 DeRubeis, Robert J. ....34, 96  
 Desai, Prakash N. ....93  
 Des Jarlais, Donald C. ....82  
 Despland, Jean-Nicolas .....34  
 Detre, J. ....94  
 Deutsch, Stephen I. ....19  
 Deutschman, Daniel A. ....7, 19, 77  
 Devanand, Davangere P. ....30  
 DeVane, C. Lindsay .....2  
 Devarajan, S. ....13  
 Devlin, Michael J. ....7, 59  
 Dewan, Mantosh J. ....38  
 Dhopes, Vasant P. ....44  
 DiCamillo, Amy .....49  
 Dickstein, Leah J. ....19, 27, 51, 77, 82  
 Di Cori, Ferruccio A. ....16  
 Dietrich, Allen .....60  
 Difede, JoAnn .....53  
 di Giannantonio, Massimo .....22  
 Dillon, James E. ....7, 77  
 Dinges, David F. ....86  
 Dinwiddie, Stephen H. ....6  
 Ditter, Susan M. ....76  
 Dixon, Lisa B. ....59, 74  
 Doddakashi, Veena R. ....93  
 Dodson, Thomas W. ....33  
 Doghranji, Karl .....13, 23, 27, 86, 92  
 Dohrenwend, Bruce .....57, 91  
 Dolan-Sewell, Regina .....17  
 Dolder, Christian .....37  
 Donegan, Nelson H. ....56  
 Dong, Yun .....81  
 Donohue, Micca .....75  
 Donovan, Sheila .....48  
 Doody, Rachelle S. ....85  
 Doraiswamy, P. Murali .....64  
 Dorce, Daphne .....89  
 Dording, Christina M. ....23, 49  
 Dorer, David J. ....30  
 Doty, Richard L. ....43  
 Downey, Jennifer I. ....18  
 Downs, Susan R. ....52  
 Doyle, Allysa .....86  
 Draeger, John H. ....22  
 Drake, Robert E. ....48, 59, 97  
 Drescher, Jack .....70, 80  
 Dresner, Nehama .....15  
 Dryden-Edwards, Roxanne C. ....50  
 Du, Nang .....49, 72, 89  
 Dubin, Hinda F. ....18  
 Dubo, Elyse D. ....22, 40  
 Dubois, Michel .....84  
 Duckworth, Kenneth S. ....49, 71  
 Dudley, Jr., Richard G. ....80  
 Duffy, Farifeh F. ....60, 98  
 Dulcan, Mina K. ....35  
 Dunayevich, Eduardo .....1  
 Dunn, Laura B. ....37, 76  
 Dunn, Robert T. ....90  
 Dunner, David L. ....13, 33, 37, 47  
 Dvorak, Ramona .....7  
 Dyck, Ingrid R. ....56
- E**
- Eaton, William W. ....82  
 Ebert, Michael H. ....77  
 Eckley, Marilyn L. ....43  
 Eddy, Kamryn T. ....30  
 Eder, Harald .....95  
 Edman, Jeanne .....49  
 Edwards, Kimberly B. ....95  
 Edwin, Ama K. ....23  
 Egan, Elizabeth .....48  
 Egger, Helen L. ....83  
 Ehram, Ronald .....94  
 Eist, Harold I. ....32, 60, 77, 89  
 Ekeberg, Oivind .....31  
 Eklund, Steve A. ....38  
 El-Guebaly, Nady .....32  
 Eldreth, Dana .....82  
 Elias, Eileen .....43  
 Eliason, Michele J. ....93  
 Elinson, Lynn I. ....60  
 Ellingrodinggold, Vicki L. ....75  
 Elliott, Delbert .....77  
 Elliott, Richard L. ....14  
 England, Mary Jane .....17, 43  
 English, Michael .....32, 97  
 Engstrom, Frederick W. ....52  
 Enomoto, Kana .....49, 58  
 Enright, Timothy .....23  
 Epstein, Steven A. ....49  
 Ercoli, Linda M. ....34  
 Ereier, Alan .....95  
 Erickson, Mark .....88  
 Erickson, Paul .....48  
 Erman, Milton K. ....13, 37  
 Ernst, Monique .....81, 82  
 Erwin, Rodney J. ....76  
 Escobar, Javier I. ....1  
 Essock, Susan M. ....97  
 Eth, Spencer .....26, 59  
 Evaldson, John R. ....88  
 Evans, Angela R. ....24, 47  
 Everett, Anita .....35
- F**
- Faber, Raymond A. ....1, 5  
 Factor, Robert M. ....97  
 Faenza, Michael M. ....73  
 Fagan, Peter J. ....82  
 Faheem, Uzma S. ....47  
 Fahrner, Rodolfo D. ....84  
 Fairburn, Christopher .....59  
 Faison, Warachal E. ....25  
 Fallon, Brian A. ....20, 29  
 Farand, Lambert .....24  
 Faraone, Stephen V. ....86  
 Farber, Nancy .....60  
 Farlow, Martin K. ....64  
 Farook, Suhaila .....55  
 Fassler, David .....90  
 Faulkner, Larry R. ....77  
 Faust, William .....32  
 Fava, Maurizio .....6, 13, 23, 49, 61, 75, 76  
 Fawcett, Jan A. ....29, 96  
 Fedoroff, J. Paul .....67  
 Feiner, Joel S. ....32  
 Feldman, Neil .....49  
 Felthous, Alan R. ....95, 96  
 Felton, Chip J. ....17, 71  
 Fenton, Wayne S. ....73  
 Ferguson, Yvonne B. ....7  
 Ferrando, Stephen J. ....29, 61  
 Ferro, Maria F. ....22  
 Fetkewicz, Janet M. ....56  
 Fichtner, Christopher G. ....1, 6, 32  
 Field, Craig .....96  
 Fiellin, David .....66  
 Fieve, Ronald R. ....23, 92  
 Fillit, Howard .....92  
 Findling, Robert L. ....5, 14, 38  
 Fink, Arlene .....33  
 Fink, Max .....1, 79  
 Finney, Joseph C. J. ....26  
 Flocchi, Elaine .....49  
 Fiorentino, Mara J. ....71  
 First, Michael B. ....14, 35, 48  
 Fischbach, Gerald D. ....20  
 Fischbein, Ellen R. ....18  
 Fischer, Gabriele .....95  
 Fisher, Garry .....80  
 Fisher, Kathleen M. ....80  
 Fisher, William .....50  
 Fishman, Marc .....84  
 Fitek, Diana J. ....94  
 Flaherty, Lois T. ....39, 89  
 Fleming, Candace M. ....5  
 Flint, Alastair J. ....30  
 Flood, Dorothy G. ....49  
 Fonagy, Peter .....31  
 Fong, Timothy W. ....42  
 Foote, William W. ....15, 39  
 Forehand, Jr., Lyle B. ....25  
 Fornash, Anna .....94  
 Forquer, Sandra L. ....25  
 Forrester, Honorable Lee .....38  
 Forstein, Marshall .....44, 61  
 Forster, Peter L. ....35, 41, 71  
 Foster, Helen M. ....72  
 Foti, Mary E. ....45  
 Foulks, Edward F. ....31  
 Frances, Richard J. ....44  
 Frank, Denise .....55  
 Frank, Ellen .....3, 13, 96  
 Frank, Guido .....30  
 Frankenburg, Frances R. ....24, 74, 81  
 Frankle, W. Gordon .....8  
 Franklin, Ophie .....44  
 Franklin, Teresa R. ....94  
 Franko, Debra .....30  
 Franques, Pascale .....95  
 Frare, Franco .....75  
 Frattaroli, Elio J. ....72  
 Frazier, Jean A. ....6  
 Frazier, Marvis .....80  
 Freedman, Joshua E. ....77  
 Freedman, Robert .....12  
 Freeman, Elsie J. ....49  
 Freyd, Pamela .....56  
 Friedberg, Jennifer .....64  
 Friedman, Lee .....87  
 Friedman, Matthew J. ....17, 71  
 Frueh, Christopher B. ....55  
 Frye, Mark A. ....2, 3, 5, 34, 63  
 Fryer, John E. ....43  
 Fulbright, Robert K. ....24, 56  
 Furedi, Janos .....75  
 Futterman, Robert .....92
- G**
- Gabbard, Glen O. ....15, 20, 33, 39, 56  
 Gal, Joseph .....2  
 Galanter, Marc .....44, 45, 55

PARTICIPANT INDEX

Galeno, Roxana ..... 88  
 Galynker, Igor I ..... 81, 82  
 Gandhi, Meeta ..... 44  
 Gangure, Dimu P. .... 23, 75  
 Gans, Jerome S. .... 14  
 Garb, Jane ..... 47  
 Gardner, David M. .... 66  
 Gardner, Eliot L. .... 62  
 Gardner, Jr., Russell J. .... 32, 56  
 Garland, David W. .... 26  
 Garrido, Pedro J. .... 23  
 Garver, David L. .... 93  
 Garza, Daniel ..... 19, 93  
 Gastfriend, David R. .... 33  
 Gaw, Albert C. .... 7, 19  
 Geddes, John ..... 66  
 Gelenberg, Alan J. .... 60, 75, 81  
 Geller, Jeffrey L. .... 32  
 Gendel, Michael H. .... 85  
 George, Mark S. .... 9, 15, 81  
 Gerbarg, Patricia L. .... 67  
 Geric, Guido ..... 95  
 Gemain, Michael ..... 47  
 Gertmerian-King, Enid C. .... 82  
 Gesy, Lawrence ..... 58  
 Ghaemi, S. Nassir ..... 33, 62, 65, 88  
 Gherardelli, Simona ..... 24  
 Ghinassi, Frank ..... 43  
 Ghorpade, Amarsingh M. .... 48  
 Ghosh-Ippen, Chandra ..... 61  
 Giannini, Carol ..... 8  
 Gilbert, Kenneth G. .... 69  
 Gillette, Sherrie ..... 95  
 Gise, Leslie H. .... 15, 23, 70  
 Gitlin, Michael J. .... 34, 90  
 Glancey, Graham G. .... 67  
 Glassman, Alexander H. .... 20, 65, 87  
 Gliatto, Michael F. .... 29  
 Glikman, Jacques ..... 59  
 Godard, Sally L. .... 70  
 Goebert, Deborah ..... 22  
 Goethe, John W. .... 47, 76  
 Goff, Donald C. .... 3  
 Goginemi, R. Rao ..... 31, 84  
 Goin, Marcia K. .... 68  
 Goisman, Robert M. .... 39  
 Gold, Marla J. .... 90  
 Goldberg, Carl ..... 26  
 Goldberg, David A. .... 26  
 Goldberg, Joel ..... 55  
 Goldberg, Joseph F. .... 11, 24, 33, 62, 63  
 Goldfein, Juli A. .... 59  
 Goldfinger, Stephen M. .... 35, 71, 89, 94  
 Goldman, Charles R. .... 94  
 Goldman, Howard H. .... 35  
 Goldman, Margo P. .... 76  
 Goldman-Rakic, Patricia S. .... 24  
 Goldner, Elliot M. .... 57, 66  
 Goldstein, Marion Z. .... 73, 82  
 Goldstein, Robert ..... 49  
 Gomez, Ivan S. .... 47  
 Goncalves, Nuno ..... 48  
 Gongora, Orlando ..... 74  
 Gonzales, Junius J. .... 32  
 Gonzalez, Abel A. .... 76, 92  
 Goodkin, Karl ..... 29, 61, 89  
 Goodman, Marianne ..... 74, 84, 87  
 Goodnick, Paul J. .... 47  
 Goodwin, Frederick K. .... 33, 62, 90  
 Goodwin, Guy M. .... 8, 11  
 Gopalakrishnan, Raman N. .... 75  
 Gordon, Edward ..... 33, 76, 89  
 Gordon, Malcolm A. .... 71  
 Gordy, Tracy R. .... 50, 89  
 Gore, John C. .... 24, 56

Gorelick, David A. .... 33, 34, 83  
 Gorman, Jack M. .... 3, 57, 63  
 Gorton, Gregg E. .... 43  
 Gottdiener, William H. .... 31  
 Gottheil, Edward ..... 75, 92  
 Gould, Elizabeth ..... 63  
 Gould, Madelyn ..... 78, 90  
 Grady, Brian J. .... 19, 62  
 Grady-Weliky, Tana A. .... 65  
 Granacher, Robert P. .... 15  
 Grant, Jon E. .... 51  
 Gray, Gregory E. .... 62, 66  
 Gray, Jason ..... 94  
 Gray, Kevin F. .... 5  
 Greden, John F. .... 68  
 Green, Bonnie L. .... 96  
 Green, Melva I. .... 46  
 Green, Stephen A. .... 87  
 Greenberg, Harvey R. .... 12, 29  
 Greenberg, Jennifer ..... 84  
 Greenberg, Ted ..... 55  
 Greenberg, William M. .... 42  
 Greene, Judy ..... 92  
 Greenfield, Shelly F. .... 26, 48  
 Greenhill, Laurence L. .... 83, 98  
 Greenspan, David I. .... 92  
 Greenstein, Robert A. .... 81  
 Greenwald, Blaine S. .... 88  
 Greiner, Carl B. .... 18  
 Greist, John H. .... 13, 64  
 Gresham, Robert L. .... 23, 76  
 Grier, Nichole D. .... 70  
 Griffin, Margaret L. .... 48  
 Griffith, James L. .... 57  
 Grilo, Carlos M. .... 24, 55, 56, 81  
 Grimaldi, Jr., John A.R. .... 25  
 Grisso, Thomas ..... 58  
 Grodin, Michael A. .... 67  
 Grodau, Danielle ..... 33  
 Gronvold, Nina ..... 31  
 Gross, Richard L. .... 39  
 Groves, Mark S. .... 22  
 Gruenberg, Alan M. .... 48  
 Grunhaus, Leon J. .... 14  
 Gu, Hongbin ..... 95  
 Gualtieri, Thomas ..... 43  
 Guarda, Angela S. .... 59  
 Gudeman, Jonathan E. .... 50  
 Gueorguieva, Ralitzia ..... 92  
 Gunderson, John G. .... 15, 24, 56, 81  
 Gur, Raquel E. .... 34, 74  
 Gurrera, Ronald J. .... 81  
 Guschwan, Marianne T. .... 93  
 Gusmorino, Paul ..... 84  
 Guynn, Robert W. .... 19

H

Haatainen, Kaisa ..... 46  
 Habeych, Miguel ..... 47  
 Hadley, Sallie J. .... 34, 64  
 Hafliger, Silvia ..... 25, 39  
 Hafter-Gray, Sheila ..... 17, 31  
 Haines, Michael ..... 97  
 Hakko, Helina ..... 91, 92  
 Hales, Deborah J. .... 89  
 Hales, Robert E. .... 13, 28, 37  
 Hall, Molly J. .... 42  
 Haller, Ellen ..... 52, 76  
 Halliday-Boykins, Colleen A. .... 95  
 Halmi, Katherine A. .... 7, 30  
 Halpern, Abraham L. .... 25  
 Hamadani, Houshang G. .... 22  
 Hamner, Mark B. .... 55  
 Haning III, William F. .... 50

Hansen, Mark R. .... 8  
 Hanson, Annette L. .... 69  
 Hanson, Graeme ..... 76, 95  
 Haponski, David ..... 8  
 Harb, Gerlinde C. .... 61  
 Harding, Richard K. .... 7, 10, 14, 29, 35, 59  
 Harkness, Kate ..... 96  
 Harlow, Bernard L. .... 57  
 Harmison, Sheila ..... 93  
 Harrington, Colin J. .... 38  
 Harris, Terry ..... 54  
 Harris-Hendriks, Jean ..... 61  
 Harrow, Martin ..... 24, 48  
 Hartikainen, Anna-Liisa ..... 48  
 Hartmann, Lawrence ..... 31, 45  
 Hartz, Arthur J. .... 75  
 Harvey, Philip D. .... 84  
 Hasin, Deborah S. .... 48  
 Haskett, Roger F. .... 23, 35  
 Haslam, David R.S. .... 66  
 Haslam, Nick ..... 31  
 Hatot, Norma ..... 77  
 Hatti, Shivkumar ..... 1  
 Hault, Connie ..... 13  
 Hausser, Lawrence A. .... 93  
 Havens, Jennifer F. .... 44  
 Hawkins, Keith A. .... 92, 95  
 Haynes, Kamlyn R. .... 90  
 Hays, Lon R. .... 75  
 Heap, Joann ..... 74  
 Hebrank, Jessica ..... 75  
 Heck, Paul W. .... 17  
 Heerlein, Andres ..... 84  
 Heidel, Stephen H. .... 7  
 Heimberg, Richard G. .... 61  
 Heinberg, Leslie J. .... 59  
 Heinze, Gerardo ..... 77  
 Heishman, Stephen J. .... 81  
 Heit, Howard A. .... 62  
 Hektner, Joel ..... 96  
 Hellerstein, David J. .... 92  
 Henderson, David C. .... 37, 64  
 Hendin, Herbert ..... 78  
 Hendrick, John P. .... 48  
 Hendriks, Vincent ..... 95  
 Henggeler, Scott W. .... 95  
 Hennekens, Charles H. .... 64  
 Hennen, John ..... 24, 48, 81  
 Henningfield, Jack E. .... 81  
 Hensley, Paula L. .... 75, 77  
 Herbeck, Diane M. .... 94  
 Herbener, Ellen S. .... 24  
 Herbst, Jeffrey H. .... 82  
 Herman, Sol ..... 19  
 Hermann, Richard C. .... 25, 69  
 Hernandez-Serrano, Ruben J. .... 84  
 Hersh, Richard G. .... 66, 88  
 Heru, Alison M. .... 18, 26  
 Herzog, David B. .... 30  
 Hester, Thomas W. .... 32  
 Hiatt, John F. .... 15, 39  
 Hicks, Daniel W. .... 51, 70  
 Hicks, Madelyn H. .... 18, 47  
 Hieble, J. Paul ..... 88  
 Hierholzer, Robert W. .... 90  
 Hill, Angela L. .... 24  
 Hill, Jerrold W. .... 92  
 Hill, Kevin J. .... 75  
 Hill, Marjorie ..... 80  
 Hilsabeck, Robin C. .... 26  
 Hilty, Donald M. .... 51, 92  
 Hinden, Beth ..... 51  
 Hirschfeld, Robert M.A. .... 3, 11  
 Hirshkowitz, Max ..... 78  
 Ho, Andrew P. .... 8, 41, 52

- Hoffman, Amy S. ....20  
Hoffman, Marcia .....74  
Hoffman, Ralph E. .... 56, 92  
Hoge, Michael A. .... 82  
Hoglund, Per A. .... 34  
Holden, Wayne .....90  
Holland, Jimmie C. ....17  
Hollander, Annette J. .... 26, 88  
Hollander, Eric ..... 34, 64, 84, 87  
Hollifield, Michael A. ....77  
Hollon, Steven D. ....96  
Holtzheimer III, Paul E. .... 25, 76, 91  
Honeyman, David L. ....47  
Hong, Victor .....49  
Hoopes, Scott P. ....22  
Hoppe, Sue K. ....98  
Houck, Patricia .....96  
Houghtalen, Rory P. ....89  
Howe, Edmund G. ....7  
Howell, Ambassador Nathaniel .....77  
Howland, Robert H. ....52  
Hsu, Fang-Chi .....82  
Hu, Rona .....13  
Hu, Yuange .....50  
Huang, Frederick Y. ....70  
Huang, Li-Shan .....48  
Hudson, James I. ....86  
Hudziak, James J. ....64  
Huey, Leighton Y. .... 76, 82  
Huggins, Teresa .....34  
Hughes, Douglas H. ....63  
Hughes, Megan E. .... 49, 61  
Hughes, Michael C. ....42  
Hughes, Rod J. ....49  
Hughes, Vincent J. ....43  
Hurwitz, Thomas D. .... 27, 78  
Husain, Mustafa M. .... 52, 64  
Husain, S. Arshad .....31  
Hussain, Mohammad Z. .... 23, 47, 76, 91  
Hussain, Seema ..... 23, 47, 76, 91  
Hwang, Michael Y. .... 19, 30  
Hyler, Steven E. .... 12, 14, 56
- I
- Iqbal, Naveed .....19  
Irani, David N. ....29  
Ishak, Waguih W. .... 38, 70  
Isohanni, Matti K. .... 48, 91, 92  
Issette, Arth .....55
- J
- Jabbarpour, Yadollah M. .... 21, 32  
Jackson, James S. .... 34, 35  
Jackson, Richard S. ....7  
Jacobs, Douglas G. ....93  
Jacobs, Selby C. ....61  
Jacobson, Lara M. ....48  
Jaffe, Ellen .....76  
Jaffe, Jerome H. ....43  
Jaffe, Richard L. ....38  
Jamieson, Patrick .....78  
Jamison, Kathleen ..... 42, 78  
Janicak, Philip G. .... 24, 38, 48  
Jarboe, Kathleen ..... 9  
Jarrett, Robin B. ....9  
Jarvelin, Marjo-Riitta .....48  
Jaycox, Lisa .....33  
Jensen, Peter S. .... 17, 90, 98  
Jensvold, Margaret F. ....26  
Jeon, Wootaeck .....22  
Jeste, Dilip V. .... 35, 37
- Jetha, M.K. ....55  
Jiang, Sue .....48  
Jibson, Michael D. ....85  
Jimerson, David C. .... 7  
Jobe, Thomas H. ....24  
Johnson, Bankole A. ....55  
Johnson, Bradley R. .... 50, 88  
Johnson, Janet J. ....55  
Johnson, Myles .....48  
Jokelainen, Jari .....48  
Jones, Beverly N. ....57  
Jones, Billy E. ....80  
Jones, Kristina L. ....25  
Jones, Peter B. ....48  
Jones-Gotman, Marilyn .....43  
Joranson, David E. ....62  
Jorge, Miguel R. .... 77, 84  
Jorgenson, Linda M. .... 19, 26  
Joukamaa, Matti ..... 91, 92  
Joy, Charles R. .... 50, 89  
Juthani, Nalini V. ....44
- K
- Kachigian, Claudia A. .... 95, 96  
Kadden, Ronald .....43  
Kahn, Jeffrey P. ....50  
Kakouros, Aphrodite .....54  
Kalasapudi, Vasundhara .....48  
Kales, Helen C. ....22  
Kalin, Ned H. ....11  
Kallaba, Melita .....57  
Kalogerakis, Michael G. ....89  
Kamble, Madhuri V. ....26  
Kamin, Marc .....22  
Kamm, Ronald L. .... 54, 80  
Kampman, Kyle M. ....94  
Kandel, Rachel .....54  
Kane, John M. .... 9, 13  
Kanefield, Marvin .....10  
Kaplan, Ana ..... 1  
Kaplan, Gabriel ..... 1, 38  
Kaplan, Tony .....61  
Kapoor, Vinay ..... 19, 26  
Kapur, Shitij .....96  
Karasic, Dan H. .... 19, 28, 76  
Karasu, T. Byram .....52  
Karim, Rezaul .....22  
Karinsky, Harry .....57  
Karp, Jordan F. ....18  
Karvois, Debra .....22  
Kastrup, Marianne C. ....60  
Kataoka, Sheryl H. ....33  
Katon, Wayne J. ....60  
Katz, Bernard A. .... 7  
Katz, Ira R. ....80  
Katz-Leavy, Judith .....51  
Katzelnick, David J. .... 60, 82  
Katzow, Jacob J. ....33  
Kauffman, Christopher I. ....29  
Kaufman, Joan .....55  
Kaushik, Saurabh .....48  
Kay, Jerald ..... 26, 29, 45, 74  
Kaye, Walter H. ....30  
Keane, Terence M. .... 55, 67  
Keck, Jr., Paul E. .... 11, 81, 93  
Keel, Pamela K. ....30  
Keith, Samuel J. .... 9  
Kelleher, Kelly .....43  
Keller, Martin B. .... 11, 22, 60  
Kellner, Charles H. .... 1, 38  
Kelly, Deanna L. ....96  
Kelly, Thomas M. ....24  
Kendell, Robert E. ....34  
Kendler, Kenneth S. ....34
- Kennedy, Gary J. .... 53  
Kennedy, Lawrence L. .... 38  
Kennedy, Robert S. .... 52  
Kent, Justine M. .... 63  
Kerbeshian, Jacob ..... 95  
Kern-Jones, Sheryl .....62  
Kernberg, Otto F. ....66  
Keshavan, Matcheri S. .... 94  
Kessler, Richard J. ....70  
Kessler, Ronald C. ....10  
Kestenbaum, Clarice J. .... 25  
Ketter, Terence A. .... 5, 24, 63  
Kettl, Paul A. .... 42, 80  
Khan, Huma K. ....44  
Khan, Shahbaz A. ....18  
Khosroshahi, Hashem .....74  
Khouzam, Hani Raoul .....90  
Kiehl, Kent .....82  
Kilts, Clinton D. ....63  
Kim, Kathleen M. ....93  
Kim, Scott Y. ....58  
Kimes, Alane S. ....82  
Kimmel, Douglas C. ....80  
King, Steven A. .... 2  
Kingsley, Ellen ..... 38  
Kinson, Bruce J. ....24  
Kinsella, Anthony .....96  
Kirchner, Chris M. ....71  
Kirmayer, Laurence J. .... 34, 35  
Kirwin, Paul D. ....67  
Kiss, Kitty .....75  
Kittay, Michael J. ....90  
Klagsbrun, Samuel C. .... 26, 70  
Kleber, Herbert D. .... 34, 43, 66  
Klee, George .....34  
Kleinman, Arthur M. ....17  
Kling, Mitchel A. ....52  
Kluft, Richard P. ....91  
Knauer, Nancy J. ....43  
Knight, Edward .....25  
Kocsis, James H. ....96  
Koenan, Karestan .....91  
Koenig, Harold G. ....76  
Koenigsberg, Harold W. .... 74, 84, 87  
Kogan, Richard .....27  
Kolodner, George F. ....49  
Kolodny, Andrew J. ....74  
Kolodziej, Monika .....48  
Komaroff, Anthony L. ....86  
Kompore, Ivan .....47  
Koopman, Cheryl .....61  
Kopala, Lilli .....13  
Koplewicz, Harold S. ....26  
Koretz, Doreen S. ....35  
Kornstein, Susan G. .... 6, 9  
Koss-Chioino, Joan D. ....62  
Kosten, Thomas R. .... 66, 95  
Kotler, Lisa A. ....59  
Korwicky, Raymond J. ....70  
Koutsogiannis, John ..... 9  
Kovaszny, Beatrice M. ....32  
Kowatch, Robert A. .... 5  
Kozel, Andrew F. ....81  
Koziupa, Diana M. ....97  
Krahn, Lois ..... 8, 13, 78  
Krakowski, Menahem I. ....91  
Kramer, Douglas A. ....32  
Kramer, Milton ..... 2  
Kramer, Peter D. ....33  
Kramer, Thomas A.M. ....89  
Kranzler, Henry R. ....55  
Kratovich, Christopher J. .... 3, 83  
Kraus, Louis J. ....89  
Kraus, Marilyn F. ....43  
Kraus, Jr., John E. ....72

PARTICIPANT INDEX

Krausz, Michael ..... 95  
 Kravitz, Howard M. .... 23  
 Kreek, Mary Jeanne ..... 21  
 Krejci, Jonathan ..... 33  
 Krishnan, Ranga K. .... 6, 11, 28  
 Kroenke, Kurt ..... 60  
 Kroll, Jerome L. .... 48  
 Krupnick, Janice L. .... 96  
 Krystal, John H. .... 35, 83, 92  
 Kumar, Anand ..... 5, 30  
 Kunkel, Elisabeth J.S. .... 44, 75  
 Kupfer, David J. .... 3, 34, 63, 96  
 Kurian, Varughese ..... 82

L

Lacy, Timothy J. .... 42  
 Lagodmos, Greta ..... 25  
 Lakia, Amaro ..... 23  
 Lam, Raymond W. .... 2  
 Langleben, Daniel D. .... 94  
 Lapeyra, Olga M. .... 55  
 Lappin, Debra ..... 60  
 Lara, Michael E. .... 92  
 Larsen, Robert C. .... 77  
 Laub, Dori ..... 12  
 Laughlan, Catherine ..... 75  
 Lauriello, John ..... 75  
 Lavretsky, Helen ..... 30  
 Lawrence, Earl C. .... 41  
 Lawson, William B. .... 17, 58, 70, 94  
 Lazarus, Arthur L. .... 25, 93  
 Leach, David ..... 29  
 Leavitt, Renee ..... 97  
 Lebovits, Allen ..... 84  
 Lecusay, Robert ..... 29  
 Lee, Diana ..... 29  
 Leguay, Denis ..... 59  
 Lehman, Anthony F. .... 35, 97  
 Lehmann, Laurent S. .... 18  
 Leibenluft, Ellen ..... 3  
 Leite, Paul ..... 61  
 Lejoyeux, Michel ..... 83  
 Lencz, Todd ..... 65  
 Lenhart, Sharyn A. .... 52  
 Leon-Andrade, Carlos ..... 84  
 Leong, Richard ..... 75  
 Leonhardt, Tami V. .... 74  
 Lesser, Michael S. .... 93  
 Levendusky, Philip G. .... 39  
 Levenson, Alan I. .... 18  
 Levenson, James L. .... 41  
 Levi-Pearl, Sue ..... 88  
 Levin, Frances R. .... 34, 44, 55  
 Levin, Harvey ..... 43  
 Levin, Saul M. .... 90, 93  
 Levine, Jeffrey M. .... 44  
 Levine, John B. .... 25  
 Levitt, Anthony J. .... 2  
 Levkoff, Sue E. .... 32  
 Levy, Ken ..... 56  
 Lewis, David A. .... 12  
 Lewis, Evelyn L. .... 43  
 Lewis, Lydia J. .... 59  
 Lewis-Fernandez, Roberto ..... 23, 57, 61, 91  
 Lewy, Alfred J. .... 8  
 Li, Xingbao ..... 81  
 Liang, Kung-Ye ..... 82  
 Liang, Warren M. .... 89  
 Lichtenstein, Bill ..... 73  
 Lidz, Charles ..... 58  
 Lieberman, Alicia F. .... 61  
 Lieberman, Jeffrey A. .... 9, 10, 12, 95  
 Liebling, David S. .... 57  
 Liebowitz, Barry D. .... 85

Liebowitz, Michael R. .... 61  
 Lief, Harold I. .... 56  
 Lim, Russell F. .... 5  
 Limoges, Richard F. .... 85  
 Lin, Keh-Ming ..... 34, 35, 49, 70, 72  
 Lindenmayer, Jean-Pierre ..... 41  
 Ling, Walter ..... 50  
 Links, Paul S. .... 81  
 Lippa, Carol ..... 73  
 Lipschitz, Deborah S. .... 55  
 Lipsitz, Joshua D. .... 97  
 Lipsius, Steven H. .... 90  
 Lisanby, Sarah H. .... 14, 81  
 Listerud, John M. .... 94  
 Litten, Raye Z. .... 83  
 Litts, David A. .... 90  
 Liu, Hong ..... 24  
 Lively, Cathy ..... 71  
 Livingston, Richard L. .... 42  
 Llorente, Maria D. .... 32  
 Lloyd, John R. .... 92  
 Loboprabhu, Sheila M. .... 5  
 Lochman, John E. .... 96  
 Lock, James D. .... 59  
 Lockhart, Paula J. .... 50  
 Loeb, Katherine L. .... 59  
 Logsdon, Linda ..... 85  
 Loirat, J. C. .... 59  
 Lomax II, James W. .... 5, 15, 39  
 Londino, Donna L. .... 93  
 London, Edythe ..... 81, 82  
 Lonsdorf, Richard G. .... 35  
 Lopez, Frank A. .... 47  
 Losonczy, Mildos F. .... 19  
 Lotan, Sandra Y. .... 79  
 Lovelace, Joe ..... 9  
 Lovett, Margaret ..... 96  
 Lowenkopf, Eugene L. .... 75, 92  
 Lu, Francis G. .... 5, 15, 43, 49, 69, 76, 80, 90, 93, 94  
 Luchins, Daniel J. .... 32  
 Lucksted, Alicia ..... 74  
 Lunn, Brian ..... 30  
 Luo, John ..... 19, 38, 52, 72  
 Lurie, Lawrence B. .... 50  
 Lydiard, R. Bruce ..... 10, 61, 87  
 Lyketsos, Constanine G. .... 7

M

Ma, Albert Y. .... 47  
 Ma, Guoquang ..... 23  
 MacIntyre II, James C. .... 69  
 MacLean, Alexandra ..... 59  
 Maffei, Cesare ..... 31  
 Magder, David M. .... 48  
 Magee, Christine ..... 91  
 Maguire, Gerald A. .... 6  
 Mahrer, David ..... 44  
 Maier, James M. .... 25  
 Maki, Pirjo H. .... 91, 92  
 Malcolm, Jr., Robert J. .... 55  
 Maldari, Liza ..... 87  
 Malhotra, Seema ..... 25  
 Mallen, Lucinda ..... 51  
 Malmquist, Carl P. .... 26  
 Malone, Kevin M. .... 24  
 Maloney, Ann S. .... 60  
 Maltzberger, John T. .... 78  
 Malur, Chitra ..... 1  
 Mancini, Catherine L. .... 22  
 Mandelkern, Mark ..... 81  
 Manji, Hussein K. .... 12  
 Mann, J. John ..... 24  
 Mann, Stephan C. .... 29, 81

Mannarino, Anthony P. .... 94  
 Manu, Peter ..... 71  
 Marangell, Lauren B. .... 9, 11, 81  
 Marazziti, Donatella ..... 7  
 March, John S. .... 87  
 Marchant, Nestor F. .... 84  
 Marcus, Eric R. .... 25, 69  
 Marcus, Steve C. .... 60  
 Marder, Stephen R. .... 9, 38, 59  
 Margo, Geoffrey M. .... 27  
 Margo, Katherine L. .... 27  
 Markovich, Phillip ..... 95  
 Markowitz, John C. .... 6, 48, 66, 96, 97  
 Marks, Robert C. .... 24  
 Markvitsa, Romana ..... 38, 70  
 Marmar, Charles R. .... 57  
 Marshall, Randall D. .... 17, 26, 57, 61, 91  
 Martija, Alfredo ..... 90  
 Martin, Eileen M. .... 24  
 Martinez, David C. .... 78  
 Martis, Brian ..... 24  
 Martorell, Arnaud ..... 33  
 Marumoto, Megan T. .... 76  
 Masand, Prakash S. .... 13, 37, 63, 96  
 Masi, Gabriele ..... 91  
 Maslansky, Robert ..... 46  
 Massie, Mary Jane ..... 40  
 Masterman, Donna ..... 86  
 Masters, Scott ..... 88  
 Masterson, Gayle ..... 18  
 Masterson, James F. .... 15  
 Mastey, Vera ..... 92  
 Matochik, John A. .... 81, 82  
 Marorin, Anu A. .... 19, 26, 70  
 Matos-Pires, Ana ..... 48  
 Matthews, Karen ..... 23  
 Maurer, Martin H. .... 20  
 Mavissakalian, Matig R. .... 22  
 Mawhinney, Joseph R. .... 71  
 Maxwell, Jane C. .... 83  
 May, Catherine S. .... 7  
 Mayault, Catherine ..... 59  
 Mayeux, Richard ..... 28  
 McCabe, Lee ..... 82  
 McCall, W. Vaughn ..... 38  
 McCance-Katz, Elinore F. .... 46  
 McCann, Una D. .... 81  
 McCarthy, Richard H. .... 71  
 McCartney, Cheryl F. .... 53  
 McCommon, Jr., Benjamin H. .... 18  
 McCue, Robert E. .... 91  
 McDonel-Herr, Betsy ..... 32  
 McDougle, Christopher J. .... 14  
 McDowell, David M. .... 34, 48, 73, 83, 92  
 McElroy, Susan L. .... 28, 86  
 McEvoy, Joseph P. .... 9, 10  
 McFarlane, Rodger ..... 36  
 McFarlane, William R. .... 97  
 McGlashan, Thomas H. .... 24, 55, 56, 81, 95  
 McGorry, Patrick D. .... 9  
 McGrath, Patrick J. .... 61  
 McGuire, Colleen ..... 74  
 McGuire, Michael ..... 56  
 McHugh, Paul R. .... 56  
 McHugo, Gregory ..... 97  
 McIntyre, John S. .... 32, 60, 93  
 McLellan, A. Thomas ..... 18, 26  
 McMahan, David F. .... 89  
 McNicholas, Laura F. .... 18, 66  
 McWilliams, Linda ..... 47  
 Meade, Brian F. .... 75  
 Meagher, David J. .... 96  
 Mee-Lee, Denis ..... 27  
 Mega, Lesly T. .... 69  
 Meisler, Neil ..... 98



Mellman, Lisa A. .... 26, 29, 40, 69  
 Mellman, Thomas A. .... 55  
 Mellott, Katherine ..... 70  
 Melonas, Jacqueline M. .... 18, 42, 72  
 Meloy, J. Reid ..... 31  
 Meltzer, Carolyn C. .... 30  
 Meltzer, Herbert Y. .... 20  
 Mendelowitz, Alan J. .... 64, 85  
 Mendelsohn, Frederick S. .... 74  
 Mendoza, Ricardo P. .... 70  
 Menza, Matthew A. .... 23, 47, 92  
 Merlino, Joseph P. .... 58  
 Metz, Jonathan M. .... 16  
 Metzner, Jeffrey L. .... 76, 97  
 Mezzano, Daniela ..... 22  
 Mezzich, Juan E. .... 20, 25, 29, 77  
 Michaelis, Benjamin H. .... 24  
 Michels, Robert ..... 51, 61  
 Michelson, David ..... 3, 47  
 Mickley, Diane ..... 59  
 Mikalac, Cecilia M. .... 7  
 Mikdowitz, David J. .... 62  
 Milberg, Laurel C. .... 27  
 Millepiedi, Stefania ..... 91  
 Miller, Anita ..... 25  
 Miller, Frederick E. .... 74  
 Miller, Gary E. .... 70  
 Miller, Karen ..... 34  
 Miller, Laura J. .... 69  
 Miller, Matthew S. .... 49  
 Miller, Milton H. .... 89  
 Miller, Paul R. .... 1, 52  
 Miller, Sheldon I. .... 29, 44  
 Miller, Susie ..... 96  
 Miller, Tandy J. .... 95  
 Milliken, Heather ..... 13  
 Millman, Robert B. .... 44  
 Milner, Karen K. .... 44  
 Milrod, Barbara L. .... 17  
 Min, Sung-Kil ..... 22  
 Miner, Christian R. .... 82  
 Mini, Louis J. .... 32  
 Minkoff, Kenneth ..... 52  
 Mintz, David L. .... 50  
 Mintz, Jim ..... 23  
 Mintzer, Jacobo E. .... 7, 25, 85  
 Miotto, Karen A. .... 83  
 Miranda, Jeanne ..... 58, 96  
 Mire, Gina ..... 55  
 Mirin, Steven M. .... 7  
 Mirski, Dario F. .... 1  
 Mischoulon, David ..... 49  
 Miskimen, Theresa M. .... 89  
 Misri, Shaila ..... 8  
 Mitchell, James E. .... 7, 30  
 Mitropoulou, Vivian ..... 74, 84, 87  
 Moak, Gary S. .... 2  
 Moberg, Paul J. .... 43  
 Moffic, Steven ..... 6  
 Moilanen, Kristiina ..... 48  
 Mok, Lillian ..... 91  
 Moller, Henry J. .... 98  
 Monahan, John ..... 10  
 Monoteaux, Michael ..... 86  
 Monterosso, John R. .... 94  
 Montgomery, Richard A. .... 38  
 Monti, Daniel A. .... 48  
 Montoya, Heidi D. .... 23, 76  
 Morecai, Donald J. .... 50  
 Moreno, Francisco A. .... 18, 64  
 Morey, Leslie C. .... 56, 81  
 Morgan, Maria G. .... 96  
 Morris, Philip ..... 83  
 Moss, Quinton E. .... 70  
 Mouratidis, Maria ..... 82

Mucci, Maria ..... 91  
 Mueser, Kim T. .... 59, 97  
 Mufson, Laura ..... 54  
 Mukherjee, Uday K. .... 44  
 Mullen, David ..... 88  
 Munoz, Alicia A. .... 17, 27  
 Munoz, Rodrigo A. .... 25, 32, 49, 60, 77, 89  
 Munoz T, Rodrigo J. .... 77  
 Murphy, Greer M. .... 9  
 Murphy, James M. .... 42  
 Muskin, Philip R. .... 10, 20, 94  
 Musselman, Dominique L. .... 13  
 Musto, David F. .... 50  
 Muszynski, Irvin L. .... 76  
 Mvsacchio, Amelia ..... 84  
 Myers, Michael F. .... 27, 51, 52, 71, 77, 85  
 Myers, Zachary ..... 19, 77  
 Myrick, Hugh ..... 55

## N

Nadelson, Carol C. .... 26, 53, 68, 82  
 Nadiga, Deepa N. .... 77  
 Nadler, Arie ..... 57  
 Nahas, Ziad H. .... 14, 52, 81  
 Najavits, Lisa M. .... 48  
 Nand, Surinder S. .... 49  
 Napier, Kimberly ..... 94  
 Narrow, William E. .... 60, 98  
 Nasrallah, Henry A. .... 13, 37  
 Navalta, Caryl P. .... 84  
 Nazarey, Margaret ..... 52  
 Ndlela, J. Charles ..... 5, 45, 46  
 Neal, Rebecca R. .... 19  
 Neault, Nicole B. .... 49, 61  
 Nelson, Daniel A. .... 91  
 Nelson, J. Craig ..... 6, 64  
 Nelson, Lewis ..... 70  
 Nelson, Lisa J. .... 50  
 Nelson, Mary E. .... 71  
 Nelson, Scott ..... 96  
 Nemeroff, Charles B. .... 11, 28, 63  
 Nestadt, Gerald ..... 82  
 Nestler, Eric J. .... 34  
 Nevfeld, Jonathan ..... 35  
 New, Antonia S. .... 74, 84, 87  
 Newcomer, John W. .... 3  
 Newkirk, Cassandra F. .... 69  
 Newman, Rita R. .... 26, 71  
 Newman, Robert G. .... 95  
 Newmark, Thomas S. .... 26, 50  
 Newport, D. Jeffrey ..... 2, 34  
 Newton, Thomas ..... 52  
 Ng, David ..... 74, 91  
 Nguyen, Cynthia M. .... 93  
 Nguyen, Hoang A. .... 37  
 Nicholson, Joanne ..... 51  
 Nierenberg, Andrew A. .... 2, 6, 23, 49, 61, 76  
 Ninan, Philip T. .... 28  
 Nir, Yehuda ..... 12  
 Nocks, James J. .... 19  
 Noel, Richard L. .... 70  
 Norko, Michael A. .... 10  
 Norris, Donna M. .... 49  
 North, Carol S. .... 8, 97  
 Northcott, Colleen J. .... 18  
 Norwood, Ann E. .... 58  
 Notman, Malkah T. .... 26, 58  
 Novac, Andrei ..... 71  
 Novotny, Sherie L. .... 64  
 Nunes, Edward V. .... 34  
 Nurnberg, H. George ..... 75  
 Nutting, Paul ..... 60  
 Nyman-Rose, Shelly ..... 95  
 Nyyssonen, Kristiina ..... 46

## O

Oakman, Jonathan ..... 22  
 O'Brien, Charles P. .... 18, 83, 94  
 O'Brien, John ..... 50  
 Obuchowski, Michael ..... 65  
 O'Dowd, Nancy ..... 18  
 Oepen, Godehard ..... 16, 25, 32  
 Oesterheld, Jessica R. .... 39  
 Offord, Dan ..... 35  
 Offsay, Julian ..... 18  
 O'Hara, Ruth ..... 9  
 Okasha, Ahmed M.F. .... 17  
 Okasha, Tarek A. .... 70  
 Okereke, N. Kalaya ..... 22, 47  
 Olarte, Sylvia W. .... 52, 89  
 Oldham, John M. .... 15, 56, 69  
 O'Malley, Mary B. .... 49, 86  
 O'Malley, Stephanie S. .... 83  
 Ormens, Russell S. .... 48  
 Orken, Steven ..... 98  
 Opler, Lewis A. .... 5, 19, 25, 30  
 Oquendo, Maria A. .... 24  
 Ordorica, Patricia I. .... 39, 45, 73  
 O'Reardon, John P. .... 96  
 Ortner, Romana ..... 95  
 Osher, Fred C. .... 97  
 Osinowo, Thomas O. .... 18  
 Oslin, David W. .... 32, 83  
 Osofsky, Howard J. .... 51, 67  
 Osofsky, Michael J. .... 51  
 Osher, David N. .... 90  
 Osterman, Janet E. .... 19, 42  
 Otto, Michael W. .... 11, 57  
 Owens, Michael J. .... 2, 28, 63, 65  
 Oxman, Thomas E. .... 60

## P

Pablo, Cristina ..... 48  
 Pacheco, Antonio ..... 84  
 Padrino, Susan L. .... 70  
 Paine, Susan ..... 75  
 Painter, Albert F. .... 7  
 Pallanti, Stefano ..... 34, 55, 64  
 Palmer, Orrin ..... 88  
 Palmer, R. Heather ..... 25  
 Panahon, Norma C. .... 19  
 Pancheri, Paolo ..... 24  
 Pandya, Anand ..... 94  
 Papakostas, George ..... 76  
 Parachini, Elizabeth A. .... 74  
 Pardes, Herbert ..... 20  
 Parikh, Parinda ..... 48  
 Parnell, Sean ..... 75  
 Parrilla, Elsie ..... 23  
 Passow, Emilie S. .... 14  
 Pastor, Sandy ..... 75  
 Patel, Vikram ..... 17  
 Patkar, Ashwin A. .... 48, 75  
 Pato, Michelle T. .... 38, 73  
 Pava, Carmenleonor ..... 74  
 Pava, Joel A. .... 61  
 Pazzagli, Adolfo ..... 55  
 Pechura, Constance M. .... 60  
 Peele, Roger ..... 33  
 Pelham, Jr., William E. .... 47  
 Pelton, Gregory H. .... 28  
 Pender, Vivian B. .... 24, 59  
 Penfold, P. Susan ..... 51  
 Penny, Rosetta H. .... 74  
 Peoples, June ..... 73  
 Perel, James ..... 74  
 Perkins, Diana O. .... 9, 13, 95  
 Perlis, Roy H. .... 23

PARTICIPANT INDEX

Perry, John C. .... 34  
 Persky, Trudy ..... 32  
 Perugi, Giulio ..... 48, 75, 91  
 Pessar, Linda F. .... 18  
 Petersen, Timothy J. .... 49, 61, 76  
 Petersen-Crair, Pamela J. .... 88  
 Peterson, Bradley S. .... 24  
 Peterson, Thomas R. .... 62  
 Petit, Jorge R. .... 1  
 Petitjean, Francois C. .... 59  
 Petkova, Eva. .... 23  
 Petrakis, Ismene L. .... 83  
 Petrides, Georgios. .... 1  
 Pettinati, Helen ..... 83  
 Pettit, Amy R. .... 60  
 Petty, Frederick ..... 87  
 Pevalin, David J. .... 47, 75  
 Pfefferbaum, Betty ..... 8  
 Pflanz, Steven E. .... 7, 44, 50, 77  
 Phelps, Micheal E. .... 34  
 Phillips, Lisa ..... 9  
 Pi, Edmond H.T. .... 70  
 Pinals, Debra A. .... 90  
 Pincus, Harold A. .... 60  
 Pine, Daniel ..... 35, 63  
 Pinson, Letitia A. .... 66  
 Pirard, Sandrine ..... 33  
 Pittman, Mary ..... 90  
 Pitts, Gloria ..... 52  
 Piwowarczyk, Linda ..... 67  
 Pizarro, Rodrigo A. .... 1  
 Pizzigallo, Eligio ..... 22  
 Plakun, Eric M. .... 19, 50  
 Plapinger, Jane D. .... 17  
 Plotkin, Daniel A. .... 23  
 Poindexter, Anthony ..... 47  
 Poitras, Jennifer ..... 23, 32, 76  
 Polan, Jonathan ..... 18  
 Polat, Asihlan ..... 75  
 Polcari, Ann M. .... 84  
 Pollack, Mark H. .... 10  
 Pollack, Professor Robert. .... 26  
 Porras, Jorge F. .... 37  
 Porter, Gayle ..... 90  
 Post, Jerrold M. .... 1, 57, 77  
 Post, Robert M. .... 34, 62, 63  
 Postolache, Teodor T. .... 43, 92  
 Postolov, Anatoly ..... 38  
 Postrado, Leticia T. .... 74  
 Potenza, Marc N. .... 83  
 Potkin, Steven G. .... 64  
 Pratts, Michael J. .... 25, 77  
 Pray, Jason ..... 72  
 Preda, Adrian ..... 56  
 Preter, Maurice ..... 12, 26  
 Preven, David W. .... 26  
 Price, Julie ..... 30  
 Price, Lee M. .... 50  
 Price, Marilyn ..... 26  
 Primm, Annelie B. .... 43  
 Prince, Jefferson B. .... 1, 78  
 Prouty, Jennifer ..... 32  
 Provost, Scott E. .... 25  
 Puchalski, Christina M. .... 90  
 Pugliese, Maria A. .... 88  
 Pumariega, Andres J. .... 90  
 Punia, Surender P. .... 18  
 Pynoos, Robert S. .... 17

Q

Quadrio, Carolyn ..... 19, 71  
 Quercioli, Leonardo ..... 55  
 Quiason, Arturo G. .... 25  
 Quigley, Rosemary ..... 60

Quinn, John F. .... 96  
 Quinn, Susan ..... 57  
 Quirk, Frederick M. .... 61  
 Qureshi, Altamash I. .... 57

R

Racciatti, Delia ..... 22  
 Racette, Stephanie ..... 23  
 Rachid, Faddie H. .... 92  
 Racy, John C. .... 18  
 Radden, Jennifer ..... 77  
 Radulovic, Ljiljana ..... 92  
 Rae, Donald ..... 98  
 Rainey, Charles J. .... 30, 38  
 Raizman, Pamela S. .... 59  
 Rakfeldt, Jaak ..... 95  
 Ram, Ranganathan ..... 75  
 Ramirez, Luis F. .... 2, 88  
 Ramirez, Paul M. .... 5  
 Randall, Jeff ..... 95  
 Rao, Nyapati R. .... 19, 94  
 Rapaport, Mark H. .... 33  
 Rasgon, Natalie L. .... 2, 34  
 Rauch, Scott L. .... 8  
 Rawson, Richard A. .... 50  
 Raykov, Tenko ..... 84  
 Read, Laura L. .... 75  
 Real, Lawrence A. .... 24  
 Realmuto, George M. .... 96  
 Reaver, Mary Lou ..... 88  
 Rechtman, Richard ..... 33  
 Recupero, Patricia R. .... 26  
 Reeman, Ilene M. .... 59  
 Regenold, William T. .... 43  
 Regier, Darrel A. .... 34, 60, 70, 79  
 Reich, James H. .... 31  
 Reichman, William E. .... 2, 7  
 Reid, William H. .... 88  
 Reifler, Burton V. .... 77  
 Reimherr, Frederick W. .... 22  
 Reinblatt, Shauna P. .... 88  
 Reinhart, William M. .... 76  
 Reiss, David ..... 35  
 Ren, Cuirong ..... 48  
 Renaud, Johanne ..... 24  
 Resnick, Phillip J. .... 5, 14, 38, 66, 89  
 Resnick, William ..... 70  
 Resnikoff, Roy O. .... 66, 93  
 Ressler, Kerry J. .... 63  
 Restrepo, Ricardo ..... 67  
 Reti, Irving M. .... 82  
 Rexach, Velda Y. .... 90  
 Reyes, Raymond M. .... 17, 51  
 Reynolds III, Charles F. .... 5, 9, 29  
 Riba, Michelle B. .... 19, 30, 44, 51  
 Ricaurte, George A. .... 83  
 Richards, Jennifer ..... 38  
 Richardson, Jarrett W. .... 8  
 Richardson, Mary Ann ..... 75  
 Richey, Angela ..... 24  
 Riddle, Mark A. .... 98  
 Rieder, Ronald O. .... 29  
 Rihmer, Annamaria ..... 93  
 Rihmer, Zoltan ..... 75, 93  
 Riley-Lazo, Kristin P. .... 76  
 Rissanen, Tiina H. .... 46  
 Risser, Richard C. .... 24  
 Ritvo, Eva C. .... 42  
 Ritvo, Jonathan I. .... 42, 55  
 Ritvo, Rachel Z. .... 30  
 Rizzo, Albert A. .... 98  
 Robbins, Michael S. .... 62  
 Robertson, Michael ..... 1  
 Robin, Authur L. .... 31

Robinson, Gail E. .... 19, 51, 52  
 Roca, Robert P. .... 80  
 Rockwell, Enid ..... 37  
 Rodenhauser, Paul ..... 7  
 Rodriguez, Mercedes M. .... 92  
 Roerig, James ..... 30  
 Roessel, Mary H. .... 42  
 Roffi, Pamela A. .... 23, 49  
 Roffman, Roger A. .... 43  
 Rogan, Gerald ..... 76, 89  
 Rogers, Kenneth M. .... 44  
 Rogers, Robert D. .... 81  
 Rogge, Scott D. .... 93  
 Rogoff, Jerome H. .... 50  
 Rohland, Barbara M. .... 35  
 Rohrbaugh, Robert M. .... 67  
 Rolland, John S. .... 14, 57  
 Roman, Brenda J. .... 42  
 Roman, Gustavo C. .... 86  
 Rome, Jeffrey D. .... 84  
 Rome, Lee H. .... 7, 77  
 Roose, Steven P. .... 5, 9, 34, 46, 47  
 Rosario, Vernon A. .... 19  
 Rose, Eric ..... 41  
 Rosekind, Mark R. .... 13  
 Rosen, Cherise ..... 48  
 Rosen, Joanna L. .... 95  
 Rosen, Raymond C. .... 47  
 Rosenbaum, Jerrold F. .... 2  
 Rosenberg, Ronald C. .... 41  
 Rosenblum, Leonard A. .... 57  
 Rosenheck, Robert A. .... 59  
 Rosenthal, Jesse S. .... 67  
 Rosenthal, Murray H. .... 23, 92  
 Rosenthal, Norman E. .... 22  
 Rosenthal, Richard N. .... 21, 34, 55, 82, 95  
 Rost, Kathryn M. .... 60  
 Roston, Diane M. .... 19  
 Roth, Brett A. .... 83  
 Roth, Thomas ..... 37, 85  
 Rothbaum, Barbara O. .... 8, 11  
 Rothe, Eugenio M. .... 25, 39, 70  
 Rothenberg, Albert ..... 23, 79  
 Rothman, Marc I. .... 18  
 Rothstein, David A. .... 57, 74, 91  
 Rounsaville, Bruce J. .... 34  
 Rousaville, Bruce ..... 83  
 Rovner, Barry W. .... 80  
 Rowe, Melissa ..... 25  
 Rozsa, Sandor ..... 75  
 Ruben, Daphne ..... 94  
 Rubenstein, David ..... 71  
 Rubenstein, Grace E. F. .... 23, 49  
 Rubenstein, Michael N. .... 88  
 Rubin, Howard C. .... 70  
 Rubio-Stupec, Maritza ..... 98  
 Rudisill, John R. .... 7  
 Ruffolo, Giuseppe ..... 48  
 Rugino, Thomas A. .... 74  
 Ruiz, Pedro ..... 7, 16, 26, 31, 43, 49, 62, 70, 77, 89  
 Rush, A. John ..... 9, 60  
 Ruskin, Paul E. .... 19  
 Russakoff, L. Mark ..... 1  
 Ryall, Jo-Ellyn M. .... 7  
 Ryan, Deirdre M. .... 8  
 Ryan, Donna H. .... 65  
 Ryan, J. Michael ..... 2, 86  
 Ryan, Neal D. .... 13, 94  
 Rychik, Abe M. .... 75, 92  
 Rynearson, Edward K. .... 19, 46, 53

S

Sacamano, James T. .... 71  
 Sachs, Gary S. .... 8, 11, 23, 92  
 Sackeim, Harold A. .... 5, 9, 81

Sadoff, Joan.....	54	Seidman, Stuart N.....	2, 34, 47	Smith, Mary Kay.....	89
Sadoff, Robert L.....	44, 54	Sellers, Brealyon M.....	49	Smith, Matthew B.....	84
Saeed, S. Atezaz.....	1, 76, 88	Seltzer, Mark F.....	85	Smoller, Jordan W.....	23
Sagan, Meredith L.....	90	Sengupta, Anjana.....	97	Snyder, David L.....	18
Said, Tewfik.....	39	Sercan, Mustafa.....	75	Soares, Claudio N.....	23, 32, 57, 76
Sajatovic, Martha.....	2	Sernyak, Michael J.....	3	Sokol, Mae S.....	2
Sakhrani, Duru.....	74	Serrant, Donna M.....	44	Sokoll, Steven.....	70, 73
Salahuddin, Kazi M.....	18	Sexson, Sandra.....	19	Solhkah, Ramon.....	18
Salomon, Richard.....	96	Shaffer, David.....	54, 55	Soloff, Paul H.....	24
Salone, Anatolia.....	22	Shah, Manoj R.....	65	Solomon, Brenda C.....	58
Salonen, Jukka T.....	46	Shalev, Arie Y.....	17, 57	Soltys, Stephen M.....	44
Sambrano, Soledad.....	83	Shanfield, Stephen B.....	42	Solursh, Lionel P.....	44
Samsock, Teresa C.....	74	Shapiro, Edward R.....	19, 50	Somasundaram, Daya.....	47
Samuel, Steven E.....	43	Shapiro, Peter A.....	41, 67	Somers, Julian.....	57
Samuels, Jack F.....	82	Shapshak, Paul.....	29	Sommers, Frank G.....	48
Sanacora, Gerard.....	64	Sharfstein, Steven S.....	31, 82, 88	Sonawalla, Shamsah B.....	49
Sanchez, Herman.....	32	Sharma, Rajiv P.....	38	Sonnenreich, Michael R.....	43
Sanchez-Lacay, J. Arturo.....	61	Sharon, Estee.....	33	Sood, Erica.....	34, 64
Sanchez-Way, Ruth.....	93	Sharp, Conni.....	42	Sotsky, Stuart M.....	51
Sane, Natasha S.....	34	Shea, M. Tracie.....	24, 35, 56, 81	Southard, Marvin.....	89
Sanguineti, Vincenzo R.....	7	Shea, Shawn C.....	15	Southwick, Steven M.....	55
Sanislow, Charles A.....	24, 55, 56, 81	Shear, M. Katherine.....	11	Sowers, Wesley.....	6
Sano, Mary.....	85	Shedlack, Karen J.....	91	Speigelman, D.....	57
Santiago, Rolando.....	90	Sheehan, David V.....	8, 13	Spencer, Thomas J.....	3, 86
Saraceno, Benedetto.....	17, 79	Sheeche, John.....	42	Sperry, Leonard T.....	17
Sartorius, Norman.....	6, 60	Shellow, Ronald A.....	89	Spiegel, David.....	61
Sassani, Andrew A.....	90	Shelton, Richard C.....	65, 87, 96	Spiegel, Herbert.....	56
Satcher, David.....	68	Shen, Hong.....	70	Spitz, Deborah.....	25, 70, 77
Satel, Sally L.....	39	Shifren, Jan L.....	23, 76	Spitz, Henry I.....	44
Satmis, Nevzat.....	75	Shinn, Ann.....	81	Springer, J. Fred.....	83
Sautter, Fredric J.....	55	Sholevar, Ellen H.....	23, 84	Spritz, Melanie E.....	19
Savage, Seddon R.....	62	Sholevar, G. Pirooz.....	61, 84	Spungen, Deborah.....	46
Scalco, Monica Z.....	32	Shriner, Diane K.....	26	Srinivasaraghavan, Jagannathan.....	93
Scasta, David L.....	43, 51	Shrout, Patrick.....	48	Stabinsky, Harvey.....	19, 91
Schafer, John.....	96	Shubert, Duane D.....	18	Stabinsky, Susan.....	19, 75
Scharf, Bruce A.....	57	Shuman, Daniel W.....	39	Stahl, Stephen M.....	37, 57
Scharf, Michael A.....	48	Shwartz, Michael.....	25	Stange, Judy L.....	90
Schatzberg, Alan F.....	9, 28, 67	Siari, Valerie.....	59	Stangler, Ronnie S.....	50, 89, 93
Scheiber, Stephen C.....	69, 77	Siddarth, Prahba.....	34	Stanley, Richard M.....	90
Schiffer, Randolph B.....	5, 26	Siegel, Glenn N.....	90	Star, Jodi E.....	70, 91
Schindler, Barbara A.....	35, 69	Siegel, Patricia.....	31	Stasko, Robert S.....	89
Schindler, Shiro.....	95	Sierles, Frederick S.....	97	Steadman, Henry.....	97
Schmidt, La.....	55	Sierra, Victor.....	49	Stecher, Vera J.....	47
Schmidt, Jr., Chester W.....	50, 78, 82, 89	Siever, Larry J.....	65, 74, 84, 87	Stein, Bradley D.....	33
Schneier, Franklin R.....	61	Sikich, Linmarie.....	48	Stein, Dan J.....	57
Schoener, Gary R.....	51, 71	Silberman, Edward K.....	38	Stein, Mark A.....	47
Schooler, Nina R.....	30, 64, 92	Silberstein, Stephen C.....	22	Stein, Mitchel J.....	71
Schottenfeld, Richard S.....	42, 46	Silk, Kenneth R.....	24, 31, 50, 74, 81	Stein, Murray B.....	61
Schouten, Ronald.....	7	Silver, Alan.....	60	Stein, Seth P.....	76
Schubmehl, James Q.....	39	Silver, Ann-Louise S.....	17, 31	Steinberg, Karen.....	43
Schuh, Leslie M.....	24	Silver, Stuart B.....	1	Steinberg, Marc.....	33
Schulman, Julie K.....	50, 70	Silverman, Jeremy.....	74	Steinberg, Maurice D.....	45, 70
Schulz, S. Charles.....	13, 87	Silverman, Samuel M.....	49	Steiner, Hans.....	14, 65
Schuster, James M.....	43	Simeon, Daphne.....	84	Stern, Jessica.....	77
Schuyler, Dean.....	27	Simkin, Deborah R.....	83, 84	Stern, Robert G.....	55
Schwab-Stone, Mary E.....	70	Simon, Gregory E.....	59	Stern, Theodore A.....	69, 72
Schwartz, Alan.....	18	Simon, Naomi M.....	10	Stevenson, Ellen M.....	48
Schwartz, Charles E.....	20	Simon, Robert I.....	39	Stewart, Altha J.....	61, 82, 94
Schwartz, Jonathan.....	49	Simon, Sara.....	81	Stewart, Bette.....	74
Schwartz, Joseph M.....	72, 82, 89	Simpatico, Thomas A.....	1, 32	Stewart, Donna E.....	40, 53, 70
Schwartz, Marc D.....	75	Simpson, D. Dwayne.....	26	Stewart, Jonathan W.....	6, 61
Scimecca, Michael M.....	19	Singh, Bruce.....	25	Stokes, Honorable Louis.....	42
Sciutto, Mary S.....	66, 88	Sinha, Rajita.....	83	Stone, Alan A.....	10, 32, 56, 80
Scott, C. Paul.....	27	Sirs, Samuel G.....	30	Stone, Michael H.....	31, 58
Scott, Jan L.....	78	Sisson, Robert.....	91	Stotland, Nada L.....	7, 49, 69, 80
Scott, Marcia.....	7	Sivertz, Kristin S.....	8	Stout, Robert L.....	24, 56, 81
Scott, Nelda F.....	75	Skiljan, Carol.....	17	Stowe, Zachary N.....	28
Scott, William M.W.....	90	Skodol II, Andrew E.....	15, 56, 81	Strain, Eric C.....	55, 66
Scotton, Bruce W.....	15	Skudlarski, Pawel.....	56	Strakowski, Stephan M.....	48
Scully, Paul J.....	96	Slovenko, Ralph.....	96	Strauss, John S.....	1
Scully, Jr., James H.....	77	Small, Gary W.....	34, 86	Strotmeyer, Stephen J.....	24
Sealy, Yvette.....	44	Smith, Christopher.....	65	Stuart, Scott P.....	1
Sederer, Lloyd I.....	17, 76	Smith, Eric G.....	90	Suchinsky, Richard T.....	18
Segal, Gerald.....	56	Smith, Eric L.....	57	Sudak, Donna M.....	18, 89
Seidman, Larry J.....	86	Smith, James.....	8	Sudders, MaryLou.....	49
				Sulfaro, Michelle.....	60

PARTICIPANT INDEX

Sullivan, Ann Marie T. .... 20, 50  
 Sullivan, Kenneth A. .... 29  
 Sullivan, Thomas J. .... 35  
 Sultzer, David L. .... 7  
 Sunday, Suzanne R. .... 30  
 Sundelin-Wahlsten, Viveka ..... 61  
 Suo-Chan, Shannon T. .... 70  
 Suppes, Patricia ..... 8, 11, 24  
 Svehlova, Jana H. .... 57  
 Swann, Alan C. .... 65, 87  
 Swartz, Holly A. .... 3, 37, 96  
 Swartz, Marvin S. .... 44  
 Swerdlow, Michael ..... 38  
 Sysko, Robyn ..... 59  
 Szadoczkzy, Erika ..... 75  
 Szarek, Bonnie L. .... 47, 76  
 Szuba, Martin P. .... 14

T

Tager, Felice A. .... 29  
 Taintor, Zebulon C. .... 61, 89  
 Talbott, John A. .... 6, 33, 59, 73  
 Tamminga, Carol A. .... 12, 20  
 Tandon, Rajiv ..... 38, 85, 93  
 Tanskanen, Antti ..... 46  
 Tapert, Susan ..... 93  
 Taranto, Richard G. .... 76  
 Targum, Steven D. .... 14  
 Tariot, Pierre N. .... 2, 7, 86  
 Tarter, Ralph E. .... 96  
 Tarver II, Donald E. .... 80  
 Tasman, Allan ..... 21  
 Tavares, Hermano ..... 32  
 Taylor, David H. .... 22  
 Taylor, Mark-Allen ..... 43  
 Tedaldi, Ellen M. .... 89  
 Teicher, Martin H. .... 84  
 Telson, Howard W. .... 75  
 Tenhundfeld, Lynda A. .... 14  
 Terr, Lenore C. .... 15, 61, 68  
 Terra, Jean-Louis ..... 59  
 Thase, Michael E. .... 6, 11, 59, 66  
 Theburge, David ..... 23  
 Thibaut, Florence ..... 83  
 Thompson, Diane S. .... 87  
 Thompson, James W. .... 43, 94  
 Thompson II, Troy L. .... 94  
 Thoret, Yves ..... 33  
 Thornton, Charles C. .... 75, 92  
 Thurrell, Richard J. .... 40, 50  
 Tighe, Patti ..... 17  
 Tignol, Jean L. .... 95  
 Tillman, Jane G. .... 19  
 Tinsley, Joyce A. .... 21, 76  
 Tofler, Ian R. .... 54  
 Tohen, Mauricio F. .... 24, 47, 48, 95  
 Toledo, Daniel ..... 88  
 Tonga, Levent ..... 74  
 Toni, Christina ..... 48, 75, 91  
 Toprac, Marcia ..... 98  
 Torti, Carlo ..... 75  
 Trachtenberg, David A. .... 93  
 Tracy, Martin G. .... 18, 42, 72  
 Traverso, Chiara ..... 48  
 Trestman, Robert L. .... 43, 74  
 Trimble, Michael R. .... 15, 81  
 Trinidad, Anton C. .... 48  
 Trivedi, Madhukar H. .... 9, 60  
 Tropnas, Jean B. .... 44  
 Trzepakcz, Paula T. .... 39  
 Tsao, Daniel ..... 47  
 Tschan, Werner ..... 19, 51, 71  
 Tso, Alice C. .... 52

Tsuang, John W. .... 52  
 Tsuang, Ming T. .... 30, 65  
 Tucker, Bethany J. .... 42, 77  
 Tucker, Phebe M. .... 8  
 Tucker, William M. .... 56  
 Tufnell, Guinevere ..... 61  
 Tuma, Farris ..... 71  
 Turgay, Atilla ..... 74, 91  
 Turkcan, Solmaz ..... 75  
 Turkel, Ann R. .... 82  
 Swartz, Charles W. .... 62  
 Turner, J. Blake ..... 57, 91  
 Turner, Samuel M. .... 55  
 Turner, Susan A. .... 70  
 Tyrer, Peter ..... 31  
 Tyssen, Reidar ..... 31

U

Uddo, Madeline ..... 55  
 Ukshini, Shqipe ..... 57  
 Ulm, Ronald R. .... 83  
 Ulmer, Helen G. .... 55  
 Ulus, Eda ..... 42  
 Ulus, M. Fuat ..... 42  
 Ungerleider, J. Thomas ..... 43  
 Unutzer, Jurgen ..... 59  
 Upadhyya, Gopalakrishna K. .... 16, 25  
 Urbaitis, John C. .... 33  
 Urcuyo, Leonel ..... 91  
 Ustun, T. Bedirhan ..... 35

V

Vaglum, Per ..... 31  
 Valera, E. .... 86  
 Valero, Janeth ..... 74  
 Van Ameringen, Michael A. .... 22  
 Van Den Brink, Wim ..... 95  
 Van Dorn, Deborah H.A. .... 66  
 Vanelle, J. M. .... 59  
 Van Gorp, Wilfred G. .... 23  
 Van Horn, John D. .... 81  
 Van Horn, Patricia ..... 61  
 Van Ommeren, Mark ..... 47  
 Van Ree, Jan ..... 95  
 Van Reekum, Robert ..... 32  
 Vargas, Janeth ..... 74  
 Vargas, Luis ..... 62  
 Vaswani, Meera ..... 74  
 Veijola, Juha M. .... 91, 92  
 Velting, Drew M. .... 54  
 Venkataraman, Sanjeev ..... 7  
 Ventura, Joseph ..... 23  
 Vergare, Michael J. .... 18, 22  
 Verma, Sumer ..... 6  
 Vermette, Heidi S. .... 90  
 Viale, Gonzalo F. .... 77  
 Vianu, Donca ..... 51  
 Vickar, Gary M. .... 33  
 Victor, Bruce S. .... 15  
 Vieweg, Walter V. .... 3  
 Viguera, Adele C. .... 11, 32  
 Vinamaki, Heimo ..... 46  
 Vitiello, Benedetto ..... 98  
 Vivek, Seeth ..... 18, 67  
 Voas, Robert ..... 95  
 Vogel-Scibilia, Suzanne E. .... 51  
 Volavka, Jan ..... 30  
 Volkan, Varnik D. .... 77  
 Volpicelli, Joseph R. .... 83  
 Von Korff, Michael ..... 60  
 Voutilainen, Sari ..... 46  
 Vreys, Tina M. .... 74  
 Vujanovic, Anna ..... 74

W

Waddington, John L. .... 96  
 Wade, Terrance J. .... 23, 47, 75  
 Wadhwa, Uttam J. .... 13  
 Wagenheim, Helen S. .... 35  
 Wagner, Karen D. .... 3, 5  
 Waheed, Rubina ..... 91  
 Wahl, David S. .... 94  
 Wainberg, Milton L. .... 94  
 Waldbaum, Marjorie E. .... 42  
 Waldron, Holly B. .... 62  
 Waldron, Jr., Sherwood ..... 17  
 Walker, R. Dale ..... 10, 42, 49, 89  
 Walker, Sandra C. .... 25, 52  
 Wall, Barry W. .... 60, 72  
 Walsh, B. Timothy ..... 59, 86  
 Walsh, James K. .... 85  
 Warnbach, Kate ..... 98  
 Wang, Jionjong ..... 94  
 Wapenyi, Khakasa H. .... 29, 75  
 Ward, Jannine ..... 9  
 Ward, Mike ..... 41  
 Warnock, Julia K. .... 65, 87  
 Warshaw, Carole L. .... 76  
 Wasilchak, Deborah ..... 43  
 Waslick, Bruce D. .... 54  
 Watkins, Katherine E. .... 42  
 Watson, Chris ..... 22  
 Weaver, Carrie ..... 82  
 Webb, Carmen T. .... 17  
 Weiden, Peter J. .... 9, 86, 92  
 Weihs, Karen L. .... 23  
 Weinberger, Daniel R. .... 6, 12, 86  
 Weiner, Stevan M. .... 57  
 Weiner, Joseph S. .... 60  
 Weiner, Richard D. .... 38  
 Weinrieb, Robert M. .... 44, 66  
 Weinstein, Henry C. .... 69  
 Weinstein, Stephen P. .... 75, 92  
 Westminster, Robert ..... 96  
 Weisberg, Risa B. .... 22  
 Weisman, Henry W.J. .... 49  
 Weiss, Francine ..... 26  
 Weiss, Roger D. .... 48  
 Weissman, Alicia M. .... 75  
 Weissman, Myrna M. .... 3, 97  
 Weissman, Sidney H. .... 58  
 Welch, Thomas P. .... 51  
 Weller, Elizabeth B. .... 77, 79, 91, 97  
 Weller, Ronald A. .... 97  
 Wells, Karen C. .... 96  
 Welner, Michael M. .... 31, 58, 91  
 Welsh, Christopher J. .... 42, 93  
 Wenk, Gary L. .... 85  
 West, Donald A. .... 42  
 West, Joyce C. .... 60, 94  
 Westman, Jack C. .... 40, 50  
 Wexler, Bruce E. .... 24, 56  
 Whitehorn, David ..... 13  
 Whiteside-Mansell, Leanne ..... 20  
 Whitman, Sarah M. .... 18, 71  
 Whyte, Heather ..... 72  
 Widiger, Thomas A. .... 35, 82  
 Wiederhold, Mark D. .... 98  
 Wieduwilt, Kristin M. .... 74  
 Wiener, Jerry M. .... 25, 79  
 Wiesner, Irving S. .... 67, 76  
 Wilcox, Richard E. .... 93  
 Wilens, Timothy E. .... 5, 47  
 Wiley, Justin ..... 55  
 Wilfley, Denise E. .... 86  
 Wilkie, Frances L. .... 29  
 Wilkins, Jeffrey N. .... 70  
 Williams, Jill ..... 33

Williams, John .....	60
Williams, Laurel L. ....	25
Williams, Mary Beth .....	71
Williams, Richard .....	1
Williams, Veronica L. ....	20
Williams, Wendy .....	80
Williams-Johnson, Denise M. ....	38
Willick, Martin S. ....	6
Wilson, Daniel R. ....	56, 88
Wilson, G. Terrence .....	59
Wilt, Susan .....	93
Wirms, Rosa .....	32
Winer, Jerome A. ....	58
Winkelman, John W. ....	10, 27, 86
Winstead, Daniel K. ....	77
Wint, Dylan P. ....	23, 70
Wirshing, Donna A. ....	3, 9
Wirshing, William C. ....	9
Wise, Thomas N. ....	44, 69
Wiseman, Claire V. ....	30
Wisner, Katherine L. ....	35, 75
Wohlford, Paul .....	32
Wolfe, Rosemarie .....	97
Wolkstein, Eileen C. ....	43
Wonderlich, Stephen A. ....	30
Wong, Frank Y. ....	93
Wong, Marleen .....	33
Wood, William G. ....	6
Woodley, Hazel .....	13

Woods, Scott W. ....	95
Woods, Sherwyn M. ....	69
Woody, George E. ....	18
Workeneh, Lishan .....	42
Worley, Linda L.M. ....	20, 51
Worthen, Mary R. ....	11
Worthington III, John J. ....	17, 23
Wozniak, Janet .....	3, 38
Wright, Harry H. ....	58, 74
Wright, Jesse H. ....	18, 26, 30, 66, 78
Wu, Nancy Sheng-Shih .....	77
Wylie, Kevan R. ....	49

## Y

Yager, Joel .....	7, 26, 30, 77
Yang, Jing-Duan .....	48
Yates, Alayne .....	22, 49
Yee, Maria R. ....	49
Yehuda, Rachel .....	8, 26, 44, 71
Yen, Shirley .....	24, 81
Yeomans, Frank E. ....	66
Yeung, Albert .....	49
Yeung, Paul P. ....	24, 47
Yoast, Bill .....	54
Yonkers, Kimberly A. ....	11, 87
Young, Alexander S. ....	25, 59
Young, Carolyn M. ....	75
Young, Keith W. ....	42, 50, 60, 88

Young, Nancy .....	97
Young, Paula R. ....	96
Young, Richard A. ....	20
Yuan Volpp, Serena .....	70
Yudofsky, Stuart C. ....	13, 20, 37, 39
Yung, Alison R. ....	9
Yuria, Yuval .....	91

## Z

Zajacka, John M. ....	37
Zakzanis, Konstantine K. ....	98
Zanarini, Mary C. ....	24, 56, 74, 81
Zapatel, Jorge A. ....	17, 89
Zarate, Jr., Carlos M. ....	24, 48
Zavodnick, Jacquelyn M. ....	84
Zerbe, Kathryn J. ....	2
Ziedonis, Douglas M. ....	33
Zil, John S. ....	69
Zilberman, Monica L. ....	32
Zimbardo, Philip G. ....	51, 67
Zipursky, Robert B. ....	95
Ziskin, Mikhail Y. ....	44
Zito, Julio M. ....	83
Zivin, Gail .....	43
Zonana, Howard V. ....	76
Zubritsky, Cynthia .....	32
Zweben, Allen .....	95



# THE WIDEST ARRAY OF

## At Your Annual Meeting Bookstore

### APPI BOOKSTORE AT THE 2002 APA ANNUAL MEETING

Grow professionally and increase your knowledge of psychiatric practices through the extensive selection at the APPI bookstore. Our wide variety of topics allows you to pick up the titles you've always wanted or find a title to complete series collections and annual reviews. We look forward to seeing you!


Make sure to visit the APPI bookstore when you're in Philadelphia—you won't be disappointed!

### APPI Bookstore Hours during the 2002 APA Annual Meeting

Saturday, May 18	11 am-5 pm
Sunday, May 19	11 am-4:30 pm
Monday, May 20	10 am-6 pm
Tuesday, May 21	10 am-6 pm
Wednesday, May 22	10 am-3 pm

### Special Hours for Members-in-Training ONLY.

On Sunday, May 19th from 8:00am to 11:00am the bookstore will be open for members-in-training only. Members-in-Training will receive a 25% discount off the retail price during these hours.



### Textbook of Anxiety Disorders

Edited by Dan J. Stein, M.B., and  
Eric Hollander, M.D.


This "one-stop" resource for both clinicians and researchers details not only the rigorous diagnostic schemas, sophisticated psychobiological models, and effective pharmacotherapy and psychotherapy interventions developed during the past few decades but also the latest advances in research, theory, and clinical knowledge in this diverse field. In this remarkable collection, 77 U.S. and international experts cover the phenomenology, etiology, psychotherapy, and pharmacotherapy of every major anxiety disorder.

2002 • 544 pages • ISBN 0-88048-829-8 • hardcover  
\$77.00 • Item #8829

American  
**Psychiatric**  
Publishing, Inc.

American Psychiatric Publishing, Inc.  
1400 K Street, NW  
Washington, DC 20005-2403  
Phone: 202-682-6262 or 1-800-368-5777  
Mon.-Fri., 9 am to 5:30 pm, ET

Fax: 1-202-789-2648 • Email: [appi@psych.org](mailto:appi@psych.org) • Web: [www.appi.org](http://www.appi.org)  
Please reference priority code AH203 when ordering




### The American Psychiatric Publishing Textbook of Consultation-Liaison Psychiatry

Psychiatry in the Medically Ill,  
Second Edition

Edited by Michael G. Wise, M.D.  
and James R. Rundell, M.D.

Today, nearly 3,000 psychiatrists in the United States work at the forefront of psychiatry's interaction with other medical specialties, devoting at least 25% of their professional time to consultation-liaison psychiatry. This second edition, meticulously researched, clearly written, and designed for ease of use, brings together the body of knowledge and skills that defines the subspecialty of consultation-liaison psychiatry. More than 100 clinical and academic leaders share their knowledge, expertise, and research within these pages, offering practical guidance based on their firsthand clinical experience in evaluating and treating psychiatric disorders in patients with concomitant medical or surgical illness.

2002 • 1130 pages • ISBN 0-88048-393-8 • hardcover  
\$175.00 • Item #8393



### The American Psychiatric Publishing Textbook of Neuropsychiatry and Clinical Neurosciences, Fourth Edition

Edited by Stuart C. Yudofsky, M.D.,  
and Robert E. Hales, M.D.

#### PRAISE FOR THE PREVIOUS EDITION

First published 15 years ago as the only multiauthored, comprehensive textbook in the field, the fourth edition of this tremendously successful volume expands its focus on the neurosciences to encompass the great strides we've made. To convey this intensified focus, the editors have added "...and Clinical Neurosciences" to the title, with new and expanded chapters that cover topics such as the epidemiology and genetics of neuropsychiatric disorders, the neuropsychiatric aspects of delirium, the growth in clinical knowledge about and clinical relevance of drug-induced delirium and encephalopathies other than delirium, and educational and certification issues in neuropsychiatry.

2002 • 1420 pages • ISBN 1-58562-004-1 • hardcover  
\$219.00 • Item #62004

### American Psychiatric Association Practice Guidelines for the Treatment of Psychiatric Disorders

Compendium 2002

American Psychiatric Association

2002 • 896 pages • ISBN 0-89042-320-2 • hardcover  
\$74.95 • Item #2320

2002 • 896 pages • ISBN 0-89042-323-7 • paperback  
\$57.95 • Item #2323



# PSYCHIATRY BOOKS—BY FAR

## REVIEW OF PSYCHIATRY VOLUME 21

### Emergency Psychiatry

Edited by Michael H. Allen, M.D.  
2002 • 224 pages • ISBN 1-58562-070-X  
paperback • \$31.95 • Item #62070

### Mental Health Issues in Lesbian, Gay, Bisexual, and Transgender Communities

Edited by Billy E. Jones, M.D., M.S.,  
and Marjorie J. Hill, Ph.D.  
2002 • 144 pages • ISBN 1-58562-069-6  
paperback • \$31.95 • Item #62069

### Cutting-Edge Medicine

What Psychiatrists Need to Know  
Edited by Nada L. Stotland, M.D., M.P.H.  
2002 • 176 pages • ISBN 1-58562-072-6  
paperback • \$31.95 • Item #62072

### The Many Faces of Depression in Children and Adolescents

Edited by David Shaffer, M.D., F.R.C.P.,  
F.R.C.Psych., and Bruce Waslick, M.D.  
2002 • 224 pages • ISBN 1-58562-071-8  
paperback • \$31.95 • Item #62071

## JANUARY

### Cultural Assessment in Clinical Psychiatry

Group for the Advancement of Psychiatry  
2002 • 208 pages • ISBN 0-87318-144-1  
paperback • \$38.00 • Item #7144

### Handbook of Geriatric Psychopharmacology

Sandra A. Jacobson, M.D., Ronald W. Pies,  
M.D., and David J. Greenblatt, M.D.  
2002 • 512 pages • ISBN 0-88048-823-9  
paperback • \$54.00 • Item #8823

### Handbook of Integrated Short-Term Psychotherapy

Arnold Winston, M.D., and  
Beverly Winston, Ph.D.  
2002 • 320 pages • ISBN 0-88048-814-X  
paperback • \$45.00 • Item #8814

## FEBRUARY

### Molecular Genetics and the Human Personality

Edited by Jonathan Benjamin, M.D.,  
Richard P. Ebstein, Ph.D., and  
Robert H. Belmaker, M.D.  
2002 • 288 pages • ISBN 0-88048-755-0  
hardcover • \$49.00 • Item #8755

### Environmental and Chemical Toxins and Psychiatric Illness

James S. Brown Jr., M.D.  
2002 • 320 pages • ISBN 0-88048-954-5  
paperback • \$45.00 • Item #8954

### Negotiating Managed Care

A Manual for Clinicians  
Michael A. Fauman, Ph.D., M.D.  
2002 • 128 pages • ISBN 1-58562-042-4  
paperback • \$24.95 • Item #62042

### Brain Circuitry and Signaling in Psychiatry

Basic Science and Clinical Implications  
Edited by Gary B. Kaplan, M.D., and  
Ronald P. Hammer Jr., Ph.D.  
2002 • 272 pages • ISBN 0-88048-957-X  
hardcover • \$45.00 • Item #8957

### Concise Guide to Geriatric Psychiatry, Third Edition

James E. Spar, M.D., and  
Asenath La Rue, Ph.D.  
2002 • 400 pages • ISBN 1-58562-064-5  
paperback • \$27.95 • Item #62064

## MARCH

### Defining Psychopathology in the 21st Century DSM-V and Beyond

Edited by John E. Helzer, M.D., and  
James J. Hudziak, M.D.  
2002 • 288 pages • ISBN 1-58562-063-7  
paperback • \$49.00 • Item #62063

## APRIL

### American Psychiatric Association Practice Guideline for the Treatment of Patients With Bipolar Disorder, Second Edition

American Psychiatric Association  
2002 • 54 pages • ISBN 0-89042-322-9  
paperback • \$29.50 • Item #2322

### Concise Guide to Neuropsychiatry and Behavioral Neurology, Second Edition

Jeffrey L. Cummings, M.D., and  
Michael R. Trimble, M.D., F.R.C.P., F.R.C.Psych.  
2002 • 336 pages • ISBN 1-58562-078-5  
paperback • \$29.95 • Item #62078

### Mastering Forensic Psychiatric Practice

Advance Strategies for the Expert Witness  
Thomas G. Gutheil, M.D., and  
Robert I. Simon, M.D.  
2002 • 192 pages • ISBN 1-58562-007-6  
paperback • \$29.95 • Item #62007

### Concise Guide to Evaluation and Management of Sleep Disorders, Third Edition

Martin Reite, M.D., John Ruddy, M.D., and  
Kim Nagel, M.D.  
2002 • 288 pages • ISBN 1-58562-045-9  
paperback • \$27.95 • Item #62045

### Retrospective Assessment of Mental States in Litigation

Predicting the Past  
Edited by Robert I. Simon, M.D., and  
Daniel W. Shuman, J.D.  
2002 • 560 pages • ISBN 1-58562-001-7  
hardcover • \$84.00 • Item #62001

### Treating Trauma Survivors With PTSD

Edited by Rachel Yehuda, Ph.D.  
2002 • 240 pages • ISBN 1-58562-010-6  
paperback • \$36.95 • Item #62010

## MAY

### Quality Indicators

Defining and Measuring Quality in Psychiatric Care  
for Adults and Children  
(Report of the APA Task Force on Quality Indicators and  
Report of the APA Task Force on Quality Indicators for  
Children and Adolescents)  
American Psychiatric Association  
2002 • 240 pages • ISBN 0-89042-291-5  
paperback • \$27.95 • Item #2291

### Quick Reference Guide to the American Psychiatric Association Practice Guidelines for the Treatment of Psychiatric Disorders Compendium 2002

American Psychiatric Association  
2002 • 250 pages • ISBN 0-89042-321-0  
paperback • \$29.00 • Item #2321

### Concise Guide to Managing Behavioral Health Care Within a Managed Care Environment

Michael Isaiah Bennett, M.D.  
2002 • 112 pages • ISBN 0-88048-738-0  
paperback • \$24.95 • Item #8738

### Concise Guide to Computers in Clinical Psychiatry

Carlyle H. Chan, M.D., John S. Luo, M.D.,  
and Robert S. Kennedy, M.A.  
2002 • 192 pages • ISBN 1-58562-100-5  
paperback • \$27.95 • Item #62100

### Agitation in Patients With Dementia

A Practical Guide to Diagnosis and Management  
Edited by Donald P. Hay, M.D.,  
David T. Klein, Psy.D., Linda K. Hay, Ph.D.,  
and George T. Grossberg, M.D.  
2002 • 288 pages • ISBN 0-88048-843-3  
paperback • \$43.95 • Item #8843

### Medical Complications of Psychiatric Illness

Claire Pomeroy, M.D., James E. Mitchell, M.D.,  
James Roerig, Pharm.D., B.C.P.P., and  
Scott Crow, M.D.  
2002 • 240 pages • ISBN 0-88048-807-7  
paperback • \$29.95 • Item #8807

### Manual of Clinical Psychopharmacology, Fourth Edition

Alan F. Schatzberg, M.D., Jonathan Cole, M.D.,  
and Charles DeBattista, M.D.  
2002 • 736 pages • ISBN 0-88048-865-4  
paperback • \$59.00 • Item #8865

### Psychiatric Illness in Women

Emerging Treatments and Research  
Edited by Freda Lewis-Hall, M.D.,  
Teresa S. Williams, B.Sc., Jill A. Panetta, Ph.D.,  
and John M. Herrera, Ph.D.  
2002 • 688 pages • ISBN 1-58562-003-3  
paperback • \$65.00 • Item #62003

## JULY

### Outcome Measurement in Psychiatry

A Critical Review  
Edited by Waguih William IsHak, M.D.,  
Tal Burt, M.D., and Lloyd I. Sederer, M.D.  
2002 • 464 pages • ISBN 0-88048-119-6  
paperback • \$69.95 • Item #8119

---

# CALL FOR PAPERS

---

## PRESIDENT'S THEME:

The Promise of Science – The Power of Healing

*Paul S. Appelbaum, M.D.  
President*

*Geetha Jayaram, M.D., Chairperson  
Scientific Program Committee*

## THE SUBMISSION SCHEDULE

<b>Format</b>	<b>Deadline</b>
Industry-Supported Symposium	June 3, 2002
Course	September 4, 2002
Reports	September 4, 2002
Symposium	September 4, 2002
Workshops	Issue: September 4, 2002 Component: September 17, 2002
New Research	January 3, 2003

**Incomplete and/or Incorrect Forms Will Not Be Considered.**

*For complete submission forms, you may download the forms at [www.psych.org](http://www.psych.org), click on the Annual Meeting logo, then click on submission forms. You may also contact the APA toll free at 1-888-357-7924, and speak directly with an Answer Center Coordinator.*

If you want to volunteer to chair a session, please send a letter to the attention of Dr. Jayaram at the American Psychiatric Association. Please indicate your name, address, area of expertise, and the type of session you would like to chair. Please be aware that we receive more requests than available slots. If you are selected as a chairperson, you will be notified by the end of November.

**INDUSTRY-SUPPORTED SYMPOSIUM 1**  
**Saturday, May 18, 7:00 p.m. - 10:00 p.m.**  
**Millennium Hall, Second Floor, Loews**

*Presented at the American Psychiatric Association 2002 Annual Meeting*

## Psychiatry Practice Paradigm

The emerging role of psychiatrists in treating Alzheimer's disease



**AGENDA May 18, 2002**

6:30 pm - 7:00 pm *Dinner*  
 7:00 pm - 9:15 pm *Symposium*  
 9:15 pm - 10:00 pm *Q&A*

**OBJECTIVES**

- At the conclusion of this program, participants will be able to:
- Define the role of the psychiatrist in the early diagnosis and management of Alzheimer's disease.
  - Identify the long-term goals of managing Alzheimer's patients.
  - Provide appropriate expectations for patients' families.
  - Develop an understanding, via case study, of the various ways the Alzheimer's patient may present.

**SPEAKERS**

- Pierre N. Tariot, MD, Chairperson - *University of Rochester Medical Center*  
 Gary S. Moak, MD - *University of Massachusetts Medical School*  
 William E. Reichman, MD - *UMDNJ-New Jersey Medical School*  
 J. Michael Ryan, MD - *University of Rochester School of Medicine and Dentistry*

**CME ACCREDITATION**

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity for up to 3 hours in category 1 credit toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

**REGISTER TODAY**

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at [www.psych.org](http://www.psych.org) or contact the APA toll free at 888-357-7924 (within the US or Canada) or 202-682-6000.



Sponsored by the American Psychiatric Association.



Supported by an unrestricted educational grant from Eisai Inc. and Pfizer Inc.

**INDUSTRY-SUPPORTED SYMPOSIUM 2**  
**Saturday, May 18, 7:00 p.m. - 10:00 p.m.**  
**Regency Ballrooms A-C, Second Floor, Loews**

## Molecules and Mood Disorders: Drug Discovery and the Treatment of Depression

APA 2002 Annual Meeting  
 Saturday, May 18, 2002

6:30 PM - 7:00 PM *Dinner*  
 7:00 PM - 10:00 PM *Scientific Program*

Loews Hotel • Regency Ballrooms A-C, Second Floor • Philadelphia, Pa

- 7:00 PM Introduction**  
 Jerrold F. Rosenbaum, MD, Chairman  
 Harvard Medical School, Massachusetts General Hospital
- 7:10 PM Antidepressant Drug Discovery: The Ways, Means, and Needs**  
 Michael J. Owens, PhD • Emory University
- 7:40 PM The Phenomenon of Single Isomer Drugs**  
 Joseph Gal, PhD • University of Colorado School of Medicine
- 8:10 PM Refining Current Therapies: Clinical Implications to the Treatment of Depression**  
 C. Lindsay DeVane, PharmD • Medical University of South Carolina
- 8:40 PM The State of the Art in Treating Depression: 2002**  
 Andrew A. Nierenberg, MD • Massachusetts General Hospital
- 9:10 PM Question-and-Answer Session**

Sponsored by the American Psychiatric Association



Supported by an unrestricted educational grant from Forest Pharmaceuticals, Inc.



**Educational Objectives:**

- Review and understand the process of antidepressant drug discovery and development, the refinement of existing therapeutic options, and the state of the art of antidepressant treatment
- Understand the process behind the development of antidepressants to enhance clinical advantage
- Review the identification and screening process, use, and significance of different animal models for the development of antidepressants
- Review the history, significance, and trend of single isomers in drug development
- Identify the clinical implications and significance of single isomers in the treatment of depression
- Review the latest treatment options for depression and discuss future trends in depression management

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for up to 3 hours of category 1 credit toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spends in the educational activity.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be on a first-come, first-served basis. For more information about the meeting, please visit the APA website at [www.psych.org](http://www.psych.org) or contact the APA toll-free at 1-888-357-7924 (within the US or Canada) or 202-682-6000.



**INDUSTRY-SUPPORTED SYMPOSIUM 3**  
**Saturday, May 18, 7:00 p.m. - 10:00 p.m.**  
**Grand Ballroom Salons E/F, Level 5, Marriott**

Please join us at the APA 2002 Annual Meeting • Sponsored by the American Psychiatric Association

**SATURDAY DINNER, MAY 18**

**BIPOLAR DISORDER:**  
**NEW NATIONWIDE DATA**  
**ON MISDIAGNOSIS & COMMUNITY COSTS**

6:30-7 PM Dinner • 7-10 PM Clinical Program  
 Philadelphia Marriott • Salons E & F, 5th Floor

<p><b>SYMPOSIUM CHAIR</b>  <b>MARK A. FRYE, MD</b></p> <p><i>Prevalence and Burden of Depression in the Community and Primary Care</i>  <b>MYRNA M. WEISSMAN, PhD</b>                  Columbia University</p> <p><i>The True Prevalence of Bipolar Spectrum Disorder</i>  <b>ROBERT M.A. HIRSCHFELD, MD</b>                  University of Texas Medical Branch</p>	<p><i>Human Suffering and Economic Burden in a Large Community Sample</i>  <b>JOSEPH R. CALABRESE, MD</b>                  Case Western Reserve University</p> <p><i>New Developments in the Treatment of Bipolar Depression</i>  <b>MARK A. FRYE, MD</b>                  UCLA</p> <p><i>The Challenge of Bipolar Disorder in Children and Adolescents</i>  <b>KAREN DINEEN WAGNER, MD, PhD</b>                  University of Texas Medical Branch</p>	<p><b>EDUCATIONAL OBJECTIVES</b>                  To evaluate clinicians on the nature and extent of bipolar spectrum disorder in the community and in the clinic, and to increase awareness of the degree of under-recognition of bipolar disorders.</p>	<p><b>AGENDA</b></p> <table border="0"> <tr><td>6:30 PM</td><td>Dinner</td></tr> <tr><td>7:00 PM</td><td>Introduction - M. Frye, MD</td></tr> <tr><td>7:10 PM</td><td>Speaker presentation</td></tr> <tr><td>9:15 PM</td><td>Question and answer session</td></tr> <tr><td>10:00 PM</td><td>Program concludes</td></tr> </table>	6:30 PM	Dinner	7:00 PM	Introduction - M. Frye, MD	7:10 PM	Speaker presentation	9:15 PM	Question and answer session	10:00 PM	Program concludes
6:30 PM	Dinner												
7:00 PM	Introduction - M. Frye, MD												
7:10 PM	Speaker presentation												
9:15 PM	Question and answer session												
10:00 PM	Program concludes												

Attendees must be registered for the APA 2002 Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at [www.psych.org](http://www.psych.org) or contact the APA toll-free at 1-888-357-7924 (within the US or Canada) or 202-682-6000.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for up to 1.0 hours in category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

This program is supported by an unrestricted educational grant from GlaxoSmithKline.

**INDUSTRY-SUPPORTED SYMPOSIUM 4**  
**Saturday, May 18, 7:00 p.m. - 10:00 p.m.**  
**Grand Ballroom Salons G/H, Level 5, Marriott**

155th APA Annual Meeting

**Improving Patient Outcomes Across the Spectrum of Bipolar Disorder**

<p><b>Agenda</b></p> <p>6:30-7:00 PM Dinner</p> <p>7:00 Welcome and Introduction  <i>David J. Kupfer, MD, Program Chairperson</i>                  Thomas Detre Professor and Chair                  Department of Psychiatry                  Western Psychiatric Institute and Clinic                  University of Pittsburgh School of Medicine                  Pittsburgh, Pennsylvania</p> <p>7:10 Managing the Pendulum of Mood in Bipolar Disorder  <i>Jack M. Gorman, MD</i>                  Lieber Professor and Vice Chair for Research                  Department of Psychiatry                  Columbia University                  New York, New York</p> <p>7:35 Acute Mania: Pharmacologic Treatment Strategies  <i>David J. Kupfer, MD</i></p> <p>8:00 Phase-Specific Psychotherapy for Bipolar Disorder  <i>Holly A. Swartz, MD</i>                  Assistant Professor of Psychiatry                  Department of Psychiatry                  Western Psychiatric Institute and Clinic                  University of Pittsburgh School of Medicine                  Pittsburgh, Pennsylvania</p>	<p>8:25 Gender Variation in Bipolar Disorder  <i>Ellen Leibenluft, MD</i>                  Chief, Affective Disorders                  Pediatrics and Developmental Neuropsychiatry Branch                  National Institute of Mental Health                  Bethesda, Maryland</p> <p>8:50 The Longitudinal Course of Bipolar Disorder Across the Lifecycle  <i>Ellen Frank, PhD</i>                  Professor of Psychiatry and Psychology                  Department of Psychiatry                  Western Psychiatric Institute and Clinic                  University of Pittsburgh School of Medicine                  Pittsburgh, Pennsylvania</p> <p>9:15 Question and Answer Session</p> <p>10:00 Adjourn</p>
--	---

*At the conclusion of this symposium, participants should be able to:*

- Describe the challenges associated with the diagnosis of bipolar disorder;
- Discuss gender differences in the manifestation of bipolar disorder;
- Review treatment strategies for acute mania and breakthrough depression in bipolar disorder;
- Discuss pharmacologic and psychotherapeutic strategies for treating bipolar disorder.



Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be on a first-come, first-served basis. For more information about the meeting, please visit the APA Web site at [www.psych.org](http://www.psych.org) or contact the APA toll-free at 1-888-357-7924 (within the United States or Canada) or 202-682-6000.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.




The APA designates this educational activity for up to 3 hours in category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

**Saturday, May 18, 2002**  
 7:00-10:00 PM  
 Grand Ballroom  
 Salons G/H, Level 5  
 Philadelphia Marriott  
 Philadelphia, Pennsylvania

**INDUSTRY-SUPPORTED SYMPOSIUM 5**  
**Saturday, May 18, 7:00 p.m. - 10:00 p.m.**  
**Wyndham Ballrooms A/B, First Floor, Wyndham**

<b>American Psychiatric Association 2002 Annual Meeting</b>	
<p><b>6:30PM DINNER</b></p> <p><b>7:00PM WELCOME AND INTRODUCTION</b>                  Christopher J. Kratochvil, MD                  Program Chair                  Assistant Professor and Assistant Director                  Psychopharmacology Research Center                  University of Nebraska Medical Center                  Omaha, Nebraska</p> <p><b>7:10PM ADHD: DSM-IV AND BEYOND</b>                  Thomas E. Brown, PhD                  Associate Director, Yale Clinic for Attention and Related Disorders, Department of Psychiatry                  Yale University School of Medicine                  New Haven, Connecticut</p> <p><b>7:35PM ADHD: PHENOTYPES AND PATHOPHYSIOLOGIES</b>                  Albert J. Allen, MD                  Senior Clinical Research Physician                  Eli Lilly and Company                  Indianapolis, Indiana</p> <p><b>8:00PM NEW ADHD TREATMENT OPTIONS ON THE HORIZON</b>                  Christopher J. Kratochvil, MD                  Program Chair</p>	<p><b>8:25PM FROM CHILDHOOD TO ADOLESCENCE: DIAGNOSIS AND COMORBIDITY ISSUES</b>                  Tom Spencer, MD                  Associate Professor of Psychiatry                  Harvard Medical School                  Assistant Chief, Clinical and Research Program in Pediatric Psychopharmacology                  Massachusetts General Hospital                  Boston, Massachusetts</p> <p><b>8:50PM ISSUES IN DIAGNOSING AND TREATING THE ADULT PATIENT</b>                  Lenard Adler, MD                  Associate Professor, Clinical Psychiatry and Neurology                  Director, Department of Neurology ADHD Program                  NYU School of Medicine                  New York, New York</p> <p><b>9:15PM DISCUSSANT</b>                  Janet Wozniak, MD                  Program Co-Chair                  Assistant Professor of Psychiatry                  Massachusetts General Hospital                  Harvard Medical School                  Boston, Massachusetts</p> <p><b>9:35PM QUESTION AND ANSWER SESSION</b>                  There will also be 5 minutes for questions and answers after each presentation.</p>
<p><b>Program Description</b></p> <p>It was at the beginning of the 20th century, in 1902, that George Still introduced us to what we now know as Attention Deficit Hyperactivity Disorder (ADHD). In a series of lectures on 23 children from his clinical practice, Dr. Still aptly described their symptoms of inattention and overactivity. This symposium will address 21st century approaches for the treatment of ADHD across the lifespan, addressing advances in the understanding of the pathophysiology, identification, and treatment of ADHD, all of which have significantly progressed the field.</p> <p><b>Learning Objectives</b></p> <p>At the conclusion of this symposium, participants should be able to:</p> <ol style="list-style-type: none"> <li>1. Recognize essential features of the symptomatology and comorbidity of ADHD from childhood through adulthood.</li> <li>2. Understand a new model of ADHD as developmental impairment of executive functions.</li> <li>3. Identify the most common ADHD phenotypes and their various hypothesized pathophysiology of ADHD, including those involving dopamine and norepinephrine.</li> <li>4. Discuss new treatment options under development for ADHD.</li> </ol> <p><b>Accreditation and Credit Designation</b></p> <p>The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.</p> <p>The APA designates this educational activity for up to 3 hours in Category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in this educational activity.</p> <p>Attendance must be registered for the APA 2002 Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at <a href="http://www.psych.org">www.psych.org</a> or contact the APA toll-free at 1-888-357-7324 (within the US or Canada) or at 202-682-6000.</p> <p>If you need special assistance, please call 217-348-5725.</p>	
	
<p><b>Saturday, May 18, 2002</b>  <b>6:30PM-7:00PM Dinner</b>  <b>7:00PM-10:00PM Educational Program</b>  <b>Wyndham, Ballrooms A/B</b>  <b>Philadelphia, Pennsylvania</b></p>	
<p>Sponsored by the American Psychiatric Association                  Supported by an unrestricted educational grant from Eli Lilly and Company</p> 	

**INDUSTRY-SUPPORTED SYMPOSIUM 6**  
**Saturday, May 18, 7:00 p.m. - 10:00 p.m.**  
**Wyndham Ballrooms C/D, First Floor, Wyndham**

<p><b>Antipsychotic Therapy and Cardiovascular Disease:</b>  <b>An Unfolding Story</b>                  A symposium to be held during the APA 2002 Annual Meeting</p>  <p>Sponsored by                    The American Psychiatric Association</p> <p>Sponsored by an unrestricted educational grant from                    JANSSEN                  Janssen Pharmaceutica, Inc.                  11-RC-100-04</p> <p>At the conclusion of this symposium, the participant should be able to assess cardiovascular health risk in psychiatric patients (eg, factors contributing to the development of micro- and macrovascular disease), and develop an informed opinion on using particular antipsychotics based on relative risks and benefits for individual patients.</p> <p>Attendance must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be on a first-come, first-served basis. For more information about the meeting, please visit the APA website at <a href="http://www.psych.org">www.psych.org</a> or contact the APA toll-free at 1-888-357-7324 (within the US or Canada) or 202-682-6000.</p>	<p align="center"><b>Saturday, May 18, 2002</b>                  Ballrooms C-D                  Wyndham Franklin Plaza Hotel                  Philadelphia, PA</p> <p align="center"><b>Agenda</b></p> <p>6:30 - 7:00 PM Dinner</p> <p>7:00 - 7:10 PM Welcome and Introduction</p> <p>7:10 - 7:35 PM Medical Vulnerability in Patients With Schizophrenia                  Donald Goff, MD (Chair)                  Harvard Medical School</p> <p>7:35 - 8:00 PM Torsade de Pointes, QT, and Antipsychotic Drugs                  W. Victor Vieweg, MD                  Medical College of Virginia</p> <p>8:00 - 8:25 PM A Focus on Health: Metabolic Consequences of Antipsychotic Therapy                  Donna A. Wirshing, MD                  Greater Los Angeles VA Healthcare</p> <p>8:25 - 8:50 PM Antipsychotics and Diabetes: A Current Perspective on Epidemiology                  Michael Sernyak, MD                  Yale University</p> <p>8:50 - 9:15 PM Mechanisms of Antipsychotic-Induced Glucose Dysregulation and Insulin Resistance                  John W. Newcomer, MD                  Washington University</p> <p>9:15 - 10:00 PM Questions and Answers</p> <p>The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.</p> <p>The APA designates this educational activity for 3 hours in category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.</p>
---	--

**INDUSTRY-SUPPORTED SYMPOSIUM 7**  
**Sunday, May 19, 8:00 a.m. - 11:00 a.m.**  
**Millennium Hall, Second Floor, Loews**

## Diagnosis and Treatment Issues in Child & Adolescent Bipolar Disorder

A BREAKFAST Program

**KAREN D. WAGNER, MD, PHD**  
PROGRAM CHAIRMAN

**SUNDAY, MAY 19, 2002**

**7:30 am - 8:00 am Breakfast**

**8:00 am - 11:00 am Scientific Program**

**Philadelphia Loews Hotel Millennium Hall — Second Floor**

8:00 - 8:05 am	Welcome and Introductions Karen D. Wagner, MD, PhD, Program Chairman <i>University of Texas Medical Branch</i>
8:05 - 8:30 am	Diagnosis and Course of Bipolar Disorder in Children and Adolescents Karen D. Wagner, MD, PhD
8:30 - 8:55 am	Genetic and Environmental Effects of Bipolar Disorder on Families KIKI D. Chang, MD, <i>Stanford University</i>
8:55 - 9:20 am	Pharmacologic Treatment of Children and Adolescents with Bipolar Disorders Robert A. Kowatch, MD, <i>University of Cincinnati Medical School</i>
9:20 - 9:45 am	Novel and Maintenance Treatment Approaches in Pediatric Bipolarity Robert L. Findling, MD, <i>University Hospitals of Cleveland</i>
9:45 - 10:10 am	Diagnostic and Treatment Implications of Psychiatric Co-morbidity in Juvenile Bipolar Disorder Timothy E. Wilens, MD, <i>Harvard University</i>
10:10 - 11:00 am	Panel Discussion / Q & A

**PROGRAM OBJECTIVE**

- Diagnose bipolar disorder in children and distinguish it from other common childhood psychiatric disorders.
- Implement current treatments for bipolar disorder in youth, including mood stabilizers, antipsychotics, newer anticonvulsants and electroconvulsive therapy.

**CREDIT DESIGNATION**

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for up to 3 hours in category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at [www.psych.org](http://www.psych.org) or contact the APA toll free at 1-888-357-7924 (within the U.S. or Canada) or 202-682-6000.

This activity is supported by an unrestricted educational grant from Abbott Laboratories.

Sponsored by the American Psychiatric Association and held at the APA 2002 Annual Meeting.

**INDUSTRY-SUPPORTED SYMPOSIUM 8**  
**Sunday, May 19, 8:00 a.m. - 11:00 a.m.**  
**Regency Ballrooms A-C, Second Floor, Loews**

## Late-Life Depression: Old Myths and New Data

---

APA 2002 Annual Meeting, Sunday, May 19, 2002, 8:00 - 11:00 a.m.  
 Breakfast 7:30 - 8:00 a.m., Regency Ballrooms A-C, Loews Philadelphia Hotel

8:00 - 8:05 a.m.	<b>Introduction</b>
8:05 - 8:35 a.m.	<b>Late-Life Depression: Neuroanatomy and Medical Comorbidity</b> Anand Kumar, MD, Department of Psychiatry, UCLA Neuropsychiatric Institute
8:35 - 9:05 a.m.	<b>Depression, Pseudodementia, and Executive Dysfunction</b> George S. Alexopoulos, MD, Cornell University Medical College, New York Hospital
9:05 - 9:35 a.m.	<b>How Long Should Antidepressant Trials be in Geriatric Depression?</b> Harold A. Sackeim, PhD, Columbia University, New York State Psychiatric Institute
9:35 - 10:05 a.m.	<b>Treatment of Depression in the Old and Old-Old</b> Steven P. Roose, MD, Columbia Presbyterian Medical Center, New York State Psychiatric Institute
10:05 - 10:30 a.m.	<b>Interpersonal Psychotherapy in Late-Life Depression: Who Benefits?</b> Charles F. Reynolds, III, MD, Western Psychiatric Institute and Clinic, University of Pittsburgh School of Medicine
10:30 - 11:00 a.m.	<b>Questions</b> (five minutes of questions will follow each presentation)

**At the conclusion of this symposium the participants should be able to:**

- Appreciate that the neurobiology of late-life depression differs from depression in younger patients, and that involvement of vascular illness and other medical co-morbidities can complicate treatment;
- evaluate the effectiveness of pharmacotherapy and psychotherapy in the treatment of late-life depression, including parameters such as speed of onset and time to response.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at [www.psych.org](http://www.psych.org) or contact the APA toll free at 1-888-357-7924 (within the U.S. or Canada) or 202-682-6000.

This program is sponsored by the American Psychiatric Association.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for up to 3 hours in category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spends in the educational activity.

This program is supported by an unrestricted educational grant from Forest Laboratories.

**Forest Laboratories, Inc.**



INDUSTRY-SUPPORTED SYMPOSIUM 9  
 Sunday, May 19, 8:00 a.m. - 11:00 a.m.  
 Grand Ballroom Salons E/F, Level 5, Marriott

# DEPRESSIVE SUBTYPES: The Multiple Faces of Depression

APA 155th Annual Meeting • Sunday, May 19, 2002  
 7:30 – 8:00 AM Breakfast • 8:00 – 11:00 AM Symposium  
 Philadelphia Marriott Hotel • Grand Ballroom Salons E/F • Level 5

Program Chair: Maurizio Fava, MD • Massachusetts General Hospital

8:00 AM <b>Introduction</b> Maurizio Fava, MD Massachusetts General Hospital	8:35 AM <b>Treatment Challenges in Anxious Depression</b> Maurizio Fava, MD Massachusetts General Hospital	9:25 AM <b>Vascular Depression</b> Ranga Krishnan, MD Duke University Medical Center
8:10 AM <b>Atypical Depression: An Often Under-Recognized Condition</b> Jonathan W. Stewart, MD New York State Psychiatric Institute	9:00 AM <b>Melancholic Depression: Are Dual-Action Antidepressants Superior to Selective Agents?</b> J. Craig Nelson, MD Yale University School of Medicine	9:50 AM <b>Practical Approaches to Psychotic Depression</b> Linda L. Carpenter, MD Brown University
		10:15 AM <b>Questions and Answers</b>

Educational Objectives: At the conclusion of this symposium, the participants should be able to recognize various subtypes of major depressive disorder and be familiar with the management options available to clinicians. Additionally, participants should also be able to summarize the results of the studies comparing the efficacy of different antidepressant classes in the treatment of these depressive subtypes.


The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity for up to 3 hours in category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the US or Canada) or 202-682-6000.

Sponsored by the American Psychiatric Association

Supported by an unrestricted educational grant from Organon Inc.

INDUSTRY-SUPPORTED SYMPOSIUM 10  
 Sunday, May 19, 8:00 a.m. - 11:00 a.m.  
 Grand Ballroom Salons G/H, Level 5, Marriott



**BREAKFAST SYMPOSIUM**

APA 155TH ANNUAL MEETING • SPONSORED BY THE AMERICAN PSYCHIATRIC ASSOCIATION  
 8:00 to 11:00 am • Breakfast 7:30 – 8:00 am

## RECOVERY FROM DEPRESSION: New Perspectives to Improve Outcomes

**AGENDA AND FACULTY:**

*Opening Remarks: (8:00–8:15)*  
 Chair, Michael E. Thase, M.D.

*Recovery from Depression: Conceptual Underpinnings (8:15–8:45)*  
 Michael E. Thase, M.D.  
 Professor of Psychiatry  
 University of Pittsburgh

*Augmentation and Combination Strategies for the Newer Antidepressants (8:45–9:15)*  
 Andrew A. Nierenberg, M.D.  
 Associate Professor of Psychiatry  
 Harvard University

*45 minutes have been allocated for questions and answers.*

Supported by an unrestricted educational grant from WYETH.

*Combining Psychotherapy and Medication for Depression (9:15–9:45)*  
 John C. Markowitz, M.D.  
 Associate Professor of Psychiatry  
 Cornell Medical College

*Maximizing Efficacy in the Treatment of Chronic Depression (9:45–10:15)*  
 Susan G. Kornstein, M.D.  
 Associate Professor of Psychiatry  
 Virginia Commonwealth University

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education to physicians. The APA designates this educational activity for up to 3 hours in category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the U.S. or Canada) or 202/682-6000.

**EDUCATIONAL OBJECTIVE:**  
 Learn about the process of recovery from depression, both in terms of risk factors and therapeutic strategies.

**INDUSTRY-SUPPORTED SYMPOSIUM 11**  
**Sunday, May 19, 8:00 a.m. - 11:00 a.m.**  
**Wyndham Ballrooms A/B, First Floor, Wyndham**

American Psychiatric Association 2002 Annual Meeting		<p><b>Treating Psychotic Illness Across the Lifespan: Are Drugs Enough?</b></p> <p><b>Sunday, May 19, 2002</b></p> <p>7:30AM-8:00AM Breakfast              8:00AM-11:00AM Educational Program              Wyndham, Ballrooms A/B              Philadelphia, Pennsylvania</p> <p>Sponsored by the American Psychiatric Association              Supported by an unrestricted educational grant from Eli Lilly and Company</p> <p><small>If you need special assistance, please call 317.848.5725.</small></p>
<b>7:30AM Breakfast</b>	<b>9:20AM Madness and the Rest of a Life</b> Anne Alonso, PhD Professor of Psychiatry, Harvard Medical School Massachusetts General Hospital Boston, Massachusetts	
<b>8:00AM Welcome and Introduction</b> Paul Barreira, MD Program Chair Chief of Community Clinical Services Director of Medical Education McLean Hospital, Belmont, Massachusetts Associate Professor of Psychiatry, Harvard Medical School	<b>9:45AM Best Practices in Psychosocial Rehabilitation for Psychotic Illness</b> Paul Barreira, MD Program Chair	
<b>8:05AM Psychotic Illness in Children</b> Jean Frazier, MD Director, Child Psychiatry Outpatient Services McLean Hospital, Belmont, Massachusetts	<b>10:10AM Is the Cheapest Alternative the Most Economical?</b> Sumner Vortma, MD Program Co-Chair Psychiatrist in Charge, Special Care Dementia Unit, McLean Hospital, Belmont, Massachusetts Lecturer on Psychiatry, Harvard Medical School Associate Professor, Department of Psychiatry, Boston University School of Medicine	
<b>8:30AM Raising the Bar of Expectations</b> Ralph Aquila, MD Assistant Clinical Professor of Psychiatry Columbia College of Physicians and Surgeons New York, New York	<b>10:35AM Question and Answer Session</b> There will also be 5 minutes for questions and answers after each presentation.	

**Program Description**  
 Psychotic illnesses may begin at any age and often profoundly affect the course of a patient's life. The age of onset of illness often has implications for pharmacological and psychosocial treatments. This program will discuss the importance of tailoring treatment to the patient's stage of life and considering potential consequences of the illness on the patient's future.

**Learning Objectives**  
 At the conclusion of this symposium, participants should be able to  
 1. Identify the impact of psychotic illness across the lifespan of the patient.  
 2. Cite the developmental considerations in diagnosing a psychotic disorder.  
 3. Utilize pharmacological and nonpharmacological interventions to promote optimal healing in patients with psychotic illness.

**Accreditation and Credit Designation**  
 The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.  
 The APA designates this educational activity for up to 3 hours in Category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.  
 Attendees must be registered for the APA 2002 Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at [www.psych.org](http://www.psych.org) or contact the APA toll-free at 1-888-357-7924 (within the US or Canada) or at 202.462.6000.

**INDUSTRY-SUPPORTED SYMPOSIUM 12**  
**Sunday, May 19, 8:00 a.m. - 11:00 a.m.**  
**Wyndham Ballrooms C/D, First Floor, Wyndham**

	<p>A P A 2 0 0 2 A N N U A L M E E T I N G</p> <p><b>Advances in the Treatment of Psychosis: Minimizing the Burden of Disease</b></p> <p>Sunday, May 19, 2002 – Wyndham Franklin Plaza, Ballroom C/D              Breakfast: 7:30 AM – 8:00 AM / Symposium: 8:00 AM – 11:00 AM • CHAIR: Daniel R. Weinberger, MD</p>
<b>Agenda:</b>	<b>Learning Objectives:</b>
<b>8:00 AM Welcome and Introduction</b>	<i>After completion of this activity, participants should be better able to</i>
<b>8:05 AM The Public Health Impact of Schizophrenia</b> Norman Sartorius, MD, PhD University of Geneva	<ul style="list-style-type: none"> <li>■ Recognize the public health burden of schizophrenia</li> <li>■ Understand the pathophysiologic rationale that led to the development of current therapies</li> <li>■ Describe real-world treatment barriers to achieving optimal therapeutic outcome: efficacy vs effectiveness</li> <li>■ Identify the challenges involved when translating clinical trial results into everyday clinical practice</li> <li>■ Describe the impact of schizophrenia on family members of patients living with the disease</li> </ul>
<b>8:35 AM Evolution of Antipsychotic Therapies: Overcoming Treatment Barriers</b> Daniel R. Weinberger, MD National Institute of Mental Health (NIMH)	
<b>9:05 AM Optimizing Management of Schizophrenia: Bridging the Gap Between Clinical Research and Real-World Clinical Practice</b> Andrew J. Cutler, MD Coordinated Research of Florida	
<b>9:40 AM Caring for a Family Member With Schizophrenia: A Personal Account</b> Martin S. Willick, MD Columbia University	
<b>10:10 AM Summary Remarks</b> Daniel R. Weinberger, MD National Institute of Mental Health (NIMH)	
<b>10:15 AM Panel Discussion / Questions and Answers</b>	

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.  
 The APA designates this educational activity for up to 3 hours in category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should only claim those hours of credit that he/she actually spent in the activity.  
 Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served.  
 For more information about the meeting, please visit the APA website at [www.psych.org](http://www.psych.org) or contact the APA toll free at 1-888-357-7924 (within the U.S. or Canada) or 202/682-6000.

Sponsored by the American Psychiatric Association.

Supported by an unrestricted educational grant from Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd.

Bristol-Myers Squibb Company Otsuka Pharmaceuticals

## INDUSTRY-SUPPORTED SYMPOSIUM 13

Sunday, May 19, 1:30 p.m. - 4:30 p.m.

Millennium Hall, Second Floor, Loews

SUNDAY, MAY 19, 2002  
1:30 PM - 4:30 PM  
*Loews Hotel  
Millennium Hall  
Second Floor*

### Recent Developments in the Science and Treatment of **PTSD**

**PROGRAM OBJECTIVES**  
After attending this continuing education program, the psychiatrist should be able to:

- Examine the latest evidence on the pathogenesis of PTSD, including risk and resilience factors
- Appreciate the contribution to our knowledge of PTSD that neuroimaging is making possible
- Review the medical strategies for management of PTSD
- Identify new tools for diagnosis, assessment, and treatment that have potential to improve outcome in PTSD.

 *Sponsored by the American Psychiatric Association.*

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for up to 3 hours in category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting please visit the APA website at [www.psych.org](http://www.psych.org) or contact the APA toll free at 1-888-357-7924 (within the US or Canada) or 202-682-6000.

SUNDAY, MAY 19, 2002

1:00 PM-  
1:30 PM Luncheon

1:30 PM **Welcome and Introduction**  
*SYMPOSIUM COCHAIRS,  
Jonathan R.T. Davidson, MD, Duke University Medical Center  
and Rachel Yehuda, PhD, Mount Sinai School of Medicine*

1:35 PM **Risk and Resilience Factors in PTSD**  
*Rachel Yehuda, PhD*

2:00 PM **What Can Neuroimaging Teach Us About PTSD?**  
*Scott L. Rauch, MD, Massachusetts General Hospital*

2:25 PM **Medical Strategies in PTSD**  
*David V. Sheehan, MD, MBA, University of South Florida*

2:50 PM **Treatment of PTSD With Exposure Therapy, EMDR, and Other New Techniques**  
*Barbara O. Rothbaum, PhD, ABPP,  
Emory University School of Medicine*

3:15 PM **Using Assessment Tools in Clinical Practice: When, Why, How?**  
*Kathryn M. Connor, MD, Duke University Medical Center*

3:40 PM **Panel Discussion with Questions and Answers**

4:25 PM **Closing Remarks, Adjournment**  
*Jonathan R.T. Davidson, MD*


*A Luncheon Symposium to be held at the American Psychiatric Association 155th Annual Meeting*

SUPPORTED BY AN UNRESTRICTED EDUCATIONAL GRANT FROM GLAXOSMITHKLINE.

## INDUSTRY-SUPPORTED SYMPOSIUM 14

Sunday, May 19, 1:30 p.m. - 4:30 p.m.

Regency Ballrooms A-C, Second Floor, Loews



This symposium will be conducted on May 19, 2002 during the 155th Annual Meeting of the American Psychiatric Association.

# CUSTOMIZING CARE FOR PATIENTS WITH BIPOLAR DISORDER

SUNDAY, MAY 19, 2002  
SYMPOSIUM 1:30 - 4:30 PM  
LUNCH 1:00 - 1:30 PM

LOEWS PHILADELPHIA HOTEL  
2ND FLOOR, REGENCY BALLROOM A-C  
PHILADELPHIA, PENNSYLVANIA

**LEARNING OBJECTIVES**

After attending this symposium, participants will be able to:

- Identify factors that may be useful in the process of selecting agents to customize care for individuals at critical decision points in the course of bipolar illness.
- Recognize evidence that psychosis is a persisting problem for a substantial portion of patients with bipolar disorder.
- Describe the growing evidence for efficacy of drugs in acute treatment of bipolar disorder and the need for pragmatic comparative studies of different mood stabilizers, individually and in combination.
- Understand better the issues which arise during the treatment of bipolar disorder and the various strategies utilized to address these issues.
- Explain the strategy that starts with the most tolerable intervention and sequentially offers well-tolerated options until therapeutic results are achieved.
- Develop a stepwise approach for medication treatment beyond monotherapy for patients with bipolar disorder.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education as a provider of continuing medical education for physicians.


The APA designates this educational activity for up to 3 hours in category 1 credit toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Attendees must be registered for the APA 2002 Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting please visit the APA website at [www.psych.org](http://www.psych.org) or contact the APA toll free at 1-888-357-7924 (within the US or Canada) or 202-682-6000.


**AGENDA**

<p>1:00 - 1:30 PM Lunch</p> <p>1:30 PM <b>Opening Remarks Introduction</b> <b>GARY S. SACHS, MD</b> (PROGRAM CHAIRPERSON) <i>Harvard Medical School</i></p> <p>1:40 PM <b>Significance of Psychosis</b> <b>CHARLES L. BOWDEN, MD</b> <i>University of Texas Health Science Center</i></p> <p>2:05 PM <b>Choosing Initial Mood Stabilizer After Acute Mania</b> <b>GUY M. GOODWIN, MD</b> <i>Oxford University</i></p> <p>2:30 PM <b>Dealing With Common Problems During Ongoing Treatment In Bipolar Disorder</b> <b>W. GORDON FRANKLE, MD</b> <i>Columbia University</i></p>	<p>2:55 PM <b>Selection of an Acute Treatment Strategy: Sequential vs. Stratified Approach</b> <b>GARY S. SACHS, MD</b> <i>Harvard Medical School</i></p> <p>3:20 PM <b>Medication Strategies for Treatment of Refractory Patients With Bipolar Disorder</b> <b>PATRICIA SUPPES, MD, PhD</b> <i>University of Texas Southwestern</i></p> <p>3:45 PM <b>Questions and Answers</b></p> <p>4:20 PM <b>Adjourn</b></p>
---	--

Sponsored by AstraZeneca



**INDUSTRY-SUPPORTED SYMPOSIUM 15**  
**Sunday, May 19, 1:30 p.m. - 4:30 p.m.**  
**Grand Ballroom Salons E/F, Level 5, Marriott**



*The Aging Brain*  
and Vulnerability to  
*Depression*


**APA 155th Annual Meeting**  
**Sunday, May 19, 2002**  
**1:00-1:30 PM Luncheon**  
**1:30-4:30 PM Symposium**  
**Philadelphia Marriott Hotel • Level 5 • Grand Ballroom Salons E/F**

**Program Chair: Charles F. Reynolds III, MD • University of Pittsburgh School of Medicine**


<p><b>1:30 PM Introduction</b>  <b>Charles F. Reynolds III, MD</b>  University of Pittsburgh School of Medicine</p>	<p><b>2:15 PM The Impact on Cognition of Pharmacological Treatment for Late-Life Depression</b>  <b>Ruth O'Hara, PhD</b>  Stanford University School of Medicine</p>	<p><b>3:15 PM Treatment of the Depressed "Old-Old" in Outpatient and Long-term Care Facility Settings</b>  <b>Steven P. Roose, MD</b>  Columbia University</p>
<p><b>1:45 PM Age, Neurobiology, and Treatment Response</b>  <b>Madhukar Trivedi, MD</b>  University of Texas Southwestern Medical Center</p>	<p><b>2:45 PM Pharmacogenetics in Geriatric Depression</b>  <b>Greer M. Murphy, Jr, MD, PhD</b>  Stanford University School of Medicine</p>	<p><b>3:45 PM Questions and Answers</b></p>

**Educational Objectives:** At the conclusion of this symposium, the participants should be able to understand why depression in the elderly differs in clinical features, biology, and treatment response from major depression as seen in younger patients.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.  
The APA designates this educational activity for up to 3 hours in category 1 credit towards the APA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.  
Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at [www.psych.org](http://www.psych.org) or contact the APA toll free at 1-888-357-7924 (within the US or Canada) or 202-682-6000.

 Sponsored by the American Psychiatric Association
 Supported by an unrestricted educational grant from Oregon Inc.

**INDUSTRY-SUPPORTED SYMPOSIUM 16**  
**Sunday, May 19, 1:30 p.m. - 4:30 p.m.**  
**Grand Ballroom Salons G/H, Level 5, Marriott**



**American Psychiatric Association 2002 Annual Meeting**  
**Long-Term Management of Mood Disorders**

**Chair:** A. John Rush, MD  
*The University of Texas Southwestern Medical Center*

**Co-Chair:** Harold A. Sackeim, PhD  
*College of Physicians & Surgeons of Columbia University*

**Location:** The Marriott Hotel, Level 5, Grand Ballroom Salons G/H

**Objectives**  
At the conclusion of this symposium, the participant should be able to:

- Identify the assumptions, strategies, and tactics of maintenance pharmacotherapy
- Review the evidence for the longer-term efficacy of the depression-specific psychotherapies
- Better understand the effects of electroconvulsive therapy (ECT) on switches to mania, potential for relapse, long-term prevention of suicide and overall mortality, and changes in the natural course of depressive illness
- Describe the mechanisms of vagus nerve stimulation (VNS) and why it may be a promising new therapy for chronic or recurrent depressions
- Discuss the longer-term efficacy of vagus nerve stimulation (VNS) in the treatment of depression.

**Sponsored by the American Psychiatric Association**

**Agenda**  
**Sunday, May 19, 2002**

1:00 - 1:30 PM Lunch  
1:30 - 1:45 PM Welcome and Introduction  
A. John Rush, MD • *The University of Texas Southwestern Medical Center*

1:45 - 2:10 PM Does Medication Change the Long-Term Course of Mood Disorders?†  
Susan G. Kornstein, MD • *Medical College of Virginia*

2:10 - 2:35 PM Does Psychotherapy Change the Long-Term Course of Mood Disorders?†  
Robin B. Jarrett, PhD • *The University of Texas Southwestern Medical Center*

2:35 - 3:00 PM Does ECT Alter the Long-Term Course of Mood Disorders?†  
Harold A. Sackeim, PhD • *College of Physicians & Surgeons of Columbia University*

3:00 - 3:25 PM Vagus Nerve Stimulation (VNS) for Depression: Methods and Mechanisms\*  
Mark S. George, MD • *Medical University of South Carolina*

3:25 - 3:50 PM Does Vagus Nerve Stimulation (VNS) Change the Long-Term Course of Mood Disorders?†  
Lauren B. Marangell, MD • *Baylor College of Medicine*

3:50 - 4:30 PM Panel Discussion  
\*Each presentation will be followed by a 2-minute Question-and-Answer Session

**Accreditation**  
The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.  
The APA designates this educational activity for up to 3 hours in category 1 credit toward the APA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit he/she actually spent in the educational activity.

**Registration**  
Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be on a first-come, first-served basis. For more information about the meeting, please visit the APA website at [www.psych.org](http://www.psych.org), or contact the APA toll-free at 1-888-357-7924 (within the US or Canada) or 202-682-6000.


**Supported by an unrestricted educational grant from Cyberonics, Inc.**


**INDUSTRY-SUPPORTED SYMPOSIUM 17**  
**Sunday, May 19, 1:30 p.m. - 4:30 p.m.**  
**Wyndham Ballrooms A/B, First Floor, Wyndham**



## The Adherence Challenge:

### Chronic Issues and Emerging Solutions With Antipsychotic Therapy

A symposium to be held during the APA 2002 Annual Meeting



Sponsored by  the American Psychiatric Association

Supported by an unrestricted educational grant from  JANSSEN  Otsuka Pharmaceutical Co., Ltd.

The objectives of this symposium are to familiarize the participants with rates of nonadherence in psychotic disorders and contributing factors. There will also be a discussion regarding data on long-acting injectable medications and their potential role in facilitating adherence and enhancing outcome.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be on a first-come, first-served basis. For more information about the meeting, please visit the APA website at [www.psych.org](http://www.psych.org) or contact the APA toll free at 1-888-357-7924 (within the US or Canada) or 202-682-6000.

**Sunday, May 19, 2002**  
 Ballrooms A-C  
 Wyndham Franklin Plaza Hotel  
 Philadelphia, PA

### Agenda

1:00 - 1:30 PM	Lunch
1:30 - 1:35 PM	Welcome and Introduction
1:35 - 2:00 PM	Approaching the Adherence Challenge <i>Stephen R. Marder, MD (Co-chair)</i> <i>Greater Los Angeles VA Healthcare Center</i>
2:00 - 2:25 PM	Pharmacologic Options for Schizophrenia: Implications for Compliance <i>John M. Kane, MD (Co-chair)</i> <i>Hillside Hospital</i>
2:25 - 2:55 PM	Research Experience With a Long-Acting Atypical Antipsychotic Medication <i>Samuel J. Keith, MD</i> <i>University of New Mexico</i>
2:55 - 3:25 PM	Views From the Nursing Perspective: Problems and Solutions <i>Kathleen S. Jarboe, RN</i> <i>Emory University</i>
3:25 - 3:45 PM	Session Recap <i>Joe Lovelace, JD (Discussant)</i> <i>NAMI Texas</i>
3:45 - 4:30 PM	Questions and Answers

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The APA designates this educational activity for 3 hours in category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

**INDUSTRY-SUPPORTED SYMPOSIUM 18**  
**Sunday, May 19, 1:30 p.m. - 4:30 p.m.**  
**Wyndham Ballrooms C/D, First Floor, Wyndham**

A P A 2 0 0 2 A N N U A L M E E T I N G

## Challenges and Opportunities in the Management of Psychotic Disorders

Sunday, May 19, 2002 - Wyndham Franklin Plaza, Ballroom C/D

Buffet Lunch: 1:00 PM - 1:30 PM / Symposium: 1:30 PM - 4:30 PM • CHAIR: Diana O. Perkins, MD, MPH



**Agenda:**

1:30 PM **Welcome and Introduction**

1:35 PM **Intervening Early in the Evolution of Schizophrenia: Need for Novel Approaches During the Prodromal Phase**  
*Patrick D. McGorry, MD, PhD*  
*University of Melbourne*

2:00 PM **New Advances in Schizophrenia Pharmacotherapy: Management of Acute Episodes**  
*Diana O. Perkins, MD, MPH*  
*University of North Carolina at Chapel Hill*

2:25 PM **Improving Long-Term Outcomes in Patients With Schizophrenia**  
*Peter J. Weiden, MD*  
*State University of New York Health Science Center*

2:50 PM **The Impact of Safety and Tolerability on Patients' Satisfaction With Therapy**  
*Joseph P. McEvoy, MD*  
*Duke University School of Medicine*

3:15 PM **Mechanism of Action as Predictor of Clinical Utility: Lessons From Schizophrenia Research**  
*Jeffrey A. Lieberman, MD*  
*University of North Carolina*

3:40 PM **Summary Remarks**  
*Diana O. Perkins, MD, MPH*  
*University of North Carolina at Chapel Hill*

3:45 PM **Panel Discussion / Questions and Answers**

**Learning Objectives:**

*After completion of this activity, participants should be better able to*

- Describe prodromal signs and symptoms of schizophrenia and the importance of and challenges associated with initiating therapy during this early phase
- Review results of recent clinical trials with current and emerging antipsychotic therapies and their implications for optimizing therapy for patients with schizophrenia
- Discuss the impact of tolerability profiles of antipsychotic drugs on the effectiveness of therapy and the patient's overall ability to function
- Understand the relationship between mechanisms of action of antipsychotic agents and their clinical profiles

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for up to 3 hours in category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should only claim those hours of credit that he/she actually spent in the activity.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served.

For more information about the meeting, please visit the APA website at [www.psych.org](http://www.psych.org) or contact the APA toll free at 1-888-357-7924 (within the U.S. or Canada) or 202/682-6000.

Sponsored by the American Psychiatric Association. 

Supported by an unrestricted educational grant from Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd.

 Bristol-Myers Squibb Company  Otsuka Pharmaceuticals



**INDUSTRY-SUPPORTED SYMPOSIUM 19**  
**Sunday, May 19, 7:00 p.m. - 10:00 p.m.**  
**Millennium Hall, Second Floor, Loews**

## Treatment of Anxiety Disorders:

*Where Are We and Where Are We Going?*

155th APA Annual Meeting

**AGENDA**

<p><b>Sunday, May 19, 2002</b> 7:00 - 10:00 PM</p> <p>Loews Philadelphia Hotel</p> <p>Millennium Hall, Second Floor</p> <p>Philadelphia, Pennsylvania</p> <p><small>Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be on a first-come, first-served basis. For more information about the meeting, please visit the APA Web site at <a href="http://www.psych.org">www.psych.org</a> or contact the APA toll free at 1-888-357-7924 (within the United States or Canada) or 202-682-6000.</small></p> <p><small>The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.</small></p> <p><small>The APA designates this educational activity for up to 3 hours in category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.</small></p>	<p>6:30 - 7:00 PM Dinner</p> <p>7:00 <b>Welcome and Introduction</b> R. Bruce Lydiard, PhD, MD, Chairperson Director, Southeast Health Consultants, LLC Charleston, South Carolina</p> <p>7:10 <b>Comorbidities and Issues to Consider in the Management of Anxiety Disorders</b> Ronald C. Kessler, PhD Professor Department of Health Care Policy Harvard Medical School Boston, Massachusetts</p> <p>7:35 <b>Management of Depression and Demoralization in Anxiety Disorders</b> Naomi M. Simon, MD Associate Director Anxiety Disorders Program Massachusetts General Hospital Boston, Massachusetts</p> <p>8:00 <b>Managing the Disordered Sleep Associated with Anxiety and Mood Disorders</b> John W. Winkelman, MD, PhD Medical Director Sleep Health Center Brigham and Women's Hospital Newton Center, Massachusetts</p>	<p>8:25 <b>Generalized Anxiety Disorder: Long-Term Treatment to Improve Outcome</b> Mark H. Pollack, MD Director, Anxiety Disorders Program Massachusetts General Hospital Associate Professor, Department of Psychiatry Harvard Medical School Boston, Massachusetts</p> <p>8:50 <b>Current and Future Treatments for Anxiety: Efficacy and Tolerability</b> R. Bruce Lydiard, PhD, MD</p> <p>9:15 <b>Question and Answer Session</b> Faculty Panel</p> <p>10:00 Adjourn</p>
--	---	---

Sponsored by the American Psychiatric Association

Supported by an unrestricted educational grant from Pfizer Inc.

**OBJECTIVES**

*At the conclusion of this symposium, participants should be able to:*

- Discuss the prevalence of comorbid conditions and their clinical implications in anxiety disorders;
- Discuss the management of depression and sleep disturbance in patients with anxiety disorders;
- Review the course of generalized anxiety disorder and the impact of acute and long-term treatment strategies on outcome;
- Explore the efficacy and tolerability of current and investigational therapies for anxiety disorders.

**INDUSTRY-SUPPORTED SYMPOSIUM 20**  
**Sunday, May 19, 7:00 p.m. - 10:00 p.m.**  
**Regency Ballrooms A-C, Second Floor, Loews**

## Atypical Depression: Overview and New Developments

Sunday, May 19, 2002  
**The Regency Ballrooms A-C**  
**Loews Philadelphia Hotel**  
**Philadelphia, Pennsylvania**

Sponsored by the American Psychiatric Association

Supported by an unrestricted educational grant from

**Program Objectives**

After completing this activity, the participants will be able to:

- Discuss the biology of atypical depression
- Recognize the role of early trauma in the biology of atypical depression and post-traumatic stress disorder (PTSD)
- Identify psychometric and diagnostic measures used to differentiate atypical depression from other forms of depression
- Discuss the role of cognitive-behavioral psychotherapy, including the use of virtual reality therapy, in the treatment of depression-related anxiety
- Recognize the role of monoamine oxidase inhibitors (MAOIs) and new delivery methods in the treatment of atypical depression

**Continuing Medical Education**

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity for up to 3 hours in category 1 credit toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

**APA 2002 Annual Meeting**

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be on a first-come, first-served basis. For more information about the meeting, please visit the APA website at [www.psych.org](http://www.psych.org) or contact the APA toll free at 1-888-357-7924 (within the United States or Canada) or 202-682-6000.

**Program Agenda**

<b>6:30 PM - 7:00 PM</b>	<b>Dinner</b>
<b>7:00 PM</b>	<b>Welcome and Introductions</b> K. Ranga Rama Krishnan, MD—Program Chair <i>Duke University Medical Center</i>
<b>7:10 PM</b>	<b>The Biology of Atypical Depression</b> K. Ranga Rama Krishnan, MD
<b>7:35 PM</b>	<b>The Biology of PTSD and Atypical Depression: The Role of Early-Life Trauma</b> Linda L. Carpenter, MD <i>Brown University</i>
<b>8:00 PM</b>	<b>Diagnostic Issues in Atypical Depression</b> Ned H. Kalin, MD <i>University of Wisconsin-Madison</i>
<b>8:25 PM</b>	<b>Psychotherapy in the Treatment of Atypical Depression</b> Barbara O. Rothbaum, PhD <i>Emory University</i>
<b>8:50 PM</b>	<b>New Treatments for Atypical Depression</b> Charles B. Nemeroff, MD, PhD—Program Co-Chair <i>Emory University</i>
<b>9:15 PM</b>	<b>Question-and-Answer Session/Panel Discussion</b>
<b>10:00 PM</b>	<b>Closing Remarks and Adjournment</b>



INDUSTRY-SUPPORTED SYMPOSIUM 21  
 Sunday, May 19, 7:00 p.m. - 10:00 p.m.  
 Grand Ballroom Salons E/F, Level 5, Marriott

## New Developments *in the* Treatment of Bipolar Disorder

A DINNER *Program*

ROBERT M.A. HIRSCHFELD, MD  
 PROGRAM CHAIRMAN

**SUNDAY, MAY 19, 2002**


**6:30 – 7:00 pm Dinner**  
**7:00 – 10:00 pm Scientific Program**  
**Philadelphia Marriott Hotel — Grand Ballroom Salons E/F — Level 5**


7:00 – 7:05 pm	Welcome and Introductions Robert M.A. Hirschfeld, MD, Program Chairman <i>University of Texas Medical Branch</i>
7:05 – 7:30 pm	Advances in the Treatment of Mania Gary S. Sachs, MD <i>Massachusetts General Hospital</i>
7:30 – 7:55 pm	Update on Treatment of Bipolar Depression Robert M.A. Hirschfeld, MD
7:55 – 8:20 pm	Stabilizing the Course of Refractory Bipolar Illness: Meeting the Challenge of Dysphoric States and Mixed Mania Trisha Suppes, MD, PhD <i>University of Texas Southwestern Medical Center</i>
8:20 – 8:45 pm	Update on Psychosocial Treatments of Bipolar Disorder Michael W. Otto, PhD <i>Massachusetts General Hospital</i>
8:45 – 9:10 pm	The Multiple Goals of Maintenance Treatment Charles L. Bowden, MD <i>The University of Texas Health Science Center</i>
9:10 – 10:00 pm	Panel Discussion / Q & A

**PROGRAM OBJECTIVE**  
 Implement treatment strategies for bipolar illness based on recent guidelines, focusing on acute mania, bipolar depression, maintenance treatment, rapid cycling and mixed mania, and psychosocial issues.


**CREDIT DESIGNATION**  
 The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.  
 The APA designates this educational activity for up to 3 hours in category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at [www.psych.org](http://www.psych.org) or contact the APA toll free at 1-888-357-7924 (within the U.S. or Canada) or 202-682-6000.

 This activity is supported by an unrestricted educational grant from Abbott Laboratories.

 Sponsored by the American Psychiatric Association and held at the APA 2002 Annual Meeting.

INDUSTRY-SUPPORTED SYMPOSIUM 22  
 Sunday, May 19, 7:00 p.m. - 10:00 p.m.  
 Grand Ballroom Salons G/H, Level 5, Marriott



## TREATMENT OF MOOD AND ANXIETY DISORDERS IN WOMEN: *What Is Evidence and What Is Art?*

**APA – 155th Annual Meeting**  
**DINNER SYMPOSIUM** Sunday, May 19, 2002  
 7:00 – 10:00 p.m. • Dinner 6:30 – 7:00 p.m.  
 The Philadelphia Marriott  
 Grand Ballroom Salons G/H, Level 5

**Agenda and Faculty:**

**Introductory Remarks (7:00–7:15)**  
 KIMBERLY A. YONKERS, M.D., CHAIR

**Treatment of Mood Disorders in Pregnancy and the Postpartum Period (7:15–7:45)**  
 LEE S. COHEN, M.D.  
 Assistant Professor of Psychiatry, Harvard Medical School

**Course of Treatment of Bipolar Illness During Pregnancy and the Postpartum Period (7:45–8:15)**  
 ADELE C. VIGUERA, M.D.  
 Assistant Professor of Psychiatry, Harvard Medical School

**New Strategies in Managing PMDD (8:15–8:45)**  
 KIMBERLY A. YONKERS, M.D.  
 Associate Professor of Psychiatry, Yale University

**Gender As a Factor (8:45–9:15)**  
 M. KATHERINE SHEAR, M.D.  
 Professor of Psychiatry, University of Pittsburgh

**Sponsored by the American Psychiatric Association**


**Educational Objective:**  
*At the conclusion of this symposium participants should have: an increased understanding of the components of treatment for women with mood and anxiety disorders that are evidence based.*

**45 minutes have been set aside for questions and answers.**

**Accreditation:**  
 The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education to physicians.  
 The APA designates this educational activity for up to 3 hours in category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit he/she actually spent in the educational activity.  
 Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at [www.psych.org](http://www.psych.org) or contact the APA toll free at 1-888-357-7924 (within the U.S. or Canada) or 202/682-6000.  
 Supported by an unrestricted educational grant from WYETH

**INDUSTRY-SUPPORTED SYMPOSIUM 23**  
**Sunday, May 19, 7:00 p.m. - 10:00 p.m.**  
**Wyndham Ballrooms A/B, First Floor, Wyndham**

## Primary Mood Stabilizers as the Cornerstone of Treatment for Bipolar Disorder




**Sunday, May 19, 2002**

**6:30PM-7:00PM Dinner**  
**7:00PM-10:00PM Educational Program**

**Wyndham, Ballrooms A/B  
Philadelphia, Pennsylvania**

Sponsored by the American Psychiatric Association  
Supported by an unrestricted educational grant  
from Eli Lilly and Company



**American Psychiatric Association 2002 Annual Meeting**

**6:30PM DINNER**  
**7:00PM WELCOME AND INTRODUCTION**  
 Paul E. Keck, Jr, MD  
 Program Chair  
 Professor of Psychiatry and Pharmacology  
 Vice Chairman for Research, Department of Psychiatry  
 University of Colorado, College of Medicine, Denver, Ohio

**7:05PM MANIA AND MOOD STABILIZATION: WHAT'S NEW?**  
 Lauren Marangoli, MD  
 Associate Professor of Psychiatry  
 Director, Mood Disorders Research  
 Johns Hopkins University  
 Johns Hopkins School of Medicine, Mood Disorders Center  
 Houston, Texas

**7:30PM PRACTICAL APPROACHES TO RECOGNIZING  
AND MANAGING SIDE EFFECTS**  
 Paul E. Keck, Jr, MD  
 Program Chair

**7:55PM TREATING DEPRESSION AND SOCIALITY**  
 Michael E. Thase, MD  
 Professor of Psychiatry  
 University of Pittsburgh School of Medicine  
 Pittsburgh, Pennsylvania

**8:20PM UPDATE ON THE TREATMENT OF RAPID-CYCLING  
BIPOLAR DISORDER**  
 Joseph Goldberg, MD  
 Assistant Professor of Psychiatry  
 West Medical College of Cornell University  
 Director, Bipolar Research Clinic  
 New York Presbyterian Hospital  
 New York, New York

**8:45PM COMPLIANCE AND OPTIMIZING FUNCTION**  
 Professor Guy Goodwin  
 B.A. Reader, Professor of Psychiatry  
 Oxford University, Oxford, England

**9:10PM THE DOCTOR-PATIENT RELATIONSHIP:  
HOW TO GET HELP FOR THE ONE YOU LOVE**  
 Mary Worthen  
 Author, *Johnny Not Ours*, *Caroline Not Ours*  
 Little Rock, Arkansas

**9:35PM QUESTION AND ANSWER SESSION**  
 There will also be 5 minutes for questions and answers  
 after each presentation.

**Program Description**  
 Mood-stabilizing medications are the cornerstone of treatment of bipolar disorder, and lithium has been the prototypic mood stabilizer for more than 50 years. The past decade has seen new medications emerge that have similar properties, and more is known about optimizing treatment adherence in conjunction with psychosocial therapies. Physicians' recognition of the predominance of depressive symptoms and manic episodes in the course of bipolar illness, together with an understanding of how these expanded treatment options offer hope for notoriously difficult-to-treat conditions, can reduce the treatment challenges of these complicated illnesses.


**Learning Objectives**  
 At the conclusion of this symposium, participants should be able to

1. Critically identify the most current data regarding the efficacy and safety of medications used to treat all aspects of bipolar disorder.
2. Review new research regarding the use of lithium, the anticonvulsants, and the atypical antipsychotic agents in the treatment of patients with bipolar disorder.
3. Discuss the optimal use of antidepressants in the treatment of rapid-cycling bipolar disorder.
4. Recognize the barriers to resolving adequate treatment for bipolar disorder and understand practical approaches for physicians and patients to forge a stronger relationship in the treatment of bipolar disorder.

**Accreditation and Credit Designation**  
 The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.  
 The APA designates this educational activity for up to 3 hours in Category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Attendees must be registered for the APA 2002 Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at [www.psych.org](http://www.psych.org) or contact the APA toll-free at 1-888-357-7924 (within the US or Canada) or at 202-682-6000.  
 If you need special assistance, please call 317-848-5725.

**INDUSTRY-SUPPORTED SYMPOSIUM 24**  
**Sunday, May 19, 7:00 p.m. - 10:00 p.m.**  
**Wyndham Ballrooms C/D, First Floor, Wyndham**



This symposium will be broadcasted on May 19, 2002, during the 2002 Annual Meeting of the American Psychiatric Association

# MOLECULES OF THE MIND

## THE SCIENCE OF SCHIZOPHRENIA

**Sunday, May 19, 2002**  
**5:00-6:00 PM Dinner**  
**6:30-7:00 PM**

**WYNDHAM FRANKLIN PLAZA HOTEL**  
**1st Floor, Wyndham Ballrooms C-D**  
**Philadelphia, Pennsylvania**

**AGENDA**

**6:30-7:00 PM** Dinner

**7:00 PM** Welcome and Opening Remarks  
**JEFFREY LIEBERMAN, MD**  
 (Moderator, Chairperson)  
 University of North Carolina  
 School of Medicine

**7:10 PM** The Neurobiology of Cognitive  
 Dysfunction in Schizophrenia  
**DAVID A. LEWIS, MD**  
 University of Pittsburgh

**7:30 PM** Molecular Biology and Genetics  
 of Cortical Function in  
 Schizophrenia  
**DANIEL R. WEINBERGER, MD**  
 National Institute of Mental Health  
 Intramural Research Program,  
 National Institutes of Health

**7:50 PM** Glutamatergic Mechanisms in  
 Schizophrenia  
**CAROL A. TAMMINGA, MD**  
 Maryland Psychiatric Research Center

**8:10 PM** White Matter Abnormalities  
 in Schizophrenia  
**KENNETH L. DAVIS, MD**  
 Mount Sinai School of Medicine

**8:30 PM** Nicotinic Receptors and the  
 Genetics of Schizophrenia and  
 Bipolar Disorder  
**ROBERT FREEDMAN, MD**  
 University of Colorado

**8:50 PM** Neuroplasticity and Cellular  
 Resilience in Mood Disorders  
**HUSSEINI K. MANJI, MD**  
 National Institute of Mental Health  
 Intramural Research Program,  
 National Institutes of Health

**9:10 PM** Q&A  
**QUESTIONS AND ANSWERS**

**9:35 PM** Closing Remarks  
**JEFFREY LIEBERMAN, MD**  
 University of North Carolina  
 School of Medicine

**10:00 PM** Adjourn


**LEARNING OBJECTIVES**

After attending this symposium, participants will be able to:

- Recognize the genetic link to schizophrenia and evaluate neurobiological data on the subject.
- Describe the molecular and neuro-genetic bases for cognitive dysfunction in schizophrenia.
- Evaluate the evidence for nicotinic receptor genes as candidate genes for the etiology of risk for schizophrenia and bipolar disorder.
- Explain the potential role of glutamate in schizophrenia.
- Recognize molecular, cellular, and imaging data implicating abnormalities in dysfunction in schizophrenia.
- Understand a mechanism of genetic susceptibility for schizophrenia.
- Understand the emerging body of data indicating that mood-stabilizing agents regulate neuroplasticity and cellular resilience.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.  
 The APA designates this educational activity for up to 3 hours in Category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Sponsored by Wyndham Hotels and Resorts, AstraZeneca, and the American Psychiatric Association. For more information about the meeting, please visit the APA website at [www.psych.org](http://www.psych.org) or contact the APA toll-free at 1-888-357-7924 (within the US or Canada) or at 202-682-6000.  
 If you need special assistance, please call 317-848-5725.



**INDUSTRY-SUPPORTED SYMPOSIUM 25**  
**Monday, May 20, and Tuesday, May 21, 7:00 a.m. - 8:30 a.m.**  
**Millennium Hall, Second Floor, Loews**

**Clinical Challenges in depression**

**PROGRAM OBJECTIVES**  
 After attending this continuing education program, the psychiatrist should be able to:

- Gain an appreciation of the types of conditions or situations that clinicians encounter that will alert them to the challenge that treatment of these depressed patients may pose
- Understand the special challenges that the treatment of bipolar depression and psychotic depression offer and learn how to better manage these patients
- Identify the lack of diagnosis and treatment knowledge and experience that the adolescent patient poses and how to deal with this population
- Identify the relationship between depression and cardiovascular disease death and the approach to management
- Review the problem of long-term compliance with treatment of depression and what can be done to improve long-term outcome.

**MONDAY, MAY 20, 2002  
 AND TUESDAY, MAY 21, 2002**  
**7:00 AM - 8:30 AM**  
*Loews Hotel  
 Millennium Hall  
 Second Floor*

 *Sponsored by the American Psychiatric Association.*

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates each morning of this educational activity for up to 1.5 hours in category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting please visit the APA website at [www.psych.org](http://www.psych.org) or contact the APA toll free at 1-888-357-7924 (within the US or Canada) or 202-682-6000.

<p><b>MONDAY, MAY 20, 2002</b></p> <p><b>6:30-7:00 AM</b> Breakfast</p> <p><b>7:00 AM</b> Opening Remarks <i>Prakash S. Masand, MD</i> <i>Symposium Chair</i> <i>Duke University Medical Center</i></p> <p><b>7:05 AM</b> Special Challenges in Treating Bipolar Depression and Psychotic Depression <i>David V. Shreehan, MD, MBA</i> <i>University of South Florida</i></p> <p><b>7:25 AM</b> Growing Up Depressed: The Underserved Child and Adolescent Population <i>Neal D. Ryan, MD</i> <i>University of Pittsburgh School of Medicine</i></p> <p><b>7:45 AM</b> Cardiovascular Disease and Depression: A Deadly Comorbidity <i>Dominique L. Musselman, MD, MS</i> <i>Emory University School of Medicine</i></p> <p><b>8:05 AM</b> Panel Discussion With Questions and Answers</p>	<p><b>TUESDAY, MAY 21, 2002</b></p> <p><b>6:30-7:00 AM</b> Breakfast</p> <p><b>7:00 AM</b> Opening Remarks <i>Prakash S. Masand, MD</i> <i>Symposium Chair</i></p> <p><b>7:05 AM</b> Can Long-Term Outcome Be Improved in Depression? The Role of Side Effects and Compliance <i>Prakash S. Masand, MD</i></p> <p><b>7:35 AM</b> Helping Patients With Sexual Dysfunction During Antidepressant Treatment <i>Lori Calabrese, MD</i> <i>Eastern Connecticut Health Network</i></p> <p><b>8:00 AM</b> Panel Discussion With Questions and Answers</p> <p><b>8:25 AM</b> Closing Remarks <i>Prakash S. Masand, MD</i></p>
---	--

*A Two-Part Breakfast Symposium to be held at the American Psychiatric Association 155th Annual Meeting*

SUPPORTED BY AN UNRESTRICTED EDUCATIONAL GRANT FROM GLANDSMITH/KUNZ.

**INDUSTRY-SUPPORTED SYMPOSIUM 26**  
**Monday, May 20, and Tuesday, May 21, 7:00 a.m. - 8:30 a.m.**  
**Regency Ballrooms A-C, Second Floor, Loews**



**Monday, May 20, 2002  
(Day One):**

**Tuesday, May 21, 2002  
(Day Two):**

A P A 2 0 0 2 A N N U A L M E E T I N G

**Novel Antipsychotic Drugs: Advances in the Treatment of a Spectrum of Psychotic Disorders**

**Monday, May 20 & Tuesday, May 21, 2002** – Loews Philadelphia, Regency Ballroom  
 Breakfast: 6:30 AM – 7:00 AM / Symposium: 7:00 AM – 8:30 AM • CHAIR: Robert E. Hales, MD • CO-CHAIR: Stuart C. Yudofsky, MD


<b>Agenda:</b>	<p><b>7:00 AM Welcome and Introduction</b> Robert E. Hales, MD – University of California, Davis Stuart C. Yudofsky, MD – Baylor College of Medicine</p> <p><b>7:05 AM From Bench to Bedside: Rational Selection of Medications for the Management of Schizophrenia</b> Rona J. Hu, MD – Stanford University</p> <p><b>7:30 AM Evolution of Antipsychotic Therapies: Impact on Long-Term Outcomes</b> John M. Kane, MD – New York University</p> <p><b>7:55 AM Summary Remarks</b> Stuart C. Yudofsky, MD – Baylor College of Medicine</p> <p><b>8:05 AM Panel Discussion / Questions and Answers</b></p>	<b>Learning Objectives:</b>
		<p><i>After completion of this 2-day symposium, the participants should be better able to</i></p> <ul style="list-style-type: none"> <li>■ Discuss current theories of the pathophysiologic basis for schizophrenia and their implications for disease management</li> <li>■ Review advances in long-term management of schizophrenia and the impact of antipsychotic therapies on cognitive function</li> <li>■ Discuss the role of novel antipsychotics in the management of acute mania</li> <li>■ Identify unique challenges in the management of psychosis in the elderly</li> </ul> <p>The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.</p> <p>The APA designates this educational activity for up to 3 hours in category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should only claim those hours of credit that he/she actually spent in the activity.</p> <p>Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served.</p> <p>For more information about the meeting, please visit the APA website at <a href="http://www.psych.org">www.psych.org</a> or contact the APA toll free at 1-888-357-7924 (within the U.S. or Canada) or 202-682-6000.</p>
	<p><b>7:00 AM Welcome and Introduction – Brief Overview of Day One</b> Robert E. Hales, MD – University of California, Davis</p> <p><b>7:10 AM The Emerging Role of Antipsychotic Agents for the Management of Acute Mania</b> John Zajecka, MD – Rush-Presbyterian-St. Luke's Medical Center</p> <p><b>7:35 AM New Approaches to the Treatment of Psychosis in the Elderly</b> Dilip V. Jeste, MD – University of California, San Diego</p> <p><b>8:00 AM Summary Remarks</b> Stuart C. Yudofsky, MD – Baylor College of Medicine</p> <p><b>8:05 AM Panel Discussion / Questions and Answers</b></p>	

Sponsored by the American Psychiatric Association. 

Supported by an unrestricted educational grant from Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd.

**INDUSTRY-SUPPORTED SYMPOSIUM 27**  
**Monday, May 20, and Tuesday, May 21, 7:00 a.m. - 8:30 a.m.**  
**Grand Ballroom Salons E/F, Level 5, Marriott**



This symposium will be conducted on May 20 and May 21, 2002 during the 2002 Annual Meeting of the American Psychiatric Association.

## ANTIPSYCHOTIC PHARMACOTHERAPY AND THE HIPPOCRATIC OATH

MONDAY, MAY 20 & TUESDAY, MAY 21, 2002  
 SYMPOSIUM 7:00-8:30 AM  
 BREAKFAST 8:30-7:00 AM

PHILADELPHIA MARriott HOTEL  
 GRAND BALLROOM SALONS E/F  
 PHILADELPHIA, PENNSYLVANIA

**ABOVE ALL, DO NO HARM**

AGENDA		LEARNING OBJECTIVES	
MONDAY, MAY 20, 2002	TUESDAY, MAY 21, 2002	After attending this symposium, participants will be able to:	
6:30-7:00 AM Breakfast	6:30-7:00 AM Breakfast	Recognize that the new generation of antipsychotics are secondary or equivalent efficacy to the treatment of psychosis, but they differ in their side-effect profiles.	
7:00 AM Opening Remarks/Introductions <b>HENRY A. NASRALLAH, MD</b> (PROGRAM CHAIRPERSON) University of Mississippi	7:00 AM Opening Remarks/Introductions <b>HENRY A. NASRALLAH, MD</b> (PROGRAM CHAIRPERSON) University of Mississippi	Discuss the high rates of morbidity and mortality with relapse to physical illness in patients with schizophrenia and the treatment issues that are specific to this group of psychiatric patients.	
7:10 AM Medical Morbidity and Mortality in Patients With Schizophrenia <b>S. CHARLES SCHULTZ, MD</b> University of Minnesota Medical School	7:05 AM Avoiding Neuroendocrine Disruptions With Atypical Antipsychotic Agents <b>DAVID C. HENDERSON, MD</b> Harvard Medical School	Explain the differential use of weight gain with atypical antipsychotics and the potential impact of antipsychotic-induced weight gain on health and quality of life with chronic illness.	
7:30 AM Minimizing Acute and Long-Term Movement Disorders With Atypical Antipsychotics <b>LILI KOPALA, MD, FRCP(C)</b> Dalhousie University	7:15 AM Emerging Biomedical Issues in Antipsychotic Pharmacotherapy: Do We Know...? <b>HENRY A. NASRALLAH, MD</b> University of Mississippi	Assess potential benefits and the importance of monitoring patients treated with atypical antipsychotic agents for hyperprolactinemia, weight gain, lipid abnormalities, and glucose intolerance.	
7:50 AM Weight Gain and Obesity Secondary to Atypical Antipsychotics: Immediate and Long-Term Health Threats <b>DIANA O. PERKINS, MD, MPH</b> University of North Carolina, Chapel Hill	8:05 AM Questions and Answers Panel Discussion	Discuss various ethical issues that surround the use of antipsychotic medications, such as the use of placebo in clinical trials, obtaining informed consent regarding the benefits and risks of antipsychotics in clinical practice, potential conflict of interest in the selection of an antipsychotic, and many other ethical issues.	
8:05 AM Questions and Answers	8:30 AM Adjourn	<p><small>Reproduction of this educational activity is prohibited by the American Psychiatric Association. Medical education is provided by AstraZeneca. The APA designates this educational activity for up to 3 hours in category 1 credit. Participants should claim only those hours of credit that he/she actually spent in the educational activity.</small></p> <p><small>Support is provided by AstraZeneca. AstraZeneca is a registered trademark of AstraZeneca. AstraZeneca is a registered trademark of AstraZeneca. AstraZeneca is a registered trademark of AstraZeneca.</small></p>	
8:30 AM Adjourn		<p><small>Reproduction of this educational activity is prohibited by the American Psychiatric Association. Medical education is provided by AstraZeneca. The APA designates this educational activity for up to 3 hours in category 1 credit. Participants should claim only those hours of credit that he/she actually spent in the educational activity.</small></p> <p><small>Support is provided by AstraZeneca. AstraZeneca is a registered trademark of AstraZeneca. AstraZeneca is a registered trademark of AstraZeneca. AstraZeneca is a registered trademark of AstraZeneca.</small></p>	

**INDUSTRY-SUPPORTED SYMPOSIUM 28**  
**Monday, May 20, and Tuesday, May 21, 7:00 a.m. - 8:30 a.m.**  
**Grand Ballroom Salons G/H, Level 5, Marriott**

**APA 155TH ANNUAL MEETING – BREAKFAST SYMPOSIUM**  
 Sponsored by the American Psychiatric Association

**7:00 am to 8:30 am / Breakfast 6:30 am to 7:00 am**

Chair: **Milton K. Erman, M.D.**, Clinical Professor  
 Department of Psychiatry, University of California San Diego



### Understanding Sleep Medicine: What the Psychiatrist Needs to Know

MONDAY, MAY 20	TUESDAY, MAY 21
<p><b>Agenda and Faculty:</b>  <b>Introductory Remarks:</b> (7:00-7:05)                      Milton K. Erman, M.D.  <b>Sleep, Safety and Public Policy</b> (7:05-7:25)                      Mark R. Rosekind, Ph.D.                      President and Chief Scientist                      Alertness Solutions  <b>Sleep Disorders: What the Psychiatrist Needs to Know</b> (7:25-7:45)                      Lois Krahn, M.D.                      Associate Professor of Psychiatry                      The Mayo Clinic  <b>Innovative Strategies in the Management of Insomnia</b> (7:45-8:05)                      Karl Doghramji, M.D.                      Associate Professor of Psychiatry                      Thomas Jefferson University</p>	<p><b>Agenda and Faculty:</b>  <b>Introductory Remarks:</b> (7:00-7:05)                      Milton K. Erman, M.D.  <b>Morbidity of Insomnia</b> (7:05-7:35)                      Thomas Roth, Ph.D.                      Chief Division of Sleep Medicine                      Henry Ford Hospital  <b>Mechanism of Action of Hypnotics</b> (7:35-8:05)                      Stephen M. Stahl, M.D., Ph.D.                      Professor of Psychiatry                      University of California San Diego</p>

25 minutes have been allotted each day for questions and answers.

Supported by an unrestricted educational grant from **Wyeth**.


The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education to physicians. The APA designates this educational activity for up to 3 hours in category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting please visit the APA website at [www.psych.org](http://www.psych.org) or contact the APA toll free at 1-888-357-7924 (within the U.S. or Canada) or 202/682-6000.

**Educational Objectives:**  
 At the conclusion of this symposium the participant should be able to: recognize previously undiagnosed sleep disorders; appreciate the role of insomnia in psychiatric comorbidity; understand mechanisms of action of hypnotics; treat sleep problems effectively.



**INDUSTRY-SUPPORTED SYMPOSIUM 29**  
**Monday, May 20, and Tuesday, May 21, 7:00 a.m. - 8:30 a.m.**  
**Wyndham Ballrooms A/B, First Floor, Wyndham**



**One Size Doesn't Fit All**  
*Depression Therapies for the 21st Century*

American Psychiatric Association  
 2002 Annual Meeting

**Monday, May 20, 2002  
 and Tuesday, May 21, 2002**

6:30AM-7:00AM Breakfast  
 7:00AM-8:30AM Educational Program

Wyndham, Ballrooms A/B  
 Philadelphia, Pennsylvania

**Part 1: Monday, May 20, 2002**

**6:30AM Breakfast**  
**7:00AM Welcome and Introduction**  
 David L. Dunner, MD  
*Program Chair*  
 Professor, Department of Psychiatry and Behavioral Sciences,  
 University of Washington  
 Director, Center for Anxiety and Depression,  
 Seattle, Washington

**7:05AM The Physical Manifestations of Depression**  
 John H. Grist, MD  
 Distinguished Senior Scientist, Madison Institute of Medicine, Inc.  
 Clinical Professor of Psychiatry, University of Wisconsin  
 Madison, Wisconsin

**7:125AM Improving Outcomes in the Long-Term  
 Treatment of Depression: Giving Patients a Choice**  
 Mauricio Fava, MD  
 Director, Depression Clinical and Research Programs,  
 Massachusetts General Hospital  
 Associate Professor of Psychiatry, Harvard Medical School  
 Boston, Massachusetts

**7:45AM Adapting Psychotherapies to a  
 Patient's Individual Needs**  
 Ellen Frank, PhD  
 Professor of Psychiatry and Psychology  
 University of Pittsburgh, School of Medicine  
 Western Psychiatric Institute and Clinic  
 Pittsburgh, Pennsylvania

**8:05AM Question and Answer Session**

---

**Part 2: Tuesday, May 21, 2002**

**6:30AM Breakfast**  
**7:00AM Welcome and Introduction**  
 David L. Dunner, MD  
*Program Chair*  
 Professor, Department of Psychiatry and Behavioral Sciences,  
 University of Washington  
 Director, Center for Anxiety and Depression,  
 Seattle, Washington

**7:05AM Lost in Depression:  
 The Treatment-Resistant Patient**  
 Holly Swartz, MD  
 Assistant Professor of Psychiatry  
 University of Pittsburgh, School of Medicine  
 Western Psychiatric Institute and Clinic  
 Pittsburgh, Pennsylvania

**7:125AM Depression and Substance Use**  
 Kathleen T. Brady, MD  
 Professor of Psychiatry, Department of Psychiatry,  
 Center for Drug and Alcohol Programs  
 Medical University of South Carolina  
 Charleston, South Carolina

**7:45AM Putting the Pieces Together: Treatments  
 for the Present and the Future**  
 David L. Dunner, MD  
*Program Chair*

**8:05AM Question and Answer Session**

**Program Description**  
 Depression is a complicated mood disorder that can be difficult to diagnose and even more difficult to treat. Not all patients with depression are the same, and not all therapies are the same; treatments must be individualized to meet patient needs. Given the wide variety of conventional and novel treatments from which to choose, today's healthcare practitioner must discern which psychotherapy and pharmacotherapy treatments will provide the best fit for the patient with depression.

**Learning Objectives**  
 At the conclusion of this symposium, participants should be able to:


1. Identify and manage physical manifestations of depression that confound its recognition and treatment.
2. Cite approaches to improving outcomes for patients with depression, including those with treatment-resistant depression, substance abuse disorders, and panic symptomatology.
3. Adapt treatments such as IPT and CBT to improve outcomes for patients with depression.

**Accreditation and Credit Designation**  
 The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates each part of this educational activity for up to 1.5 hours in Category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Attendees must be registered for the APA 2002 Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at [www.psych.org](http://www.psych.org) or contact the APA toll-free at 1-888-357-7924 (within the US or Canada) or at 202-682-6000.

Sponsored by the American Psychiatric Association  
 Supported by an unrestricted educational grant from Eli Lilly and Company





If you need special assistance, please call 317.848.5725.


**INDUSTRY-SUPPORTED SYMPOSIUM 30**  
**Monday, May 20, and Tuesday, May 21, 7:00 a.m. - 8:30 a.m.**  
**Wyndham Ballrooms C/D, First Floor, Wyndham**

**Breaking the Silence of Children's Mental Illness:**  
**National Initiatives, Early Detection, and New Pharmacotherapies**

A symposium to be held during the APA 2002 Annual Meeting



Sponsored by  
  
 the American Psychiatric Association

Supported by an unrestricted educational grant from  
  
 JANSSEN  
 01-RS-1000-9C

The objectives of this symposium are to familiarize the participants with the diagnostic criteria and treatment options specific in pediatric psychiatry, stress the importance of early recognition and appropriate treatment selections, and discuss the expanded treatment options as clinical trial data have emerged over the last decade.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The APA designates this educational activity for 3 hours in category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be on a first-come, first-served basis. For more information about the meeting, please visit the APA website at [www.psych.org](http://www.psych.org) or contact the APA toll-free at 1-888-357-7924 (within the US or Canada) or 202-682-6000.

**Monday, May 20, & Tuesday, May 21, 2002**  
**Ballrooms C-D**  
**Wyndham Franklin Plaza Hotel**  
**Philadelphia, PA**

**Agenda Part I: May 20**

6:30 - 7:00 AM Breakfast  
 7:00 - 7:05 AM Welcome and Introduction  
 Robert L. Findling, MD (Chair)  
 University Hospital

7:05 - 7:30 AM Mental Illness in Children: Diagnosing Outside the Box  
 Hans Steiner, MD  
 Stanford University

7:30 - 8:00 AM An Increasing Role for Atypical Antipsychotics in Pediatric Psychiatry: Efficacy in Well-Designed Trials  
 Christopher J. McDougle, MD  
 Indiana University

8:00 - 8:30 AM Questions and Answers

**Agenda Part II: May 21**

6:30 - 7:00 AM Breakfast  
 7:00 - 7:05 AM Welcome and Introduction  
 Robert L. Findling, MD (Chair)

7:05 - 7:35 AM Evolving Treatments for Psychiatric Disorders in Young Patients With Evidence From Bipolar and Other Conditions  
 Janet R. Wozniak, MD  
 Massachusetts General Hospital


7:35 - 8:00 AM Atypical Antipsychotic Pharmacotherapy in Children and Adolescents: What Is the Evidence for Long-Term Safety?  
 Robert L. Findling, MD

8:00 - 8:15 AM Keynote Address: A Parent's Perspective on Interventions for Children's Mental Health  
 Ellen Kinsley, MA  
 ADDitude Magazine

8:15 - 8:30 AM Questions and Answers

**INDUSTRY-SUPPORTED SYMPOSIUM 31**  
**Tuesday, May 21, 7:00 p.m. - 10:00 p.m.**  
**Ballrooms A/B, Ballroom Level, Convention Center**

*Please join us at the APA 2002 Annual Meeting • Sponsored by the American Psychiatric Association*



## **BIPOLAR DEPRESSION & RAPID CYCLING: CURRENT MANAGEMENT STRATEGIES**

### **TUESDAY DINNER MAY 21**

**6:30 – 7 PM Dinner**  
**7–10 PM Clinical Program**  
**Philadelphia Convention Center**  
**Ballrooms A & B, Ballroom Level**

**Symposium Chair**  
**JOSEPH R. CALABRESE, MD**  
 Case Western Reserve University

**The Underestimated Need and Treatment Challenges of Bipolar Depression**  
**MARK A. FRYE, MD**  
 UCLA

**Stabilizing Mood in Bipolar Disorder From Below Baseline Over Long Periods**  
**JOSEPH F. GOLDBERG, MD**  
 Cornell University


**Rapid Cycling: Clinical Presentation and Treatment Approaches**  
**ROBERT M. POST, MD**  
 Chevy Chase, Maryland

**Managing Common-Benign and Uncommon-Serious Side Effects**  
**TERENCE A. KETTER, MD**  
 Stanford University

**EDUCATIONAL OBJECTIVES:** To differentiate and diagnose patients with bipolar depression and to become knowledgeable about the most current data on strategies for addressing unmet needs in bipolar disorder and improving the quality of care of these patients.

**REGISTRATION:** Attendees must be registered for the APA 2002 Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at [www.psych.org](http://www.psych.org) or contact the APA toll-free at 1-888-357-7924 (within the US or Canada) or 202-682-6000.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity for up to 3.0 hours in category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

This program is supported by an unrestricted educational grant from  GlaxoSmithKline.

**AGENDA**

6:30 PM	Dinner
7:00 PM	Introduction – J. Calabrese, MD
7:10 PM	Speaker presentations
9:15 PM	Question and answer session
10:00 PM	Program concludes


**INDUSTRY-SUPPORTED SYMPOSIUM 32**  
**Tuesday, May 21, 7:00 p.m. - 10:00 p.m.**  
**Millennium Hall, Second Floor, Loews**

**TUESDAY, MAY 21, 2002 | 7:00 PM – 10:00 PM**  
*Loews Hotel | Millennium Hall | Second Floor*

## The New Neurobiology of **mood** and **anxiety** disorders

**PROGRAM OBJECTIVES**  
 After attending this continuing education program, the psychiatrist should be able to:

- Examine the intricate interplay of the neurohormones in the brain and the latest evidence that norepinephrine has a major role in mood and anxiety disorders
- Appreciate the contribution of childhood trauma to our understanding of the neurobiology of mood disorders
- Review the evidence and strides being made in brain imagery to improve our understanding of the functional and dysfunctional brain
- Review evidence on stress, sleep disorders, and neurogenesis and how their understanding has provided new insights into mood disorders.

 *Sponsored by the American Psychiatric Association.*

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity for up to 3 hours in category 1 credit towards the AMA Physician's Recognition Award and for the CME requirements of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting please visit the APA website at [www.psych.org](http://www.psych.org) or contact the APA toll free at 1-888-357-7924 (within the US or Canada) or 202-682-6000.

**TUESDAY, MAY 21, 2002**

6:30 PM–	Dinner
7:00 PM	Welcome and Program Introduction <i>SYMPOSIUM COCHAIRS, Charles B. Nemeroff, MD, PhD, Emory University School of Medicine and K. Ranga Rama Krishnan, MD, Duke University Medical Center, Durham, North Carolina</i>
7:05 PM	Clinical Relevance of Norepinephrine in Mood Disorders <i>Kerry J. Ressler, MD, PhD, Emory University School of Medicine</i>
7:30 PM	Childhood Trauma and the Neurobiology of Mood Disorders <i>Charles B. Nemeroff, MD, PhD</i>
7:55 PM	Advances in Functional Brain Imaging in Psychiatry <i>K. Ranga Rama Krishnan, MD</i>
8:20 PM	Neurobiology, Sleep, and Mood Disorders: A New Look <i>David J. Kupfer, MD, University of Pittsburgh School of Medicine</i>
8:45 PM	Stress, Neurogenesis, and the Adult Brain <i>Elizabeth Gould, PhD, Princeton University</i>
9:10 PM	Panel Discussion with Questions and Answers
9:55 PM	Closing Remarks, Adjournment <i>Charles B. Nemeroff, MD, PhD</i>

*A Dinner Symposium to be held at the American Psychiatric Association 155th Annual Meeting*

SUPPORTED BY AN UNRESTRICTED EDUCATIONAL GRANT FROM GLAXOSMITHKLINE.





**INDUSTRY-SUPPORTED SYMPOSIUM 33**  
**Tuesday, May 21, 7:00 p.m. - 10:00 p.m.**  
**Regency Ballrooms A-C, Second Floor, Loews**


## Managing Aggression Across the Lifespan:

### From the Pediatric to the Geriatric Patient

A symposium to be held during the APA 2002 Annual Meeting



Sponsored by  
  
 the American Psychiatric Association

Supported by an unrestricted educational grant from  
  
 JANSSEN  
 8196-000-00

The objectives of this symposium are to familiarize the participants with the rationale for and specific considerations in the treatment of aggression across ages and psychiatric disorders, including current evidence for the efficacy and safety of antipsychotics and other therapies.

Alcoholics must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be on a first-come, first-served basis. For more information about the meeting, please visit the APA website at [www.psych.org](http://www.psych.org) or contact the APA toll free at 1-888-357-7924 (within the US or Canada) or 202-482-6000.

**Tuesday, May 21, 2002**  
**Regency Ballrooms A-C**  
**Loews Philadelphia Hotel**  
**Philadelphia, PA**

### Agenda

6:30 – 7:00 PM	Dinner
7:00 – 7:05 PM	Welcome and Introduction <i>Douglas H. Hughes, MD (Chair)</i> <i>Boston University Medical School</i>
7:05 – 7:25 PM	Managing the Aggressive Patient <i>Douglas H. Hughes, MD</i>
7:25 – 7:55 PM	Evidence-Based Approach to Pharmacotherapy of the Aggressive Child <i>Jorge L. Armenteros, MD</i> <i>University of Miami</i>
7:55 – 8:25 PM	Aggression and Psychiatric Disorders: Confronting the War Within <i>Robert R. Conley, MD</i> <i>Maryland Psychiatric Research Center</i>
8:25 – 8:55 PM	Strategies and Interventions for Late-Life Aggression <i>Soo Borson, MD</i> <i>University of Washington</i>
8:55 – 9:15 PM	Long-Term Adverse Effects of Antipsychotic Therapy <i>Prakash S. Masand, MD</i> <i>Duke University Medical Center</i>
9:15 – 10:00 PM	Questions and Answers

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The APA designates this educational activity for 3 hours in category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

**INDUSTRY-SUPPORTED SYMPOSIUM 34**  
**Tuesday, May 21, 7:00 p.m. - 10:00 p.m.**  
**Grand Ballroom Salons E/F, Level 5, Marriott**

## TREATING fEAR

## Perspectives on the Biology and Therapy of Anxiety Disorders

**APA 2002 ANNUAL MEETING . TUESDAY, MAY 21, 2002 . DINNER: 6:30-7:00 PM . SYMPOSIUM: 7:00-10:00 PM**  
**GRAND BALLROOM SALONS E/F . LEVEL 5 MARRIOTT . PHILADELPHIA, PA**

<p><b>7:00 – 7:10 PM</b>    <b>Welcome and Introduction</b> <i>Jack M. Gorman, MD • Chairperson</i> <i>Columbia University</i></p> <p><b>7:10 – 7:35 PM</b>    <b>Neurobiology of Fear and Social Anxiety</b> <i>Justine M. Kent MD • Columbia University</i></p> <p><b>7:35 – 8:00 PM</b>    <b>Developmental Antecedents of Anxiety Disorders</b> <i>Daniel Pine, MD • The Ross Center</i></p> <p><b>8:00 – 8:25 PM</b>    <b>New Developments in Pharmacotherapy of Anxiety Disorders</b> <i>Jonathan R.T. Davidson, MD • Duke University</i></p> <p><b>8:25 – 8:50 PM</b>    <b>Accelerating Response and Treating Comorbidity in Anxiety</b> <i>Eric Hollander, MD • Mt. Sinai School of Medicine</i></p> <p><b>8:50 – 9:15 PM</b>    <b>Minimizing Side Effects and Enhancing Compliance of Anti-Anxiety Treatments</b> <i>Francisco A. Moreno, MD • University of Arizona</i></p> <p><b>9:15 – 10:00 PM</b>    <b>Question and Answer Session</b></p>	<p><b>Educational Objectives:</b> At the conclusion of this symposium, participants will be able to:</p> <ul style="list-style-type: none"> <li>• Define the neurobiology of fear, specifically social phobia</li> <li>• Integrate childhood anxiety disorders as antecedents to adult anxiety disorders</li> <li>• Discuss new developments, accelerated response time and side effects of anti-anxiety pharmacotherapies.</li> </ul> <p>Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at <a href="http://www.psych.org">www.psych.org</a> or contact the APA toll free at 1-888-357-7924 (within US or Canada) or 202 682-6000.</p> <p style="font-size: x-small;"><i>The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.</i></p> <p style="font-size: x-small;"><i>The APA designates this educational activity for up to 3 hours in category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.</i></p> <p style="font-size: x-small;"><i>This symposium is sponsored by the American Psychiatric Association. Supported by an unrestricted educational grant from Solvay Pharmaceuticals, Inc.</i></p>
--	--

**INDUSTRY-SUPPORTED SYMPOSIUM 35**  
**Tuesday, May 21, 7:00 p.m. - 10:00 p.m.**  
**Grand Ballroom Salons G/H, Level 5, Marriott**

APA 155th Annual Meeting

## Raising Expectations in **Schizophrenia:** Enhancing Long-Term Outcomes

**Agenda**

**6:30-7:00 PM Dinner**

**7:00 Welcome and Introduction**  
*Daniel E. Casey, MD, Program Cochairperson*  
 Chief, Psychiatric Research/Psychopharmacology  
 Associate Director of Research, VISN 20 MIRECC  
 Veterans Affairs Medical Center  
 Portland, Oregon

*Nina R. Schooler, PhD, Program Cochairperson*  
 Director of Research  
 Hillside Hospital  
 Glen Oaks, New York

**7:10 Acute Psychotic Agitation: Challenges and Treatment**  
*Alan J. Mendelowitz, MD*  
 Unit Chief of Inpatient Research and Residency Training  
 Hillside Hospital  
 Glen Oaks, New York  
 Assistant Professor of Psychiatry  
 Albert Einstein College of Medicine  
 Bronx, New York

**7:25 Long-Term Treatment Goals**  
*Nina R. Schooler, PhD*

**8:00 Adverse-Effects Profile of New Antipsychotic Agents**  
*Daniel E. Casey, MD*

**8:25 Mechanisms of Medication-Associated Glucose Metabolism Impairment**  
*David C. Henderson, MD*  
 Assistant Professor of Psychiatry  
 Massachusetts General Hospital  
 Harvard Medical School  
 Boston, Massachusetts

**8:50 Schizophrenia and the Risk of Cardiovascular Disease**  
*Charles H. Hennekens, MD*  
 Visiting Professor of Medicine and Epidemiology and Public Health  
 University of Miami School of Medicine  
 Miami, Florida

**9:15 Question and Answer Session**

**10:00 Adjourn**

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be on a first-come, first-served basis. For more information about the meeting, please visit the APA Web site at [www.psych.org](http://www.psych.org) or contact the APA toll free at 1-888-357-7924 (within the United States or Canada) or 202-682-6000.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for up to 3 hours in category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

At the conclusion of this symposium, participants should be able to:

- Discuss the burden of cardiovascular disease in patients with schizophrenia, including strategies for the primary prevention of major risk factors;
- Identify medications that impact glucose metabolism and their mechanisms of action;
- Identify the differences between typical and atypical antipsychotics in the long-term treatment of schizophrenia;
- Discuss the side-effect profiles of the typical and atypical antipsychotics and their effects on patients' quality of life;
- Identify the challenges in treating agitated patients in the emergency room setting and describe strategies for successfully evaluating and managing symptoms.

**Tuesday, May 21, 2002**  
 7:00-10:00 PM  
 Grand Ballroom  
 Salon G-H, Level 5  
 Philadelphia Marriott  
 Philadelphia, Pennsylvania

Sponsored by the American Psychiatric Association

**INDUSTRY-SUPPORTED SYMPOSIUM 36**  
**Tuesday, May 21, 7:00 p.m. - 10:00 p.m.**  
**Wyndham Ballrooms A/B, First Floor, Wyndham**

## Clinical Differences in Serotonin and Norepinephrine Antidepressant Effects

**Tuesday, May 21, 2002**

**6:30PM-7:00PM Dinner**  
**7:00PM-10:00PM Educational Program**

Wyndham, Ballrooms A/B  
 Philadelphia, Pennsylvania

American Psychiatric Association 2002 Annual Meeting

**6:30PM Dinner**

**7:00PM Welcome and Introduction**  
*J. Craig Nelson, MD*  
 Program Chair  
 Professor of Psychiatry  
 Yale University School of Medicine  
 New Haven, Connecticut

**7:10PM Serotonin and Norepinephrine Mechanisms of Action**  
*Gerard Sanacora, MD, PhD*  
 Assistant Professor  
 Director, Yale Depression Research Program  
 Yale University School of Medicine  
 New Haven, Connecticut

**7:35PM Clinical Outcome of Serotonin and Norepinephrine Agents in Depression**  
*Pedro L. Delgado, MD*  
 Douglas C. Bond Professor and Chairman  
 Department of Psychiatry,  
 Case Western Reserve University/  
 University Hospitals of Cleveland  
 Cleveland, Ohio

**8:00PM The Spectrum of Serotonin-Responsive Disorders**  
*John H. Greist, MD*  
 Distinguished Senior Scientist,  
 Madison Institute of Medicine, Inc.  
 Clinical Professor of Psychiatry,  
 University of Wisconsin  
 CEO, Healthcare Technology Systems, Inc.  
 Madison, Wisconsin

**8:25PM The Spectrum of Norepinephrine-Responsive Disorders**  
*James J. Hudziak, MD*  
 Associate Professor, Psychiatry and Medicine  
 Director, Child and Adolescent Division  
 Director, Behavioral Genetics  
 University of Vermont  
 Burlington, Vermont

**8:50PM Combining Serotonin and Norepinephrine Mechanisms in Depression**  
*J. Craig Nelson, MD*  
 Program Chair

**9:15PM Question and Answer Session**

**Program Description**

The primary goal of antidepressant therapy is to induce remission and prevent relapse. Given that current antidepressant therapies demonstrate a response rate of 50 to 60% and a remission rate of only 20 to 30%, many areas for improvement remain. Emerging treatments focus on therapeutic targets designed to increase rates of remission, while clinical studies indicate that antidepressants that act on serotonin as well as norepinephrine may offer efficacy advantages. Physicians may utilize this information in the treatment of patients with depression.

**Learning Objectives**

At the conclusion of this symposium, participants should be able to

1. Describe the role of serotonin and norepinephrine in antidepressant response and the differences which characterize their clinical effects.
2. Identify the spectrum of disorders which respond to treatment with norepinephrine and/or serotonergic antidepressants.
3. Administer combination strategies or dual action agents to enhance response in depression and related disorders.

**Accreditation and Credit Designation**

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for up to 3 hours in Category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Attendees must be registered for the APA 2002 Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at [www.psych.org](http://www.psych.org) or contact the APA toll-free at 1.888.357.7924 (within the US or Canada) or at 202.682.6000.

Sponsored by the American Psychiatric Association  
 Supported by an unrestricted educational grant from Eli Lilly and Company

If you need special assistance, please call 317.848.5725.

**INDUSTRY-SUPPORTED SYMPOSIUM 37**  
**Tuesday, May 21, 7:00 p.m. - 10:00 p.m.**  
**Wyndham Ballrooms C/D, First Floor, Wyndham**

**INVITATION**

**Behavioral Disturbances in Dementia: Diagnostic and Treatment Guidelines for the Practicing Clinician**

Tuesday 21 May 2002  
 19.00-22.00  
 Wyndham Ballrooms C/D

Refreshments served  
 18.30-19.00 and  
 22.00-22.30



APA 2002 Annual Meeting

- 19.00 Chairs' Welcome**  
*Steven G Potkin MD, Robert R Sprague Director of UCI Brain Imaging Center and Mustafa M Husain MD, University of Texas Southwestern Medical Center at Dallas*

---

- 19.10 The Pathophysiology of Abnormal Behavior and Mood in Dementia**  
*Mustafa M Husain, MD, as above\**

---

- 19.40 Impact of Cholinesterase Inhibitors on Sleep Disturbance in Alzheimer's Disease**  
*P Murali Doraiswamy, MD, Duke University Medical Center†*

---

- 20.10 Dementia with Lewy Bodies: The Frontiers of Effective Treatment and Diagnosis**  
*Martin R Farlow, MD, Indiana University School of Medicine‡*

---


- 20.40 Treating the Behavioral Disturbances Observed in Alzheimer's Disease: Pharmacologic and Non-pharmacologic Interventions**  
*Steven G Potkin, MD, as above‡*

---

- 21.10 Questions and Answers**


Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at [www.psych.org](http://www.psych.org) or contact the APA toll free at 1-888-357-7924 (within the US or Canada) or 202-682-6000. Sponsored by the American Psychiatric Association. Supported by an unrestricted educational grant from Novartis Pharmaceuticals Corporation. The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity for up to 3 hours in category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

- \*Recognize and describe the pathophysiology associated with dementing illness, and the mechanisms leading to behavior and mood disturbances.
- †Understand sleep disorders associated with Alzheimer's disease and demonstrate the impact of cholinesterase inhibitor on sleep disturbances.
- ‡Accurately diagnose and identify symptoms commonly observed in Lewy body dementia.
- §Demonstrate an in-depth knowledge of the behavioral disturbances observed in dementia. Explain the pathophysiology behind the illness, recognize the clinical manifestations, and effectively treat the dementias.



**INDUSTRY-SUPPORTED SYMPOSIUM 38**  
**Wednesday, May 22, and Thursday, May 23, 7:00 a.m. - 8:30 a.m.**  
**Ballrooms A/B, Ballroom Level, Convention Center**

*Please join us at the APA 2002 Annual Meeting • Sponsored by the American Psychiatric Association*



**TWO-PART BREAKFAST SYMPOSIUM**

**Part I - Wednesday, May 22**  
**Part II - Thursday, May 23**

6:30 - 7 AM Breakfast  
 7 - 8:30 AM Clinical Program


Philadelphia Convention Center  
 Ballrooms A & B, Ballroom Level

**CHRONIC EPISODIC DISORDERS: COMORBIDITY & COMPREHENSIVE INTEGRATED TREATMENT**

EDUCATIONAL OBJECTIVES: Describe the shared features and pathophysiological links between depressive disorders and pain syndromes, irritable bowel syndrome, sexual disorders, and anxiety. Identify the unique and similar treatment strategies for each predominantly female comorbid disorder with a focus on serotonin dysregulation and the impact of the sex steroid.

REGISTRATION: Attendees must be registered for the APA 2002 Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at [www.psych.org](http://www.psych.org) or contact the APA toll free at 1-888-357-7924 (within the US or Canada) or 202-682-6000.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity for up to 3.5 hours in category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

This program is supported by an unrestricted educational grant from 

**Symposium Chair**  
**JULIA K. WARNOCK, MD, PhD**

*Unraveling the Complexity: Comorbidity, Mechanistic Link and Pharmacologic Response*  
**ANITA H. CLAYTON, MD**  
 Symposium Co-Chair  
 University of Virginia Health System

*New Developments in Obesity*  
**DONNA H. RYAN, MD**  
 Louisiana State University


*Reproductive Life Events: Depression and Sexual Dysfunction*  
**JULIA K. WARNOCK, MD, PhD**  
 University of Oklahoma

*The Relationship of Psychiatric Illness and Irritable Bowel Syndrome*  
**R. BRUCE LYDIARD, PHD, MD**  
 Southeast Health Consultants

*Management of Pain Syndromes: Fibromyalgia, Migraines, and Chronic Pain*  
**DIANE S. THOMPSON, MD**  
 University of Hawaii

PART I - WEDNESDAY, MAY 22	PART II - THURSDAY, MAY 23
6:30 AM Breakfast	6:30 AM Breakfast
7:00 AM Introduction - Dr. Warnock	7:00 AM Introduction & Recap of Part I - Dr. Warnock
7:05 AM Presentations: Drs. Clayton, Ryan, & Warnock	7:20 AM Presentations: Drs. Lydiard & Thompson
8:05 AM Questions and answer session	8:05 AM Questions and answer session
8:30 AM Part I concludes	8:30 AM Program concludes

**INDUSTRY-SUPPORTED SYMPOSIUM 39**  
**Wednesday, May 22, and Thursday, May 23, 7:00 a.m. - 8:30 a.m.**  
**Millennium Hall, Second Floor, Loews**



**Age,  
Gender,  
& Diagnosis**

**INFLUENCES  
on DRUG  
RESPONSE**

**MAY 22-23, 2002**  
7:00 - 8:30 AM  
Millennium Hall, Second Floor  
Loews Philadelphia Hotel  
Philadelphia, Pennsylvania

**DAY 1**  
**Wednesday, May 22, 2002**

6:30-7:00 AM **Breakfast**

7:00 **Welcome and Introduction**  
Alexander H. Glassman, MD  
Program Chairperson  
Professor of Clinical Psychiatry  
Department of Psychiatry  
Columbia University  
New York, New York

7:15 **Can Treating Depression Alter Cardiovascular Disease?**  
Alexander H. Glassman, MD

7:40 **Comorbidity and Its Implication on Treatment: Change over Life Span**  
Tana A. Grady-Weliky, MD  
Associate Professor  
Department of Psychiatry  
University of Rochester School of Medicine and Dentistry  
Rochester, New York

8:05 **Question and Answer Session**

8:30 **Adjourn**

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be on a first-come, first-served basis. For more information about the meeting, please visit the APA Web site at [www.psych.org](http://www.psych.org) or contact the APA toll free at 1-888-357-7924 (within the United States or Canada) or 202-662-6000.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for up to 3 hours in category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

**DAY 2**  
**Thursday, May 23, 2002**

6:30-7:00 AM **Breakfast**

7:00 **Welcome and Introduction**  
Alexander H. Glassman, MD

7:15 **Epidemiology, Course, and Drug Response: How Are Mood and Anxiety Disorders Different in Children?**  
John S. March, MD  
Director, Program in Child and Adolescent Anxiety Disorders  
Department of Psychiatry  
Duke University Medical Center  
Durham, North Carolina

7:40 **The Treatment of Women with Mood Disorders**  
Kimberly A. Yonkers, MD  
Associate Professor  
Department of Psychiatry  
Yale University School of Medicine  
New Haven, Connecticut

8:05 **Question and Answer Session**

8:30 **Adjourn**

At the conclusion of this symposium, participants should be able to:

- Review the safety and efficacy of treating depression in the immediate postpartum period, and recognize that treatment changes the risk of morbidity and mortality;
- Review the diagnostic and treatment implications of comorbid mood and anxiety disorders;
- Discuss the course of illness of anxiety disorders associated with major depression in children and adolescents, and assess possible treatment strategies;
- Evaluate the therapeutic potential of the SSRIs and TCAs in women.

Sponsored by the American Psychiatric Association

Supported by an unrestricted educational grant from Pfizer Inc.

**INDUSTRY-SUPPORTED SYMPOSIUM 40**  
**Wednesday, May 22, and Thursday, May 23, 7:00 a.m. - 8:30 a.m.**  
**Regency Ballrooms A-C, Second Floor, Loews**

**Part 1 - Wednesday, May 22, 2002**

6:30am Breakfast

7:00am **Welcome and Introduction**  
Richard C. Shelton, MD  
Program Chair  
Professor, Psychiatry and Pharmacology  
Department of Psychiatry, Medical Center  
North Carolina

7:05am **Pharmacological Properties of Antipsychotics: Teasing Out Potential Mechanisms of Action**  
Michael J. Owens, PhD  
Associate Professor  
Department of Psychiatry and Behavioral Sciences  
Duke University  
Durham, North Carolina

7:25am **Augmentation Strategies to Expand Pharmacotherapeutic Potential in Treatment-Refractory Major Depression**  
Richard C. Shelton, MD  
Program Chair

7:45am **Restoring the Balance in Manic or Depressive Bipolar Patients Through Thoughtful Pharmacotherapy**  
S. Nassir Ghafari, MD  
Assistant Professor of Psychiatry  
Harvard Medical School  
Division of Geriatric Psychiatry Program  
Cambridge, Massachusetts

8:05am **Question and Answer Session**

**Program Description**  
As a higher proportion of patients are being treated in primary care and other nonpsychiatric environments, psychiatrists are being called upon preferentially to manage the most difficult patients. The psychiatrist of the future must have a deep understanding of underlying disease mechanisms and their treatments. New therapeutic strategies will be essential in managing the increasingly complex patient.

**Learning Objectives**  
At the conclusion of this symposium, participants should be able to

1. Use new strategies to more effectively manage the increasingly complex case load that psychiatrists face in practice.
2. Analyze existing therapeutic strategies for bipolar, treatment-resistant depression, and PTSD patients.
3. Identify a range of newer treatment options in managing these patient profiles.

**Part 2 - Thursday, May 23, 2002**

6:30am Breakfast

7:00am **Welcome and Introduction**  
Richard C. Shelton, MD  
Program Chair  
Professor, Psychiatry and Pharmacology  
Department of Psychiatry, Medical Center  
North Carolina

7:05am **Prognosis and Pharmacological Management of Men and Women With Posttraumatic Stress Disorder**  
Frederick Putty, MD, PhD  
Professor and Vice Chair for Research  
Department of Psychiatry, Emory University  
Director of Research in Mental Health  
Emory University Medical Center  
Atlanta, Georgia

7:25am **Interplay Between Disease and Treatment Regimen: Special Safety Considerations**  
Olga Braverman-Mintzer, MD  
Assistant Professor of Psychiatry  
Director, Anxiety Management Clinic  
Medical Director for CME, Research and Business Development  
The Clinical Research Group/MSD Psychiatry  
In Research Development  
Merck & Co., Inc.  
Kenilworth, New Jersey

7:45am **Question and Answer Session**

**Accreditation and Credit Designation**  
The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates each part of this educational activity for up to 1.5 hours in Category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Attendees must be registered for the APA 2002 Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at [www.psych.org](http://www.psych.org) or contact the APA toll-free at 1-888-357-7924 (within the US or Canada) or at 202-662-6000.

Sponsored by the American Psychiatric Association  
Supported by an unrestricted educational grant from Eli Lilly and Company

If you need special assistance, please call 217.848.5725.


American Psychiatric Association 2002 Annual Meeting

**Therapeutic Challenges,  
Novel Approaches: Antipsychotics  
in the Management of Mood  
and Anxiety Disorders**

**Wednesday, May 22, 2002 and  
Thursday, May 23, 2002**

**Loews Regency Ballrooms A-C, 2nd Floor  
Philadelphia, Pennsylvania**

**6:30am-7:00am Breakfast  
7:00am-8:30am Educational Program**



**INDUSTRY-SUPPORTED SYMPOSIUM 41**  
**Wednesday, May 22, and Thursday, May 23, 7:00 a.m. - 8:30 a.m.**  
**Grand Ballroom Salons E/F, Level 5, Marriott**

## The Pathophysiology Treatment of Impulsivity and Aggression in Psychiatric Disorders

**TWO-PART BREAKFAST  
Program**

**ALAN C. SWANN, MD, PROGRAM CHAIRMAN**

**PROGRAM OBJECTIVES**


- ▶ Understand mechanisms of impulsive behavior, their adaptations over time, and their role in major psychiatric disorders including bipolar, cluster B personality, substance use, stress-related disorders, and disruptive behavior disorders of childhood and adolescence.
- ▶ Learn the role of pharmacologic and other strategies in the physiologically based treatment of disorders where impulsivity is prominent.


**CREDIT DESIGNATION**

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for up to 3 hours in category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at [www.psych.org](http://www.psych.org) or contact the APA toll free at 1-888-357-7924 (within the U.S. or Canada) or 202-682-6000.

 This activity is supported by an unrestricted educational grant from Abbott Laboratories.

 Sponsored by the American Psychiatric Association and held at the APA 2002 Annual Meeting.

**MAY 22-23, 2002**

**6:30 - 7:00 am Breakfast**

**7:00 - 8:30 am Scientific Program**


**Philadelphia Marriott Hotel — Grand Ballroom Salons E/F — Level 5**


<b>WEDNESDAY, MAY 22, 2002</b>	<p>7:00 - 7:05 am Welcome and Introductions Alan C. Swann, MD, Program Chairman <i>University of Texas Medical School at Houston</i></p> <p>7:05 - 7:30 am Mechanisms of Impulsivity Alan C. Swann, MD</p> <p>7:30 - 7:50 am Mood Stabilizers as Adjunctive Treatment in Schizophrenia Daniel E. Casey, MD, <i>Portland Veterans Administration Medical Center</i></p> <p>7:50 - 8:15 am Aggression, Violence and Psychopathology: A Developmental Approach Hans Steiner, MD, <i>Stanford University School of Medicine</i></p> <p>8:15 - 8:30 am Panel Discussion / Q&amp;A</p>
<b>THURSDAY, MAY 23, 2002</b>	<p>7:00 - 7:05 am Welcome and Introductions Alan C. Swann, MD</p> <p>7:05 - 7:30 am Violence, Substance Use Disorders and PTSD Kathleen T. Brady, MD, PhD, <i>Medical University of South Carolina</i></p> <p>7:30 - 8:00 am The Impulsive-Aggression Symptom Domain in Borderline Personality Disorder Eric Hollander, MD, <i>Mount Sinai School of Medicine</i></p> <p>8:00 - 8:30 am Panel Discussion / Q&amp;A</p>

**INDUSTRY-SUPPORTED SYMPOSIUM 42**  
**Wednesday, May 22, and Thursday, May 23, 7:00 a.m. - 8:30 a.m.**  
**Grand Ballroom Salons G/H, Level 5, Marriott**

## New Perspectives on Schizophrenia Spectrum Disorders and Their Treatment

A symposium to be held during the APA 2002 Annual Meeting



Sponsored by  
 JANSSEN  
01-RS-1005-01

The objectives of this symposium are to familiarize the participants with the schizophrenia spectrum disorders, to aid in the recognition of these subjects in a clinical setting, and update themselves with the latest information regarding pharmacologic treatment options in these disorders.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The APA designates this educational activity for 3 hours in category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be on a first-come, first-served basis. For more information about the meeting, please visit the APA website at [www.psych.org](http://www.psych.org) or contact the APA toll free at 1-888-357-7924 (within the U.S. or Canada) or 202-682-6000.

**Wednesday, May 22, & Thursday, May 23, 2002**  
**Grand Ballroom Salons G & H**  
**Marriott Hotel**  
**Philadelphia, PA**

**Agenda Part I: May 22**

6:30 - 7:00 AM Breakfast

7:00 - 7:10 AM Welcome & Introduction

7:10 - 7:35 AM Schizotaxia: Implications for Treatment and Prevention  
*Ming T. Tsuang, MD*  
*Harvard University*

7:35 - 8:00 AM The Schizophrenia Prodrome: Early Treatment Findings  
*Barbara Cornblatt, PhD*  
*Hillside Hospital*

8:00 - 8:30 AM Questions & Answers

**Agenda Part II: May 23**

6:30 - 7:00 AM Breakfast

7:00 - 7:20 AM Neurobiology of Schizotypal Personality: Implications for Pharmacology  
*Larry J. Siever, MD*  
*Mt. Sinai School of Medicine*

7:20 - 7:40 AM Cognitive Enhancers in the Schizophrenia Spectrum  
*Marianne Goodman, MD*  
*Mt. Sinai School of Medicine*

7:40 - 8:00 AM The Promise of Atypical Antipsychotics for Borderline Disorders  
*S. Charles Schulz, MD*  
*University of Minnesota*

8:00 - 8:30 AM Questions & Answers



**INDUSTRY-SUPPORTED SYMPOSIUM 43**  
**Wednesday, May 22, 7:00 p.m. - 10:00 p.m.**  
**Ballrooms A/B, Ballroom Level, Convention Center**

## Non-Cholinergic Treatment for Alzheimer's Disease: Present Knowledge, Future Hope

APA 2002 Annual Meeting, Wednesday, May 22, 2002, 7:00 - 10:00 p.m., Dinner 6:30 - 7:00 p.m.  
 Ballrooms A/B, Pennsylvania Convention Center

- 7:00 - 7:05 p.m. **Introduction**
- 7:05 - 7:35 p.m. **The Diagnosis and Treatment of Alzheimer's Disease: An Overview**  
 Barry D. Lebowitz, PhD, National Institute of Mental Health
- 7:35 - 8:05 p.m. **Current Treatments for Alzheimer's Disease: Cholinesterase Inhibitors**  
 Rachele Doody, MD, PhD, Baylor College of Medicine
- 8:05 - 8:35 p.m. **The Neuroanatomy of Alzheimer's Disease**  
 Gary L. Wenk, PhD, Graduate Program in Cognition and Neural Systems, University of Arizona
- 8:35 - 9:05 p.m. **Beyond Acetylcholine: The Search for Better Treatment Options (Part I)**  
 Jacobo Mintzer, MD, Department of Psychiatry, Medical University of South Carolina
- 9:05 - 9:30 p.m. **Beyond Acetylcholine: The Search for Better Treatment Options (Part II)**  
 Mary Sano, PhD, Department of Neurology, Columbia Presbyterian Medical Center
- 9:30 - 10:00 p.m. **Questions** (five minutes of questions will follow each presentation)

**At the conclusion of this symposium the participants should be able to:**

- Understand existing cholinergic treatments of Alzheimer's disease;
- Better comprehend the neuroanatomy of Alzheimer's disease;
- Recognize alternative options that may be used alone or in combination with existing treatments; and
- Consider the future of Alzheimer's disease treatments.



Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at [www.psych.org](http://www.psych.org) or contact the APA toll free at 1-888-357-7924 (within the U.S. or Canada) or 202-682-6000.

This program is sponsored by the American Psychiatric Association.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for up to 3 hours in category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spends in the educational activity.

This program is supported by an unrestricted educational grant from Forest Laboratories.

Forest Laboratories, Inc.

**INDUSTRY-SUPPORTED SYMPOSIUM 44**  
**Wednesday, May 22, 7:00 p.m. - 10:00 p.m.**  
**Millennium Hall, Second Floor, Loews**

**SLEEP DISORDERS AND PSYCHIATRIC ILLNESSES:  
 Scientific Foundations**

Wednesday, May 22, 2002 • 7:00-10:00 PM  
 Millennium Hall, Second Floor, Loews Hotel, Philadelphia, PA  
 American Psychiatric Association 155th Annual Meeting

**EDUCATIONAL OBJECTIVES**

- At the conclusion of this symposium, participants should be able to:
- recognize that insomnia is a correlative of both disease and psychosocial dysfunction, and that it has a very significant impact on healthcare costs.
  - recognize the relationship between sleep disturbance and a number of psychiatric diseases, as well as understand the benefits of treating sleep disturbance in this patient population.
  - have a better understanding of the commonly used treatments for insomnia and sleep disorders related to psychiatric illnesses and their neurobiological mechanisms

**ACCREDITATION**

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for up to 3 hours in category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

**REGISTRATION**

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at [www.psych.org](http://www.psych.org) or contact the APA toll free at 1-888-357-7924 (within the U.S. or Canada) or 202/682-6000.

**AGENDA**

- 6:30-7:00 PM **Dinner**
- 7:00 **Welcome and Introduction**  
 Ruth M. Benca, MD, PhD  
 Chair  
 Professor  
 Department of Psychiatry  
 University of Wisconsin-Madison
- 7:15 **Epidemiology and Economic Burden of Insomnia**  
 James Walsh, PhD  
 Clinical Professor  
 Department of Psychiatry  
 St. Louis University
- 7:55 **Sleep and Psychiatric Illness**  
 Thomas Roth, PhD  
 Clinical Professor  
 University of Michigan
- 8:35 **Current and Next-Generation Therapeutic Approaches to Sleep**  
 Ruth M. Benca, MD, PhD
- 9:15 PM **Question and Answer Session**  
 Ruth Benca, MD, PhD



Sponsored by the American Psychiatric Association




SEPRACOR Supported by an unrestricted educational grant from Sepracor Inc.



**INDUSTRY-SUPPORTED SYMPOSIUM 45**  
**Wednesday, May 22, 7:00 p.m. - 10:00 p.m.**  
**Regency Ballrooms A-C, Second Floor, Loews**

This symposium will be conducted on May 22, 2002, during the 2002 Annual Meeting of the American Psychiatric Association.



# THE BURDEN OF SCHIZOPHRENIA

## WHEN PATIENTS DON'T GET BETTER

WEDNESDAY, MAY 22, 2002  
 SYMPOSIUM 7:00 - 10:00 PM  
 DINNER 6:30-7:00 PM

LOEWS PHILADELPHIA HOTEL  
 2ND FLOOR, REGENCY BALLROOMS A-C  
 PHILADELPHIA, PENNSYLVANIA

**LEARNING OBJECTIVES**

After attending this symposium, participants will be able to:

- Understand state-of-the-art assessment and available treatment strategies to deal with "treatment-refractory schizophrenia."
- Distinguish different facets of "refractoriness" in treatment with conventional and atypical antipsychotics, become knowledgeable about the effectiveness of all available treatment options, provide state-of-the-art assessment, and develop a best-practice treatment algorithm to deal with antipsychotic treatment refractoriness.
- Recognize clinical situations in which patients have some subjective responses to antipsychotic therapy, whereas the potential etiology of this suboptimal response and implement changes in their treatment plan to improve patient care.
- Understand the evaluation of and treatment options for negative symptoms and cognitive function in patients with schizophrenia.
- Explain the impact of comorbid depression and substance abuse in schizophrenia and the management thereof.
- Recognize current obstacles to achieving better outcomes with newer medications through improving compliance.


**AGENDA**

<p>6:30-7:00 PM Dinner</p> <p>7:00 PM Opening Remarks/Introduction  <b>RAJIV TANDON, MD</b>        (PROGRAM CHAIRPERSON)  <i>University of Michigan Medical Center</i></p> <p>7:10 PM Defining Nonresponse in Schizophrenia: Why Patients Don't Do Well  <b>RAJIV TANDON, MD</b>  <i>University of Michigan Medical Center</i></p> <p>7:35 PM When Psychosis Doesn't Improve  <b>ALAN J. MENDELOWITZ, MD</b>  <i>Albert Einstein College of Medicine</i></p> <p>8:00 PM Negative and Cognitive Functions  <b>MICHAEL D. JIBSON, MD, PhD</b>  <i>University of Michigan Medical Center</i></p>	<p>8:25 PM Comorbidity in Schizophrenia: Depression and Substance Abuse  <b>PETER F. BUCKLEY, MD</b>  <i>Medical College of Georgia</i></p> <p>8:50 PM Why Patients Stop Their Antipsychotics and What to Do About It  <b>PETER J. WEIDEN, MD</b>  <i>State University of New York Health Science Center</i></p> <p>9:15 PM Questions and Answers</p> <p>10:00 PM Adjourn</p>
---	---

The American Psychiatric Association (APA) is approved by the American Board of Psychiatry and Neurology (ABPN) to provide continuing medical education (CME) activities. The APA designates this educational activity for up to 1.5 CME credits. Credit cannot be claimed for this symposium until the CME requirements of the APA. CME participants should claim only those hours of credit that they actually spent in the educational activity. Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at [www.psych.org](http://www.psych.org) or contact the APA toll free at 1-888-357-7924 (within the U.S. or Canada) or 202-582-6000.


**INDUSTRY-SUPPORTED SYMPOSIUM 46**  
**Wednesday, May 22, 7:00 p.m. - 10:00 p.m.**  
**Grand Ballroom Salons E/F, Level 5, Marriott**

## IDENTIFICATION AND MANAGEMENT OF DAYTIME FATIGUE AND SLEEPINESS IN PSYCHIATRY


  
 Sponsored by the American Psychiatric Association

**Participation:** Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at [www.psych.org](http://www.psych.org) or contact the APA toll free at 1-888-357-7924 (within the U.S. or Canada) or 202-582-6000.


<p><b>OBJECTIVE</b></p> <p>Describe the differential diagnoses and intervention options for daytime fatigue and sleepiness in patients with psychiatric disorders.</p> <p><b>ACCREDITATION/DESIGNATION</b></p> <p>The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.</p> <p>The APA designates this educational activity for up to 3 hours in category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.</p> <p><b>PARTICIPATION</b></p> <p>Attendees must be registered for the APA Annual Meeting to attend this Symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at <a href="http://www.psych.org">www.psych.org</a> or contact the APA toll free at 1-888-357-7924 (within the U.S. and Canada) or 202/682-6000.</p>	<p><b>EDUCATIONAL COUNCIL</b></p> <p><i>Chairperson</i>  <b>John W. Winkelman, MD, PhD</b>        Harvard Medical School        Boston, MA</p> <p><b>David F. Dinges, PhD</b>        University of Pennsylvania School of Medicine        Philadelphia, PA</p> <p><b>Mary O'Malley, MD, PhD</b>        Norwalk Hospital        Norwalk, CT</p> <p><b>Karl Doghramji, MD</b>        Thomas Jefferson University Hospital        Philadelphia, PA</p> <p><b>Anthony L. Komaroff, MD</b>        Harvard Medical School        Boston, MA</p> <p><b>Daniel R. Weinberger, MD</b>        National Institute of Mental Health        Bethesda, MD</p>	<p><b>AGENDA</b> Dinner will be provided from 6:30 pm to 7:00 pm.</p> <p><b>7:00 PM to 7:10 PM</b> INTRODUCTION        John W. Winkelman, MD, PhD</p> <p><b>7:10 PM to 7:30 PM</b> SLEEPINESS AND FATIGUE: NEUROBEHAVIORAL AND PHYSIOLOGICAL FEATURES        David F. Dinges, PhD</p> <p><b>7:30 PM to 7:50 PM</b> PRIMARY SLEEP DISORDERS ASSOCIATED WITH EXCESSIVE DAYTIME SLEEPINESS        Mary O'Malley, MD, PhD</p> <p><b>7:50 PM to 8:10 PM</b> FATIGUE AND EXCESSIVE DAYTIME SLEEPINESS IN PSYCHIATRIC DISORDERS        Karl Doghramji, MD</p> <p><b>8:10 PM to 8:35 PM</b> CLINICAL MANIFESTATIONS OF FATIGUE IN CHRONIC FATIGUE SYNDROME        Anthony L. Komaroff, MD</p> <p><b>8:35 PM to 9:00 PM</b> NOVEL MOLECULAR TARGETS IN DEFICIT SYNDROME        Daniel R. Weinberger, MD</p> <p><b>9:00 PM to 9:15 PM</b> DISCUSSANT        John W. Winkelman, MD, PhD</p> <p><b>9:15 PM to 10:00 PM</b> PANEL DISCUSSION/QUESTIONS &amp; ANSWERS        Panel</p>
---	---	--

 Supported by an unrestricted educational grant from Cephalon Inc.

**INDUSTRY-SUPPORTED SYMPOSIUM 47**  
**Wednesday, May 22, 7:00 p.m. - 10:00 p.m.**  
**Grand Ballroom Salons G/H, Level 5, Marriott**

<p align="center">A P A 2 0 0 2 A n n u a l M e e t i n g</p> <p align="center"><b>Adult Attention Deficit Hyperactivity Disorder:</b>  <i>From Research to Clinical Practice</i></p>		<p align="center"><b>Wednesday, May 22,</b>  <b>6:30 – 7:00 PM Dinner</b>  <b>7:00 – 10:00 PM Program</b>  <b>Marriott Hotel</b>  <b>Level 5</b>  <b>Grand Ballroom</b>  <b>Salons G &amp; H</b></p> <p>Attendees must be registered for the APA 2002 Annual Meeting to attend the symposium. Seating is limited and based on first-come, first-served. For more information about the meeting, please visit the APA website at <a href="http://www.psych.org">www.psych.org</a> or contact the APA toll free at 1-888-357-7924 (within the US or Canada) or (202) 682-6000.</p> <p align="center">Sponsored by  <b>The American Psychiatric Association</b></p>  <p align="center">Supported by an unrestricted educational grant from Shire US, Inc.</p> <p align="center"><b>Shire</b></p>
<p><b>PROGRAM</b></p> <p><b>7:00 PM</b>  <b>Welcome/Introduction</b>          Joseph Biederman, MD, <b>Chair</b>          Thomas J. Spencer, MD, <b>Co-Chair</b></p> <p><b>7:15 PM</b>  <b>Overview and Patterns of Comorbidity in Adults with ADHD</b>          Joseph Biederman, MD          Massachusetts General Hospital</p> <p><b>7:40 PM</b>  <b>The Neuropsychology of Adult ADHD</b>          Larry J. Seidman, PhD          Massachusetts Mental Health</p> <p><b>Learning objectives</b></p> <ol style="list-style-type: none"> <li>1. Be familiar with neuropsychology, genetics and imaging studies in adults with ADHD.</li> <li>2. Be able to recognize the essential features of comorbidity, and apply the principles of treatment of ADHD in adulthood.</li> </ol> <p>The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity for up to 3 hours of Category 1 credit towards the Physician's Recognition Award of the American Medical Association and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.</p>	<p><b>8:00 PM</b>  <b>A Genetic Perspective of the Validity of Adult ADHD</b>          Stephen V. Faraone, PhD          Massachusetts General Hospital</p> <p><b>8:20 PM</b>  <b>Functional and Structural Neuroimaging in ADHD</b>          George Bush, MD          Massachusetts General Hospital</p> <p><b>8:50 PM</b>  <b>Pharmacotherapy of Adults with ADHD</b>          Thomas J. Spencer, MD          Massachusetts General Hospital</p> <p><b>9:15 PM</b>  <b>Question &amp; Answer Session</b></p>	

**INDUSTRY-SUPPORTED SYMPOSIUM 48**  
**Wednesday, May 22, 7:00 p.m. - 10:00 p.m.**  
**Wyndham Ballrooms A/B, First Floor, Wyndham**

 <p align="center"><b>Advances in the Understanding and Treatment of Binge Eating Disorder</b></p> <p align="center"><i>An educational symposium to be presented at the 2002 Annual Meeting of the American Psychiatric Association</i></p> <p align="center"><b>Wednesday, May 22, 2002</b></p> <p>6:30 PM – 7:00 PM    <b>RECEPTION</b>          7:00 PM – 10:00 PM    <b>SYMPOSIUM</b>          10:00 PM – 10:30 PM    <b>REFRESHMENTS</b></p> <p align="center"><b>Wyndham Hotel</b>  <b>Wyndham Ballrooms A/B</b>  <b>Philadelphia, Pennsylvania</b></p> <p align="center">Sponsored by the American Psychiatric Association</p> <p align="center">Supported by an unrestricted educational grant from Ortho-McNeil Pharmaceutical, Inc.</p>	<p>6:30 PM – 7:00 PM    <b>Reception</b>          7:00 PM – 7:05 PM    <b>Welcome and Introduction</b>          Cochairpersons:  <i>James I. Hudson, MD, SM</i> – McLean Hospital, Harvard Medical School  <i>Denise E. Wilfley, PhD</i> – San Diego State University and University of California, San Diego</p> <p>7:05 PM – 7:30 PM    <b>Diagnosis and Behavior</b>  <i>B. Timothy Walsh, MD</i> – College of Physicians and Surgeons, Columbia University</p> <p>7:30 PM – 7:55 PM    <b>Epidemiology and Risk Factors</b>  <i>William B. Carter, MD</i> – McLean Hospital, Harvard Medical School</p> <p>7:55 PM – 8:15 PM    <b>Questions and Answers</b>  <b>Treatment With Antidepressants</b>  <i>James I. Hudson, MD, SM</i></p> <p>8:40 PM – 9:05 PM    <b>Treatment With Appetite Suppressants and Anticonvulsants</b>  <i>Susan L. McElroy, MD</i> – University of Cincinnati College of Medicine</p> <p>9:05 PM – 9:30 PM    <b>Psychological Treatment</b>  <i>Denise E. Wilfley, PhD</i></p> <p>9:30 PM – 9:35 PM    <b>Summary and Conclusions</b>  <i>James I. Hudson, MD, SM</i></p> <p>9:35 PM – 10:00 PM    <b>Questions and Answers</b>          10:00 PM – 10:30 PM    <b>Refreshments</b></p>
	<p><b>Educational Objectives</b></p> <p>Upon completion of the program, participants should be able to:</p> <ul style="list-style-type: none"> <li>Review the prevalence and complexity of binge eating disorder and its associated comorbidities as distinct from anorexia nervosa and bulimia nervosa</li> <li>Discuss the diagnostic challenges posed by binge eating disorder as distinct from other eating disorders.</li> <li>Understand the epidemiologic factors associated with the development of binge eating disorder and the risks, including psychological risks and physical risks (such as overweight), posed by binge eating disorder contrasted to anorexia nervosa and bulimia nervosa</li> <li>Discuss current and promising new emerging therapies in the management of binge eating disorder compared with other eating disorders</li> </ul>

**INDUSTRY-SUPPORTED SYMPOSIUM 49**  
**Wednesday, May 22, 7:00 p.m. - 10:00 p.m.**  
**Wyndham Ballrooms C/D, First Floor, Wyndham**

<div style="border-bottom: 1px solid black; padding-bottom: 5px;"> <p style="margin: 0;"><b>Explorations in</b> <b>DEMENTIA</b></p> <p style="text-align: right; margin: 0;">May 22, 2002</p> </div> <p style="margin-top: 5px;"><b>AGENDA</b></p> <table border="0" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 15%; vertical-align: top;">6:30 - 7:00 PM</td> <td style="width: 35%; vertical-align: top;">Dinner</td> <td style="width: 15%; vertical-align: top;">8:15</td> <td style="width: 35%; vertical-align: top;"> <p><b>Charting the Course of Cerebrovascular Dementia</b>                      Gustavo C. Roman, MD                      Professor of Medicine, Neurology                      University of Texas Health Science Center                      San Antonio, Texas</p> </td> </tr> <tr> <td style="vertical-align: top;">7:00</td> <td style="vertical-align: top;"> <p><b>Welcome and Introductions</b>                      Gary W. Small, MD, <i>Chairperson</i>                      Director, UCLA Center on Aging                      Parlow-Solomon Professor on Aging                      University of California at Los Angeles                      School of Medicine                      Los Angeles, California</p> </td> <td style="vertical-align: top;">8:35</td> <td style="vertical-align: top;"> <p><b>Alzheimer's Disease Therapy in the 21st Century: Examining the Evidence</b>                      Pierre N. Tariot, MD                      Professor of Psychiatry, Medicine,                      and Neurology                      University of Rochester Medical Center                      Rochester, New York</p> </td> </tr> <tr> <td style="vertical-align: top;">7:15</td> <td style="vertical-align: top;"> <p><b>Early Detection and Genetic Risk Assessment in Alzheimer's Disease</b>                      Gary W. Small, MD</p> </td> <td style="vertical-align: top;">8:55</td> <td style="vertical-align: top;"> <p><b>Managing Behavioral Disturbances in Dementia: Practical Approaches to Treatment</b>                      Donna L. Masterman, MD, <i>Cochairperson</i>                      Director, Katherine and Benjamin Kagan                      Alzheimer's Disease Treatment Program                      Assistant Clinical Professor of Neurology                      University of California at Los Angeles                      School of Medicine                      Los Angeles, California</p> </td> </tr> <tr> <td style="vertical-align: top;">7:35</td> <td style="vertical-align: top;"> <p><b>Differential Diagnosis of Dementia Syndromes: A Psychiatric Perspective</b>                      J. Michael Ryan, MD                      University of Rochester Medical Center                      Program in Neurobehavioral Therapeutics                      Monroe Community Hospital                      Rochester, New York</p> </td> <td style="vertical-align: top;">9:15</td> <td style="vertical-align: top;"> <p><b>Question and Answer Session</b>                      Faculty Panel</p> </td> </tr> <tr> <td style="vertical-align: top;">7:55</td> <td style="vertical-align: top;"> <p><b>Contemporary Issues in Mild Cognitive Impairment: Fact or Fiction?</b>                      Bradley F. Boeve, MD                      Assistant Professor of Neurology                      Department of Neurology                      Mayo Clinic                      Rochester, Minnesota</p> </td> <td style="vertical-align: top;">10:00</td> <td style="vertical-align: top;">Adjourn</td> </tr> </table>		6:30 - 7:00 PM	Dinner	8:15	<p><b>Charting the Course of Cerebrovascular Dementia</b>                      Gustavo C. Roman, MD                      Professor of Medicine, Neurology                      University of Texas Health Science Center                      San Antonio, Texas</p>	7:00	<p><b>Welcome and Introductions</b>                      Gary W. Small, MD, <i>Chairperson</i>                      Director, UCLA Center on Aging                      Parlow-Solomon Professor on Aging                      University of California at Los Angeles                      School of Medicine                      Los Angeles, California</p>	8:35	<p><b>Alzheimer's Disease Therapy in the 21st Century: Examining the Evidence</b>                      Pierre N. Tariot, MD                      Professor of Psychiatry, Medicine,                      and Neurology                      University of Rochester Medical Center                      Rochester, New York</p>	7:15	<p><b>Early Detection and Genetic Risk Assessment in Alzheimer's Disease</b>                      Gary W. Small, MD</p>	8:55	<p><b>Managing Behavioral Disturbances in Dementia: Practical Approaches to Treatment</b>                      Donna L. Masterman, MD, <i>Cochairperson</i>                      Director, Katherine and Benjamin Kagan                      Alzheimer's Disease Treatment Program                      Assistant Clinical Professor of Neurology                      University of California at Los Angeles                      School of Medicine                      Los Angeles, California</p>	7:35	<p><b>Differential Diagnosis of Dementia Syndromes: A Psychiatric Perspective</b>                      J. Michael Ryan, MD                      University of Rochester Medical Center                      Program in Neurobehavioral Therapeutics                      Monroe Community Hospital                      Rochester, New York</p>	9:15	<p><b>Question and Answer Session</b>                      Faculty Panel</p>	7:55	<p><b>Contemporary Issues in Mild Cognitive Impairment: Fact or Fiction?</b>                      Bradley F. Boeve, MD                      Assistant Professor of Neurology                      Department of Neurology                      Mayo Clinic                      Rochester, Minnesota</p>	10:00	Adjourn	<p style="text-align: center;"><b>155TH APA ANNUAL MEETING</b></p> <p><b>Ballrooms C/D</b>  <b>First Floor</b>  <b>Wyndham Philadelphia at Franklin Plaza</b>  <b>Philadelphia, Pennsylvania</b></p> <p><i>At the conclusion of this symposium, participants should be able to:</i></p> <ul style="list-style-type: none"> <li>• Identify methods of early detection and genetic risk factors in Alzheimer's disease (AD);</li> <li>• Use effective differential diagnosis techniques to pursue optimal patient management;</li> <li>• Recognize the existence of mild cognitive impairments and its implications;</li> <li>• Identify strategies to diagnose vascular dementia and its emerging pharmacotherapies;</li> <li>• Recognize the impact of cholinesterase inhibitors in the management of AD.</li> </ul> <p>Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be on a first-come, first-served basis. For more information about the meeting, please visit the APA Web site at <a href="http://www.psych.org">www.psych.org</a> or contact the APA toll free at 1-888-357-7824 (within the United States or Canada) or 202-682-6000.</p> <p>The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.</p> <p>The APA designates this educational activity for up to 3 hours in category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.</p> <p style="text-align: center;">          Sponsored by the American Psychiatric Association     </p> <p style="text-align: center;">          Supported by an unrestricted educational grant from Eisai Inc. and Pfizer Inc.     </p>
6:30 - 7:00 PM	Dinner	8:15	<p><b>Charting the Course of Cerebrovascular Dementia</b>                      Gustavo C. Roman, MD                      Professor of Medicine, Neurology                      University of Texas Health Science Center                      San Antonio, Texas</p>																			
7:00	<p><b>Welcome and Introductions</b>                      Gary W. Small, MD, <i>Chairperson</i>                      Director, UCLA Center on Aging                      Parlow-Solomon Professor on Aging                      University of California at Los Angeles                      School of Medicine                      Los Angeles, California</p>	8:35	<p><b>Alzheimer's Disease Therapy in the 21st Century: Examining the Evidence</b>                      Pierre N. Tariot, MD                      Professor of Psychiatry, Medicine,                      and Neurology                      University of Rochester Medical Center                      Rochester, New York</p>																			
7:15	<p><b>Early Detection and Genetic Risk Assessment in Alzheimer's Disease</b>                      Gary W. Small, MD</p>	8:55	<p><b>Managing Behavioral Disturbances in Dementia: Practical Approaches to Treatment</b>                      Donna L. Masterman, MD, <i>Cochairperson</i>                      Director, Katherine and Benjamin Kagan                      Alzheimer's Disease Treatment Program                      Assistant Clinical Professor of Neurology                      University of California at Los Angeles                      School of Medicine                      Los Angeles, California</p>																			
7:35	<p><b>Differential Diagnosis of Dementia Syndromes: A Psychiatric Perspective</b>                      J. Michael Ryan, MD                      University of Rochester Medical Center                      Program in Neurobehavioral Therapeutics                      Monroe Community Hospital                      Rochester, New York</p>	9:15	<p><b>Question and Answer Session</b>                      Faculty Panel</p>																			
7:55	<p><b>Contemporary Issues in Mild Cognitive Impairment: Fact or Fiction?</b>                      Bradley F. Boeve, MD                      Assistant Professor of Neurology                      Department of Neurology                      Mayo Clinic                      Rochester, Minnesota</p>	10:00	Adjourn																			

American Psychiatric Association  
54<sup>th</sup> Institute on Psychiatric Services  
Wednesday, October 9–Sunday, October 13, 2002  
Chicago, IL

## “Community Counts: Creating and Supporting Systems of Care”

### • Distinguished Lecturers •

• CME Courses •

• Leadership and  
Career Development Seminars •  
*(for Residents and  
Early Career Psychiatrists)*

### • Industry-Supported Symposia •

• Medical Updates •

• Symposia •

• Workshops •

• Debates •

• Forums •

• Full-Day Sessions •

• Poster Sessions •

• Discussion Groups •

• Innovative Programs •

• Clinical Consultations •



### INSTITUTE OBJECTIVES:

At the conclusion of the 2002 Institute on Psychiatric Services, participants will:

1. Acquire new knowledge and skills in clinical psychiatry, which can be utilized to improve patient care;
2. Better understand how the current health care system affects patient care;
3. Gain new knowledge and skills useful in public psychiatric settings; and
4. Understand the importance of all disciplines working together to ensure high quality patient care.

### Did you know that...

- ☞ You can earn up to 48 hours of category 1 credit for attending the Institute?
- ☞ APA members receive a 40% discount on their cost for registration?
- ☞ Industry-Supported Breakfast, Lunch and Dinner Symposia are presented each day?
- ☞ All scientific sessions will be held in the Palmer House Hilton Hotel in Chicago?
- ☞ There are prize drawings, beverages and receptions held daily in the exhibit hall?
- ☞ The 2001 Institute received the highest attendee-rated evaluations?

*For further information, please call or write to:*

Annual Meetings Department  
American Psychiatric Association  
1400 K Street, N.W.  
Washington, DC 20025

Telephone: 1 (888) 357-7924 (Toll Free)

Fax: (202) 682-6345

E-Mail: [apa@psych.org](mailto:apa@psych.org)


Web: <http://www.psych.org>



The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians. The APA designates this educational activity for up to 48 hours in category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.



# As Questions Arise at the APA Annual Meeting, Keep One Place in Mind



## Answers to all these questions and more can be found at the APA Resource Center.

Along with new research abstracts on CD-ROM, complimentary copies of the latest APA publications, and opportunities to advertise or apply for position openings, you'll find the latest HIV/AIDS treatment information; fellowship opportunities; how to report, track, and attain additional CME credits; and other resources of benefit to the 21st century psychiatrist. Even a place to reconnect to your 21st century life at the Internet Village.

So make the APA Resource Center part of your Annual Meeting experience and find out how the programs and resources of APA equip the 21st century psychiatrist and specifically how APA membership can work for you.

### APA Resource Center Exhibit Halls A-C Exhibit Hall Level, Convention Center

#### Hours of Operation

Saturday, May 18: 10:00 a.m.–5:00 p.m.  
Sunday, May 19: 8:00 a.m.–4:30 p.m.\*  
Monday, May 20: 10:00 a.m.–6:00 p.m.  
Tuesday, May 21: 10:00 a.m.–6:00 p.m.  
Wednesday, May 22: 10:00 a.m.–3:00 p.m.

\*Early closing for Opening Session

